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ABSTRACT (REGULATION 1.1.3)
The experiments presented here arose from an interest in endothelial function and, particularly,
a wish to better understand the pharmacology and physiology of the endothelin (ET) system in
human blood vessels in health, and the influence of cardiovascular disease on the ET system.
This work followed from the discovery of ET-1 as a peptide endothelial mediator of vascular
tone in 1988. Publications are grouped into sections representing different aspects of the work.
Section 1 is concerned with exploring pharmacological responses to the ET family of peptides,
the sarafotoxin analogue peptides, and ET antagonists, in human blood vessels in vivo. This
was amongst the first work with ET-1 in humans, and certainly the first to use the sarafotoxins,
ET receptor antagonists and ET converting enzyme (ECE) inhibitors. After characterisation of
the pharmacological tools, it was possible to show clearly that endogenous ET-1 plays a
physiological role in the control of peripheral resistance and blood pressure in healthy humans,
suggesting important clinical applications for these agents. It was also shown that the ETA
receptor is the major vasocontrictor receptor and that the major role in health of the ETB
receptor is endothelium-dependent vasodilatation, enhancement of which may contribute to the
beneficial clinical attributes of ETA receptor antagonism. In addition, local ET-1 infusion in
the forearm circulation was shown to be a system whereby the clinical efficacy of systemically
administered ET receptor antagonists could be modelled pharmacodynamically.
Sections 2-4 cover work confirming the substantial clinical utility of ET receptor antagonists
and ECE inhibitors as vasodilators, particularly in essential hypertension, heart failure and renal
failure. Other work, following congenital heart surgery, suggests that a cautious approach may
be needed in some cases of pulmonary hypertension. Studies with neutral endopeptidase (NEP)
inhibitors show unequivocally, but unexpectedly, that these agents are peripheral
vasoconstrictors, and the evidence presented is consistent with this effect occurring because
endogenously generated vascular ET-1 is an important substrate for NEP.
Section 5 contains some miscellaneous but related studies, together with a series of review
articles written from 1991-98 synthesising the literature at each stage and drawing conclusions
about potential areas of major clinical interest in cardiovascular disease.
STATEMENT (REGULATION 1.1.4)
(a) Part of the work in Paper 1 was presented in my MD thesis (University of London,
1990). Work in Papers 4, 6-8, and 22 was presented in Dr William Haynes' thesis
(University of Sheffield, 1995). Work in Papers 13, 18 and 25 was presented in Dr
Charles Ferro's MD thesis (University of Edinburgh, 1998).
(b) This work was performed in close collaboration with a number of young physicians
who came under my research supervision between 1990 and 1999. By the nature of
complex clinical research, this work was multidisciplinary, often in collaboration
with specialist physicians whose patients we were grateful to have the opportunity to
study. I was leader of the research team responsible for all the work presented here.
In particular, I was responsible for the conception and design of the studies,
applications for grant funding, teaching of the research techniques, development of
new methods, initiation of the experiments, clinical supervision of the work during
its performance, and preparation of the work for publication. I also had the final
responsibility of vouching for the content of the submitted manuscripts and of
making the decisions on the journals to which the work should be sent.
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Endothelin is a potent long-lasting vasoconstrictor in men. Am.
J. Physiol. 257 (HeartCirc. Physiol. 26): H2033-H2035,1989.-
Endothelin, a 21-amino acid peptide synthesized by cultured
porcine aortic endothelial cells, has recently been identified
and shown to produce a potent and prolonged constriction of
mammalian blood vessels in vitro. We have studied the effect
of local infusion of this peptide on resistance and capacitance
vessels of normal volunteers. Infusion of endothelin (5 pmol/
min) reduced forearm blood flow by 39 ± 7% from control
observations. The maximum response was seen after —55 min
of infusion. After stopping the infusion, return of flow to basal
values took -120 min. This contrasts with the short onset and
duration of action observed when angiotensin II was infused.
During coinfusion studies, reversal by nicardipine (0.3-10 ng/
min) occurred at similar concentrations in both endothelin-
induced and angiotensin-induced flow reduction. This obser¬
vation suggests that nicardipine nonspecifically antagonizes
the flow-reducing effects of endothelin. A pattern of slow onset
of constriction was found on local infusion of endothelin (5
pmol/min) into dorsal hand veins. During coinfusion of nicar¬
dipine (1.5 jig/min), no reversal of endothelin-induced (5 pmol/
min) constriction of dorsal hand veins occurred. The pharma¬
cological profile of this peptide in the peripheral circulation of
humans suggests that it may be involved in long-term regula¬
tion of vascular tone.
vascular; artery; vein; human; endothelium; nicardipine
FOLLOWING REPORTS THAT endothelial cell culture su¬
pernatant exhibits vasoconstrictor activity (5, 9, 16),
Yanagisawa et al. (23) have isolated and characterized a
novel constrictor peptide, endothelin, from the culture
supernatant of porcine aortic endothelial cells. They
have shown in vitro that the potency of endothelin as a
vasoconstrictor is greater than that of other known con¬
strictor agents, including angiotensin II.
Initially, the structural similarity with other peptides
that affect membrane ion channels and its sensitivity to
nicardipine and extracellular calcium suggested a role for
endothelin as an endogenous ligand for voltage-depend¬
ent dihydropyridine-sensitive calcium channels (11).
However, contractile responses to endothelin, obtained
in calcium-free media, unaffected by nifedipine, suggest
that endothelin may modulate intracellular calcium (8).
Endothelin also developed a slow and sustained contrac-
0363-6135/89 $1.50 Copyright © 19:
tion in rat aorta in a calcium free medium. When calcium
was replaced, a tonic contraction was obtained, which
was insensitive to potential-dependent calcium blockers
(1). Nicardipine attenuated the sustained but not the
initial rise of calcium in cultured vascular smooth muscle
cells (10). The contractile properties of a dihydropyridine
agonist (BAY K 8644) were compared with endothelin
and were found to differ markedly (1). Endothelin failed
to displace the binding of a dihydropyridine ([3H]PN
200/110), a phenylakylamine ([3H)desmethoxyverapa-
mil), and a benzothiazepine (cis-[3H]diltiazem) in cardiac
membranes (7). Calcium channel blockers did not affect
the binding of endothelin to cultured vascular smooth
muscle cells (10).
Using forearm plethysmography, we have compared
the constrictor response of resistance and capacitance
vessels to endothelin with the response to angiotensin II
and have studied the effect of both peptides in the
presence of a dihydropyridine calcium channel blocking
agent, nicardipine.
METHODS
Subjects. Twelve healthy male volunteers between 20
and 41 years of age participated in these studies, which
were conducted with the approval of the Institutional
Ethics Committee and with the informed consent of each
volunteer. Studies were performed after subjects had
rested supine in a quiet clinical laboratory for a minimum
of 30 min. Room temperature (between 25 and 28*C) was
maintained within ±1"C for each study.
Forearm arterial studies. Forearm blood flow was
measured in both arms using venous occlusion plethys¬
mography with temperature-compensated mercury-in-
Silastic strain gauges (20). Collecting cuff pressure was
40 mmHg, and wrist cuff occlusion pressure was 200
mmHg. A 27 standard wire gauge unmounted steel can¬
nula was inserted into the left brachial artery using 1%
lignocaine hydrochloride to provide local anesthesia.
Drugs were dissolved in saline and were infused at a
constant rate of either 0.5 or 1.0 ml/min throughout the
experiment by means of constant-rate infusion pumps
(Harvard 944A). In experiments where two drugs were
infused simultaneously, a Y-connector delayed mixing
until the solutions entered the cannula. Flows were re¬
corded for 10 s in every 15 s. The mean of the final five
89 the American Physiological Society H2033
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measurements of each recording period was used for
analysis. The percentage change in forearm blood flow
after drug administration was calculated according to the
method of Greenfield (6). Blood flow was measured dur¬
ing infusion of sterile, toxin-free endothelin (Peninsula
Laboratories) or angiotensin II (Calbiochem) for 60 min
each at 5 pmol/min. The infusions were followed in nine
studies (5 endothelin, 4 angiotensin II) by saline alone
for a further 120 min and in eight studies (4 endothelin,
4 angiotensin II) by nicardipine (0.3, 1.0, 3.0, 10 /ig/min,
each for 5 min).
Venous studies. Endothelin (5 pmol/min) was infused
alone for 60 min at a constant rate (0.25 ml/min) into
dorsal hand veins of nine normal volunteers, and per¬
centage change in vein size was measured by a modifi¬
cation of the method of Nachev et al. (15). A lightweight
lever connected to a transducer was rested on the summit
of the vein, 1 cm downstream from the tip of the infusing
needle. Vein size was taken as the vertical displacement
of this lever on deflating an upper aim cuff inflaLed lu
30 mmHg. In four subjects, after 60 min of endothelin
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FIG. 1. Endothelin (■. n = 9) nr angiotensin II (a n - 8) was infused
into left brachial artery for 60 min (horizontal bar) each at 5 pmol/
min. Endothelin produced a slowly developing reduction in (low, which
persisted on stopping infusion, whereas effect of angiotensin II was of
























2. Forearm blood flow was measured as in Fig. 1. Nicardipine
fused (hatched bars) in addition to either endothelin (■, 5 pmol/
= 4) or angiotensin II (a, 5 pmol/min, n = 4). Reversal of flow
ion with nicardipine was similar with both peptides.
RESULTS
The reduction in forearm blood flow resulting from
brachial arterial infusion of 5 pmol/min of endothelin
(39 ± 7%) was similar to that induced by 5 pmol of
angiotensin II (40 ± 7%) but was slower in onset, taking
—55 min to reach maximum (Fig. 1), and reversed only
slowly on stopping the infusion (Fig. 1). Addition of
nicardipine (0.3-10 pg/min) to either endothelin or an¬
giotensin II infusion resulted in a similar reversal of flow
reduction in both cases (Fig. 2).
A similar constrictor response was seen when endothe¬
lin (5 pmol/min) was infused into dorsal hand veins, the
maximal mean reduction in size (83 ± 12%) being pro¬
gressive over 60 min. Nicardipine failed to reverse the
endothelin-induced venoconstriction (n = 4).
DISCUSSION
The demonstration that cultured mammalian vascular
endothelial cells synthesize a potent pressor peptide,
cndothclin, has provided further evidence of the impor
tancc of the endothelium in control of vascular smooth
muscle tone. The kinetics of endothelin-induced con¬
striction in human vessels in this study infer that this
may be the same constrictor agent originally isolated by
Hickey et al. (9) from endothelial cell culture superna¬
tant.
In this study wc have demonstrated a potent and long
lasting constriction of the forearm resistance vessels and
the dorsal hand veins of men. These findings are in
agreement with previous in vitro and in vivo obscrva
tions. However, there are recent reports of vasodilator
responses to relatively low doses of cndothclin (12, 14,
21, 22). Wc too observed transient increases of forearm
blood flow during the first 5 min of the endothelin
infusion, but the changes were small and statistically
insignificant (Fig. 1).
The effects of other constrictor peptides (2) may be
partly due to enhancement of sympathetically induced
constriction. In isolated peripheral vascular tissue, en¬
dothelin may interact with sympathetic nerve activity in
addition to having a direct vasoconstrictor action, and
this may contribute to its effect on forearm resistance
vessels (19). Because the dorsal hand veins of warm,
relaxed volunteers have no basal sympathetic tone (4),
this mechanism is unlikely to be important in the veno¬
constriction seen in this study.
With the use of the forearm plethysmography tech¬
nique, it is difficult to differentiate between reversal of
endothelin-induced and reversal of basal flow reduction
after administration of calcium channel blocking agents.
However, the observation that nicardipine reverses flow
reduction caused by both endothclin and angiotensin II
at similar concentrations suggests that it is not a specific
antagonist of the constrictor effects of endothclin. Given
the large multisubunit structure of the Ca2+ channel
complex (3), endothelin might interact with the L-type
Ca2+ channel, perhaps by utilizing other binding sites.
Alternatively, endothclin may act by increasing free cy-
tosolic calcium, as has been demonstrated in vascular
smooth muscle (10); endothelin produces a rapid increase
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in '"Ca2* efflux from aortic smooth muscle cells even
when no extracellular calcium is present, implying that
endothelin probably mobilizes Ca2+ from intracellular
storage sites (13). A third possible mechanism could
relate to the effect of endothelin on protein kinase C
affinity for calcium, since protein kinase C inhibition
can reverse endothelin-induced contraction (18).
The failure of nicardipine to reverse the venoconstric-
tor action of endothelin at a dose that we (unpublished
observations) and others (17) have found to completely
abolish KMnduced constriction suggests that the mech¬
anism of action in veins is independent of voltage-de-
pendent calcium channels.
The pattern of slow onset and offset of action might
suggest a role for this novel peptide in the long-term
control of peripheral vascular resistance and venous tone.
Nicardipine was supplied courtesy of Svntex Research.
N. Benjamin is a Wellcome Research training fellow.
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The effect of intra-arterial endothelin on resting blood flow and
sympathetically mediated vasoconstriction in the forearm ofman
J. R. COCKCROFT, J G. CLARKE1 & D. J. WEBB2
Departments of Clinical Pharmacology and 'Cardiovascular Medicine, RPMS, Hammersmith Hospital, London W12 ONN, and
department of Pharmacology and Clinical Pharmacology, St George's Hospital Medical School, London SW17 ORE
1 The hypothesis that endothelin (ET) influences sympathetically mediated vasoconstric¬
tion was investigated in 13 healthy, male subjects.
2 ET (1 pmol min-1) was infused for 60 min into the left brachial arteries of seven
healthy male subjects. Resting forearm blood flow, and sympathetic vasoconstriction
produced by lower body negative pressure (LBNP; 15 mm Hg), was measured in both
arms by strain gauge plethysmography. In a further six subjects, noradrenaline (NA) was
infused intra-arterially at doses of 150-600 pmol min-1, with and without co-infusion of
ET (1 pmol min-1), with blood flow measured in both forearms.
3 ET produced a small but significant reduction of blood flow in the infused forearm
from 3.9 ± 0.6 ml 100 ml-1 min-1 during infusion of saline, to 3.3 ± 0.7 ml 100 ml-1
min-1 during infusion of ET at 60 min (P < 0.05). Blood flow in the non-infused forearm
was not altered by ET infusion.
4 NA produced a significant and dose-dependent reduction of blood flow in the infused
forearm, from 3.13 ± 0.5 ml 100 ml-1 min-1 during saline infusion, to 1.49 ± 0.2 ml
100 ml-1 min-1 with NA at 600 pmol min-1 (P < 0.001). During co-infusion of ET, blood
flow was reduced similarly in the infused arm from 3.15 ± 0.7 ml 100 ml-1 min-1 during
saline infusion to 1.55 ± 0.2 ml 100 ml-1 min-1 with NA at 600 pmol min-1. Blood flow
in the non-infused arm was not altered by ET and NA infusion.
5 During saline infusion, LBNP reduced blood flow in the infused and non-infused
forearms from 3.9 ± 0.6 to 3.0 ± 0.4, and from 4.5 ± 0.6 to 3.2 ± 0.5 ml 100 ml-1 min-1
respectively. Following ET for 60 min, blood flow in the infused and non-infused forearms
was similarly reduced by LBNP, from 3.3 ± 0.7 to 2.5 ± 0.4, and from 4.7 ± 1.2 to
3.6 ± 0.7 ml 100 ml-1 min-1 respectively. Infusion of ET did not affect responses to LBNP.
6 We conclude that ET is a potent vasoconstrictor of resistance vessels in the forearm
circulation in man, producing a slowly progressive effect which is unique among the
known constrictor agents and supports a role for ET in long-term maintenance of vascular
tone. Intra-arterial ET does not, however, appear to affect NA or sympathetically
(LBNP) mediated vasoconstriction in the human forearm.
Keywords endothelin sympathetic nervous system forearm blood flow
lower body negative pressure
Introduction
Endothelin (ET) is a 21 amino acid peptide first isolated
from the medium of porcine aortic endothelial cells in
culture (Yanagisawa et al., 1988). It is a potent vaso¬
constrictor in vivo both in animals (Yanagisawa et al.,
1988) and in man (Clarke et al., 1989), with a slow onset,
and prolonged duration of action.
Evidence from animal studies suggests that there may
be an interaction between ET and the sympathetic
nervous system. ET attenuates sympathetic activity in
the perfused guinea pig femoral artery (Wiklund et al.,
1988), at least in part by reducing noradrenaline (NA)
release presynaptically. ET increases catecholamine
release from bovine adrenal cells in culture (Boarder &
Marriott, 1989), and enhances the response to infused
Correspondence: Dr D. J. Webb, University Department of Medicine, Western General Hospital, Edinburgh EH4 2XU
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NA in the perfused rat mesenteric artery (Tabuchi et al.,
1989).
In the present experiments, we have investigated the
effects of prolonged arterial infusion of ET (60 min) on
resting blood flow of the upper limb in man, and on the
vasoconstriction produced by lower body negative
pressure (LBNP) and NA infusion. The dose of ET used
(1 pmol min-1) was selected to produce only a moderate
reduction in resting forearm blood flow, based on earlier
studies in man (Clarke et al., 1989).
throughout the study. LBNP (15 mm Hg) was applied
for the second 3 min of each measurement period.
The effect of ET on responses to LBNP and NA, was
assessed by repeated measures analysis of variance
followed by application of the Wilcoxon signed rank test




Thirteen healthy male volunteers, aged between 21 and
24 years, participated in these studies which were
conducted with the approval of the St George's Hospital
Ethics Committee and with the informed consent of
each volunteer. Studies were performed after subjects
had rested supine in a quiet clinical laboratory for a
minimum of 30 min. Room temperature (between 25
and 27° C) was maintained constant ± 1° C for each
study.
Blood flow was measured in both forearms using
venous occlusion plethysmography with temperature
compensated mercury-in-silastic strain gauges (Whitney,
1953). Collecting cuff pressure was 40 mm Hg and wrist
cuff occlusion pressure was 200 mm Hg. Flows were
recorded for 10 s in every 15 s, and the mean of the final
five measurements of each recording period was used for
analysis. A 27 gauge (SWG) steel cannula was inserted
into the left brachial artery using lignocaine hydrochloride
(1%; Antigen Ltd, Ireland) to provide local anaesthesia.
Saline (0.9%; Travenol, UK), ET (1 pmol min-1 in
0.9% saline; Penninsula Labs, Europe), and NA (150-
600 pmol min-1 in 0.9% saline (with ascorbic acid as
antioxidant); Winthrop, UK) were given at a rate of 0.5
ml infusate min-1 throughout the experiments by means
of a constant-rate infusion pump (Harvard 944A).
Lower body negative pressure (LBNP) was applied
using the method described by Brown and colleagues
(Brown et al., 1966). Subjects rested supine in a plastic-
covered steel cage enclosing the lower limbs and hips
and sealed above the level of the anterior superior iliac
spines. Suction was applied using an industrial vacuum
cleaner to produce a constant negative pressure of 15
mm Hg below atmospheric pressure. The alteration
from atmospheric pressure was both applied and relieved
rapidly.
In the first series of experiments six subjects received
saline for 12 min, followed by three incremental doses
of NA (150, 300, then 600 pmol min-1), with each dose
given for 12 min. After a further 12 min period of saline
infusion, subjects received ET (1 pmol min-1) for 12 min
before, and then throughout a second period of incre¬
mental infusion of NA (150, 300, then 600 pmol min-1),
with each dose again given for 12 min. Forearm blood
flow was measured for the second 6 min of each 12 min
infusion period throughout the study.
In the second series of experiments, seven subjects
received saline for 12 min, followed by ET (1 pmol
min-1), given for 60 min. Forearm blood flow was
measured for the second 6 min of each 12 min period
1 during ET alone to 1.6
with NA at 600 pmol min"
NA alone produced a significant and dose related reduc¬
tion in blood flow in the infused forearm from 3.1 ±
0.5 ml 100 ml-1 min-1 during saline infusion, to 1.5 ±
0.2 ml 100 ml-1 min-1 with NA at 600 pmol min-1
(P < 0.001). During co-infusion of ET (1 pmol min-1),
NA reduced blood flow in the infused forearm from
3.2 ± 0.7 ml 100 ml-1 min
0.2 ml 100 ml-1 min-1
(P < 0.001). The absolute and percentage reductions in
forearm blood flow (Figure 1) produced by NA were,
however, unaffected by co-infusion of ET. Blood flow
in the non-infused forearm was not affected by infusion
of either NA or ET.
Infusion of ET for 60 min produced a 15% reduction
in blood flow in the infused forearm, from 3.9 ± 0.6 ml
100 ml-1 min-1 during saline infusion to 3.3 ± 0.7 ml
100 ml-1 min-1 after 60 min ET (P < 0.05). Blood flow
in the non-infused forearm, during the same period,
increased from 4.5 ± 0.6 to 4.7 ± 1.2 ml 100 ml- min-1
(NS) (Figure 2, Table 1).
Blood flow was consistently reduced in both forearms
in all subjects by LBNP. During saline infusion, LBNP
reduced blood flow from 3.9 ± 0.6 to 3.0 ± 0.4 ml 100
ml-1 min-1, and from 4.5 ± 0.6 to 3.2 ± 0.5 ml
100 ml-1 min-1 in the infused and non-infused forearms
respectively. After 60 min ET infusion, LBNP reduced
blood flow from 3.3 ± 0.7 to 2.5 ± 0.4 ml 100 ml-1
min-1, and from 4.7 ± 1.2 to 3.6 ± 0.7 ml 100 ml-1
min-1 in the infused and non-infused forearms respec¬
tively. The reduction in forearm blood flow produced by
LBNP was unaffected by infusion of ET, either in terms























Figure 1 Effect on forearm blood flow of infusion of
incremental doses of noradrenaline (150-600 pmol min 1) with
(■) and without (□) co-infusion of endothelin (1 pmol
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Table 1 Effect of endothelin (1 pmol min ') on resting forearm blood flow (mean ± s.e. mean, ml
100 ml-1 min-1) and on the response to lower body negative pressure (15 mm Hg; LBNP)
Time (min)
0 12 24 36 48 60
Blood flow: infused arm
Resting 3.9 + 0.6 3.8 ±0.6 3.5 ±0.7 3.4 ±0.6 3.3 ±0.6 3.3 ±0.7
During LBNP 3.0 ±0.4 2.8 ±0.5 2.7 ±0.5 2.7 ±0.5 2.6 ±0.5 2.5 ±0.4
Blood flow: non-infused arm
Resting 4.5 ±0.6 4.5 ±0.7 4.3 ±0.9 4.6 ±1.0 4.7 ±1.1 4.7 ± 1.2
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Figure 2 Effect of endothelin (1 pmol min-1), given for 60
min, on resting forearm blood flow (upper panel), and on
percentage change in blood flow during lower body negative
pressure (lower panel), in the infused (■) and non-infused
(□) forearms.
Discussion
Endothelin (ET) is a recently discovered peptide vaso¬
constrictor (Yanagisawa et al., 1988). Although the
potency of ET in the forearm of man is similar to that
of angiotensin II (Clarke et al., 1989), the slowly pro¬
gressive onset and offset of its action (Clarke et al., 1989;
Hughes et al., 1989) is unique, differing from the actions
of other constrictor agents in the forearm. In the present
study in man, as in previous experiments employing a
higher dose of ET (5 pmol min"1), there was a slowly
progressive reduction in forearm blood flow during ET
infusion, maximal at the end of the 60 min infusion
period. The maximum 15% reduction of blood flow
associated with infusion of ET at 1 pmol min 1 compares
with a 39% reduction at 5 pmol min"1 given for 60 min
(Clarke et al., 1989), showing this response to be dose
dependent. Experiments with shorter infusions of ET at
5 pmol min"1 suggest that the maximum effect does not
develop when ET infusion is stopped before 60 min
(unpublished observations). The characteristics of the
response to ET are compatible with progressive and
tight binding of the peptide to its receptor in vascular
smooth muscle. These experiments provide no evidence
for the tachyphylaxis to ET which has been demonstrated
in vitro (Hughes et al., 1989) and the characteristics of
the response to ETwould provide support for its role in
long term, rather than short term regulation of vascular
tone (Editorial, 1988).
Immunoreactive ET has recently been detected in the
plasma of uraemic patients undergoing haemodialysis,
with the majority of patients having circulating plasma
levels greater than 4 x 10"12 mol l"1, and some as high
as 20 x 10"12 mol l"1 (Kovama et al., 1989). Infusion of
ET (1 x 10"12 mol min ) in the present study, into a
forearm blood flow of approximately 50 ml min"1,
would be predicted to produce local concentrations of
ET in blood in the order of 20 x 10"12 mol l"1, similar
to dialysed patients with the highest plasma levels of ET.
If, as our experiments suggest, the response to circulating
ET in man is dose dependent, and if the effect on
forearm resistance vessels is common to other resistance
vessels in man, similar circulating concentrations of ET
might be expected to exert a direct effect on arteriolar
tone. This view is supported by the results of a recent
report of responses to systemic infusion of ET in man
(Vierhapper et al., 1990). Infusion of ET at a dose
sufficient to provide a circulating plasma ET concentration
of 50 x 10 mol min"1 produced a significant increase
in arterial pressure. Assuming that measurement of
plasma immunoreactive ET provides a true reflection of
its biological activity, our findings are consistent with the
hypothesis that ET could act as a circulating pressor
agent in patients with renal failure.
In the present experiments in man, ET had no effect
on vasoconstriction in forearm resistance vessels produced
either by NA or LBNP. The latter has been shown to be
a reliable stimulus for reflex sympathetic vasoconstriction
in the upper limb (Ardill et al., 1967) and a moderate
degree of LBNP, as with the 15 mm Hg used in our
experiments, produces constriction of the resistance
vessels of forearm muscle through activation of low
pressure cardiopulmonary baroreceptors (Abboud et
al., 1979; Johnson etal., 1974), with no change in heart
rate or arterial pressure (Johnson el al., 1974). The
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absence of an effect of ET on responses to exogenous
NA in human resistance vessels in vivo indicates that ET
does not affect postsynaptic responses to NA in man,
contrasting with its enhancement of the response to NA
in the rat mesenteric artery (Tabuchi era/., 1989). In the
absence of a postsynaptic action, the lack of an effect of
ET on the response to LBNP suggests that ET does not
affect presynaptic neurotransmitter release in human
resistance vessels in vivo. This contrasts with its effect
on guinea pig femoral artery (Wiklund etal., 1988), and
with the enhancement of responses to LBNP produced
by the pressor peptide angiotensin II via a presynaptic
action (Webb era/., 1988). It is possible, however, that
concentrations of ET close to sympathetic nerves in
vascular smooth muscle, and generated locally by vascular
endothelial cells, may be much higher than those in
plasma. If ET acts predominantly as a local rather than
circulatingmediator, it is not possible to entirely exclude
an effect of ET on peripheral sympathetic function in
man.
In conclusion, the infusion of ET causes constriction
of the resistance vessels in the forearm circulation in
man, producing a slowly progressive effect which is
unique among the known constrictor agents. The concen¬
trations of ET producing vasoconstriction intra-arterially
are similar to those detected in the plasma of patients
with renal failure, suggesting that circulating ET may
contribute to elevated peripheral vascular tone in this
circumstance. Intra-arterial ET does not, however, appear
to affect NA or sympathetically (LBNP) mediated vaso¬
constriction in the human forearm.
References
Abboud, F. M., Eckberg, D. L., Johannsen, U. J. & Mark,
A. L. (1979). Carotid and cardiopulmonary baroreceptor
control of splanchnic and forearm vascular resistance during
venous pooling in man. J. Physiol.. 286, 173-184.
Ardill, B. L., Bannister, R. G., Fentem, P. H., Greenfield,
A. D. M. (1967). Circulatory responses of supine subjects
to the exposure of parts of the body below the xiphisternum
to subatmospheric pressure. J. Physiol.. 193, 57-72.
Boarder, M. R. & Marriott, D. B. (1989). Characterization of
endothelin-1 stimulation of catecholamine release from
adrenal chromaffin cells. J. cardiovasc. Pharmac.. 13
(suppl. 5), S223-S224.
Brown, E., Goei, J. S., Greenfield, A. D. M. & Plassaras,
G. C. (1966). Circulatory responses to simulated gravitational
shifts of blood in man induced by exposure of the body
below the iliac crests to sub-atmospheric pressure. J. Physiol.,
183, 607-627.
Clarke, J. G., Benjamin, N., Larkin, S. W., Webb, D. J.,
Davies, G. J. & Maseri, A. (1989). Endothelin is a potent
long-lasting vasoconstrictor in men. Am. J. Physiol., 257,
H2033-H2035.
Editorial (1988). Yin and yang in vasomotor control. Lancet,
ii, 19-20.
Hughes, A. D., Thorn, S. A. McG., Woodall, N., Schachter,
M., Hair, W. M., Martin, G. N. & Sever, P. S. (1989).
Human vascular responses to endothelin-1: observations in
vivo and in vitro. J. cardiovasc. Pharmac., 13 (suppl. 5),
S225-S228.
Johnson, J. M., Rowell, L. B., Niederberger, M. & Eisman,
M. M. (1974). Human splanchnic and forearm vasocon¬
strictor responses to reductions of right atrial and aortic
pressures. Circulation Res., 34, 515-524.
Koyama, H., Tabata, T., Nishzawa, Y., Inoue, T., Morii, H.
& Yamaji, T. (1989). Plasma endothelin levels in patients
with uraemia. Lancet, i, 991-992.
Tabuchi, Y., Nakamaru, M., Rakugi, H., Nagano, M. &
Ogihara, T. (1989). Endothelin enhances adrenergic vaso¬
constriction in perfused rat mesenteric arteries. Biochem.
Biophys. Res. Comm., 159, 1304—1308.
Vierhapper, H., Wagner, O., Nowotny, P. & Waldhausl, W.
(1990). Effect of endothelin-1 in man. Circulation, 81,
1415-1418.
Webb, D. J., Seidelin, P. H., Benjamin, N., Collier, J. G.,
Struthers, A. D. (1988). Sympathetically mediated vaso¬
constriction is augmented by angiotensin II in man. J.
Hypertension, 6 (suppl. 4), S542-S543.
Whitney, R. J. (1953). The measurement of volume changes
in human limbs. J. Physiol., 121, 1-27.
Wiklund, N. P., Ohlen, A. & Cederqvist, B. (1988). Inhibition
of adrenergic neuroeffector transmission by endothelin in
the guinea-pig femoral artery. Acta physiol. Scand., 134,
311-312.
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y.,
Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. & Masaki,
T. (1988). A novel potent vasoconstrictor peptide produced
by vascular endothelial cells. Nature, 332, 411-415.
(Received 21 August 1990,
accepted 28 November 1990)
Vol. 185. No. 2, 1992 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
June 15, 1992 Pages 630-635
THE POTASSIUM CHANNEL OPENER BRL 38227 INHIBITS BINDING OF
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Binding of [125I]-labelled endothelin-1 (ET-1) to rat cardiac membranes and the effects of
endothelin-1 (ET-1), endothelin-3 (ET-3), the calcium channel antagonist nifedipine, and both
enantiomers of the potassium channel opener cromakalim (BRL 34915) on binding have been
examined. Specific binding of [125I]-ET-1 was inhibited in a concentration dependent manner
by both unlabelled ET-1 (10 12 . io-7 M) and ET-3 (10-12 - 10 6 M). Nifedipine (10"" - 10-5
M) did not affect [125I]-ET-1 binding. However, BRL 38227 (10-H - 10-5 M), the biologically
active isomer of cromakalim, significantly inhibited [1251]-ET-1 binding. The inactive isomer,
BRL 38226 (10-n - lO5 M) had no effect. These findings provide the first evidence for a
stereospecific interaction between BRL 38227 and an ET-1 binding site in rat cardiac
membranes. c 1992 Academic Press, Inc.
The endothelins (ETs) are a recently discovered group of vasoactive peptides. ET-1 is a 21-
amino acid peptide which was first identified in the culture medium of porcine endothelial cells,
and has potent vasoconstrictor properties (1). Binding sites for ET-1 have been identified, in
high density, in areas related to regulation of the cardiovascular system. Pharmacological
studies suggest the existence of at least three distinct ET receptor subtypes based on their
relative affinities for ET isoforms: those which bind ET-1 > ET-3 (the ETa subtype); those
which bind ET-1 and ET-3 with equal affinity (ETb), and those which bind ET-3 > ET-1 (the
proposed ETc subtype). Two ET receptor subtypes (ETA and ETq) have now been cloned (2,
3). One group have identified a single population of specific, high affinity binding sites for
[ labelled porcine ET-1 ([ 1) in rat cardiac membranes, binding to which is
unaffected by a variety of vasoactive compounds: the Ca2+ agonist Bay K8644; the Ca2+
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Copyright © 1992 by Academic Press, inc.
All rights of reproduction in an\ form reserved 630
Vol. 185, No. 2, 1 992 8I0CHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
antagonists nicardipine and cis-diltiazem; Na+-H+ exchange inhibitors; otp and (3j-
adrenoceptor antagonists; angiotensin II; vasopressin; glyceryl trinitrate; and ergometrine (4).
In guinea pig and rat aorta, trachea and pulmonary artery, potassium (K+) channel openers
such as cromakalim (5) and pinacidil (6, 7) inhibit ET-1-induced contractions in a concentration
dependent manner. In vitro studies have also shown that ET-1 attenuates the vasodilator
responses to BRL 38227, the active isomer of cromakalim (8). Cromakalim has also been
shown to prevent ET-1-induced venoconstriction in vivo in human subjects (9). In vivo
studies in the feline pulmonary vascular bed have shown that vasodilatation in response to ET
isopeptides is mediated by K+ channel activation (10). Since ET-1 receptor binding is closely
linked to its biological actions (11), the present study was undertaken to examine the effects of
the K+ channel opener BRL 38227, its inactive stereoisomer BRL 38226, and the Ca2+
channel antagonist nifedipine on [125I]-ET-1 binding to rat cardiac membranes.
Materials and Methods
Cardiac membranes were prepared by an adaptation of methods previously described (4, 12).
Briefly, ventricles from adult male Sprague Dawley rats (250-300 g) were minced into 1 mm
pieces, washed in 50 ml of ice-cold saline, filtered through 20 pm gauze and then homogenised
in 10 ml ice-cold 20 mM NaHCC>3,0.1 mM phenylmethylsulphonylfluoride (PMSF), pH 7.4,
while contained in a tube surrounded in ice, using two 15 s bursts of a Polytron homogeniser
operating at 4/5 maximum speed. The homogenate was centrifuged at 1000 x g for 10 min at
4°C, and the supernatant diluted in ice-cold Tris buffer (50 mM Tris-HCl containing 0.1 mM
PMSF; pH 7.4) to provide a final concentration of 2 mg protein ml1.
Binding was performed in 12 x 75 mm glass tubes, in duplicate for 2 h at 37°C, using 0.5
mg protein per tube. The reaction mixture contained 0.5 nM [125I]-ET-1, prepared by the
chloramine T method (13) with specific activity 500 Ci mmoH, and increasing concentrations
of unlabelled ET-1, unlabelled ET-3, nifedipine, BRL 38227 or BRL 38226 in a final volume
of 0.5 ml. Nifedipine was dissolved in dimethylsulphoxide (DMSO), whereas BRL 38227 and
BRL 38226 were dissolved in ethanol. The final concentration of DMSO or ethanol in the
reaction mixture did not exceed 1.0% (v/v). Non-specific binding was defined in the presence
of 106M ET-1, and was subtracted from the total bound activity to give specific binding.
After incubation for 2 h at 37°C, binding was terminated by the addition of 3 ml of ice-cold
lOmM Tris-HCl buffer containing 6.6% polyethyleneglycol 6000, pH 7.4. Bound and free
[I25i]-ET-1 were separated by rapid filtration across Whatman GF/C glass microfibre filters
(1.2pm retention), thus removing any cytosolic components included in the homogenate after
the low speed spin. The filters were washed 3 times with 10 ml additions of the above buffer,
and the radioactivity of the filters counted (67% efficiency) in a Nuclear Enterprises NE1612
multiwell y-counter. Results are expressed as a percentage of the specific binding in the
presence of [125I]-ET-1 alone (%B/Bo). Statistical significance was determined by two-way
analysis of variance performed using the untransformed data.
ET-1 and ET-3 were obtained from NovaBiochem Ltd. PMSF and nifedipine were obtained
from Sigma Chemical Co. BRL 38227 and BRL 38226 were kind gifts from SmithKline
Beecham Pharmaceuticals. Sephadex G-25 was purchased from Pharmacia Ltd. All other
reagents were obtained from BDH Ltd.
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Results
Rat cardiac membranes incubated with 10"12 - 10~7 M unlabelled ET-1 (Fig 1) showed a
concentration dependent inhibition of [125I]-ET-1 binding (P = 0.0001; n = 8). Binding was
almost completely inhibited in the presence of 10"7 M ET-1. Analysis of data for inhibition of
[125I]-ET-1 binding by unlabelled ET-1 using the non-linear logistic expression Y = MXP/
(Xp + IC5op) (14), yielded values for M, P, and IC50of 93.6 ± 6.1, -0.49 ± 0.10 and 1.56 ±
0.78 nM respectively (Fig 1).
Rat cardiac membranes incubated with 10"12 - 10"6 M ET-3 showed a concentration
dependent inhibition of [125I]-ET-1 binding (P = 0.001; n = 3) with 50% inhibition of binding
at 200 nM (Fig 1).
Incubation of [125I]-ET-1 with BRL 38227 (10"*1 - 10"^ M) also caused a concentration
dependent inhibition of binding (P = 0.042; n = 5) and %B/Bo reduced to 48.9 ± 9.4 % at the
highest concentration of BRL 38227. BRL 38226 and nifedipine (both 10"11 - 10"5 M) had no
effect on binding of [125I]-ET-1 (Fig 2).
Control experiments showed that neither DMSO nor ethanol at 1.0% (v/v) affected [125I]-ET-
1 binding. Incubation of [125I]-ET-1 for 2 h at 37°C followed by separation through a 49 x 1
Figure 1. [125I]-ET-1 binding to rat cardiac membranes in the presence of ET-1 (•) and ET-
3 (O). Mean values; n = 8 for ET-1, n = 3 for ET-3. Vertical bars show s.e. mean.
Inhibition of [1251]-ET-1 binding to rat cardiac membranes in the presence of ET-1 is fitted to
the logistic expression Y = MXP / (Xp + IC50P).
120
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Figure 2. [125I]-ET-1 binding to rat cardiac membranes in the presence of endothelin (•)
nifedipine (▲), BRL 38227 (■) and BRL 38226 (□). Mean values; n = 5. Vertical bars
show s.e. mean.
cm column of Sephadex G-25 showed that there was no significant degradation of [125I]-ET-1.
When membrane preparations were examined under light microscopy no reformed membrane
vesicles were detected.
Discussion
These results demonstrate that binding of [125I]-ET-1 to rat cardiac membranes is inhibited by
unlabelled ET-1 and unlabelled ET-3 (Fig 1); but not by the dihydropyridine Ca2+ channel
blocker nifedipine (Fig 2), in agreement with the previous studies (4). Inhibition of [,25I]-ET-1
binding by unlabelled ET-1 yielded an IC50 of 1.56 ±0.78 nM, a value similar to those
obtained by others (15, 16). The potency of inhibition of [125I]-ET-1 binding by unlabelled
ET-3 was approximately 130 times less than that shown by unlabelled ET-1, a similar order of
potency to that reported previously (17). These results indicate that rat cardiac membranes
preferentially bind ET-1 > ET-3, suggesting the presence of an ETa receptor subtype.
Since analysis of the inhibition of [125I]-ET-1 binding by unlabelled ET-1 (Fig 1) gives a
value for the slope of the logistic fit of substantially less than unity (-0.49; P in the logistic
expression above), this may indicate binding site heterogeneity in the membrane. Functional
evidence for more than one type of endothelin binding site in coronary tissues has been
reported recently (15, 18). Our findings contrast with previous studies (4), which found a
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single population of high affinity sites. However, multiple ET receptors have been described in
rat heart (15), and a recent study which investigated the existence of ET receptor subtypes
using similar binding competition experiments and peptide mapping techniques (16) showed
direct evidence for multiple ET receptors in bovine atrial membranes.
Here, we show for the first time that the K+ channel opener BRL 38227, but not its inactive
isomer BRL 38226, inhibits [125I]-ET-1 binding to rat cardiac membranes in a concentration
dependent manner (Fig 2). This effect contrasts with the lack of effect of a wide range of other
vasoactive substances on binding (4). As no reformed vesicles were found on examination of
the membrane preparations, our findings cannot be explained on the basis of membrane
hyperpolarisation associated with K+ channel opening (19). Furthermore, as BRL 38227 does
not fully inhibit binding, BRL 38227-sensitive and -insensitive [12^I]-ET-1 binding sites may
be present in rat cardiac membranes.
The inhibition of [125I]-ET-1 binding by BRL 38227 may be competitive in nature, and reflect
a direct interaction with a subpopulation of ET-1 binding sites. Alternatively, BRL 38227 may
have an indirect effect, for example, by converting the binding site for ET-1 from a high to a
low affinity state. Our findings are consistent with the previously demonstrated antagonism of
ET-1-induced vasoconstriction in vitro by cromakalim (5) and with our in vivo studies in
humans (9), where cromakalim inhibited venoconstriction at similar concentrations to those
which inhibit [125I]-ET-1 binding in rat cardiac tissue (1-4 |iM). These observations suggest
that there may be a relationship between ET-1 binding to its receptors and the activity of K+
channels.
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Endothelium-dependent modulation of responses to
endothelin-l in human veins
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1. We have investigated whether local vascular pro¬
duction of nitric oxide or prostacyclin regulates veno-
constriction induced by the endothelium-derived pep¬
tide, endothelin-l, in vivo in man.
2. Six healthy subjects received local dorsal hand vein
infusion of endothelin-l for 60min alone or, on two
separate occasions, co-infused with the donator of
nitric oxide, glyceryl trinitrate, or the vasodilator
prostaglandin, prostacyclin. In further studies,
endothelin-l was co-infused with an inhibitor of nitric
oxide production, /V^-monomethyl-l.-arginine, or
after oral administration of the irreversible inhibitor
of prostaglandin production, acetylsalicylic acid
(aspirin).
3. At a low dose (Spmol/min), endothelin-l alone
caused slowly developing and long-lasting veno-
constriction (maximal constriction: 66+ 4%).
Although glyceryl trinitrate partially prevented
endothelin-l-induced venoconstriction (maximum:
33 + 5%), inhibition of nitric oxide production did not
affect endothelin-l-induced venoconstriction (maxi¬
mum: 55 + 4%).
4. Prostacyclin was more effective at blocking the
venoconstriction in response to endothelin-l than gly¬
ceryl trinitrate (maximum: 12 + 3%), and there was
substantial potentiation of endothelin-l-induced veno¬
constriction after pretreatment with aspirin (maxi¬
mum: 90 ±3%).
5. Despite the capacity of nitric oxide to attenuate
responses to endothelin-l, A^-monomethyl-L-arginine
did not potentiate endothelin-l-induced veno¬
constriction, suggesting little or no stimulated produc¬
tion of nitric oxide in human veins. However, the
potentiation of responses to endothelin-l by aspirin
indicates that endothelial production of prostacyclin
attenuates responses to endothelin-l in human veins
in vivo.
INTRODUCTION
Endothelin-l is a 21-amino acid peptide [1], and
is a member of a family of related peptides [2, 3],
Endothelin-l appears to be the predominant iso-
form generated by the vascular endothelium [2],
and is a potent long-lasting vasoconstrictor and
pressor agent in animals [1] and humans [4, 5].
Endothelin-l is more potent and effective as a
constrictor of isolated veins than it is of isolated
arteries [6, 7], and increased venous sensitivity to
endothelin-l can also be indirectly observed in rat
pulmonary and mesenteric vascular beds [8, 9],
Endothelin-l causes transient vasodilatation in
vitro, and hypotension in vivo [10], before the
development of prolonged vasoconstriction and
hypertension. Endothelial denudation of the isolated
rat mesenteric bed abolishes the initial dilatation
caused by endothelin-l, and potentiates the subse¬
quent constriction, suggesting a role for
endothelium-derived dilators in the modulation of
these responses [10]. These dilators may include
prostacyclin [11] and non-prostanoid relaxing
factors, such as nitric oxide [12].
Evidence from studies in vitro and in vivo in
animals has shown that both nitric oxide [13, 14]
and prostaglandins [8, 15, 16] may have a role in
modulation of responses to endothelin-l. However,
the role of the endothelium in the regulation of
responses to endothelin-l has not been investigated
in man. We have therefore examined, in vivo in man,
whether nitric oxide or prostaglandins modulate the
responses of human dorsal hand veins to local doses
of endothelin-l. We have studied responses in
human subjects because the known interspecies
heterogeneity of endothelium-dependent vascular
responses limits the value of extrapolating from
results in animals to man [17], and have used local
doses of drugs because, when given systemically, any
direct vascular action may be obscured by direct
effects on other organs, such as the heart and
kidney. Furthermore, if systemic doses of a drug
were to alter blood pressure, stimulation of cardiac,
hormonal and neurally mediated reflexes would
make any vascular effects difficult to interpret. We
have studied responses in veins because of the
potential clinical relevance of the effects of
endothelin-l on the venous system, in particular in
chronic heart failure [18] and ischaemic heart dis¬
ease [19, 20],
In order to examine whether nitric oxide or
dilator prostaglandins can influence responses to
Key words: aspirin, endothelium, Nc-monomethyl-t-jrginine. nitric oxide, prostacyclin, prostaglandins, veins.
Abbreviations: GTN, glyceryl trinitrate; l-NMMA, N-monomethyk-arginine
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endothelin-1, we have used glyceryl trinitrate
(GTN), an organic nitrate that is converted to nitric
oxide in vascular smooth muscle [2], and the
vasodilator prostaglandin, prostacyclin. We have
then investigated whether endogenous generation of
nitric oxide, or prostaglandins, modulates responses
to endothelin-1, by examining whether inhibitors of




Six healthy male subjects, between 20 and 28
years of age, participated in each of the studies,
which were conducted with the approval of the local
Ethics Review Committee and with the written,
informed consent of each volunteer. Subjects rested
semi-recumbent in a quiet room maintained at a
constant temperature for each study (between 25
and 27°C). The left hand was supported above the
level of the heart by means of an arm rest. A dorsal
hand vein was then selected, as described previously
[21], and a 23 SWG cannula (Abbott) was sited in
this vein in the direction of flow. Local anaesthesia
was not employed. The same dorsal hand vein was
used in each study.
The internal diameter of the dorsal hand vein,
distended by inflation of an upper arm cuff to
30mmHg, was measured by the technique of Aellig
[22], In brief, a magnetized lightweight rod rested
on the summit of the infused vein approximately
1 cm downstream from the tip of the infusion can¬
nula. This rod passed through the core of a linear
variable differential transformer supported above
the hand by a small tripod, the legs of which rested
on the dorsum of the hand, distant from any dorsal
hand vein. If venoconstriction occurs during cuff
inflation, or if the upper arm cuff is deflated with
consequent emptying of the vein, there is a down¬
ward displacement of the lightweight rod. This
displacement causes a linear change in the voltage
generated by the linear variable differential trans¬
ducer, and thus allows determination of the internal
diameter of the vein, after calibration against
standard displacements. Vein size was measured at
5min intervals throughout each study.
Blood pressure was measured in the non-infused
arm using a well-validated semi-automated tech¬
nique (Takeda UA-751 sphygmomanometer) [23].
Recordings were made three times, at lOmin inter¬
vals, before infusion of endothelin-1, with the last
measurement used as basal, and then every 30min
after starting endothelin-1 infusion.
Drugs
Endothelin-1 (NovaBiochem, Nottingham, U.K.)
was administered in a dose of 5 pmol/min, based on
results from previous studies [24]. A single dose was
used because the slow onset and long-lasting action
of endothelin-1 precludes the use of repeated doses
in a single study to examine conventional dose-
response relationships.
GTN (American Hospital Supply, Newbury, Berks,
U.K.) was administered in a dose of 2nmol/min.
GTN exerts its venodilator actions through vascular
generation of nitric oxide, independent of nitric
oxide synthase [2], A dose of 2nmol/min should
maximally reverse constriction of dorsal hand veins,
as it is 100-fold higher than that necessary to
abolish constriction induced by noradrenaline [25],
and is sufficient to cause vasodilatation of the
forearm vasculature when given intra-arterially [26].
However, GTN at 2nmol/min is at least 10-fold
lower than a systemically active dose [27],
NG-Monomethyl-l-arginine (l-NMMA; Nova¬
Biochem), a specific substrate analogue inhibitor of
nitric oxide synthase in animals [12] and man [28],
was administered in a dose of lOOnmol/min. This
dose of l-NMMA has no effect on basal hand vein
size, but prevents venodilatation of noradrenaline-
preconstricted veins by the nitric oxide-releasing
agent acetylcholine [25]. A dose of lOOnmol/min l-
NMMA is approximately 10 times lower than the
intra-arterial doses needed to constrict the forearm
vasculature [28], and is 1000 times lower than doses
used systemically [29].
The vasodilator prostaglandin, prostacyclin
(Wellcome, Beckenham, Kent, U.K.), was adminis¬
tered in a dose of 100 pmol/min. Prostacyclin is the
most potent vasodilator prostaglandin produced by
blood vessels [11], and is a selective venodilator of
the human dorsal hand vein as compared with the
forearm resistance bed [30]. The dose used was
shown in pilot experiments to maximally reverse
noradrenaline-induced venoconstriction, and is suffi¬
cient to cause vasodilatation of the forearm vascul-
ture when given intra-arterially [30]. However, it is
at least 10-fold lower than a systemically active dose
[31].
Aspirin (600 mg, as soluble tablets; Boots,
Nottingham, U.K.) was dissolved in 200 ml of water
and was administered 30min before the start of the
endothelin-1 infusion. Aspirin irreversibly acetylates,
and thus inhibits, fatty acid cyclo-oxygenase
(prostaglandin-endoperoxide synthase, EC 1.14.99.1)
[32], which is responsible for the production of
prostaglandins and thromboxanes. When given at a
dose of 600 mg, aspirin inhibits bradykinin-
stimulated endothelial production of prostacyclin by
at least 85%, with recovery occurring over the next
6h [33]. Platelet thromboxane generation is also
inhibited by this dose of aspirin, although for much
longer periods [33].
All drugs, except for aspirin, were dissolved in
saline (0.9% NaCl; Travenol) and infused through
the venous cannula. The toal rate of infusion was
maintained constant throughout all studies at
0.25ml/min. Where two agents were administered
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simultaneously, the two infusions mixed close to the
cannula.
Study design
Comparison between the effects of different agents
on responses to endothelin-1 was facilitated by use
of the same subjects in five separate studies, each at
least 2 weeks apart. In each of these studies, after
initial saline infusion for 30min, endothelin-1 was
infused for 60min, and was followed by saline
infusion for 30min. On each of four separate
occasions saline placebo, GTN, prostacyclin and L-
NMMA were co-infused with endothelin-1, with this
infusion maintained for 90min (see Fig. 1). In the
remaining study, subjects received a systemic dose
of aspirin orally 30min before the start of the
endothelin-1 infusion. The order of the studies was
as follows: in the first study, subjects received
endothelin-1 with saline placebo; in the second and
third studies, subjects received endothelin-1 with
GTN and L-NMMA, with the order governed by
balanced randomization; in the remaining studies,
subjects received endothelin-1 with prostacyclin and
aspirin, with the order again governed by balanced
randomization.
Data presentation and statistics
Basal vein size was calculated, in mm, as the
mean of the last three measurements taken before
starting endothelin-1 infusion. Vein size during drug
administration was calculated for each lOmin per¬
iod by averaging the two recordings in each period,
and expressed as the percentage change in vein size
from basal. Unless otherwise stated, all results are
expressed as means+SEM. Data were analysed
using a repeated measures analysis of variance,
except when comparing basal vein size and blood
pressures, where Student's paired f-test was used.
Statistical significance was accepted at the 5% level.
RESULTS
All six subjects completed each part of the study.
Internal vein diameter, before infusion of
endothelin-1 and drugs, did not differ significantly
between studies. Basal vein diameter was 1.1+0.1,
1.0 + 0.2, 0.9 + 0.1, 1.1+0.1 and 1.0 + 0.1 mm before
infusion of endothelin-1 with saline placebo, GTN,
L-NMMA, prostacyclin and aspirin, respectively.
Endothelin-1 alone caused a slowly developing
venoconstriction (Fig. 1), with a maximum 66 + 4%
reduction in basal internal vein diameter at 60min
(P = 0.0001 versus basal). Venoconstriction was slow
to reverse, with 55 + 8% venoconstriction still
present 30 min after stopping endothelin-1.
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Fig. I. Responses of veins to endothelin-l alone and with GTN or
prostacyclin. Endothelin-1 was infused intravenously in six subjects with
saline placebo (■, 5pmol/min), and. on separate occasions, with co-infusion
of GTN (O. 2nmol/min) or prostacyclin (#, lOOpmol/min). There was
significantly less venoconstriction during co-infusion of prostacyclin with
endothelin-1 than with GTN.
to endothelin-1 (P = 0.0001 versus basal; P = 0.004
versus endothelin-1 alone), with a maximum
33 + 5% reduction in vein size at 60 min (Fig. 1). By
contrast, the decrease in vein size during infusion of
prostacyclin with endothelin-1 was not significant,
with a 12 + 3% reduction in vein size at 60min
(P = 0.06 versus basal; P = 0.0001 versus endothelin-
1 alone). The response to endothelin-1 during co-
infusion of prostacyclin was significantly less than
that during co-infusion of GTN (P = 0.04).
Co-infusion of L-NMMA with endothelin-1 (Fig.
2) led to a response that was not significantly
different from that to endothelin-1 alone (P = 0.124),
with a 55 + 4% venoconstriction at 60min
(P = 0.0001 versus basal). By contrast, infusion of
endothelin-1 after oral aspirin caused a significantly
greater venoconstriction than endothelin-1 alone
(P = 0.001 versus endothelin-1), with a 91 ±2% veno¬
constriction at 60min (P = 0.0001 versus basal).
There was no significant difference between any of
the basal values for the mean systolic and diastolic
blood pressures, and blood pressure did not change
significantly after administration of any drug (Table
1). There were no significant differences in trends for
blood pressure after administration of endothelin-1
alone compared with endothelin-1 given with each
of the agents investigated.





Table I. Mean systolic and diastolic blood pressures before and
during administration of drugs for each of the studies. Values are
means + SD. There was no significant difference between any of the basal
values (paired t-test) and blood pressure did not change significantly after
administration of any drug (paired t-test).
Blood pressure (mmHg)
Time... Basal 30 min 60 min




Systolic 120 + 4 120 + 6





Systolic 123 + 12 123 + 10





Systolic 121 + 12 120 + 8
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Fig. 2. Responses of veins to endothelin-l alone and with l-NMMA
or after aspirin. Endothelin-l was infused intravenously in six subjects
with saline placebo (■, 5pmol/min). and, on separate occasions, with
co-infusion of l-NMMA (O. lOOnmol/min) or after oral aspirin (#.
600 mg). Aspirin, but not l-NMMA, significantly potentiated
endothelin-l-induced venoconstriction.
DISCUSSION
In these studies, in healthy humans, we have
investigated local modulation of responses to
endothelin-l in hand veins by the endothelium-
derived mediators nitric oxide and prostacyclin. We
have shown that although donation of nitric oxide
by an organic nitrate partially prevents endothelin-
l-induced venoconstriction, inhibition of nitric oxide
synthase does not potentiate venoconstriction in
response to endothelin-l. In contrast with the find¬
ings for nitric oxide, the vasodilator prostaglandin,
prostacyclin, almost completely inhibited responses
to endothelin-l, and inhibition of endogenous
prostaglandin generation markedly potentiated res¬
ponses to endothelin-l. These findings suggest a role
for vascular generation of vasodilator prosta¬
glandins in the modulation of venoconstriction to
endothelin-l in man.
In warm, comfortable, unstressed, semi-recumbent
subjects, human dorsal hand veins have no tone [21,
26] and, in previous studies, have been shown to
exhibit highly reproducible responses to agonists
such as noradrenaline at room temperatures of
between 22 and 26°C [22, 34], The lack of basal
tone contrasts with human forearm resistance ves¬
sels, which have also been used to investigate local
vascular responses. Intrinsic vascular tone is a dis¬
advantage when investigating inhibition by dilator
agents of the effects of constrictors. For example,
brachial artery administration of nicardipine, into a
forearm where the resistance vessels have been
preconstricted with endothelin-l, causes an increase
of forearm blood flow to above basal [4], This
implies that at least some, and perhaps all, of the
effect of nicardipine is mediated against basal arter¬
iolar tone, rather than specifically against vaso¬
constriction to endothelin-l. Other workers have
used an alternative approach to overcome the
problem of basal tone in the forearm vasculature, by
eliciting maximum vasodilatation in response to
intra-arterial nitrates before administration of
endothelin-l [35]. However, this does not remove
all underlying tone, as the maximum forearm blood
flow during post-ischaemia hyperaemia is substan¬
tially greater than that achieved using vasodilator
agents [36]. Also, in the prolonged studies needed
to examine the effects of endothelin-l, the doses of
vasodilators required for these types of forearm
studies may be close to those exerting systemic
effects, with potential for stimulation of reflex neuro¬
humoral responses.
The use of a constant rate of infusion helped to
avoid the possibility that changes in flow through a
vein might alter local release of endothelium-derived
mediators. In any case, changes in flow are unlikely
to have biased our results, as previous studies have
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shown that increasing the rate of infusion by up to
100%, but keeping the dose of drug infused con¬
stant, does not alter dorsal hand vein responses to a
number of agents [22, 26]. The order of studies
performed was not fully randomized, leaving open
the possibility that an order effect may have
occurred. However, tachyphylaxis in response to
endothelin-1 seems unlikely in view of the poten¬
tiated responses to endothelin-1 observed with
aspirin pretreatment late in the study.
In these studies, endothelin-1 alone caused veno-
constriction of slow onset, confirming earlier obser¬
vations [24]; a long biological half-life is confirmed
by the presence of substantial venoconstriction
30min after stopping endothelin-1 infusion (Fig. 1).
This prolonged effect of endothelin-1 contrasts with
the known short-lasting actions of noradrenaline, 5-
hydroxytryptamine and angiotensin II in human
dorsal hand veins [34].
The attenuation of endothelin-1-induced veno¬
constriction by GTN in this study suggests that
nitric oxide can, at least partially, prevent responses
to endothelin-1 in humans. It is of interest that
GTN did not completely prevent responses to
endothelin-1, even at a maximally effective dose, as
nitric oxide-releasing agents are capable of reversing
venoconstriction induced by most other constrictor
agents [26] It is unlikely that our failure to observe
complete prevention of responses to endothelin-1
was due to an inadequate dose, as GTN is maxi¬
mally effective against noradrenaline-induced veno¬
constriction even at doses 100-fold lower than those
used in this study [26]. However, our results are in
accord with studies in vitro, which have demon¬
strated less attenuation of responses to endothelin-1
with the nitric oxide donator sodium nitroprusside
in the saphenous vein than in the human internal
mammary artery [37], The only studies in vivo in
man have examined endothelin-1-induced vaso¬
constriction of the forearm resistance bed, and have
shown no effect of nitric oxide-releasing agents on
arteriolar constriction to endothelin-1 [35].
l-NMMA, at the dose used in this study, has no
effect alone on human hand veins, but maximally
prevents acetylcholine-induced venodilatation [25],
Hand veins, therefore, do not seem to produce nitric
oxide basally, but are capable of generating nitric
oxide when stimulated. Our finding, that L-NMMA
does not potentiate endothelin-1-induced veno¬
constriction, suggests that human dorsal hand veins
do not generate nitric oxide when stimulated by
endothelin-1. This contrasts with previous obser¬
vations using cultured endothelial cells [38], and
studies in the rat pulmonary and mesenteric vascu¬
lar beds [10]. Furthermore, inhibition of nitric
oxide synthase potentiates responses to endothelin-1
in vitro in the rat mesenteric bed [13] and in vivo in
the rat [14], However, there is evidence of heteroge¬
neity between species, with rabbit aorta producing
nitric oxide in response to endothelin-1, whereas pig
coronary artery generates prostacyclin [38], In man,
there is evidence to suggest heterogeneity between
arterial and venous beds in the production of nitric
oxide. Brachial artery administration of L-NMMA
leads to substantial forearm vasoconstriction [28],
whereas L-NMMA alone has no effect on dorsal
hand vein size [25]. This suggests that there is
differential basal production of nitric oxide in the
resistance and capacitance beds of man. As human
saphenous veins in vitro are much less capable of
generating nitric oxide when exposed to platelets
than are internal mammary arteries [39], there may
also be differences between arteries and veins in the
stimulated generation of nitric oxide.
We have demonstrated that prostacyclin mar¬
kedly attenuates venoconstriction induced by
endothelin-1. Previously, studies in vitro have shown
that exogenous prostacyclin can reverse endothelin-
1-induced constriction in human hand vessels,
although preferentially in arteries [40]. In our study,
the relatively greater efficacy of prostacyclin, as
compared with GTN, suggests that the mechanisms
of action of endothelin-1 in veins may be more
sensitive to increases in cyclic AMP than to
increases in cyclic GMP.
The potentiation of endothelin-1-induced veno¬
constriction in our study by aspirin suggests that
endothelin-1 stimulates vascular generation of vaso¬
dilator prostaglandins by the venous endothelium in
man. Previous studies of the effects on responses to
endothelin-1 of cyclo-oxygenase inhibition have
mainly examined the resistance vasculature of ani¬
mals, and have given conflicting results. Although
aspirin pretreatment potentiates renal vaso¬
constriction to endothelin-1 in dogs, it has no effect
on endothelin-1-induced femoral vascular bed con¬
striction [16]. In rats, indomethacin potentiates
endothelin-1-induced mesenteric vasoconstriction,
although it also prevents renal vasoconstriction,
indicating that the peptide may release both dilator
and constrictor eicosanoids in vivo [15], Endothelin-
1-stimulated release of constrictor eicosanoids is
supported by the demonstration that generation of
thromboxane is responsible, in part, for the
endothelin-l-induced venoconstriction of guinea-pig
lung [8], In the only previous study in human veins,
indomethacin did not potentiate responses to
endothelin-1, but these experiments were performed
in vitro [40],
Our results are consistent with data showing that
endothelin-1 stimulates prostacyclin generation in
vitro by cultured endothelial cells [38], dog kidney
[16] and guinea-pig lung [8], Endothelin-1 also
stimulates production of prostaglandin E2 [16], the
other major vasodilator prostaglandin produced by
the vasculature [41], and of the vasoconstrictor
eicosanoid, thromboxane A2 [10]. That aspirin
potentiated, rather than inhibited, venoconstrictor
responses in this study suggests that, on balance,
there is relatively greater production of dilator than
of constrictor eicosanoids in endothelin-1 -
constricted veins. Of the vasodilator prostaglandins,
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prostacyclin is the most likely candidate for the
effects we have observed, since it is the major
prostaglandin product of large blood vessels [42],
whereas prostaglandin E2 is produced predomi¬
nantly in the microvasculature [41, 43]. It would be
of interest to examine whether prostacyclin also
modulates responses to endothelin-1 in the human
resistance vasculature. Unlike L-NMMA [28],
aspirin does not influence basal forearm resistance
vessel tone in man in vivo [44], and therefore results
should be easier to interpret.
There are at least two distinct receptors for
endothelins [3]. The ETA receptor is the predomi¬
nant subtype on vascular smooth muscle, selectively
binding endothelin-1, and accounting for the major¬
ity of the vasoconstrictor actions of the peptide.
Vascular expression of the ETB receptor seems to be
confined to endothelial cells, and stimulation of this
receptor may be responsible for the endothelin-1-
mediated production of vasodilator prostaglandins
that we have demonstrated. The stimulation of
generation of prostacyclin, but not nitric oxide, by
endothelin-1 suggests that there are differences in
the mechanisms of signal transduction for endothe¬
lial production of these two dilator agents. Indeed,
although generation of both nitric oxide and prosta¬
cyclin are dependent on increases in intracellular
free Ca2 + , studies in vitro have shown differences in
the pattern of elevation of intracellular free Ca2 +
required for their production [45].
Elevated plasma concentrations of endothelin-1 in
patients with chronic heart failure [18], together
with our demonstration that endothelin-1 is a
potent long-lasting constrictor of human veins, sug¬
gests that endothelin-1 may contribute to the raised
cardiac filling pressures observed in heart failure.
Circulating endothelin-1 concentrations are also
raised in patients with atherosclerosis, in proportion
to the severity of the disease, with strong immuno-
staining for endothelin-1 in atherosclerotic arteries
[19], These findings, taken with its potent constric¬
tor [6] and mitogenic [46] effects, may indicate a
role for endothelin-1 in atherosclerosis. As athero¬
sclerotic saphenous veins that have been used for
coronary artery bypass grafting have particularly
high immunostaining for endothelin-1 [20], it may
contribute to the high rates of late occlusion of
these grafts [47], Saphenous veins have a relative
deficiency, in vitro, of stimulated nitric oxide pro¬
duction as compared with internal mammary arter¬
ies [39], Thus, with only the production of
prostacyclin to attenuate constrictor influences, and
with the known increased sensitivity of large veins
to endothelin-1 [6], grafted saphenous veins may
be more likely to constrict and thus occlude. It
is interesting to speculate that our findings may
offer a further mechanism whereby prostacyclin-
sparing doses of aspirin may prevent saphenous
vein graft stenosis after coronary artery surgery
[48],
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Endothelin-1 and Aggregation of Human Platelets In Vitro
Mark E. C. Dockrell, William G. Haynes, Brent C. Williams, and David J. Webb
University of Edinburgh, Department ofMedicine, Western General Hospital, Edinburgh, Scotland
Summary: Endothelin-1 (ET-I) is a potent vasoconstrictor
peptide produced by endothelial cells. We investigated
whether ET-1, like other potent endothelium-derived va¬
soactive agents, interacts directly with human platelets in
vitro. Platelet-rich plasma was obtained from healthy male
volunteers and incubated with ET-1 (1 pM) or vehicle
(sodium chloride 154 mM) for 10 min at 37°C. Platelet
aggregation was measured by the Born method, using light
transmittance through the plasma sample as an index of
activation. Although a significant increase in light trans¬
mittance was observed when plasma was incubated with
ET-1 compared with vehicle, (3.8 ± 0.4% versus 2.7 ±
0.2%; n = 24; p = 0.038), this effect was small and is
unlikely to be of biologic significance. To investigate the
possibility that ET-l-stimulated platelet nitric oxide (NO)
synthesis might be masking a direct aggregatory effect of
ET-1, in a second study in six subjects NG-monomethyl-
L-arginine (t.-NMMA, 10 and 100 |xM), an inhibitor ofNO
synthase, was preincubated with the plasma before the
addition of ET-1 (1 nM and 1 p.M). No significant differ¬
ence war. observed whether samples were incubated with
i.-NMMA alone or with i.-NMMA and ET-1. The results
of this study suggest that ET-1 does not have a major
direct effect as a platelet aggregating agent. Key Words:
Human—Platelets—Endothelin-1—Nitric oxide.
Endothelin-1 (ET-1) is a potent 21-amino acid va¬
soconstrictor peptide produced by endothelial cells
(1). Bolus administration of ET-1 causes transient
vasodilation (2) followed by prolonged vasocon¬
striction (1). Whereas the prolonged vasoconstrictor
effects of ET-1 are paracrine and are believed to be
mediated by an ETA receptor subtype situated on
vascular smooth muscle (3), the brief vasodilator ef¬
fects appear to be autocrine and mediated by an F.TB
receptor situated on endothelial cells (4). Vasodila¬
tion can be caused by production of either nitric
oxide (NO), prostacyclin (PGG), or a combination
of the two, depending on the species and the vascu¬
lar bed studied (5,6).
Previous studies have shown that ET-1 inhibits
platelet aggregation in vivo and ex vivo (7,8). As
this is associated with a rise in platelet cAMP, it
has been attributed to endothelial PGE production,
although the effect is only partially attenuated by
indomethacin (7). We examined the direct effects of
ET-1 on human platelets in vitro in the absence of
the influence of other endothelial factors, using
Born aggregometry. To investigate whether platelet
aggregation induced by ET-I is masked by stimula¬
tion of platelet NO synthase, we also performed ex¬
periments in the presence and absence of the NO
synthase inhibitor NCi-monomethyl-l-arginine (l-
NMMA).
METHODS
Subjects were healthy men aged 21 to 44 years (n =
24). None of the participants had taken vasoactive drugs
or drugs known to alter platelet activity, including nonste¬
roidal anti-inflammatory drugs, in the preceding 10 days.
All subjects had abstained from tobacco and alcohol for
a minimum of 2 h, and rested supine for 30 min before
venesection.
The aggregation protocol was based on that described
by Gow et al. (9). Venous blood (54 ml) was drawn
through a 19 SWG steel needle into a polypropylene sy¬
ringe and immediately transferred into six 10-ml tubes,
each containing 1 ml acid citrate dextrose (8 mg/ml citric
acid, 22 mg/ml sodium citrate, 20 mg/ml glucose). Blood
was centrifuged at 110 g for 10 min at room temperature
to obtain platelet-rich plasma (PRP). PRP was removed
and the residue was spun for a further 20 min at 3,000 g
to obtain platelet-poor plasma (PPP). PRP was stored
under 5% C02)95% O: in sealed polypropylene tubes at
room temperature until required. Aggregation was as¬
sessed at 37°C on a six-channel aggregometer (Malin)
linked to a Macintosh computer through a Mac Lab digital
analogue converter.
Experiments were performed according to the method
Address correspondence and reprint requests to Dr. D. J. Webb at University of Edinburgh. Department of Medicine, Western
Cieneral Hospital, Edinburgh ET14 2XU, Scotland.
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of Bom (10). Briefly, the extent of aggregation was calcu¬
lated by the change in light transmittance, where light
transmittance through PRP was taken as 0% aggregation
and that through PPP as 100% aggregation. Aggregometer
recordings were examined for the three classical signs of
platelet activation and aggregation: shape change, pri¬
mary aggregation, and secondary irreversible aggregation.
In the first study in 24 subjects, 900 p.1 of sample was
incubated for 3 min before the addition of 50 p.1 vehicle
(sodium chloride 154 m4f), followed 1 min later by 50 p.1
ET-1 (final concentration I \i.M) or vehicle. In the second
study in six subjects, 900 p.1 of sample was incubated for
3 min before the addition of 50 pi l-NMMA, (final concen¬
trations 10 and 100 pAf) or vehicle, followed 1 min later
by the addition of 50 jxl ET-1 (final concentrations 1 nM
and 1 pM) or vehicle. Responses were followed for 10
min after the addition of ET-1. Both l-NMMA (Sigma
Chemical Co. Ltd, Poole, U.K.) and ET-1 (NovaBio-
chem, Nottingham, U.K.) were dissolved in sodium chlo¬
ride 154 mM. Results are expressed as means ± SEM.
Statistical analysis was by analysis of variance followed
by Student's paired t test where applicable, with a value
of p s 0.05 accepted as significant.
RESULTS
Aggregation was slightly but significantly greater
in the 10-min period after the addition of ET-1 than
after saline (3.8 ± 0.4% and 2.7 ± 0.2%, respec¬
tively; n = 24; p = 0.038). There were no significant
differences in the responses to l-NMMA whether
or not ET-1 was present, showing that l-NMMA did
not unmask aggregation to ET-1 (Table 1). No shape
change or secondary aggregation was observed in
any of these studies.
DISCUSSION
A slight but significant difference in aggregation,
as observed by light transmittance, was noted be¬
tween the control sample and the sample incubated
with ET-1 (1 |xM) in the first study. Such a differ¬
ence is unlikely to be of biological significance and
may not be related to platelet aggregation. It is un¬
likely that a substantial aggregatory effect would
emerge with higher ET-1 concentrations because the
concentration employed was substantially higher
than the Kd for either the ETA or ETB receptor (3,4),
which is in the nanomolar range, and higher than
concentrations associated with biologic activity (5).
TABLE 1. Aggregation, as measured by change in
light transmittance, front coincubation of \-NMMA
with ET-1 or vehicle (n = 6)
Vehicle FT-1 (1 nM) ET-1 (1 pM)
Vehicle 2.3 ± 0.29% —
i -NMMA It) pA/ 3.2 ± 0.42% 3.0 - 0.85% 2.8 ± 0.79%.
i-NMMA 100 pA/ 3.3 ± 0.31% 3.8 ± 0.53% 2.8 ± 0,77%.
From these data it can be concluded that ET-1 has,
at most, very limited aggregating properties and is
unlikely to act directly as an aggregating agent at
physiologic concentrations.
Light transmittance after incubation of platelets
with l-NMMA at concentrations of 10 and 100 pM
was not significantly different in the presence or ab¬
sence of ET-1 at either 1 nM or 1 \iM. This result
excludes the possibility that ETB-mediated stimula¬
tion of NO generation masks a direct aggregatory
effect of ET-1.
Although ET-1 may not stimulate platelet aggre¬
gation directly, there is evidence that it modulates
platelet aggregation initiated by other agonists. ET-
1 can modify epinephrine- (11,12) and thrombin-in-
duced aggregation (13). Dequeker et al. (13) also
demonstrated that endothelin-3 produces a small but
significant decrease in Ca2+ mobilization when
coincubated with thrombin. Stimulation of the ETA
receptor might be expected to mediate phosphati-
dylinositol hydrolysis, resulting in platelet aggrega¬
tion and a concomitant rise in intracellular calcium
[Ca2 + ]i. By activating NO synthase, stimulation of
the ETb receptor might reduce [Ca2 + L and inhibit
platelet aggregation. ET-1 may act like other potent
vasoactive agents, angiotensin II (14) and epineph¬
rine (15), via specific membrane-bound receptors to
modify the actions of other aggregating agents with¬
out directly initiating platelet aggregation. This re¬
quires further investigation.
From our results, we conclude that ET-1 causes
significant but not physiologically relevant platelet
aggregation and that aggregatory effects are not
masked by ETB-mediated NO production.
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Venoconstriction to endothelin-1 in humans:
role of calcium and potassium channels
WILLIAM G. HAYNES AND DAVID J. WEBB
Department of Medicine, Western General Hospital, University of Edinburgh,
Edinburgh EH4 2XU, United Kingdom
Haynes, William G., and David J. Webb. Venoconstric¬
tion to endothelin-1 in humans: role of calcium and potassium
channels. Am. J. Physiol. 265 (Heart Circ. Physiol. 34): H1676-
H1681,1993.—Recent studies in vitro have suggested that there
may be an interaction between endothelin-1 and ATP-sensitive
K+ channels in vascular smooth muscle. Here we have investi¬
gated whether agents acting on membrane Ca2+ and K* chan¬
nels modulate endothelin-l-induced venoconstriction in vivo in
human subjects. In a series of studies, six healthy subjects re¬
ceived, on separate occasions, local infusions into dorsal hand
veins of endothelin-1 coinfused with 1) the ATP-sensitive K+
channel opener, cromakalim; 2) the dihydropyndine Ca2+ an¬
tagonist, nicardipine; 3) a control vasodilator, hydralazine; and
4) saline placebo. Endothelin-1 caused local venoconstriction
with a mmimnm reduction in vein size of 66 ± 4% at 60 min (P
= 0.0001 vs. basal). Cromakalim prevented endothelin-l-in-
duced venoconstriction (9 ± 10% maximum constriction; P =
0.68 vs. basal). By contrast, nicardipine, in a dose sufficient to
block depolarization-induced constriction caused by K+ infu¬
sion, had only a partial effect on endothelin-l-induced venocon¬
striction (35 ± 8% maximum constriction; P = 0.001 vs. basal;
P = 0.02 vs. endothelin-1), whereas a 10-fold higher dose of
nicardipine had no additional effect and hydralazine had no
effect. In further studies, cromakalim, but not nicardipine, re¬
versed endothelin-l-induced venoconstriction. Cromakalim did
not prevent constriction induced by norepinephrine. Although
calcium entry through dihydropyridine-sensitive Ca~~ channels
may account in part for the vasoconstrictor action of endothe-
lin-l in humans, the abolition of endothelin-1 responses by a K+
channel opener suggests additional mechanisms of action for
endothelin-1.
human; in vivo; cromakalim; nicardipine
endothelin-1 is a 21-amino acid peptide produced by
vascular endothelial cells (32) and is a member of a
family of related peptides, the actions of which have
been widely reviewed (14, 27, 29). Endothelin-1 appears
to be the major isoform generated by the vascular endo¬
thelium (14), causing long-lasting constriction of resis¬
tance and capacitance vessels in animals (6) and humans
(5). There is substantial experimental evidence to sug¬
gest that endothelin-1 is involved in the pathophysiol¬
ogy of vasospastic conditions, acute renal failure, and
myocardial infarction (14). Inhibitors of endothelin-1
generation and antagonists of endothelin type A (ETA)
receptors reduce blood pressure in both normotensive
and hypertensive rats, indicating a role for the peptide
in regulation of blood pressure (14).
In view of the characteristically prolonged vasocon¬
strictor effects of endothelin-1, much interest has fo¬
cused on the mechanisms underlying the sustained rise
in free intracellular Ca2+ caused by endothelin-1. It was
initially proposed that endothelin-1 might be an endog¬
enous agonist of the dihydropyridine-sensitive voltage-
operated Ca2+ channel (12, 32). This hypothesis was
based on the similarity in structure of endothelin to
H1676 0363-6135/93 $2.00 Copyright © 19'
peptides that influence membrane ion channels, the an¬
tagonism of endothelin contractions by dihydropyridine
Ca2+ antagonists, an apparent dependence of endothe-
lin-induced contractions on extracellular Ca2+, and in¬
creases in the Ca2+ current in whole cell patch clamping
studies. However, it has since been shown that I) the
effect of dihydropyridine Ca2+ antagonists on endothe-
lin-induced contractions in vitro is noncompetitive (24);
2) contractions to endothelin can still develop, though
to a lesser extent, in the absence of extracellular Ca2+
(2); 3) dihydropyridine Ca2+ channel antagonists are
unable to inhibit the sustained rise in intracellular free
Ca2+ (25); and 4) that endothelin-1 binding is unaf¬
fected by dihydropyridine calcium antagonists (13, 28).
On this basis, it is unlikely that endothelin-1 is an en¬
dogenous agonist at this channel or that entry of Ca2+
into cells occurs solely through indirect activation of
these Ca2+ channels.
However, there is increasing evidence that endothe¬
lin-1 interacts closely with membrane K+ channels. The
ATP-sensitive K+ channel opener, cromakalim, and the
K+ ionophore, valinomycin, antagonize endothelin-1-
induccd contractions of rat aortic strips, whereas the
Ca2+ channel antagonists, verapamil and nicardipine,
are less effective (15). Pinacidil, another K+ channel
opener, reverses cndothclin induced contractions of rat
pulmonary artery (20). Also, endothelin-1 attenuates va¬
sodilator responses to K+ channel openers but not di¬
hydropyridine Ca2+ antagonists (17). In addition, cro¬
makalim has been shown to prevent the systemic pressor
and coronary vasoconstrictor effects of endothelin-l in
dogs (26). The balance of published evidence from in
vitro and in vivo animal studies suggests that openers of
ATP-sensitive K+ channels may be more effective than
other vasodilators, particularly Ca2+ antagonists, at
blocking responses to endothelin-1.
So, with continuing uncertainty regarding the mecha¬
nisms of action of endothelin-1, and its potential patho¬
physiological role in vascular disease, we have investi¬
gated the interaction between endothelin-1 and
membrane ion channels, using an in vivo model in hu¬
mans. Using a well-validated technique (1, 11, 30), we
have examined the effects of endothelin-1 on the venous
tone of human dorsal hand veins, blood vessels in which
endothelin-1 is known to produce vasoconstriction (5).
Studies were performed with endothelin-1 administered
alone or coadministered with vasoactive agents acting
on voltage-operated Ca2+ channels (nicardipine) (23)
and ATP-sensitive K+ channels (cromakalim) (10).
Each of these drugs was given in a dose chosen to be
maximally effective in dorsal hand veins. As a negative
control, we performed separate studies with hydralazine,
which, like dihydropyridine Ca2+ antagonists (22) and
3 the American Physiological Society
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openers of ATP-sensitive channels (30), is a rela¬
tively arterioselective vasodilator (8) but does not ap¬
pear to have effects on membrane ion channels.
METHODS
Sixteen healthy male subjects, between 20 and 38 yr of age,
participated in each of the studies, which were conducted with
the approval of the local Ethics Review Committee and the
written informed consent of each volunteer. Subjects rested
semirecumbent in a quiet room maintained at a constant tem¬
perature for each study (between 25 and 27°C). The left hand
was supported above the level of the heart by means of an arm
rest. A dorsal hand vein was then selected as described previ¬
ously (30), and on each occasion a 23 SWG cannula (Abbott)
was sited in this vein in the direction of flow. Local anesthesia
was not used. Internal diameter of the dorsal hand vein, dis¬
tended by inflation of an upper arm cuff to 30 mmHg, was
measured by the technique of Aellig (1). In brief, a magnetized
lightweight rod rested on the summit of the infused vein — 1 cm
downstream from the tip of the infusion cannula. This rod
passed through the core of a linear variable differential trans¬
former supported above the hand by a small tripod, the legs of
which rested on areas of the dorsum of the hand that were free
of veins. If venoconstriction occurs during cuff inflation, or if
the upper arm cuff is deflated with consequent emptying of the
vein, there is a downward displacement of the lightweight rod.
This displacement causes a linear change in the voltage gener¬
ated by the linear variable differential transformer, and thus
allows determination of the internal diameter of the vein after
calibration against standard displacements. Unless otherwise
stated, vein size was measured at 5-min intervals throughout
each study.
Blood pressure was measured in the noninfused arm using a
well-validated semiautomated technique (UA 751 sphygmoma¬
nometer, Takeda) (31). Recordings were made three times be¬
fore infusion of endothelin-1, with the last pressure used as
basal and then at 30-min intervals after starting endothelin-1
infusion.
The following agents were administered via the local venous
cannula: endothelin-1 (5 pmol/min, Nova Biochem, Notting¬
ham, UK); hydralazine (100 ag/min, Ciba-Geigy, Horsham,
UK), the dihydropyridine Ca2"" antagonist, nicardipine (1.5 and
15 (ig/tnin, Syntex, Maidenhead, UK); the benzopyran ATP-
sensitive K4" channel opener, cromakalim (1 (ig/miii; Smith-
Kline Beecham, Harlow, UK); norepinephrine (4-32 ng/min;
Winthrop, Guildford, UK); K4" chloride (100 mM; Travenol);
and saline (0.9%; Travenol). Endothelin-1 and drugs were dis¬
solved in saline. Ascorbic acid (Evans Medical, Horsham, UK)
was added to norepinephrine solutions, at a final concentration
of 10 Mg/ml, to prevent degradation by oxidation (8). The total
rate of infusion was maintained constant throughout all studies
at 0.25 ml/min.
Five protocols were followed, with the same six subjects com¬
pleting all parts of the first three protocols, four further subjects
completing the fourth protocol, and an additional six subjects
completing the fifth protocol. The first and second protocols
were designed to examine whether the mechanisms underlying
the action of any one of the vasodilators used would prevent or
reverse development of venoconstnction to endothelial. The
third protocol examined whether cromakalim prevents the de¬
velopment of venoconstriction to an alternative venoconstnctor
agent, norepinephrine. The fourth protocol examined whether
nicardipine, at the dose used in the first two protocols, reverses
venoconstriction induced by depolarization produced by infu¬
sion of K4" chloride. The final protocol examined the effects on
endothelin-1-induced vasoconstriction of a dose of nicardipine
10-fold higher than that used earlier.
Protocol I prevention of endothelin-1-induced uenoronstric-
tion. Subjects participated in four separate studies, each at least
2 wk apart. In each of the four studies, after initial saline infu¬
sion for 30 mm. endothelin-1 was infused for 60 min and fol¬
lowed by saline infusion for 30 min. One of the vasodilators,
either hydralazine, nicardipine (1.5 ag/min). cromakalim, or
saline placebo was then coinfused from the start of endothelin-1
infusion, with this second infusion maintained for 90 min (Fig.
1). The two infusions mixed close to the cannula. The order of
the studies was as follows: in the first study, subjects received
endothelin-1 with saline placebo; in the second and third stud¬
ies, subjects received hydralazine and cromakalim, with the or¬
der governed by balanced randomization; in the last 3tudy, sub¬
jects received endothelin-1 coinfused with nicardipine. In this
protocol, hydralazine served primarily as a control dilator be¬
cause it is not understood to act on membrane ion channels or
to act as a venodilator.
Protocol 2: reversed of endothelin-1-induced venoconstriction.
Subjects participated in two separate studies, at least 2 wk
apart. As in the prevention experiments, saline was infused for
30 min, followed by endothelin-1 for 60 min, and then by saline
for 30 min. Nicardipine (1.5 ag/min) or cromakalim was then
coinfused from 45 min after the start of endothelin-1 infusion
and given for 45 min (Fig. 2). The order of these studies was
governed by balanced randomization.
Protocol 3: prevention of norepinephrine-induced venocon¬
striction. Subjects were studied on one occasion only. Initially,
after saline infusion for 30 min, norepinephrine was infused in
incremental doses (2, 4, 8, 16, and 32 ng/min) until a stable
venoconstriction of —50% was achieved. Each dose was given
for 6 min. with vein size measured at the end of this period,
because the effect of norepinephrine has been shown to be maxi¬
mal at this time (8). Norepinephrine was then stopped and.
when vein size had returned to basal, norepinephrine, at the
dose producmg 50% constriction, was reinfused with cromaka¬
lim for 60 min.












Fig 1. Kndothelin-1 (5 pmol/min) was infused intravenously in 6 sub¬
jects with saiine placebo (C) and. on separate occasions, coinfused with
cromakalim I ^g/ann). nicardipine (a. 1.5 ng/min). and hydralazine
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Fig. 2. Endothelin-1 (5 praol/min) was infused intravenously in 6 sub¬
jects with saline placebo (□) and, on separate occasions, with coinfusion
of cromakalim (■, 1 pg/min) or nicardipine (a, 1.5 Mg/min) starting at 45
nun. Cromakalun. but not nicardipine, prevented further development
of endothelin-1-induced venoconstriction after 45 mm.
Four subjects were studied on one occasion only. Initially, after
saline infusion for 30 min, K+ chloride was infused at a con¬
centration of 100 mM for 30 min. Vein size was measured twice
at the end of this period. Nicardipine, at a dose of 1.5 pg/min,
was then coinfused with K*" for 40 mm. with vein size measured
twice at the end of this period.
Protocol 5: high-dose nicardipine and endothelin-1-induced
venoconstriction. Subjects participated in two separate studies,
at least 2 wk apart. As in the prevention experiments, saline was
infused for 30 min, followed by endothelin-1 for 60 min, and
then by saline for 30 min. On the separate study days, high dose
nicardipine (15 pg/min) and saline placebo were then coinfused
with endothelin-1 and given for 90 min The order of these
studies was governed by balanced randomization.
Data presentation and statistics. Basal vein size was calcu¬
lated by taking the mean of the last three measurements before
endothelin-1 infusion and was expressed in millimeters. Vein
size during drug administration was calculated for each 10-min
period by averaging the two recordings in each period and ex¬
pressed as percentage change in vein size from basal. Unless
otherwise stated, all results are expressed as means ± SE. Data
were examined using analysis of variance with statistical testing
by Scheffe's F test, except when comparing basal blood pres¬
sures with those after treatment and vein size in the norepi¬
nephrine and K~ studies, where Student's paired r test was used.
Statistical analyses were performed using STATVIEW 512 +
software for the Macintosh (Brainpower, Calabasas, CA).
RESULTS
Internal vein diameters, before infusion of endothe-
lin-1 and drugs, did not differ significantly between stud¬
ies. In protocol 1, basal vein diameter was 1.1 ± 0.1. 1.0 ±
0.2, 1.2 ± 0.2, and 1.0 ± 0.2 mm before coinfusion of
endothelin-1 with saline, hydralazine, nicardipine, and
cromakalim, respectively. In protocol 2, basal vein diam¬
eter was 1.1 ± 0.1, 1.1 ± 0.2, and 1.2 ± 0.2 mm before
infusion of endothelin-1 with saline, nicardipine, and cro¬
makalim, respectively. In protocols 3 and 4, basal vein size
was 1.1 ± 0.2 and 1.0 ± 0.1 mm, respectively; in protocol
5 vein size was 0.9 ± 0.2 and 0.8 ± 0.2 mm before coin-
fusion of endothelin-1 with saline and high dose nicar¬
dipine, respectively. Endothelin-1 alone caused a slowly
developing venoconstriction (P = 0.0001 vs. basal), with
a maximum 66 ± 4% reduction of basal internal vein
diameter at 60 min (Fig. 1). Venoconstriction was slow to
reverse, with 55 ± 8% venoconstriction still present 30
min after stopping endothelin-1.
Protocol 1: prevention of endothelin-1-induced veno¬
constriction. In these studies (Fig. 1), hydralazine did not
affect endothelin-1-induced venoconstriction (P = 0.0001
vs. basal; P = 0.55 vs. endothelin-1 alone), with a maxi¬
mum 66 ± 8% reduction in vein size at 60 min. Nicar¬
dipine reduced but did not prevent the response to endo¬
thelin-1 (P — 0.01 vs. basal; P = 0.02 vs. endothelin-1
alone), with a maximum 35 ± 8% reduction in vein size at
60 min. Cromakalim prevented venoconstriction, with a
maximum reduction in vein size of only 9 ± 10% at 60
min (P = 0.68 vs. basal; P = 0.001 vs. endothelin-1 alone).
Protocol 2: reversal of endothelin-1 - induced venocon¬
striction. In these studies (Fig. 2) there was no difference
in venoconstriction to the 45-min infusion of endothe¬
lin-1 alone before coinfusion of either nicardipine (47 ±
6%) or cromakalim (39 ± 6%; P = 0.39) nor was there a
difference between these rccponsos and those to endothc
lin-1 with saline placebo at 45 min (50 ± 7%; P = 0.80 vs.
nicardipine; P = 0.23 vs. cromakalim). Coinfusion of
nicardipine did not affect the further development of
endothelin-1-induced venoconstriction, with a reduction
in vein size of 56 ± 2% at 60 min (P = 0.07 vs. endothelin-
1). By contrast, coinfusion of cromakalim reversed endo¬
thelin-1-induced venoconstriction, with a reduction in
vein size of only 31 ± 5% at 60 min (P = 0.0006 vs.
endothelin-1). Interestingly, the rate at which reversal of
endothelin-1 induced constriction occurred when cro¬
makalim infusion was started was similar to that seen
after stopping the infusion of endothelin-1 when given
alone.
Protocol 3: prevention of noreptnephrtne-induced veno¬
constriction. The mean dose of norepinephrine required
to induce a stable venoconstriction of ~50% was 20 ± 5
ng/min (means ± SE; range 8-32 ng/min). In these stud¬
ies, cromakalim did not prevent the development of veno
constriction induced by norepinephrine, with a vein size
of 47 ± 4% of basal with norepinephrine alone, compared
with a vein size of 49 ± 4% of basal (P = 0.23) after 60
min of norepinephrine coinfuccd with cromakalim (Fig
3).
Protocol 4: nicardipine and K~*-induced venoconstric-
tion. Infusion of K+ chloride (Fig. 4) caused a marked
venoconstriction (82 ± 5%). Coinfusion of nicardipine, at
a dose of 1.5 ag/min, abolished this effect, with onlv a 5
± 2% constriction present after 40 min of nicardipine (P
= 0.01 vs. K+ chloride alone).
Protocol 5: high-dose nicardipine and endothelin-1 -in¬
duced venoconstriction. Constriction to endothelin-1 was
still present when nicardipine was infused at a high local
dose (15 i(g/min), with a maximum 29 ± 3% reduction in
vein size at 60 min compared with a 53 ± 6% constriction
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Fig. 3. In reversal experiments, ascending doses of cromakalim (CROM;
0.001-1 ng/'mini were infused into norepinephrine (NE) preconstricted
veins: response to maximum dose (1 ^R/nstn) is shown (data from Ref.
30). In prevention experiments, NE was coinfused with CROM (1 ng/
mm) for 60 min (see METHODS for details). CROM did not reverse or
prevent NE-induced venoconstriction, in contrast to its effect on endo-






















tion of cardiac, hormonal, and neurally mediated reflexes,
making vascular responses difficult to interpret. We
chose to examine responses in human dorsal hand veins
because these vessels have no intrinsic tone (8, 30), unlike
the human forearm resistance vessels that have been ex¬
amined in other studies.
Brachial arterial administration of nicardipine into a
forearm where the resistance vessels have been precon¬
stricted with endothelin-1 causes an increase of forearm
blood flow to levels substantially above basal (5). This
implies that at least some of the effect of nicardipine is
mediated against basal arteriolar tone, rather than spe¬
cifically against vasoconstriction to endothelin-1. A lack
of specificity against endothelin-1 is also supported by
the observation that nicardipine causes greater reversal of
forearm vasoconstriction induced by angiotensin II (5).
Other workers have used an alternative approach to over¬
come the problem of basal tone by eliciting maximum
vasodilatation to intra-arterial Ca2+ antagonists before
administration of endothelin-1 (16). However, this by no
means removes all of the underlying tone, as the maxi¬
mum forearm blood flow during postischemia hyperemia
is substantially greater than that achieved using Ca-'1"
antagonists (3). Also, in the prolonged studies needed to
examine the effects of endothelin 1, the dose3 of vasodi
lators used intra arterinlly arc close to those exerting sy3
temic effects, with potential for stimulation of reflex re
sponscs. By contrast, in hand veins, effective doses arc at
least an order of magnitude lower, and since there is no
Table 1. Mean systolic and diastolic blood pressures
before (basal) and after administration
of drugs for each protocol
Fig. 4. Effect of nicardipine on K "'-induced venoconstriction. K~ ions
(100 mM as KC1) were infused into dorsal hand vein of 4 subjects for 30
min with development of marked venoconstriction. Coinfusion of nicar¬
dipine (1.5 (ig/min) for 40 min caused reversal of venoconstriction.
to endothelial alone (P = 0.03 vs. basal; P — 0.0003 vs.
endothelin-hK«iis response was not significantly differ¬
ent from thai obtained with nicardipine at 1.5 pg/min (35
± 8%; P = 0.32).
Blood pressure. Basal systolic and diastolic blood pres¬
sures were not significantly different between studies and
did not change consistently during any of the studies
(Table 1).
DISCUSSION
In these studies in healthy humans, we have investi¬
gated modulation of responses to endothelin-1 by drugs
that influence membrane ion channels and have shown
that the ATP-sensitive K+ channel opener cromakalim
prevents venoconstriction to endothelin-1. We examined
responses in human subjects because the known interspe¬
cies heterogeneity of endothelium-dependent vascular re¬
sponses limits the value of extrapolating from results in
animals to humans (18). We used local doses of drugs
because, when they are given systemically, the direct vas¬
cular action of these agents may be obscured by stimula-
Treatment Basal 30 Min 60 Min 90 Min
ET-1 (protocols 1 and 2)
Systolic 120±4 120=6 120=6 124=9
Diastolic 69=4 69=7 67=3 69=5
ET-l/cromakalim (protocol 1)
Systolic 117=13 115=9 116=12 118=10
Diastolic 68=5 68=4 68=7 73=3
ET-l/nicardipine (protocol 1)
Systolic 117=8 121=7 121=5 123=5
Diastolic 71=6 73=6 71=7 72=5
ET-l/hydralazine (protocol I)
Systolic 123=12 121 = 11 118=13 116=11
Diastolic 75=8 75=7 72=5 73=9
ET-l/cromakalim (protocol 2)
Systolic 118=7 115=7 116=10 118=8
Diastolic 67=4 68=7 65=5 67=6
ET-l/nicardipine (protocol 2)
Systolic 119=6 116=9 118=11 116=12
Diastolic 70=10 70=9 69=8 69 = 7
NE/cromakalim (protocol 3)
Systolic 116=8 119=6 118=9 1 16 = 4
Diastolic 68=5 69=9 68=6 71=8
K "/nicardipine (protocol 4)
Systolic 121=9 122=8 124=10 -noCI
Diastolic 73 = 7 76=9 80=7 74=9
ET-1 (protocol 5)
Systolic 114=8 117=9 115 = 11 119=10
Diastolic 71=6 69=8 71 ±7 73=9
ET-l/nicardipine (protocol 5)
Systolic 118=9 119=9 121=9 123 = 8
Diastolic 73=6 71=7 70=6 68 = 6
Values are means i SE. ET 1. endothe■1 in -1: NE. norepinephrine
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basal tone, any drug-induced dilatation of endothelin-1 -
induced venoconstriction is likely to be specific.
A single dose of endothelin-1 (5 pmol/min) was used
because the slow onset and long-lasting action of endo¬
thelin-1 precludes the use of repeated doses in a single
study to examine conventional dose-response relation¬
ships (5). The long biological half-life of endothelin-1 was
confirmed by the presence of substantial venoconstric¬
tion 30 min after stopping infusion of the peptide (Fig. 1).
This prolonged effect of endothelin-1 contrasts with the
known short-lasting actions of angiotensin II (7) and nor¬
epinephrine (8) in human dorsal hand veins. In view of
the prolonged action of endothelin-1, it was also imprac¬
tical to use a wide range of doses of cromakalim or nica¬
rdipine against constriction elicited by endothelin-1, so
single maximally effective doses were used. Comparison
between the effects of different agents on responses to
endothelin-1 was facilitated by use of the same subjects in
all studies.
The K+ channel opener cromakalim (1 /ig/min) both
prevented and reversed endothelin-l-induced venocon¬
striction. This effect appears to be selective for endothe-
lin-1, as the same dose of cromakalim neither reverses
(29) nor prevents norepinephrine-induced venoconstric¬
tion (Fig. 3). In earlier experiments, this dose of cromaka¬
lim was sufficient to cause forearm vasodilatation when
infused into the brachial artery (29). Because it is known
that vasodilator doses one to two orders of magnitude
greater than those having effects in the dorsal hand vein
are needed to have effects via the brachial artery (8), the
dose of cromakalim we used should be sufficient to exert
maximal K+ channel opening properties.
The results with cromakalim contrast with the partial
prevention and lack of reversal of endothelin-l-induced
venoconstriction by nicardipine, at a dose which com¬
pletely abolishes K^-induced venoconstriction (1.5 iLg/
min; Fig. 4) and at a 10-fold higher dose (15 jxg/min). It
appears, therefore, that there is a qualitative difference
between responses to nicardipine and cromakalim. Hy¬
dralazine. at a dose previously shown to have modest
venodilator activity in norepinephrine preconstricted
hand veins (8), had no effect on endothelin-l-induced
venoconstriction. Because there was slightly greater
venoconstriction to endothelm-1 in the presence of hy¬
dralazine than to endothelin-1 alone (Fig. 1), the de¬
creased response to endothelin-1 with cromakalim cannot
be attributed to development of tachyphylaxis after re¬
peated exposure to the peptide. The results of these stud¬
ies provide evidence supporting an interaction between
endothelin-1 and ATP-sensitive K+ channels and may
also have implications for the mechanisms of action of
drugs that open these channels. These possibilities are
detailed below.
Mechanisms of action of endothelin-1. These studies
show that endothelin-1 responses in human veins depend
only in part on Ca2+ entry through dihvdropyridine-sen-
sitive Ca2+ channels because the K' channel-opening
drug cromakalim is more effective than the dihydropvri-
dine Ca2* antagonist nicardipine in preventing endothe¬
lial induced venoconstriction Endothelin-1 may addi¬
tionally act to open voltage-operated Ca2'' channels of the
T or N type, which are insensitive to dihydropyridines
but are closed by the membrane hyperpolarization in¬
duced by K"' channel opening (9). However, as nicar¬
dipine completely abolishes K+ induced venoconstric¬
tion, dihydropyridine-sensitive L type channels are likely
to be the predominant voltage-operated Ca2+ channels in
the vascular smooth muscle of human hand veins. Alter¬
natively, endothelin-1 may act through a receptor-oper¬
ated Ca2-f channel that is closed by the hyperpolarization
induced by opening of K+ channels (9). Our results would
also be consistent with endothelin-1 acting as a direct
antagonist at ATP-sensitive K+ channels, with mem¬
brane depolarization then causing vasoconstriction by
mechanisms additional to opening of voltage-operated
Ca2+ channels. Mechanisms that may be linked to depo¬
larization and contribute to endothelin-l-induced veno¬
constriction include changes in other ion transport
mechanisms and activation of protein kinase C (14). In¬
deed, endothelin-1 has recently been shown to close ATP-
sensitive K+ channels, and thus cause membrane depo¬
larization, in electrophysiological studies of porcine
coronary arterial smooth muscle cells (19).
Mechanisms of action of cromakalim. Drugs that open
ATP-sensitive K+ channels include the established hy¬
potensive agents minoxidil and diazoxide, as well as
newer drugs such as pinacidil and cromakalim (10).
Opening of these channels allows the efflux of K+ ions,
leading to membrane hyperpolarization and consequent
closure of dihydropyridine-sensitive voltage-operated
Ca2+ channels (21). It is generally believed that the va¬
sodilator effects of K' channel openers are mediated
through the closure of these Ca2+ channels. However,
these studies in dorsal hand veins suggest that the vaso¬
relaxant actions of K~ channel openers do not depend
solely on closure of dihydropyridine-sensitive Ca2+ chan¬
nels and that other actions must be invoked (10). ATP-
sensitive K+ channel openers have been shown to impair
both the release of Ca2' from intracellular stores and the
replenishment of these stores (4, 21). so K' channel open¬
ers may modulate intracellular Ca2^ fluxes and so prevent
endothelin-1 induced rises in cytosolic Ca2*". This possi¬
bility is rendered less likely by our demonstration that
cromakalim has no effect on constriction induced by nor¬
epinephrine, which exerts at least some of its contractile
actions through release of Ca2"1" from intracellular stores.
Recent studies have shown that binding of endothelin-1
to rat cardiac membrane preparations is inhibited by the
active enantiomer of cromakalim, levcromakalim but not
by the inactive enantiomer, D-cromakalim (28). Such dis¬
placement of endothelin-1 receptor binding might occur
through a direct interaction with the K+ channel opening
drug or by an allosteric interaction between the endothe¬
lial receptor and the ATP-sensitive K+ channel. Hence,
an alternative additional action of cromakalim may in¬
volve inhibition of endothelin-1 binding to the vascular
smooth muscle of human dorsal hand veins. The finding
that the rate of reversal of constriction by cromakalim
was similar to that seen after halting the infusion of
endothelin-1 alone (Fig. 2), would be consistent with an
effect on endothelin-1 binding.
ION CHANNELS AND ENDOTHELIN-1 H1681
We have demonstrated an important interaction be¬
tween ATP-sensitive K+ channels and endothelin-1 in
vivo in humans. Our findings suggest that the mecha¬
nisms of action of endothelin-1 may include closure of
ATP-sensitive K+ channels and offer insights into differ¬
ences between K* channel-opening drugs and Ca2'" an¬
tagonists. Because endothelin-1 may play a role in the
pathogenesis of a variety of cardiovascular disorders, it is
possible that K* channel-opening drugs may offer novel
therapeutic benefits in these diseases.
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Contribution of endogenous generation of endothelin-1 to basal
vascular tone
William G Haynes, David J Webb
Summary
Endothelin-l is an endothelium-derived vasoconstrictor
peptide, possibly involved in the pathophysiology of
cardiovascular disease. We examined the contribution of
endogenously generated endothelin-1 to maintenance of
peripheral vascular tone in healthy subjects by local intra¬
arterial administration of an inhibitor of endothelin converting
enzyme, phosphoramidon, and of a selective endothelin
receptor A antagonist, BQ-123.
Brachial artery infusion of local doses of proendothelin-1,
the precursor to endothelin-1, caused a slow-onset dose-
dependent forearm vasoconstriction which was abolished by
co-infusion of phosphoramidon. Phosphoramidon did not
affect responses to endothelin-1. Phosphoramidon caused
slow-onset vasodilatation when infused alone, with blood flow
increasing by 37% at 90 min (p = 0 03). Vasoconstriction to
endothelin-1 was abolished by co-infusion of BQ-123
(p = 0 006), with forearm blood flow tending to increase.
Infusion of BQ-123 alone caused progressive vasodilatation,
with blood flow increasing by 64% after 60 min (p = 0 007).
These results show that endogenous production of
endothelin-1 contributes to the maintenance of vascular tone.
Endothelin converting enzyme inhibitors and receptor
antagonists may have therapeutic potential as vasodilators.
Lancet 1994; 344: 852-54
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Introduction
Endothelin-1 is an endothelium-derived 21-aminoacid
peptide with sustained vasoconstrictor actions.1 It is
generated from a 38-aminoacid precursor,
proendothelin-1, through the action of endothelin-
converting enzyme (ECE), a membrane-bound neutral
metalloprotease inhibited by phosphoramidon.2'3
Endothelin-1 binds to at least two receptors:4 the ETa
receptor appears to be the major receptor causing
vasoconstriction in arteries, the ETr receptor mediates
release of endothelium-dependent vasodilator substances
and is also present in some resistance and capacitance
vessels where it contributes to vasoconstriction.
Endothelin-1 may play a part in the pathophysiology of
several conditions associated with vasoconstriction,
including chronic heart failure, hypertension, Raynaud's
disease, and renal failure.4,5 Inhibitors ofECE, and recently
described antagonists of endothelin receptors, may
therefore have potential as vasodilator drugs.5 However, the
contribution of endogenous endothelin generation to
resistance vessel tone in human beings is not known. We
examined the effects of local inhibition of ECE and
antagonism of the ETa receptor on forearm blood flow.
Methods
18 healthy men, 21-37 years old, participated in these studies,
which were conducted with the approval of the Lothian ethics
review committee and with the written, witnessed, informed
consent of each volunteer. All subjects abstained from vasoactive
drugs for 1 week, from alcohol for 24 hours, and from food,
caffeine-containing drinks, and tobacco for 3 hours before each
study. Subjects rested recumbent in a quiet room maintained at a
constant temperature of24-26°C. A 27 G cannula was inserted into
the brachial artery of the non-dominant arm under local
anaesthesia for drug infusion. Local doses ofendothelin-1 (Clinalfa
AG, Liiufelfingen, Switzerland), proendothelin-1 (Clinalfa AG),
the ECE and neutral endopeptidase inhibitor phosphoramidon
(Clinalfa AG), the neutral endopeptidase inhibitor thiorphan
(NovaBiochem, Laufelfingen, Switzerland), and the ETa
antagonist BQ-123 (Cyclo[—D-Asp—L-Pro—D-Val—L-Leu—
D-Trp—]; American Peptide Company, Sunnyvale, CA, USA)
were dissolved in 0-9% saline and infused intra-arterially at a
constant rate of 1 mL/min. Blood flow was measured in both
forearms by venous occlusion plethysmography before and at
5 min interval after dosing.' Blood pressure was measured in the
non-infused arm before and at 10 min intervals after dosing with a
Takeda UA-751 semi-automated sphygmomanometer (Takeda
Medical Inc, Tokyo, Japan).
6 subjects received, on six separate occasions and in random
order, proendothelin-1 (5, 15, or 50 pmol/min) given alone for 90
min, proendothelin-1 (50 pmol/min) given for 90 min with
phosphoramidon (30 nmol/min) for the first 60 min, endothelin-1
(5 pmol/min) given alone for 90 min, and endothelin-1 (5
pmol/min) given for 90 min with phosphoramidon (30 nmol/min)
for the first 60min (table). A second group of 6 subjects received on
two separate occasions phosphoramidon alone and thiorphan







Proendothelin 1 (5 pmol/min)
Proendothelln 1 (15 pmol/nwi)
Proendouwin 1 (50 pmol/min)
Proen**helin 1 (50 pmol/min) and
P6ospnonnudon (30 nmol/min)4
Emtthslin1 (5 pmol/min)
Endolhoiinl (5 pmol/min) and
Phosphoramidon (30 nmol/min )j
-6 ( - 18 to 7)
- 8 ( - 18 to 2)
- 33 ( - 49 to - 17)*
0( - 11 to 10)t
28 ( -40 to - 17)*
- 24 ( -43 to - 6)1
- 2 (-17 to 14)
- 13 ( -21 to -5)*
- 42 ( 55 to 29)*
20 ( 36 to 4)tt
- 41 (-58 to - 24)*
-36 (-51 to -21)*
*p<0 01 w proendothdin 1 (50 pmol/min) atone-. tp< 0 01 vs basal; tp<0 05 vs basal;
Iphosphoromidon baited at 60 min in these studies
Table-. Effects of proendothelln-1 end endothelln-L, alone or
coinfused with phosphoramldon, on (vsnge forearm blood flow
alone, both at 30 nmot/min for 90 min. A further 6 subjects
received, on three separate occasions and in random order,
endothelin-1 (5 pmol/min) given alone for 90 min, cndothelin-1 (5
pmol/min) given for 90 min with BQ-123 (100 nmol/min) for the
first 60 min, and BQ-123 (100 nmol/min) given alone for 60 min
followed by saline for 30 min. The doses of phosphoramidon and
BQ-123 were chosen to achieve local concentrations in the forearm
that were equivalent to the ICS0 of phosphoramidon for ECE and
10-fold higher than the pA2 at the ETa receptor respectively.'-7
Percentage change from basal values in the ratio of blood flow
between infused and non-infused arms was calculated with blood
flow in the non-infused arm as a concurrent control.* These results
are shown as means with 95% CI in the table, and with standard
errors in the figures. Because serial measurements were made with
each treatment, mean responses over each infusion period were
calculated as a summary measure to avoid making multiple
comparisons." Data were analysed by paired t tests.
Results
Systolic, diastolic, and mean arterial pressure, heart rate,
and blood flow in the non-infused arm did not change
significantly after infusion of any study agent, confirming



































Figure 2; Forearm blood flow after Intra-arterlal Infusion of
endothelln-1 and BQ-123
Vasoconstriction to intra arterial endothelin-1 is abolished by intra arterial
infusion of BQ 123 (0 = 0 006 vs endothelin-1). BQ 123 alone causes
progressive forearm vasodilatation (p = 0 007).
Blood flow in the infused arm was progressively reduced
by endothelin-1 and proendothelin-1, reaching a maximum
at 60-90min (table). The effect ofproendothelin-1 was dose
dependent. Phosphoramidon prevented vasoconstriction
by proendothelin-1. Stopping phosphoramidon infusion
after 60 min resulted in vasoconstriction. Comparing
individuals, endothelin-1 was 11-fold more potent as a
constrictor of the forearm bed than proendothelin-1 (95%
CI; 4 to 18 fold). Infusion of phosphoramidon alone
resulted in progressive forearm vasodilatation (figure 1). In
contrast, infusion of the same dose of thiorphan caused
vasoconstriction (figure 1). Coinfusion of BQ-123 with
endothelin 1 prevented vasoconstriction, even after halting
BQ-123 at 60 min, and infusion of BQ-123 alone caused
forearm vasodilatation (figure 2).
Discussion
O BQ-123 (100 nmol/min)
and endothelin-1 (5 pmol/min)
• Endothelin-l (5 pmol/min)
We have shown that local inhibition of the generation or
actions of endothclin 1 causes forearm vasodilatation; thus
demonstrating, for the first time, a physiological role for
endogenous generation of endothelin-1 in regulation of
vascular tone.
Proendothelin-1 caused a dose-dependent forearm
vasoconstriction that was blocked by phosphoramidon,
suggesting that the effects of the precursor are mediated
through conversion to the mature peptide by ECE. Because
circulating blood does not show ECE activity,' conversion
in the forearm probably occurs through the action of ECE
within the forearm blood vessels. The approximately
10-fold lower potency of proendothelin-1 as a constrictor
30-
I I I I I I 1 1 1
30 15 0 15 30 45 60 75 90
Time (m.n)
Figure 1 Forearm blood flow after Intra arterial infusion of
phosphoramidon and thiorphan
Phosphoramidon produces progressive vasodilation (p 0 03), whereas
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than endothelin-1 suggests that local ECE converts
about 10% of luminally presented proendothelin-1 to
endothelin-1.
The finding that phosphoramidon alone caused
forearm vasodilatation suggests that generation of
endothelin-1 provides an important contribution to the
maintenance of basal vascular tone. Thiorphan, a relatively
selective neutral endopeptidase inhibitor,310 caused
vasoconstriction, perhaps because of impaired breakdown
of constrictor peptides, such as angiotensin II and
endothelin-1. Thus, inhibition of neutral endopeptidase
cannot explain the vasodilatation we observed to
phosphoramidon, which is probably due to inhibition of
ECE. Indeed, vasodilatation to phosphoramidon through
ECE inhibition may be offset to some degree by
vasoconstriction through inhibition of neutral
endopeptidase.
Vasodilatation caused by local infusion of the specific and
ET-selective receptor antagonist BQ-1231112 confirms and
extends the findings with the ECE inhibitor. The results
with BQ-123 show that endogenous generation of
endothelin-1 maintains vascular tone through activation of
ETs receptors. However, ETb receptors may also mediate
vasoconstriction. Our results extend the findings of animal
studies, in which infusions of phosphoramidon or BQ-123
decrease blood pressure by about 10% in both
normotensive and hypertensive rats.312 14
Our study shows that a phosphoramidon-sensitive ECE
is present in resistance vessels and that endogenous
generation of endothelin-1 contributes to maintenance of
basal vascular tone in human beings, acting (at least in part)
through ETa receptors. Orally active ECE inhibitors and
endothelin-receptor antagonists may therefore have
potential as vasodilators in the treatment of hypertension
and heart failure.515
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Endothelin ETA and ETB Receptors Cause
Vasoconstriction of Human Resistance and
Capacitance Vessels In Vivo
William G. Haynes, BSc, MD, MRCP; Fiona E. Strachan, BN, RGN; David J. Webb, MD, FRCP, FFPM
Background The role of endothelin FTB receptors in medi¬
ating vasoconstriction in humans is unclear As yet, there have
been no in vivo studies in resistance vessels, and in vitro data
have been contradictory. We therefore investigated the func¬
tion of ETb receptors in vivo in human forearm resistance and
hand capacitance vessels using endothelin-1 as a nonselective
agonist at ETA and ETB receptors and endothelin-3 and
sarafotoxin S6c as selective agonists at the ETB receptor.
Methods and Results A series of single-blind studies were
performed, each in six healthy men. Brachial artery infusion of
endothelin-1 and endothelin-3 caused slow-onset dose-depen¬
dent forearm vasoconstriction. Although endothelin-3 caused
significantly less forearm vasoconstriction than endothelin-1 at
low doses, vasoconstriction was similar to the two isopeptides
at the highest dose (60 pmol/min). Endothelin-3 caused tran-
The endothelins are a family of 21-amino-acidpeptides with potent and characteristically sus¬taine vasoconstrictor and vasopressor actions.1
Endothelin-1 is the predominant isopeptide generated
by the vascular endothelium.2 Endothelin-2 and endo-
thelin-3 are more difficult to detect in humans and are
probably less important in their cardiovascular effects.
Two specific receptors for the endothelins have been
isolated by in vitro expression of cloned human cDNA.3 4
The ETa receptor has a high affinity for endothelin-1,
with a K, of 0.6 nmol/L for endothelin-1 compared with
140 nmol/L for endothelin-3.5 ETA receptor mRNA was
initially reported to be highly expressed in human aorta
but not cultured human endothelial cells, suggesting
selective vascular expression of this receptor in smooth
muscle cells.3 The ETB receptor has equal affinity for all
three endothelins, with K, values for endothelin-1 and
endothelin-3 of 0.12 and 0.06 nmol/L, respectively.5 The
ET„ receptor has been reported to be highly expressed in
cultured endothelial cells4 but not vascular smooth mus¬
cle cells.6
On the basis of the greater vasoconstrictor potency of
endothelin-1 than endothelin-3 and the apparently ex¬
clusive expression of ETA receptors in vascular smooth
muscle, vasoconstriction to endothelin-1 was initially
thought to be mediated solely by vascular smooth muscle
cell ETa receptors. Vascular ETB receptors located on
endothelial cells were thought only to mediate generation
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sient forearm vasodilatation at thia dose, whereas cndothclin 1
showed only a nonsignificant trend toward causing early vaso
dilatation. Intra-arterial sarafotoxin S6c caused a progressive
reduction in forearm blood flow, although less than that to
endothelin-1 (P=.04). Dorsal hand vein infusion of sarafotoxin
S6c caused local venoconstriction that was also less than that to
endothelin-1 (P=.002).
Conclusions Selective ETB receptor agonists cause constric¬
tion of forearm resistance and hand capacitance vessels in vivo in
humans, suggesting that both ETA and ET„ receptors mediate
vasoconstriction. Hence, antagonists at both ETA and ETB recep¬
tors, or inhibitors of the generation of endothelin-1, may be
necessary to completely prevent vasoconstriction to endogenously
generated endothelin-1. (Circulation. 1995;92:357-363.)
Key Words • endothelin • vasoconstriction • vessels
of endothelium-derivcd dilator substances. More recent
evidence suggests that ETB receptor mRNA is expressed in
human vascular smooth muscle obtained from the aorta,
pulmonary artery, and coronary artery,7 consistent with a
potential vasoconstrictor role for this receptor. Indeed, in
animals, there is functional evidence for ETB receptor-
mediated vasoconstriction in vitro, particularly in venous
tissue.813 In addition, selective ETU receptor agonists have
pressor effects in animals in vivo.1214"16 However, the
contribution of ETB receptors to vasoconstriction is vari¬
able and appears to depend markedly on species, vessel
type, and vessel size.17 Furthermore, the functional signifi¬
cance of such vascular smooth muscle ETB receptors in
humans is unclear, with in vitro studies reporting that ETB
receptors make either a minimal1117-24 or, at most, a
moderate contribution25 27 to vasoconstriction, depending
on the types of vessel studied.
The relevance of this issue is emphasized by the recent
development of both selective and nonselective antago¬
nists at ETa and ET„ receptors. For example, selective
ETa receptor antagonists will block vasoconstriction
mediated by ETA receptors but may not block all con¬
striction to endothelin-1 if there are also vasoconstrictor
ETb receptors. However, if the putative constrictor ETB
receptor is relatively unimportant in humans, then
blocking both ETA and ETB receptors may cause less
vasodilatation than blocking the ETA receptor alone,
because such receptor antagonists will also block the
endothelial dilator ET„ receptor.
In view of the inconsistent results with and the poten¬
tial disadvantages of in vitro studies, we investigated the
function of endothelin ETA and ET„ receptors in blood
vessels in vivo in humans. We used endothelin-1 as a
nonselective agonist at ETA and ETh receptors and
endotheiin-3 and sarafotoxin Sbc as selective ET„ receptor
annnists: these nentides have about 2000- and 300 000-
358 Circulation Vol 92, No 3 August I, 1995
fold selectivity, respectively, for the ET„ over the ETA
receptor.528 Using locally active doses of these agents,
we assessed responses both of resistance vessels, using
brachial artery administration,29 and of capacitance ves¬
sels, using dorsal hand vein administration.30 32 We used
local doses of peptides so that interpretation of the
results would not be confounded by direct effects of
systemic administration on kidney, heart, or brain or by
reflex effects consequent to changes in blood pressure.
Methods
Subjects
Twenty-four healthy male subjects between 22 and 38 years
of age participated in these studies, which were conducted with
the approval of the Lothian Medicine and Clinical Oncology
Ethics of Medical Research Subcommittee and with the written
informed consent of each subject. No subject received vasoac¬
tive or nonsteroidal anti-inflammatory drugs in the week before
each phase of the study, and all abstained from alcohol for 24
hours and from food, caffeine-containing drinks, and cigarettes
for at least 3 hours before any measurements were made. All
studies were performed in a quiet room maintained at a
constant temperature of between 22°C and 25°C.
Drugs
Pharmaceutical-grade endothelin-1 (Clinalfa, NovaBio-
chem), endothelin-3 (Clinalfa), and sarafotoxin S6c (Sigma
Chemical Co Ltd) were administered. A single dose of each
peptide was used in individual studies because the slow onset
and long-lasting action of the endotheiin isopeptides preclude
the use of repeated doses in a single study to examine
conventional dose-response relations.33 The peptides were
dissolved in physiological saline (0.9%; Baxter Healthcare Ltd).
Intra-arterial Administration
The left brachial artery was cannulated under local anesthe¬
sia (1% lignocaine; Astra Pharmaceuticals) with a 27-standard
wire gauge steel needle (Coopers Needle Works) attached to a
16-gauge epidural catheter (Portex Ltd). Patency was main¬
tained by infusion of 0.9% physiological saline via a Welmed
P1000 syringe pump (Welmed Clinical Care Systems). The
total rate of intra-arterial infusion was maintained constant
throughout all intra arterial studies at 1 mL/min.
Intravenous Administration
A vein on the dorsum of the left hand was cannulated in the
direction of flow with a 23-gauge butterfly needle (Abbott)
attached to a 16-gauge epidural catheter, without use of local
anesthesia. The same vein was used in each subject for each
individual study. Patency was maintained by infusion of 0.9%
physiological saline via a Welmed P1000 syringe pump. The
total rate of intravenous infusion was maintained constant
throughout all studies at 0.25 mL/min.
Measurements
Forearm Blood Flow
Blood flow was measured in the infused and noninfused
forearms by venous occlusion plethysmography34 using indium/
gallium-in-Silastic strain gauges29 that were securely applied to
the widest part of each forearm. The hands were excluded from
the circulation during each measurement period by inflation of
a wrist cuff to 220 mm Hg. Upper-arm cuffs were intermittently
inflated to 40 mm Hg for 10 in every 15 seconds to temporarily
prevent venous outflow from the forearm and thus obtain
plethysmographic recordings. Recordings of forearm blood
flow were made repeatedly over 3-minute periods unless oth¬
erwise staled. Voltage output from a dual-channel Vasculab
SPG 16 strain-gauge plethysmograph (Medasonics Inc) was
transferred to a Macintosh personal computer (Classic II,
Apple Computer Inc) with a MacLab analog-to-digital con-
v.-rtiT and ( maim software (v. 3.2 H- both from AT) Instru¬
ments). Calibration was achieved by use of the internal stan¬
dard of the Vasculab plethysmography unit.
Dorsal Hand Vein Diameter
The left hand was supported above the level of the heart by
means of an arm rest. The ID of the dorsal hand vein,
distended by inflation of an upper arm cuff to 30 mm Hg, was
measured by the technique of Aellig.30 In brief, a magnetized
lightweight rod rested on the summit of the infused vein = 1 cm
downstream from the tip of the infusion cannula. This rod
passed through the core of a linear variable differential trans¬
former (LVDT; model 025 MHR, Lucas Schaevitz Inc) sup¬
ported above the hand by a small tripod, the legs of which
rested on areas of the dorsum of the hand free of veins. If
venoconstriction occurred while this cuff was inflated or if the
cuff was deflated with consequent emptying of the vein, there
was a downward displacement of the lightweight rod that
caused a linear change in the voltage generated by the LVDT.
The voltage output from the LVDT was transferred to a
Macintosh personal computer by use of a MacLab analog-to-
digital converter and chart software. Standard displacements
were used to calibrate the LVDT to determine the ID of the
vein.
Blood Pressure
A well-validated semiautomated noninvasive oscillometric
sphygmomanometer (Takeda UA 751, Takeda Medical Inc)
was used to make duplicate measurements of blood pressure in
the noninfused arm.33
Study Design
Four single-blind studies were performed, with the experi¬
mental subjects but not the investigators blinded to the peptide
and dose administered in each study.
Forearm Resistance Bed Protocols
Subjects rested recumbent throughout each study. Strain
gauges and arm cuffs were applied, and the left brachial artery
cannula was sited. Saline was infused for 30 minutes, during which
two measurements of forearm blood flow were made (at -20 and
-10 minutes). Blood pressure was measured immediately after
each forearm blood flow measurement, thereby avoiding any
effect on forearm blood flow measurements of the venous con¬
gestion caused by this procedure.36 Three protocols were then
followed, each in separate groups of subjects, els follows.
Protocol I: Low-dose intra-arterial endothelin-1 and endothe¬
lin-3. On four separate occasions, in random order, six subjects
received brachial artery infusion of endothelin-1 and endothe¬
lin-3 at 1 and 5 pmol/min, each for 60 minutes. The choice of
doses was based on previous work showing, in vivo, that 5
pmol/min of endothelin-1 causes slow-onset vasoconstriction in
human forearm resistance vessels, reducing blood flow by
=40%.29-33 Forearm blood flow was recorded from 3 minutes
before to 5 minutes after the endotheiin infusion was begun.
Thereafter, measurements were made at 5-minute intervals for
60 minutes. Blood pressure was measured 60 minutes after the
infusion was begun.
Protocol 2: High-dose intra-arterial endotheiin-1 and endothe-
lin-3. On two separate occasions, in random, balanced order,
six subjects received endothelin-1 and endothelin-3 via the
brachial artery at 60 pmol/min for 5 minutes, followed by
physiological saline for 55 minutes. Because no significant
vasodilatation had been observed in previous studies using
intra-arterial endothelin-1 at 5 pmol/min,29-33 we chose a dose
of 60 pmol/min with the intention of stimulating sufficient
endothelial generation of dilator substances to cause vasodila¬
tation before the development of vasoconstriction. Forearm
blood flow was recorded from 3 minutes before to 10 minutes
after the endotheiin infusion was begun. Thereafter, measure¬
ments were made at 5-minute intervals for 60 minutes. Blood
pressure was measured 10 and 60 minutes after the infusion
was het'iin
Haynes et al ET„ Receptor Function in Humans 359
Table 1. Mean Arterial Pressure, Heart Rate, and Forearm Blood Flows Before
and After Brachial Artery Administration of Peptides in the Two Study Protocols
(1 and 2) Comparing Endothelin-1 and Endothelin-3















Basal 89±5 88±6 90 ±5 88±4 87 ±5 83±4
10 min 89±6 87 ±3
60 min 91 ±6 89±7 89±4 86±4 89±6 90±4
HR, bpm
Basal 65±4 66 ±3 67 ±5 66±4 66±2 66±2
10 min 63±4 65±3
60 min 71 ±6 67 ±4 68±6 62 + 5 64±5 65±2
Infused FBF,
mL-100
mL"1 • min '
Basal 3.9±0.9 4.0±0.7 3.9±0.9 4.4±1.3 3.7 ±0.6 3.0±0.3
60 min 3.4±0.9 3.7 ±0.8 3.1+1.0 3.3±0.5 3.2 + 0.4 2.4±0.3
Noninfused FBF,
mL -100
mL 1 ■ min 1
Basal 3.0 + 0.5 3.2±0.5 3.0±0.5 4.1 ±0.6 3.4±0.7 3.3±0.2
60 min 2.8±0.5 3.1 ±0.6 3.9 + 0.9 4.0±1.0 3.6±0.6 3.7±0.6
ET indicates endothelin; MAP, mean arterial pressure; HR, heart rate; bpm, treats per minute; and FBF,
forearm blood flow. Values are meaniSEM. There were no significant differences in basal MAP, HR, and FBF
between study days. MAP, HR, and FBF in the noninfused arm did not change significantly on any study day
after infusion of peptides.
Protocol 3: Intra-arterial endothelin-1 and sarafotoxin S6c. On
two separate occasions, in random, balanced order, six subjects
received endothelin-1 and sarafotoxin S6c via the brachial
artery at 5 pmol/min for 60 minutes. Forearm blood flow was
recorded from 3 minutes before to 5 minutes after peptide
infusion was begun. Thereafter, measurements were made at
5-minute intervals for 60 minutes. Blood pressure was mea¬
sured at 60 minutes, just before the infusion was terminated.
Hand Vein Studies
Protocol 4: Intravenous endothelin-1 and sarafotoxin S6c. Six
subjects were studied on two separate occasions, in random,
balanced order. Subjects rested semirecumbent throughout.
The dorsal hand vein cannula and the LVDT were sited. Saline
was infused for 30 minutes, during which vein diameter was
measured every 5 minutes, Endothelin-1 and sarafotoxin S6c
were infused at 5 pmol/min for 60 minutes, with measurements
of vein diameter every 5 minutes. The choice of this dose was
based on previous work that showed, in vivo, that endothelin-1
at 5 pmol/min causes slow-onset venoconstriction of «=60% in
human skin capacitance vessels.29-31 Blood pressure was mea¬
sured twice before the dose was given and at 60 minutes, just
before the infusion was terminated.
Data Analysis and Statistics
Plethysmography data listings were extracted from the
chart data files, and forearm blood flows were calculated for
individual venous occlusion cuff inflations by use of a template
spreadsheet (excel 4.0; Microsoft Ltd). Because wrist cuff
inflation results in a transient forearm vasoconstriction,17 re¬
cordings made in the first 60 seconds after wrist cuff inflation
were not used for analysis. Usually, the last five flow recordings
in each 3-minute measurement period were calculated and
averaged for the infused and noninfused arms. However, to
detect early transient changes in blood flow, every recording
made immediately before and after the start of peptide infusion
was analyzed. Basal blood How was taken as the average of all
flow recordings made in the 2 minutes before infusion of
peptides was begun. The intersubject, intrasubject (interstudy),
and intrasubject (intrastudy) coefficients of variation for basal
(interstudy), and intrasubject (intrastudy) coefficients of varia¬
tion for the basal ratio of blood flow between infused and
noninfused arms in our laboratory are 22%, 15%, and 8%,
respectively. Therefore, to reduce the variability of blood flow
data, the ratio of flows in the two arms was calculated for each
time point, in effect using the noninfused arm as a contempo¬
raneous control for the infused arm.38 Forearm blood flow
results are shown as a percentage change from basal in the ratio
of blood flow between infused and noninfused arms.29
Basal vein diameter was calculated as the mean of the last
three measurements before the start of the peptide infusion,
expressed in millimeters. The intersubject, intrasubject (inter¬
study), and intrasubject (intrastudy) coefficients of variation for
basal hand vein diameter measurements in our laboratory are
43%, 26%, and 5%, respectively. Given the high intersubject
and interstudy variability in hand vein diameter, responses after
infusion of peptides are expressed as percentage change in vein
diameter from basal.32 Duplicate blood pressure measurements
were averaged at each time point. Basal blood pressure was
taken as the average of the second set of measurements made
before infusion of peptides.
To obtain an estimate of the contribution of ET„ receptors to
vasoconstriction, the ratio of constriction to the ETB agonist
compared with constriction to endothelin-1 was calculated for
each subject at the 60-minute time point. Because these data
had a skewed distribution, ratios were logarithmically trans¬
formed for statistical analysis. Data are shown as mean values,
with 95% confidence intervals (CI) shown in the text and SEM
in the figures. Data were examined by a repeated-measures
ANOVA with statistical testing of overall significance by
Scheffe's F test (ANOVA) using statvif.w 512* software
(Brainpower Inc) for the Apple Macintosh personal computer.
Results
Basal blood pressure, heart rate, forearm blood How,
and vein diameter were similar on the different study
days, and there was no significant difference in basal
forearm blood flow between the infused and noninfused
arms (Tables 1 and 2). Blood pressure, heart rate, and
blood How in the noninfused arm did not change signif¬
icantly after infusion of any study agent, confirming that
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Table 2. Mean Arterial Pressure, Heart Rate, Forearm
Blood Flow, and Hand Vein Size Before and After
Administration of Peptides in the Two Study Protocols
(3 and 4) Comparing Endothelin-1 and Sarafotoxin S6c
Protocol 3 Protocol 4
ET-1 S6c ET-1 S6c
Parameter (5 pmol IA) (5 pmol IA) (5 pmol IV) (5 pmol IV)
MAP, mm Fig
Basal 82 ±3 82 ±3 89 ±5 84 ±3
60 min 85 ±3 85±4 89 ±4 84±2
HR, bpm
Basal 62±8 63±3 70±4 65 ±4
60 min 55±3 64±4 68±5 59±5
Infused FBF,
mL-100
mL ' ■ min '
Basal 3.1 ±0.4 3.1 ±0.5
60 min 1.4±0.3 1.8±0.3
Noninfused FBF,
mL - 100
mL 1 • min 1
2 7 + n A 2.7±0.4
60 min 2 3+0? 2 3+ 0 5
Vein size, mm
Basal 0.37 ±0.08 0.44 ±0.08
IA indicates intra-arterial; IV, intravenous. Other abbreviations as in
Table 1. There were no significant differences in basal MAP, HR, FBF, and
hand vein diameter between study days. MAP, FIR, and FBF in the
noninfused arm did not change significantly after infusion of peptides.
Protocol 1: Low-Dose Intra-arterial Endothelin-1
and Endothelin-3
Endothelin-1 at 1 pmol/min caused a modest but
significant forearm vasoconstriction, with an 11% reduc¬
tion in forearm blood flow at 60 minutes (CI, -22% to
— 1%; ANOVA, P=.02; Fig 1). Endothelin-3 at 1 pmol/
min tended to decrease forearm blood flow, with a 5%
reduction in blood flow at 60 minutes, but this was not
significant (CI, -14% to +3%; ANOVA, P=. 163; Fig
1). There was no significant difference between the
responses to endothelin-1 and endothelin-3 at 1 pmol/
jliDdofbtUn-^/l^idotbtUn-^UaJ
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Time (min I
Fig 1. Graph. Six subjects received brachial artery infusion of
endothelin-3 (o, 1 pmol/min; i), 5 pmol/min) and on a separate
occasion, endothelin-1 (•, 1 pmol/min; ■, 5 pmol/min), each for
60 minutes. Shaded bar indicates period of infusion of endothe-
lin isopeptides. Endothelin-1 caused significant forearm vaso¬
constriction at both doses, whereas the effect of endothelin-3
was significant only at 5 pmol/min. For clarity, error bars have
been removed from that pari of the figure showing results for the
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Fig 2. Graph. Six subjects received brachial artery infusion of
endothelin-1 (■, 60 pmol/min) and on a separate occasion,
endothelin-3 (□, 60 pmol/min), each for 5 minutes. Shaded area
indicates period of infusion of endothelin isopeptides. Forearm
vasodilatation occurred initially with ondotholin 3 but not with
endothelin-1. Both isopeptides then caused vasoconstriction of
similar degree, ia indicates intra-arterial.
min (ANOVA, P=.454). There was no significant vaso¬
dilatation early in the course of infusion of either
peptide. The average ratio of forearm vasoconstriction
to endothelin-3 and endothelin-1 was 0.16, although this
estimate had wide CIs (CI, 0.03 to 0.98).
Endothelin-1 at 5 pmol/min caused substantial fore¬
arm vasoconstriction, with a 40% reduction in forearm
blood flow at 60 minutes (CI, —52% to -28%; ANOVA,
P=.()002; Fig 1). The same dose of endothelin-3 also
significantly reduced forearm blood flow, with a 25%
reduction in blood flow at 60 minutes (CI, —36% to
- 13%; ANOVA, P=.001; Fig 1). There was significantly
greater vasoconstriction after endothelin-1 than endo¬
thelin-3 (ANOVA, P=.04). There was no significant
vasodilatation early in the course of infusion of either
peptide. The average ratio of forearm vasoconstriction
to endothelin-3 and endothelin-1 was 0.58 (CI, 0.39 to
0.87).
Protocol 2: High-Dose Intra-arterial Endothelin-1
and Endothelin-3
Endothelin-1, at 60 pmol/min for 5 minutes, caused a
trend to transient nonsignificant forearm vasodilatation
in the first 2 minutes of infusion, with a maximum
increase of 16% (CI, —7% to +23%; Fig 2) at 2 minutes.
Thereafter, vasoconstriction occurred, with the maxi¬
mum decrease in blood flow occurring at 10 minutes
(-28%; CI, -48% to -9%), although flow was still
reduced after 60 minutes (-17%; CI, -30% to —4%).
Endothelin-3 caused significant early forearm vasodila¬
tation, with a maximum increase in flow of 24% at 3
minutes (CI, +4% to +43%; Fig 2). Forearm vasocon¬
striction occurred after 10 minutes, with a maximum
reduction in blood flow of 24% at 60 minutes (CI, -43%
to -5%). There was a significant difference between the
overall responses to endothelin-1 and endothelin-3 over
the 60 minutes after bolus administration of isopeptide
(ANOVA, P= .04). However, maximum vasoconstriction
to the isopeptides was similar (Fig 2). The average ratio
of forearm vasoconstriction to endothelin-3 and endo¬
thelin-1 was 0.82, although this estimate had wide CIs
(CI. 0.13 to 5.07).
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Fig 3. Graph. Six subjects received brachial artery infusion of
endothelin-1 (a, 5 pmol/min) and on a separate occasion,
sarafotoxin S6c (□, 5 pmol/min), each for 60 minutes. Shaded
bar indicates period of infusion of peptides. Both peptides
caused significant forearm vasoconstriction, although the effect
of sarafotoxin S6c was less than that of endothelin-1. ia indi¬
cates intra-arterial.
Protocol 3: Intra-arterial Endothelin-1 and
Sarafotoxin S6c
Endothelin-1 at 5 pmol/min did not cause early vaso¬
dilatation but did produce slow-onset forearm vasocon¬
striction, with a maximum reduction in forearm blood
flow of 48% at 60 minutes (CI, -60% to -37%;
ANOVA, P=,0001; Fig 3). There was no significant
vasodilatation to sarafotoxin S6c early in the course of
the infusion, although there may have been a trend for
this to occur (Fig 3). Like endothelin-1, sarafotoxin S6c
caused slow-onset forearm vasoconstriction (ANOVA
versus basal, P=.002; Fig 3). However, the maximum
change in blood flow with sarafotoxin S6c at 60 minutes
( — 25%; CI, —37% to -13%) was significantly less than
that to endothelin-1 (ANOVA, P=.04). The average
ratio of forearm vasoconstriction to sarafotoxin S6c and
endothelin-1 was 0.48 (CI, 0.30 to 0.75).
Protocol 4: Intravenous Endothelin-1 and
Sarafotoxin S6c
Endothelin-1 caused a slow-onset and marked de¬
crease in hand vein diameter, with a maximal reduction
at 60 minutes ( — 68%; CI, —84% to -52%; ANOVA.
P=.0()1; Fig 4). Sarafotoxin S6c also caused venocon-
striction, although the maximum decrease in hand vein
size at 60 minutes (— 19%; CI, —29% to -9%; ANOVA
versus basal, P=.003; Fig 4) was significantly less than
that to endothelin-1 (ANOVA, P=.()02). The average
ratio of venoconstriction to sarafotoxin S6c and endo¬
thelin-1 was 0.25 (CI, 0.14 to 0.44).
Discussion
These studies show that selective agonists at endothe-
lin ET„ receptors constrict forearm resistance and hand
capacitance vessels in vivo in humans. In addition, high
doses of endothelin-3, and perhaps of endothelin-1,
cause transient forearm vasodilatation. These results
suggest an important role for ET,( receptors in mediating
the vascular effects of endothelin-1. it is possible that
different findings might have been obtained if other
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Fig 4. Graph. Six subjects received dorsal hand vein infusion of
endothelin-1 (■, 5 pmol/min) and on a separate occasion,
sarafotoxin S6c (□, 5 pmol/min), each for 60 minutes. Shaded
bar indicates period of infusion of peptides. Both peptides
caused significant venoconstriction, although the effect of
sarafotoxin S6c was less than that of endothelin-1. iv indicates
intravenous.
human forearm resistance vessels and dorsal hand veins
are thought to be broadly representative of responses in
other resistance and capacitance beds.-19 Given that
resting forearm blood flow is =50 mL/min,39 doses of 1,
5, and 60 pmol/min of peptide should achieve local
concentrations of =0.02, =0.1, and =1 nmol/L, respec¬
tively. Endothelin-1 would be expected to act equally on
both ETa and ET„ receptors at these concentrations,
while endothelin-3 would be expected to be relatively
selective for the ETB receptor, because this isopeptide
has a K, at ETA receptors of about 140 nmol/L.5 Sarafo¬
toxin S6c at 5 pmol/min should have been highly selec¬
tive for the ET,) receptor, because the calculated con¬
centration in forearm blood (0.1 nmol/L) is at least
70 000-fold lower than its K, at ETA receptors (>7300
nmol/L).5
Administration of endothelin-3 at 60 pmol/min caused
significant early forearm vasodilatation, and there was
also a tendency for similar transient vasodilatation to
occur with endothelin-1, although this was not statisti¬
cally significant. Vasodilatation is likely to have been due
to activation of ET,t receptors on endothelial cells,
causing generation of endothelium-derived dilator sub¬
stances.11 The apparent absence of significant vasodila¬
tation to high-dose endothelin-1 may have been due to
additional early vasoconstriction mediated by ETA re¬
ceptors masking dilatation, although it should be noted
that the CIs at these time points were sufficiently wide
for an =20% vasodilatation to endothelin-1 to have
been missed by chance. Ixiwer doses of endothelin-1 and
sarafotoxin S6c failed to cause early vasodilatation. The
lack ol vasodilatation to endothelin-1 contrasts with
previous findings,4" possibly because of differences in
doses used and experimental design. In view of the
relatively high doses required to cause vasodilatation, il
is likely that vasodilatation to the endothelins represents
a pharmacological rather than a physiological phenom¬
enon. Because human dorsal hand veins have no basal
tone, it is not possible to demonstrate whether endothe¬
lin-1 or sarafotoxin S6c causes venmlihitation without
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preconstriction of the vein. Previous work has shown no
venodilatation to endothelin-1 or endothelin-3 in pre-
constricted dorsal hand veins.41 Nonetheless, inhibition
of prostaglandin but not nitric oxide generation poten¬
tiates venoconstriction to endothelin-1 in vivo in hu¬
mans.11 Thus, the venous endothelium may generate
vasodilator substances in response to endothelin, but the
vasodilator effects of such substances appear to be
masked by the simultaneous direct venoconstriction
caused by the peptide and serve only to modulate
venoconstriction.
Given that both endothelin-3 and sarafotoxin S6c
caused vasoconstriction, our results suggest the presence
of vasoconstrictor ETB receptors. However, constriction
to the ETb agonists was almost always less than that to
the nonselective ETA and ETB agonist endothelin-1,
implying that both ETA and ETB receptors contribute to
vasoconstriction. The 95% CIs of the ratio of forearm
vasoconstriction to sarafotoxin S6c and endothelin-1 are
consistent with ETB receptors contributing substantially
to constriction, accounting for between 30% and 75% of
the response to endothelin-1. Although the magnitude
of the ETb contribution in vitro appears to differ be¬
tween vessels,17 the similarity of responses in forearm
resistance vessels and cutaneous capacitance vessels of
the hand suggests that ETB receptors may be of wide¬
spread functional importance in human blood vessels.
Our finding of ETB receptor-mediated vasoconstric¬
tion of resistance vessels contrasts with some in vitro
studies that suggest little contribution of ETB receptors
to constriction of human arteries.1 1 17 24 This difference
may reflect the fact that we examined responses in an
intact resistance bed, because ETB receptor-mediated
vasoconstriction appears to play a relatively greater role
in smaller vessels, particularly those responsible for
determining resistance.1742 All of the in vitro studies in
which human vessels exhibited little or no ETB-mediated
arterial vasoconstriction examined vessels >400 p.m in
diameter.1117 24 In addition to the influence of vessel size
on the contribution of ETB receptors, there may be
regional differences. Local injection of the ETA antago¬
nist PD147953 has been shown to completely prevent
vasoconstriction of human skin vessels caused by intra¬
dermal injection of endothelin-1, suggesting that vaso¬
constriction is mediated mainly by ETA receptors in this
microvascular bed.41 The effects of sarafotoxin S6c,
compared with those of endothelin-1, were less in hand
veins than in forearm resistance vessels, despite in vitro
evidence from animal vessels that responses to ETB
agonists are greater in veins than arteries.8-9'12-11 This
may reflect a true species difference, because endothe¬
lin-1 is about eightfold more potent as a venoconstrictor
than endothelin-3 in human hand veins,41 which also
suggests that ETA receptors predominate in these
vessels.
Although vasoconstriction to the ET„ agonists endo¬
thelin-3 and sarafotoxin S6c is most likely to be caused
by stimulation of vascular smooth muscle ET„ receptors,
there are alternative explanations. First, ET„ receptors
may be confined to endothelial cells but cause late-onset
vasoconstriction through stimulation of the generation
of endothelium-derived vasoconstrictor agents. These
substances might include constrictor prostanoids or even
endothelin-1, because endothelin-3 is known to stimu¬
late production of endothelin-! in vitro.44 Second, some
ol the eflects of endothelin-3 could have been mediated
by a putative FT, (endothelin-3-selective) receptor sit¬
uated on endothelial cells. However, although there is
evidence from binding44 and functional41 studies to
support the existence of an endothelin-3-selective re¬
ceptor in the vasculature, and a potential candidate has
been identified in Xenopus laevis melanophores,46 this
receptor has not been identified in humans. Any contri¬
bution from the putative ETC receptor will depend on its
isolation and pharmacological characterization. Third,
there may be receptor-mediated clearance of endoge-
nously generated endothelin-1 by ETB receptors, as has
been shown in animals.47 If this were the case, ETB
agonists might prevent local clearance of endothelin-1,
which would then act on ETA receptors to cause vaso¬
constriction. However, this possibility appears highly
unlikely, given that ETA antagonists do not influence
vasoconstriction to sarafotoxin S6c in vitro.8-10-13-26-48 In
future, studies with selective ETB receptor antagonists
should clarify this issue, because such agents would be
expected to potentiate responses to endothelin-1 if ET„
receptor-mediated clearance of endothelin-1 does
occur.
Thus, the most likely explanation for our results is that
there are functionally active ETA and ETB receptors on
vascular smooth muscle cells causing vasoconstriction, to
both of which endothelin-1 would have access. These
findings have implications for the future development of
antiendothelin therapies, because they suggest that full
inhibition of vasoconstriction to endogenously gener¬
ated endothelin-1 may be obtained only by use of either
combined ET^d endothelin receptor antagonists49 or
inhibitors of endothelin generation.29
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Endothelium-Dependent Modulation of Venoconstriction
to Sarafotoxin S6c in Human Veins In Vivo
Fiona E. Strachan, William G. Haynes, and David J. Webb
University of Edinburgh, Department of Medicine. Western General Hospital. Edinburgh, Scotland
Summary: We investigated the vascular effects mediated
by ETa and ETB receptors in human dorsal hand veins in
vivo, using sarafotoxin S6c (SFTX6c) as a selective ago¬
nist of ET„ receptors and endothelin 1 (ET 11 as a non
selective agonist of ETA and ET„ receptors. The cyclo-
oxygenase inhibitor aspirin and the nitric oxide synthase
inhibitor L-NMMA were used to examine the modulating
role of endothelial vasodilators on the response to
SFTX6c. Drugs were all infused into the hand veins, at
locally but not sysiemically active doses, via a 2? SWG
butterfly cannula, with the exception of aspirin, which
was administered orally. Hand vein size was measured by
the Aeliig tecnnique. The studs was performed in six
healths male subjects. Data tmean - SEMi were exam¬
ined by ANON A. Results are expressed as percent
change from baseline at 60 min. ET-I (5 pmol/min for 60
mini caused venoconstriction of 68 = 6T tp = 0.00011.
SFTX6c at the samg dose caused venoconstriciion of 19
r 49f (p = 0.003). The response to SFTX6c was signifi¬
cantly less than to ET-1 (p = 0.002). Constriction to
SFTX6c tended to increase when this agent was co
administered with aspirin (25 r 79r| or L-NMMA (24 -
I09r) and was significantly potentiated when these agents
were co-admintsiered (45 z: 49~c: p = 0.01 vs. SFTX6c
alone). We have demonstrated that the selective ETH ag¬
onist SFTX6c produces venoconstriciion in human hand
veins in vivo and that this venoconstnction is modulated
by the generation of endothelium derived vasodilators. In
this vascular bed. venoconsiriciion rather than vcnodila-
tation appears to be the predominant effect of stimulation
of ETh receptors with SFTX6c. Rev Words: Human—
Venoconstnction—Endothelin-1—Sarafotoxin S6c—
Endothelium.
The endothelins are a family of 21-amino-acid
peptides with potent and characteristically sus¬
tained vasoconstrictor and vasopressor actions (1).
Endothelin-I (ET-1) is the predominant isopeptide
generated by the vascular endothelium (2) and
therefore appears to be the most important isoform
mediating cardiovascular effects. Two specific re
ceptors for the endothelins have been isolated by in
vitro expression of cloned human cDNA (3.4). The
ETa receptor has a high affinity for ET-1 compared
with endothelin-3 (ET-3). whereas the ETB receptor
has equal affinity for both endothelins.
Vasoconstriction to ET-I was initially believed to
be mediated solely by vascular smooth-muscle cell
ETa receptors, and endothelial cell ETB receptors
were believed only to mediate generation of endo-
thelium-derived dilator substances. Indeed, there is
considerable evidence that stimulation of endothe¬
lial FTb receptors can cause production of nitric
oxide and dilator prostanoids, both to cause the ini¬
tial depressor effect of systemic bolus administra¬
tion of ET-I and to modulate the sustained vaso¬
constriction associated with ET-1 (5). More re¬
cently. it has been shown that ETB receptor mRNA
is expressed in human vascular smooth muscle (6).
consistent with a potential vasoconstrictor role for
the ETe receptor. Indeed, in animals and in hu¬
mans. there is functional evidence for ETB recep¬
tor-mediated vasoconstriction in vitro, particularly
in veins (7-9). However, the contribution of ETB
receptors to ET-l-mediated constriction can vary
depending on species, vessel type, and vessel size.
In human hand veins, venoconstriciion to ET-I is
attenuated by dilator prostanoids but not by nitric
oxide (10). Here, we have examined the role of the
endothclium-derived dilators nitric oxide and pros¬
tacyclin in modulating venoconstnction to locally
but not systemically active doses of sarafotoxin S6c
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Six healthy men (age range 25-39 years) participated in
the study, with local Ethics Review Committee approval.
Subjects rested semirecumbent in a quiet room main¬
tained at a constant temperature for each study (25-27°C).
Drugs were infused via a 23 SWG cannula (Abbott) sited
in a selected dorsal hand vein in the direction of flow, as
described previously (10). Local anesthesia was not em¬
ployed. The same dorsal hand vein was used in each
study. Internal diameter of the dorsal hand vein was mea¬
sured by the Aellig displacement technique (12) at 5-min
intervals throughout each study period. Blood pressure
was measured in the noninfused arm at 30-min intervals.
Drugs
On separate occasions. ET-1 (NovaBiochem. Notting¬
ham. U.K.) and SFTXS6c (Sigma Chemical Co Ltd..
Nottingham. U.K.) were administered for 60 min at a
constant rate of 5 pmol/min. based on results from previ¬
ous studies (10.13). A single dose was used because the
slow onset and long-lasting action of the endotheiins pre¬
cludes the use of repeated doses in a single study to ex¬
amine conventional dose-response relationships. L-.V1'-
monomethyl-arginine (L-NMMA: NovaBiochem. Not¬
tingham. U.K.). a specific substrate analogue inhibitor of
nitric oxide synthase in humans (14). was administered in
a dose of 100 nmoi/min (10). This dose of L-NMMA has
no effect on basal hand vein size (15). Aspirin i600 mg.
soluble: Reckitt & Coleman. Hull. U.K.) was dissolved in
200 ml water and administered 30 min before local peptide
infusions. Aspirin irreversibly inhibits cyclo-oxygenase
(EC 1.14.99.1) and. when given at this dose, inhibits
bradykinin-stimulated endothelial production of prosta¬
cyclin by at least 859e. with recovery developing over the
next 6 h (16). All drugs, with the exception of aspirin,
were dissolved in saline (0.9%: Travenol). In each study,
saline was infused for 30 min before infusion of the study
agent. The total rate of infusion was maintained constant
throughout all studies at 0.25 ml/min.
Study design
The study involved five separate study periods in the
same subjects, each study period separated by at least 1
week. Responses to ET-1 and SFTX6c alone were exam¬
ined. In addition, responses to SFTX6c were investigated
in the presence of aspirin and L-NMMA, administered
both independently and together. The order of the study
periods was randomized, with the exception of the sarafo-
toxin and combined L-NMMA and aspirin study, which
was the final study period for each subject.
Data presentation and statistics
Basal vein size was calculated in millimeters as the
mean of the last two measurements taken during saline
infusion. Vein size during drug administration was ex¬
pressed as percentage change in vein size from basal, at
60 min. All results are expressed as mean ± SEM. Data
were examined by repeated measures analysis of vari¬
ance. Statistical significance was accepted at the 5%
level.
RESULTS
In the six subjects, basal vein size was similar for
each study and blood pressure did not alter signifi¬
cantly throughout any of the study periods. ET-1
alone caused a slowly developing venoconstnction.
with a maximum 68 = 6% reduction of basal inter¬
nal vein diameter at 6(1 min (p = 0.0001 vs. basal).
SFTX6c also caused significant venoconstnction
(19 = 4%: p = 0.003 vs. basal). The response to
ET-l was substantially greater than that to SFTX6c
(p = 0.002) (Fig. I). Venoconstriction to SFTX6c
tended to increase after administration of aspinn (25
~ 7%) and during co-infusion of L-NMMA (24 x
10%). but was not significantly different than that to
SFTX6c alone (Fig. 2). Venoconstriction to
SFTX6c was substantially and significantly in¬
creased in the presence of aspirin and L-NMMA
together (46 - 9%v p = 0.01 vs. SFTXbc: p =
0.0001 vs. basal). Venoconstriction to SFTX6c in
the presence of both aspinn and L-NMMA was less
prominent than, but did not differ significantly
from, that to ET-1 when infused alone ip - 0.1)
(Figs. I and 2).
DISCUSSION
In these studies we have investigated the veno-
constrictor effects of SFTX6c and their modulation
by the endothelium-denved dilators nitric oxide and
prostacyclin. We have confirmed the earlier find¬
ings that ET-1 (10) and SFTX6c (13) constrict hu¬
man hand veins. As before (13). an equivalent dose
of SFTX6c causes less venoconstriction than ET-1.
p m O.OI
p ■ 0. |
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RG. 1. Endothelial (5 pmol/min; open circles), sarafotoxin
S6c (5 pmol/min alone; closed circles), and sarafotoxin S6c
(5 pmol/min with L-NMMA 100 nmol/min and after aspirin 600
mg; closed squares).
J Cardiovusc Plutrmtu fd™. Vtd. 26 (Suppl. J). 1905
SI82 F. E. STRACHAN ET AL.
0 IU 20 30 40 50 50
Time (mini
FIG. 2. Sarafotoxin S6c (5 pmol/min alone; closed circles),
co-infused with L-NMMA (ODen triangles), after asoirin 600
mg (closed triangles), and with both L-NMMA and aspirin
(closed squares).
These findings suggest that ETB receptors contrib¬
ute to but do not wholly account for ET-1 -mediated
venoconstriction.
In addition, we have demonstrated that the veno¬
constriction to SFTX6c is significantly and substan¬
tially increased when generation of both nitric oxide
and dilator prostanoids, most likely prostacyclin, is
blocked. Combined inhibition of nitric oxide and
prostacyclin appeared to produce a greater effect on
venoconstriction to SFTX6c than the addition of
the individual effects of inhibition of generation of
either nitric oxide or prostacyclin alone. This may
reflect a capacity for the endothelium to compen¬
sate for inhibition of one dilator mediator by in¬
creased production of another. We have shown pre¬
viously that responses to ET-1 are potentiated by
aspirin administration but not by co-infusion of
L-NMMA (10). It would be important to further
investigate responses to ET-1 in human hand veins
in vivo in the presence of L-NMMA and aspirin,
both alone and given together. It appears from our
results with SFTX6c that the endothelial ETB re¬
ceptor modulates the constrictor effects produced
by stimulation of the vascular smooth muscle ETB
receptors, through generation of vasodilator sub¬
stances by the endothelium. However, in these ex¬
periments the vasoconstrictor action predominates.
In diseases such as chronic heart failure, in which
endo'helium-dependent vasodilatation is impaired,
ven< :onstrictor effects of ET -1 may be enhanced as
a ret It of unopposed vasoconstrictor effects medi¬
ated 7V both ETA and ETB receptors on vascular
smooth muscle. Given that the overall effect of
combined stimulation of the vascular smooth mus¬
cle and endothelial cell ETB receptors is venocon¬
striction. it may be necessary to block both ETA
and ETb receptors to completely block venocon-
striction to ET-1. Drugs that would act specifically
on the vascular smooth-muscle receptors (17) may
be more effective vasodilators, because they would
fully block ET-1 mediated vasoconstriction while
allowing the potentially desirable effects of the en¬
dothelial ETb receptors to be preserved.
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The Effect of Cooling on the Contractile Response to
Endothelin-1 in Small Arteries from Humans
*"i"Pauia J. W. Smith, *Daniel S. McQueen, and tDavid J. Webb
"Department of Pharmacology. University of Edinburgh. Edinburgh; and rDepartment ofMedicine. Western General
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Summary: The pathogenesis of the prolonged cold-
induced vasospasm of Raynaud's disease (RDl is un¬
known. Cooling has been shown to decrease the sensitiv¬
ity of cutaneous rabbit ear arteries to endoihetin-1 (ET-I).
perhaps by increasing the availability of nitric oxide
(NO). If the endothelium in RD lacks this NO-mediated
innibitory function during cooling, increased production
and enhanced constriction to ET-I could cause vaso-
soasm. This study examined the effect of cooling on the
contractile response to ET-I in human microvesseis.
Small arteries were dissected from biopsy specimens of
human fat and were cannulated in a small vessel arterio-
grapn. Cumulative concentration-response curves to
ET-I (10 to 3 x 10 ' M) were obtained in vessels at
37°C In = 8) and 24°C In = 7). Cooling to 24°C resulted
in an eightfold decrease in sensitivity to ET-1 (EC,0 6.6 =
2.5 x lb" 10 M at 37°C vs. 5.5 = 2.5 x 10"* M at 24°C; p
< 0.05. unpaired i test). The £max was not significantly
different at 37°C and 24°C (114 = 9 at 37°C vs. 138 =: 14
at 24°C: p = 0.18). These results suggest that cooling
decreases the sensitivity of human microvesseis to ET-1.
Further investigation is needed to establish the mecha¬
nism of this effect, including studies in vessels obtained
from patients with RD. K.ev Words: Endothelin—Nitric
oxide—Cooling—Human—Resistance arteries—Ray¬
naud's disease.
Raynaud's disease (RDl is characterized by in¬
tense vasospasm of the extremities, particularly the
digits, in response to cold exposure or marked emo¬
tion. It causes numbness and pallor, followed by
cyanosis, and can produce extreme local discomfort
on reperfusion. The pathogenesis of RD remains
unknown and available treatments are not particu¬
larly effective. The vascular endothelium plays a
major role in the regulation of vascular tone. Endo¬
thelial dysfunction occurs in a number of vascular
conditions, including hypertension, diabetes melli-
tus. and atheromatous disease (1.2). Clinical studies
implicate the endothelium-derived constrictor en¬
dothelin-1 (ET-1) in mediating the prolonged cold-
induced vasospasm of RD (3). Using cutaneous ar¬
teries from rabbit ear. Monge et al. (4) have shown
that cooling decreases sensitivity to ET-1. perhaps
owing to increased availability of nitric oxide (NO).
If the endothelium in Raynaud's patients lacks this
NO-mediated inhibitory function during cooling, in¬
creased production and enhanced constriction to
ET-1 might lead to the development of vasospasm.
This study examined the effect of cooling on the
response to ET-1 in human microvesseis isolated
from biopsy specimens of subcutaneous fat ob¬
tained at surgery.
MATERIALS AND METHODS
Subcutaneous fat biopsy specimens obtained from pa¬
tients undergoing elective gastrointestinal surgery at the
Western General Hospital were placed in a dissecting
dish containing physiologic salt solution (PSS: in mAL 118
NaCl. 4.7 K.C1. 2.5 CaCL. 1.2 MgSO«, 1.2 KH,P04. 25.0
NaHCO,. 0.026 EDTA. and 5.5 glucose). Small arteries
with a mean luminal diameter of 300 - 28 p.m In = 15)
were excised under a dissection microscope and cannu¬
lated in a small vessel arterioeraph (Living Systems In¬
strumentation Inc., Burlington. VT. U.S.A.). A pressure
servo unit maintained intraluminal pressure, without
flow, at 50 mm Hg. Luminal diameter was measured us¬
ing a video dimension analyzer. After a 6(3-90 min period
of equilibration, during which the vessel chamber was
superfused with PSS, continuously gassed with 95% OJ
5% CO-, and the temperature raised to 37°C, the contrac¬
tility of the arterioles was assessed separately using phen-
Address correspondence and reprint requests to Ms. P. J. W. Smith at Department of Medicine. Western General Hospital. Crewe
Road South. Edinburgh EH3 2XU. Scotland.
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FIG. 1. The effect of cooling on the contractile
response to E7-1 in human arterioles: concen¬
tration-response curves to ET-1 (expressed as
percentage response to KCI. 60 mM) at 37°C (C;
n = 81 and 24JC (•: n = 7). All values are mean
_ SEM. ~p < 0.05.
I ET-11 (log \l)
vlephnne I0~? Xf (PE: Sigmai and potassium chloride 60
mAf (KCI: Sigmai. Acetylcholine 10~" XI (ACh: Sigmai
was given during maximal contraction to PE to assess
endotheiial integnty. Cooling was achieved by passing
the superrusate through a rapid heat-exchange Peltier el¬
ement (Moor Instruments Ltd.. .Vlillwey. Axminster. De¬
von. U.K.) before it entered the anenograph. Cumulative
concentration-response curves to ET-1 10 — 1 ~ to 3 < 10"
XI (Novabiochemi were obtained in vessels at jTC l/i =
8) and 24"C (/i = T\. Mean resting lumal diameter, per¬
centage contraction to KCI. and percentage relaxation to
ACh at 3TC did not differ significantly between groups,
and the age and sex ratio of the patients in each group
were not significantly different (Table I).
Data analysis
Responses were expressed as percentage of the con¬
traction to KCI at 3TC. EC«0 (the concentration produc¬
ing half-maximum KCI contraction) and £majl values (the
maximal contraction relative to KCH are shown as mean
d SEM. Student's unpaired r test was used to compare
the responses in vessels studied at 37"C and 24°C. Statis¬
tical significance was achieved at p < 0.05.
RESULTS
ET-1 produced a concentration-dependent con¬
striction in all vessels. Cooling to 24°C caused a
TABLE 1. Patient details and baseline data for vessels
Studied at 37°C and 24"C
37*C 24°C
Age (years) 58 r 6 57 - 10
Sex ratio (M:F) 6:2 5:2
LD 278 = 26 328 = 56
% Contraction to KCI 39 = 6 51 = 7
% Relaxation to ACh 86 = 8 77 r 14
LD. resting luminal diameter (|im): KCI. potassium chloride
(60 m/VO; ACh. acetylcholine (10"" M). Values are mean =
SEM.
decrease in sensitivity to ET-l. as seen by a right-
ward shift of the concentration-response curve
i Fin. 1) and an eiuhtfold increase in the EC<„ (6.6 =
2.5 x 10"'" M at 37"C vs. 5.5 = 2.5 < 10"" XI at
2-J"C: o < 0.051. There was a tendency for the max¬
imal contraction to be higher during cooiing. but the
difference was not statistically sientficani 1114 r 9
at }"C vs. 138 = l-i at 24°C: p = 0.18).
DISCUSSION
This study shows that cooling decreases the sen¬
sitivity to ET-1 in small arteries from humans. In a
similar study using the rabbit ear artery. Monge et
al. (4) examined the effect of L-NAME. an inhibitor
of NO synthase, and also de-endothelialization. on
responses to ET-1 at 3TC and 24°C. Their findings
suggest that the decrease in ET-l sensitivity during
cooling is caused either by an increased availability
ot NO. which could be due to increased generation
or reduced clearance or. alternatively, is caused by
increased sensitivity to NO. The role of NO in mod¬
ulating the actions of ET-1 during cooling in human
arterioles requires further investigation. If the en¬
dothelium in patients with RD lacks this apparent
increase in NO availability during cooling, possibly
through injury to the endothelial cells, increased
production and enhanced constriction to ET-1
could cause vasospasm. Evidence that the endothe¬
lium may be injured in RD comes from studies
showing that factor VIII and von Willebrand factor
antigen levels are raised in Raynaud's patients (5).
and higher levels are associated with greater sever¬
ity of the disease (6). An alternative explanation for
our present results is a decrease in vascular smooth-
muscle sensitivity or responsiveness to ET-l at
24°C. This is presently the subject of investigation
in our laboratory.
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In conclusion, this study suggests that cooling de¬
creases the sensitivity to ET-1 of small arteries from
humans. Further experiments are required to exam¬
ine the mechanism of this effect, including studies
comparing responses in vessels obtained from pa¬
tients with RD with those from healthy subjects.
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Phosphoramidon inhibition of the in vivo conversion of big
endothelin-1 to endothelin-1 in the human forearm
'Christopher Plumpton, '"William G. Haynes, "David J. Webb & Anthony P. Davenport
Clinical Pharmacology Unit, University ofCambridge, Box 110, Addenbrooke's Hospital, Cambridge, CB2 2QQ and "Department
of Medicine, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU
1 The vasoconstrictor peptide, endothelin-1 (ET-1) and a biologically inactive C-terminal fragment
(CTF) are generated from an intermediate big ET-1 by a putative ET converting enzyme, sensitive to
phosphoramidon. We have developed a procedure using selective solid-phase extraction and specific
radioimmunoassays to measure the levels of immunoreactive (IR) big ET-1 and the products of
conversion (ET-1 and CTF) in human plasma. These techniques have been used to determine the levels
of the three peptides in venous plasma following local infusions of ET-1 and big ET-1, both alone and
together with phosphoramidon.
2 Infusion of ET-1 into the brachial artery (5 pmol min ') significantly increased (P<0.05) IR ET
levels from a basal level of 2.3 pM to 55.2 pM in plasma from the infused arm after 60 min of infusion.
This corresponded with a marked decrease in forearm blood flow from a basal level of 2.6 ml dl 1 min 1
to 1.7 ml dl"1 min-1. The levels of IR big ET-1 and CTF were unchanged. Co-infusion of
phosphoramidon (30 nmol min ') with ET-1 had no significant effect on the plasma IR levels of ET,
big ET-1, CTF, or blood flow.
3 Big ET-1 (50 pmol min ') significantly increased (P<0.05) venous concentrations of all three IR
peptides after 60 min compared to basal (ET: from 2.2 to 7.7 pM, big ET-1: from 0 to 386.0 pM, CTF:
from 0.2 to 37.0 pM). Forearm blood flow decreased significantly (P<0.05) from a basal level of
3.0 ml dl"1 min"1 to 1.6 ml dl"1 min"1.
4 When phosphoramidon was co-infused with big ET-1, both the rise in IR ET and associated
vasoconstriction were abolished. However, IR CTF was still detected, suggesting that either some
conversion by phosphoramidon-insensitive enzyme(s) was occurring, and/or that CTF was being
protected from further degradation by phosphoramidon.
5 These data show that in the human forearm the activity of a phosphoramidon-sensitive ET
converting enzyme is at least in part responsible for the vasoconstrictor properties of exogenous big ET-
1. Furthermore, because measurable levels of newly synthesized ET-1 are likely to be rapidly reduced in
the blood/plasma through receptor binding, assay of IR big ET-1 and CTF may be a more sensitive
measure of ET-1 generation in disease.
Keywords: Endothelin; big endothelin; endothelin converting enzyme; phosphoramidon; selective solid-phase extraction;
radioimmunoassay; human brachial artery; vasoconstriction
Introduction
The vasoconstrictor peptide, endothelin-1 (ET-1, Yanagisawa
et al., 1988) is thought to be synthesized from a 212 amino acid
precursor preproET-1, initially by removal of the signal se¬
quence to form proET-1. Subsequently dibasic pair proteo¬
lysis, carboxypeptidase and possibly furin activity (Laporte el
al., 1993) forms the intermediate 38 amino acid peptide, big
ET-1. The final stage of synthesis is an unusual cleavage cat¬
alysed by a putative ET converting enzyme (ECE) between
residues 21 and 22 (tryptophan and valine) to form the bio¬
logically active, mature ET-1 and a C-terminal fragment
(CTF) of big ET-1 (big ET-1(22.38)) in an equimolar ratio. In
support of this biosynthetic pathway, both mature ET and big
ET-1 have been localized to the cytoplasm of endothelial cells
from a range of human vascular beds (Howard el al., 1992)
and ET-1, big ET-1 and CTF have been identified in the
conditioned medium from cultured endothelial cells (Sawa-
mura et al., 1989; Hexum et al., 1990; Ikegawa el al., 1990).
Big ET-1 shows little vasoconstrictor activity compared
with ET-1 in human isolated blood vessels (Howard et al.,
1992). However, local brachial artery infusion of big ET-1
causes a slow onset, long-lasting vasoconstriction, with a po¬
tency about one tenth that of mature ET-1, suggesting an
approximately 10% conversion of the luminally presented big
' Author for correspondence
ET-1 (Haynes & Webb, 1994). In addition, systemic in¬
travenous infusion of big ET-1 in healthy human volunteers
results in significant, long-lasting cardiovascular effects (Ahl-
borg et al., 1991). Vasoconstrictor responses elicited by big ET-
1 in animals and man can be blocked or inhibited by the me-
talloprotease inhibitor, phosphoramidon (Gardiner et al.,
1991; McMahon et al., 1991; Bennett & Gardiner, 1994;
Haynes & Webb, 1994). Moreover, in cultures of human en¬
dothelial cells, treatment with phosphoramidon simulta¬
neously reduces the secretion of immunoreactive (IR) ET-1,
whilst increasing that of the big ET-1, consistent with the in¬
hibition of a phosphoramidon-sensitive ECE (Plumpton et al.,
1994). In further support of a phosphoramidon-sensitive en¬
zyme, metalloprotease ECEs have recently been cloned from
rat, bovine and human sources (Ikura et al., 1994; Schmidt et
al., 1994; Shimada et al., 1994; Xu et al., 1994).
Conversion of big ET-1 to ET-1 appears to be essential to
elicit the full haemodynamic effects observed in vivo with big
ET-1; therefore human ECE may represent a useful ther¬
apeutic target in clinical conditions where ET-1 generation is
increased. However, because ET-1 binds with high affinity to
its receptors, we hypothesized that using circulating ET-1
concentrations as an index of the formation of ET-1 from
exogenous big ET-1 may be misleading. A more complete
picture would be obtained by measuring the precursor and
both products of conversion. Our aim in the present study was
to quantify plasma !R ET-1, big ET-1 and CTF following
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brachial artery infusion of ET-1 or big ET-1 in human vo¬
lunteers and to compare the levels with the corresponding
forearm blood flow responses. Secondly, we tested the effects
of coinfusion of phosphoramidon with ET-1 or big ET-1 in the
same system. A preliminary account of part of this work has
been presented to the British Pharmacological Society
(Plumpton et al., 1995).
Methods
Clinical procedures
Six healthy males, aged 27 - 34 years, participated in this study
with the approval of the local ethical committee, as previously
described (Haynes & Webb, 1994). Briefly, all volunteers ab¬
stained from vasoactive drugs for one week, from alcohol for
24 h, and from food, caffeine-containing drinks and tobacco
for 3 h before each infusion. Subjects rested recumbent in a
quiet room maintained at a constant temperature of 24 - 26°C.
A 27G cannula was inserted into the brachial artery of the
non-dominant arm, under local anaesthesia, for drug infusion,
and into the antecubital vein of both arms for the withdrawal
of blood samples. ET-1, big ET-1 and phosphoramidon were
dissolved in 0.9% saline and infused locally at a constant flow
rate of 1 ml min"1. Blood flow was measured in both forearms
by venous occlusion plethysmography before and 60 and
90 min after dosing. Venous blood samples were taken before
and 60 and 90 min after dosing where appropriate. Blood was
collected into EDTA tubes and separated immediately. The
resulting plasma was stored at — 70°C until assayed.
On separate occasions, each subject received in random
order, ET-1 (5 pmol min"1) given alone for 60 min, ET-1
(5 pmol min ') given for 90 min with phosphoramidon
(30 nmol min "') being co-infused for the first 60 min, big ET-1
(5, 15, or 50 pmol min"1) given alone for 60 min, and big ET-1
(50 pmol min ') given for 90 min with phosphoramidon
(30 nmol min"1) being co-infused for the first 60 min. Drug
doses were designed to have local activity in the infused fore¬
arm, but not systemically. The dose of phosphoramidon was
chosen to achieve local concentrations in the forearm equiva¬
lent to the IC50 for ECE as determined by McMahon et al.
(1991). None of the agents had any effect on systemic hae-
modynamics (forearm blood flow in the contralateral arm,
arterial pressure or heart rate).
Sample preparation
After thawing, 4 ml EDTA-plasma samples were acidified by
adding 1 ml hydrochloric acid 2 M, and clarified by centrifu-
ging for 15 min at 2000 g at 4°C. The resulting supernatants
were applied to activated 500 mg Spe-ed C,8 (14% carbon
coverage) disposable mini-columns using a vacuum manifold
(Applied Separations, Laboratory Impex Ltd, Middx.). Un¬
bound materials were washed from the mini-columns with
5 ml 0.1% trifluoroacetic acid and discarded. Immunoreactive
CTF was eluted with 5 ml of 50% methanol, 0.1% TFA and
immunoreactive (IR) ET and big ET-1 were separately eluted
with a subsequent 2 ml of 80% methanol, 0.1% TFA. Eluates
were evaporated to dryness in polypropylene tubes using a
Savant sample concentrator (Life Sciences International
(U.K.) Ltd, Basingstoke, Hants).
Radioimmunoassay
Plasma IR ET, big ET-1 and CTF were determined by radio¬
immunoassay as previously described (Plumpton et at., 1993)
using rabbit antisera raised against the C-termini of ET (ET-
I(i5-2i)) and big ET-1 (big ET-1(3|.38)). Briefly, plasma extracts
were reconstituted in assay buffer (50 mM sodium phosphate,
0.25% bovine serum albumin (BSA), 0.01 % Tween 20, 0.05%
sodium azide, pH 7.4) and incubated in duplicate with diluted
antisera overnight at 4°C. Following a further overnight in¬
cubation with ~ 10,000 c.p.m./tube tracer ([l25I]-ET-l or [125I]-
big ET-1, Amersham International pic, Amersham, Bucks),
bound counts were separated using Amerlex-M reagent
(Amersham International pic, Amersham, Bucks) and radio¬
activity determined in a gamma counter (Canberra Packard,
Pangbourne, Berks). Immunoreactivity was calculated by re¬
ference to standard curves (0.5-1000 fmol/tube) of authentic
ET-1 (Peptide Institute, Scientific Marketing Associates, Bar-
net, Herts) or Novabiochem Ltd, Nottingham), or big ET-1
(Peninsula Laboratories Ltd, St. Helens, Lanes). For both as¬
says, EDw values were 20 - 25 fmol/tube, inter- and intra-assay
coefficients of variation were < 13% in the range 6-30 fmol/
tube and the sensitivities of detection (defined as two s.d. above
zero standard) were < 1.25 fmol/tube (equivalent to sample
sensitivities of < 1.56 pM under the current extraction proce¬
dure). The recoveries of ET-1, big ET-1 and CTF were 57.5%,
39.8% and 76.6%, respectively (n = 4). Plasma IR peptide
concentrations are shown uncorrected for recovery.
The mature ET RIA cross-reacted 100% with ET-1, ET-2
and ET-3 as expected since the immunogen contained the se¬
ven C-terminal residues of ET-1 common to all three mature
ET isoforms. Cross-reactivities with ET-1(i.20), big ET-1(22.38),
big ET-1, big ET-2 and big ET-3 were <0.02%. The big ET-1
RIA showed <0.007% cross-reactivity with the mature ETs,
big ET-2 and big ET-3 and cross-reacted 143% with big ET-
1(22-38) thus allowing the quantification of CTF following
fractionation. Neither of the assays showed any detectable
cross-reactivity (<0.000014%) with phosphoramidon. Fur¬
thermore phosphoramidon did not interfere with either the ET
or big ET-1 assays as indicated by superimposable standard
curves at concentrations an order of magnitude higher than
that of the infusate. No cross-reactivity was detected
(< 0.005%) at the highest concentrations tested with unrelated
vasoactive peptides such as angiotensin II, atrial natriuretic
factor and a-calcitonin gene-related peptide.
Drugs
The ET-1, big ET-1 and phosphoramidon for infusion were
obtained from Clinalfa AG, Laufelfingen, Switzerland.
Statistical analysis
Results are given as the mean of six individuals ± s.e.mean.
There was no evidence for non-normality of the data using the
Shapiro-Francia test (Shapiro et al., 1968) and so results were
analysed by analysis of variance.
Results
Sample extraction
The extraction characteristics for synthetic ET-1, big ET-1 and
CTF were determined by applying each peptide to a range of
disposable reverse-phase minicolumns with differing packing
chemistries and from various manufacturers. Immunoreactive
peptides, determined by RIA, were eluted with a stepwise
gradient of increasing concentrations of methanol. The C18
minicolumns obtained from Applied Separations gave the best
resolution of the three peptides and were therefore chosen for
further optimisation of conditions. The final extraction pro¬
cedure described in the methods resulted in 96.0% of IR CTF
eluting in the 50% methanol fraction and 99.7% and 96.9% of
IR ET-1 and big ET-1, respectively eluting in the 80% me¬
thanol fraction (n = 6).
ET-1 infusions
Infusion of ET-1 at 5 pmol min 1 resulted in a marked
increase in the levels of IR ET above basal in the infused
arm (Figure lb) and was accompanied by a significant
decrease in forearm blood flow again only in the infused
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ann (Figure la). Coinfusion of phosphoramidon had no
effect on the blood flow or IR ET levels both after 60 min
coinfusion and 30 min after withdrawal of phosphoramidon
(Figure le and f). The endogenous levels of IR big ET-1
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infusion of ET-1 (Figure 3a). Tlic levels of IR big ET-1 and
CTF increased in a dose-dependent fashion from both arms
(Figures 2c,d,g,h and 3c and d), although the concentrations in
the non-infused arm were negligible and accordingly were not
associated with any detectable vasoconstriction (Figure 3a).
In the presence of phosphoramidon, there was no significant
increase in IR ET from the infused arm after 60 min (Figure
3Q and the associated vasoconstriction observed with big ET-1
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Figure 3 As Figure I, except infusates were big ET-1 (SOpmolmin ') for 60min (a.h.c.d) and big ET-1 (SOpmolmin ') for 90min
with co-infusion of phosphoramidon {30nmolmin ') for the first 60min (e.f.g.h).
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alone was also abolished (Figure 3e). The levels of IR big ET-1
from the infused arm were lower and the proportion detected
from the non-infused arm higher than those in the absence of
phosphoramidon (Figure 3g) However, 30 min after the
withdrawal of phosphoramidon, the forearm blood flow and
levels of IR big ET-1 show a return to the levels detected after
60 min without phosphoramidon (Figure 3e and g). The levels
of IR CTF essentially mirrored those of IR big ET-1 despite
the lack of vasoconstriction after 60 min (Figure 3h).
Discussion
This study has shown that in healthy human volunteers, bra¬
chial artery infusion of ET-1 resulted in a marked increase in
local venous plasma IR ET. A significant increase in IR ET
was also detected when the precursor big ET-1 was infused.
Local brachial artery infusions of ET-1 have been shown to
cause significant vasoconstriction (Clarke et al., 1989; Pernow
et al., 1991; Haynes & Webb, 1994) and systemic intravenous
infusion of ET-1 elicits a sustained pressor response (Weitz-
berg et al., 1991). In addition, ET-1 is a potent constrictor of
human isolated blood vessels in vitro, with an ECW of 3-
18 nM in a range of human isolated blood vessels (Davenport
et al., 1989; Maguire & Davenport, 1995). Infusion of big ET-1
also results in vasoconstriction, presumably by conversion to
biologically active ET-1 (Ahlborg et al., 1994; Haynes &
Webb, 1994).
High-performance liquid chromatography coupled with
immunoassays have identified ET-1, big ET-1 and CTF in
extracts of cultured animal endothelial cells (Sawamura et al.,
1989; Hexum et al., 1990; Ikegawa et al., 1990) and demon¬
strated that CTF is the major form of IR big ET-1 in porcine
lung (Kitamura et al., 1990). In addition, in human subjects,
we have detected significant IR CTF in conditioned medium
from cultured endocardial endothelial cells and umbilical vein
endothelial and smooth muscle cells (unpublished observa¬
tions). Therefore in the present study we measured the plasma
IR levels of all three peptides by RIAs. Measurements were
made following local infusions of either ET-1 or big ET-1 both
with and without phosphoramidon which blocks the func¬
tional responses to big ET-1 (Haynes & Webb, 1994). Two-site
enzyme-linked immunosorbent assays previously used for
quantifying ET-1 and big ET-1 could not be used to measure
CTF because this peptide contains only one of the two epitopes
necessary to generate a signal in these assay systems (Plumpton
et al., 1994). However, the big ET-1 RIA used in the present
study showed a marked cross-reactivity with CTF and could
be used to determine plasma IR CTF following a fractionation
step This is the first report of CTF measurement with this
technique, which may be useful for assessing the effects of
orally active ET antagonists on the levels of ET synthesis. The
levels of IR ET detected in the basal samples were in good
agreement with previously reported normal human plasma
levels using a similar RIA technique (Davenport et al., 1990a).
Previously reported basal levels for plasma IR big ET-1 (Su¬
zuki et al., 1990) are below the detection limit of the RIA under
these conditions, possibly explaining why endogenous IR big
ET-1 was not detected.
Infusion of F.T-1 into the hrachial artery of the human
forearm resulted in the expected significant rise in the levels of
IR ET from the infused arm, with concomitant vasoconstric¬
tion. Since ET-1 has been shown to be a substrate for neutral
endopeptidase -24.11 (EC. 3.4.24.11, NEP) (Sokolovsky et al.,
1990; Turner, 1993) causing rapid inactivation, co-infusion of
phosphoramidon might have been expected to increase the
levels of IR ET. However, no significant differences were ob¬
served indicating that other mechanisms controlling the levels
of ET may be involved.
Big ET-1 infusion caused a dose-dependent increase in the
levels of IR big ET-1, and decrease in blood flow in the infused
arm. Furthermore there was a dose-dependent increase in the
levels of IR CTF from the infused arm and at the highest dose,
a small but significant increase in the IR ET. These data are
consistent with local conversion of exogenous big ET-1 in the
infused arm, in accord with animal studies (Gardiner et al.,
1991; Bennett & Gardiner, 1994; Corder & Vane, 1994). Al¬
though the vasoconstrictor effects were confined to the infused
arm, there were detectable increases of IR big ET-1 and CTF
from the contralateral arm indicating systemic increases in the
levels of these peptides. Since the vasoconstrictor responses to
both ET-1 and big ET-1 reached significance by 5 min (un¬
published observations), the effects are unlikely to be due to de
novo synthesis, although the processing of stored precursors
cannot be excluded. We have been unable to detect binding
sites for ['"I]-big ET-1 in human cardiovascular tissues at
concentrations up to 1 nM (Davenport et al., 1990b) suggesting
that there are no specific high affinity receptors for big ET 1. In
addition, 1 fiM big ET-1 does not compete for the binding of
[125I]-ET-1 binding sites. In human isolated saphenous vein,
CTF, at concentrations up to 1 /iM, has no detectable vaso¬
constrictor action nor docs it antagonize the actions of ET 1
(unpublished observations). Taken together, these results
strongly suggest that the vasoconstrictor effects are due to the
formation of biologically active ET-1 from exogenous big ET-
1 rather than a direct effect of CTF or big ET-1 itself.
The small rise in IR ET is in good agreement with animal
studies where the levels of ET-1 have been measured (Hemsen
et al., 1991; Corder & Vane, 1994). In particular the apparent
discrepancy between the levels of IR ET following local infu¬
sion of ET-1 and big ET-1 which resulted in similar fuctional
responses are concordant with the results of systemic infusion
of these peptides in human subjects (Weitzberg et al., 1991;
Ahlborg et al., 1994). We propose that the detected increases in
plasma IR ET were modest following infusion of big ET-1
owing to ET binding to its receptors with a high affinity im¬
mediately following synthesis (Davenport et al., 1995) in sup¬
port of a 'stoichiometric' model for ET-1 binding and action
(Frelin & Guedin, 1994). Furthermore, once bound, the pep¬
tide dissociates slowly from its receptors in the vasculature
(Molenaar et al., 1993). These data question the ability of
plasma IR ET estimations to provide relevant information. It
is likely that measurement of big ET-1 and CTF in addition to
ET will be of greater value in monitoring the generation of ET.
Co-infusion of phosphoramidon with big ET-1 results in the
abolition of vasoconstriction and increase in IR ET in the
infused arm. This is consistent with the inhibition of a phos¬
phoramidon sensitive ECE and in agreement with in vitro data
from cultured animal (Ohnaka et al., 1991; Sawamura et al.,
1991) and human endothelial cells (Plumpton et al., 1994), and
porcine (Fukuroda et al., 1990) and human isolated blood
vessels in vitro (Mombouli et al., 1993). The presence of CTF
following coinfusion of phosphoramidon suggests that other
ECEs may still be active, for example an aspartyl protease that
has been identified in human endothelial cell cultures
(Plumpton et al., 1994). In addition, phosphoramidon may
protect CTF, generated from endogenous and exogenous big
ET-1, from proteolysis by NEP as CTF has been shown also to
be a substrate for this enzyme (Murphy et al., 1994). Phos¬
phoramidon caused an increase in the levels of big ET-1 from
the non-infused arm suggesting a systemic protection against
degradation and/or conversion. In contrast, the levels in the
infused arm decreased when compared to the infusion of big
ET-1 alone. We propose that this effect was due to the in¬
creased dilution effect of the relatively higher blood flow. This
is supported by the return of blood flow and IR big ET-1 levels
towards those found after big ET-1 infusion following the
withdrawal of phosphoramidon.
The precise location of big ET-1 conversion in the present
study is not clear. Watanabe et al. (1991) have demonstrated
that whole human blood is not a major site of conversion. In
addition, Fukuroda et al. (1990) and Mombouli et al. (1993)
have shown that in porcine and human isolated blood vessels,
phosphoramidon-sensitive conversion of big ET-1 is in¬
dependent of the endothelium. The concentrations of phos¬
phoramidon used jn the present study were low compared with
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reported IC50 values for ECE inhibition (Opgenorth et al.,
1992) and the inhibitor does not enter cells efficiently (Turner,
1993). It is therefore most likely that the ECE is located on the
extracellular surface of the vascular smooth muscle cells of the
resistance vessels of the forearm, proximal to target vasocon-
trictor ETA receptors (Davenport & Maguire, 1993; Davenport
et al., 1995; Maguire & Davenport, 1995). Specific antisera or
other selective probes for ECE will undoubtedly aid the loca
tion of the ECE involved. We predict that this ECE is phy¬
siologically relevant as the local infusion of phosphornmidon
alone resulted in vasodilatation presumably due to inhibition
of endogenous ET synthesis (Haynes & Webb, 1994). How¬
ever, it is possible that other ECEs contribute to endogenous
ET synthesis.
In conclusion, we have shown that big ET-l-induced fore¬
arm vasoconstriction is associated with a significant increase in
1R ET and CTF after 60 min. The increases in IR ET and
vasoconstriction are blocked by coinfusion of phosphor-
amidon, suggesting that a phosphoramidon sensitive ECE is at
least in part responsible for the vasoconstrictor properties of
big ET-1. This enzyme is, therefore, a valid target for ther¬
apeutic agents in human subjects. The development of more
potent, specific and orally active ECE inhibitors may lead to
specific vasodilator drugs use which may be of clinical benefit
perhaps in addition to specific antagonists at ET receptors.
Such drugs may have potential in lowering the levels of cir
culating ET1 in cardiovascular diseases where the levels of
ET 1 are raised. Measurable levels of newly synthesized ET-1
are likely to be reduced through rapid receptor binding,
therefore assay of IR big ET 1 and CTF may be a more sen
sitive measure of the overexpression of ET-1 in disease.
This work was supported by the British Heart Foundation, Newton
Trust, Royal Society and Scottish Home and Health Department.
The authors gratefully acknowledge Dr Janet J. Maguirc, Clinical
Pharmacology Unit, Addenbrooke's Hospital for the CTF in vitro
pharmacology and Dr Norman Lannigan and Mrs Elizabeth
Stanley, Pharmacy Department, Western General Hospital for the
preparation of peptides for clinical use.
References
AHLBORG, G„ OTTOSSON-SEEBERGER, A., HEMSEN, A. & LUND-
BERG, J.M. (1994). Big ET-1 infusion in man causes rcnnl ET 1
release, renal and splanchnic vasoconstriction, and increased
mean aterial blood pressure. Cardiovasc. Res., 28, 1559-1563.
BENNETT, T. & GARDINER, S.M. (1994). Recent developments in
endothelin research. J. Hum. Hypertens., 8, 587-592.
CLARKE, J.G., BENJAMIN, N., LARKIN, S.W , WEBB, D.J., KEOGH,
BE., DAVIES, G.J. & MASERI, A. (1989). Endothelin is a potent
long-lasting vasoconstrictor in men. Am. J. Physiol., 257, (Heart
Circ. Physiol., 26, H2033-2035.
CORDER, R. A VANE, J R. (1994). Radioimmunoassay evidence that
the pressor effect of big endothelin-1 in anaesthetised rats is due
to local conversion to endothelin-1 Br J Pharmacol., Ill, 225P.
DAVENPORT, A.P., ASHBY, M.J., EASTON, P., ELLA, S„ BEDFORD,
J., DICKERSON, C„ NUNEZ, D.J., CAPPER, S.J. & BROWN, M.J.
(1990a). A sensitive radioimmunoassay measuring endothelin-
like immunoreactivity in human plasma: comparison of levels in
patients with essential hypertension and normotensive control
subjects. Clin. Sci., 78, 261 -264.
DAVENPORT, A.P. & MAGUIRE, J.J (1994). Is endothelin-induced
vasoconstriction mediated only by ETA receptors in man? Trends
Pharmacol. Sci., 15, 9 - 11.
DAVENPORT, A.P., NUNEZ, D.J & BROWN. M.J. (1990b). Localisa¬
tion of binding sites for iodinated endothelin and sarafotoxin
peptides using quantitative receptor autoradiography. Eur. J.
Pharmacol., 183, 2153.
DAVENPORT, A.P, NUNEZ, D I, HALL, J.A , KAUMANN, A.J. &
BROWN, M.J. (1989). Autoradiographical localisation of binding
sites for [l25I] endothelin-1 in humans, pigs and rats: functional
relevance in man. J. Cardiovasc. Pharmacol., 13, (Suppl. 5)
S166 — S170.
DAVENPORT, A.P, O'REILLY, G. & KUC, R E. (1995). Endothelin
ETa and ETB mRNA and receptors expressed by smooth muscle
in the human vasculature: majority of the ETA sub type. Br J.
Pharmacol., 114, 1110-1116.
FRELIN, C & GUEDIN, D. (1994). Why are circulating concentra¬
tions of endothelin-1 so low? Cardiovasc. Res., 28, 1613- 1622.
FUKURODA, T , NOGUCHI, K , TSLCHIDA, S., NISHIKIBE, M ,
IKEMOTO, F , OKADA, K. & YANO. M (1990). Inhibition of
biological actions of big endothelin-1 by phosphoramidon.
Biochem. Biophys. Res. Commun.. 172, 390 - 395.
GARDINER, S.M., COMPTON, A.M., KEMP, P A & BENNETT, T
(1991). The effects of phosphoramidon on the regional
haemodynamic responses to human proendothelin (1-38) in
conscious rats. Br. J. Pharmacol., 103, 2009 -2015.
HAYNES, W.G. & WEBB, D.J. (1994). Contribution of endogenous
generation of endothelin-1 to basal vascular tone. Lancet, 344,
852- 854.
HEMSEN, A , PERNOW. J. & LUNDBERG, JM (1991). Regional
extraction of endothelins and conversion of big endothelin to
endothelin-1 in the pig. Acta Physiol Scand., 141, 325 334.
HEXUM, T D , HOEGER.C , RIVIHR, J E BAIRD, A & BROWN, M R
(1990). Characterisation of endothelin secretion by vascular
endothelial cells. Biochem Biophys Res. Commun , 167, 294 300.
HOWARD, P.G., PLUMPTON, C. & DAVENPORT, A.P. (1992).
Anatomical localisation and pharmacological activity of mature
endothelins and their precursors in human vascular tissue.
Hypertension., 10, 1379-1386.
IKEGAWA, R„ MATSUMURA, Y„ TSUKAHARA, Y„ TAKAOKA, M &
MORIMOTO, S. (1990). Phosphoramidon, a metalloproteinase
inhibitor, suppresses the secretion of endothelin-1 from cultured
endothelial cells by inhibiting a big endothelin-1 converting
enzyme. Biochem. Biophys. Res. Commun., 171, 669-675.
IKURA, T., SAWAMURA, T„ SHIRAKI, T„ HOSOKAWA, H„ KIDO, T„
HOSHIKAWA, H„ SHIMADA, K„ TANZAWA, K„ KOBAYASHI, S„
MIWA, S. & MASAKI, T. (1994). cDNA cloning and expression of
bovine endothelin converting enzyme. Biochem. Biophys. Res.
Commun., 203, 1417-1422.
KITAMURA, K„ YUKAWA, T„ MORITA, S„ ICHIKI, Y„ ETO, T &
TANAKA, K. (1990). Distribution and molecular form of
immunoreactive big endothelin-1 in porcine tissue. Biochem.
Biophys. Res. Commun., 170, 497-503.
LAPORTE, S , DENAULT, J.-B , D'ORLEANS-JUSTE, P. & LEDUC, R.
(1993). Presence of Furin mRNA in cultured bovine endothelial
cells and possible involvement of Furin in the processing of the
endothelin precursor. J. Cardiovasc. Pharmacol., 22 (Suppl. 8),
S7-S10.
MAGUIRE, J.J & DAVENPORT, A.P. (1995). ETA receptor-mediated
constrictor responses to endothelin peptides in human blood
vessels in vitro. Br J Pharmacol., 115, 191 - 197.
MCMAHON, E.G., PALOMO, M.A. & MOORE, W.M (1991). Phosphor¬
amidon blocks the pressor activity of big endothelial-39] and
lowers blood pressure in spontaneously hypertensive rats. J.
Cardiovasc Pharmacol., 17 (Suppl. 7), S29-S33.
MOLENAAR, P., O'REILLY, G., SHARKEY, A , KUC, R E., HARDING,
DP, PLUMPTON, C„ GRESHAM, G.A & DAVENPORT, A P
(1993). Characterisation and localisation of endothelin receptor
subtypes in the human atrioventricular conducting system and
myocardium. Circ. Res., 72, 526-538.
MOMBOULI, J.V., LE, S.Q , WASSF.RSTRUM, N & VANHOUTTE. P.M
(1993). Endothelins 1 and 3 and big endothelin-1 contract
isolated human placental veins. J. Cardiovasc. Pharmacol., 22,
(Suppl. 8), S278-S281.
MURPHY. L.J , CORDER, R , MALLET, A.I. & TURNER, A.J (1994).
Generation by the phosphoramidon-sensitive peptidases, endo-
peptidase-24.11 and thermolysin, of endothelin-1 and C-terminal
fragment from big endothelin-1. Br. J. Pharmacol., 113, 137
142.
OHNAKA, K , TAKAYANAGI, R , OHASHI, M , & NAWATA, H
(1991). Conversion of big endothelin isopeptides to mature
endolhelin isopeptides by cultured bovine endothelial cells. J
Cardiovasc. Pharmacol., 17 (Suppl. 7), S17 S19.
OPGENORTH, T.J., WU-WONG, J.R & SHIOSAKI, K (1992).
Endothelin-converting enzymes FASEB J , 6, 2653 2659.
PERNOW, J , HEMSEN, A , LUNDBERG, J M . NOWAK, J & KAIJSER,
L (1991). Potent vasoconstrictor effects and clearance of
endothelin in the human forearm. Acta Physiol. Scand., 141,
319 324
1828 C. Plumpton et a/ Big •ndotfwUn conversion in human forttrm
PLUMPTON, C„ CHAMPENEY, R , ASHBY, M.I , KUC, R E A
DAVENPORT, A.P (1993). Characterisation of endothelin iso-
forms in human heart: Endothelin-2 demonstrated. J. Cardio-
vasc. Pharmacol., 22, S26-28.
PLUMPTON, C„ HAYNES, W.G., WEBB, D.J. & DAVENPORT, A P
(1995). Phosphoramidon inhibits the in vivo conversion of big
ET-1 to ET in man. Br. J. Pharmacol., 114, 76P.
PLUMPTON, C , KALINKA, S , MARTIN, RC , HORTON, I K A
DAVENPORT, A.P (1994). Effects of phosphoramidon and
pepstatin A on the secretion of endothelin-1 and big endothe¬
lin-1 by human umbilical vein endothelial cells: measurement by
two-site enzyme-linked immunosorbent assays. Clin. Sci., 87,
245-251.
SAWAMURA, T„ KIMURA, S„ SHINMI, O., SUGITA, Y„ YANAGISA-
WA, M. & MASAK.I, T. (1989). Analysis of endothelin related
peptides in culture supernatant of porcine aortic endothelial cells:
evidence for biosynthetic pathway of endothelin-1. Biochem.
Biophys. Res. Commun., 162, 1287- 1294.
SCHMIDT, M , KROGER, B , JACOB, E„ SEULBERGER, II., 5UB-
KOWSKI, T., OTTER, R , MEYER, SCHMALZING, G & HILLEN,
H. (1994). Molecular characterization of human and bovine
endothelin converting enzyme. FEBS Lett., 356, 238-243.
SHAPIRO, S.S., WILK, M B. & CHEN, H.T. (1968). A comparative
study of the various tests for normality. J. Am. Statist. Assoc., 63,
1343-1372.
SHIMADA, K..TAKAHASHI, M.4TANZAWA, K. (1994). Cloning and
functional expression of endothelin-converting enzyme from rat
endothelial cells. J. Biol. Chem., 269, 18275-18278.
SOKOLOVSKY, M„ GALRON, R„ KLOOG, Y , BDOLAH, A., INDIG,
F.E., BLUMBERG, S. & FLEMINGER, G. (1990). Endothelins are
more sensitive than sarafotoxins to neutral endopeptidase:
Possible physiological significance. Proc. Natl. Acad. Sci.
U.S.A., 87, 4702-4706.
SUZUKI, N , MATSUMOTO, H , KITADA, C„ KIMURA. S„ MIYAU-
CHI, T A FUJINO, M. (1990). A sandwich-type enzyme
immunoassay to detect immunoreactive big-endothelin-1 in
plasma. J. Immunol. Methods, 127, 165-170.
TURNER, A.J. (1993). Endothelin-converting enzymes and other
families of metallo-endopeptidases. Biochem. Soc. Trans., 21,
697-701.
WATANABE, Y., NARUSE, M„ MONZEN, C„ NARUSE, K„ OHSUMI,
K , HORIUCHI, J , YOSHIHARA, I., KATA, Y., NAKAMURA, N.,
KATA, M„ SUGINO, N A DEMURA, H. (1991). Is big endothelin
converted to endothelin-1 in circulating blood? J. Cardiovasc.
Pharmacol., 17 (Suppl. 7), S503-S505.
WEITZBERG, E„ AHLBORG, G. A LUNDBERG, J.M. (1991). Long-
lasting vasoconstriction and efficient regional extraction of
endothelin-1 in human splanchnic and renal tissues. Biochem.
Biophys. Res. Commun., 180, 1298-1303.
XU, D , EMOTO, N„ G1AID, A., SLAUGHTER, C., KAW, S., DEWIT, D.
& YANAGISAWA, M. (1994). ECE-1: A membrane-bound
mctalloprotcasc that catalyzes the proteolytic activation of big
endothelin-1. Cell, 78, 473-485.
YANAGISAWA, M., KURIHARA, H„ KIMURA, S., TOMOBE, Y.,
KOBAYASHI, M„ MITSUI, Y„ YAZAKI, Y., GOTO, K. A MASAKI,
T. (1988). A novel potent vasoconstrictor peptide produced by
vascular endothelial cells. Nature, 332, 411 -415.
(Received May 18, 1995
Revised June 2, 1995
Accepted June 7, 1995)
Br J Clin Pharmacol 1995; 40: 307-311
An investigation into the direct and indirect venoconstrictor
effects of endothelin-1 and big endothelin-1 in man
WILLIAM G. HAYNES, SHARON MOFFAT & DAVID J. WEBB
University of Edinburgh, Department of Medicine, Western General Hospital, Edinburgh, UK
1 Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide that is gener¬
ated through cleavage of its precursor big endothelin-1 by 'endothelin converting
enzyme' (ECE) in resistance vessels, including those of the forearm vascular bed.
In some animal tissues, but not in resistance vessels of healthy human subjects,
endothelin-1 appears to potentiate the actions of the sympathetic nervous system.
We examined whether ECE activity is present in human hand veins and whether
endothelin-1 or big endothelin-1 potentiate sympathetically mediated venoconstric-
tion.
2 Six healthy subjects received dorsal hand vein infusion of local, non-systemic
doses of endothelin-1 (5 pmol mirT1), big endothelin-1 (50 pmol min"1) and, as a
control, sodium chloride (0.9%; w/v) for 90 min. Vein diameter was measured
using the Aellig displacement technique. Sympathetically mediated venoconstric-
tion was elicited using the single deep breath reflex.
3 Endothelin-1 caused a progressive decrease in hand vein diameter, by 49% at 90
min (95% confidence intervals [CI]: -68 to -30%; P = 0.0001). Vein diameter did
not change significantly after 90 min infusion of big endothelin-1 (+3%; CI: -11 to
+ 17%; P = 0.0007 vs endothelin-1; P = 0.40 vs baseline) or sodium chloride (+2%;
CI: -12 to +16%; P - 0.0002 vs endothelin-1; P = 0.60 vs baseline). Venoconstric-
tion to deep breath was not potentiated by endothelin-1.
4 These results suggest that, in contrast to the situation in forearm resistance vessels,
there is little or no local ECE activity in human hand veins and that endothelin
does not potentiate sympathetic responses in these cutaneous capacitance vessels.
Keywords vasoconstrictor peptide blood pressure endothelium veins
sympathetic nervous system
Introduction
The endothelins are a family of peptides with
extremely potent and characteristically sustained
vasoconstrictor and vasopressor actions [1]. Endothe¬
lin-1 is the predominant isoform in the vascular
endothelium [2], where it is generated from its pre¬
cursor, big endothelin-1 by the action of 'endothelin
converting enzyme' (ECE) [3]. In humans, brachial
artery infusion of big endothelin-1 causes a dose-
dependent forearm vasoconstriction that can be
blocked by the ECE inhibitor phosphoramidon [4].
Because circulating blood contains no ECE activity
[5], these findings suggest that the forearm resistance
vessels contain an ECE able to cleave luminally pre¬
sented big endothelin-1 to the mature peptide. It is
not known whether human capacitance vessels also
exhibit ECE activity.
In addition to its direct vascular effects [1],
endothelin-1 may mediate vasoconstriction indirectly
by potentiating the activity of the sympathetic ner¬
vous system, either centrally [6] or peripherally
[7, 8]. However, in man, brachial artery administra¬
tion of endothelin-1 does not potentiate forearm vaso¬
constriction to application of lower body negative
pressure [9], a model which has been used to show
that angiotensin II facilitates sympathetically medi¬
ated vasoconstriction (10].
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Therefore, the aims of this study were to assess
whether ECE activity is present in human hand veins
and whether endothelin-1 potentiates local activity of
the sympathetic nervous system in these vessels. In
order to investigate whether ECE was present, we
examined the effect of local intravenous infusion of
big endothelin-1, endothelin-1 and, as a control,
sodium chloride on dorsal hand vein diameter. The
interaction between endothelin-1 and the sympathetic
nervous system in veins was assessed using the single
deep breath manoeuvre [11], a reflex that causes brief
sympathetically mediated venoconstriction. This
reflex has been used to demonstrate that sub-constric¬
tor doses of angiotensin II facilitate sympathetically
mediated venoconstriction in humans [12], We exam¬
ined responses in veins because the venous system is
an important influence on cardiac output. In addition,
abnormalities of venous tone occur in chronic heart
failure, essential hypertension and chronic renal fail¬
ure, and may contribute to the pathophysiology of
these conditions. We chose the dorsal hand vein
because responses to vasoactive drugs in these veins
are similar to those predicted from the pharmacologi¬
cal profile of action following systemic dosing in vivo
[13]. In addition, there is clear evidence that cuta¬
neous limb veins are under sympathetic venomotor
control, whereas skeletal muscle veins do not partici¬
pate in these reflexes [14, 15]. Thus, cutaneous
capacitance vessels would appear to play an impor¬
tant role in the physiological regulation of venous
capacitance and cardiac preload. Finally, these studies
do not require systemically active doses of drugs that
may obscure any direct vascular action by direct
effects on other organs, such as the heart and kidney,




Six healthy male subjects between 19 and 22 years of
age participated in these studies, which were con¬
ducted with the approval of the Lothian Medicine and
Clinical Oncology Medical Research Ethics Sub-
Committee and with the written informed consent of
each subject. No subject received vasoactive or non¬
steroidal anti-inflammatory drugs in the week before
each phase of the study, and all abstained from food
for 4 h, and from alcohol, caffeine containing drinks
and cigarettes for at least 12 h before any measure¬
ments were made. All studies were performed in a
quiet room maintained at a constant temperature of
between 24 and 26° C.
Drugs
A 23 SWG cannula (Abbott. Sligo, Republic of Ire¬
land) was sited in a selected dorsal hand vein, with
out use of local anaesthesia, in the direction of flow.
Patency was maintained by infusion of sodium chlo
ride (0.9% w/v; Baxter Healthcare Ltd, Thetford,
UK). The total rate of infusion was maintained con¬
stant throughout all studies at 0.25 ml min"1.
Endothelin-1 (Clinalfa AG, Laufelfingen, Switzer¬
land) was dissolved in sodium chloride (0.9% w/v) to
a final strength of 20 pmol ml-1. Big endothelin-1
was dissolved in sodium chloride (0.9% w/v) to a
final strength of 200 pmol ml"'. The dose of endothe¬
lin-1 (5 pmol min1) was based on that shown in pre¬
vious hand vein studies to cause an ~50%
venoconstriction [16]. The dose of big endothelin-1
(50 pmol min"1) was based on the apparent ten-fold
lower potency of big endothelin-1 than endothelin-1
in the forearm resistance bed [4],
Measurements
Dorsal hand vein size The left hand was supported
above the level of the heart by means of an arm rest.
Internal diameter of the cannulated dorsal hand vein,
distended by inflation of an upper arm cuff to 30
mmHg, was measured by a displacement technique
using a linear variable differential transformer (LVDT;
Model 025 MHR, Lucas Schaevitz Inc, Pennsauken,
NJ, USA), as previously described [16,17]. Standard
displacements were used to calibrate the LVDT in
order to determine the internal diameter of the vein.
The background 'noise' of the signal from the LVDT
whilst recording hand vein size, expressed as the
standard deviation of the baseline signal, is ± 5 pm.
The sensitivity of this method, defined as a signal to
noise ratio of more than 3, is 15 pm.
Single deep breath venoconstrictor stimulus The
deep breath stimulus was performed as previously
described [16]. When vein size was stable, subjects
were asked to breath out fully before breathing in as
deeply as possible. They were asked to hold this
inspiration for 10 s and avoid any tendency to breath
out. The technique was practised before the study
to ensure that subjects did not perform a Valsalva
manoeuvre. This manoeuvre usually causes a 5-20%
venoconstriction within ~30 s [12, 16].
Blood pressure A well-validated semi-automated
technique (Takeda UA 751 sphygmomanometer,
Takeda Medical Inc, Tokyo, Japan) was used to mea¬
sure blood pressure in the non-infused arm [18].
Study design
This was a three phase, single-blind, randomised
crossover study. Subjects rested recumbent during
each phase. The dorsal hand vein cannula and LVDT
apparatus were sited. Sodium chloride (0.9% w/v)
was infused for 30 min during which vein size was
measured every 2 min. Blood pressure was measured
20, 15 and 5 min before dosing. Subjects were asked
to take single deep breaths, to elicit sympathetically
mediated venoconstriction, 25 and 10 min before dos¬
ing. On three separate occasions, in random order,
subjects received intravenous infusion of sodium
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chloride (0.9% w/v; control), endothelin-1 (5 pmol
min"1) or big endothelin-1 (50 pmol min '), each for
90 min. Vein size was measured every 5 min and
blood piessuic every 30 min. Single deep breaths
were taken 28, 58 and 88 min after starting the study
drug infusion.
Data presentation and statistics
Basal vein size was calculated by taking the mean of
the last five measurements before the start of the
study infusion, and is expressed in millimeters.
Because basal vein size varies between subjects,
responses to big endothelin-1 and endothelin-1 are
expressed as percentage change in vein size from
basal in order to reduce the inter subject variability.
The deep breath response was taken as the maxi¬
mum decrease in vein size in the 30 s after the
manoeuvre and expressed as a percentage change
from the last measurement of vein size. Because
endothelin-1 caused venoconstriction, deep breath
responses are also analysed in terms of the absolute
change in vein size. In order to obtain a summary
measure of the change in deep breath responses from
baseline on each day, we calculated the mean post-
treatment deep breath response in each individual
study session by averaging the 28, 58 and 88 min
responses. The effect of the treatment is expressed as
a ratio (mean post treatment response/baseline
response). These ratios had a skewed distribution and
were therefore log transformed for analysis. The
mean of the last two blood pressure measurements
during baseline sodium chloride infusion was used as
baseline. Data are shown as mean values, with 95%
confidence intervals (CI) shown in the text and
s.e. mean in Figure 1 and Table 1. All data were
examined by a repeated measures analysis of variance
(ANOVA), with significance testing by Scheffe's
F-test, using StatView 512+ software (Brainpower
Inc, Calabasas, CA, USA) for the Apple Macintosh
personal computer.
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Results
Baseline vein sizes were similar on the three study
days. No study agent significantly altered blood pres
sure or heart rate, confirming the non systemic nature
of the doses used (Table 1).
There was no significant change in vein size in the
control session, with a change from basal in vein
diameter, after infusion of sodium chloride for 90
min, of only +2% (CI: -12 to +16%; P = 0.60 vs
basal) (Figure 1). Intravenous infusion of big
endothelin-1 did not cause venoconstriction, with a
change in vein size at 90 min of +3% (CI: -11 to
+ 17%; P = 0.40 vs basal; P = 0.65 vs control) (Figure
1). In contrast, a 10-fold lower dose of endothelin-1
caused progressive venoconstriction, with a maximal
reduction at 90 min of 49% (CI: -68 to -30%;
20 r
Time (min)
Figure 1 Changes in hand vein diameter following
infusion of sodium chloride (0.9% w/v; O), endothelin-1
(5 pmol min ▲) and big endothelin-1 (50 pmol min-1;
■ ). Significant venoconstriction occurs only during
infusion of endothelin-1 (P = 0.0001).
Table 1 Mean arterial pressure (MAP), heart rate (HR), hand vein
diameter, and venoconslriction (% and mm) to deep breath before and after
brachial artery administration of sodium chloride (SAL), big endothelin-1
(big ET-1) and endothelin-1 (ET-1).
Parameter Time SAL BigET-l ET-1
MAP Basal 85 ± 2 84 ± 2 84 ± 3
(mm Hg) 90 min 87 ± 4 87 ± 4 89 ± 2
HR Basal 57 ± 3 62 ± 3 63 ± 4
(beats min"') 90 min 58 ± 3 64 ± 5 62 ± 4
Hand vein size (mm) Basal 1.5 ± 0.2 1.3 ± 0.1 1.6 + 0.1
Venoconstriction Basal 16 + 6 11+4 20 ± 9
to deep breath (%) 28 min 13 + 5 11+4 9 ± 3
58 min 12 ± 3 11+4 12 ± 4
88 min 10 ± 4 9 ± 4 19 ± 6
Venoconstriction Basal 0.17 ± 0.07 0.14 + 0.05 0.25 ±0.12
to deep breath 28 min 0.13 ± 0.04 0.14 ± 0.05 0.1 1 ± 0.03
(mm) 58 min 0.15 ± 0.04 0.13 ± 0.05 0.1 1 ± 0.03
88 min 0.10 ± 0.0.3 0.11 ± 0.05 0.14 ± 0.04
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P = 0.0001 vs basal; P = 0.0002 vr control;
P = 0.0007 ws big endothelin-1) (Figure 1).
The single deep breath manoeuvre caused signifi
cant venoconstnction from baseline before and during
infusion of sodium chloride (P = 0.01), big endothe¬
lin-1 (P = 0.002) and endothelin-1 (P = 0.01; Tabie
1). The ratio of post-treatment to baseline responses
was 0.98 (95% CI: 0.69 to 1.36) following sodium
chloride and was not significantly different from con¬
trol following infusion of endothelin-1 (ratio = 0.97;
95% CI: 0.80 to 1.17; P = 0.72 vs control) and big
endothelin-I (ratio = 0.97; 95% CI: 0.71 to 1.32;
P = 0.79 vs basal). When venoconstriction to deep
breath is expressed in absolute terms, absolute
responses decreased following endothelin-1 (ratio =
0.69; 95% CI: 0.54 to 0.89), but this was not signifi¬
cantly different from control (ratio = 1.02; 95% CI:
0.73 to 1.40; P = 0.25 vs endothelin 1) (Table 1).
Discussion
In these studies, we have shown that big endothe¬
lin-1, the precursor to endothelin-1, does not constrict
human hand veins. It is unlikely that any significant
ECE activity is present in these veins because we
found no venoconstnction despite using a dose of big
endothelin-1 that was ten-fold higher than a dose of
endotheiin-1 sufficient to cause 50% venoconstric¬
tion. In addition, we have demonstrated that big
endothelin-1 and endothelin-1 are unlikely to sub¬
stantially potentiate sympathetically mediated veno¬
constriction in healthy subjects. We were only able to
test responses to a single dose of endothelin 1
because the slow onset and sustained actions of
endothelin-1 preclude the use of repeated doses in a
single study to examine conventional dose-response
relationships [16]. Hand vein size did not alter during
sodium chloride infusion, confirming that these veins
are fully relaxed under our experimental conditions.
The lack of effect of big endothelin-1 in human
hand veins contrasts with the forearm vasoconstrictor
actions of the same dose of big endothelin-1 admin¬
istered via the brachial artery [4], Big endothelin-1
is - 10-fold less potent as a vasoconstrictor than
endothelin-1 in the forearm, implying that ~10% of
exogenously administered big endothelin-1 is cleaved
by ECE to the mature peptide in resistance vessels.
This functional estimate of forearm ECE activity is
supported by assay of plasma concentrations of endo¬
thelin peptides in venous blood draining the infused
arm [19]. It could be argued that this difference
between hand veins and forearm resistance vessels is
due to the fact that the segment of the hand vein
under study is too small (~1 cm), to allow adequate
biochemical conversion of big endothelin-1. How¬
ever. similar studies have shown that angiotensin I
constricts human hand veins, this effect being
blocked by an angiotensin convening enzyme (ACE)
inhibitor, demonstrating the presence of ACE in these
vessels [20, 21], There is only a small difference in
constrictor potency between angiotensin I and II in
hand veins, similar to the observations with angio¬
tensin peptides in the forearm resistance bed [20],
The latency of response for angiotensin I is only
about 30 s longer than that for angiotensin II [20],
suggesting that precursors to vasoconstrictor peptides
can be convened relatively quickly within small seg¬
ments of hand veins if the relevant enzyme is
expressed. Complementary DNA for one membrane-
associated isoform of ECE (ECE-1) has recently been
identified and the enzyme characterised [22], It
appears that ECE-1 is expressed predominantly in
endothelial cells, both intracellularly and extracellu-
larly, the latter site most likely being responsible for
conversion of exogenous big endothelin-1 in sites
where it occurs.
There is experimental evidence to suggest that
endothelin-1 has central actions in the nervous sys¬
tem to increase sympathetic nerve outflow [6], and
thus cause venoconstriction [23]. However, the inter¬
actions between endothelin-1 and the peripheral sym
pathetic nervous system are less clear. In vitro,
threshold concentrations of endotheiin-1, insufficient
to exert a direct vasoconstrictor effect, have been
shown to markedly potentiate vasoconstriction to
sympathetic nerve stimulation in rabbit ear arteries
[7]. However, endothelin-1 may have a biphasic
effect on peripheral sympathetic function because
higher concentrations appear to inhibit noradrenaline
release from nerve terminals and thus attenuate sym¬
pathetically mediated vasoconstriction in vitro in
guinea pig femoral artery [24], In human vessels in
vitro, endothelin-1 potentiates vasoconstriction to
noradrenaline in human isolated mammary arteries
[8]. However, forearm resistance vessel constriction
to lower body negative pressure and noradrenaline is
not potentiated by low doses of endothelin ■ 1 adminis
tered via the brachial artery [9]. Given that the Aellig
LVDT methodology is sufficiendy sensitive to have
detected even small changes in venoconstriction to
deep breath, the results of the present study suggest
that endothelin 1 does not potentiate peripheral sym
pathetic nervous system activity in human capaci¬
tance vessels. Indeed, although percentage
venoconstriction to deep breath appeared not to
change during endothelin-1 infusion, absolute
responses to deep breath tended to be lower after
endothelin 1, although they were not significantly dif
ferent from control. The possibility that peripheral
sympathetic responses are inhibited by endothelin-1
in man needs further investigation. These results are
in marked contrast to the situation in patients with
untreated essential hypertension, in whom venocon¬
striction to deep breath is potentiated -5-fold by
locally administered endothelin-1 [16],
In conclusion, our results show that human hand
veins lack the capacity to convert exogenous big
endothelin-1 and suggest that these capacitance ves¬
sels exhibit little or no ECE activity. Under physio¬
logical circumstances, endothelin-I does not appear
to potentiate the activity of the sympathetic nervous
system in these veins.
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Systemic Endothelin Receptor Blockade
Decreases Peripheral Vascular Resistance and
Blood Pressure in Humans
William G. Haynes, BSc, MRCP, MD; Charles J. Ferro, BSc, MRCP;
Kevin P.J. O'Kane, BSc, MRCP; David Somervilie, RGN;
Charmaine C. Lomax, RGN; David J. Webb, MD, FRCP, FFPM
Background Although local inhibition of the generation or
actions of endothelin-1 has been shown to cause forearm
vasodilatation, the systemic effects of endothelin receptor
blockade in healthy humans are unknown. We therefore inves¬
tigated the cardiovascular effects of a potent peptide endothe¬
lin ETa/b receptor antagonist, TAK-044, in healthy men.
Methods and Results Two randomized, placebo-controlled,
crossover studies were performed. In nine subjects, TAK-044
(10 to 1000 mg IV over a 15-minute period) caused sustained
dose-dependent peripheral vasodilatation and hypotension.
Four hours after infusion of the highest dose (1000 mg), there
were decreases in mean arterial pressure of 18 mm Hg and
total peripheral resistance of 665 AU and increases in heart
rate of 8 bpm and cardiac index of 0.9 L ■ min 1 • itT2 com¬
pared with placebo. TAK-044 caused a rapid, dose-dependent
increase in plasma immunoreactive endothelin (from 3.3 to
35.7 pg/mL within 30 minutes after 1000 mg). In a second
study in eight subjects, intravenous administration of TAK-
The endothelins are a family of three isopeptideswith extremely potent and characteristically sus¬tained vasoconstrictor and pressor actions.1
They also have mitogenic and neuroendocrine proper¬
ties that act to increase blood pressure.2 Endothelin-1 is
the predominant isopeptide in the vascular endotheli¬
um3 and is therefore likely to be the most physiologically
relevant of the three isopeptides in regulation of vascu¬
lar tone. Endothelin-1 is generated from a precursor, big
endothelin-1, through the action of a unique neutral
metalloprotease, ECE.4 Two distinct endothelin recep¬
tors have been identified and characterized.5 6 The ETA
receptor has a high affinity for endothelin-1 and is
selectively expressed in vascular smooth muscle cells.5
The ET„ receptor has equal affinity for all three endo¬
thelins. Although vascular expression of the ETB recep¬
tor has been thought to be limited to vascular endothe¬
lial cells,6 recent evidence suggests that ETh receptors
are expressed in vascular smooth muscle cells7 and are
functionally active.Kg
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044 at doses of 30, 250, and 750 mg also caused peripheral
vasodilatation, and all three doses abolished local forearm
vasoconstriction to brachial artery infusion of endothelin-1.
Brachial artery infusion of TAK-044 caused local forearm
vasodilatation.
Conclusions The endothelin ETA;B receptor antagonist
TAK-044 decreases peripheral vascular resistance and, to a
lesser extent, blood pressure; increases circulating endothelin
concentrations; and blocks forearm vasoconstriction to exoge¬
nous endothelin-1. These results suggest that endogenous
generation of endothelin-1 plays a fundamental physiological
role in maintenance of peripheral vascular tone and blood
pressure. The vasodilator properties of endothelin receptor
antagonists may prove valuable therapeutically. (Circulation.
1996;93:1860-1870.)
Key Words • endothelin • receptors • vasculature •
blood pressure • drugs • hemodynamics
The physiological relevance of endogenous generation
of endothelin-1 in control of blood pressure has been
unclear. If basal generation of endothelin-1 contributes
to resistance-vessel tone, then drugs that inhibit the
generation or actions of endothelin would be expected
to cause vasodilatation and decrease blood pressure and
might have potential therapeutic value in diseases asso¬
ciated with sustained peripheral vasoconstriction, such
as hypertension and chronic heart failure. However,
results of animal studies using ECE inhibitors and
endothelin receptor antagonists have been contradic¬
tory. Some have shown no apparent effect of antiendo-
thelin therapy on blood pressure in normotensive ani¬
mals. 1<M5 However, most of these studies had not been
designed primarily to test this hypothesis, with the result
that they may have lacked statistical power to confidently
exclude a hypotensive effect. In addition, in some, blood
pressure was not measured for sufficient time after
dosing to detect the expected slow-onset hypotensive
effect of antiendothelin therapy. Other studies have
shown that endothelin blockade apparently reduces
blood pressure significantly only in hypertensive ani¬
mals,1617 leading to suggestions that endothelin-1 has a
pathological rather than a physiological role. However,
there were similar percentage decreases in blood pres¬
sure in normotensive and hypertensive animals in these
and other studies,"' IK suggesting that endothelin plays
;t similar role in hypertensive and normotensive ani¬
mals. The lack of a significant effect of antiendothelin
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Selected Abbreviations and Acronyms
AU = arbitrary units
AUC = area under the concentration-time curve
Cma> = maximum drug concentration
ECE = endothelin-converting enzyme
ETa, ETb = endothelin receptors
HPLC = high-performance liquid chromatography
therapy on blood pressure in normotensive animals may be
due to the relative imprecision of measurement of small
changes in blood pressure. Other studies have shown that
ECE inhibitors and endothelin receptor antagonists do
decrease blood pressure in normotensive animals.18 22
These positive studies have usually examined hemodynam¬
ic responses for several hours after drug administration,
thereby taking into account the known slow reversal of
endothelin-1-induced vasoconstriction by antiendothelin
therapy.23
In the first such study in humans, we recently demon¬
strated that brachial artery infusion of the ECE inhibitor
phosphoramidon and the ETA receptor antagonist BQ-
123 causes progressive forearm vasodilatation.24 These
effects of phosphoramidon and BQ-123 on forearm
blood flow indicate a physiological role for basal gener¬
ation of endothelin-1 in maintenance of vascular tone.
However, homeostatic mechanisms often obscure the
blood pressure effects of quite large changes in resis¬
tance vessel tone, with the result that changes in blood
pressure may be quite small in relation to the effects of
a drug on peripheral resistance.25 Thus, the magnitude
of any potential effect of an endothelin antagonist on
blood pressure is difficult to predict without systemic
administration. As far as we are aware, the effects of
systemic endothelin receptor blockade on hemodynam¬
ics in healthy human subjects have not previously been
reported.
Therefore, we examined the hemodynamic effects of
systemic administration of a potent combined FTA and
ET„ receptor peptide antagonist, TAK-044,26 29 in
healthy male subjects. Because animal data show that
endothelin receptor antagonists increase circulating en¬
dothelin concentrations,30-31 we also measured plasma
immunoreactive endothelin concentrations. In addition,
in a second study, we investigated whether systemic
pretreatment with TAK-044 blocked forearm vasocon¬
striction to brachial artery infusion of endothelin-1 and
whether local administration of TAK-044 caused direct
vasodilatation of forearm resistance vessels.
Methods
Subjects
Eighteen healthy male subjects between 21 and 60 years of
age and within 15% of ideal body weight were recruited.
Studies were conducted with the approval of the Lothian
Healthy Volunteer Research Ethics Subcommittee and the
Inveresk Clinical Research Ethics Committee and with the
written, informed consent of each subject. No subject received
vasoactive or nonsteroidal medication in the week before or
during the study. In addition, subjects abstained from alcohol
for 48 hours, from caffeine-containing drinks and cigarettes for
at least 24 hours, and from food for at least 10 hours before any
measurements were made.
Drugs
TAK-044 is a cyclic hexapeptide (cyclo[D-a-aspartyl-3-[(4-phe-
nylpiperazin-l-yl)carbonylj-L-alanyl-L-a-aspartyl-D-2-(2-thienyl)-
glycyl-L-leucyl-D-tryptophyl] disodium salt; molecular weight, 972)
that potently antagonizes l25l-endothelin-l binding at both ETA
(10,1=0.08 nmol/L) and ET„ (IO>=120 nmol/L) receptors in
vitro.26 TAK-044 also blocks constriction of isolated coronary
vessels to endothelin-1 (ETA and ETB receptor agonist) and
sarafotoxin S6c (ETB receptor agonist).26 Specificity of TAK-044
for endothelin receptors has been shown in vitro in porcine
coronary arteries, in which it does not affect vasoconstriction to
histamine, serotonin, acetylcholine, U-46619, and potassium and
in which it is without direct vasoactive effects even at concentra¬
tions of 100 p.mol/1 J9 Specificity has also been shown in vivo,
where systemic pretreatment of rats with TAK-044 at 10 mg/kg
does not alter pressor or depressor responses to phenylephrine,
angiotensin II, nitroglycerin, and acetylcholine.28 In contrast,
TAK-044 dose-dependently blocks the pressor response to bolus
doses of endothelin-1 and sarafotoxin S6c in rats, with 90%
blockade apparent at a dose of 10 mg/kg, the effects of which
persist for 3 hours.28-29 For the clinical studies in humans, we chose
to use doses of TAK-044 ranging from 10 to 1000 mg. This dose
range was based on the animal evidence of specificity and efficacy
at doses from 0.1 to 10 mg/kg and also on the safety profile of
TAK-044 in toxicological studies at higher doses (information on
file, Takeda Euro R&D Centre GmbH). Pharmaceutical grade
TAK-044 for parenteral use was obtained from Takeda Euro
R&D Centre GmbH and was dissolved in physiological saline
(0.9%; Baxter Healthcare Ltd). The placebo was dextrose (50
mg), also dissolved in physiological saline.
Endothelin-1 was administered intra-arterially at a dose of 5
pmol/min, based on previous work showing that this dose of
endothelin-1 causes slow-onset vasoconstriction of human fore¬
arm resistance vessels in vivo.9-24 Pharmaceutical grade endo¬
thelin-1 was obtained from Clinalfa AG (NovaBiochem) and
dissolved in physiological saline (0.9%; Baxter Healthcare Ltd)
to a final concentration of 5 pmol/mL.
Drug Administration
For intravenous administration of TAK-044, an antecubital
vein was cannulated at least 1 hour before dosing. TAK-044 or
placebo was dissolved in physiological saline and infused at 200
mL/h over a period of 15 minutes (total volume, 50 mL). This
cannula was not used for blood sampling. For intra-arterial
infusion of endothelin-1 or TAK-044, the left brachial artery
was cannulated under local anesthesia (1% lidocaine; Astra
Pharmaceuticals Ltd) with a 27-standard wire gauge steel
needle attached to a 16-gauge epidural catheter (Portex Ltd).
Patency was maintained by infusion of 0.9% physiological
saline via a Welmed P1000 syringe pump (Welmed Clinical
Care Systems). The total rate of intra-arterial infusion was
maintained constant throughout all intra-arterial studies at 1
mL/min.
Measurements
Systemic hemodynamics. Blood pressure and heart rate were
measured with semiautomated oscillometric monitors (study 1,
Hewlett-Packard M1165A, Hewlett-Packard GmbH; study 2,
Takeda UA 751, Takeda Medical Inc). Cardiac function
(stroke volume, cardiac output, and heart rate) was measured
with a noninvasive bioimpedancc methodology (BoMed NC-
COM3, BoMed Medical Manufacturer Ltd). Absolute cardiac-
output measured by bioimpedance has been validated against
thermodilution measurements with correlation coefficients
ranging from 0.83 to 0.90 and mean differences ranging from
2% to 12%.1215 In addition, bioimpedance measures of
changes in cardiac output after drug intervention are in close
agreement with simultaneous thermodilution measurements.15
Furthermore, within-subject coefficient of variation is lower
with bioimpedance than with thermodilution (4.1% versus
7.8%)." The safety and reproducibility of the bioimpedance
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technique confers specific advantages in studies of drug action
in healthy subjects.25
Side-effect assessments. The following assessments were per¬
formed to detect potential adverse effects: 12-lead ECGs, visual
analogue scale (for sedation), urinalysis, clinical chemistry
screen (liver enzymes, electrolytes, creatinine, blood urea,
protein), and hematology screen (full blood cell count, white
blood cell differential count).
Forearm blood flow. Blood flow was measured simultaneously
in both forearms by venous occlusion plethysmography using
indium/gallium-in-Silastic strain gauges as previously de¬
scribed,9-24 except that single-channel Hokanson EC 4 plethys-
mographs (DE Hokanson Inc) were used. Recordings of
forearm blood flow were made repeatedly over 3-minute
periods.
Pharmacokinetic and endothelin assays. Fifteen-milliliter ve¬
nous blood samples were obtained at intervals for assay of
serum TAK-044 and plasma immunoreactive endothelin con¬
centrations. TAK-044 was extracted from sodium acetate (pH
5) buffered serum by methanol/acetic acid-conditioned Varian
Certify II cartridges and was measured by HPLC. Eluates were
evaporated to dryness under vacuum at 40°C, and the dry
residues were taken up in 200 (xL of 39% acetonitrile. Chro¬
matographic separation was achieved by a column-switching
technique using two Alltech C18 HPLC columns with Gilson
model 307 HPLC pumps. The first mobile phase comprised
40% acetonitrile and 60% 0.01 mol/L KH2P04/0.005 mol/L
tetrabutylammonium bromide, pH 3.8. The second mobile
phase comprised 45% acetonitrile/1% acetic acid/54% water.
Detection was achieved by fluorimetry (excitation, 286 nm;
emission, 348 nm) with Hitachi F-1050 fluorescence detectors.
The limit of quantification of the assay, defined as the lowest
quantifiable amount of compound at which the loss of precision
was <20% and the accuracy was between ±20%, was 5 ng/mL
of TAK-044.
Plasma immunoreactive endothelin was measured by radio¬
immunoassay (ITS Production BV) as previously described.16
The sensitivity of this assay is 2 pg/mL immunoreactive endo¬
thelin. The assay does not cross-react with TAK-044. Cross-
reactivity of the assay with endothelin-1, endothelin-2, endo-
thelin-3, and big endothelin-1 is 100%, 52%, 96%, and 7%,
respectively.
Study Design
Study 1: Dose-Ranging Hemodynamic Study
Two groups of five subjects were recruited to a double-blind,
ascending-dose, crossover study with a randomized placebo
phase. Group 1 subjects were studied on five occasions, receiv¬
ing placebo and 10, 100, 500, and 1000 mg of TAK-044, with 7
days between phases. Group 2 subjects were studied on four
occasions, receiving placebo and 30, 250, and 750 mg of
TAK-044, with 7 days between phases. The ascending-dose
design enabled us to evaluate safety and tolerability of TAK-
044 at lower doses before proceeding to higher doses and
entailed that the study days for groups 1 and 2 occur on
different days of the same week for the first 4 weeks of dosing.
For example, in the first week, subjects in group 1 received
either placebo or 10 mg on Monday and group 2 subjects
received placebo or 30 mg on Wednesday.
In each study phase, subjects were admitted to the research
unit the day before dosing and fasted from 11 pm. At least 1
hour before dosing, an antecubital venous cannula was sited in
each arm for administration of TAK-044 and blood sampling.
Subjects received a 15-minute intravenous infusion of TAK-044
or placebo at ^9 am and, apart from voiding, were not
permitted to stand until 4 hours after dosing. Hemodynamic
measurements were made and blood samples were obtained for
TAK-044 and endothelin concentrations before and after dos¬
ing (see Figs I through 4). Sedation was assessed and 12-lead
ECGs were recorded before and after dosing. Blood and urine
samples were obtained for safety assessments before and 24
hours after dosing. Subjects were fasted until 4 hours after
dosing, when they received a light meal. An evening meal was
provided 10 hours after dosing. Subjects were discharged 24
hours after dosing.
Study 2: Effect of TAK-044 on Forearm
Vasoconstriction to Endothelin-1
Eight subjects were recruited to a five-phase, double-blind,
randomized, placebo-controlled crossover study, with at least 7
days between phases. These studies using forearm plethysmogra¬
phy were performed in a quiet clinical research ward maintained
at a constant temperature between 22°C and 25°C. In each phase,
subjects were admitted to the research unit at 7 am, and blood and
urine samples were obtained for safety assessments before dosing.
At least 1 hour before dosing, an antecubital venous cannula was
sited in each arm for administration of TAK-044 and blood
sampling. In the first four phases, subjects received, in random
order, placebo and 30, 250, and 750 mg of TAK-044 IV over 15
minutes, at =»9 am. Brachial artery cannulation was performed
after the infusion of TAK-044 or placebo had finished, and intra¬
arterial infusion of endothelin-1 (5 pmol/min) commenced 60
minutes after the start of TAK-044 dosing and continued for 120
minutes thereafter (ie, until 180 minutes after TAK-044 dosing).
Measurements were made of forearm blood flow (see Fig 5) and
blood pressure and cardiac output (-25, -15, -5, +15, +30,
+45, +60, +90, +120, +150, and +180 minutes). Blood samples
were obtained at —15, +15, +60, +120, and +180 minutes for
assay of TAK-044 and endothelin concentrations. In the fifth
phase, TAK-044 was infused intra-arterially via the brachial
artery, with subjects receiving 10 mg over 1 hour followed by 100
mg over 1 hour. Measurements were made of forearm blood flow
(see Fig 6), blood pressure, and cardiac function (-10 and +120
minutes), and blood samples were obtained for assay of endothe¬
lin (-15, +15, +60, and +120 minutes). In each phase, subjects
remained supine until 3 hours after dosing and were fasted until 4
hours after dosing, when they received a light meal. Subjects were
discharged 6 hours after dosing.
Data Presentation and Statistical Analysis
Mean arterial pressure was calculated as diastolic blood
pressure plus one third pulse pressure. Data for stroke volume
and cardiac output were corrected for body surface area,
calculated according to a standard nomogram, to provide
measures of stroke and cardiac indexes. Total peripheral
resistance index was calculated as mean arterial pressure
divided by cardiac index and expressed in AU. For the systemic
hemodynamic data, the change from the last measurement
before dosing was calculated at each time point and corrected
for the changes that occurred at the same time point after
placebo. Plethysmographic data listings were extracted from
computer data files and forearm blood flows (mL • dL forearm
tissue ' • min ') calculated for individual venous occlusion cuff
inflations using a template spreadsheet (Excel 4.0; Microsoft
Ltd). The last five flow recordings in each 3-minute measure¬
ment period were averaged. To reduce the variability of blood
flow data, the ratio of flows in the infused and noninfused arms
was calculated for each time point and expressed as a percent¬
age change from the last baseline measurement ( + 55 minutes
for phases A through D; -10 minutes for phase E), in effect
using the noninfused arm as a contemporaneous control for the
infused arm.17-18
Pharmacokinetics of TAK-044 were analyzed by use of
S1PHAR software (version 4, SIMED). The following param¬
eters were calculated: AUG, Cm„, and elimination half-life.
Plasma immunoreactive endothelin concentrations were ana¬
lyzed in a similar manner, with AUG and GnM> being calculated.
Absolute values are presented as mean±SEM. Placebo-
corrected hemodynamic changes from baseline were arithmet
ieally averaged over the relevant measurement period (0 to 24
hours for study I; 0 to 3 hours for study 2), with uniform
weighting given to each time point, and are shown in the tables
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Table 1. Baseline Hemodynamic Values in Groups 1 and 2 of Study 1
SBP, DBP, Heart Rate, Stroke Index, Cardiac Index,
mm Hg mm Hg bpm mLVm2 L ■ min"' ■ m"' TPRI, AU
Placebo (group 1) 110±4 50±9 5616 6516 3.410.4 14801301
Placebo (group 2) 112±7 53±7 5717 6613 3.810.5 14001237
10 mg (group 1) 115±6 5316 5917 67112 3.711.0 1496 1 334
30 mg (group 2) 111*4 57 ±6 59111 59l3 3.510.8 16281426
100 mg (group 1) 114*7 53±6 6017 71110 4.211.0 13041260
250 mg (group 2) 113*4 57± 10 56112 6014 3.411.0 1744 1 540
500 mg (group 1) 111 ±5 52±6 59 ±3 6418 3.710.7 14281368
750 mg (group 2) 110*6 57 ±6 6015 5716 3.410.8 1686 1 564
1000 mg (group 1) 110*6 54 ±11 5415 6215 3.310.4 1605 1 320
There were no significant differences between baseline values on the different study days for either group 1 or 2. SBP
indicates systolic blood pressure; DBP, diastolic blood pressure; and TPRI, total peripheral resistance index.
with 95% CIs. Data were analyzed statistically by repeated-
measures ANOVA. Factors included in the ANOVA were
subject, dose of TAK-044, time point, and dose-time point
interaction. In none of the analyses was there evidence of a
statistically significant dose-time point interaction. Therefore,
the adjusted dose group means from the ANOVA were
compared with the null hypothesis, for all time points com¬
bined, by a two-sided I test. In addition, dose-response trends
were assessed statistically by the technique of linear contrast.
Linear contrast analyzes trends between groups of subjects that
are categorized quantitatively, using variances derived from an
ANOVA. Each linear contrast was calculated as the sum of the
mean of each group multiplied by a coefficient that represented
that group's dose (adjusted so that the sum of all coefficients
equals zero).39 Statistical testing of a linear contrast involved
calculation of its SEM using the pooled estimate of variance
from the ANOVA, with a / statistic given by the linear contrast
divided by this SEM. Simple regression analysis was used to
explore whether there was a correlation between plasma endo¬
thelin and hemodynamic changes. Statistical analyses were




In study 1, one subject withdrew from group 1 after
the second phase for non-study-related reasons and was
not replaced; he did not receive placebo and was there¬
fore not included in the analysis. All other subjects
completed the study protocols. TAK-044 was well toler¬
ated, with no difference between placebo and TAK-044
phases in the prevalence of minor symptoms. There were
no serious adverse events in either study, and no clini¬
cally significant abnormalities were detected on safety
monitoring (urinalysis, hematology, clinical chemistry,
ECG, and sedation scores).
Study 1: Dose-Ranging Hemodynamic Study
Baseline hemodynamic parameters did not differ be¬
tween study days (Table 1). Compared with placebo, all
doses of TAK-044 reduced blood pressure, with the
hypotensive effect apparent within 30 minutes, maximal
between 1 and 6 hours, and persisting to 24 hours at the
higher doses (Figs 1 and 2). For example, after the 30-
and 1000-mg doses, mean arterial pressure was reduced
at 4 hours by 8 and 18 mm Hg from baselines of 75 and
72 mm Hg, respectively. Diastolic and mean arterial
pressures were reduced by all doses; systolic pressure
was significantly decreased by all doses except 750 mg.
Heart rate was significantly increased by TAK-044 at
all doses except 30 and 100 mg; this increase persisted to
=8 hours for doses >250 mg (Figs 1 and 2). Most doses
of TAK-044 significantly increased stroke and cardiac
indexes (Fig 2). Total peripheral resistance index was
significantly and substantially reduced at all doses, and
this effect was sustained for up to 24 hours (Figs 1 and
2). For example, after the 30- and 1000-mg doses, total
peripheral resistance index was reduced at 4 hours by
378 and 665 AU from baselines of 1628 and 1605 AU,
respectively. There were significant dose-related trends
on linear contrast testing for heart rate, stroke index,
O.M 4.00 A06 1 2.00 14.00 20.00 24.00
TkM frota MlaliWrilioa of TAK-044 (hr)
Fig 1. Time course of the effects of the highest dose of
TAK-044 (1000 mg) on mean arterial pressure (MAP), heart rate
(HR), stroke index (SI), cardiac index (CI), and total peripheral
resistance index (TPRI) in group 1 from study 1. TAK-044
significantly decreased MAP (P<.001) and TPR (Pc.001) and
increased HR (P<.001), SI (P .034), and CI (Pc.001); these
effects were maximal at 4 hours and sustained for at least 12
hours. Data shown represent placebo-corrected changes from
predose (change from predose [active] minus mean change from
predose [placebo]).
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Fig 2. Mean hemodynamic changes (A) over 24 hours after dosing with TAK-044 in study 1. For the placebo columns (open), mean
change from predose is shown. For the active treatment columns (stippled), placebo-corrected changes from predose are shown
(change from predose [active] minus mean change from predose [placebo]). *Ps.05 for comparison with predose; tP- 05 for linear
contrast test of trend with dose. SBP indicates systolic blood pressure; DBP, diastolic blood pressure; other abbreviations as in Fig 1.
cardiac index, and total peripheral resistance, although
not for blood pressure (Fig 2).
TAK-044 increased plasma immunoreactive endothe-
lin concentrations in a dose-dependent manner, with
significant increases at all doses except for 10 mg (Table
2). For example, after 1000 mg, plasma endothelin
concentrations increased from 3.3 to 35.7 pg/mL within
30 minutes. Compared with the sustained hemodynamic
effects of TAK-044, increases in plasma endothelin were
maximal within 30 minutes and waned rapidly, even at
the highest doses (Fig 3). Even so, there was a significant
correlation between the increase in plasma endothelin
and the change in total peripheral resistance in both
group 1 (/-=-.15; P=.032) and group 2 (r=-.156;
P=.021). In group 2 only, plasma endothelin was also
correlated with change in systolic (r=-.189; P=.005)
and mean arterial (r=-.160; P=.018) pressures. TAK-
044 plasma concentrations increased dose-dependently
(Fig 4); the terminal half-life was short (30 to 60
minutes) and tended to increase with dose (Table 2).
Study 2: Effect of TAK-044 on Forearm
Vasoconstriction to Endotheiin-1
As in the first study, all intravenous doses of TAK-044
significantly decreased diastolic blood pressure, in¬
creased heart rate and cardiac index, and caused periph¬
eral vasodilatation (Table 3), with the effects sustained
over the measurement period. There were significant
dose-related trends for systolic blood pressure, mean
arterial pressure, and total peripheral resistance (Table
3). As in study 1, plasma immunoreactive endothelin
concentrations were increased in a dose-dependent
manner, with significantly higher Cmax values after 250
mg (22.9 pg/mL; P<.0001) and 750 mg (37.2 pg/mL;
P<.0001) compared with placebo (7.8 pg/mL). Similarly,
there were significant correlations between plasma en¬
dothelin concentrations and changes in cardiac index
(r=.226; P=.012), diastolic pressure (r= — .225; P=.011),
mean arterial pressure (r=-.206; P=.021), and total
peripheral resistance (r=-.249; P=.006).
In the first four phases, forearm blood flow in the
infused arm was not significantly different from that in
Table 2. Summary Pharmacokinetic Parameters for Plasma Immunorcactive Endothelin Concentrations and
TAK-044 Concentrations in Study 1
Plasma Endothelin Plasma TAK-044
C™„. pg/mL AUC, pg h/mL Cm„, ng/mL AUC, ng h/mL *1/2 . 6
Placebo (group 1) 4.3±0.1 88 ±7
Placebo (group 2) 4.8±0.3 83 ±3
10 mg (group 1) 7.4±0.8* 90 ±4 581±183 NA NA
30 mg (group 2) 9.6± 1.0 112±8' 1679-268 557 ±89 0.51 ±0.09
100 mg (group 1) 13.3-1.4 128± 10" 7912±1810 2279 ±263 0.72-0.07
250 mg (group 2) 29.3±4 3 136-121 16 228*2994 5764 ±1025 0.73*0.09
500 mg (group 1) 33.2- 1.7f 160-141 34 425-2402 11 687- 1013 0 69*0.13
750 mg (group 2) 42.8- 1 9t 166-111 66 760* 13 658 24 571 -4175 1 04 * 0.07
1000 mg (group 1) 38 4 -3.2t 212-131 123 000 - 10 916 40 748 ± 1248 1.01 *0.11
Cm„ indicates maximal endothelin concentrations after dosing; t„
insufficient for calculation.
*P<.05 vs placebo; tP< 005 vs placebo.
, terminal half-life of compound; NA, parameters not available because data were
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Time from idmlniitration of TAK-044 (hr)
Fig 3. Effect of TAK-044 on plasma immunoreactive endothelin
levels in study 1. A, Group 1 results after infusion of placebo (♦)
and TAK-044 at 10 mg (□), 100 mg (•), 500 mg (o),and 1000 mg
(■). B, Group 2 results after infusion of placebo (♦) and TAK-044
at 30 mg (n), 250 mg (•), and 750 mg (o). TAK-044 dose-
dependently increased circulating endothelin concentrations.
the noninfused arm at baseline on any phase, and
baseline blood flows were similar between the different
treatment days (Table 4). Blood flow in the noninfused
arm did not change significantly after placebo. Brachial
artery infusion of endothelin-1 in the placebo phase
caused a significant slow-onset local forearm vasocon¬
striction, reaching =30% after 60 minutes (P= .0031
versus basal; Fig 5). Systemic administration of TAK-044
did not significantly change blood flow in the noninfused
arm compared with placebo. However, forearm vasocon¬
striction to endothelin-1 was completely blocked by
TAK-044 at doses of 30 mg (P=.34 versus basal; P=.()2
versus placebo), 250 mg (/'=.60 versus basal; />=.0I
versus placebo), and 750 mg (P =.89 versus basal; P= .01
versus placebo), with no significant difference between
doses (Fig 5, Table 4).
In the fifth phase, brachial artery infusion of TAK-044
at 10 mg caused significant local vasodilatation, with an
increase in the ratio of blood flow between infused and
noninfused arms of =20% (P= .0062; Fig 6, Table 4) At
the higher dose (100 mg/h), blood flow remained ele¬
vated in the infused arm but also increased in the
noninfused arm, with the result that the percentage
increase in the ratio of blood flow between the infused
and noninfused arms fell toward baseline (/>=.10; Fig 6,
Table 4). A possible systemic effect of TAK-044 at the
higher dose is supported by the tact thai total peripheral
0.00 1.00 2.00 3.00 4.00
Tim« from administration of TAK-044 (hr)
Fig 4. Graphs showing pharmacokinetic profiles of TAK-044 in
study 1. A, Results after infusion of TAK-044 at 10 mg (a), 30 mg
(o), and 100 mg (a). B, Results after infusion of TAK-044 at 250
mg (□), 500 mg (a), 750 mg (o), and 1000 mg (a). Results are
shown here only for the first 4 hours after dosing, although
pharmacokinetic calculations were based on all time points up to
24 hours (see Table 2). Plasma levels after 4 hours were <0.025
pig/mL for all doses.
resistance decreased by 347±113 AU at 2 hours, com¬
pared with an increase of 158±134 AU at 2 hours in the
placebo phase. In addition, although circulating endo¬
thelin concentrations did not differ from placebo at
baseline or 1 hour after the start of intra-arterial dosing,
endothelin concentrations at 2 hours (17.3± 1.6 pg/mL)
were significantly greater than at 2 hours in the placebo
phase (4.6±0.2 pg/mL; /*= .01).
Discussion
These studies are the first report of the effects of
systemic endothelin receptor blockade in healthy hu¬
mans. We have shown that a 15-minute infusion of the
endothelin ET^,, receptor antagonist TAK-044 de¬
creased systolic blood pressure (by =4%), diastolic
blood pressure (by =18%), and total peripheral resis¬
tance (by =26%>) over a 24-hour period. Systemic ETv,,
receptor blockade also increased circulating immunore¬
active endothelin (by up to 1000%) and blocked periph¬
eral vasoconstriction to exogenous endothelin 1. In ad¬
dition, local administration of TAK-044 caused forearm
vasodilatation. These findings have implications for the
physiological role of endothelin-1 generation, the phar-
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Table 3. Mean Hemodynamic Changes Over 24 Hours After Dosing With TAK-044 in Study 2
TAK-044, mg
Placebo 30 250 750
SBP", mm Hg
Baseline value
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Abbreviations as in Table 1. For the placebo column, mean change from prodoso is shown. For the active treatment columns, placebo
corrected changes from predose are shown (change from predose [active] minus mean change from predose [placebo]).
'P--.05 for linear contrast test of trend with dose.
macology of endothelin receptor antagonists, and their
ultimate therapeutic relevance.
Physiological Role of Endothelin-1 in Regulation of
Blood Pressure
As noted earlier, animal data on the hemodynamic
effects of systemic endothelin receptor antagonism are
apparently contradictory. We have previously shown
that brachial artery administration of an ECE inhibitor
or ETa antagonist causes local forearm vasodilation,
suggesting that basal vascular generation of endothelin-1
contributes to vascular tone.-4 Our demonstration here
that systemic administration of an ET,VI) antagonist
causes peripheral vasodilation and hypotension confirms
that endogenous generation of endothelin plays a fun¬
damental physiological role in the maintenance of blood
pressure in humans.
Pharmacology of Endothelin Receptor Antagonists
TAK-044 decreased mean arterial pressure and in¬
creased heart rate and cardiac index, resulting in a
substantial decrease in calculated peripheral resistance.
The greater reduction in diastolic as opposed to systolic
pressure is consistent with a primary action of TAK-044
on peripheral resistance. TAK-044 also increased lore-
arm blood How when administered via the brachial
artery, although this local action was obscured at the
higher dose by systemic vasodilatation. Taken together,
these effects indicate that the resistance vessels are the
major site of action after endothelin ETa/b receptor
blockade with TAK-044. In spontaneously hypertensive
rats, a 6-hour infusion of an ET^, endothelin receptor
antagonist (SB 209670) also decreases blood pressure
through an effect on total peripheral resistance.4" How¬
ever, heart rate tends to decrease in these animals,
suggesting other sites of action for endothelin receptor
antagonists. The difference between our results and
these animal data may reflect differences in species,
resting blood pressure, or mode of administration of the
antagonist.
Vasodilatation and hypotension caused by TAK-044
occurred within 15 minutes and persisted for 12 to 24
hours. In contrast to its sustained hemodynamic actions,
the marked increase in plasma endothelin concentrations
caused by TAK-044 was relatively short in duration, and
TAK-044 itself appeared to have a short half-life. In
animals, the blood pressure-lowering effects of ECE inhi¬
bition or endothelin ETA receptor blockade usually take
several hours to reach maximum,"-2' and forearm vasodi¬
latation to these agents is also slow in onset.-'4 This gradual
effect is thought to be related to the slow dissociation of
endothelin-1 from its receptor, resulting in persistent vaso¬
constriction even after new receptor binding is inhibited.
There are two speculative explanations for the rapid onset
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Table 4. Forearm Blood Flows and Ratio of Blood Flows Between Infused and Noninfused Arms in Study 2
Time From IV
TAK-044 Placebo
Phases 1 to 4 Phase 5
IV TAK-044
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TAK-044)
+ 60 min (after 10 mg
IA TAK-044)











IV indicates intravenous; IA, intra-arterial. Forearm blood flow is expressed as mL • 100 dL forearm tissue ' ■ mm 1 For all columns, -10 min is the
baseline measurement before dosing with TAK-044. For the columns containing data from the intravenous systemic TAK-044 phases, the +55 min row
contains the last measurements before IA infusion of endothelin-1 was started (at +60 min). For the column containing data from the IA TAK-044 phase,
the +60 min row contains measurements made at the end of the 10 mg/h treatment period.
*P—.05 vs baseline ratio before endothelin-1 (+55 min); fP- 05 vs placebo for change in ratio during endothelin-1 infusion (+60 min to +180 min);
.05 vs baseline ratio before TAK-044 (-10 min).
of vasodilatation observed here. First, the rapid effects of
TAK-044 may be related to its potency as an endothelin
receptor antagonist, with plasma concentrations being
achieved that were sufficient to reverse, rather than pre-
*
# -30
■ Of TAK-044 (min)
Fig 5. Effect of TAK-044 on forearm vasoconstriction to locally
administered endothelin-1 in study 2. On four separate occa¬
sions, subjects received a 15-minute intravenous infusion of
placebo (•) and TAK-044 at 30 mg (o), 250 mg (■), and 750 mg
(i i), followed 60 minutes later by brachial artery infusion of
endothelin-1 (5 pmol/min for 120 minutes). Endothelin-1 caused
a slow-onset forearm vasoconstriction after infusion of placebo.
All three doses of TAK-044 significantly (P< 05) blocked forearm
vasoconstriction to endothelin-1.
vent, endothelin-1 receptor binding. Second, TAK-044 is
active at ETB as well as ETA receptors2*-29; there is some
evidence that vasoconstrictor ETB receptors may have a
more rapid onset of action than ETA receptors.41
Endothelin-1: has a slow onset of action, and this may
partially explain the sustained vasodilatation caused by
ET^ receptor blockade with TAK-044. In addition,
although TAK-044 had a short half-life (30 to 60 min¬
utes), TAK-044 concentrations were substantially
greater than the IC50 for binding to ETA receptors (0.08
nmol/L or 0.08 ng/mL) for at least 12 hours at doses
>500 mg. Furthermore, it is possible that TAK-044
concentrations were above this level for longer periods
or at lower doses; however, the limit of quantification for
the TAK-044 assay was 5 ng/mL, =50-fold higher than
the IC50 at ETa receptors. Finally, the dissociation
between pharmacokinetic and pharmacodynamic param¬
eters may reflect entry into and activity of TAK-044 in
another tissue compartment. This might be within the
vasculature or in the central or peripheral nervous
system. Entry into and actions in other tissue compart¬
ments appear to explain the similar dissociation between
actions and plasma concentrations observed for inhibi¬
tors of the renin-angiotensin system.4241
The trend analysis shows that vasodilatation to
TAK-044 was dose dependent. However, given that
vasodilatation occurred at almost all doses, including
the lowest (10 mg), it is probable that doses <10 mg
may be effective. Indeed, the pharmacokinetic results,
together with the in vitro pharmacology data dis¬
cussed earlier, suggest that the initial plasma levels
were probably sufficiently high even after 10 mg to
block endothelin ETA receptors for at least 2 hours.
This is confirmed by the complete blockade of fore-
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arm vasoconstriction to endothelin-1 at 3 hours by
doses as low as 30 mg in the second study. We did
demonstrate a dose response for the elevation of
circulating immunoreactive endothelin by TAK-044.
In addition, peripheral vasodilatation was related to
plasma endothelin concentrations, further supporting
a dose-dependent effect on peripheral resistance.
The increase in plasma immunoreactive endothelin
after TAK-044 may have several components. The ra¬
dioimmunoassay we used detected both endothelin-1
and endothelin-3. Although it also cross-reacted with big
endothelin-1, this was to a limited degree (7%) and
therefore is unlikely to explain the substantial increases
in circulating endothelin concentrations. The increase in
circulating endothelin may have been due to increased
generation or decreased receptor-mediated clearance of
endothelin isopeptides. Decreased clearance of endo¬
thelin by ETb receptors appears to be the most likely
explanation, for several reasons. First, in animals, block¬
ade of endothelin receptors of the ETB subtype but not
of the ETa subtype increases plasma endothelin-1 and
endothelin-3 concentrations30 and prolongs the half-life
of exogenous 125I-endothelin-l.31 Second, blockade of
endothelin receptors increases plasma endothelin-1
within 15 minutes,30 whereas de novo generation is
thought to take several hours.1 Third, endothelin recep¬
tor blockade does not increase big endothelin-1 concen¬
trations.30 The substantial increase in total immunore¬
active endothelin in this study, together with the animal
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Fig 6. Graph showing effect of brachial artery administration of
TAK-044 on forearm blood flow in the last phase of study 2.
TAK-044 was infused at 10 and 100 mg/h sequentially, each for
60 minutes. TAK-044 caused significant local vasodilatation of
the cannulated arm during infusion at 10 mg/h (P .0062). At 100
mg/h, local vasodilatation appears to diminish (P .10); this is
probably related to an increase in blood flow in the noninfused
arm, which decreases the blood flow ratio between infused and
noninfused arms (see text and Table 5).
important mechanism in clearance of endogenous endo¬
thelin peptides.
It would be useful for the clinical development of
endothelin receptor antagonists to have a simple and
reproducible index of endothelin receptor blockade.
Although increases in plasma immunoreactive endo¬
thelin correlated with decreases in total peripheral
resistance, this association was relatively weak, with
correlation coefficients of =0.2. Changes in circulating
endothelin concentrations probably only reflect antag¬
onism at the ETb receptor, which, in addition to its
functional roles, appears to mediate clearance of
circulating endothelin-1.3031 For a drug with ETA
receptor blocking properties, such as TAK-044, phar¬
macodynamic effects may be apparent at concentra¬
tions that do not substantially increase circulating
endothelin concentrations, as was the case here. This
may help to explain the different timings of changes in
circulating endothelin and peripheral resistance, as
well as the rather weak correlation between these
parameters. In the second study, we used forearm
vasoconstriction to endothelin-1 1 to 3 hours after
dosing with TAK-044 to test endothelin receptor
blockade. Vasoconstrictor responses to locally infused
endothelin-1 were completely inhibited by all three
doses, consistent with the similar hemodynamic re¬
sponses to these doses. This model is safer than using
intravenous infusion of systemic doses of endothelin-1
to increase blood pressure, particularly given the
sustained and potent nature of vasoconstriction to
endothelin-1. Given that both ETA and ETB receptors
mediate vasoconstriction to endothelin-1 in the fore¬
arm,9 blockade of vasoconstriction to endothelin-1 is
likely to reflect antagonism at both ETA and ETB
receptors. Antagonism at ETB receptors could be
tested by brachial artery administration of a selective
ET„ receptor agonist, such as sarafotoxin S6c.9
Potential Therapeutic Role of Endothelin
Receptor Antagonists
Experimental evidence supports a pathophysiologi¬
cal role for endothelin-1 in several diseases thought to
be associated with acute vasoconstriction or vaso¬
spasm. These include acute renal failure,21 coronary
vasospasm,44 unstable angina,45 myocardial infarc¬
tion,4" and cerebral vasospasm associated with sub¬
arachnoid hemorrhage.21 The potent inhibition of
peripheral vasoconstriction to exogenous endothe¬
lin-1, as a model of vasospasm, by TAK-044 in this
study suggests that it could be of benefit in such
conditions. Indeed, in experimental animal models,
TAK-044 has been shown to prevent postischemic
acute renal failure27 and limit myocardial infarction
size.29 The sustained vasodilator actions of TAK-044
in healthy subjects suggest that orally available endo¬
thelin receptor antagonists with a similar profile of
action may have a valuable therapeutic role in dis¬
eases associated with chronic peripheral vasoconstric¬
tion, such as essential hypertension, chronic heart
failure, and chronic renal failure.
In conclusion, we have shown that systemic endo¬
thelin ETa and ETB receptor blockade with the
peptide TAK-044 causes sustained and substantial
peripheral vasodilatation and, to a lesser extent, hypo¬
tension. This response suggests a fundamental physi-
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ological role for endogenously generated endothelin-1 in
cardiovascular regulation. Circulating immunoreactive en¬
dothelin concentrations were increased dose-dependently,
and TAK-044 blocked forearm vasoconstriction to intra¬
arterial endothelin-1. Blockade of forearm vasoconstriction
to brachial artery infusion of endothelin-1 appears to be a
sensitive model for detecting endothelin receptor antago¬
nism in humans. These findings support the development
of endothelin receptor antagonists as therapies for diseases
associated with acute and sustained peripheral
vasoconstriction.
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Activation of the endothelin B receptor
causes a dose-dependent accumulation of
cyclic GMP in human platelets
M. E. C. Dockrell, D. J. Webb and B. C. Williams
(Received 22 January 1996; aaccepted I February 1996)
Endothelins modulate in vitro aggregation of human platelets in a bi-directional manner. Thus endothelin-1 has been shown to act as a
potentiator of primary aggregation and an inhibitor of secondary aggregation. The endothelin receptors and corresponding second
messengers which cause these effects have not yet been characterised. This study investigated the effect of endothelin-1, an agonist at both
the ETa and the ET„ receptors and sarafotoxin (SRTX) S6c, a selective ETB agonist, on human platelet cyclic nucleotide levels. Neither
endothelin-1 (10 "-10 7 M) nor SRTX Stic (10 "-10 7 M) significantly altered platelet cAMP levels. In contrast, both agonists produced a
dose-dependent increase in platelet cGMP. From these data, we conclude that activation of the ETB receptor in human platelets is responsible
for an increase in platelet cGMP and may contribute to the inhibition of platelet aggregation caused by the endothelins.
Key words-. Platelet, endothelin, sarafotoxin S6c, cAMP, cGMP.
Introduction
The endothelins are a family of three 21-amino acid
vasoactive peptides, endothelin-1, endothelin-2 and
endothelin-3, of which endothelin-1 is considered to be
the predominant isoform in the human vasculature. First
identified in 1988, endothelin-1 is produced by the vascu¬
lar endothelial cells and is the most powerful vasocon¬
strictor known.' Local infusion of endothelin-1 into the
human brachial artery induces a characteristically sus¬
tained vasoconstriction, while infusion of the ETA recep¬
tor antagonist BQ-123 induces vasodilatation, suggesting
a role for endothelin in the maintenance of basal vascular
tone.2 The cellular actions of endothelin are mediated by
two G-protein-linked cell-surface receptors; the ETA
receptor, that has a greater affinity for endothelin-1 than
for endothelin-3, and the ETB receptor, which has an
equal affinity for the endothelin isoforms. Both recep¬
tors are present on vascular smooth muscle cells mediat¬
ing contraction. However, relaxation can be induced
indirectly through activation of an endothelial ETB
receptor leading to release of the endothelium derived
dilators prostacyclin and nitric oxide. In addition to the
stimulation of phosphoinositide hydrolysis, in many cell
types endothelin-1 can modulate the levels of cyclic nuc¬
leotide second messengers. Studies in isolated prepara¬
tions of bovine vascular smooth muscle cells have shown
that endothelin-1 increases cyclic AMP (cAMP) levels via
the ETa receptor, presumably linked to a Gs protein,
while in bovine endothelial cells the ETB receptor attenu¬
ates forskolin stimulation of adenylate cyclase.3 In
transfected Chinese hamster ovary cells a similar pattern
is observed.4 In rat aortic strip preparations, however,
ETb receptor activation caused an increase in cyclic
GMP (cGMP) which was abolished by pre incubation
with the nitric oxide synthase inhibitor N-monomethyl-
L-arginine.5 This suggests that ETg receptor activation
could lead to an increase in nitric oxide production,
which in turn increases cellular cGMP levels, the second
messenger for nitric oxide.
In studies on human platelets endothelin-1 appears to
have two potentially opposing effects; potentiating
The authors are with the Department ofMedicine, University ofEdinburgh, Western General Hospital, Edinburgh, UK. Address correspondence to
Professor D. J. Webb, Clinical Pharmacology Unit, University Department ofMedicine, Western General Hospital, Edinburgh EH4 2XU, UK. Tel
( + 44) lit 332 120); Fax: (+44) 131 J4J 6017; Email D.J.Webb@edac.uk
178 Blood Coagulation and Fibrinolysis, Vol 7, 19% '« • 19% Rapid Science Publishers
Platelet endothelin receptors
adrenaline induced primary aggregation* but inhibiting
secondary aggregation.7 The contrasting effects of
endothelin-1 may, at least in part, be due to the presence
of different endothelin receptor subtypes exerting
opposing effects. However, to date, the endothelin rcccp
tor or receptors involved in signal transduction in plate¬
lets have not been conclusively characterised.
Inhibitory pathways including both cAMP and
cGMP are well characterised in the platelet. To investi¬
gate the possible modulation of cyclic nucleotide second
messengers in platelets by endothelin receptor activation
we have examined the effect of in vitro incubation of
endothelin-1 with human platelet-rich plasma on platelet
cAMP and cGMP concentrations. The snake venom
peptide sarafotoxin S6c (SRTX S6c) has a close struc¬
tural similarity to the endothelins and 30000-fold selec¬
tivity for the ET„ receptor. Therefore, in order to eluci¬
date the possible receptor type involved we have




Six healthy male subjects, aged 27 35 years, participated
in this study, with ethics approval. None of the subjects
received vasoactive or non-steroidal anti-inflammatory
drugs in the week before each study, or alcohol or caf¬
feine on the day of the study. Venous blood was collected
into acid citrate dextrose (final concentrations; citric acid
0.8 mg ml ', sodium citrate 2.2 mg ml ', glucose 2.0 mg
ml '), and promptly centrifuged at 120 x gfor 20 min at
room temperature to obtain platelet-rich plasma. Plasma
was divided into sub-aliquots and stored at room temper¬
ature under 95%0^:5%C0, until required. Plasma was
stirred at 37°C for 4 min prior to the addition of
endothelin-1 (lCT" 1CT7 M), SRTX S6c (10 "
10 7 M) or vehicle (0.9% sal ine). Dose-response studies
to each agonist were performed in separate parallel
aliquots. After 5 min, the platelet-rich plasma was imme¬
diately cenirifuged at 10 000 x g for 2 min at 4°G, the
plasma was removed, the platelet pellet resuspended in 2
ml ethanol and incubated at room temperature for 15
min. The ethanol was centrifuged at 1200 x gfor 15 min
and the supernatant decanted and dried down. The
samples were resuspended in assay buffer and stored at
— 20 G until required for assay.
Materials
Citric acid, sodium citrate and glucose used in the anti¬
coagulant were all obtained from Sigma (Poole, Dorset).
Endothelin-1 was obtained from Novabiochem (Not¬
tingham, UK), SRTX S6c from Alexis Corporation
(Nottingham, UK) and sodium chloride for the vehicle
and activated charcoal were obtained from Sigma (Poole,
Dorset).
Cyclic nucleotide assays
Cyclic nucleotide concentrations were measured by in
house radioimmunoassay as previously described*
Briefly, 500 /(I samples were acetylated by the addition of
10 /(I triethylamine and 5 fl\ acetic anhydride; 50 /tl
aliquots of samples were incubated for 18 h at 4*C with
100 p\ of antibody and 150 //I of iodinated tracer.
Antibody-bound tracer was separated from free by cen
trifugation with activated charcoal at 4°C for 30 min at
1700 x g . Free radioactivity was measured on a LKB
multiwell gamma counter. Cyclic nucleotide levels are
expressed as pmol ml ~ 1 of platelet-rich plasma.
Statistics
Statistical analysis was by repeated measure analysis of
variance. Differences were considered to be statistically
significant at the 5% level. All statistical analysis was
performed using the computer software package Stat
view 512 + (BrainPower Inc., Calabasas, CA, USA).
Results
Neither endothelin-1 (P = 0.11, n = 6) nor SRTX S6c
(P = 0.15, n=6) caused a significant change in platelet
cAMP concentrations (Figure l). However, both
endothelin-1 and SRTX S6c caused a significant dose-
dependent increase in platelet cGMP concentrations,
(P < 0.05 and P < 0.01 respectively, n = 6; Figure 2).
Discussion
Incubation of platelet rich plasma with the non selective
ETa/ETb receptor agonist endothelin-1 or with the ET„
selective agonists SRTX S6c did not significantly alter
platelet cAMP levels. However, both agonists signifi¬
cantly increased platelet cGMP. This would suggest that
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Figure 1. Change in platelet cAMP, mean ± SEM, in response to
treatment with endothelin-1 (open circles; P = 0.1l) and SRTX S6c
(closed circles; P = 0.15) in pmol ml of plasma. Statistical analysis
by repeated measures ANOVA.
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Figure 2. Change in platelet cGMP, tnean±SEM, in response to
treatment with endothelin-l (open circles; P< 0.05) and SRTX S6c
(closed circles; P< 0.01) in pmol ml 1 of plasma. Statistical analysis
was by repeated measures ANOVA.
human platelets contain an endothelin receptor which is
responsible for increasing platelet cGMP concentrations
either through stimulation of guanylate cyclase or inhi¬
bition of a specific cGMP phosphodiesterase. On the
basis of the findings with SRTX S6c, this is probably an
ETb receptor. The marked elevation of cGMP by SRTX
S6c contrasts with the slight effect seen with endothelin-
1. This may reflect an ETA mediated inhibition of gua¬
nylate cyclase stimulation or of an increase in cGMP
degradation.
Selective activation of the ETB receptor in rat aorta by
IRL 1620, in the presence of an intact endothelium, stim¬
ulates an increase in cGMP and leads to relaxation of the
aorta by a mechanism which can be blocked by the nitric
oxide synthase inhibitor N-monomethyl-L-arginine.5
This demonstrates that the ETB receptor is able to
induce an increase in cGMP in neighbouring vascular
smooth muscle cells by stimulation of nitric oxide pro¬
duction from the endothelium. In cultured porcine
epithelial cells both endothelin-l and endothelin-3 were
able to cause an increase in cGMP in the target cell, by a
mechanism which was also blocked by N-monomethyl-
L-arginine,9 demonstrating that ETR stimulated nitric
oxide can have an autocrine as well as paracrine role.
The platelet L-arginine:nitric oxide pathway was char¬
acterised in 1990,10 demonstrating that platelet derived
nitric oxide inhibited platelet aggregation through elev¬
ation of intra-platelet cGMP. It is, therefore, likely that
activation of the platelet ETB receptor stimulates platelet
nitric oxide, and by activation of soluble guanylate
cyclase, increases cGMP.
However, there is evidence for an insulin receptor
linked mechanism for increasing platelet cGMP which is
independent of nitric oxide synthase," and recently the
benzylindazole derivative YC-1 has also been shown to
activate soluble guanylate cyclase through a nitric oxide
independent mechanism in human platelets.12 This not
only indicates that platelet guanylate cyclase may be
activated by several different pathways but also confirm
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that the elevation of cGMP per se inhibits platelet aggre
gation. Therefore, we are not able to conclude that the
platelet ETg receptor is linked to nitric oxide synthase.
This could be investigated either by inhibition of the
enzyme or direct measurement of nitric oxide.
In conclusion, we have provided evidence for the
existence of an endothelin ETB receptor on human plate¬
lets. Activation of this receptor stimulates cGMP accu¬
mulation, which is known to be involved in the
inhibition of platelet aggregation. This not only provides
a useful model for investigating regulation of this recep¬
tor but may also be important in the wide range of dis¬
ease states where abnormalities in platelet activity has
been reported, such as myocardial infarction and cirrho¬
sis of the liver.
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The increase in human plasma immunoreactive endothelin but
not big endothelin-1 or its C-terminal fragment induced by
systemic administration of the endothelin antagonist TAK-044
Christopher Plumpton, ""Charles J. Ferro, ""William G. Haynes, ""David J. Webb &
'Anthony P. Davenport
Clinical Pharmacology Unit, University of Cambridge, Box 110, Addenbrooke's Hospital, Cambridge, CB2 2QQ, and
•Department of Medicine, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU
1 We examined the effects of systemic infusion, in healthy human volunteers, of the endothelin
antagonist TAK-044 on the plasma concentrations of mature endothelin, big endothelin-1 and the C-
terminal fragment of big endothelin-1, by selective solid-phase extraction and specific radio¬
immunoassays.
2 Unlabelled TAK-044 competed with specific [125I]-endothelin-l binding to human left ventricle tissue
in a biphasic manner giving kD values of 0.11 nM and 26.8 nM at the ETA and ETB receptor subtypes,
respectively, indicating a 244 fold selectivity for the ETA receptor subtype.
3 A 15 min intravenous infusion of placebo or 30 mg TAK-044 (giving a serum concentration of 2 nM,
calculated to block >95% of ETA but <5% ETB receptors) had no effect on the immunoreactive plasma
concentrations of the three peptides.
4 At the higher dose of 750 mg TAK-044 (giving a serum concentration of 80 nM, calculated to block
>99% of ETa and >75% ETB receptors), the immunoreactive plasma endothelin concentrations were
increased 3.3 fold over basal levels (/><0.01). The concentrations of big endothelin-1 or C-terminal
fragment of big endothelin-1 were unchanged.
5 At both doses of TAK-044, there were significant decreases in diastolic blood pressure, and
peripheral vascular resistance, with corresponding increases in cardiac index and stroke index. There
were no changes in systolic or mean arterial blood pressures or heart rate.
6 Since only the concentrations of the mature peptide were increased, we conclude that the most likely
sources of endothelin contributing to the observed rise were displacement of receptor-bound peptide and
reduction in plasma clearance rather than peptide synthesis.
Keywords: Endothelin; big endothelin; C-terminal fragment; human vasodilatation; selective solid-phase extraction; radio¬
immunoassay
Introduction
The endothelins are a family of three potent vasoconstrictor
peptides (endothelin-1 (ET-1), ET-2 and ET-3, Inoue et al.,
1989). ET-1 and a biologically inactive C-terminal fragment
(CTF, big ET-1(22 jg)) are generated from an intermediate big
ET-1, following an unusual cleavage, by one or more en-
dothelin-converting enzymes (Battistini et al., 1995). In func¬
tional assays the endothelins exert their actions through two
distinct receptor subtypes, ETA and ETB, distinguished by the
rank order of potency of the three endothelin isoforms (Arai et
al., 1990, Sakurai et al., 1990).
We have previously demonstrated that local infusion of the
ETA-se!ective antagonist BQ123 causes vasodilatation sug¬
gesting that endothelin contributes to basal vascular tone in
man (Haynes & Webb, 1994). In addition, we have previously
shown that local infusion of exogenous big ET-1 results in an
increase in immunoreactive (IR) plasma CTF as well as IR
endothelin (Plumpton et al., 1995a, b). All three peptides can
be detected in the conditioned medium from cultured en¬
dothelial cells (Plumpton et al., 1996a), suggesting that any de
novo synthesis of endothelin would be accompanied by a rise in
CTF.
Animal and human studies have suggested that endothelin
is important in a range of clinical conditions and have de¬
monstrated the potential therapeutic beneficial effects of en-
1 Author for correspondence
dothelin receptor antagonism (Ferro & Webb, 1996).
However, plasma concentrations of IR endothelin are in¬
creased following non-selective endothelin receptor antagon¬
ism (Loffler et al., 1993; Donckier et al., 1995; Kiowski et al.,
1995; Teerlink et al., 1995). Our aim was to determine whether
the systemic infusion of the cyclic hexapeptide endothelin re¬
ceptor antagonist TAK-044 (cyclo[D-oc-aspartyl-3-[(4-phe-
nylpiperazin -1 - yl) carbonyl] -L-analyl -L-oc- aspartyl -D -2 - (2-
thienyl) glycyl-L-leucyl-D-tryptophyl] disodium; Kikuchi et al.,
1994) altered the concentrations of IR endothelin in human
plasma. Secondly, to distinguish between possible sources of
IR plasma endothelin, we also measured the concentrations of
the precursor big ET-1, and by-product CTF. A preliminary
account of this work has been presented to the British Phar¬
macological Society (Plumpton et al., 1996b).
Methods
Competition binding experiments
The selectivity of TAK-044 was determined for native human
endothelin receptors as previously described (Davenport et al.,
1995). The human left ventricle was used as this expresses both
endothelin receptor subtypes and allows the selectivity of
competing ligands to be determined in the same assay. Frozen
sections of left ventricle (10/iM, n = 3) were thaw mounted
onto gelatine coated microscope slides and pre-incubated for
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15 min at 23°C in 50 mM HEPES, 5 mM MgCl2, 0.3% BSA
pH 7.4. Sections were then incubated for 2 h at 23°C in the
same buffer containing 0.1 nM [l25I]-ET-l (2000 Ci mmol ')
and increasing concentrations of TAK-044 (20 pM 100 pM).
Total ET-1 binding was determined in the absence ofTAK-044
and non-specific binding was defined by inclusion of 1 pM
unlabelled ET-1. Sections were washed three times in ice-cold
Tris-HCl (pH 7.4) for a total of 15 min then wiped from the
slides and counted using a gamma counter. Protein estimations
were made by use of a modified Lowry assay (Bio-Rad) by
reference to bovine serum albumin (BSA) standards. Pseudo
Hill coefficients were determined by use of EBDA (McPherson,
1983) from which the final values of equilibrium dissociation
constant (A"D) were calculated with the iterative curve fitting
program LIGAND (Munson & Rodbard, 1980).
Clinical procedures
Healthy male volunteers (25-60 years of age, mean age 40)
participated in the study with the approval of the local ethical
committee. Each subject had an antecubital vein of the left and
right arm cannulated for administration of infusate and
withdrawal of blood samples, respectively. TAK-044 was
synthesized and supplied by Takeda Chemical Industries Ltd,
Osaka, Japan. Blood pressure and heart rate were measured by
semi-automated oscillometry monitors, cardiac function
(stroke volume, cardiac output and heart rate) was measured
by a non-invasive bioimpedance methodology (Haynes et al.,
1996). Eight subjects received either 50 ml sucrose placebo,
30 mg or 750 mg TAK-044 dissolved in saline over 15 min on
separate occasions in a single-blind, three phase, randomised,
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044 resulted in serum concentrations of 2 and 80 nM TAK-044
after 15 min of infusion, respectively as determined by high
performance liquid chromatography (h.p.l.c.). In six subjects,
venous blood samples were taken before and 15 min after
dosing. Blood was collected into EDTA tubes and separated
immediately. The resulting plasma was stored at — 70°C until
assayed.
Radioimmunoassays for endothelin peptides
After being thawed, 5 ml plasma samples were assayed for IR
endothelin, big ET-1 and CTF by selective solid-phase ex¬
traction and radioimmunoassay as previously described
(Plumpton et al., 1995a; 1996a) using rabbit antisera raised
against the C-termini of endothelin (ET-1(!5 _2i) and big ET-1
(big ET-1 (3, 3g). For both assays, ED50 values were 20-
25 fmol/tube, inter- and intra-assay coefficients of variation
were < 13% in the range 6-30 fmol/tube and the sensitivities
of detection (defined as two s.d. above zero standard) were
< 1.25 fmol/tube. The recoveries of ET-1, big ET-1 and CTF
were 57.5%, 39.8% and 76.6%, respectively (n = 4). Plasma IR
peptide concentrations are shown uncorrected for extraction
recovery.
Under the present conditions, the mature endothelin RIA
cross-reacted 100% with ET-1, ET-2 and ET-3. Cross-re¬
activity with ET-1(1 20), big ET-1(22.. 38), big ET-1, big ET-2 and
big ET-3 were <0.02%. The big ET-1 RIA showed <0.007%
cross-reactivity with the mature endothelins, big ET-2 and big
ET-3, and cross-reacted 143% with big ET-1 (22-38) thus al-
Kigure I Competition assays showing the inhibition of [l25I]-
endothelin-l (ET-1) binding to sections of human left ventricle by
TAK-044. Results are expressed as percentages of the specific
binding. Mean values (n = 3) are shown and vertical lines indicate
s.e.mean.
lowing the quantification of CTF following fractionation.
Neither of the assays showed any detectable cross reactivity
(<0.000002%) with TAK-044. Furthermore, TAK-044 did
not interfere with cither assay as indicated by superimposable
standard curves at concentrations five orders of magnitude
greater than the serum TAK-044 levels achieved. No cross-
reactivity was detected (< 0.005%) at the highest concentra¬
tions tested with unrelated vasoactive peptides such as angio
tensin II, atrial natriuretic factor, and a-calcitonin gene-related
peptide.
Results
TAK-044 competed biphasically for the binding of [125I]-ET-1
giving Kd values of 0.11 nM and 26.8 nM at the ETA and ETB
receptor subtypes, respectively (Figure 1). Based on these af¬
finities, the concentration of TAK-044 measured in the serum
following the low dose was calculated to block >95% of the
ETa but <5% of the ETB receptors. However, at the high
dose, the majority (>75%) of the ETB receptors were calcu¬
lated to be blocked in addition to >99% of the ETA re¬
ceptors.
At both doses of TAK-044, there were significant decreases
in diastolic blood pressure, and peripheral vascular resistance,
with corresponding increases in cardiac index and stroke in¬
dex. There were no changes in systolic or mean arterial blood
pressures or heart rate in any of the phases (Table 1). These
findings are in agreement with an action of TAK-044 as an
arteriolar vasodilator. Although most of the changes in the
haemodynamic parameters appeared greater after 750 mg than
30 mg TAK-044, none of these differences reached statistical
significance. TAK-044 was well tolerated in all volunteers as
assessed by direct questions, visual analogue scales, routine
electrocardiography, biochemistry and haematology. In parti¬
cular, no serious or clearly drug-related adverse effects were
detected.
When placebo or TAK-044 at the 30 mg dose was infused
there were no significant changes in the concentration of IR
peptide compared with basal levels (Figure 2). However, at the
higher dose of 750 mg TAK-044, although there were no de¬
lectable changes in the concentrations of IR big ET-1 or CTF,
the IR endothelin increased from 4.0± 1.5 pM to 13.3 + 2.2 pM
(P <0.01, compared to pre-infusion).
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Teble 1 Baseline values and mean changes (A) over I5min for systolic blood pressure (SBP), diastolic blood pressure (DBP), heart
rate, stroke index, cardiac index and peripheral vascular resistance (PVR) after dosing with TAK-044
Placebo TAK-044
30mg 750mg
Baseline Mean A over Baseline Mean hover Baseline Mean hover
value 15min 95% CI value 15 min 95% CI value 15min 95% CI
SBP 127 ±5 4 + 2 -3 to + 10 128 + 5 1 + 1 -2 to +5 129+5 -8 + 4 -18 to +2
(mmHg)
DBP 75 ±2 I + l -2 to +5 73 + 2 -3 + 1* -5 to -1 74 + 2 -4+ 2* -8 to 0
(mmHg)
MAP 92 + 3 2+ 1 -2 to +6 91 + 1 -2+1 -4 to + 1 92 + 3 -6+ 2 -9 to +1
(mmHg)
Heart rate 58 + 3 1 + 1 -2 to +3 57 + 4 1+2 -5 to +6 59 + 2 1 + 1 -2 to +4
(beats min ')
Cardiac index 3.2 + 0.3 -0.1+0.04 -0.2 to +0.1 3.0 + 0.2 0.3 + 0.1* + 0.1 to +0.5 2.8 + 0.2 0.4+0.1* + 0.1 to +0.6
(1 minm 2)
Stroke index 56 + 5 0+1 -2 to +2 51+3 3 + 1** + 1 to + 5 47 + 5 5+1** + 2 to +8
(mlnT2)
PVR 2392 + 237 77 + 57 -66 to + 220 2472+117 -259 + 61** -413 to -105 2719 + 248 -452+41*** -554 to -350
(dyns cnT5nT2)
For the placebo column, mean change from predose is shown. For the active treatment columns, placebo corrected changes from
predose are shown. Mean values (n = 8) are shown+ s.e.mean and 95% confidence intervals (CI). Statistical differences were analysed
by ANOVA followed by paired Student's t tests. *P<0.05; **P<0.01; ***/"<0.0001 compared to basal.
Placebo 30 mg 750 mg Placebo 30 mg 750 mg
Pre-infusion Post-infusion
Figure 2 Effect of intravenous infusion of placebo or TAK-044
(30 mg or 750mg) for 15min on immunoreactive plasma endothelin
(solid columns), big endothelin-1 (hatched columns) and C-terminal
fragment of big endothelin-1 (open columns). Mean values (n = 6) are
shown and vertical lines indicate s.e.mean. Statistical differences were
analysed by ANOVA followed by Student's / tests. */><0.01
compared to basal.
Discussion
This study shows that in healthy human volunteers, systemic
infusion of 750 mg TAK-044, but not placebo or 30 mg TAK-
044, results in a significant increase in venous plasma 1R en¬
dothelin compared to basal levels, with no detectable changes
in the corresponding concentrations of either big ET-1 or CTF.
Local infusion of big ET-1 in healthy human volunteers
results in significant increases of 1R plasma endothelin and
CTF compared to basal (Plumpton et at., 1995a, b). There¬
fore, if the present rise in IR endothelin were due to an in¬
creased synthesis, we would predict altered concentrations of
big ET-1 and/or CTF, but no change from basal levels was
detected. Taken together with the rapid rate of increase in
plasma IR endothelin, the effects are unlikely to be due to de
novo synthesis, although the processing of stored precursors
cannot be excluded. These data support other endothelin
peptide measurements obtained following endothelin receptor
antagonism in animals (Loffler et al., 1993; Donckier et al.,
1995; Teerlink et al., 1995) and patients with chronic heart
failure (Kiowski et al., 1995).
At the serum concentrations achieved with both doses of
TAK-044, it was calculated that virtually all of the ETA re¬
ceptors are blocked and may therefore produce the observed
haemodynamic changes, since ET-1 predominantly mediates
vasoconstriction via ETA receptors (Davenport & Maguire,
1994; Maguire & Davenport, 1995). In contrast, only at the
higher dose are the majority of the ETB sub-type antagonised.
This suggests that the increase in human plasma IR endothelin
following the infusion of 750 mg TAK-044 could be associated
with displacement of ETB receptor-bound peptide and/or
blockade of clearance receptors. This is consistent with the
identification of a high density of non-vascular ETB receptors,
possibly clearance receptors, in human kidney (Karet et al.,
1993) and their efficient regional extraction of mature en-
dothelins (Weitzberg et al., 1991; Gasic et al., 1992).
We conclude that the increase in IR plasma endothelin
following infusion ofTAK-044 under the present conditions, is
most likely due to the displacement of mature endothelin from
binding sites and/or blockade of clearance from the circula¬
tion.
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Hay iie», William («., Malcolm F. Hand, Mark E. C.
Dockrell, David W. Eadington, Michael R. Lee, Ziad
Ilusscin,Nigel Benjamin, andDavid J.Webb. Physiologi¬
cal role of nitric oxide in regulation of renal function in
humans. Am. J. Physiol. Ill (Renal Physiol. 41): F364—F371,
1997.—The physiological role of endogenous nitric oxide in
regulation of renal function in humans is unclear. Eight
healthy men received an inhibitor of nitric oxide synthase,
NG-monomethyl-iy-arginine (l-NMMA, 3 mg/kg), and saline
placebo intravenously on two occasions. l-NMMA signifi¬
cantly increased mean arterial pressure (+7%) and total
peripheral resistance (+36%). However, because renal plasma
flow did not decrease significantly, the increase in renal
vascular resistance (+21%) was significantly less than the
increase in total peripheral resistance. Glomerular filtration
rate (-19%), filtration fraction (-10%), urine flow rate
(—18%), sodium (—28%), and free water excretion ( 25%) all
decreased significantly. Fractional distal, but not proximal,
sodium reabsorption increased. l-NMMA also oignificantly
dccreaoed plasma nitrate and urinary excretion ofnitrate and
dopamine. Thcro woro no significant changes in plasma renin
activity, plasma ondothelin, and aldosterone or in platelet
number and ex vivo aggregation. l-NMMA had a plasma
half-life of 75 min Basal generation of nitric oxide appears to
contribute less to vascular tone in the kidney than systemi-
cally but may alter afferent arteriolar tone. Decreased frac¬
tional sodium excretion supports an important physiological
role for nitric oxide in inhibition of tubular sodium reabsorp¬
tion, possiblymediated by the renal dopaminergic system.
endothelium-derived relaxing factor; kidney; endothehns;
dopamine; platelet
NITRIC OXIDE is a free radical molecule that has many
biological actions, including smooth muscle relaxation,
inhibition of platelet aggregation, and neurotransmis¬
sion (18). Nitric oxide is generated from L-arginine by a
family of synthase enzymes and has a very short
half-life, being rapidly oxidized in blood to nitrite and
nitrate (30). Animal studies suggest that endogenously
produced nitric oxide may play an important role in
regulation of renal hemodynamics and tubular function
(17, 20). However, several contradictory results have
been obtained. For example, there is debate about
whether nitric oxide acts predominantly on the afferent
(10) or efferent renal arteriole (13, 20). In addition,
sodium excretion has been reported to be increased (3),
unchanged (20), or decreased (13, 19) following nitric
oxide synthase inhibition. Furthermore, the role of
nitric oxide in regulation ofproximal and distal tubular
sodium reabsorption is uncertain (17,19).
We and othcro have ohown that syotcmic administra
tion of the nitric oxide synthase inhibitor A^-mono-
methyl-l-arginine (l-NMMA) to humans causes vaso¬
constriction and increases arterial pressure, confirming
that nitric oxide is generated physiologically to oppose
vasoconstrictor influences in resistance vessels (7, 9,
25). We also reported that l-NMMA increased urine
sodium excretion but did not change creatinine clear¬
ance over a 2.5 h period in healthy male subjocts (9).
However, we did not perform frequent urine collections
in these studies, nor did wo measure the effects of
l NMMA on indexes of renal hemodynamics and tubu
lar function. Given the animal data supporting an
important role for endogenous nitric oxide in regulation
of renal function, we have now performed a more
rigorous evaluation of the renal effects of nitric oxide
synthase inhibition in humans. We tested the adequacy
of nitric oxide synthase blockade by measuring plasma
and urine nitrate concentrations (2). Because it is not
clear whether the hemodynamic and renal actions of
endogenous nitric oxide are solely due to direct effects,
we also assessed plasma renin activity, plasma aldoste¬
rone and endothelin concentrations, and urinary free
dopamine excretion. In addition, in view of the potent
anti aggregatory properties of nitric oxide (18), we
examined whether l NMMA altered platelet number or
ex vivo platelet aggregation.
METHODS
Subjects. Eight healthy male subjects (age range, 19-38 yr)
participated in this study, which was conducted with the
approval of the local Ethics Review Committee and with the
writton informed conocnt of each volunteer. No oubjoct re
ceived vasoactive or nonsteroidal anti-inflammatory drugs in
the week prior to each study day, and all were asked to
abstain from alcohol for 24 h and from food, caffeine-
containing drinks, and cigarettes for at least 16 h before
baseline measurements were made. A 24-h collection of urine
was performed by all subjects beginning at 7:00 AM on the
day before each study day. Subjects received a physiologically
inert dose of oral lithium carbonate (Camcolit, 250 mg
sustained release; Norginc, Harcficld, UK) before each study
day (~ 14 h before baseline measurements) to assess proximal
tubular reabsorptive capacity of sodium (5).
Assessments. Blood pressure was measured in the right
arm in duplicate using a well-validated semi-automated
oscillometric technique (Takeda UA751 sphygmomanometer;
Takeda Medical, Tokyo, Japan) (31). Cardiac function (stroke
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volume, cardiac output, and heart rate) was measured using a
noninvasive bioimpedance method (BoMed NCCOM3, BoMed
Medical Manufacturer, Irvine, CA). Both absolute cardiac
output and changes in cardiac output measured by bioimped¬
ance agree closely with thermodilution measurements, and
the within-subject coefficient of variation is lower with bio¬
impedance (26). Effective renal plasma flow (ERPF) and
glomerular filtration rate (GFR) were estimated by measur¬
ing the renal clearances of p-aminohippurate sodium (PAH;
Merck, Hoddesdon, UK) and polyfructosan-S (Inutest; Laevo-
san, Linz, Austria), respectively. Priming doses of PAH (0.45
g) and polyfructosan-S (3.5 g) were diluted in 100 ml of 0.9%
saline and infused over 15 min, followed by a maintenance
infusion of PAH (8.3 g/1) and polyfructosan-S (10 g/1) in 0.9%
saline at 120 ml/h. An equilibration period of 90 min allowed
plasma concentrations of PAH and polyfructosan-S to stabi¬
lize before baseline collections started.
Sample collection. Venous blood samples were collected
into heparinized tubes for assay of plasma polyfructosan-S,
PAH, sodium, potassium and aldosterone concentrations, and
plasma osmolality; into EDTA tubes for assay of plasma
immunoreactive endothelin, plasma renin activity, hemato¬
crit (Hct), and platelet counts; into plain glass tubes for assay
of serum lithium concentrations; and into acid citrate dex¬
trose tubes for platelet aggregation studies. Plasma was
separated and frozen within 15 min of sampling. Urine was
collected into plain plastic containers, except for those for
dopamine estimations, where 20ml urine was added to 0.5 ml
of 4 M hydrochloric acid. All samples were stored at -80°C
before assay.
Assay techniques. Polyfructosan-S and PAH concentrations
were assayed using established semi-automated chemical
methods (5). Electrolytes were assayed by emission-flame
photometry with lithium as the internal standard for sodium
and potassium estimations and cesium as the internal stan¬
dard for lithium estimations. Total plasma and urine nitrite/
nitrate concentrations were assayed using the Griess reaction
(6). Briefly, passage of urine or deproteinized plasma samples
at high pressure through a cadmium column reduced nitrate
to nitrite, which then reacted with Griess reagent (0.05%
napthylethylenediamine and 0.05% sulfanilamide) to form a
purple azo dye, the absorbance of which at 546 nm was
detected by a spectrophotometer. The procedure for determin¬
ing plasma l-NMMA concentrations utilized pre-column de-
rivatization with o-phthaladehyde, separation of the isoin-
dole derivative by reverse-phase high-performance liquid
chromatography (HPLC) and fluorescence detection. This
method had an intra-assay precision of 10.2, 7.4, 6.6, and 7.9
(coefficient of variance in %) at nominal concentrations of0.4,
2, 4, and 100 pmol/1, respectively. The accuracy (expressed as
%bias).at the same l-NMMA concentrations was 0.0, 2.0, 0.0,
and 4.0, respectively. Urine dopamine was measured using
HPLC with electrochemical detection as previously described
(15). Plasma aldosterone concentrations and renin activity
were measured by radioimmunoassay as previously de¬
scribed (5). Plasma immunoreactive endothelin was mea¬
sured by radioimmunoassay (ITS Production, Utrecht, The
Netherlands) as previously described (8); the sensitivity of
this assay is 2 pg/ml immunoreactive endothelin, and cross
reactivities with endothelin-1, endothelin-2, endothelin-3,
and big endothelin-1 are 100, 52, 96, and 7%, respectively.
Platelet aggregation studies. Blood collected for platelet
aggregation studies was promptly centrifuged at room tem¬
perature for 10 min at 120 g to obtain platelet-rich plasma;
the remaining blood was centrifuged for a further 20 min at
3,000 g to obtain platelet-poor plasma. Platelet aggregability
was measured at 37°C using the fight transmittance method
ofBorn (1) in aMalin 6 channel aggregometer. Light transmit¬
tance through platelet-rich plasma prior to the addition of the
aggregating agent was taken as 0% aggregation and through
platelet-poor plasma as 100% aggregation. Separate afiquots
of platelet-rich plasma were incubated with vehicle or differ¬
ent doses ofADP (0.1-10 pM) for 10 min.
Study design. This was a randomized, single-blind, cross¬
over study comparing l-NMMAwith vehicle placebo. The two
phases were separated by at least 6 days. Studies were
performed in a quiet clinical research laboratory maintained
at a constant temperature of between 22 and 25°C. On the
morning of each study day, subjects were asked to drink 450
ml of water at 7:00 AM (~3 h before the first baseline
measurements). After arrival at the laboratory, subjects
voided urine and then drank 450 ml water at 8:00 AM.
Subjects were then asked to void at intervals of~30min, with
water intake adjusted before dosing with l-NMMA or placebo
to induce a diuresis of ~10 ml/min. Except when voiding,
subjects rested in a recumbent position. A plastic cannula was
inserted under local anesthesia into a superficial antecubital
vein of each arm, one for drug administration and one for
blood sampling. Intravenous infusion of the priming doses of
PAH and inulin commenced at ~8:30 AM. During the 90-min
equilibration period, the subject was acclimatized to the
hemodynamic assessments by measuring blood pressure and
cardiac function every 15 min. Baseline assessments started
at ~10:00 AM, when blood samples were obtained before and
after two accurately timed 30-min urine collections.At ~ 11:00
AM, l-NMMA (3 mg/kg; Clinalfa, Laufelfingen, Switzerland)
or vehicle placebo (0.9% saline) was infused intravenously
over 5 min. An additional four accurately timed 30-min urine
collections were then made. After dosing, to maintain strict
fluid balance, water intake was varied only to match fluid
losses (urine and blood), taking into account intravenous
infusion volumes. Blood pressure and cardiac function were
measured at 5-min intervals before and after dosing with
l-NMMA. Blood samples were obtained at 30-min intervals
throughout, except for samples for estimation of plasma
l-NMMA concentrations, which were also obtained 5,10, and
15 min after starting infusion of l-NMMA. Blood for estima¬
tion of platelet aggregation was obtained just before and 15
min after l-NMMA.
Data analysis. Mean arterial pressure (MAP) was calcu¬
lated as diastolic blood pressure plus one-third pulse pres¬
sure. Data for stroke volume and cardiac output were cor¬
rected for body surface area, calculated according to a standard
nomogram, to provide measures of stroke and cardiac index.
Tbtal peripheral resistance was calculated as (MAP X 72.269)/
cardiac index, and expressed in dyn • s • cm-5. Data for arterial
pressure and cardiac index were averaged over each 30-min
clearance period. Renal clearance was calculated using the
formula UV/P, where U is the urinary concentration, V is the
urinary flow rate, and P is the mean of the plasma concentra¬
tions at the beginning and end of a clearance period. Effective
renal vascular resistance (ERVR) was calculated using a
formula that assumed a constant renal venous pressure of 10
mmHg
(1 - Hct)
ERVR = 72,269 X (MAP - 10) X dyn -s cm"5
Cjxvi r
Filtration fraction was calculated as (GFR/ERPF) X 100%.
Lithium ions are reabsorbed almost exclusively in the proxi¬
mal tubule and to the same degree as sodium and water. Thus
clearance of lithium (C^) is thought to be representative of
proximal tubular sodium clearance. The following formulae
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were used to estimate proximal and distal sodium reabsorp-
tion: fractional proximal tubule sodium reabsorption = (1 -
Cn/GFR) x 100%; and fractional distal tubule sodium reab¬
sorption = (1 - CNs/Cu) x 100%, where CNa is sodium
clearance.
Data are presented as means ± SE. Data from the two
baseline clearance periods were never significantly different,
and the mean of these periods was used in the analyses.
Absolute changes from baseline are shown in the text. To aid
interpretation of the relative magnitude of changes in differ¬
ent parameters in the figures, the percentage change from
baseline after l-NMMA or placebo was calculated and the
percentage change after placebo was subtracted from the
percentage change after l-NMMA. Baseline data for the
placebo and l-NMMA study days were compared using Stu¬
dent's paired t-test. All other comparisons were made using a
two-way, repeated-measures analysis of variance, with test¬
ing of statistical significance by Scheffe's F-test. Significance
levels were adjusted for multiple comparisons using Tukey's
test. Statistical analyses were performed using Microsoft
Excel Statistical Analysis ToolPak software (GreyMatter
International, Cambridge, MA) on an Apple Macintosh per¬
sonal computer.
RESULTS
Baseline data. There were no significant differences
between basal values for any parameter on the placebo
and l-NMMA study days (Table 1). There were no
significant changes in any parameter following admin¬
istration of placebo.
Systemic hemodynamics. Compared with placebo,
infusion of L-NMMA caused a modest but significant
increase in MAP (P < 0.001), with an increase of 6 ± 2
mmHg over the first 30 min (Fig. 1). Both systolic and
Table 1. Baseline values before administration of
l-NMMA and placebo
i^nmma Placebo
Mean arterial pressure, mmHg 84 + 2 84 ±2
Heart rate, beata/min 58 ±2 60 ±3
Stroke index, ml/m2 60±6 64 ±5
Cardiac index, 1 ■ min 1 ■ m2 3.5 + 0.3 3.7 ±2
Tbtal peripheral resistance, dyn • s • cm 5 1,843 ± 152 1,680 ±94
Effective renal plasma flow, ml/min 684 ±93 677 ±75
Effective renal vascular resistance,
dyn-s-cm~R 6,149 ±488 5,225 ±517
Glomerular filtration rate, ml/min 97 ±8 88 ±9
Filtration fraction, % 17 ±4 14 ±2
Sodium excretion in previous 24 h,
mmol/day 199 ± 13 204 ±20
Baseline sodium excretion, pmol/min 261+25 269 ±18
Urine flow rate, ml/min 13 ±1 12 ± 1
Fractional sodium excretion, % 1.9±0.2 2.2 ±0.3
FNa+R™,% 76 ±3 70 ±3
FNa+Rji,t, % 91 ±1 92 ±1
Plasma lithium concentration, pmol/1 80 ± 6 80 ±4
Dopamine excretion, nmol/min 1.60 ±0.08 1.76 ±0.18
Plasma NQj. umol/1 24 ± 4 25 ±4
Urine NO^ excretion, pmol/min 0.98 ±0.11 1.07 ±0.13
Plasma endothelin, pg/ml 4.2 ±0.8 4.8 ±0.7
Plasma renin activity, ng ml ' h 1 0.44 ±0.12 0.54 ±0.13
Plasma aldosterone, pmol/1 115 ± 21 138 ±44
Platelets, X109 colls/1 196 ± 19 191 ± 14
Values are means ± SE in 8 subjects. l-NMMA, NG-monomethyl-l-
argirtine; FNa ' Rp„„, proximal tubule fractional sodium reabsorption;
FNa^RdPt. distal tubule fractional sodium reabsorption.
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Fig. 1. Effects of N^monomethyl-l-arginine (l-NMMA, 3 mg/kg)
given intravenously over 5 min (solid area) on mean arterial pressure
(MAP), heart rate (HR), cardiac index (CI), and total peripheral
resistance index (TPRI). Percentage changes (%A) from basal are
shown corrected for changes with placebo. Values are means ± SE in
8 subjects. *p < 0.05 vs. baseline.
diastolic blood preooure incrcaocd, although this was
only significant for diastolic pressure (P < 0.0001), with
an increase of 8 ± 1 mmHg in the first 30 min. There
were aignificant reductions in both heart rate (P < 0.05)
and stroke index (P < 0.0001), leading to a substantial
fall in cardiac index (P < 0.0001), with a decrease of
0.6 ± 0.1 1/min after 30 min (Fig. 1). There was,
therefore, a substantial increase (649 ± 119 dyn a cm 5,
P < 0.0001) in total peripheral resistance index, which
persisted for at least 60 min (Fig. 1).
Renal hemodynamics. In contrast to the substantial
effects on cardiac index, infusion of L NMMA did not
significantly alter ERPF (P = 0.836), with a decrease of
only 62 ± 55 ml/min in the first 30 min (Fig. 2).
Although renal vascular resistance did increase signifi
cantly following infusion of l-NMMA (P < 0.05; 1,281 ±
430 dyn s cm 5 at 30 min; Fig. 2), in percentage tcrmo
( + 21 ± 9%), this was significantly less than the change
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in total peripheral resistance ( + 36 ± 7%; P < 0.05 vs.
renal vascular resistance). However, GFR fell signifi¬
cantly (P < 0.01), with a decrease of 18 ± 8 ml/min in
the first 30 min (Fig. 2). The combination of a decrease
in GFR with an unchanged ERPF meant that filtration
fraction decreased significantly (Fig. 2).
Tubular function. Infusion of L-NMMA significantly
reduced urine flow rate by 2.3 ± 0.8 ml/min at 30 min
(P < 0.05; Fig. 3). Sodium excretion was significantly
reduced by 73 ± 31 pmol/min (P < 0.05). The reduction
in sodium excretion was not solely due to a decrease in
filtered load following the fall on GFR, because frac¬
tional sodium excretion also decreased by 0.27 ± 0.07%
(P < 0.05). Lithium clearance did not change signifi¬
cantly. Proximal tubule fractional sodium reabsorption
tended to decrease, but this did not achieve statistical
significance (P = 0.10). Distal tubule fractional sodium
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Fig. 2. Effects of l-NMMA (3 mg/kg) given intravenously over 5 min
(solid area) on effective renal plasma flow (ERPF), effective renal
vascular resistance (ERVR), glomerular filtration rate (GFR), and
filtration fraction (FF). Percentage changes from basal are shown
corrected for changes with placebo. Values are means ± SE in 8











































Fig. 3. Effects of l-NMMA (3 mg/kg) given intravenously over 5 min
(solid area) on urine flow rate, free water excretion (FWE), Na+
excretion (exc), and fractional Na+ excretion. Percentage changes
fiuiii basal ait shown collected for changes with placebo. Values are
means ± SE in 8 subjects. *p < 0.05 vs. baseline.
min (P < 0.05) (Fig. 4). Potassium clearance did not
change significantly after l-NMMA.
Nitrate, l-NMMA, and hormone assays. Infusion of
l-NMMA significantly and progressively reduced
plasma nitrate concentrations (P < 0.01), with a maxi¬
mum decrease of 9.8 ± 2.6 pmol/1 at 120 min (Fig. 5).
Urinary nitrate excretion rate also reduced signifi¬
cantly by 0.38 ± 0.07 pmol/min at 30 min (P < 0.01).
Unlike plasma nitrate, urino nitrate oxcrotion rapidly
returned to baseline after 30 min (Fig. 5). Plasma
concentrations of l NMMA were maximal at 9 pg/ml
immediately after the end of the 5 min infusion and
declined in a two phase manner to a concentration of
~ 1 pg/ml after 60 min. l-NMMA plasma clearance and
elimination half-life averaged 9.5 ± 0.6 ml • min1 -kg 1
and 75 ± 9 min, respectively. Initial and steady-state
volumes of distribution wore 281 ± 32 and 631 ± 65
ml/kg, respectively. Urine dopamine excretion rate fell
significantly after l-NMMA (P < 0.05), with a decrease




Fig. 4. Effects of l-NMMA (3 mg/kg) given intravenously over 5 min
(solid area) on proximal tubule fractional sodium reabsorption
(FNa' Rpr0I) and distal tubule fractional sodium reabsorption
(FNa+Rjirt). Percentage changes from basal are shown corrected for
changes with placebo. Values are means ± SE in 8 subjects. *P < 0.05
vs. baseline.
renal vascular resistance than on total peripheral
resistance. l-NMMA did not significantly decrease re¬
nal plasma flow, yet substantially reduced GFR and
thus filtration fraction. These effects of l-NMMA are
consistent with a role for endogenous nitric oxide in
control of afferent arteriolar tone in humans, in line
with some animal studies (10,13).
Tubular effects. We found that l-NMMA substan¬
tially decreased urine flow rate and sodium and water
excretion in human subjects, although arterial pres¬
sure was increased. The decrease in urinary sodium
excretion differs from the results from our earlier study
(9). Because subjects in the earlier study had only one
urine collection performed over the whole experimental
period (including baseline), baseline differences may
have contributed to the apparent increase in sodium
excretion in that study. Although some of the decrease
in sodium excretion in the current study was due to a
reduction in filtered load of sodium, the decrease in
fractional sodium excretion implies that nitric oxide
had effects on tubular sodium handling. No effect on
proximal tubule handling of sodium was apparent, as
evidenced by the absence of a change in lithium clear¬
ance, but distal tubule fractional sodium reabsorption
increased by 2.4% (equivalent to an —25% decrease in
distal tubule sodium excretion). There are several
from basal of 0.3 ± 0.06 nmol/min at 30 min (Fig. 5).
l-NMMA did not cause significant changes in plasma
renin activity (—0.09 ± 0.13 ng ml_1h_1 at 30 min) or
in plasma concentrations of immunoreactive endothe-
hn (+0.63 ± 0.38 pg/ml at 30 min) or aldosterone (+ 1 ±
29 pmol/1 at 30 min).
Platelet numbers and aggregation. There was a ten¬
dency for total platelet number to decrease after
l-NMMA ( — 7 ± 8 x 109 cells/1 at 30 min), which did not
achieve statistical significance (P = 0.322). Similarly,
there was no significant difference between placebo and
l-NMMA study days in the extent of ex vivo platelet
aggregation to ADP (Fig. 6).
discussion
This study confirms previous findings (7, 9, 25) that
the nitric oxide synthase inhibitor l-NMMA increases
arterial pressure and systemic vascular resistance in
healthy human subjects. We report here several impor¬
tant new results. First, despite a marked increase in
systemic vascular resistance, renal vascular resistance
only increases modestly after l-NMMA. Second,
l-NMMA increases tubular sodium and water reabsorp¬
tion, possibly because it also inhibits urinary dopamine
excretion. Third, l-NMMA decreases plasma nitrite/
nitrate concentrations and urine nitrite/nitrate excre¬
tion. Fourth, we provide the first description of the
pharmacokinetics of l-NMMA. l-NMMA does not ap¬
pear to alter plasma renin activity, plasma endothelin
and aldosterone concentrations, or platelet number and
ex vivo aggregability toADP.
Hemodynamic effects.Although it has been suggested
that the renal circulation is particularly sensitive to the
effects of nitric oxide synthase inhibition (10, 13), we











































Fig. 6. Effects of l-NMMA (3 mg/kg) given intravenously over 5 min
(solid area) on plasma nitrate (N03) concentrations, urine nitrate
excretion rate, and dopamine urinary excretion rate. Percentage
changes from basal are shown corrected for changes with placebo.
Values are means ± SE in 8 subjects. *P < 0.05 vs. baseline.
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Fig. 6. Dose response for platelet aggregation to ADP
before (O) and after (•) placebo (A) administration and
before (□) and after (■) L-NMMA (B) administration.
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potential mechanisms for the increase in fractional
sodium reabsorption, including changes in renal inter¬
stitial pressure (19), medullary blood flow (1G), and
tubular sodium transport (17).
Plasma nitrate. Administration of l-NMMA caused a
progressive decrease in plasma nitrite/nitrate concen¬
trations and a less sustained decrease in urinary
nitrite/nitrate excretion rate. The decrease in urinary
nitrite/nitrate excretion was not solely due to a de¬
crease in GFR, because urinary nitrate concentrations
also decreased. Although human studies have previ¬
ously shown that nitrate is the predominant metabolite
of exogenously administered nitric oxide gas (30) and
that labeled arginine is metabolized to labeled nitrate
(2), this is the first demonstration that blockade of
endogenously produced nitric oxide decreases plasma
nitrate in humans. Because nitrate is cleared from
plasma with a half-life of ~5 h (2), the magnitude of the
deci ease in plasma nitrate may not have fully reflected
the degree of inhibition of endogenous nitric oxide
generation.
Eruluvi live. The renal effects of l-NMMA may be
mediated indirectly through alterations in other neuro¬
humoral systems. Although inhibition of nitric oxide
synthesis did not alter circulating endothelin concentra¬
tions, endothelin-1 is a locally acting paracrine sub¬
stance, and plasma endothelin concentrations provide
only an approximation of local tissue endothelin-1
generation. Inhibition of nitric oxide generation has
been shown to increase plasma endothelin concentra¬
tions in anesthetized dogs (20), although not in sheep
(27). Renal vasoconstriction induced by l-NMMAwould
be expected to decrease clearance of endothelin-1 (11).
However, this should have increased, rather than de¬
creased, circulating endothelin concentrations and thus
make it less likely that overall endothelin-1 generation
increased. We found no alteration in plasma renin
activity or aldosterone by l-NMMA. In animal studies,
inhibition of nitric oxide synthesis has been shown to
have contradictory cffcctc on plasma renin activity (21,
23), perhaps reflecting differences in renal perfusion
pressures. We were unable to maintain a constant
renal perfusion pressure andmay therefore havemissed
an effect of l-NMMA on renin release. Dopamine is
generated within the proximal tubule by the action of
the enzyme aromatic l amino acid decarboxylase on its
substrate l-dopa, which is actively transported into
renal epithelial cells (14). We found that l-NMMA
significantly decreased urinary dopamine excretion rate.
Previous animal data suggest that it is unlikely that
nitric oxide acts tonically to promote aromatic-l-amino-
acid decarboxylase activity (24). However, nitric oxide
could affect the transport of l-dopa into renal epithelial
cells. Dopamine increases renal blood flow and GFR,
inhibits proximal tubular sodium reabsorption, and
blocks the cffecto ofantidiuretic hormone on the collect¬
ing duct (14). Thus some of the hemodynamic and
tubular effects we observed may have been attributable
to withdrawal of endogenous dopamine production.
Platelet effects. Nitric oxide is generated in platelets,
and exogenous nitric oxide inhibits platelet aggregabil-
ity in vitro (18). However, l-NMMA did not alter
platelet number or ex vivo aggregation to ADP. This
suggests that human endothelial and platelet nitric
oxide production is not sufficiently high to influence
spontaneous platelet aggregation and aggregability to
ADP under physiological conditions. This finding is
consistent with previous work showing that brachial
artery infusion of l-NMMA does not potentiate local
whole blood ex vivo platelet aggregation (28).
Limitations. Several potential limitations should be
considered when interpreting this study. First, we did
not test higher doses of l-NMMA. We may, therefore,
have underestimated the renal and other effects of
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endogenously produced nitric oxide. However, previous
dose-ranging studies by ourselves suggest that maxi¬
mal systemic vasoconstriction is achieved at threefold
lower doses than we used here (9). In addition, there
were substantial reductions in plasma and urine ni¬
trate concentrations after administration of l-NMMA.
Even so, our data do not allow us to exclude the
possibility that a higher dose of l-NMMAmay have had
a greater effect on renal function or platelet aggregabil-
ity. l-NMMA had a significantly greater effect on total
peripheral resistance than on renal vascular resis¬
tance. Nonetheless, although the renal vasculature
may be less sensitive to l-NMMA than other beds, it is
still likely that nitric oxide contributes importantly to
modulation of renal vascular tone. Second, renal vaso¬
constriction to l-NMMA is proportional to sodium
intake (4), and we did not study subjects at different
levels of sodium intake. However, because our subjects
had relatively high sodium excretion, sodium status
cannot account for the lesser degree of renal vasocon¬
striction to l-NMMA. Third, l-NMMA induced changes
in arterial pressure may have altered renal hemodynam¬
ics and tubular function. For example, in animals, low
doses of l-NMMA cause sodium retention without
changing arterial pressure; higher doses of l-NMMA
that elevate arterial pressure cause natriuresis (13).
Thus a rise in renal perfusion pressure may induce a
pressure natriuresis that opposes a putative direct
tubular effect of l-NMMA to increase sodium reabsorp-
tion. However, such an effect would tend to have
underestimated the increase in sodium reabsorption
that we observed after l-NMMA. Fourth, concerns have
been raised regarding the validity of lithium clearance
as an estimate ofproximal nephron sodium excretion in
humans, because other renal sites may handle lithium
and because lithium may not be inert at certain doses
(12). It is therefore possible that lithium reabsorption
at more distal sites obscured a proximal tubular effect
of l-NMMA. At the low dose we used, pharmacological
effects of lithium are unlikely to have confounded our
results.
Perspectives. In contrast to some animal studies,
inhibition of nitric oxide generation in humans caused
only modest renal vasoconstriction, possibly reflecting
more rigorous homeostatic control of the renal circula¬
tion in humans. Alternatively, it is possible that nitric
oxide contributes less to control of vascular tone in
renal vessels than in the rest of the peripheral circula¬
tion. The relative effects of l-NMMA on renal plasma
flow and glomerular filtration rate suggest that endog¬
enous nitric oxide has a greater effect on the afferent
than the efferent renal arteriole. Even so, the magni¬
tude of the effect on GFR suggests that endogenously
generated nitric oxide may also influence mesangial
cell contractile tone, as has been reported in vitro (22).
The substantial decrease in fractional distal sodium
excretion after l-NMMA suggests an important physi¬
ological role for nitric oxide in regulation of distal
tubular sodium reabsorption. Given our data suggest¬
ing that endogenous nitric oxide stimulates renal dopa¬
mine formation, it is possible that some of these tubular
actions of nitric oxide are mediated by dopamine.
Metabolites of L-arginine, such as L-NMMA, are endog¬
enous circulating substances, and levels are increased
in chronic renal failure (29). Plasma concentrations of
L-NMMA 60 min after infusion, when total peripheral
resistance was still increased, were similar to those of
L-arginine metabolites seen in renal failure (29), imply¬
ing that circulating L-NMMA may have a role in the
peripheral vasoconstriction and sodium retention asso¬
ciated with renal impairment.
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The peptide endothelin receptor antagonist, TAK-044, produces sustained
inhibition of endothelin-1 mediated arteriolar vasoconstriction
C. J. Ferro, W. G. Haynes, N. R. Johnston, C. C. Lomax, D. E. Newby & D. J. Webb
Clinical Pharmacology Unit and Research Centre, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU
Aims Endothelin-1 (ET-1) has been implicated in the pathophysiology of a number
of cardiovascular diseases for which endothelin receptor antagonists are currendy
under clinical development. We have previously reported that systemic administration
of the combined endothelin A/B receptor antagonist, TAK-044, abolishes the
forearm vasoconstriction caused by intrabrachial ET-1 infusion for at least 3 h. In
this study we investigated whether TAK-044 can inhibit ET-1 mediated forearm
vasoconstriction for longer periods.
Methods Eighteen subjects were recruited to a randomized, placebo-controlled,
single-blind, three-way, crossover study. Subjects were divided into three groups of
six. Groups received 25 mg, 50 mg or 100 mg TAK-044 on two separate occasions,
6 and 10 h before the start of a 2 h intrabrachial infusion of ET-1 (5 pmol min ).
On a third occasion subjects received only placebo before intra-arterial ET-1
infusion. Forearm vasoconstriction to ET-1 was measured by venous occlusion
plethysmography.
Results In the placebo phase, ET-1 caused significant, slowly-progressive local
forearm vasoconstriction of ~30% (P<0.01) in all three groups. All three doses of
TAK-044, administered at both timepoints, tended to blunt the vasoconstriction
caused by ET-1. When the responses from all three groups were combined,
TAK-044 significantly reduced ET-1 mediated vasoconstnction compared with
placebo -9% (95% CI -15 to -3; P=0.01) at 8 h and by -9% (95% CI -17
to —2; P=0.01) 12h after dosing.
Conclusions TAK-044 attenuated, but did not abolish, local ET-1 mediated
vasoconstriction, for up to 12 h after administration. Vasoconstriction to local intra¬
arterial administration of ET-1 appears to represent a safe and reproducible
pharmacodynamic index of systemic endothelin receptor antagonism in humans.
Keywords: endothelin, endothelin antagonists, pharmacodynamics, forearm blood flow,
humans
Introduction
The endothelium denved vasoconstrictor peptide
endothehn-1 (ET-1) has been implicated in the pathophysio¬
logy of a number of conditions associated with sustained
elevation of vascular tone, such as hypertension and congestive
cardiac failure, as well as in vasospastic disorders, such as
subarachnoid haemorrhage and acute ischaemic renal failure
[1], Two endothelin receptor subtypes, ETA [2] and ET[, [3],
both of which have been identified and cloned in man, can
mediate vasoconstnction [4J. Antagonists at these receptors
may, therefore, have therapeutic potential in these conditions.
We have previously shown that systemic intravenous
administration of the cyclic hexapeptide combined ETA/1)
receptor antagonist, TAK-044 [5], at doses of 10 to 1000 mg,
is well tolerated and produces dose-dependent, long-lasting
vasodilatation resulting in decreases of blood pressure and
systemic vascular resistance persisting, at the highest dose,
for at least 24 h [6], In a separate study, systemic
Correspondence: Professor D. J. Webb. Clinical Pharmacology Unit and Research
Centre, University of Edinburgh, Western General Hospital. Edinburgh EH4 2XU
administration of TAK-044, at doses of 30, 250 and 750 mg
abolished vasoconstriction to locally infused ET-1, as a
model of ET-1 induced 'vasospasm', for up to 3 h [6|.
Endothelin receptor antagonists are currently under clinical
development [1], Peptide antagonists such as TAK-044
requiring intravenous administration are better suited for the
treatment ofacute vasospastic conditions in which endothelin
has been implicated in the pathophysiology. These conditions
include subarachnoid haemorrhage, acute ischaemic renal
failure and myocardial infarction. In these clinical situations
intermittent dosing might have both practical and economic
advantages over continuous infusion. We, therefore, studied
the potential ofTAK-044 to inhibit the forearm vasoconstric¬
tion produced by brachial artery infusion of ET-1 for up to
12 h after dosing.
Methods
Subjects
Eighteen healthy male subjects between 19 and 41 years of
age participated in these studies, which were conducted
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with the approval of the Lothian Research Ethics Committee
and with the written informed consent of each subject. All
had normal baseline results on routine biochemical and
haematological screening tests. None of the subjects received
vasoactive or non-steroidal anti-inflammatory drugs in the
2 weeks before the study or during the study penod. All of
the subjects abstained from alcohol for 48 h, from caffeine
containing drinks and cigarettes for at least 24 h, and from
food for 12 h before the start of the ET-1 infusion. All
studies were performed in a quiet room maintained at a
constant temperature of 24-26° C.
Systemic haemodynamics A well-validated semi-automated
non invasive oscillometnc sphygmomanometer (Takeda UA
751, Takeda Medical Inc, Tokyo, Japan) was used to make
duplicate measurements of blood pressure and heart rate in
the non-infused arm, which were then averaged [8].
Forearm blood flow Blood flow was measured in both arms
by venous occlusion plethysmography [9] using mercury-
m-Silastic strain gauges that were securely applied to the
widest part of each forearm. The hands were excluded from
the circulation during each measurement period by inflation
of a wrist cuff to 220 mmHg. Upper arm cuffs were
intermittently inflated to 40 mmHg for 10 s in every 15 s to
temporarily prevent venous outflow from the forearm and,
thus, obtain plethysmographic recordings. Recordings of
forearm blood flow were made every 10 min over 3 min
periods. Voltage output from two single channel Hokanson
EC 4 strain gauge plethysmographs (DE Hokanson Inc,
Bellevue, WA) was transferred to a Macintosh personal
computer (Performa 475, Apple Computer Inc, Cupertino,
CA) using a MacLab analogue digital converter and Chart
software (v. 3.3.3; both from AD Instruments, Castle Hill,
NSW, Australia). Calibration was achieved using the internal
standard of the Hokanson plethysmography units.
Drugs
TAK-044, cyclo[d-a-aspartyl-3-[(4-phenylpiperazin-l-yl)
carbonyl ]l - alanyl - l - a - aspartyl - d - 2 - (2 - thienyl)glycyl - l -
leucyl-d-tryptophyl] disodium salt (Takeda Chemical
Industries Ltd, Japan), is a potent hexapeptide endothelin
receptor antagonist that inhibits the binding of ET-1 to
endothelin receptors on rabbit ventricular (mainly ETA) and
cerebellar membrane fractions (mainly ETB) with IC50
values of 3.8 nM and 130 nM respectively in vitro [5].
TAK-044 inhibits, with equal efficacy, both ETA and ETU
mediated responses in vivo [5, 7], The initial dose of
TAK-044 studied, 25 mg, was chosen on the basis that
30 mg TAK-044 completely inhibited ET-1 mediated
vasoconstriction for up to 3 h after administration [6].
Depending on whether or not 25 mg TAK-044 abolished
the vasoconstriction to ET-1, it was intended to study either
lower (10 and 5 mg) or higher (50 and 100 mg) doses of
TAK-044 respectively. TAK-044 and 50 mg sucrose placebo
were dissolved in physiological saline (0.9%; Baxter
Healthcare Ltd, Thetford, UK) and administered as a 50 ml
intravenous infusion over 15 min using two Welmed P1000
synnge pumps (Welmed Clinical Care Systems, Bramley,
Hampshire, UK) via a right antecubital fossa vein cannulated
with an 18G intravenous cannula (Venflon; Viggo-
Spectramed, Helsinborg, Sweden). This cannula was not
used for blood sampling.
The left brachial artery was cannulated under local
anaesthesia (1% lignocaine; Astra Pharmaceuticals, Kings
Langley, UK) with a 27 standard wire gauge steel needle
(Cooper's Needle Works, Birmingham, UK) attached to a
16(1 epidural catheter (Portex Ltd, Hythe, Kent, UK).
Patency was maintained by infusion of physiological saline
via a Welmed P1000 syringe pump. Pharmaceutical grade
ET-1 (Clinalfa, Nottingham, UK) dissolved in physiological
saline was infused at a rate of 5 pmol min-1. The rate of
mtra-arterial infusion was maintained constant throughout
all studies at 1 ml min 1.
Measurements
Side-effect assessments The following assessments were
performed to detect potential adverse effects; 12-lead
electrocardiographs, repeated questioning for symptoms,
urinalysis, clinical chemistry screen (liver enzymes, electro¬
lytes, creatinine, blood urea, protein), and haematology
screen (full blood count, white blood cell differential count).
Plasma assays Venous blood samples were taken from a
right antecubital fossa vein cannulated with an 18G
intravenous cannula attached to a manometer connecting
tube (Portex Ltd, Hythe, Kent, UK). All assays were
performed as single batches. Plasma endothelin was measured
by radioimmunoassay (New England Nuclear Endothelin
1,2 kit) as previously described [10], The sensitivity of this
assay is 2.2 pg ml ' immunoreactive ET. Cross-reactivity
of this assay with ET-1, ET-2, ET-3 and big ET-1 is 100%,
53%, 4% and 70% respectively. The normal range for this
assay is 12-28 pg ml
TAK-044 was extracted from buffered (Merck 9437;
pH 5) plasma by methanol/buffer-preconditioned Bakerbond
SPE cartridges and was measured by high performance
liquid chromatography (h.p.l.c.). Eluate was evaporated to
dryness under nitrogen at 40° C, and the residue reconsti¬
tuted in 100 gl water. Chromatographic separation was
achieved using two Merck LiChrospher columns with
Hewlett Packard 1090 h.p.l.c. pumps. The first mobile
phase comprised 40% acetonitrile and 60% 6 mmol 1 '
KH2P04/3 mmol 1 ' tetrabutylammonium bromide. The
second mobile phase comprised 52% acetonitnle/0.5% acetic
acid/47.5% water. Detection was achieved by fluorimetry
(excitation, 286 nm; emission 348 nm) with Jasco 821
fluorescence detectors. The limit of quantification of this
assay, defined as the lowest quantifiable amount of compound
at which the loss of precision was <15% and the accuracy
was +15%, was determined to be 2.1 ng ml '.
Study design
Eighteen subjects took part in a randomized, placebo-
controlled, single-blind, three-way, crossover study Subjects
were studied on three occasions, each 1 week or more
apart. They were admitted to the clinical research centre at
20.00 h on the day before the study and were discharged at
3/8 © 1997 Blackwell Science Ltd Br J CJm Pharmacol. 44. 377-363
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13.00h on the study day. On two occasions subjects
received TAK-044 either at 24.00 h or 04.00 h. Sucrose
placebo was substituted for TAK-044 at the other timepoint.
On a third occasion subjects received only sucrose placebo
at both rimepoints. The first group of six subjects (group 1)
was studied using 25 mg TAK-044. Because this dose did
not appear to abolish ET-1 mediated vasoconstriction,
groups 2 and 3 were studied using 50 and 100 mg TAK-044
respectively as previously determined. ET-1 was infused
lntra-arterially starting at 10.00 h and ending at 12.00 h, the
end of the infusion corresponding to either 8 or 12 h after
administration of TAK-044. Venous blood samples (10 ml)
were obtained at 10.00 h and 12.00 h for assay of plasma
endothelin and venous samples (5 ml) were obtained at
08.00 h, 10.00 h and 12.00 h for assay of serum TAK-044.
Blood and urine samples were collected for safety assessments
before the start of the study and at the end of the third
study phase. Electrocardiographs were recorded before
dosing, at 09.30 h and before discharge on every study day.
Data presentation and statistical analysis
From previous studies using intrabrachial ET-1 infusions
done in our unit (data on file), studying six subjects at each
dose would have 95% power to detect a 50% reduction in
the vasoconstriction produced by ET-1 at the 5% level.
However, studying six subjects would lack the power to
detect smaller differences in ET-1 vasoconstriction.
Therefore, the a priori decision to pool the data from all 18
subjects was taken. Combining the responses from all 18
subjects, would give 90% power of detecting a 25% decrease
at the 5% level. Power calculations were done using
Graphpad lnstat software (GraphPad Software, San Diego,
CA, USA).
Plethysmographic data were extracted from the Chart
data files and forearm blood flows were calculated for
individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel 5.0; Microsoft). Recordings
from the first 60 s after wrist cuff inflation were not used
because of the reflex vasoconstriction this causes [11].
Usually, the last five flow recordings in each 3 min
measurement period were calculated and averaged for each
arm. To reduce the variability of blood flow data, the ratio
of flows in the two arms was calculated for each time point:
in effect using the non-infused arm as a contemporaneous
control for the infused arm [9]. The analysis of all of the
forearm blood flows was performed by one of the
investigators (CJF) who was blinded to the study phases.
Data are described as mean + s.e. mean, with 95%
confidence intervals where appropriate. Mean arterial press¬
ure was calculated as diastolic pressure plus one third of the
pulse pressure. Hacmodynamic data are presented as absolute
values and as placebo-corrected changes from baseline
(24.00 h). Data were examined by repeated measures analysis
of variance (ANOVA) using Stat View 512 4- software
(Brainpower Inc, Calabasas, CA, USA) for the Apple
Macintosh computer. Where the F value obtained by
ANOVA was significant (P< 0.05), the Fisher PLSD
(protected least significant difference) multiple comparison
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Group 2
50 mg TAK-044





04 00 09-30 10-00 12-00 h
igure 1 Placebo corrected changes (A) in mean arterial pressure (MAP) and heart rate (HR) from baseline (24.00 h) following
travenous administration of 1AK 044 at 24.00 h (open bars) and 04.00 h (shaded bars) for group 1, 2 and 3. *P<0.05 from baseline.
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Results
TAK-044 was well tolerated, with no difference between
placebo and TAK-044 phases in the prevalence of minor
symptoms. There were no serious adverse events dunng the
study, and no clinically significant abnormalities were
detected on safety monitoring (urinalysis, haematology,
clinical chemistry and electrocardiograph).
Mean arterial pressure showed a tendency to decrease
after infusion ofTAK-044 (Figure 1). However, this decrease
was only significant in group 2 after 50 mg TAK-044
(maximum decrease: —10 + 4 mm Hg; P= 0.005). Similar
trends were noted for systolic and diastolic pressures. Heart
rate (Figure 1) increased only after dosing with 100 mg
TAK-044 at 24.00 h (maximum increase: 8 + 3 beats min ;
P= 0.03). There were no differences between phases in any
of the haemodynamic parameters measured at the start of
the intra-brachial ET-1 infusion at 10.00 h (Table 1). Mean
artenal pressure and heart rate did not change dunng
infusion of ET-1 (Figure 1). Administration of TAK-044
did not cause an increase in immunoreactive endothelin
concentrations after 8 or 12 h compared with placebo
(Table 2).
In group 1, TAK-044 plasma concentrations were not
higher than the limit of quantification of the assay
(2.1 ng ml ') at any time in any of the subjects. In group
2, TAK-044 was detectable in >50% of subjects only at
08.00 h and only after administration ofTAK-044 at 04.00 h.












TAK-044 at 24.00 h
TAK-044 at 04.00 h
109 + 6 (95 to 123)
118 + 6 (103 to 132)
113 + 2 (107 to 119)
62 + 4 (52 to 72)
58 ±3 (51 to 66)
58 ±3 (49 to 66)
51+2 (46 to 55)
52+1 (49 to 55)
57 + 3 (50 to 64)
2.8 + 0.3 (2.0 to 3.6)
2.8 ±0.3 (2.0 to 3.5)




TAK-044 at 24.00 h
TAK-044 at 04.00 h
121 ±6 (104 to 137)
124 + 7 (107 to 142)
115 + 4 (105 to 125)
64 + 3 (55 to 72)
63 + 3 (55 to 71)
57 ±3 (51 to 63)
53 + 4 (44 to 62)
56 + 1 (52 to 60)
56 + 3 (48 to 64)
3.5 ±0.3 (2.7 to 4.3)
3.4 + 0.4 (2.3 to 4.5)




TAK-044 at 24.00 h
TAK-044 at 04.00 h
109 + 6 (115 to 137)
118 ± 6 (113 to 133)
113 + 3 (115 to 138)
68 + 3 (60 to 75)
59 ±4 (49 to 69)
62 + 2 (56 to 67)
52 ±2 (46 to 57)
54 ±2 (48 to 61)
56 + 3 (48 to 63)
3.4 + 0.7 (1.6 to 5.1)
3.7 + 0.7 (2.0 to 5.4)
4.0 ±0.9 (1.7 to 6.3)
There were no significant
in brackets.
differences between baseline values on the different study days for any of the three groups. 95% confidence intervals are shown
Table 2 Plasma TAK-044 and plasma endothelin concentrations in groups 1, 2 and 3.
Plasma TAK-044 concentration (ng ml )
08.00 h 10.00 h 12.00 h
Plasma ET concentration (pg ml 1)




TAK-044 at 24.00 h







12.3 ±1.1 (9.5 to 15.0)
16.1 ±1.3 (12.9 to 19.4)
13.4 + 1.0 (10.8 to 16.0)
12.9 + 0.6 (11.3 to 14.5)
13.6 + 0.7 (11.7 to 15.5)




TAK-044 at 24.00 h
TAK-044 at 04.00 h
<2.1 <2.1
<2.1 <2.1




11.6 + 0.8 (9.5 to 13.7)
11.7 + 0.5 (10.3 to 13.1)
10.9±0.3 (10.3 to 11.6)
12.8 ±0.5 (11.6 to 13.9)
13.1 ±1.0 (10.5 to 15.6)




TAK-044 at 24.00 h
TAK-044 at 04.00 h
<2.1 <2.1





1 1.4 ±0.8 (9.4 to 13,4)
11.7 ±(1.5 (10.4 to 13.0)
13.2 ±0.5 (12.0 to 14.4)
11.6 ±0.4 (10.7 to 12.6)
11.9 ±0.6 (10.4 to 13,5)
13.7 ± 0.7 (11.9 to 15.4)
1 )csi riptive statistics for pi
> 2.1 ng ml , the limit <
asrn.l 1AK 04-1 concentrations were
it quantification of the assay. There
calculated only for the timepoints where >50% of the subjects
were no significant differences between plasma endothehn cone
showed concentrations
entrations in any of the
groups.
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In group 3, TAK-044 was detectable at 08.00 h after
administration ofTAK-044 at 24.00 h and 04.00 . TAK-044
was also detectable in plasma at 10.00 h after administration
ofTAK-044 at 24.00 h (Table 2). The inter-subject variation
for this assay was high at > 50%.
There were no differences between any of the phases in
absolute forearm blood flows at the start of the intra-brachial
ET-1 infusions (Table 1). Blood flow in the non-infused
arm did not change significantly during infusion of ET-1 in
any of the phases. Brachial artery infusion of ET-1 caused
significant slowly-progressive local forearm vasoconstriction.
Infusion of ET-1 reduced forearm blood flow over 120 min
by 30 + 5% (P=0.0001 us basal), 30 + 4% (P=0.0001) and
28 + 5% (P=0.013) after placebo groups 1, 2 and 3
respectively (Figure 2, Table 3). TAK-044 at all three doses
and administered at both timepoints tended to blunt the
vasoconstriction caused by ET-1 but these effects failed to
achieve statistical significance (Figure 2, Table 3). However,
when the responses from all three groups were combined,
vasoconstriction to ET-1 was reduced by TAK-044 adminis¬
tered 8 and 12 h previously (Figure 3, Table 3), when
compared with placebo.
Discussion
The combined endothelin ETA/B receptor antagonist,
TAK-044, given as a 15 min intravenous infusion, attenuated
peripheral vasoconstriction to exogenous ET-1 by ~30%
for up to 12 h after administration. This inhibition occurred
at a time when plasma concentrations of TAK-044 were
below the limit of quantification of the assay and plasma
concentrations of endothelin were not elevated. These
findings have important implications for the clinical develop¬
ment of endothelin receptor antagonists.
A simple and reliable pharmacodynamic index of endo¬
thelin receptor blockade would be useful for the clinical
development of endothelin receptor antagonists. Forearm
vasoconstnction to intra-brachial administration of ET-1 is
highly reproducible [4, 6, 12] and this model may be safer
than using systemic intravenous infusions ofET-1 to increase
blood pressure, given the sustained and potent nature of
vasocontriction to ET-1, especially in the coronary, renal
and cerebral circulations [1, 13, 14]. It is possible that
endothelin receptor antagonism may produce different
effects in other blood vessels. However, responses in forearm
resistance vessels are generally thought to be broadly
representative of those in other vascular beds [9, 15],
The vasoconstriction produced by intra-artenal ET-1 in
this study was consistent with other published reports [4, 6,
12], The results demonstrate that bolus doses of TAK-044
up to 100 mg can still inhibit ET-1 mediated forearm
vasoconstriction by ~30% for up to 12 h after adminis¬
tration. However, this contrasts with complete inhibition
for up to 3 h of ET-1 mediated vasoconstnction by
TAK-044 30 mg [6] and suggests a marked time dependence
for this inhibitory action. This was a small study with
insufficient power to exclude a dose dependent effect and,
therefore, studies with larger doses would be needed to
show whether greater inhibition of ET-1 induced vasocon¬
striction could be achieved. However, the finding that
25 mg TAK-044 seemed to be as effective as 50 and 100 mg
09-30 10-00 12-00 h
Time
Figure 2 Percentage change in forearm blood flow produced by
brachial artery infusion of endothelin-1 (5 pmol min for 2 h)
following intravenous administration of TAK-044 at 24.00 h
(open circles) and at 04.00 h (closed circles) and during the
placebo phase (open squares) for groups 1, 2 and 3. Standard
errors have been omitted for sake of clanty.
TAK-044 suggests that 25 mg may achieve maximum
inhibition at this late stage after systemic administration and
that increasing the dose of TAK-044 further might not
produce greater inhibition of ET-1 mediated vasoconstnc-
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Group 1 (n = 6) — 30+5 -20 + 4 - 10 (-20 to + 13) — 22 + 3 -8 (-22 to +5)
(TAK-044 25 mg)
Group 2 (n = 6) — 30 ±4 -20 + 3 -11 (-26 to +5) — 20 ±7 -10 (-30 to+ 10)
(TAK-044 50 mg)
Group 3 (ri = 6) -28 ±4 -21 ±4 -7 (-22 to +7) -19 + 3 -9 (-26 to +6)
(TAK-044 100 mg)
All (n = 18) -29 + 2 -20 + 2 -9 (-17 to -2)* -20 + 3 -9 (-15 to -3)*
*0 — 0.01.95% confidence intervals for differences for placebo are shown in brackets.
TAK-044 given at 24-00 h
(12h before end of endothelin-1 infusion)
TAK-044 given at 04-00 h























09-30 10-00 12-00 h 09-30 10-00
Time
12-00 h
Figure 3 Percentage changes in forearm blood flow for all three groups of subjects combined, following brachial artery infusion of
endothelin-1 (5 pmol mm for 2 h from 10.00 h to 12.00 h) following intravenous administration of placebo (open squares) and
TAK-044 at 04.00 h (closed circles) and at 24.00 h (open circles). Endothelin-1 caused a slowly progressive forearm vasoconstriction
during the placebo phase. TAK-044 (25—100 mg) administered at either 04.00 h and 24.00 h (corresponding to 8 and 12 h before the
end of the endothelin-1 infusion) significantly inhibited this vasoconstriction (P= 0.01).
tion. Therefore, if an inhibition > 30% is required, more
frequent dosing (3 to 6 hourly) or a continuous infusion,
may be needed. Clinical trials with endothelin receptor
antagonists, including TAK-044, are currently in progress.
These should indicate the doses required for clinical effect
and the forearm model can then be used to determine
effective doses of other endothelin receptor antagonists. The
effects of repeated dosing with TAK-044 on ET-1 mediated
vasoconstriction are not yet known and it is possible that a
cumulative inhibition might be achieved in this manner if
the clearance mechanisms for TAK-044 were to become
saturated. These issues remain to be addressed.
Although increases in plasma endothelin concentrations
have been shown to correlate with some of the haemo-
dynamic changes observed, these associations were relatively
weak, with correlation coefficients of ~0.2 [6], Furthermore,
changes in circulating endothelin concentrations are likely
to reflect only antagonism of the ETh receptor [6, 16]
which, in addition to its functional roles, appears to mediate
clearance of circulating ET-1 (17. IS], For a drug with ETA
and E I',, receptor blocking activity, such as TAK-044, effects
on systemic haemodynamics may be apparent at concen¬
trations that do not substantially increase circulating endo¬
thelin concentrations, as was the case in our previous study
[6|. Similarly, here we found that plasma endothelin
concentrations were not raised 12 h after administration of
TAK-044 despite continuing inhibition of ET-1 mediated
vasoconstnction.
TAK-044 was not detected in any of the volunteers 12 h
after administration of any of the doses. These findings are
in close agreement with our previously reported study in
which the plasma half-life of TAK-044 was 30 to 60 min
[6], FTowever, the IC50 for TAK-044 at ETA receptors is
0.08 ng ml 1 [6) ~25 fold below the limit of quantification
of the assay (2.1 ng ml '). It is, therefore, possible that
circulating TAK-044 remains present in plasma at concen¬
trations sufficient to inhibit the vasoconstriction produced
by exogenous ET-1 at 12 h. It is also conceivable that
TAK-044 binds tightly to endothelin receptors and remains
bound for several hours in a similar manner to ET-1 |19j.
Indeed, in intact cells ET-1 appears only to become
dissociated from its receptors following receptor internalis-
ation 120]. Thus, prolonged receptor binding may explain
the sustained inhibition of ET-1 mediated vasoconstriction
by TAK-044. Another possible explanation for the observed
inhibition could be the entry of TAK-044 into another
382 © 1997 Blackwell Science Ltd Br J Gin Pharmacol, 44, 377 383
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tissue compartment, probably within the vasculature. A
similar situation arises with inhibitors of the renin-
angiotensin system, where entry into and actions in other
tissue compartments appear to explain the dissociation
between actions and plasma concentrations observed [21,
22]. These possibilities require further investigation.
Our previous study showed that TAK-044 lowers systemic
vascular resistance and blood pressure [6]. The current study
was not designed primarily to assess these measures and
factors such as diurnal variation of blood pressure, disturbed
sleep and the measurement of forearm blood flow may all
have interfered with their optimal assessment. Thus, although
the study was placebo controlled, small changes in blood
pressure and heart rate may have been obscured by these
factors. Nevertheless, systolic, diastolic and mean arterial
pressure tended to decrease after administration ofTAK-044,
to a similar extent to that reported previously [6], and heart
rate was increased after administration of the highest dose
of TAK-044. However, in this study we did not measure
systemic vascular resistance, the most sensitive index of
peripheral vasodilatation in our previous study [6],
In conclusion, the cyclic hexapeptide, combined ETA/B
receptor antagonist, TAK-044, inhibited local ET-1 mediated
vasoconstriction by ~ 30% for up to 12 h after administration.
This inhibition occurred at a time when plasma concen¬
trations of TAK-044 were below the limit of quantification
of the assay and plasma concentrations of endothelin were
not elevated. Therefore, in this study, the most sensitive
index of effect of endothelin receptor antagonism was
inhibition of ET-1 mediated vasoconstriction. Although
TAK-044 is a peptide, these features may be common to
non-peptide endothelin receptor antagonists and this study
sets up a marker against which other endothelin receptor
antagonists can now be compared. The long lasting effects of
the short lived peptide, TAK-044, are generally encouraging
for the clinical development of endothelin receptor antagon¬
ists and emphasise the valuable contribution that the combi¬
nation of local intra-artenal administration of ET-1 and
forearm plethysmography can make to the early clinical
evaluation of this novel class of vasoactive drugs.
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Endothelin-A Receptor Antagonist—Mediated
Vasodilatation Is Attenuated by Inhibition ofNitric Oxide
Synthesis and by Endothelin-B Receptor Blockade
Marianne C. Verhaar, MI); Fiona E. Strachan, BN, RGN; David E. Newby, BSc, MB, MRCP;
Nicholas L. Cruden, BSc, MB, ChB; Hein A. Koomans, Ml), PhD;
Ton J. Rabelink, Ml), PhD; David J. Webb, Ml), FRCP
Background—The role of endothelin (ET)-l in maintenance of basal vascular tone has been demonstrated by local and
systemic vasodilatation to endothelin receptor antagonists in humans. Although the constrictor effects mediated by the
vascular smooth muscle ETA receptors are clear, the contribution from endothelial and vascular smooth muscle ET„
receptors remains to be defined. The present study, in human forearm resistance vessels in vivo, was designed to further
investigate the physiological function of ETA and ETU receptor subtypes in human blood vessels and determine the
mechanism underlying the vasodilatation to the ETA-selective receptor antagonist BQ-123.
Methods and Results—Two studies were performed, each in groups of eight healthy subjects. Brachial artery infusion of
BQ-123 caused significant forearm vasodilatation in both studies. This vasodilatation was reduced by 95% (P=.006) with
inhibition of the endogenous generation of nitric oxide and by 38% (P<.0()1) with coinfusion of the ET,j receptor
antagonist BQ-788. In contrast, inhibition of prostanoid generation did not affect the response to BQ-123. Infusion of
BQ-788 alone produced a 20% reduction in forearm blood flow (P<.001).
Conclusions—Selective ETA receptor antagonism causes vasodilatation of human forearm resistance vessels in vivo. This
response appears to result in major part from an increase in nitric oxide generation. ETH receptor antagonism either alone
or on a background ofETA antagonism causes local vasoconstriction, indicating that ET,, receptors in blood vessels respond
to ET-1 predominantly by causing vasodilatation. (Circulation. 1998;97:752-756.)
Key Words: endothelin ■ nitric oxide ■ flow ■ receptors ■ prostaglandins
The endothelin (ET) family of peptides (ET-1, ET-2, ET-3)are generated in a variety of tissues and act primarily as
paracrine and autocrine factors. The major isoform in the
cardiovascular system, ET-1, is generated in the endothelium
from a precursor, big ET-1, through cleavage by a specific
endothelii l-converting enzyme (ECE). Its actions are mediated
by two receptors, the ETA and the ET„ receptor, which have
been characterized and cloned1'2 and are pharmacologically
distinct. The ETA receptor has a higher affinity for ET-1
(ET-15$>ET-3), whereas the ET,, receptor is nonisopeptide
selective (ET-l = ET-3). ETA receptors are expressed on vas¬
cular smooth muscle cells, and their activation by ET-1 leads to
vasoconstriction. The physiological importance of endogenous
ET-1 in the maintenance of basal vascular tone and blood
pressure in humans has been demonstrated by local1'4 and
systemic1 vasodilatation in response to inhibitors of the endo¬
thelin system. An important role for the ETA receptor in
mediating this response is suggested by the substantial forearm
vasodilatation to local administration of the selective ETA
receptor antagonist BQ-1235 in healthy subjects.
Initially, it was thought that ET„ receptors were present only
on endothelial cells, where they cause vasodilatation through
release of endothelium-derived vasodilators, including nitric
oxide (NO) and prostacyclin.6'7 However, it is now recognized
that ET„ receptors are also present on the smooth muscle of
human arteries" and can mediate vasoconstriction,'' " although
their contribution to ET-1-mediated constriction in humans
remains to be defined.12 Therefore, although ETA receptor-
mediated vasoconstriction is undisputed, it is unclear whether
the balance of the effects of endogenous ET-1 on the endo¬
thelial and vascular smooth muscle ET|, receptors results
predominantly in a vasodilator or constrictor tone.
In addition to mediating vasodilator effects of endothelial
ET„ receptor activation, endothelium-derived dilators can in
turn modulate the production and actions ofET-111 ls In the
short term NO inhibits production of ET-111 whereas chronic
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exposure causes upregulation of ETA receptors.Ih In addition,
endothelin receptor antagonists attenuate the pressor response
to NO inhibition,17'18 suggesting that this response may not
simply be due to loss of basal NO-mediated dilator tone. These
interactions indicate the existence of a complex relationship
between the endothelin and NO systems.
As a consequence of its potent vasoconstrictor1'' and growth-
promoting properties,20 ET-1 has also been implicated in the
pathophysiology of diseases such as hypertension, heart failure,
and renal failure.21 The recognition of the endothelin system as
a new therapeutic target in the treatment of cardiovascular
disease has lead to the rapid development of pharmacological
agents that inhibit either the production of ET-1 or its actions.
Recently, potent intravenous and orally active endothelin
receptor antagonists with different pharmacological profiles
have become available for clinical studies.21'22 We are now in a
position where it would be valuable to explore the contribu¬
tion of the ETb receptor to the vascular effects of ET-1.
The present study, in human forearm resistance vessels in
vivo, was designed to further investigate the physiological role
of ETa and ETU receptor subtypes and their possible interac¬
tions in mediating the vasodilator response to selective ETA
receptor antagonism. The first part of the study aimed to
investigate whether increased release of the endothelium-
dependent relaxant factors NO and prostacyclin contributes to
the vasodilator response to selective ETA receptor antagonism.
We therefore compared the response to the selective ETA
receptor antagonist BQ-123 during local inhibition of NO
synthase and during systemic inhibition of prostanoid genera¬
tion with the response to BQ-123 alone. In the second part of
the study, to investigate the role of the ET„ receptor in
BQ-123-induced vasodilatation, we examined the effects of
simultaneous ETA and ET„ receptor blockade compared with
ETa or FT,, receptor blockade alone.
Methods
Subjects
Twenty-two healthy subjects (I woman) ranging in age from 20 to 43
years participated in two studies that were performed in the University
Hospital Utrecht (study 1) and the University Department of Medi¬
cine, Western General Hospital, Edinburgh (study 2), with the
approval of the local research ethics committees of each hospital and
the written informed consent of each subject. The investigations
conformed with the principles outlined in the Declaration of Helsinki.
No subjects had received vasoactive medication or nonsteroidal
anti-inflammatory drugs within the week before each phase of a study,
and all subjects abstained from alcohol for 24 hours and from food,
caffeine-containing drinks, and tobacco for at least 4 hours before any
measurements were made. All studies were performed in a quiet room
maintained at a controlled temperature between 22°C and 24.5°C.
Drug Administration
I lie brachial artery of the noiidominant arm was cannul.ited with a 22
(study I) or 27 SWG cannula (study 2) under lidocaine local anesthesia
(hdocaine 2%; Astra Pharmaceuticals Ltd). Drugs, with the exception
of aspirin, were dissolved in physiology al saline (If9%; Baxter
1 Ir.iltlie.ii e 1 til) and infused intra artenullv at locally at live doses. The
infusion i.ite was kept constant at SO nil h (study I) or (ill nil /h
(study 2) All solutions were prepared aseptieally from sterile stor k
solutions oi ampules on the day oi the studs*.
Drugs
11Q-123 (KM) nmol/min, study 1; 10 nmol/niin, study 2), was used as a
selective ETA receptor antagonist (study 1: American Peptide Go; study 2:
Clinalfa AG). We have demonstrated previously local forearm vasodila¬
tation to intra-aitenal infusion of BQ-123 (100 nmol/min).1 In study 2,
we used a 10-fold lower dose of BQ-123 (10 nmol/min) because more
recent studies have shown that this causes vasodilatation of equal magni¬
tude to that seen with the higher dose.11 BQ-788 (1 nmol/min) was used
as a selective E I), receptor antagonist14 (American Peptide Co). This dose
has been shown to completely inhibit venoconstriction to the selective
ET„ receptor agonist sarafotoxin S6c.25
The endogenous NO system in the forearm was inhibited by use of
an "NO clamp," as described previously.26 The NO synthase inhibitor
l.-N*' monomethyl-arginine (L-NMMA; Institut fur Pharmazie, Uni-
versitat Leipzig) was continuously infused at a rate of 200 /xg/100 mL
forearm volume per minute to achieve maximal inhibition of local
NO synthase.27"29 Sodium nitroprusside (SNP), an exogenous NO
donor (Merck) was then coinfused at titrated doses (12 to 30 ng/min).
After 8 minutes of L-NMMA infusion, when steady state forearm
blood flow was obtained, SNP was coinfused in incremental doses
and titrated until baseline forearm blood flow had been restored.
L-NMMA and SNP were then coinfused, at these rates, for the
remainder of the study. This allowed simulation of normal basal NO
activity during continuous inhibition of endogenous NO synthesis.
Aspirin (600 nig calcium acetylsalicylic acid; Carbasalatum Calcium,
Dagra Pharma BV) was administered orally 30 minutes before mea¬
surements in one phase of study 1. Aspirin irreversibly inhibits
cyclooxygenase (EC 1.14.99.1), which is responsible for the produc¬
tion of prostaglandins and thromboxanes. When given at a dose of 600
mg, aspinn inhibits bradykinin-stimulated endothelial production of




Forearm blood flow was measured simultaneously in both arms by
venous occlusion plethysmography using calibrated mercury-in-Silas-
tic strain-gauges applied to the widest part of the forearm.1,27'11 The
hands were excluded from the circulation during each measurement
period by inflation of a wrist cuff to 220 mm Hg. Upper arm cuffs
were intermittently inflated to 40 mm Hg for 10 seconds every 15
seconds to temporarily prevent venous outflow from the forearm and
thus obtain plethysmography recordings. Recordings of forearm
blood flow were made over 2.5-minute periods at 5-minute intervals
(study 1) and over 3-minute periods at 10-minute intervals (study 2).
Venous occlusion plethysmography was performed using a dual-
channel strain-gauge plethysmograph (Hokanson), and calibration was
achieved using the internal standard of the Hokanson plethysmogra¬
phy unit. In study 1, a microcomputer-based R-wave—triggered
system for online semicontinuous monitoring was used, " whereas in
study 2, voltage output was transferred to a Macintosh personal
computer (Classic II; Apple Computer) using a MacLab analog-digital
converter and Chart software (version 3.2.8; both from AD
Instruments).
Blood Pressure
Blood pressure was monitored during eac h study using either contin¬
uous intra-artenal measurements 111 the infused arm (study I) or a
semiautomated noninvasive oscillometry method in the noninfused
arm (study 2).u Blood pressure in study 2 was measured immediately
after each forearm blood flow measurement, thereby avoiding any
effect of venous congestion caused by this procedure on blood flow.
General Study Design
Subjects rested recumbent throughout each study with both forearms
resting slightly above the level of the heart. Strain gauges and arm cuffs
were applied, and the left brachial artery cannula was sited. Before the
administration of drugs, saline was infused for at least 3(1 minutes.
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Baseline Hemodynamic Values During Saline infusion Before Infusion of Drugs
Study 1 Study 2
BQ-123 BQ-123+ BQ-123+ BQ-123 BQ-123+ BQ-788
Parameter (100 nmol/min) NO-Clamp Aspirin (10 nmol/min) BQ-788 (1 nmol/min)
Forearm blood How (ml/100 mL
per minute)
Infused arm 3.7+0.4 3.7+0.3 4.1+0.5 3.6±0.6 4.5±1.0 4.5±0.7
Control arm 4.6±0 5 3.4+0.2 3.4±0.5 3.4±0.6 3.3±08 3.1 ±0.4
Mean arterial pressure, mm Hg 78±2 82±3 79±2 83± 5 90 ±3 93±4
Fnrearm blood flow in infused and control arm and mean arterial pressure in each phase of studies 1 and 2 at baseline before infusion of, respectively, BQ 123; BQ-123
SNP, and L-NMMA; BQ-123; BQ-123; BQ-123 and BQ-788; and BQ-788. There were no significant differences in baseline forearm blood flow or mean arterial pressure between
the phases of each study.
n=8 in each phase of studies 1 and 2.
during which baseline measurements of forearm blood flow were
made.
Study 1: Inhibition ofNO Synthase and
Prostanoid Generation With ETA
Receptor Blockade
Eight subjects were studied on three separate occasions, each separated
by at least 1 week. After baseline infusion of saline, BQ-123 was
infused for hO minutes; on one occasion, dunng saline coinfucion; on
another, after stabilization of the NO-clamp; and on another, after
systemic inhibition of prostanoid generation. The effects of the
NO-clamp on forearm blood flow were studied during a 2-hour
penod in 3 subjects (time control NO-clamp).
Study 2: Separate and Combined Blockade of ETA
and ETb Receptors
On 2 separate study days, in 8 subjects, the ETA receptor antagonist
HQ-123 was infused for 120 minutes alone or dunng coinfusion of
BQ-788, also for 120 minutes. On a separate occasion, BQ-788 was
infused alone for 120 minutes in 8 subjects (2 of whom also
participated in the earlier parts of study 2).
Analysis
Blood flow in both forearms was obtained from the mean of the last
five consecutive recordings of each measurement penod. Because
wrist cuff inflation results in a transient forearm vasoconstriction,
recordings made in the first 60 seconds after wrist cuff inflation were
not used for analysis. The ratio of flows in the infused and nomnfused
arms was calculated for each time point and expressed as percentage
change from baseline or, in the NO-clamp experiments, as percentage
change from the average of the last four recordings during NO-
clamping, before the administration of BQ-123. In both studies,
plethysmography data listings were extracted from data files, and
forearm blood flows were calculated for individual venous occlusion
cuff inflations using a template spreadsheet (Excel 5.0; Microsoft). All
results are expressed as mean±SEM. Data were examined by repeated
measures ANOVA (study 1, SigmaStat; Jandel Corp; study 2, Excel
5.0; Microsoft). Statistical significance was taken at the 5% level.
Results
There were no significant changes in baseline hemodynamics
between phases of each study (Table) and no change in blood
pressure or blood flow in the nonmfused forearm during the
course of the studies.
Study 1
Baseline forearm blood flow was restored during the NO-
clamp (basal infused forearm blood flow; 3.710.3: during basal
NO clamp; 3.410.2; P=.15) and kept stable for at least 40
minutes before BQ-123 infusion was started. Blood flow in the
infused forearm in the time control NO clamp protocol varied
by <5% between baseline (pre—NO clamp) and with 120
minutes of NO clamping in 3 subjects.
BQ-123 caused progressive vasodilatation during coinfusion
of saline and after inhibition of prostanoid generation (P<.01
for both). The response appeared to plateau at 60 minutes, and
no differences were observed in these responses (3819% versus
4217% at 90 minutes; P=.5). The vasodilator response to
BQ-123 was markedly reduced during NO-clamping (215%
at 90 minutes, P=,006 versus saline coinfusion) (Fig 1).
Study 2
Both BQ-123 alone and coadministration of BQ-123 and
BQ-788 caused progressive vasodilatation (P<.()01) that ap¬
peared to plateau at 60 minutes (Fig 2). The vasodilatation to
BQ-123 alone was significantly greater than that during
coinfusion with BQ-788 (76113% versus 47114% at 120
minutes, P<.0()1). BQ-788 alone caused a small but consistent
reduction in forearm blood flow (2013% at 120 minutes,
P<.001) (Fig 2).
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Figure 1. Eight subjects received brachial artery infusion of
BQ-123 (100 nmol/min) during coinfusion of saline (•), BQ-123
(100 nmol/min) during inhibition of prostanoid generation (A), or
BQ-123 (100 nmol/min) during inhibition of NO generation (■).
Slow-onset vasodilatation occurred in response to BQ-123; this
response was attenuated during NO clamp but not during inhi¬
bition of prostanoid generation.
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Figure 2. Eight subjects received brachial artery infusion of
BQ-123 (10 nmol/min) alone (•), BQ-788 (1 nmol/min) alone (A),
or BQ-123 (10 nmol/min) coinfused with BQ-788 (1 nmol/min)
(O). Slow-onset vasodilatation occurred in response to BQ-123;
this response was attenuated during coinfusion of BQ-788.
BQ-788 infusion alone caused a small but significant
vasoconstriction.
Discussion
In two centers, we have demonstrated slow-onset forearm
vasodilatation in response to local arterial infusion of the
selective ETA receptor antagonist BQ-123, confirming the
importance of endogenous ET-1 in the mediation of vascular
tone. From these data, it appears that this vasodilator response
is caused in large part by increased generation of NO, which
could be mediated by stimulation of the endothelial ET„
receptor. Indeed, our observation that the vasodilator response
to combined ETA and ET„ receptor antagonism was signifi¬
cantly less than that to selective ETA receptor antagonism alone
probably reflects the presence of an endogenous ETH-mediated
vasodilator tone. This is further supported by the local vaso¬
constrictor effect of ETn receptor antagonism in the forearm
resistance vessels.
In the present study, to exclude the influence of the
endogenous NO system in mediation or modulation of the
effects of ET-1, L-NMMA was infused to inhibit endogenous
local generation ofNO. SNE was coinfused with L-NMMA to
restore baseline blood flow2" because local inhibition of NO
would otherwise result in vasoconstriction. In this situation,
endogenous NO is replaced with exogenous NO, in effect
applying a clamp to the local endogenous NO system. Using
this technique we have shown, for the first time in humans in
vivo, that the vasodilatation to BQ-123 is in large part related
to NO generation. Inhibition of endogenous prostanoid gen¬
eration by oral administration of aspirin has no effect on basal
forearm blood flow or systemic hemodynamics and, more
importantly, had no effect on the response to BQ-123,
indicating that the dilator prostanoids do not provide an
important contribution to the vasodilator response to BQ-123.
Almost all of the response to BQ-123 appeared to be blocked
by NO clamping. However, on the basis of vasodilatation to
the E(.E inhibitor phosphoramidon" m previous studies,1 we
think it is likely that at least part of the response to BQ-123 is
directly due to withdrawal of endogenous ETA-inediated
vasoconstriction.
Selective E fA antagonism inhibits the actions of ET-1 at the
E. I A receptor while allowing its actions at the ET„ receptor to
be unopposed. EE I can stimulate both the endothelial EEH
receptor to cause dilatation and the vascular smooth muscle
ET„ receptor to cause vasoconstriction. Therefore, the overall
effect depends on a balance between these two actions.
Unfortunately, there are no available pharmacological tools
that have been shown clearly to distinguish between the
endothelial and vascular smooth muscle ET„ receptors. We
have shown that coinfusion of the ET„ receptor antagonist
BQ-788 reduces the vasodilator response to BQ-123, suggest¬
ing that the balance of effects of ET-1 favors vasodilatation via
the endothelial ET„ receptor. This is further supported by the
vasoconstriction in these vessels to BQ-788 alone and by the
lesser degree of vasodilatation to the combined ETA/ET„
endothelin receptor antagonist TAK-0444 than to the ETA-
selective agent BQ-123.1 It is possible that the predominant
effects of intra-luminal infusion of BQ-788 selectively affect
the endothelial ET„ receptor because the drug has better access
to the endothelial than to the smooth muscle receptors.
However, we believe this is unlikely because ET-1 and
BQ-123 find ready access to the smooth muscle. The response
to BQ-788 may indicate either displacement of ET-1 from, or
failure of clearance ofET-1 by, ET„ receptors.11 However, our
present results cannot distinguish between these effects.
The observation that selective ETA receptor blockade not
only antagonizes direct ETA receptor-mediated constriction
but also preserves beneficial ET„ receptor—mediated vasodila¬
tor tone and enhances endogenous NO generation may have
important implications in the use of endothelin antagonists as
treatments in cardiovascular disease. For example, the increased
NO generation caused by ETA receptor antagonists is poten¬
tially beneficial in ischemic heart disease. However, the clinical
relevance of our findings in various pathophysiological condi¬
tions cannot be fully determined from the present study
because endothelin receptors may be modified under these
circumstances. Indeed, in ischemic heart disease, there appears
to be upregulation of human coronary ET„ receptors,16 and this
is associated, in heart failure, with enhanced vasoconstrictor
responses to sarafotoxin S6c in both the forearm17 and coronary
circulation, * whereas the response to BQ-788 appeared similar
to that of controls.1' Clearly, at some stage, it will be necessary
to examine the integrated physiology of systemic ETA and ETlt
blockade in physiological and pathophysiological conditions to
fully understand the relative importance of the receptor
subtypes.
In summary, we have demonstrated that the local vasodilator
response to selective ETA receptor antagonism in human
forearm resistance vessels is derived in large part from increased
NO-mediated vasodilatation, most probably mediated by the
endothelial ET„ receptor. Although our observations were
made in the forearm resistance vessels, these vessels are gener¬
ally representative of other vascular beds""1 and, importantly,
reflect the interaction of these systems in vivo. Our results may
indicate new therapeutic uses lor ETA receptor antagonists
because increased NO synthesis may be a desirable elici t in, lor
example, ischemic heart disease. One could also postulate that
enhanced endogenous NO generation may lie responsible lor
the headaches that are a recognized side effect ol E. I receptor
antagonists.
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Systemic Blockade of the Endothelin-B Receptor Increases
Peripheral Vascular Resistance in Healthy Men
Fiona E. Strachan, James C. Spratt, Ian B. Wilkinson, Neil R. Johnston,
Gillian A. Gray, David J. Webb
Abstract—Endothelin-1 (ET-1) is an important mediator of vascular tone in humans, and a number of endothelin receptor
antagonists are currently in clinical development as vasodilator agents. While the vasoconstrictor role of the ETA
receptor is undisputed, the role of the ETB receptor remains unclear. Hemodynamic effects of systemic doses of the
ETB-selective antagonist BQ-788 were investigated in 5 healthy male volunteers (age range, 33 to 48 years) in a
placebo-controlled, four-way crossover study. After a 15-minute infusion of BQ-788 (3, 30, or 300 nmol/min) or
placebo, plasma ET-1 and big ET-1, blood pressure, heart rate, cardiac index, and stroke index were measured. Total
peripheral vascular resistance was calculated from cardiac index and mean arterial pressure. Hemodynamic data are
expressed as maximum, placebo-corrected, percentage change from baseline following BQ-788 (300 nmol/min) and
were examined by ANOVA. Plasma ET-1 increased by 3.7±1.2 pg/mL (maximum at 15 minutes, P=0.02), whereas
there was no significant change in plasma big ET-1. Although BQ-788 had no effect on mean arterial pressure, there
was a reduction in heart rate (13±7% at 50 minutes; P=0.002), cardiac index (17±5% at 40 minutes; P<0.0001), and
stroke index (8±4% at 40 minutes; P=0.002) and an increase in total peripheral vascular resistance (24±5% at 40
minutes; P<0.0001). The selective ET„ receptor antagonist BQ-788 causes peripheral vasoconstriction in healthy
volunteers, suggesting that the overall balance of effects of endogenous ET-1 at the vascular ETB receptor favors
vasodilatation. Further investigation is now clearly required to address whether selective ETA or combined ETA/ETB
receptor blockade will be more effective in the clinical setting. (Hypertension. 1999;33[part II]:581-585.)
Key Words: endothelin ■ vasoconstriction ■ blood pressure ■ receptors, endothelin ■ endothelin receptor antagonist
The importance of endothelin-1 (ET-1) as a mediator ofbasal vascular t ne in vivo in humans has been demon¬
strated by local1"3 and systemic2 vasodilatation in response to
endothelin receptor antagonism. The potent vasoconstrictor
effects of ET-1,4'5 combined with the increased plasma
concentrations of ET-1 associated with cardiovascular dis¬
eases, including heart failure'' and renal failure,7 provide
strong evidence to support a functional role for ET-1 in the
development and maintenance of the increased peripheral
vascular resistance associated with these conditions.
The vascular effects of ET-1 are mediated by two distinct
receptors: the ET- 1-selective ETA receptor* and the
nonisopeptide-selective ETB receptor.9 The sustained vaso¬
constrictor effects of ET-1 are predominantly mediated by the
ETa receptor, although vascular smooth muscle ETB receptors
have also been described10 and may. under some circum¬
stances, contribute to ET-1-mediated vasoconstriction in
animal models" and humans in vivo.12 ET„ receptors were
first described on endothelial cells, where they act to modu¬
late the vasoconstrictor effects of ET-1 through generation of
nitric oxide13 and prostacyclin.14 The ETB receptor also has a
role in the clearance of ET-1 from the circulation,15 although
the exact site of the clearance receptor remains to be
confirmed. The contribution of the vascular ETB receptor to
the recognized endogenous ET-1-mediated constrictor tone
depends on the balance between the ETB receptor-mediated
effects of vasodilatation, vasoconstriction, and ET-1
clearance.
Local vasoconstriction to ETB receptor agonists has been
described in healthy volunteers1216 and in patients with heart
failure.17 However, more recently, vasoconstriction after local
administration of the selective ETB receptor antagonist BQ-
788'* has been described in healthy volunteers3 and in
patients with heart failure.19 The results with antagonists are
particularly important as they indicate that the endogenous
effect of vascular ETB receptor stimulation in vivo favors
vasodilatation. Indeed, hypertension has been described after
administration of systemic doses of the selective ET„ receptor
antagonists A192621 in rats and BQ-788 in rabbits in vivo, as
well as in rescued ETB knockout mice.20-21 The vasoconstric¬
tor effects of ETb antagonism may result directly from
blockade of an endothelial ET„ receptor-mediated dilator
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tone or indirectly from displacement of endogenously gener¬
ated ET-1 to vasoconstrictor ETA receptors, or as a result of
reduced clearance of ET-1 by vascular ETB receptors. Con¬
firmation of the balance of the vascular effects mediated by
the ETb receptor in different circumstances is important in
understanding the physiology of the endothelin system and in
determining whether selective ETA receptor antagonists or
combined ETA/ETB receptor antagonists are likely to be more
effective vasodilator agents in the clinical setting. Although
both selective and nonselective endothelin receptor antago¬
nists have demonstrated vasodilator effects in healthy sub¬
jects,12 in patients with heart failure22 23 and in patients with
hypertension,24-25 the question of whether selective ETA or
combined ETA/ETB receptor antagonism will be of more
benefit as vasodilator therapy remains to be clarified.
As a first step in understanding the contribution of the ETB
receptor to the maintenance of vascular tone in vivo, we




Five healthy male subjects between 18 and 50 years of age were
recruited to the study, which was performed in the Clinical Research
Center at the Western General Hospital, Edinburgh, with the ap¬
proval of the local research ethics committee and the written
informed consent of each subject. The investigations conformed with
the principles outlined in the Declaration of Helsinki. No subject
received vasoactive medication or nonsteroidal anti-inflammatory
drugs in the week before each phase of a study, and all subjects
abstained from alcohol for 24 hours and from food, caffeine-
containing drinks, and tobacco for at least 4 hours before any
measurements were made. All studies were performed in a quiet
room kept at a controlled temperature between 22°C to 24°C.
Drugs
BQ-788 (Clinalfa AG) was used as a selective ET„ receptor
antagonist on the basis of both a 1000-fold selectivity of BQ-788 for
the ET„ receptor, in the nanomolar range, in human cell lines1" and
inhibition of ET-3 binding to recombinant human ETB receptors
expressed in Chinese hamster ovary cells, also in the nanomolar
range.2'1 The dose range (3 to 300 nmol/min) used in the current
study was selected from previous work investigating the local effects
of BQ-788 in the forearm circulation3 and from a dose ranging pilot
study in which 2 volunteers were studied at each dose level (data not
shown). Selected doses (1 to 300 nmol/min) were administered in the
pilot study to identify a no-effect dose and select an appropriate
maximum dose for the main study.
BQ-788 was dissolved in physiological saline (0.9%, Baxter
Healthcare, Ltd). Saline (0.9%, Baxter Healthcare, Ltd) was admin¬
istered as placebo. BQ-788 and placebo were administered in a
single-blind manner and infused intravenously at a constant rate for
15 minutes via an 18 standard wire gauge (SWG) cannula sited in the
left antecubital vein. All solutions were prepared from sterile stock
solutions on the day of the study.
Measurements
Plasma ET-1 and Big ET-1
Blood samples were obtained before dose and at 5, 15, 60, and 240
minutes after dose via an 18 SWG cannula sited in the noninlused
arm. In brief, l()-ml. samples were collected into sterile EDTA tubes
(K3 EDTA, Vacutainer, Becton Dickinson Vacutainer Systems),
centrifuged immediately at 2000,t; for 20 minutes, and stored in plain
tubes at Kt) \ before assay. ET-1 and big l.T-1 (Peninsula
Laboratories Europe) were determined by standard radioimmunoas¬
say, as previously described.
Blood samples were also taken on admission and before discharge
for routine biochemistry and hematology blood tests (sodium,
potassium, creatinine, urea, alkaline phosphatase, y-glutamyl
transpeptidase, hemoglobin, and white cell count).
Hemodynamic Recordings
Hemodynamic recordings were made at 10-minute intervals from 30
minutes before dose until 1 hour after the start of the infusion, with
an additional blood pressure measurement at 15 minutes correspond¬
ing with the end of the infusion. Recordings were again made at
3()-minute intervals until 2 hours and hourly until 4 hours after the
start of the infusion.
Blood pressure and heart rate (HR) were recorded in duplicate at
each time point using a semiautomated noninvasive oscillometric
method in the noninfused arm (Takeda UA 751 sphygmomanometer,
Takeda Medical lnc)M; values were averaged for each time point.
Blood pressure is presented as mean arterial pressure (MAP; diastol¬
ic blood pressure+1/3 pulse pressure, in millimeters of mercury).
Cardiac output and stroke volume were recorded by a well-
validated noninvasive bioimpcdancc technique (NCCOM3; BoMed
Medical Manufacturer Ltd).30 These parameters were corrected for
body surface area and described as cardiac index (CI, liters per
minute per meters squared) and stroke index (SI, milliliters per meter
squared).2 Total peripheral vascular resistance index (TPVRI) was
calculated as MAP divided by CI and expressed in arbitrary units
(AU).
Study Design
Responses to BQ-788 (3, 30, and 300 nmol/min) and placebo were
investigated in a placebo-controlled, four-way crossover study.
Study drugs were administered in a single-blind manner. The order
of treatments was randomized. Five subjects attended for 4 separate
study visits, each separated by at least 5 days. Subjects were resident
in the research center for at least 6 hours. Subjects rested supine for
at least 20 minutes before hemodynamic measures, and baseline
measures were made in the 30 minutes before study drug
administration.
Analysis
Plasma ET-1 and big ET-1 are represented as absolute change from
predose (picograms per milliliter), with statistical significance as¬
sessed by paired I test. Hemodynamic results are expressed as
maximum placebo-corrected percentage changes from baseline
±SEM.2 Statistical analysis was performed on untransformed data.
Responses were examined by repeated-measures ANOVA. Statisti¬
cal significance was taken at the 5% level, and analysis was
performed using an Excel data analysis package (Excel 5.0,
Microsoft Ltd).
Results
All 5 healthy male subjects (age range, 33 to 48 years)
completed the study. No adverse events were reported, and
there were no clinically relevant changes in routine biochem¬
istry and hematology blood tests.
Plasma ET-1 and Big ET-1
Predose plasma ET-1 concentrations did not differ signifi¬
cantly for any of the treatments (range of baseline mean
values, 4.4 to 4.9 pg/mL). Plasma ET-1 concentration in¬
creased significantly after administration of BQ-788 (from
4.6±0.8 to 8.4± 1.8 pg/mL at 15 minutes with 300 nmol/min.
/,=0.02) but not during treatment with the lower doses of
BQ-788 or placebo (Figure 1). In contrast, concentrations of
big ET-1 did not change significantly with treatment.
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Figure 1. Change in plasma ET-1 concentrations after
15-minute intravenous infusion of BQ-788 or saline placebo in 5
subjects. Solid columns indicate BQ-788 at 300 nmol/min;
shaded columns, BQ-788 at 30 nmol/min; hatched columns,
BQ-788 at 3 nmol/min; and open columns, placebo. Plasma
ET-1 concentrations increased significantly after administration
of BQ-788 at 300 nmol/min.
Hemodynamic Parameters
Baseline measurements for hemodynamic parameters during
the placebo treatment period were as follows; MAP,
79±3 mm Hg; HR, 79±3 bpm; CI, 2.6±0.2 (L/min)/m2; SI,
49±3 mL/m2; and TPVRI, 31.1 ± 1.8 AU. Baseline values
were similar for each of the other treatment periods. MAP did
not alter significantly after administration of BQ-788 at any
dose (3±2% at 90 minutes with 300 nmol/min; P=0.4)
(Figure 2). After administration of BQ-788, there were
changes in all other hemodynamic parameters when com¬
pared with placebo that appeared to be dose-related and that
were significant at 300 nmol/min; HR decreased (13±7% at
50 minutes after dose; P=0.002), CI decreased (17 ±5% at 40
minutes; P<0.(MX)1), and there was a small reduction in SI
(8±4% at 40 minutes; P=0.002). TPVRI increased (24±5%
at 40 minutes; /><0.()()()1).
Discussion
We have demonstrated substantial systemic vasoconstric¬
tion, associated with a reduction in HR and CI but no
change in MAP, in response to administration of the
selective ET,t receptor antagonist BQ-788 in healthy men.
Consistent with our earlier work in the forearm circula¬
tion,1 these observations are highly suggestive of the
overall effect of endogenous ETB receptor-mediated vas¬
cular tone favoring vasodilatation. An alternative explana¬
tion for the hemodynamic effects is that BQ-788 is directly
negatively chronotropic and that peripheral effects are
indirect. However, this is unlikely given our earlier work1
and the lack of evidence of an important positive chrono¬
tropic and inotropic role of the cardiac ET„ receptor.11
Although peripheral resistance was substantially in¬
creased. blood pressure was unaffected because of a
decrease in HR that was probably ref lex in origin. We have
also demonstrated increases in plasma Iff-1, but not big



















Figure 2. Placebo-corrected mean percentage change in MAP,
HR, CI, SI, and TPVRI after 15-minute intravenous infusion of
BQ-788 or saline placebo in 5 subjects. Closed circles indicate
BQ-788 at 300 nmol/min; open circles, BQ-788 at 30 nmol/min;
and shaded diamonds, BQ-788 at 3 nmol/min. There was no
change in MAP, but there was a reduction in HR, CI, and SI and
an increase in TPVRI after administration of BQ-788 at 300
nmol/min.
tent with reduced clearance of ET-I by the ET„ receptor.IS
All of these effects were prominent with BQ-788 at the
highest dose but were not clearly seen at lower doses.
The vasoconstrictor effects of ETB receptor antagonism
may result directly from blockade of the vasodilator ef fects of
the endothelial ET„ receptor or indirectly from displacement
of endogenously generated ET-I from ETB receptors to
unoccupied ETA receptors. It is unlikely that these effects are
mediated by nonselective ETA/ETB receptor blockade because
they are the opposite of those found with selective ETA
receptor antagonists in healthy subjects (unpublished data,
1998) and patients with heart failure22 and of those found
with combined ETA/ET„ receptor antagonists in healthy
subjects.2 Clearly, the indirect effects of ET-I on ETA
receptors are more relevant with administration of selective
Elj, antagonists than with nonselective ETA/ETB receptor
antagonists, because in this latter situation the constrictor F.I x
receptor is also blocked. Indeed, vasodilator effects have been
ili'nmnsirated wuh bulb selective1 1 and nonselective 1
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endothelin receptor antagonists in humans, and the nonselec¬
tive ETa/ETb antagonist bosentan has recently been shown to
effectively lower blood pressure in patients with hyperten¬
sion.25 However, direct comparison of the effects of selective
and nonselective endothelin receptor antagonism will be
important in assessing the relative contribution of each
receptor subtype to the vascular effects of ET-1.
We and others have previously demonstrated forearm
vasodilatation in response to local ETA receptor antagonism
with BQ-123.'-3-32 In the presence of BQ-788 in healthy
volunteers, this effect was attenuated,3 suggesting that the
overall effect of vascular ETB receptor stimulation by endog¬
enous ET-1 is vasodilatation. This attenuation of BQ-123-
mediated vasodilatation by BQ-788 suggests that the vaso¬
constrictor effect of ETb receptor blockade is not mediated by
displacement of ET-1 onto the ETA receptor but is due to
direct blockade of ETB-mediated vasodilator tone. We have
also shown, using a "nitric oxide clamp" technique, that the
vasodilator response to BQ-123 is in part mediated by nitric
oxide3 and, therefore, probably mediated by the endothelial
ETb receptor. Loss of endothelial cell ETB-mediated vasodi¬
lator tone may occur in cardiovascular diseases, such as
essential hypertension and hypercholesterolemia, in which
there is associated endothelial dysfunction.33-34 Here, because
of a reduced capacity for ET„ receptor-mediated, nitric
oxide-dependent dilatation, selective ETA receptor antago¬
nists may be less effective.
In summary, we have demonstrated systemic vasocon¬
striction in response to acute ETB receptor blockade with
the selective ETB receptor antagonist BQ-788 in healthy
men in vivo, indicating that the predominant endogenous
effect of stimulating vascular ETB receptors is vasodilata¬
tion. One exciting possibility is that tonic endogenous
ET-1 release, acting via the endothelial ETB receptor, is
responsible for the physiological basal release of nitric
oxide. This now needs to be addressed in clinical studies.
Further investigation of the influence of ETB receptor
antagonism on the sympathetic nervous system and renal
function are also warranted. In addition, direct comparison
of the effects of chronic administration of selective ETA
and combined ETA/ETB receptor antagonists is required in
patients with cardiovascular disease, with and without
endothelial dysfunction, in order to confirm which of these
approaches is likely to be more effective in the clinical
setting.
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Direct and Sympathetically Mediated Venoconstriction
in Essential Hypertension
Enhanced Responses to Endothelin-1
William G. Haynes, Malcolm F. Hand, Heather A. Johnstone, Paul L. Padfield, and David J. Webb
Department ofMedicine, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, United Kingdom
Abstract
Endothelin-l is a potent endothelium-derived vasoconstric¬
tor peptide. Although circulating concentrations are not in¬
creased in essential hypertension, enhanced sensitivity to
endothelin-1 has been observed in animal models of hyper¬
tension. We investigated dorsal hand vein responses to local
infusion of endothelin-1 and norepinephrine in 12 patients
with essential hypertension who had never received treat¬
ment and in 12 age and sex matched normotensive control
subjects.
The maximal venoconstriction and the geometric mean
of the dose of norepinephrine that caused 50% of maximal
venoconstriction were similar in hypertensive (mean±SE;
80±4%; 31±8 pmol/min) and normotensive subjects
(87±5%; 22±9 pmol/min). In contrast, mean venoconstric
tion to endothelin-1 was significantly greater in hypertensive
(49±5%) than in normotensive subjects (27±2%; P
= 0.004). Sympathetically mediated venoconstriction elic¬
ited by deep breath was substantially potentiated by endo¬
thelin-1 in hypertensive (67±7% at 90 min) but not normo¬
tensive subjects (11±3% at 90 min; P = 0.001). Venocons¬
triction to endothelin-1 correlated positively with mean
arterial pressure in the hypertensive subjects (r = 0.82;
p = 0.001) but negatively in the normotensive subjects (r
= -0.58; p = 0.047).
Endothelin-1 may contribute to the reduction of venous
compliance occurring in the early stages of essential hyper¬
tension and to the altered systemic hemodynamics in this
condition. (J. Clin. Invest. 1994. 94:1359-1364.) Key words:
vasoconstrictor peptide • blood pressure • endothelium •
veins • sympathetic nervous system
Introduction
The endothelins are a family of peptides with extremely potent
and characteristically sustained vasoconstrictor and vasopressor
actions (1). Endothelin-1 is the predominant isoform in the
vascular endothelium, where it is generated from its precursor,
proendothelin-1 or 'big endothelin-1' (2). In addition to its
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direct vascular effects (3), endothelin-1 has inotropic (4) and
mitogenic properties (5), influences salt and water homeostasis
(6) and stimulates generation of renin, angiotensin II, aldoste¬
rone and epinephrine (6). Furthermore, centrally (7, 8) and
peripherally (9, 10) administered endothelin-1 alters peripheral
sympathetic activity. In view of these actions, there has been
interest in the potential role that endothelin-1 may play in the
pathophysiology of hypertension (11, 12).
Several investigators have invoked elevated concentrations
of circulating immunoreactive endothelin-1 as evidence of in¬
creased production in essential hypertension (13, 14). However,
endothelin-1 is cleared from the blood by the kidneys (14, 15)
and the very high concentrations found in severe and accelerated
phase hypertension are probably secondary to impaired renal
clearance. Studies in hypertensive patients with normal renal
function have shown similar concentrations of cndothclin 1 to
those in normotensives (16, 17). Indeed, in one study a negative
correlation between blood pressure and plasma cndothclin 1
was observed in the hypertensive group (16), making a global
increase in generation of endothelin-1 unlikely as a cause of
essential hypertension.
The results of studies examining vascular sensitivity to en-
dothelin in hypertension are complex. In animal studies compar¬
ing WKY and SHR, both conduit (renal artery and aorta) and
mesenteric resistance vessels from the hypertensive rat have
been shown to be more sensitive to the effects of endothelin-1
by some investigators (18-21). Other investigators have re¬
ported decreased sensitivity to endothelin in the aorta and iso¬
lated mesenteric resistance arteries from SHR (22), DOCA-salt
(23) and renovascular hypertensive rats (24). In vivo, endo¬
thelin-1 has been shown to have a greater pressor effect in SHR
than WKY rats (25). In patients with essential hypertension, in
vitro efficacy of endothelin in subcutaneous resistance arteries
appears to be reduced (26). To date, in vivo responses to endo¬
thelin-1 have not been examined in patients with essential hy¬
pertension.
With continuing uncertainty regarding the vascular actions
of endothelin-1 in hypertension, we have investigated whether
venoconstriction to endothelin-1 is enhanced in patients with
essential hypertension as compared with normotensive control
subjects. We examined responses in veins for two reasons. First,
the venous system is an important influence on cardiac output
in its own right, and has been reported to be abnormal in early
hypertension (27, 28). This raises the possibility that abnormal
venous responses may contribute directly to the pathophysiol¬
ogy of essential hypertension. Second, studies of pressor re¬
sponses or vasoconstriction in resistance beds in vivo may be
confounded by the presence of vascular hypertrophy in resis¬
tance vessels (29), whereas this process does not appear to
occur in veins (30).
We examined the effect of local intravenous infusion of
endothelin-1 and norepinephrine on dorsal hand vein diameter.
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using norepinephrine as a control constrictor to detect any po¬
tential confounding effect produced by alterations in venous
structure or function in hypertension. In view of the potential
interaction between endothelin and activity of the sympathetic
nervous system, and the known increase in sympathetic nerve
activity in hypertension (31), we used the single deep breath
response (32, 33) to assess the effect of endothelin-1 on sympa¬
thetically mediated venoconstriction in hypertensive and normo-
tensive subjects. We chose the dorsal hand vein because re¬
sponses to vasoactive drugs in these veins are very similar to
those predicted from the pharmacological profile of action after
systemic doses in vivo (34). In addition, there is clear evidence
that cutaneous limb veins are under sympathetic venomotor
control, whereas skeletal muscle veins do not participate in
these reflexes (35, 36). Thus, responses in hand veins should
reflect responses of the component of the venous system that
is most important in physiological regulation of venous capaci¬
tance and cardiac preload. Finally, these studies do not require
systemically active doses of drugs that may obscure any direct
vascular action by direct effects on other organs, such as the




Consecutive patients with hypertension (BP > 160/100 mmHg) at¬
tending the Cardiovascular Risk Clinic at the Western General Hospital
were considered for the study. Patients were only eligible for recruitment
if there was no evidence of a secondary cause for hypertension; if
mean daytime awake blood pressure was more than 140/90 mmHg on
ambulatory monitoring (measurements every 30 min using Spacelabs
90207) (37); if there were no significant concurrent illnesses; and if
they had never received antihypertensive therapy. Normotensive (BP
< 140/90 mmHg) control subjects matched for age, sex, weight and
height were recruited by advertisement. On the basis of power calcula¬
tions (see Data presentation and statistics), we recruited 12 hyperten¬
sive and 12 normotensive control subjects. No subject received vaso¬
active or nonsteroidal anti-inflammatory drugs in the week before each
phase of the study, and all abstained from alcohol for 24 h, and from
food, caffeine containing drinks, and cigarettes for at least 3 h before
any measurements were made. The studies were conducted with the
approval of the Lothian Medicine and Clinical Oncology Ethics of Medi¬
cal Research Sub-Committee and with the written, witnessed, informed
consent of each subject.
Drugs
A 23 SWG cannula (Abbott, Sligo, Republic of Ireland) was sited in
a selected dorsal hand vein, without use of local anesthesia, in the
direction of flow, for infusion of endothelin-1 (5 pmol/min; Clinalfa
AG, Laufelfingen, Switzerland) and norepinephrine (6-768 pmol/min;
Sterling-Winthrop, Guildford, United Kingdom). These doses, based on
an estimated dorsal hand vein flow of 1 ml/min (34), would be expected
to achieve local concentrations, within the infused hand vein, approxi¬
mating to 10 8 M for endothelin-1 and to between 10~8 and 10 6 M for
norepinephrine. Drugs were dissolved in saline. Ascorbic acid (Evans
Medical, Horsham, UK) was added to norepinephrine solutions, at a
final concentration of 10 pg/ml, to prevent degradation by oxidation
(34). The total rate of infusion was maintained constant throughout all
studies at 0.25 ml/min.
Measurements
Dorsal hand vein size. The left hand was supported above the level of
the heart by means of an arm rest. Internal diameter of the dorsal hand
vein, distended by inflation of an upper arm cuff to 30 mmHg, was
measured by the technique of Aellig (38). In brief, a magnetized light¬
weight rod rested on the summit of the infused vein ~ 1 cm downstream
from the tip of the infusion cannula. This rod passed through the core
of a linear variable differential transformer (LVDT) supported above
the hand by a small tripod, the legs of which rested on areas of the
dorsum of the hand free of veins. If venoconstriction occurs while this
cuff is inflated, or if the cuff is deflated with consequent emptying of
the vein, there is a downward displacement of the lightweight rod. This
displacement causes a linear change in the voltage generated by the
LVDT, and thus allows determination of the internal diameter of the
vein, after calibration against standard displacements. Voltage output
from the LVDT was transferred to a Macintosh personal computer file
using a MacLab analogue-digital converter and Chart software (v. 3.2.8;
both from AD Instruments, Castle Hill, NSW, Australia).
Single deep breath venoconstrictor stimulus. When vein size was
stable, subjects were asked to breath out fully before breathing in as
deeply as possible (32). They were asked to hold this inspiration for
10 s and avoid any tendency to breath out. The technique was practiced
before the study to ensure that subjects did not perform a Valsalva
maneuver. The deep breath Stimulus usually causes a 5-20% venocon¬
striction in the 30 s after the maneuver (33).
Blood pressure. A well-validated semi-automated technique
(Takeda UA 751 sphygmomanometer, Takeda Medical Inc., Tokyo,
Japan) was used to measure blood pressure in duplicate in the non-
infused arm (39).
Endothelin assay. Plasma immunoreactive endothelin was measured
by radioimmunoassay (40). Immunoreactive endothelin was extracted
from acidified plasma using SepPak C18 silica columns (Waters Associ¬
ates, Milford, MA). Duplicate extracted samples and standards were
incubated with rabbit polyclonal antibody raised against endothelin-1
(ITS Production B.V., Wijchen, The Netherlands; in 100 p\ distilled
water) and l25I-endothelin-l (ITS; in 100 pi distilled water). After
incubation for 18 h at 4°C, donkey anti-rabbit gamma globulin bound
on solid phase (ITS; 100 p\) was added, and tubes were incubated for
30 min at room temperature. The amount of radioactivity in the anti-
body-bound fraction was determined by gamma counting for 3 min.
The recovery of added endothelin-1 was 84%. Intra- and inter-assay
coefficients of variation were 2.4% (n = 6) and 4.2% (n = 5), respec¬
tively. The sensitivity of this assay is 2 pg/ml endothelin. Cross reactiv¬
ity of the assay with endothelin-1, endothelin-2, endothelin-3 and proen-
dothelin-1 is 100, 52, 96, and 7%, respectively.
Study design
Subjects rested recumbent during each phase, in a quiet room maintained
at a constant temperature of between 22 and 25°C. An intravenous
cannula was placed in the right antecubital vein under local anesthesia
for blood sampling and the dorsal hand vein cannula and the LVDT
sited. Saline was infused for 30 min during which vein size and blood
pressure were measured every 5 min. Subjects were asked to take single
deep breaths, to elicit sympathetically mediated venoconstriction, after
5 and 20 min of saline infusion. A venous blood sample was obtained
from the non-infused arm for assay of circulating endothelin concentra¬
tions. Norepinephrine was then infused at incremental doubling doses
of between 6 and 768 pmol/min for 10 min each to obtain a full dose
response curve. Vein size was measured 5 and 10 min after starting
infusion of each dose of norepinephrine. Blood pressure was measured
10 min after starting each dose of norepinephrine. Once a maximal
response to norepinephrine was obtained saline was infused until vein
size returned to basal values. Endothelin-1 was then infused at 5 pmol/
min for 90 min with vein size measured every 5 min and blood pressure
every 30 min. The sustained duration of action of endothelin-1 in human
veins precluded randomizing the order of infusions of norepinephrine
and endothelin-1 (41). Single deep breaths were taken at 28, 58, and
88 min. In a subset of subjects (n = 8 from each group), a further
blood sample was obtained from the non-infused arm at the end of the
endothelin infusion for assay of circulating endothelin concentration.
Data presentation and statistics
The power of the study to detect a 20% difference in endothelin-1 ~
induced venoconstriction between 12 hypertensive and 12 normotensive
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Table I. Subject Characteristics
Hypertensives Normotensives
Number (n) 12 12
Age (yr) 47 ± 3 48 ± 4
Sex (M/F) 8/4 8/4
Supine systolic blood pressure (mmHg) 159 ± 5* 120 ± 3
Supine diastolic blood pressure (mmHg) 103 ± 2* 75 ± 2
Mean arterial blood pressure (mmHg) 122 ± 3* 90 + 2
Daytime ambulatory systolic pressure (mmHg) +100v-> 6
Daytime ambulatory diastolic pressure (mmHg) 103 ± 4
Creatinine (jxmol/1) 106 ± 5 90 ± 4
Cholesterol (mmol/1) 5.3 ± 0.2 y\ 1+ O N>
Basal vein diameter (mm) +1000 0.1 0.9 ± 0.2
* Indicates P < 0.05 for difference from normotensive subjects.
subjects was 90% at the 0.01 significance level. This calculation is based
on the standard deviation of venoconstriction to endothelin-1 (10%)
observed in a previous study (41). Basal vein size was calculated by
taking the mean of the last three measurements before the start of the
norepinephrine infusion, and is expressed in millimeters. Because basal
vein size varies between subjects, responses to deep breath, norepineph¬
rine and endothelin-1 are expressed as percentage change in vein size
from basal in order to reduce the inter-subject variability. Venoconstric¬
tion with each dose of norepinephrine was calculated by averaging
the two measurements for each dose. Individual norepinephrine dose-
response curves were then analyzed using an iterative non-linear curve
fitting program (Kaleidagraph, Abelbeck Software, CA) to obtain esti¬
mates of maximal responses () and norepinephrine dose producing
a half-maximal response (ED50). Individual EDW values were log trans¬
formed for statistical analysis and results shown as geometric means.
Because serial measurements were made in each subject following infu¬
sion of endothelin-1, mean constriction to endothelin-1 over 90 min was
calculated as a summary measure for each individual in order to avoid
making multiple comparisons of data (42). The mean of the last two
duplicate blood pressure measurements during saline infusion was used
as baseline. All results are expressed as mean± standard error of the
mean. Data were examined using Student's unpaired l test and by simple
regression analysis. Statistical analyses were performed using StatView
512+ software for the Macintosh (Brainpower Inc., Calabasas, CA).
Results
There was no significant difference between hypertensive and
normotensive subjects in age, sex distribution, basal hand vein
size, or renal function (Table I). Hypertensive and control sub¬
jects did not differ significantly in their venous sensitivity (P
= 0.46 for ED50) or responsiveness (P = 0.30 for E,tui,) to
norepinephrine (Fig. 1). Vein diameter was no different from
baseline following washout of the venoconstriction induced by
norepinephrine before infusion of endothelin-1 in the hyperten¬
sive (0.8±0.1 mm; P = 0.80) and normotensive subjects
(0.9±0.1 mm; P = 0.69).
Venoconstriction to endothelin-1 was substantially greater
in hypertensive subjects (49±5%) than control subjects
(27±2%; P = 0.004) (Fig. 2). Basal venoconstriction to a
single deep breath was not different between hypertensive
(17±3%) and control subjects (13±3%; P = 0.37). However,
sympathetically mediated venoconstriction to deep breath was
greater in hypertensive (67±7% at 90 min) but not normoten¬
sive subjects (11 ±3% at 90 min) after infusion of endothelin-
1 (P — 0.001; Fig. 3). This was true even when venoconstriction
too
T
Figure I. The norepinephrine dose producing a half maximal response
(EDso; a measure inversely proportional to sensitivity) and the maxi¬
mum responsiveness to norepinephrine (E„„,). ED50 is expressed as a
geometric mean dose. There is no significant difference between normo
tensive (NT) and hypertensive (HT) subjects, either for EDW (P
= 0.46) or E™ (P = 0.30).
to deep breath was expressed as the absolute change in vein
size rather than percentage change in order to account for the
differences in underlying venoconstriction to endothelin-1 in
hypertensive (0.14±0.03 mm at 90 min) and normotensive sub¬
jects (0.06±0.02 mm; P = 0.03).
Circulating plasma endothelin concentrations were similar
in hypertensive (5.0±0.6 pg/ml) and control subjects (5.4±0.8
pg/ml; P = 0.65). Circulating endothelin concentrations did
not change significantly from baseline following local infusion
of endothelin in the hypertensives (baseline = 5.3± 1.0; posten-
dothelin = 6.2± 1.1; P = 0.32; n = 8) or the normotensives
(baseline = 5.5±1.2; postendothelin = 6.9±1.4; P = 0.26; n
= 8). Blood pressure and heart rate did not alter significantly
during infusion of norepinephrine or endothelin-1.
Venoconstriction to endothelin-1 was positively correlated
on regression analysis with baseline systolic (r = 0.85; P
= 0.0004), diastolic (r = 0.69; P = 0.01) and mean arterial
pressure (r = 0.82; P = 0.001) in the hypertensive subjects.
In contrast, in the normotensive subjects, venoconstriction to
endothelin-1 was negatively correlated with baseline systolic (r
= -0.50; P - 0.10), diastolic (r — -0.51; P = 0.09) and mean
arterial pressure (r = -0.58; P = 0.047; Fig. 4). Venoconstric¬
tion to endothelin-1 did not correlate with basal vein size, ED50
or E^,, to norepinephrine or plasma endothelin concentrations
in either the hypertensive or normotensive subjects. There was
no correlation, in either group, between blood pressure and
plasma endothelin, or blood pressure and the ED50 or Em„ to
norepinephrine.
Discussion
In these studies, we have shown that patients with essential
hypertension have enhanced venoconstriction to endothelin-1
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Figure 2. Venoconstriction to endothelin-1 in normotensive (O) and
hypertensive (•) subjects. There is a significantly greater response in
the hypertensive subjects (P = 0.004 vs. normotensives).
that is positively correlated with blood pressure. In addition, we
have demonstrated that endothelin-1 substantially potentiates
sympathetically mediated venoconstriction in hypertensive but
not in normotensive subjects. We have also confirmed earlier
work showing that essential hypertension is not associated with
increased plasma endothelin concentrations (16) or with altered
dorsal hand vein responses to norepinephrine (30).
We were only able to test responses to a single dose of
endothelin-1 because the slow onset and long lasting action of
endothelin-1 precludes the use of repeated doses in a single
study to examine conventional dose-response relationships
(41). Thus we cannot say whether the enhanced venous respon¬
siveness to endothelin-1 in hypertension is due to increased
sensitivity or responsiveness to the peptide. Different basal vein
blood flow may have resulted in different concentrations of
agonist reaching venous smooth muscle. However, total forearm
blood flow is not decreased in essential hypertension (43), and
there is no evidence for a selective redistribution of blood flow
from the superficial to deep hand veins in hypertension. In
addition, venous diameter was similar in the two groups, im¬
plying that any change in blood flow in the veins under consider¬
ation would have to be accounted for solely by an increase
in velocity of blood flow. Furthermore, the almost identical
responses to norepinephrine would suggest that delivery of ago¬
nist was similar in hypertensives and normotensives. The use
of a constant rate of infusion helped to minimize the possibility
that changes in flow through a vein might alter local release of
endothelium derived mediators. In any case, such changes in
flow are unlikely to have biased our results, as previous studies
have shown that increasing the rate of drug infusion by up to
100%, but keeping the dose infused constant, does not alter
Figure 3. Sympathetically mediated venoconstriction induced by single
deep breath before and during infusion of endothelin-1 in hypertensive
and normotensive subjects. Endothelin-1 potentiates sympathetically
mediated venoconstriction in the hypertensive subjects only (P = 0.001
v. normotensives).
dorsal hand vein responses to a number of agents (34, 38). The
interval of at least 3 h between the last meal and first measure¬
ment minimized the possibility that high insulin levels may
have altered responses. It is possible, however, that caffeine,
which has a long half-life, may have been present in quantities
sufficient to alter cardiovascular responses at the time of the
study. It is very unlikely that the presence of vascular hypertro¬
phy resulted in amplification of responses to endothelin because
we examined responses in vessels which are not thought to
undergo hypertrophy in hypertension and because responses to
norepinephrine were not altered.
Our results are different from previous in vitro work that
showed an apparent diminished efficacy of endothelin-1 in iso¬
lated small arteries of hypertensive patients after correction for
media hypertrophy (26). This difference may be accounted for
by methodological differences, such as the in vivo nature of the
dorsal hand vein technique, the avoidance of local anesthesia,
which might influence sympathetic responses, and the absence
of vessel wall hypertrophy. Alternatively, the difference may
be due to the type of vessel studied. However, in diseases associ¬
ated with abnormalities in resistance or conduit vessels, such
as essential hypertension and Raynaud's disease, similar abnor¬
malities are found in hand veins (44, 45).
There are several potential mechanisms for enhanced venous
responsiveness to endothelin-1 in essential hypertension. First,
there may be decreased local venous endothelin-1 generation.
Plasma concentrations of immunoreactive endothelin, which are
thought to reflect local concentrations at the interface between
endothelial and vascular smooth muscle cells (2), were no dif¬
ferent between hypertensive and control subjects, suggesting
that there was no global increase in endothelin generation in
the hypertensive subjects. However, because endothelial gener¬
ation of endothelin-1 is directed mainly abluminally (2), it is
conceivable that local endothelin generation differs between
hypertensive and normotensive subjects. Thus, it is possible,
though perhaps unlikely, that our findings may have been due
to increased endothelin receptor number or affinity caused by
decreased vascular generation of endothelin.
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Figure 4. Regression curves (with 95% con¬
fidence intervals) for the correlation between
blood pressure and change in vein size to
endothelin-1 in normotensive (O) and hyper¬
tensive (•) subjects. There is a negative cor¬
relation in normotensive subjects but a posi¬
tive correlation in hypertensive subjects.
Second, the modulating influence of endothelium derived
vasodilator substances on endothelin-1 induced venoconstric-
tion may be abnormal in essential hypertension (46), resulting
in enhanced responses without changes in generation or sensi
tivity. This would presuppose that impaired endothelial function
in hypertension is not the result of elevated pressure per se;
recent studies in resistance vessels suggest that impaired endo
thelial function is not normalized with lowering of blood pres¬
sure by anti-hypertensive treatment (47). There is no published
work examining endothelium dependent responses in veins of
hypertensive subjects, although insulin mediated venodilata
tion, which may be endothelium dependent, is clearly abnormal
in mild hypertension (44). However, the unaltered response to
norepinephrine in hypertensives, which has endothelial effects,
would suggest that endothelial abnormalities are unlikely to
fully account for our findings.
Third, it is possible that these findings represent an abnor
mality of venous smooth muscle in hypertension. The underly
ing abnormality may be a change in receptor sub-type expres¬
sion, receptor number or receptor affinity. Alternatively, there
may be an abnormality in second messenger systems resulting
in a specific amplification of responses to endothelin-1, for ex¬
ample in G-proteins.
Finally, our results may be due to enhanced facilitation of
sympathetic vasoconstriction by endothelin in hypertension. It
has been suggested from in vitro studies that endothelin may
increase peripheral sympathetic activity through postsynaptic
potentiation of the effects of norepinephrine (10). However,
these findings have not been confirmed in vivo in the forearm
resistance bed of healthy subjects (48). The potentiation of
sympathetically induced venoconstriction by endothelin-1 only
in hypertensive subjects would be consistent with this explana¬
tion for our findings. However, at least in normal subjects,
dorsal hand veins have no underlying sympathetic tone, so facil
itaiion of sympathetic activity is unlikely to be the sole or
initiating mechanism involved.
Although enhanced venoconstriction to endothelin-1 in hy¬
pertension may be an epiphenomenon, not causally related to
the elevation of blood pressure, this appears unlikely given the
positive correlation with blood pressure in hypertensive subjects
(Fig. 4). Even so, enhanced venoconstriction to endothclin 1
may occur only secondarily to the increase in blood pressure.
However, if this was the case one might also expect a positive
correlation between blood pressure and endothelin induced ven
oconstriction in normotensive subjects. That there is a negative
correlation in these subjects suggests that enhanced vcnocons
triction to endothelin 1 may be a causative factor in patients
with essential hypertension.
These findings in capacitance vessels suggest that exagger¬
ated responsiveness to endothelin 1 may contribute to reduced
venous compliance in hypertension. This may, in turn, contrib
ute to the raised cardiac preload and cardiac output observed
in the early stages of essential hypertension (27, 28). Further
in vivo studies in resistance vessels will help to show whether
there is a global abnormality in endothelin responsiveness in
essential hypertension, although such studies will need to take
account of structural changes in these vessels. The role of endo
thelin in hypertension may be further clarified with the use of
endothelin receptor antagonists, which are currently entering
clinical investigation (49).
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Serial changes in blood pressure, renal
function, endothelin and lipoprotein (a) during
the first 9 days of cyclosporin therapy in males
Nigel D.C. Sturrock, Chim C. Lang,
Lesley J. MacFarlane, Mark E.C. Dockrell*,
Michael Ryan+, David J. Webb* and Allan D. Struthers
Objective: To elucidate the sequential mechanisms underlying cyclosporin-induced
hypertension and nephrotoxicity.
Design: A study of healthy males over the first 9 days of drug ingestion to permit the
detection of serial changes in renal function and blood pressure in a situation free
from the confounding variables of concomitant disease or drugs.
Methods: Double-blind, placebo-controlled, randomized crossover study with
cyclosporin (5mg/kg twice a day) or placebo. Blood pressure and urinary sodium
excretion were measured each day, and glomerular filtration rate (GFR) and effective
renal plasma flow (ERPF) were measured on days 1, 4, 7 and 9. Cholesterol,
lipoprotein (a) and endothelin were measured on days 1 and 9.
Results: GFR decreased by 9% with cyclosporin and was significantly lower than
with placebo on day 4 of therapy. ERPF fell by 24%. The fall in GFR correlated
significantly with suppressed plasma renin activity (P< 0.0001). Cyclosporin-induced
hypertension occurred in the absence of any change in urinary sodium output or in
plasma endothelin. Cyclosporin did not affect lipoprotein (a) levels during 9 days of
cyclosporin therapy.
Conclusions: Cyclosporin-induced hypertension and renal vasoconstriction are well
established after 9 days of cyclosporin 5 mg/kg twice a day. We found no evidence
to implicate either circulating endothelin or renal sodium retention in the onset
of cyclosporin-induced hypertension. Cyclosporin-induced renal vasoconstriction
appeared to occur when the protective mechanism of plasma renin activity
suppression became exhausted.
Journal of Hypertension 1995, 13:667-673
Keywords: Cyclosporin, hypertension, kidney,
renin, endothelin, lipoprotein (a), man.
Introduction
Cyclosporin is an important therapeutic agent with a
wide range of applications, not only in transplantation
but also in numerous autoimmune diseases. Unfortu¬
nately, its well-recognized side effects of nephrotox¬
icity and hypertension preclude its more-widespread
use. Strategies to combat these side effects have pro¬
duced variable results, but are significandy hampered
by a basic lack of understanding of the pathogenetic
mechanisms involved in its development. Animal studies
of these side effects are difficult to interpret and their
findings cannot be directly transcribed to humans be¬
cause animals are generally resistant to the side effects of
cyclosporin even at very high doses [1—3]. In humans
most of the data concerning cyclosporin come from pa¬
tients who have been treated with cyclosporin for several
months, by which time nephrotoxicity and hypertension
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are well established [4—7], Furthermore, these patients
have the contaminating factors of concomitant disease
and coincidental drug therapy.
Clearly, the best scenario for studying the pathogene¬
sis of the side effects of cyclosporin is to follow closely
the early effects of cyclosporin in normal humans to the
point where hypertension and renal changes occur. To
do this, single-dose effects of cyclosporin have previ¬
ously been assessed by two groups of workers. Weir
et al. [8] administered the intravenous preparation of
cyclosporin to healthy females and found that a small
but significant fall in glomerular filtration rate (GFR)
occurred within a few hours of injection, whereas re¬
nal blood flow (RJ3F) remained unchanged. However,
the preparation of cyclosporin used contained the po¬
tent vasoconstrictor Cremophor-EL, which is known to
exert major renal haemodynamic effects itself [9], Conte
et al. [10] administered a single oral dose of cyclo¬
sporin to eight healthy males at a dose of 12mg/kg,
which achieved a peak drug level of 1500-2000 ng/ml,
and they reported a 27% decline in GFR by 100 min
and a similar fall in RBF. We have misgivings concern¬
ing these dramatic acute findings for three reasons. First,
that study was not placebo-controlled. Secondly, Conte
et al. repeated the study on another occasion and found
no consistent change in GFR when using the same pro¬
tocol [11]. Thirdly, we have performed several detailed
studies of the effects of cyclosporin over the first 4 days
of therapy in normal humans [12,13], and in those stud¬
ies cyclosporin usually increased blood pressure after the
first dose. However, administering cyclosporin to more
than 50 different healthy human subjects, we have con¬
sistently found that even various different doses ofcyclo¬
sporin consistently produced no significant change in
renal haemodynamics up to 4 days of therapy.
From our findings [12,13] we have concluded that the
healthy kidney has inherent homeostatic mechanisms
which, at least in the short term (up to 4 days), pro¬
tect against cyclosporin-induced renal vasoconstriction.
To support this, an earlier patient study [14] suggested
that the renal effects of cyclosporin become manifest
after 7—14 days of treatment. We have therefore now
extended our studies of the initial effects of cyclosporin
from 4 to 9 days of therapy, in order to establish the point
at which cyclosporin-induced renal vasoconstriction oc¬
curs and to examine possible pathogenetic mechanisms.
We report here on the neurohormonal, renal and blood
pressure effects of cyclosporin administered daily over a
9-day period in healthy males. We have also included the
definitive study of two issues which are of current inter¬
est for cyclosporin. First, endothelin might contribute to
the ability of cyclosporin to vasoconstrict according to
animal work and to the finding of elevated endothelin
levels in transplant patients [15], There are many com¬
plicating factors in that previous work, and the present
study provides a cleaner experimental model to an¬
swer finally the question of whether cyclosporin itself
increases endothelin levels. Secondly, transplant recipi¬
ents are susceptible to coronary atherosclerosis, and an
increase in lipoprotein (a) was found in one study of
transplant patients [16]. We therefore took this oppor¬
tunity to investigate whether cyclosporin itself alters
lipoprotein (a) levels, at least in the first 9 days of ad¬
ministration.
Methods
Nine normal, healthy, salt-replete male volunteers [mean
age 32.3 years (95% confidence interval 26.9—37.7),
mean weight 77.7 kg (60.0-89.1)] were recruited into
the study. They were screened by a full medical his¬
tory and examination, as well as by haematological and
biochemical parameters before inclusion. They had no
illnesses and were taking no medications (prescribed
or proprietary). Written informed consent was ob¬
tained before randomization. The study was approved
by the Tayside Committee on Medical Ethics. Sub¬
jects were given dietary advice to follow in the form
of a diet sheet and general recommendations, aimed
at maintaining dietary sodium intake at approximately
150mmol/day. Subjects were not admitted to hospital
for the present study, therefore there was not absolute
control over their dietary intake.
The study was randomized, double-blind, placebo-
controlled and crossover. Subjects were treated with
either cyclosporin (Sandimmun; Sandoz Pharmaceuti¬
cals, Camberley, Surrey, UK) at a dose of 5 mg/kg twice
a day or placebo (provided by our pharmacy) for 9 days.
Treatment periods were separated by a washout period
of at least 14 days. The half-life of cyclosporin is ap¬
proximately 8h [17] and we found no cyclosporin in
the bloodstream during the placebo phase (if the lat¬
ter was given first), as evidenced by whole-blood cy¬
closporin levels on the first day of each treatment period.
Renal haemodynamic assessments were performed on
days 1, 4, 7 and 9 of each treatment period. The pro¬
tocol for this was as follows [18]. On days 1, 4, 7 and
9 subjects attended the laboratory at 0800 h after hav¬
ing fasted from midnight. They were waterloaded over
a 30-min period using a previously reported method and
given their morning dose of trial medication [16]. In
essence, the subjects were given 20ml/kg water to drink.
A 90-min period of equilibration was then allowed, af¬
ter which subjects voided their urinary bladders com¬
pletely every 20 min and were given the equivalent vol¬
ume ofwater to drink. A (bolus of /wra-aminohippurate
sodium; Merch Sharp & Dohme, West Point, Pennsyl¬
vania, USA) and inulin (Inutest; Laevosan-Gessellschaft,
mbH, Linz, Austria), followed by infusion, was admin¬
istered via or through an intravenous cannula situated in
the right antecubital vein at doses calculated to obtain
steady plasma levels of 200 and 25 mg/1 for ;wra-amino-
hippurate and inulin, respectively. A 2-h equilibration
period was then allowed, during which 20-min renal
clearance periods were performed such that by the end
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of this period urine output was steady and varied by <5%
for each individual. Formal 20-min renal clearance pe¬
riods were then observed for the subsequent 100 min.
These consisted of subjects voiding their urinary blad¬
der completely every 20 min and being given the equiv¬
alent volume of water to drink. Aliquots of urine
were saved for estimation of urine sodium, para-amino-
hippurate and inulin. Blood was sampled at the midpoint
of each period for plasma concentration ofpara-amino-
hippurate and inulin. Data from the last three clearances
ofpdw-aminohippurate and inulin were meaned for each
individual, the values being used for subsequent statisti¬
cal analysis. The reasoning for this was that our previous
experience has shown that the peak drug level and drug
effect of cyclosporin was between 3 and 4 h after inges¬
tion. Clearance data are taken from this period for anal¬
ysis. The urine collected during day 9 of both placebo
and cyclosporin treatments was also pooled for assay of
urinary endothelin-1.
At the beginning and end of each study session, and af¬
ter 30min supine, blood was taken for hormonal analy¬
sis of plasma renin activity, aldosterone and endothelin,
as well as for cholesterol and lipoprotein. Whole-blood
cyclosporin levels were measured hourly on these study
days. Supine blood pressure was also measured at the
midpoint of each period by a semi-automated sphygmo¬
manometer (Dinamap; Critikon Inc., Tampa, Florida,
USA).
On days 2, 3, 5, 6 and 8 subjects attended the Depart¬
ment of Clinical Pharmacology approximately 4h after
the morning dose of their trial drug. Blood pressure was
recorded as described above, and 24-h urine collections
from days 1-9 were performed, aliquots being saved for
electrolyte and water excretion measurements. The total
sodium output during the waterloading study was added
to the 24-h urine collection data to provide day-to-day
sodium output data plus a total for each subject over each
9-day study period.
Laboratory methods
Urinary sodium was measured by flame photometry (In¬
strumentation Laboratory, Milan, Italy). Commercially
available radioimmunoassay kits were used to measure
whole-blood cyclosporin levels (Cyclo-Trac; Incstar
Corporation, Stillwater, Minnesota, USA), plasma aldo¬
sterone (Diagnostic Products Corporation, Abingdon,
Oxfordshire, UK) and plasma renin activity (by genera¬
tion of angiotensin I at 37°C for 90 min; Incstar Cor¬
poration). Plasma and urine para-anunohippurate and
inulin concentrations were analysed as described previ¬
ously [19], as were plasma and urine endothelin levels
[20]. Cholesterol and lipoprotein (a) were kindly as¬
sayed by M. Ryan (Biochemical Medicine, Ninewells
Hospital and Medical School, Dundee, UK). Choles¬
terol was measured by the cholesterol oxidase method
(AXON system method SM4-2139F90; Technicon In¬
struments Co. Ltd, Basingstoke, Hampshire, UK) on a
Technicon AXON analyser in a laboratory accredited
by CPA (UK) Ltd. Lipoprotein (a) was measured by
an enzyme-linked immunosorbent assay technique (Tint
Elize Catalogue No. 610120; Porton Products Ltd,
Oxford, UK).
Calculations
Mean arterial pressure was calculated by adding one-
third of the pulse pressure to the diastolic blood pressure.
GFR and effective renal plasma flow (ERPF) were esti¬
mated from the clearances of inulin and para-aminohip-
purate respectively, and were corrected for a body surface
area of 1.73 m2. Clearance was defined as urinary con-
centratiommultiplied by urine volume divided by plasma
concentration.
Statistical analysis
Values are expressed as means (95% confidence interval).
All renal parameters were analysed by repeated-measures
analysis of variance. Student's t test was used to detect
changes in hormonal and lipid parameters. Pearsons lin
ear correlation coefficient and linear regression analysis
were used to assess the relationships between PRA and
GFR and between endothelin and mean arterial pres¬
sure. P< 0.05 was considered statistically significant.
Results
Whole-blood cyclosporin levels on day 9 were 187 ng/ml
(119-255) at trough and 941 ng/ml (651—1231) at 4h.
No cyclosporin was detected on placebo days. Cy¬
closporin induced a fall in GFR and ERPF by day 4
compared with placebo, although when compared with
baseline day 1 cyclosporin values there was no significant
difference in GFR until day 7 (Fig. 1). Cyclosporin also
exerted a hypertensive effect by day 4 (Fig. 2). Although
absolute values of the plasma renin activity and aldo¬
sterone did not change significantly (Table 1), there was
a strong correlation between plasma renin activity and
GFR on cyclosporin treatment, with plasma renin ac¬
tivity suppression being associated with the lowest GFR
(P< 0.0001; Fig. 3). There was no evidence whatsoever
of sodium retention occurring during cyclosporin ther¬
apy (Table 2).
The effects of cyclosporin were not associated with any
change in plasma endothelin levels (Table 1) over the 9-
day course, neither was there any correlation between
blood pressure and plasma endothelin levels (Pearsons
correlation coefficient 0.27, r2 =0.07, P=0.01). Urinary
endothelin levels on day 9 of therapy were not signifi¬
cantly different between placebo [16.8 ng/h (12.1-21.5)]
and cyclosporin [21.5 ng/h (15.2—27.8)]. Lipoprotein (a)
and cholesterol levels were not affected by cyclosporin
(Table 1).
Discussion
The present study allowed new insights into the de¬
velopment of cyclosporin-induced nephrotoxicity and























Day1 Day4 Day7 Day9
He. 1. The effects of cyclosporin A •) and placebo
(Ll O) on glomerular filtration rate (GFR) and effective renal
plasma flow (ERPF). Values are expressed as means±95%
confidence interval. *P< 0.05, **P<0.01, ttP<0.005,
*"*P< 0.0001, versus placebo.
hypertension in humans. We found that the healthy
kidney can initially counteract cyclosporin-induced re¬
nal vasoconstriction and thus maintain renal perfusion
and glomerular filtration. However, between days 4 and
7 these homeostatic mechanisms are overcome and an
8.4% fall in GFR occurs, accompanied by a 24% fall in
ERPF. By day 4 hypertension also occurs, yet urinary
sodium excretion remains unchanged.
Fig. 2. The effects of (•) cyclosporin and (O) placebo on
mean arterial pressure (MAP) measured 4 h after dosing on
days 1-9. Values are expressed as means ±95% confidence
interval. *P<0.05, **P<0.005, versus placebo.
It is well established that cyclosporin induced renal vaso
constriction is the initial process in the kidney lead¬
ing ultimately to nephrotoxicity with ischaemic and
fibrotic histological changes [5]. However, the patho¬
genetic mechanisms which underlie the initial renal
vasoconstriction remain uncertain. Clearly, a model for
cyclosporin induced changes in humans is desirable for
studying in detail the abnormalities which cyclosporin
produces. The present experimental design of 9 days of
clinically relevant doses of cyclosporin to healthy males
Table 1. The effects of cyclosporin compared with placebo on plasma renin activity, aldosterone, endothelin, lipoprotein (a) and cholesterol
Plasma renin activity (ng/ml per h) Aldosterone (pg/ml) Endothelin (pg/ml) Lipoprotein (a) (mg/1) Cholesterol (mmol/1)
Placebo Cyclosporin Placebo Cyclosporin Placebo Cyclosporin Placebo Cyclosporin Placebo Cyclosporin
Day 1
Pre 0.94 1.23 113 148 4.87 7.33 100 103 3.9 4.2
(0.40-1.49) (0.60-1.86) (86-140) (112-184) (3.17-6.58) (3.79-10.87) (57-142) (65-142) (3.3—4.4) (3.7-4.7)
Post 0.46 0.75 84 135 6.57 7.29
(0.18-0.75) (0.34-1.16) (53-115) (103-167) (5.29-7.85) (5.88-8.70)
Day .4
Pre 1.04 0.65 128 146 6.07 6.71 113 85
(0.30-1.78) (0.28-1.02) (91-165) (114-178) (4.80-7.34) (5.38-8.04) (66-159) (53-116)
Post 0.66 0.41 84 93 6.34 7.65
(0.29-1.03) (0.19-0.63) (54-114) (79-107) (4.92-7.76) (5.49-9.81)
Day 7
Pre 1.13 0.69 134 127 7.06 7.34 94 75
(0.76-1.50) (0.14-1.24) (95-173) (99-155) (5.31-8.81) (5.40-9.28) (51-138) (40-111)
Post 0.63 0.49 80 111 6.71 8.09
(0.34-0.92) (0.18-0.80) (58-102) (97-125) (4.31-9.11) (6.02-10.16)
Day 9
Pre 0.98 0.71 123 131 6.50 6.60 109 94 4.0 4.3
(0.53-1.43) (0.32-1.10) (87-159) (103-159) (5.32-2.68) (4.93-8.27) (60-158) (61-128) (3.6-4.4) (3.8-4.9)
Post 0.76 0.50 58 93 7.18 8.56
(0.33-1.19) (0.25-0.75) (41-75) (76-110) (5.01-9.35) (6.27-6.85)
Values are expressed as means (95% confidence interval).
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Fie. 3. The correlation between plasma renin activity
(PRA) and glomerular filtration rate (GFR) on cyclosporin
therapy with linear regression analysis. r = 0.602, n = 36,
y- 15.25x + 64.60 (P<0.0001).
has proved safe and suitable for such studies. This study is
a natural progression from our previous work [12,13], in
which we found that neither single doses of cyclosporin
nor 4 days of therapy had any effect on renal haemody-
namic parameters We have not been able to plot serially
the changes in renal function which occur between days
4 and 9.
We have confirmed our previous findings that renal
function is maintained initially after acute cyclosporin
dosing, which again contrasts widi the results of otliei
groups [8,10]. We have demonstrated an initial resilience
of the healthy kidney to cyclosporin. This homeostalic
mechanism broke down between days 4 and 7. We
had previously found that cyclosporin had no effects
on renal function by day 4 [13]. We do not believe
there is a fundamental difference in the results of the
present and the previous study [13] for the following
reasons. First, significance was not attained until day
7, when day 1 results for cyclosporin were used as
baseline instead of comparing placebo and cyclosporin
on each day. Statistically significant results were ob¬
tained on day 4 primarily because of the change in
placebo values which showed simply natural variation.
Thirdly, the present subjects were different from in
our previous study, and their ability to compensate by
suppressing their renin angiotensin aldosterone system
may have been different, which might account for the
variation found between the present and our previous
study. With regard to renal change, we found a strik
ing correlation between reduced CFR and plasma renin
activity suppression after cyclosporin. In another pre
vious study (Sturrock NDC, Lang CC and Struthers
AD, unpublished results, 1994) we artificially stimu¬
lated the renin—angiotensin system, and this amplified
cyclosporin induced renal vasoconstriction. Because of
this knowledge, the correlation between plasma renin ac
tivity and CFR in the present study can be interpreted as
suggesting that cyclosporin induced renal vasoconstric
tion occurs when the protective mechanism ofPRA sup
pression becomes exhausted. The time course of renal
effects found in the present study mirrors events in pa
tient studies. Balletta et al. [21] found that cyclosporin
did not induce a fall in GFR on day 2 after therapy,
but by 1 month it had produced a significant reduc
tion. Similarly, other workers have found that changes
in renal function begin to appear in week 2 of ther
apy [14] or in a dose-dependent manner by 2 months
[22]. Such changes in GFR, at least initially, may be
transient and related to the time of dosing [23]. There¬
fore, there appears to be a time within the first week of
cyclosporin therapy when renal function is maintained,
which is also when nephroprotective treatments should
be started. Certainly workers have reported [24] that for
vasodilator drugs such as nifedipine to be most effec¬
tive at counteracting the renal effects of cyclosporin
they must be given as early as possible and, indeed, at
the time of onset of the cyclosporin therapy. One group
Table 2. (a) Twenty-four-hour urinary sodium data (mmol/day) for cyclosporin and placebo.



































(b) Individual total sodium output (mmol) for 9 days.
Subject
1 2 3 4 5 6 7 8 9 Mean
Placebo 1309 999 925 1507 984 1176 1256 1173 1306 1182 (1066-1297)
Cyclosporin 1296 1314 963 1486 1429 1079 1395 1665 1036 1185 (1019-1350)
Values are expressed as means (95% confidence interval).
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has found nifedipine to be effective even though it had
no effect on systemic blood pressure [25],
In the present study we found that hypertension did
not occur until day 4, in contrast to our earlier data
using higher doses of cyclosporin [12,13]. It is plau¬
sible that the different doses explain this discrepancy.
We have again been unable to demonstrate any link be¬
tween blood pressure rise and sodium retention. Urinary
sodium excretion did not change, confirming our pre¬
vious conclusions that alterations in sodium balance play
no role in the early hypertensive effect of cyclosporin.
Clearly, this leaves open the possibility that changes in
sodium balance could contribute to the hypertension in
the longer term, especially once renal function is frankly
abnormal. We therefore sought other hormonal mech¬
anisms to account for the presumed systemic vasocon¬
striction. We and others have been unable to demon¬
strate a role for the sympathetic nervous system [12,26],
despite earlier data to the contrary [27]. We therefore
measured levels of the vasoconstrictor hormone endo-
thelin in order to investigate whether this changed after
cyclosporin, and to assess whether there is any correla¬
tion between endothelin levels and cyclosporin-induced
hypertension. Animal studies had initially suggested a
role for endothelin, with the finding that cyclosporin
induces endothelial disruption, elevates endothelin levels
and subsequently induces renal vasoconstriction, and that
these effects could be attenuated by antibodies against
endothelin [28—33]. In humans endothelial destruction
has been reported in renal biopsies with cyclosporin
nephrotoxicity [32] and transplant recipients have been
found to have raised endothelin levels [15]. However, cy¬
closporin does not augment endothelin-induced changes
in blood pressure in humans [33]. In the present study we
found no change in plasma endothelin levels over the 9
days of the study, despite cyclosporin producing marked
cyclosporin-induced renal and blood pressure changes;
furthermore, endothelin levels did not correlate with
blood pressure changes. The present study does not
discount the possibility that endothelin could act locally
within tissues. Our observation that cyclosporin does not
alter urinary endothelin significantly excludes a major
effect ofcyclosporin on urinary endothelin, but does not
exclude a small effect.
There are major reasons to be interested in the effect
of cyclosporin on lipoprotein (a), because the combina¬
tion of raised lipoprotein (a) and hypertension would be
potendy atherogenic, and a worrying feature of cardiac
transplant patients is that they rapidly develop coronary
artery disease. A recent study [15] found an increase
in lipoprotein (a) in renal transplant recipients, but we
could not confirm this in healthy subjects, and, in¬
deed, others have found suppression of lipoprotein (a) by
cyclosporin [34], The present model has the advantage of
no confounding variables but the disadvantage of being
a relatively short-term assessment.
In summary, the present study has demonstrated the
progressive effect of cyclosporin on renal function and
has delineated the point at which homeostatic mecha¬
nisms in the healthy kidney are overcome. The study
also suggests that suppression of plasma renin activity
is one such homeostatic mechanism which is eventu¬
ally overcome. We have also virtually excluded a role
for circulating endothelin or renal sodium retention in
initiating cyclosporin-induced hypertension in humans.
Finally, this paper describes a human model which can
be used in the future for comparative studies to define
which is the best nephroprotective or antihypertensive
therapy against cyclosporin.
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Erythropoietin enhances vascular responsiveness to
norepinephrine in renal failure
Malcolm F. Hand, William G. Haynes, Heather A. Johnstone, John L. Anderton,
and David J. Webb
The University of Edinburgh, Department ofMedicine. Western General Hospital. Edinburgh, Scotland, United Kingdom
Erythropoietin enhances vascular responsiveness to norepinephrine in
renal failure. The mechanism of hypertension induced by recombinant
human erythropoietin (rHuEPO) is unclear butmay include an increase in
peripheral vascular resistance. We studied changes of arterial pressure
and plasma endothelin in nine consecutive hemodialysis patients before,
and 6 and 12 weeks after, starting rHuEPO. In six patients, changes in
cardiac index (CI), stroke index (SI) and total peripheral resistance index
(TPRI) were measured by bio impedance, and forearm vascular respon¬
siveness to intra-arterial norepinephrine (30 to 240 pmoi/min) and endo¬
thelial (S pmol/min) were assessed. Six healthy age and sex matched
subjects also underwent assessment of forearm vascular responsiveness to
norepinephrine and endothelin-1. Treatment with rHuEPO significantly
increased hemoglobin and mean arterial pressure (MAP). TPRI also
increased by 35 s 11%. Plasma endothelin, although elevated basailv,
remained unchanged. Intra-artenal infusion of norepinephrine caused a
maximal increase in forearm vascular resistance (FVR) of 17 - 9% before
rHuEPO, significantly less than the 32 — 5% increase in healthy control
subjects (P - 0.04). The response increased to 55 i 15% (P - 0.03) after
12 weeks rHuEPO treatment (P - 0.51 vs. controls). Endothelin-1 caused
a maximal increase of FVR at 60 minutes of 45 — 24% before rHuEPO,
which was not significantly different from controls, and tended to decrease
with rHuEPO therapy. The response to endothelin-1. but not norepineph¬
rine, correlated inversely with MAP (r — -0.52; P - 0.03) and TPRI (r -
—0.51: P - 0.04). In conclusion, these studies show that anemia in chronic
renal failure is associated with depressed vascular responsiveness to
norepinephrine which is restored by rHuEPO therapy. In contrast,
vascular responses to endothelin-1 tend to reduce with rHuEPO therapy.
The change in vascular responsiveness to norepinephrine may contribute
to the increase in arterial pressure associated with rHuEPO therapy.
Recombinant human erythropoietin (rHuEPO) corrects the
anemia of chronic renal failure [1, 2]. It is recognized, however,
that rHuEPO may increase arterial pressure in previously normo
tensive subjects, or exacerbate pre-existing hypertension [3]. Al¬
though the mechanism for this hypertension is unknown, it is
likely to be multifactorial [4],
Hypertension following rHuEPO is associated with an increase
in peripheral vascular resistance [5] and may be exacerbated by
failure of an elevated cardiac output to decrease in response to
increases in hemoglobin [6, 7). Although increases of hematocrit
and viscosity secondary to rHuEPO therapy may contribute to the
rise in vascular resistance [8], and although the development of
hypertension may occur in parallel with the increase in hemato¬
crit, one fifth of individuals who become hypertensive do so some
months after the hematocrit has stabilized at its new higher level
[6]. Also, studies in animals suggest that when the hematocrit is
increased to a similar extfent with rHuEPO or transfusion, arterial
pressure increases in the rHuEPO, but not the transfused, group
[9]. In addition, although increasing the hematocrit in humans
from 20 to 40% by transfusion increases arterial pressure [10],
hypertension does not appear to occur when the hematocrit is
increased only to 30% [11]. Furthermore, several studies have
failed to find a relationship between changes in arterial pressure
and changes in hematocrit or viscosity [4, 6,12], Finally, although
rHuEPO increases whole blood viscosity, peripheral vascular
resistance increases to a much greater extent than would be
predicted from this effect [13],
Increased circulating concentrations of vasoactive hormones
may contribute to the increase in arterial pressure in patients
treated with rHuEPO [14], However, reports of the effects of
rHuEPO have been conflicting: renin activity and atrial natriuretic
peptide concentrations do not change [II, 14, 15] or decrease
[16-18], and changes in the renin-angiotensin system appear to be
secondary to alterations in red cell mass and plasma volume [19].
Norepinephrine concentrations may increase [20], decrease [13]
or, like epinephrine and dopamine, remain unchanged [11].
Plasma concentrations of the locally active hormone endothelin-1
have been reported as unchanged [15] or, increased [12, 17, 21] in
response to treatment with rHuEPO.
Although animal studies and in vitro studies in humans have
been undertaken, it is not known whether in vivo vascular
reactivity to norepinephrine or endothelin-1 is altered in patients
with chronic renal failure receiving rHuEPO. Hence, we have
investigated the effect of treatment with rHuEPO on systemic
hemodynamics and responsiveness of the forearm resistance
vessels to local doses of norepinephrine and endothelin-1 given
via the brachial artery.
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Subjects
We studied nine consecutive patients (5 men, 4 women; 24 to 67
years) with established end-stage renal disease (Table 1), who had
been maintained on hemodialysis given three times each week for
at least three months before starting rHuEPO. Subjects had all
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Antihypertensive Iron Phosphate l-Aipha
Pauent Diagnosis Age Sex medicauon Ranitidine sulphate binders calcidol NSAIDs
1 Obstructive uropathy 67 M None - +■ 4- 4- 4-
2 Chronic pyelonephritis 39 F None - — - - -
3 Chronic pyelonephritis 34 M None - + 4- 4- -
4 Bilateral nephrectomy 59 F None - + 4- 4- -
5 Mesangiocapillary glomerulonephritis 32 M Enalapril, Nifedipine SR + - + 4- -
6 Focal necrotizing glomerulonephritis 26 F None - - +• 4- -
7 Chronic pyelonephritis 58 F None + -t- — 4- -
8 Crescennc glomerulonephritis 42 M Nifedipine SR + 4* - - 4-
9 Mesangiocapillary glomerulonephritis 32 M None + +• 4- — 4-
Subjects 1-6 underwent both intra-artenai and hemodynamic studies; subjects 7-9 underwent blood pressure monitoring and blood sampling only.
Non-steroidal anti-inflammatory drugs (NSAIDs) were avoided for 1 week before each intra-arterial study. Abbreviations are: M. male; F, female: +,
drug used; —, drug not used.
maintained a stable arterial pressure for the preceding three
months, had not previously received rHuEPO, and had a stable
hemoglobin of 8 g/dl or less. All studies were conducted with the
approval of the local Ethics Review Committee and patients gave
their written informed consent to participate. Patients avoided
non-steroidal anti-inflammatory drugs for the week before, and
caffeine-containing drinks or cigarettes on the day of, each study.
In addition, patients were fasted for at least three hours before
each study.
Six subjects (3 men, 3 women; 24 to 67 years: mean age 43 r 5
years) completed the full study protocol. The other three subjects
(2 men. 1 woman. 32 to 58 years), because of poor vascular access,
underwent blood sampling and arterial pressure monitoring but
not intra-arterial drug infusion. All patients were self-medicating
(Table 1) and their diet was high in calories but limited to a daily
intake of 1 g/kg body wt protein. 80 to 100 mmol sodium and 1
mmol/kg bodywt potassium, with a daily fluid restriction of 500 ml
plus a volume equal to the previous 24 hours urine output.
Six healthy age and sex matched subjects (4 men. 2 women; 29
to 63 years, mean age 43 £ 5 years) were studied at a later date
to establish vascular responsiveness to norepinephrine and endo¬
thelial in a healthy control group. These subjects had normal
renal function (plasma creatinine 83 £ 8 pmol/liter), did not
receive rHuEPO, and underwent intra-arterial drug infusion on
one occasion only.
Procedures
A 21 SWG cannula was inserted under local anesthesia using
1% lignocaine hydrochloride (Astra Pharmaceuticals Limited,
Kings Langley, UK) into a vein on the fistula arm, but not into the
fistula, for the purpose of blood sampling in the hemodialysis
patients, or into the dominant arm in controls. A 27 SWG steel
cannula (Cooper's Needle Works, Birmingham, UK) was inserted
into the brachial artery of the non-fistula arm, or non-dominant
arm in controls, under local anesthesia for the purpose of
intra-arterial infusion of drugs. Forearm blood flow was measured
only in the infused arm, using venous occlusion plethysmography
[22] adapted for use with indium-and-gallium-in-silastic strain
gauges [23]. Measurements were made for 10 seconds in every 15
seconds over a three minute period. Blood flow to the hand was
excluded during each three minute measurement period.
Arterial pressure was measured using a well-validated semi-
automated oscillometric method (Takeda UA 751 [24, 25]).
Cardiac output and stroke volume were uicuautcd using a well-







Hemoglobin g/dl 7.0 £ 0J
Hematocrit % 20.4 - 0.9
Mean cellular volume fl 92 £ 2
Platelets xHfUiter 212 £ 30
White blood count X ICfUiter 6.4 £ 0.8
Plasma viscosity cp 1.59 £ 0.05
7.8 £ 0.6" 9.1 £ 0.6*
2ZS £ 1.8 26.5 £ 1.7*
94 £ 2 91 £ 2
219 £ 26 228 £ 25
5.7 £ 0.6 623 £ 0.6
1 _56 £ 0.04 1J8 £ 0.04
* P < 0.02 (pre vs. 12 weeks)
validated non-invasive bioimpedance method (model NCCOM3;
BoMed Medical Manufacturer Ltd, Irvine, CA. USA) [26, 27],
Drugs
All patients received subcutaneous recombinant human eryth-
ropoietin-beta (rHuEPO; Recormon-Boehringer Mannheim UK.
Livingston, UK), three times weekly after dialysis, at a dose of 50
U/kg. Our local protocol dictated that this dose should be
adjusted to allow no more than a 4% rise of hematocrit every two
weeks. Intra-arterial norepinephrine (30, 60, 120 and 240 pmol/
min; Sanofi Winthrop Limited, Guildford, UK), endothelin-L (5
pmol/min; Clinalfa. Laufelfingen, Switzerland) and physiologic
saline (0.9%; Baxter Healthcare Limited, Thetford, UK) were
administered at locally but not systemically active doses via the
brachial artery cannula. The dose of endothelin-1 was based on
previous work showing that it produced progressive vasoconstric¬
tion, with a maximum reduction in forearm blood flow of —40%
after 60 minutes [23]. The doses of norepinephrine were based on
previous studies [28], and intended to cause a similar reduction in
local blood flow. Vasoconstriction to endothelin-l is sustained
whereas that to norepinephrine is short-lasting. Therefore, it was
necessary to give norepinephrine first rather than randomize the
order of infusions. All solutions were made up in physiologic
saline containing 100 ptg/ml ascorbic acid (Evans Medical Ltd,
Dunstable, UK) to avoid oxidation. The total rate of intra-arterial
infusion was kept constant at 1 ml/min.
Design
Studies were performed before, and at 6 and 12 weeks after,
starting rHuEPO therapy, on a mid-week non-dialysis day in a
quiet room maintained at a constant temperature of between 25
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Basal FBF before norepinephrine mU100 mllmm 3.2 -0.5 3.6 £ 0.7 35 £ 0.5 2.6 £ 0.3
Basal FVR before norepinephrine AU 35 £ 5 34 £ 7 32 £6 32 £ 5
FBF before endorhelin-1 mlllOO mllmm 45 -05 3.0 £ 0.6 3.6 £ 05 3.2 £ 05'
FVR before endothelin-1 All 26 -5 43 £ 5' 36 £9 27 £2
Baseline systolic pressure mm Hij 120 £ 12 130 £ 13" 131 £ 12' 121 £5
Baseline diastolic pressure mm Hg 66 £ 5 77 £ 7 77 £5' 69 £3
Baseline mean arterial pressure mm Hg S4 £7 95 £9° 95 £ 7" 86 £3
Total peripheral resistance index dynlmmlcnPlm- 24 £ 5 32 £ 7" 29 £ 6
Cardiac index literlmmlnr 3.8 £05 35 £ 05" 3.8 £ 0.7
Stroke index mUnr 48 £ 5 45 £3 52 £9
Heart rate beats/mm 81 £3 76 £4 73 £ 3 62 £3"
Abbreviations are: FBF, forearm blood flow, FVR, forearm vascuiar resistance.
* P = 0.03 (compared to basai FVR before norepinephrine)
6 P - 0.06, 'Ps 0.05, 'Ps 0.01: all versus pre-rHuEPO. "PS 0.04 versus pre, 6 weeks and 12 weeks rHuEPO
and 28°C. The rime and day of each study was the same for each
patient.
Subjects initially rested supine for 30 minutes after which,-in the
patients only, cardiac output and stroke volume were measured.
Brachial artery and venous cannuiation were then performed.
Saline was infused via the brachial artery cannula for 30 minutes,
after which blood was withdrawn from the venous cannula to
measure plasma endothelin-1, plasma renin activity, and serum
sodium, potassium, urea, creatinine, calcium, albumin and phos¬
phate. Hemoglobin, hematocrit, platelet count, white blood count
and plasma viscosity were also measured. Norepinephrine was
then infused at incremental doses, each dose for 10 minutes, via
the brachial artery cannula, after which saline was infused for 20
minutes to allow washout of vasoconstriction to norepinephrine,
and was followed by infusion of endothelin-1 for one hour.
Forearm blood flow was recorded at 10 mmute intervals during
infusion of saline and endothelin-1, and at the end of each
10-minute incremental infusion of norepinephrine. The mean of
the final five measurements of each recording period was used for
analysis. Studies were performed in a similar way in the control
subjects, although venous blood was sampled only to measure
creatinine and hemoglobin concentrations. Arterial pressure was
measured in the infused arm immediately after each blood flow
recording.
Analytical
Venous plasma samples for radioimmunoassay of endothelin-l
and renin were separated within 10 minutes and stored at -20°C.
Plasma electrolytes, hemoglobin, platelet count and plasma vis¬
cosity were assayed immediately after each study. Plasma bio¬
chemistry was measured using a Kodak Ectachem System E700
XRC analyzer (Kodak Diagnostics Ltd, UK) in the Department of
Clinical Chemistry, Western General Hospital, Edinburgh. Full
blood count and plasma viscosity were measured in the Depart¬
ment of Hematology, Western General Hospital, Edinburgh,
using a Coulter STKS analyzer (Coulter Electronics Ltd, UK) and
a Luckhams viscometer (Denley, UK), respectively.
Plasma immunoreactive endothelin was measured using an
established method [29] with a previously validated assay [30].
The recovery of added endothelin-1 was 84%. The sensitivity of
the assay was 2 pg/ml endothelin and the mean intra- and
inter-assay coefficient of variations in our laboratory are 2.4% and
4.2%, respectively. Cross reactivity of the assay with endothelin-1.
endotheiin-2. endothelin-3 and proendothelin-1 was 100%, 52%.
96% and 7%. respectively. Plasma renin activity was measured
using a commercially available radioimmunoassay method
(RIANEN, Europath Ltd, Cornwall, UK). The minimal detect¬
able activity was 0.3 ng/ml/hr and the mean intra- and inter-assav
coefficient of variations in our laboratory was 12.5%.
Data presentation and statistics
Mean anerial pressure was calculated as diastolic arterial
pressure + '/j pulse pressure. Forearm blood flow was calculated
in ml/100 ml of forearm tissue/min. Changes in forearm blood
flow are expressed as the percentage change in blood flow at a
particular timepoint from the basal recording. Forearm vascuiar
resistance was calculated as mean arterial pressure divided by
forearm blood flow. Data for cardiac output and stroke volume
were corrected for body surface area, calculated according to a
standard nomogram, to provide measures of cardiac (CI) and
stroke index (SI) and are expressed as liter/min/m" and ml/m".
respectively. Total peripheral resistance index (TPRI) was calcu¬
lated as mean arterial pressure divided by cardiac index, and
expressed as dyne/min/cm^m2.
All results are expressed as mean £ sem. The maximal response
to the norepinephrine and endothelin-1 infusions, as well as
biochemical, hematological and hemodynamic data, were ana¬
lyzed by Student's paired r-test and by simple regression analysis,
as appropriate. Dose-response relationships were compared using
analysis of variance (ANOVA). The relationships between per¬
centage change in responsiveness of forearm blood flow and
vascular resistance to norepinephrine and endothelin associated
with rHuEPO, and the percentage change in blood pressure,
peripheral resistance and hemoglobin with this treatment were
also examined. Comparisons between control subjects and pa¬
tients for dose-response relationships were examined by analysis
of variance (ANOVA) whereas other comparisons with controls
were analyzed using Student's unpaired t-test. Statistical analysis
was performed using the STATVIEW 512+™ software (Brain¬
power Inc., Calabasas, CA. USA) for the Apple Macintosh micro¬
computer. Values of P < 0.05 were considered statistically signifi¬
cant. Simple regression analysis was used primarily for hypothesis
generation and the P values accepted for statistical significance were,
therefore, not corrected for multiple comparisons.
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Results
Hematology
rHuEPO caused a progressive rise in hemoglobin and hemat¬
ocrit (Table 2). In no case was it necessary to change the dose of
rHnFPO according to the requirements of our local schedule.
Two patients (patients 3 and 8) failed to have a sustained response
to rHuEPO, both as a result of iron deficiency, but also, in patient
8, because of an associated hereditary elliptocytosis. Other hema¬
tological parameters, white blood count, platelet count and
plasma viscosity remained unchanged throughout the study (Ta¬
ble 2). The hemoglobin of the control subjects (12.9 £ 0.5 g/dl)
was significandy higher than that of patients (P < 0.001) through¬
out the study (Table 2).
Arterial pressure and hemodynamics
There was a progressive increase in resting systolic, diastolic
and mean arterial pressure with rHuEPO therapy (Table 3). In
one patient (patient 5), there was a rapid increase in the diastolic
pressure from 80 to 130 mm Hg requiring aggressive medical
intervention. It was necessary to increase the dose of nifedipine to
40 mg twice daily and enaiapnl to 20 mg twice daily, and to add
doxazosin 2 mg three times daily and metoprolol 50 mg twice
daily, to control the arterial pressure. Over the period of the
study, resting diastolic, but not systolic or mean arterial pressure,
correlated with hemoglobin (r = 0.45; P = 0.02) and hematocrit (r
= 0.44; P = 0.02). Also, % change in hemoglobin with treatment
correlated with % change in resting systolic (r = 0.60; P = 0.05),
diastolic (r = 0.75; P = 0.008) and mean arterial (r = 0.76; P =
0.007) pressure. TPRI increased markedly and significantly (P =
0.01) after six weeks of treatment, but then decreased slightly by
12 weeks, though still tending to be higher than before treatment
(Table 3), consistent with the major effect of rHuEPO being on
peripheral vascular resistance. There was a reduction in CI at six
weeks (P = 0.05), returning to pre-treatment levels by 12 weeks,
whereas SI did not change (Table 3).
Forearm blood flow responses
There was no effect of rHuEPO on resting forearm blood flow
or vascular resistance (Table 3). In the studies performed six
weeks after starting rHuEPO, but not in the other studies,
forearm vascular resistance had not returned to basal levels {P =
0.03) after norepinephrine and before endothelin-1, and may have
tended to mask subsequent changes in forearm vascular resistance
to endothelin-1. Local infusion of norepinephrine and endothe-
lin-1 had no effect on pulse rate or arterial pressure.
Norepinephrine caused a dose-dependent reduction in forearm
blood flow. This response was increased significantly by rHuEPO.
The maximum dose of norepinephrine (240 pmol/min) reduced
blood flow by 13 i 4% before rHuEPO, by 44 i: 8% (P = 0.01 vs.
prc-treatment; P = 0.07; ANOVA) at six weeks, and by 32 i 7%
(P = 0.07 vs. pre-treatment; P = 0.24; ANOVA) at 12 weeks of
rHuEPO therapy (Fig. 1). There was no significant relationship
between the % change in forearm blood flow with norepinephrine
(240 pmol/min) and resting systolic (r = -0.36; P = 0.15),
diastolic (r - -0.14; P - 0_59) or mean arterial pressure (r =
-0.27; P = 0.30), total peripheral resistance (r - -0.19; P = 0.45)
or hemoglobin (r — 0.03; P = 0.92). Forearm vascular resistance
increased significantly with rHuEPO in response to norepineph¬
rine (240 pmol/min); by 17 z: 9% before rHuEPO, by 123 r 51%
A
30 60 120 260
B
30 60 120 240
Dose of norepinephrine, pmol/min
Fig. 1. Effect of irura-artcnal norepinephrine on forearm blood flow (A) and
forearm vascular resistance IB). Symbols are: patients before EPO therapy
(O). after six weeks of EPO (A), and after 12 weeks of EPO (Bj.
(P = 0.08 vs. pre-treatment; P = 0.07; ANOVA) at six weeks, and
by 65 - 15% (P = 0.03 vs. pre-treatment: P = 0.08; ANOVA) at
12 weeks of rHuEPO therapy. There was no significant relation¬
ship between the % change in forearm vascular resistance with
norepinephrine (240 pmol/min) and resting systolic (r = -0J5;
P = 0.17), diastolic (r » -0.24; P = 0.35) or mean arterial
pressure (r = -0.31; P = 0.23), total peripheral resistance (r =
-0.24; P = 0.35) or hemoglobin (r = —0.27; P = 0.30). There was
no significant relationship between the % change in vascular
responsiveness to norepinephrine (240 pmol/min) associated with
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rHuEPO therapy and the % change in artenal pressure. TPR1 or
hemoglobin with this treatment.
The control subjects were more responsive to norepinephrine
than the patients. The maximum dose of norepinephrine (240
pmol/min) reduced blood flow by 38 ± 5% in the controls, an
effect that was significantly greater than in pauents before (P =
0.01; ANOVA) but not after 6 (P = 0.70; ANOVA) or 12 weeks
(P = 0.20; ANOVA) of rHuEPO therapy. The maximum dose of
norepinephrine (240 pmol/rain) increased forearm vascular resis¬
tance by 32 r 5% in the controls, an effect that was also
significantly greater than the response in patients before (P =
0.04; ANOVA) but not after 6 (P = 0.31; ANOVA) or 12 weeks
(P = 0-51; ANOVA) of rHuEPO therapy.
Endothelin-1 caused a progressive reduction in forearm blood
flow, maximal by 60 minutes. Forearm blood flow at 60 minutes
reduced by 15 ± 15% before rHuEPO, by 14 r 12% at six weeks
(P = 0.93 vs. pre-treatment: P = 0.74; ANOVA), and by 7 i 10%
at 12 weeks (P = 0-59 vs. pre-treatment: P = 0.42; ANOVA) (Fig.
2). The % change in forearm blood flow at 60 minutes correlated
inversely with resting systolic arterial pressure (r = -0.55; P =
0.02) and total peripheral resistance (r = -0.51; P = 0.04) but not
diastolic (r = -0.33; P = 0.20) or mean arterial pressure (r =
-0.46; P = 0.06), or hemoglobin (r = -0.30; P = 0.25). Forearm
vascular resistance at 60 minutes increased by 45 r 24% before
rHuEPO, by 33 ± 18% (P = 0.63 vs. pre-treatment: P = 0.72;
ANOVA) at six weeks, and by 20 — 14% at 12 weeks (P = 0.20 vs.
pre-treatment: P =* 0.29; ANOVA) of rHuEPO therapy (Fig. 2).
The % change in forearm vascular resistance to endothelin-l at 60
minutes correlated inversely with resting systolic (r = -0.53; P =
0.03) and mean arterial pressure (r = -0-52: P = 0.03), and total
peripheral resistance (r = —0.51; P = 0.03; Fig. 3), but not with
diastolic pressure (r = —0.45; P = 0.07) or hemoglobin (r =
-0.43; P = 0.08). There was no significant relationship between
the % change in vascular responsiveness to endothelin-1 that
occurred with rHuEPO therapy, based on the 60 minute re¬
sponses, and the % change in artenal pressure, TPRI or hemo¬
globin.
Forearm blood flow with 60 minutes of endothelin-1 was
reduced by 23 r 10% in the control subjects which was not
significantly different to before (P = 0.87; ANOVA) or after 6 (P
= 0.56; ANOVA) or 12 weeks (P = 0.23; ANOVA) of rHuEPO
therapy. Forearm vascular resistance at 60 minutes was increased
by 27 — 2% in the control subjects which was not significantly
different to before (P = 0.92; ANOVA) or after 6 (P ** 0.57;
ANOVA) or 12 weeks (P = 0.13; ANOVA) of rHuEPO therapy.
If subject 5 was excluded, on the assumption that the change in
antihypertensive medication may have influenced his results, the
maximum dose of norepinephrine reduced forearm blood flow by
10 r 4% before rHuEPO. by 46 m 10% {P = 0.007 vs. pre-
treatment: P = 0.05; ANOVA) at six weeks, and by 35 - 8% (P =
0.04 vs. pre-treatment; P = 0.18; ANOVA) at 12 weeks of
rHuEPO therapy. Forearm vascular resistance increased by 10 r
7% before rHuEPO, by 139 r 59% (P = 0.08 vs. pre-treatment:
P = 0.05; ANOVA) after six weeks, and by 69 r 18% (P = 0.02
vs. pre-treatment: P = 0.06; ANOVA) after 12 weeks of rHuEPO
therapy. After infusing endothelin-1 for 60 minutes, forearm
blood flow reduced by 26 ± 12% before rHuEPO, by 14 r 15%
(P = 0.50 vs. pre-treatment; P = 0_50; ANOVA) at six weeks, and
by 3 T. 12% (P = 0.004 vs. pre-treatment: P = 0.15; ANOVA) at
12 weeks of rHuEPO therapy. Forearm vascular resistance in-
A
'0 10 20 30 40 50 60
8
0 10 20 30 40 50 60
Time, minutes
< -*■
Fig. 2. Effect of intra arsenal endothelin-l on forearm blood flow (X) and
forearm vascular resistance fBJ. Symbols are: patients before EPO therapy
(O), after six weeks of EPO (A) and after 12 weeks of EPO (■).
creased by 56 ~ 26% before rHuEPO, by 38 s: 21% (P = 0.55 vs.
pre-treatment; P = 0.68; ANOVA) after six weeks, and by 17 ±
17% (P = 0.02 vs. pre-treatment: P = 0.21; ANOVA) after 12
weeks of rHuEPO therapy.
Plasma endothelin and plasma renin activity
Plasma endothelin concentration, although substantially ele¬
vated at 16.2 T. 4.1 pg/ml before rHuEPO (normal as measured in
our laboratory 5.4 : 0.8 pg/ml) [29], did not change significantly
across the study, being 11.1 r 0.9 and 11.6 - 0.6 pg/ml at 6 and
12 weeks of treatment with rHuEPO, respectively. There was no
significant relationship between plasma endothelin concentration
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Fig. 3. Correlation between the % increase in forearm vascular resistance
(FVR) with endotheiin-l at 60 minutes and (A) mean arterial pressure (mm
Hgt and 08) total penpheral vascular resistance index (dyn/mimcm1imf).
Symbols arc: patients before EPO therapy (O), after six weeks of EPO (A)
and after 12 weeks of EPO (■).
and arterial pressure or % change in vasoconstriction to endothe¬
lial or norepinephrine across the period of the study. Plasma
renin activity did not change significandy across the study; at 1.7
— 0.9 ng/ml/hr before rHuEPO, and 1_3 ri 0.6 and 1.2 ri 0.5
ng/ml/hr at 6 and 12 weeks treatment with rHuEPO, respectively.
There was no significant relationship between plasma renin
activity and changes in arterial pressure or % change in vasocon¬
striction to endothelin-1 or norepinephrine across the period of
the study.
Plasma biochemistry
Apart from small changes in plasma urea and albumin concen¬
trations, the measured biochemical parameters did not alter. The
number of hours of dialysis for each patient and the clinically
assessed dry weight did not change during the study. Plasma
endothelin concentrations correlated positively with creatinine (r
*• 0-56; P = 0.003), urea (r «■ 0-51; P = 0.008) and the number of
hours dialyzed per week (r = 0-50; P - 0.01).
Discussion
In anemic hemodialysis patients with chronic renal failure
selected to start treatment with rHuEPO, we have demonstrated
an impaired responsiveness to norepinephrine which is corrected
by chronic administration of a dose of rHuEPO sufficient to cause
an increase in arterial pressure and hematocrit. In contrast, in the
same subjects, the responsiveness of forearm resistance vessels to
endothelin-1 is unaffected, or even decreased by rHuEPO ther¬
apy.
The increase in total peripheral resistance with rHuEPO in our
study confirms previous observations [5]. Although failure of the
cardiac output to decrease with rHuEPO may contribute to
rHuEPO-associated hypertension [6, 7], the significant decrease
in cardiac index after treatment with rHuEPO for six weeks, but
not 12 weeks, in our study suggests that the relationship may be
more complex. These results are likely to be reliable, within the
limitations of bioimpedance technology [26, 27], but need to be
confirmed using other techniques.
In contrast to previous studies demonstrating either impaired
[31, 20] or normal vascular responsiveness [32] to norepinephrine
in hemodialysis patients, our study did not use systemically active
doses of drugs that might obscure any direct vascular action by
direct effects on other organs, such as the heart and kidney, or
activate reflex mechanisms due to changes in arterial pressure. As
in our previous studies [23, 28], the lack of a systemic effect is
indicated by the absence of a change in arterial pressure or pulse
rate during infusion of either norepinephrine or endothelin-1.
Thus, our study directly and specifically examines the responsive¬
ness of forearm resistance vessels in rHuEPO-treated hemodial¬
ysis patients.
Changes of vascular responsiveness during rHuEPO therapy
might occur as a result of a change in vascular structure or of a
non-specific effect of treatment on the vascular smooth muscle
cells. In studies of a similar nature in patients with essential
hypertension, vascular responsiveness to norepinephrine is cither
unaltered [33] or increased [34,35] compared with healthy control
subjects, probably as a consequence of vascular structural changes
including hypertrophy [35]. In our study, correction of the im¬
paired responses to norepinephrine in hemodialysis patients by
rHuEPO treatment are unlikely to be explained by vascular
structural or non-specific functional effects of rHuEPO given the
contrasting changes in response to norepinephrine and endothe¬
lin-1.
Our results are consistent with those of Bode-Bdger et al [36],
who showed rHuEPO caused enhancement of the vascular re¬
sponse to norepinephrine in rabbit aorta, and of Muller et al [13],
who found that anemia caused a disturbance of post-svnaptic
alphas-receptor function in end-stage renal disease, leading to
diminished vascular responsiveness to sympathetic stimuli that
was corrected by treatment of the anemia. In addition, Berglund
and Ekblom [37] demonstrated an increase in arterial pressure
with exercise in healthy men treated with rHuEPO, suggesting an
accentuation of the arterial pressure reaction to sympathetic
stimulation. The increase in arterial vessel responsiveness with
rHuEPO therapy to locally active doses of norepinephrine in our
study, however, contrasts with the observation of a decreased
pressor effect of systemic norepinephrine after rHuEPO therapy
[20], although this effect may occur through a central mechanism.
High plasma concentrations of norepinephrine occur in end-
stage renal disease [38], and may contribute to impaired respon¬
siveness to norepinephrine because alpha,-adrenoceptor numbers
are reduced on exposure to high levels of physiological agonists.
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Receptor down-regulation is supported indirectly through evi¬
dence of impaired pressor responses to norepinephrine [311, and
more directly by reductions in platelet alpha-.-receptor density and
affinity [13), in hemodialysis patients. Interestingly, there was an
inverse correlation between hemoglobin and both platelet alphas-
receptor density and affinity in the latter study, suggesting that
renal anemia may contribute to this effect. This would certainly be
consistent with our finding of reduced responsiveness to norepi¬
nephrine before rHuEPO. and the subsequent increase in respon¬
siveness with partial correction of the anemia by rHuEPO. It may
also explain the higher standing blood pressures that have been
reported when the associated anemia of primary autonomic
failure is treated with rHuEPO [39, 40). The absence of a
correlation between vasoconstriction to norepinephrine and ei¬
ther total peripheral resistance or arterial pressure in our study
suggests that enhanced adrenergic responsiveness may not fully
account for the pressor effects of rHuEPO. On the basis of
sympathetic microneurography, nerve activity does not appear to
contribute because, although basally increased in hemodialysis
patients, it is not further enhanced by rHuEPO.[41).
In contrast with the responses to norepinephrine, the vascular
responsiveness to endothelin-1 tended to decrease rather than
increase with rHuEPO therapy. With some variability within the
data, the lack of statistical significance may reflect a type II
statistical error, indeed, the responsiveness to endothelin-1 did
decrease significandy when analyzed after exclusion of the patient
who had uncontrolled hypertension requiring a substantial change
in treatment during the study. Endothelin-1 induced vasoconstric¬
tion correlated significantly but negatively with systolic arterial
pressure, mean arterial pressure and total peripheral resistance by
simple regression analysis, as has been observed previously in
normotensive but not hypertensive subjects [29]. This may have
several possible explanations. First, there may be a specific
reduction in responsiveness to endothelin-1 caused by an effect on
signal transduction mechanisms coupled to endothelin receptors,
but not to those for norepinephrine. This has been shown in the
blood vessels of hypertensive patients [42], Second, there may be
true down-regulation of receptor expression. Third, there may be
decreased endothelin-1 receptor number owing to prior receptor
occupation by increased local concentrations of endothelin. This
might be expected if increased endothelin-1 production occurs.
Increased local production of endothelin-1 in response to
rHuEPO could account for the decreased blood vessel respon¬
siveness to exogenous endothelin. while still being a factor in
causing the increase in arterial pressure and total peripheral
resistance. Conversely, increased systolic arterial pressure may
itself cause down-regulation of the endothelin receptor such as
has been described in some animal models [43, 44). Such receptor
down-regulation would yield similar responses to exogenous en¬
dothelin, but would occur as a result of changes in arterial
pressure and not as a cause. Further studies, using local infusion of
endothelin receptor antagonists, may serve to differentiate between
receptor down-regulation and increased receptor occupancy.
Although plasma endothelin concentrations were elevated in
our patients, they did not increase further following rHuEPO, in
contrast with some other studies [12, 17, 21). This may have been
because rHuEPO was given subcutaneously and did not achieve
the same maximum plasma concentrations as when given by the
intravenous route [45]. Experimental evidence that rHuEPO
induces an increase in endothelin-1 production has usually re¬
quired plasma concentrations of rHuEPO similar to those founo
with intravenous rather than subcutaneous administration (36.
45). However, because 80% of endothelin-l derived from the
vascular endothelial cell is released towards the vascular smooth
muscle (46), an unaltered plasma concentration of endothelin with
rHuEPO treatment does not exclude increased local vascular
production [47]. Increased generation of endothelin-1 might
contribute to the increasing vascular responsiveness to norepi¬
nephrine because low concentrations of endothelin-l have been
shown in organ bath experiments to potentiate contractions to
norepinephrine [48],
Plasma endothelin did not correlate with the increase in
hemoglobin, arterial pressure or total peripheral resistance, but
did correlate with plasma urea, creatinine and the number of
hours dialyzed per week. These associations are probably multi¬
factorial in origin, involving such variables as protein and carbo¬
hydrate intake, body mass, the catabolic/anaboiic state and clear¬
ance of urea and creatinine by dialysis. How these indices of
protein metabolism relate to the concentration of endothelin-l is
at present unclear.
In conclusion, this study has demonstrated that rHuEPO in¬
creases blood pressure, and corrects the anemia and the impairea
vascular responsiveness to norepinephrine, in hemodialysis pa¬
tients. In contrast, there was a trend for responsiveness to
endothelin-I to be reduced by rHuEPO, and responsiveness to
endothelin-l correlated inversely with the changes in artenai
pressure. The mechanisms underlying the changes in vascular
responsiveness to norepinephrine and endothelin-1 with rHuEPC
treatment merit further investigation in studies using selective
antagonists at adrenergic and endothelin receptors [23].
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Inhibition of Neutral Endopeptidase Causes Vasoconstriction
of Human Resistance Vessels In Vivo
Charles J. Ferro, BSc, MRCP; James C. Spratt, BSc, MRCP;
William G. Haynes, MD, MRCP; David J. Webb, MD, FRCP
Background—Neutral endopeptidase (NEP) degrades vasoactive peptides, including the natriuretic peptides, angiotensin
II, and endothelin-l. Systemic inhibition of NEP does not consistently lower blood pressure, even though it increases
natriuretic peptide concentrations and causes natriuresis and diuresis. We therefore investigated the direct effects of local
inhibition of NEP on forearm resistance vessel tone.
Methods and Results—Four separate studies were performed, each with 90-minute drug infusions. In the first study, 10
healthy subjects received a brachial artery infusion of the NEP inhibitor candoxatrilat (125 nmol/min), which caused a
slowly progressive forearm vasoconstriction (12±2%; P=0.001). In a second two-phase study, 6 healthy subjects
received, 4 hours after enalapril (20 mg) or placebo, an intra-arterial infusion of the NEP inhibitor thiorphan (30
nmol/min). Thiorphan caused similar degrees of local forearm vasoconstriction (P=0.6) after pretreatment with both
placebo (13±1%, P=0.006) and enalapril (17±6%, P=0.05). In a third three-phase study, 8 healthy subjects received
intra-arterial thiorphan (30 nmol/min), the endothelin ETA antagonist BQ-123 (100 nmol/min), and both combined.
Thiorphan caused local forearm vasoconstriction (13±1%, P=0.0001); BQ-123 caused local vasodilatation (33±3%,
P=0.0001). Combined thiorphan and BQ-123 caused vasodilatation (32±1%, P=0.0001) similar to BQ-123 alone
(P=0.98). In a fourth study, 6 hypertensive patients (blood pressure >160/100 mm Hg) received intra-arterial thiorphan
(30 nmol/min). Thiorphan caused a slowly progressive forearm vasoconstriction (10±2%, P=0.0()01).
Conclusions—Inhibition of local NEP causes vasoconstriction in forearm resistance vessels of both healthy volunteers and
patients with hypertension. The lack of effect of ACE inhibition on the vasoconstriction produced by thiorphan and its
absence during concomitant ETA receptor blockade suggest that it is mediated by endothelin-l and not angiotensin II.
These findings may help to explain the failure of systemic NEP inhibition to lower blood pressure. (Circulation.
1998;97:2323-2330.)
Key Words: natriuretic peptides ■ vasoconstriction ■ endothelin ■ angiotensin II ■ human
Neutral endopeptidase (EC 3.4.24.11, enkephalinase) is aplasma membrane-bound zinc metalloprotease that was
initially isolated from renal epithelial brush border cells and
cleaves peptide substrates at the amino side of hydrophobic
amino acids.' It catalyzes the degradation of a number of
endogenous vasodilator peptides, including ANP,2 brain na¬
triuretic peptide,3 C-type natriuretic peptide,4 substance P,5
and bradykinin,1 as well as vasoconstrictor peptides, includ¬
ing ET-16 and Ang II.' In addition to degrading vasoactive
peptides to inactive breakdown products, NEP can also
convert big ET-1 to the active peptide ET-1.7 Therefore, the
physiological actions of NEP in vivo will be the balance of its
effects on the breakdown of vasodilators and vasoconstrictors
and on the synthesis of ET-1 from big ET-1 (Figure 1).
NEP is inhibited by several agents, including candox¬
atrilat8; thiorphan9 and its prodrug, sinorphan10; and phos-
phoramidon.1 ANP has potent natriuretic" and vasodilator
properties1213 and inhibits activity of the renin-angioten-
sin-aldosterone system by reducing both renin14 and aldo¬
sterone15 release. Therefore, increasing the circulating
concentrations of ANP through inhibition of NEP is an
attractive therapeutic approach to a number of cardiovas¬
cular diseases such as hypertension and heart failure.16
However, although NEP inhibitors increase circulating
ANP concentrations in humans and cause the expected
natriuresis,10'17"9 they do not generally lower blood pres¬
sure in normotensive subjects.'0 I8'20'2' Indeed, both candox-
atril22 and candoxatrilat23 have been reported as raising
blood pressure in normotensive subjects. Although NEP
inhibitors have been reported to lower blood pressure in
patients with essential hypertension,24-31 this finding has
not been universal.19,32-35 Thus, the therapeutic value of
NEP inhibitors in hypertension remains uncertain. In
patients with heart failure, these agents do not reduce
afterload although they do reduce pulmonary capillary
wedge pressure, presumably because of natriuresis.17'36
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Selected Abbreviations and Acronyms
Ang II = angiotensin II
ANP = atrial natriuretic peptide
CV = coefficient of variation
ET = endothelin
ETA = endothelin receptor A
NEP = neutral endopeptidase
We hypothesized that if the predominant substrates for
vascular NEP were vasodilator peptides, then local inhibition
of this enzyme should cause peripheral vasodilatation. How¬
ever, in previous studies using brachial artery administration
of the NEP inhibitor thiorphan, we observed a modest
vasoconstriction,37,38 suggesting accumulation of vasocon¬
strictor peptides such as Ang II or ET-1. Therefore, in the
present study, we examined the effects of brachial artery
administration of a structurally different NEP inhibitor, can-
doxatrilat, on forearm blood flow to determine whether the
vasoconstriction produced by thiorphan is a class effect of
NEP inhibitors. We also investigated whether an accumula¬
tion of Ang II was the cause of the forearm vasoconstriction
produced by thiorphan by infusing thiorphan into the brachial
artery in the presence or absence of concurrent systemic ACE
inhibition. Furthermore, we investigated whether accumula¬
tion of ET-1 was the cause of the forearm vasoconstriction in
response to thiorphan by coinfusing an ETA antagonist,
BQ-123, together with thiorphan. We also examined the
effects of brachial artery administration of thiorphan in a
group of hypertensive patients to confirm the clinical rele¬
vance of our findings in healthy subjects.
Methods
Subjects
Twenty-four healthy male subjects and 6 hypertensive male patients
(mean age, 45 ±3 years; 24-hour ambulatory mean arterial pressure,
116±3 mm Hg) who had not yet received any treatment participated
in these studies, which were conducted with the approval of the local
ethics committee and with the written informed consent of each
subject. None of the subjects received vasoactive or nonsteroidal
anti-inflammatory drugs in the week before each phase of the study,
and all abstained from alcohol for 24 hours and from food,
caffeine-containing drinks, and cigarettes for at least 3 hours before
any measurements were made. All studies were performed in a quiet
room maintained at a constant temperature of between 22°C
and 25°C.
Drugs
Candoxatrilat (Pfizer) and thiorphan (Sigma) were administered
intra-arterially dissolved in physiological saline (0.9%; Baxter
Healthcare Ltd). We used ( + )candoxatrilat (UK-73,967) in this
study; this eutomer has twice the potency as an NEP inhibitor than
the racemate, (i)candoxatrilat (UK-69,578),19 and is the active
metabolite of the orally available prodrug candoxatril. The dose of
candoxatrilat (125 nmol/min) was chosen to achieve forearm blood
concentrations >5()-fold higher than the 1CMI (40 nmol/L) of (+ )can-
doxatrilat in vitro." The dose of thiorphan (30 nmol/min) used in this
study has been shown to produce =20% reduction in forearm blood
Bow when infused via the brachial artery." This dose is known to
achieve local concentrations in forearm blood after brachial artery
administration, > 10-fold higher than the IC\> of thiorphan (35
nmol/L) for NEP in vitro."
VASODILATATION
VASOCONSTRICTION
Figure 1. NEP catalyzes the metabolism of the vasoconstrictor
peptides ET-1 and Ang II, as well as the metabolism of several
vasodilator peptides, including bradykinin (BK), ANP, brain and
C-type natriuretic peptides (BNP and CNP, respectively), and
substance P (SP). NEP is also involved in the enzymatic conver¬
sion of big ET-1 to its active form, the vasoconstrictor peptide
ET-1. The balance of effects of NEP inhibition on vascular tone,
therefore, will depend on whether the predominant substrate(s)
degraded by NEP are vasodilators or vasoconstrictors and on
the extent of NEP involvement in the processing of big ET-1.
The peptide ETA antagonist BQ-123 (Cyclo[—D-Asp—L-Pro—
d-Val—L-Leu—D-Trp—]; American Peptide Co) was administered
intra-arterially (100 nmol/min) dissolved in physiological saline.
This dose achieves local concentrations in the forearm > 10-fold
higher than the Pa2 at the ETA receptor and is known to produce
=40% increase in blood flow when infused via the brachial artery."
The ACE inhibitor enalapril (Merck, Sharp & Dohme Ltd) was
administered orally in ascending, single, daily doses of 2.5, 5, 10,
and 15 mg over a period of 4 days. This ascending dose design was
used to minimize the already low risk of hypotension. On the fifth
day, subjects were admitted to the clinical research center and, after
lying supine for 30 minutes, received 20 mg enalapril orally at 8:30
am. The final dose of 20 mg was chosen because it reduces plasma
concentrations of Ang 11 to a level close to the detection limit of
radioimmunoassay 4 hours after administration.40
Intra-arterial Administration
The left brachial artery was cannulated under local anesthesia (1%
lidocaine) with a 27-standard wire gauge needle attached to a
16-gauge epidural catheter. Patency was maintained by infusion of
physiological saline via a Welmed PI000 syringe pump. The total
rate of intra-arterial infusion was maintained constant throughout at
1 mL/min. In all studies, physiological saline was infused for 30
minutes before infusion of vasoactive agents.
Measurements
Forearm Blood Flow
Blood flow was measured in both forearms by venous occlusion
plethysmography41 by use of indium/gallium-in-Silastic gauges as
previously described.17 Recordings of forearm blood flow were made
repeatedly over 3-minute periods. Voltage output from a dual-
channel Vasculab SPG 16 strain-gauge plethysmograph (Medason-
ics, Inc) was transferred to a Macintosh personal computer by use of
a MacLab analogue digital converter and Chart software (AD
Instruments). Calibration was achieved by use of the internal
standard of the Vasculab plethysmography units. In all studies,
forearm blood flow was recorded in both arms every 5 minutes
during infusion of the study agents.
Blood Pressure
A well-validated semiautomated noninvasive oscillometry sphyg¬
momanometer (Takeda UA 751) was used to make duplicate
measurements of blood pressure in the noninfused arm, which were
then averaged.41 In all studies, blood pressure was measured at
l()-minute intervals during infusion of the study agents.
Plasma Assays
Venous blood samples (40 mL) were obtained at intervals for assay
of concentrations of plasma active renin. Ang II. aldosterone, ANP,
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and ET from both arms. This technique of bilateral venous sampling,
from deep veins in the antecubital fossae and with intra-brachial
artery infusion of locally active agents, has been reported previous¬
ly.4' Samples were collected into chilled tubes, centrifuged at 15()0g
for 20 minutes at 4°C, and stored at —80°C until assay. Samples for
renin were collected into tubes coated with potassium EDTA, and
plasma active renin concentration was measured by an antibody
trapping technique.44 The intra-assay CV for this assay is 3.4%.
Samples for Ang II were collected into plain tubes containing
potassium EDTA/o-phenanthroline, and plasma concentration of
Ang II was measured by radioimmunoassay.45 The intra-assay CV is
10%. Venous blood samples for plasma aldosterone concentrations
were collected into lithium heparin tubes, and plasma aldosterone
was measured by use of a solid-phase (coated tube) radioimmuno¬
assay with a commercially available kit (Diagnostic Products UK
Ltd). The intra-assay CV is <8.3%. Samples for ANP were collected
into EDTA/trasylol tubes, and plasma ANP concentration was
measured by radioimmunoassay.46 The intra-assay CV is 3.9%.
Samples for ET assay were collected into tubes coated with EDTA,
and plasma ET was assayed with a commercially available kit
(Endothelin-1 Radioimmunoassay, Peninsula Laboratories) as previ¬
ously described,41 except samples were extracted with acetic acid.48
This method gives an extraction recovery of ET-1 of 89%. The
intra-assay CV is <6%, and the cross-reactivities of this assay with
ET-1, ET-2, ET-3, and big ET-1 are 100%, 7%, 7%, and 10%,
respectively. All assays were done in single batches.
Study Design
Four single-blind studies were performed.
Protocol 1: Intra-arterial Candoxatrilat
Ten subjects participated in this single-phase, single-blind study.
Candoxatrilat (125 nmol/min) was infused for 90 minutes.
Protocol 2: Intra-arterial Thiorphan and Systemic
ACE Inhibition
Six subjects participated in this two-phase, single-blind, crossover
study. In each phase, subjects were administered orally either
increasing single daily doses of enalapril (as detailed above) or
matching placebo. On the fifth day, subjects were admitted to the
clinical research center at 8:00 am, and deep veins in both antecubital
fossae were cannulated with 18-gauge intravenous cannulas for
blood sampling. After the subject lay recumbent for 30 minutes (8-30
am), a venous blood sample was taken from the right (noninfused)
arm for assays of renin, Ang II. aldosterone, ANP, and ET concen¬
trations. Blood pressure was measured, and enalapril 20 mg or
placebo was administered at 8:30 am. Blood pressure was then
measured at 30-minute intervals for 3.5 hours with the subjects
remaining recumbent. At midday, physiological saline was infused
via the left brachial artery for 30 minutes. At 12:30 i'm, thiorphan (30
nmol/min) was infused for 90 minutes, 4 hours after administration
of the final dose of enalapril or placebo. Before the start of the
thiorphan infusion, a venous blood sample was taken for aldosterone,
renin, and clinical biochemistry from the right (noninfused) arm.
Blood samples were also taken from both arms at the beginning and
end of the period of thiorphan infusion for measurement of plasma
Ang II, ANP, and ET concentrations.
Protocol 3: Intra-arterial Thiorphan and
Intra-arterial BQ-123
Eight subjects participated in this randomized three-phase, single-blind
study. In random order and on separate occasions at least I week apart,
either thiorphan (30 nmol/min) or BQ-123 (1 (X) nmol/min) alone or both
in combination was infused for 90 minutes.
Protocol 4: Intra-arterial Thiorphan in
Hypertensive Patients
Six hypertensive patients participated in this single-phase, single-
blind study. Thiorphan (30 nmol/min) was infused for 90 minutes.
Candoxatrilat (125 nmol/min)
I 1 1 1 1
-30 0 30 60 90
Time (min)
Figure 2. Effect of brachial artery administration of candoxatrilat
(125 nmol/min) on forearm blood flow in 10 healthy, male volun¬
teers. Candoxatrilat produced a slowly progressive vasocon¬
striction confined to the infused forearm (P=0.001).
Data Analysis and Statistics
Plethysmography data listings were extracted from the Chart data
files, and forearm blood flows were calculated for individual venous
occlusion cuff inflations. Because flow stabilizes only after 60
seconds of wrist cuff inflation,4'' recordings made in the first 60
seconds were not used for analysis. The last five flow recordings in
each measurement period were calculated and averaged for the
infused and noninfused arms. To reduce the variability of blood flow
data, the ratio of flows in the two arms was calculated for each time
point, in effect using the noninfused arm as a contemporaneous
control for the infused arm.4' Forearm blood flow results are shown
as a percentage change from basal in the ratio of blood flow between
the infused and noninfused arm.
Data are shown as mean±SEM in the figures and as mean±SEM
with 95% confidence intervals in the tables. Forearm blood flows
were examined by repeated-measures ANOVA with Statview 5124
software (Brainpower Inc, USA). The overall forearm blood flow
responses are described in the text as the area under the curve51' and
as individual maximum responses. Hemodynamic and assay mca
sures were analyzed by ANOVA and Student's t test as appropriate.51
Results
Protocol 1: Intra-arterial Candoxatrilat
Brachial artery infusion of candoxatrilat did not alter systolic,
diastolic, or mean arterial pressure (86±2 to 90±2 mm Hg)
or heart rate (63±3 to 64±3 bpm). Also, blood How in the
noninfused arm did not alter significantly after infusion of
candoxatrilat. confirming that drug effects were confined to
the infused arm. Brachial artery infusion of candoxatrilat
caused a slowly progressive forearm vasoconstriction, with
blood flow decreasing by a mean (area under the curve) of
12±2% and maximum of —28±3% (P=0.001; Figure 2)
during the 90-minute infusion.
Protocol 2: Intra-arterial Thiorphan and Systemic
ACE Inhibition
There were no significant differences between plasma urea,
electrolytes, and creatinine concentrations at the start of the
thiorphan infusion during the placebo and enalapril phases.
Heart rate and mean arterial pressure were not significantly
different at the start of thiorphan infusion in either phase and
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TABLE I. Head Rale, Blood Pressure, Plasma Active Renin, and Aldosterone Concentrations Before (8:30 am, Basal) and
4 Hours After (12:30 pm) Oral Administration of Placebo or Enalapril 20 mg
Placebo Phase Time Enalapril Phase Time
8:30 am 12:30 PM 8:30 AM 12:30 PM
Heart rate, bpm 58 ±3 (51-65) 57±3 (47-63) 56±3 (49-63) 61 ±3 (52-69)
Systolic blood pressure, mm Hg 126±6 (110-141) 130±6 (113-146) 124 ±7 (104-142) 124 ±7 (104-142)
Diastolic blood pressure, mm Hg 63 ±2 (57-69) 69 ±5 (55-84) 57 ±2 (51-62) 65 ±2 (59-71)
Mean arterial pressure, mm Hg 84 ±3 (75-92) 89 ±5 (55-84) 79±3 (70-87) 85±4 (75-94)
Plasma active renin, p.U/mL 22±4 (12-25) 19±2 (12-25) 75±9f (52-99) 136±12*4 (106-166)
Aldosterone concentration, ng/mL 15.8±2.5 (8.9-21.9) 11.4 ±1.3 (8.0-14.9) 12.3±1.5f (8.3-16.1) 6.9±0.7*f (5.0-8.8)
Values are mean±SEM. Values in parentheses are 95% confidence intervals.
*Ps0.05 vs basal (8:30 am); tPsO.05 vs placebo phase; tP<0.005 vs placebo phase.
did not change during the intra-arterial infusion of thiorphan
in either phase (Table 1).
Plasma active renin concentrations were higher after 4 days
of treatment with enalapril than with placebo. Plasma active
renin concentration increased further 4 hours after adminis¬
tration of 20 mg enalapril, with no change during the placebo
phase (Table 1). Plasma Ang II concentration tended to be
lower after 4 days of enalapril, although this difference
between phases did not reach statistical significance
(P=0.09; Table 2). Plasma Ang II concentrations did not
change significantly during the placebo phase in either the
infused or noninfused arm. Four hours after administration of
20 mg enalapril, there was a substantial reduction in plasma
Ang II concentration (Table 2). Plasma Ang II concentration
did not change further during the 90-minute thiorphan infu¬
sion in the enalapril phase in either the infused or noninfused
arm (Table 2). Venous aldosterone concentration was lower
after 4 days of enalapril than after 4 days of placebo (Table
2). During both phases, aldosterone concentration tended to
decrease after 4 hours of supine posture. However, this
decrease was significant only after 20 mg enalapril compared
with basal (Table 2).
Neither oral enalapril nor intra-arterial thiorphan had any
effect on plasma ANP or plasma ET concentrations in either
the infused or noninfused arm (Table 2).
Basal forearm blood flow in the infused arm tended to be
lower during the enalapril phase than the placebo phase,
although this was not statistically significant (2.9±0.4 and
TABLE 2. Plasma ANP, Ang II, and ET Concentrations Taken From the Infused
and Noninfused Arms Before (Basal, 8:30 am) and 4 Hours After (12:30 pm) Oral
Administration of Enalapril 20 mg and After 90-Minute Intra-arterial Infusion of
Thiorphan 30 nmol/min (2:00 pm; 5.5 Hours After Enalapril 20 mg Orally)
Arm
ouncerurauori,
mg/mL Phase Time Noninfused Infused
ANP Placebo 8:30 am 13.0 ±3.4 (4.4-21.7) NA
12:30 pm 14.8±3.6 (4.7-24.9) 21.5±7.9 (1.2-41.8)
2:00 pm 21.8+ 5.5 (7.8-35.8) 18.6±3.6 (9.3-28.0)
Enalapril 8:30 am 15.2 ± 2.3 (9.2-21.1) NA
12:30 pm 13.0 ± 3.1 (5.0-21.0) 17.1 ±3.1 (9.2-25.0)
2:00 pm 17.2±2.6 (10.6-23.8) 21.5±5.3 (7.9-35.0)
Ang II Placebo 8:30 am 12.7±2.5 (6.2-19.2) NA
12:30 pm 12.6 ±2.6 (6.0-19.1) 10.0±1.9 (5.2-14.8)
2:00 pm 7.8 ±1.8 (3.4-12.2) 8.2±3.3 (4.7-11.7)
Enalapril 8:30 am 7.4±1.2 (4.2-10.6) NA
12:30 pm 1.7±0.3*f (0.8-2.5) 1.6±0.4*f (0.6-2.7)
2:00 pm 1.5±0.4*f (0.5-2.6) 1.5±0.4*f (0.6-2.4)
ET Placebo 8:30 am 3.8±0.3 (3.0-4.6) NA
12:30 pm 3.7±0.4 (2.6-4.6) 4.3±0.3 (3.6-4.9)
2:00 pm 4.3±0.5 (2.9-5.7) 3.6±0.5 (2.3-4.1)
Enalapril 8:30 am 4.1 ±0.2 (3.5-4.7) NA
12:30 pm 3.8±0.2 (3.3-4.4) 3.9±0.4 (3.7-4.6)
2:00 pm 4.5±0.8 (2.8-5.1) 3.4 ±0.5 (2.2-4.7)
Values are mean±SEM. Values in parentheses are 95% confidence intervals.
*A=0.05 vs basal (8:30 am); fPsO.005 vs placebo.
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Thiorphan (30 nmol/min)
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Figure 3. Effect of brachial artery administration of thiorphan
(30 nmol/min) on forearm blood flow after oral placebo (O) or
oral enalapril (•) in six healthy, male volunteers. Thiorphan pro¬
duced a slowly progressive vasoconstriction during both the
placebo (P=0.05) and enalapril (P=0.01) phases, with no signifi¬
cant difference between the two phases (P=0.6).
3.7±0.4 mL • 100 mL• min"1, respectively; P=0.12).
Blood flow in the noninfused arm did not change signifi¬
cantly after infusion of thiorphan, confirming that drug
effects were confined to the infused arm. Brachial artery
administration of thiorphan caused a slowly progressive
forearm vasoconstriction, with blood flow decreasing during
both the enalapril phase (mean, 17±6%; maximum, 33±7%;
P=0.05) and placebo phase (mean, 13±3%; maximum,
24±2%; P=0.006). The reductions in blood flow were
similar during either phase (P=0.6; Figure 3).
Protocol 3: Intra-arterial Thiorphan and
Intra-arterial BQ-123
Brachial artery administration of BQ-123 alone caused a
progressive forearm vasodilatation (mean, 33±3%; maxi¬
mum, 47±9%; P=0.0001), whereas thiorphan caused a
slowly progressive vasoconstriction (mean, -14±1%; max¬
imum, -22±4%; P=0.0001). Coinfusion of BQ-123 and
thiorphan caused a vasodilatation (mean, 32±2%; maximum,
48±6%; P=0.0001) that was not different from that observed
with BQ-123 alone (P=0.98; Figure 4).
Protocol 4: Intra-arterial Thiorphan in
Hypertensive Patients
In hypertensive patients, brachial artery administration of
thiorphan caused a slowly progressive forearm vasoconstric¬
tion (mean, —10±2%; maximum, — 20±3%; P=0.()()01).
This was not significantly different from that observed in the
healthy volunteers in the third study (P=0.39; Figure 5).
Discussion
We have shown that the specific NEP inhibitors candoxatrilat
and thiorphan cause slowly progressive vasoconstriction
when given by direct brachial artery infusion to healthy
subjects and patients with essential hypertension. The vaso¬
constriction caused by thiorphan was not reversed by sys¬
temic ACE inhibition but was abolished by ET receptor
Time (min)
Figure 4. Effect of brachial artery administration of thiorphan (□,
30 nmol/min) and BQ-123 (O, 100 nmol/min) and coinfusion of
both agents (•) on forearm blood flow. Thiorphan produced a
slowly progressive vasoconstriction (P=0.0001), whereas
BQ-123 caused a slowly progressive vasodilatation (P=0.0001).
Coinfusion of BQ-123 and thiorphan produced a vasodilatation
(P=0.0001) not significantly different from that produced by
BQ-123 alone (P=0.98).
antagonism. Our findings are unlikely to be due to other
actions of these agents because both candoxatrilat8,917 and
thiorphan52" are highly specific for NEP. Furthermore, the
finding that two structurally independent inhibitors of NEP
produce vasoconstriction strongly suggests that this is a class
effect of NEP inhibition on human resistance vessels. It is
possible that different effects may be obtained in other blood
vessels, although responses in forearm resistance vessels are
generally thought to be broadly representative of those in
other vascular beds.41,54 Our findings have potential implica¬
tions both for the physiological role of NEP and for the
therapeutic use of NEP inhibitors.
Although it was initially thought that the most important
site of natriuretic peptide metabolism by NEP was the
kidney,2 candoxatrilat is just as effective in reducing clear-
-30 0 30 60 90
Time (min)
Figure 5. Effect of brachial artery administration of the NEP in¬
hibitor thiorphan (30 nmol/min) on forearm blood flow in six
hypertensive patients. Thiorphan produced a slowly progressive
vasoconstriction confined to the infused forearm (P 0.0001).
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ance of ANP in nephrectomized animals,5' implying other,
nonrenal sites of action. NEP is now known to be expressed
in blood vessels by both endothelial56 and vascular smooth
muscle cells.57 Despite the clear evidence for vascular gener¬
ation and metabolism of natriuretic peptides, we found that
local NEP inhibitors caused vasoconstriction rather than
vasodilatation. This finding implies that under physiological
conditions, vasoconstrictor peptides, such as Ang II and
ET-I, are more important substrates for vascular NEP than
dilator substances, such as the natriuretic peptides and bra-
dykinin (Figure 1). However, our finding that brachial artery
administration of thiorphan produces forearm vasoconstric¬
tion in the presence of substantial systemic ACE inhibition
implies that Ang II accumulation is not responsible for the
observed vasoconstriction. In addition, ANP blocks activity
of the renin-angiotensin system by reducing renin release14
and blocking aldosterone secretion,15 so Ang II generation is
likely to be decreased by NEP inhibition.
The vasoconstriction to candoxatrilat and thiorphan was
slowly progressive, which is more in keeping with an effect
of ET-1 than Ang II, on the basis of the known rate of onset
of forearm vasoconstriction after brachial artery infusion of
these peptides.58 This is supported by a recent study in which
systemic oral doses of candoxatril in healthy men produced
an increase in both systolic blood pressure and venous plasma
ET concentration.22 In another recent study, systemic admin¬
istration of candoxatrilat in healthy subjects produced a
significant increase in systolic blood pressure.23 However,
because this rise was prevented by pretreatment with enala-
pril, it was suggested that the increase in blood pressure was
caused by potentiation of Ang II. Our findings do not support
this conclusion. Indeed, in our study, thiorphan produced
arterial vasoconstriction in the presence of systemic ACE
inhibition despite the very low Ang II concentrations. Fur¬
thermore, we did not detect any increase in Ang II concen¬
trations in venous blood draining the infused arm during the
placebo phase of our study, suggesting that NEP inhibition
does not cause an accumulation of Ang II.
We did not demonstrate a significant decrease in blood
pressure after 20 mg enalapril orally despite the very low
concentrations of Ang II produced. However, our study was
not designed to specifically measure changes in systemic
hemodynamics. The hypotensive effect of enalapril would be
expected to have been greatest when subjects were being
prepared for the intra-arterial stage of the study. This in¬
volved subjects standing to pass urine and having the blood
pressure cuff repositioned over the rapid inflation cuffs
required for forearm plethysmography, as well as insertion of
an intra-arterial needle.
In this study, enalapril had no effects on plasma ANP
concentrations. This is in agreement with other published
reports.23'59,60 Intra-arterial thiorphan did not produce a detect¬
able increase in ANP concentrations in venous blood draining
the infused arm. However, any changes in local ANP con¬
centrations are likely to be small and may have been below
the sensitivity of the assay. In addition, not all studies of acute
NEP inhibition have demonstrated an increase in ANP
concentrations.21'2215 ANP may also be metabolized by an
aminopcptidase, which is insensitive to thiorphan.''1 Although
incomplete local NEP inhibition is possible, it is highly
unlikely because the doses of both eandoxatrilat and thior¬
phan used were chosen to achieve local blood concentrations
in the forearm >50-fold and > 10-fold higher than the 1C5(I of
(-l-)candoxatrilat and thiorphan, respectively, for ANP in
vitro.39
Consistent with earlier work,''2 systemic ACE inhibition
with enalapril had no effect on plasma ET concentrations. In
addition, intra-arterial thiorphan did not increase plasma ET
concentrations in samples collected from the infused arm.
However, ET produced by endothelial cells is preferentially
secreted abluminally,63 and inhibition of local ET degradation
may not have resulted in increased plasma ET concentrations.
Furthermore, any measurable increase in plasma ET concen¬
trations is likely to be rapidly reduced through tissue receptor
binding.43 Therefore, the absence of any detectable increase in
plasma ET does not exclude local accumulation of the
peptide, and it is still possible that decreased ET-1 breakdown
is the cause of the vasoconstriction produced by NEP
inhibitors.
ET-1 mediates vasoconstriction primarily by effects on
the vascular smooth muscle ETA receptor.64 We find that the
selective ETA receptor antagonist BQ-123 abolishes the
vasoconstriction produced by thiorphan. This provides strong
evidence that accumulation of ET-1, resulting from an inhi¬
bition of its degradation, mediates the vasoconstriction
caused by local NEP inhibition. Nevertheless, it is also
possible that accumulation of an as-yet undiscovered vaso¬
constrictor may contribute to the observed vasoconstriction,
although its abolition by BQ-123 makes this unlikely.
In clinical trials, NEP inhibitors have been shown to cause
a natriuresis and diuresis.1017 However, a reduction in blood
pressure has not been clearly demonstrated in normotensive
subjects,1018'20'21 and two studies have even reported an in¬
crease in blood pressure22,23 despite the potent vasodilator
actions of the natriuretic peptides.'213,16 Also, several studies
on hypertensive patients19,32 35 have not demonstrated a reduc¬
tion in blood pressure. Interestingly, and perhaps relevant to
our own findings, a recent study in patients with chronic heart
failure showed that candoxatril increases systemic vasocon¬
striction and decreases cardiac index.65 Our results help to
explain these apparent contradictions. The hemodynamic
effects of systemic NEP inhibition will depend on the balance
between its cardiac, renal, and vascular actions. We have
shown that local NEP inhibition causes forearm vasoconstric¬
tion in healthy subjects and, of greater clinical relevance, that
this effect occurs in untreated essential hypertensive patients.
Thus, peripheral vasoconstriction may play an important role
in counteracting the antihypertensive actions of NEP
inhibition.
Our study shows that the vasoconstriction produced by
NEP inhibitors may be mediated by ET-1 or other vasocon¬
strictor peptides. Given that systemic NEP inhibition has been
shown to increase venous ET concentrations,22 it is possible
that the combination of NEP inhibition and ET antagonism
may be useful therapeutically. Indeed, phosphoramidon, a
combined ET-converting enzyme and NEP inhibitor, is
known to produce substantia] vasodilatation when infused
intra-arterially in humans3718 and can lower blood pressure in
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normotensive and hypertensive rats." Nevertheless, even
without redueing blood pressure, NEP inhibition may offer
therapeutic benefits in hypertension and heart failure. For
example, infusion of ANP causes sympathoinhibition in
humans.22 In addition, NEP inhibitors appear to possess
favorable antimitogenic effects in models of left ventricular
hypertrophy66 and atherosclerosis.67 Such effects would need
to be counterbalanced against potential mitogenic actions of
ET-1,68
In conclusion, local inhibition of NEP causes slowly
progressive vasoconstriction in healthy subjects and essential
hypertensive patients, suggesting that the predominant phys¬
iological substrates for vascular NEP are vasoconstrictor
peptides. The slowly progressive nature of the vasoconstric¬
tion, together with the finding that it is not blocked by
systemic ACE inhibition but is abolished by ET antagonism,
supports accumulation of ET-1 as the cause. Vasoconstriction
produced by NEP inhibitors may help to explain some of the
apparently contradictory hemodynamic results obtained after
systemic dosing with NEP inhibitors.
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Reduced endogenous endothelin-l-mediated vascular tone in
chronic renal failure.
Background. Endothelin-1 generated by the vascular endo¬
thelium contributes to basal vascular tone and blood pressure
in healthy humans. Plasma concentrations of endothelin-1,
which are elevated in chronic renal failure (CRF), may contrib¬
ute to increased vascular tone.
Methods. We investigated the contribution of endogenous
and exogenous endothelin-1 to the maintenance of vascular
tone in patients with CRF (creatinine > 200 pmol/liter) and
in age- and sex-matched healthy subjects. In a series of experi¬
ments, we measured forearm vascular responses to intra-arterial
norepinephrine (30 to 240 pmol/min), endothelin-1 (5 pmol/min),
the selective endothelin A (ETA) receptor antagonist BQ-123
(3 mg/hr), the mixed endothelin-converting enzyme and neutral
endopeptidase inhibitor phosphoramidon (30 nmol/min), and
the selective neutral endopeptidase inhibitor thiorphan (30
nmol/min).
Results. The maximum reduction in forearm blood flow
(FBF) to norepinephrine in CRF (33 ± 7%) was similar to that
in controls (43 ± 7%, P = 0.53). Endothelin-1 also produced
a similar reduction in FBF in CRF (35 ± 6%) and controls
(36 ± 5%, P = 0.81). BQ-123 increased FBF in CRF (11 ±
4%) but significantly less than in controls (44 ± 10%, P =
0.02). Phosphoramidon increased FBF in CRF (68 ± 20%),
again significantly less than in controls (181 ± 41%, P = 0.001).
Thiorphan reduced FBF similarly in CRF (22 ± 6%) and con¬
trols (14 ± 6%, P = 0.39). Responses to phosphoramidon were
substantially greater than to BQ-123.
Conclusions. These studies show that endogenous genera¬
tion of endothelin-1 contributes to the maintenance of resting
vascular tone in patients with CRF, as well as in healthy subjects.
Although the contribution of endogenous endothelin-1 to resting
vascular tone appears to be reduced in CRF, ETA receptor
antagonism, and particularly endothelin-converting enzyme in¬
hibition, should be explored as means by which to reduce
vascular tone and blood pressure in patients with CRF.
Key words: endothelin receptors, BQ-123, blood pressure, vasocon¬
striction, hypertension, renal failure.
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Endothelin-1 is an endothelium-derived 21 -amino acid
peptide with sustained vasoconstrictor properties [1], En-
dothelin-1 is generated from an inactive 38-amino acid
precursor, big endothelin-1, through the action of endo¬
thelin-converting enzyme (ECE), a unique membrane-
bound neutral metalloprotease [2). Endothelin-1 binds
to at least two receptors [3]: The endothelin A (ETA)
receptor is present on vascular smooth muscle cells in
which it plays a major role in causing vasoconstriction
[4]; the ETB receptor is present on endothelial cells in
which it mediates release of endothelium-derived vasodi¬
lator substances [5], and also on vascular smooth muscle
cells in which it mediates vasoconstriction [6]. Endoge¬
nous generation of endothelin-1 has been shown to con¬
tribute to the maintenance of basal vascular tone [4] and
blood pressure [7] in healthy humans.
Plasma concentrations of immunoreactive big endo¬
thelin-1 and endothelin-1 are elevated in renal failure
[8, 9]. Because these high plasma endothelin concentra¬
tions may be within a range sufficient to cause vasocon¬
striction [10], plasma endothelin-1 may play a role in the
development, or maintenance, of hypertension in chronic
renal failure (CRF). Indeed, plasma endothelin concen¬
trations are positively correlated with blood pressure in
hemodialysis patients [11]. This contrasts to findings in
patients with mild to moderate essential hypertension in
whom no such relationship was found [12]. However, it is
not known whether endothelin-1 contributes to elevated
basal resistance vessel tone in patients with CRF.
Therefore, we have investigated the responses of fore¬
arm resistance vessels to brachial artery infusion of endo¬
thelin-1 and a control constrictor, norepinephrine, in pa¬
tients with stable CRF who were independent of dialysis
and in healthy age- and sex-matched control subjects.
We also examined the contribution of endothelin-1 acting
via the ETA receptor to basal vascular tone by brachial
artery infusion of a maximally effective dose [13, 14] of
the specific ETA receptor antagonist, BQ-123 [4, 15]. We
further examined the contribution of endogenous gener¬
ation of endothelin-1 to the maintenance of forearm vas-
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cular tone by comparing responses to brachial artery infu¬
sion of the combined ECE and neutral endopeptidase
(NEP) inhibitor, phosphoramidon [4, 16, 17], with those
to the selective NEP inhibitor, thiorphan [4, 17],
METHODS
Subjects
A total of 11 patients (10 male, 1 female) with estab¬
lished chronic renal disease (creatinine s 200 pmol/liter
and stable blood pressure for 6 months or more) caused by
IgA nephropathy (N = 3), obstructive uropathy (N = 2),
reflux nephropathy (N = 2), nephrosclerosis (N = 2),
interstitial nephritis (/V = 1), and Alport's syndrome
(/V = 1) were recruited. All patients were independent
of dialysis. Three subjects underwent all of the study
protocols. Five subjects underwent the protocols involv¬
ing infusion of norepinephrine, endothelin-1, and BQ-123
only, and three subjects underwent infusion of phos¬
phoramidon and thiorphan only. If patients were taking
antihypertensive or other vasoactive medication, this was
withdrawn at least one week before each study. Ten age-
and sex-matched healthy control subjects (nine male, one
female) who were not taking any vasoactive medication
were also recruited, of whom four undertook all the study
protocols, and four the protocols involving infusion of
norepinephrine, endothelin-1, and BQ-123 only. Two sub¬
jects underwent infusion of phosphoramidon and thior¬
phan only. All studies were conducted with the approval
of the local ethics review committee, and all subjects gave
their written informed consent to participate. Subjects
avoided nonsteroidal anti-inflammatory drugs for the
week before and caffeine-containing drinks or cigarettes
on the day of each study. In addition, subjects fasted for
at least three hours before each study.
Procedures
A 21 SWG cannula was inserted into a vein on the
dominant arm under local anesthesia using 1% lidocaine
hydrochloride (Lidocaine; Astra Pharmaceuticals Ltd.,
Kings Langley, UK) for the purpose of sampling blood.
A 27 SWG steel cannula (Cooper's Needle Works, Bir¬
mingham, UK) was inserted into the brachial artery of
the nondominant arm, under local anesthesia, for the
purpose of intra-arterial infusion of drugs. Forearm blood
(low (FBF) was measured in both arms using venous
occlusion plethysmography [18] adapted for use with
indium-and-gallium-in-silastic strain gauges [4], Mea¬
surements were made for 10 seconds in every 15 seconds
over a three-minute period. Blood flow to the hands was
excluded during each three-minute measurement period.
Arterial pressure was measured using a well-validated
semiautomated oscillometric method (Takeda UA 751;
Takeda, Tokyo, Japan) [19, 20].
Drugs
Norepinephrine (30,60,120, and 240 pmol/min; Sanofi
Winthrop Ltd., Guildford, UK), endothelin-1 (5 pmol/
min; Clinalfa, Laufelfingen, Switzerland), BQ-123 (3 mg/
hr; American Peptide Company, Sunnyvale, CA, USA),
phosphoramidon (30 nmol/min; Clinalfa), thiorphan (30
nmol/min; Sigma Chemicals, Poole Dorset, UK), and
physiologic saline (0.9%; Baxter Healthcare Ltd., Thet-
ford, UK) were administered at locally but not systemi-
cally active doses via the brachial artery cannula. These
doses were based on previous studies [4, 21]. All solu¬
tions were made up in physiologic saline. The norepi¬
nephrine solutions were made up in physiologic saline
containing 100 (xg/ml ascorbic acid (Evans Medical Ltd.,
Dunstable, UK) to avoid oxidation. The total rate of
intra-arterial infusion was kept constant at 1 ml/min.
Design
Studies were performed in a quiet room maintained at
a constant temperature of between 22°C and 25°C. After
brachial artery and venous cannulation, saline was infused
via the brachial artery cannula for 30 minutes, and blood
was withdrawn from the venous cannula to measure
plasma creatinine, endothelin 1, big cndothelin 1, and he
moglobin. In eight patients with CRF and in eight control
subjects, norepinephrine was then infused at incremental
doses (30, 60, 120, and 240 pmol/min, each dose for 6
min) via the brachial artery cannula. After infusion of
norepinephrine, saline was infused for 20 minutes to
allow for the reversal of vasoconstriction. Endothelin-1
was then infused at a single dose of 5 pmol/min for one
hour. FBF was recorded at 10-minute intervals during
infusion of saline and during the last three minutes of
each increment of the norepinephrine infusion and at
10-minute intervals during the endothelin-1 infusion. On
a separate day, after the 30-minute infusion of saline,
BQ-123 was infused in these subjects at a single dose of
3 mg/hr for one hour, and FBF was measured at five-
minute intervals. In a further subgroup of three CRF
patients and seven control subjects, the BQ-123 was in¬
fused at 3 mg/hr and was continued for two hours.
In a separate study in six patients with CRF and in
six control subjects, after a 30-minute infusion of saline,
phosphoramidon or thiorphan was infused, on separate
days, at a single dose of 30 nmol/min for 90 minutes,
and FBF was measured at 10-minute intervals.
In all studies, the mean of the final five blood flow
measurements of each recording period was used for
analysis. Arterial pressure was measured in the nonin-
fused arm immediately after each blood flow recording.
In each subject, infusions were on separate days, at least
one week apart. The order in which the experiments
were undertaken was randomized. However, vasocon¬
striction to endothelin-1 is sustained, whereas that to
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norepinephrine is short lasting. Therefore, in the com¬
bined norepinephrine/endothelin-1 study, it was neces¬
sary to give norepinephrine first rather than randomize
the order of infusions.
Analytical
Venous plasma samples for radioimmunoassay of endo-
thelin-1 and big endotheiin-1 were separated within 10
minutes and were stored at -80°C. Plasma biochemistry
was measured using a Kodak Ectachem System E700 XRC
analyzer (Kodak Diagnostics Ltd., Hemel Hempstead,
Herts., UK) in the Department of Clinical Chemistry,
Western General Hospital (Edinburgh, UK). Hemoglo¬
bin was measured in the Department of Hematology,
Western General Hospital, using a Coulter STKS ana¬
lyzer (Coulter Electronics Ltd., Luton, Beds., UK).
Plasma immunoreactive endothelin-1 and big endothe-
lin-1 concentrations were measured using an acetic acid
extraction technique [22] and a modified commercial ra¬
dioimmunoassay using rabbit antihuman endothelin-1 or
big endothelin-1 (Peninsula Laboratories Europe, St.
Helens, UK) [23], Briefly, sample extract was incubated
with either endothelin-1 or big endothelin-1 antibody for
24 hours at 4°C. Following incubation, 12SI-labeled endo-
thelin-1 (NEN Life Science Products, Boston, MA, USA)
or big endothelin-1 (Peninsula Laboratories Europe) was
added, and incubation was continued for an additional
20 hours at 4°C. Complexes were precipitated with Amer-
lex™ donkey antirabbit antibody (Amersham Life Sci¬
ences Ltd., Little Chalfont, Bucks., UK) and were counted
for radioactivity. All endothelin values were expressed
as picograms permilliliter. Recovery of endothelin-1 and
big endothelin-1 was 89% and 91%, respectively. Intra-
assay and interassay coefficients of variations in our labo¬
ratory are 6.3% and 7.2%, respectively; the sensitivity
of the assay for endothelin-1 was 0.25 pg/ml, and for big
endothelin-1, sensitivity was 1 pg/ml.
Cross-reactivities of the endothelin-1 assay were cndo-
thelin-1 (100%), endothelin-2 (0%), endothelin-3 (0%),
and big endothelin-1 (10%). The cross-reactivities of the
big endothelin-1 assay were endothelin-1 (0%), endo-
thelin-2 (0%), endothelin-3 (0%), and big endothelin-1
(100%).
Data presentation and statistics
Mean arterial pressure was calculated as diastolic arte¬
rial pressure plus one-third pulse pressure. FBF was cal¬
culated in milliliters per 100 ml of forearm tissue per
minute. The ratio of FBF in the infused arm compared
with that in the control arm was calculated for each
measurement period. The ratio of FBF (infusedxontrol
arm) was measured in response to drugs and was ex¬
pressed as a percentage of the ratio (infusedxontrol arm)
measured during the control period [24], This method
uses the noninfused arm as a contemporaneous control
and compensates for the continual small adjustments
affecting the circulation of both arms that occur even at
rest and for other external systemic factors such as the
level of arousal that may otherwise act as confounding
factors [24].
All results are expressed as mean ± sem. Dose-
response relationships were compared using analysis of
variance. All other parameters were analyzed by Stu¬
dent's paired or unpaired r-test as appropriate. Statistical
analysis was performed using the STATVIEW 512+™
software (Brain-power Inc., Calabasas, CA, USA) for
the Apple Macintosh microcomputer. Values of P of less
than 0.05 were considered statistically significant.
RESULTS
There was no significant difference in age, sex, hemo¬
globin, or resting FBF between the patients with CRF
and the healthy control subjects when receiving norepi¬
nephrine, endothelin-1, or BQ-123 (Tables 1 and 2).
However, resting FBF was higher in patients with CRF
who underwent the phosphoramidon/thiorphan studies
compared with control subjects (Table 2). FBF in the
noninfused arm did not change during any infusion pe¬
riod apart from when endothelin-1 and thiorphan was
infused in control subjects (Table 2) when the FBF in
the control arm increased, whereas the blood flow in the
infused forearm decreased. Plasma creatinine and mean
arterial pressure were elevated in the CRF groups when
compared with control subjects (Table 1). The plasma
immunoreactive endothelin-1 concentration was higher
in CRF patients (3.9 ± 0.2 pg/ml, N = 9) than in control
subjects (2.9 ± 0.2 pg/ml, N = 10, P = 0.0001). Similarly,
the plasma immunoreactive big endothelin-1 concentra¬
tion was higher in the CRF patients (43.5 ± 4.0 pg/ml,
N = 9) than in control subjects (31.4 ± 3.5 pg/ml, N =
10, P = 0.03).
Infusion of norepinephrine and endothelin-1
Norepinephrine caused a dose-dependent reduction
in FBF (Fig. 1 and Table 2) with a change in blood flow
at the highest dose of -33 ± 7% in patients with CRF
and —43 ± 7% in control subjects, which was similar
between the two groups (P = 0.53). Saline infusion fol¬
lowing the norepinephrine infusion allowed FBFs to re¬
turn to baseline flows of 2.8 ± 0.3 ml/100 ml/min before
endothelin-1 and 3.1 ± 0.6 ml/100 ml/min before norepi¬
nephrine (P = 0.40) for patients and, similarly, 2.9 ± 0.2
ml/1 (X) ml/min before endothelin-1 and 3.4 ± 0.4 ml/100
ml/min before norepinephrine (P = 0.24) for control
subjects. Endothelin-1 caused a progressive reduction in
FBF (Fig. 2 and Table 2) with a change in blood flow
after 60 minutes of infusion of -35 ± 6% in patients
with CRF and —36 ± 5% in control subjects (P = 0.81).
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Table 1. Subject characteristics
Norepinephrine/
endothelin-1 BO-123 Phosphoramidon Thiorphan
Control CRF Control CRF Control CRF Control CRF
Number 8 8 8 8 6 6 6 6
Age years 46 ± 5 47 ± 6 46 ± 5 47 ± 6 40 ± 8 41 ± 8 £o 1+ OC 41 ± 8
Sex M/F 7/1 7/1 7/1 7/1 6/0 6/0 6/0 6/0
Hemoglobin g/dl 12.7 ± 0.5 11.1 ± 0.8 12.7 0.5 11.1 ± 0.8 13.0 ± 0.6 11.6 ± 0.7 13.0 ± 0.6 11.6 ±0.7
Creatinine fimol/liler 87 ± 5 391 ± 54' 87 -+- 5 391 ± 54' 84 ± 7 449 ± 66' 84 ± 7 449 ± 66'
Mean arterial pressure mm Hf> 88 ± 3 104 ± 2' 85 ± 3 100 ± 4' 86 ± 4 110 ± 6» 87 + 6 108 ± 4"
Results are expressed as mean ± se:m.
1 P < 0.002, h P < 0.05 when compared to control subjects
Table 2. Forearm blood flows (FBF) before and during infusions
Norepinephrine Endothelin-1 BQ-123 Phosphoramidon Thiorphan
Control CRF Control CRF Control CRF Control CRF Control CRF
Control arm FBF
ml/100 ml/min
Basal 2.4 ± 0.2 3.0 ±0.6 2.7 ±0.3 2.8 ± 0.5 2.4 ± 0.3 3.2 ±0.4 2.9 ±0.4 3.4 ± 0.4 1.7 ±0.2 3.9 ± 0.7'
End of infusion 2.9 ±0.3 2.8 ± 0.6 3.2 ± 0.4" 3.0 ± 0.7 2.1 ±0.3 3.5 ±0.6' 3.6 ± 0.7 3.5 ±0.4 2.5 ± 0.3b 2.8 ± 0.7C
Infused arm FBF
ml/100 ml/min
Basal 3.0 ± 0.3 3.1 ±0.6 2.9 ±0.2 2.8 ±0.3 2.6 ±0.3 3.7 ±0.5 2.5 ± 0.4 4.6 ± 0.8" 1.9 ±0.2 5.4 ±1.3'
End of infusion 2.0 ±0.2" 1.8 ±0.2" 2.4 ± 0.3b 1.8 ±0.3" 3.2 ± 0.4b 4.5 ± 0.7" 7.4 ± 0.8b 6.9 ± 0.7" 2.4 ± 0.3b 3.9 ± 0.7bc
a P < 0.05 for resting blood flow when compared to control subjects (f-test)
b P < 0.05, compared to basal value (paired Mest)
c P < 0.05, compared to control response to infusion (ANOVA)
Infusion of BQ-123
Infusion of BQ-123 caused a progressive increase in
FBF (Fig. 3 and Table 2), maximal at 60 minutes, of
11 ± 4% in patients with CRF and 44 ± 10% in control
subjects; the response in patients with CRF was signifi¬
cantly reduced (Fig. 3) when compared with that of the
control subjects (P = 0.02). In those subjects undergoing
the two-hour infusion, there was no further vasodilation
after 60 minutes of BQ-123 in either patients (13 ± 11 %
at 60 min, -3 ± 3% at 120 min, P = 0.35) or control
subjects (46 ± 11% at 60 min, 48 ± 9% at 120 min, P =
0.76), respectively.
Infusion of phosphoramidon and thiorphan
Infusion of phosphoramidon caused a progressive in¬
crease in FBF (Fig. 4 and Table 2), maximal at 90 min¬
utes, of 68 ± 20% in patients with CRF and 181 ± 41%
in control subjects. The response of the patients with
CRF to phosphoramidon was reduced (Fig. 4) when com¬
pared with that of the control subjects (P = O.tXH). Infu¬
sion of thiorphan caused a progressive reduction in FBF
(Table 2), maximal at 90 minutes, of -22 ± 6% in pa¬
tients with CRF and -14 ± 6% in control subjects and
was similar when comparing the two groups (P = 0.39;
Fig. 4).
DISCUSSION
We have shown, using the ECE inhibitor, phosphora¬
midon, and the ETA antagonist, BQ-123, that endoge¬
nous endothelin-1 contributes to the maintenance of rest¬
ing forearm vascular tone in patients with CRF. We have
also demonstrated, using BQ-123, that the contribution
of endothelin-1 to resting vascular tone mediated through
the ETa receptor is decreased in patients with CRF com¬
pared with healthy controls. In addition, using phos¬
phoramidon, the reduced contribution of endothelin-1
to the maintenance of vascular tone in patients with CRF
appears to be due at least in part to reduced generation
of endothelin-1. These functional responses are in con¬
trast to the observed elevated concentrations of endo¬
thelin-1 and big endothelin-1 in CRF.
These studies involved infusion of locally but not sys-
temically active doses of vasoactive agents into the fore¬
arm vascular bed. Indeed, FBF in the noninfused arm
did not change during any infusion period apart from
when endothelin-1 and thiorphan were infused in control
subjects (Table 2), when the FBF in the control arm
increased and the blood flow in the infused forearm
decreased. The use of locally active doses of vasoactive
agents is important in these studies, as systemic doses
may obscure any direct vascular action through effects
on other organs, such as the heart and kidney, or through




















































Fig. 3. Effect of BQ-123 infusion on FBF. Symbols are: (•) patients
with CRF and (O) healthy control subjects (P = 0.02 by ANOVA).
30 60 120 240
Dose of norepinephrine, pmol/min
Fig. 1. Effect of norepinephrine infusion on forearm blood flow (FBF).
Symbols are: (•) patients with CRF and (O) healthy control subjects






























Fig. 2. Effect of cndothelin-1 infusion on FBF. Symbols are: (•) pa¬
tients with CRF and (O) healthy control subjects (P = 0.81 by ANOVA).
activation of reflex mechanisms caused by changes in
blood pressure [25]. The forearm vascular bed was cho¬
sen because the responses to vasoactive agents within
this vascular bed are thought to be broadly representa¬
tive of responses in other functionally important resis¬
tance beds [25, 26].
In contrast to the impaired responsiveness of the fore¬
arm resistance vessels to norepinephrine in patients with
CRF who are dialysis dependent and anemic [21], there
was no difference in the responsiveness to norepineph¬
rine of the forearm resistance vessels between the dial¬
ysis-independent CRF patients and control subjects in
this study. Also, in response to infusion of endothelin-1,
there was a progressive vasoconstriction that was of a
similar magnitude in the patients and control subjects,
suggesting that responsiveness to endothelin-1 is not re¬
duced in CRF in the way it is in chronic heart failure [27],
In addition, similar vascular responsiveness to infusion of
norepinephrine and endothelin-1 in CRF patients and
control subjects implies vascular functional integrity with
respect to these two endogenous vasoactive mediators.
The specific ETA receptor antagonist BQ-123 produced
a progressive vasodilation in both patients with CRF and
the control subjects, implying that endothelin-1, acting
through the ETA receptor, has a role in the maintenance
of resting vascular tone. Furthermore, we have demon¬
strated, in both patients and controls, that the response
to BQ-123 was maximal at 60 minutes. However, the
response to BQ-123 in the patient group was significantly
impaired when compared with control subjects. This im-
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Fig. 4. Effect of phosphoramidon and thiorphan infusion on FBF. Sym¬
bols are: patients with CKF receiving phosphoramidon (•) and thior¬
phan (■) and healthy control subjects receiving phosphoramidon (O,
P = 0.001 by ANOVA) and thiorphan (□, P = 0.39 by ANOVA).
paired response may have occurred for several reasons.
First, elevated circulating concentrations of biologically
active endothelin-1, either as a result of increased gener¬
ation or decreased clearance, may have been sufficiently
high that the dose of BQ-123 used was not sufficient to
block the ETA receptor. However, because the dose of
BQ-123 infused was at least 10-fold higher than that
previously shown to cause a maximal effect in the fore¬
arm in healthy subjects [13, 14], this is unlikely to be the
explanation.
Second, in renal failure, endothelin-1 may cause vaso¬
constriction by acting on the ETB receptor. ETB agonists
can cause vasoconstriction [6], Our observations in renal
failure may be consistent with those in chronic heart
lailure where there appears to be a relative up-regulation
of the constrictor ETB receptor [27, 28], ETB-mediated
vasoconstriction in CRF may be of greater importance
than in heart failure because ETB-mediated vasodilation
may be reduced, perhaps as a result of endothelial dys¬
function, in CRF patients as compared with healthy sub
jects. However, our studies were not designed to fully
investigate potential changes in ET„ receptor function
in CRF.
Third, the altered response to infused BQ-123 in CRF
may occur as a consequence of diminished responsiveness
of the vascular smooth muscle cell in CRF. However,
our findings of similar responsiveness to exogenous en
dothclin-1 between patients with CRF and control sub¬
jects are against this hypothesis.
Fourth, despite the increased concentrations of immu-
noreactive endothelin 1 and big cndothelin 1 observed by
our experiments and others [9], concentrations of biologi¬
cally active endothelin-1 may be decreased in patients with
CRF as a consequence of impaired generation of endo¬
thelial. Fractionation of plasma samples reveals that
the elevation in immunoreactive endothelin-1 in CRF may
be due to marked increases in immunoreactive big endo
thelin-1 degradation products [29] rather than biologi¬
cally active endothelin-1. Furthermore, Shichiri reported
similar concentrations of immunoreactive endothelin-1
in patients with renal failure and healthy control subjects
when using an assay that docs not cross react with either
big endothelin-1 or the C-terminal fragment [30].
Fifth, the increased blood pressure observed in the
patients with CRF may contribute to the different re¬
sponses between the CRF group and the control subjects
rather than the altered renal function. However, this is
unlikely because a study similar to ours found no differ¬
ence in response to BQ-123 when comparing hyperten¬
sive subjects with normal renal function and control sub¬
jects [13]. Also against this is the inverse relationship
between blood pressure and forearm vascular respon
siveness to endothelin 1 in patients with dialysis depen
dent renal failure using human recombinant erythropoie
tin [21].
Sixth, BQ-123-induced vasodilation may not only oc¬
cur as a consequence of abolition of a constrictor stimu
lus but may, in part, be mediated by nitric oxide-
dependent vasodilator tone [31], The reduced response
to BQ-123 observed in the CRF subjects may reflect an
abnormality in nitric oxide-mediated vascular tone, possi¬
bly as a consequence of impaired endothelial function as
described in patients with end-stage renal failure [32],
Infusion of the NEP and ECE inhibitor, phosphorami¬
don, caused forearm vasodilation. In contrast, infusion
of the selective NEP inhibitor thiorphan caused a slow-
onset vasoconstriction that was similar between the pa¬
tients with CRF and control subjects. The vasodilator
effect of the infused phosphoramidon was therefore
likely to be an action of inhibiting ECE rather than NEP
[4]. Vasodilation of the forearm vasculature in response
to phosphoramidon suggests that endothclin-l genera¬
tion by the vascular endothelium is important in the
maintenance of resting vascular tone in healthy subjects
and shows that this is also the case in patients with CRF,
although to a lesser extent, (liven that constriction to
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endothelin-1 was identical in CRF patients and controls,
the implication is that there may be reduced generation
of endothelin-1 in patients with CRF. Flowever, this in¬
terpretation must be accepted with some caution because
our renal failure patients had higher resting FBFs than
control subjects, which may have reduced the concentra¬
tion, and responses, to phosphoramidon. Also, the phos-
phoramidon responses observed in this study were
greater than responses observed previously [4, 27], In
support ofour conclusion, however, responses in patients
to phosphoramidon and BQ-123 were reduced using the
percentage change in FBF as a ratio of the infused to
noninfused arm, this measure being less sensitive to dif¬
ferences in baseline blood flow [33]. In addition, the
resting FBFs in the renal failure patients receiving BQ-
123 and phosphoramidon were similar (infused arms,
P = 0.36; noninfused arms, P = 0.80; Table 2), allowing
direct comparison of inhibition of endothelin generation
with phosphoramidon to blockade of the ETA receptor
with BQ-123. The greater increase in FBF in renal failure
patients caused by phosphoramidon is consistent with
an important vasoconstrictor role for the ETB receptor
in the maintenance of resting vascular tone in patients
with CRF, although further studies with selective ETB
antagonists are required to confirm this observation.
In conclusion, we have confirmed elevated concentra¬
tions of immunoreactive endothelin-1 and big endothe¬
lin-1 in CRF. Furthermore, we have demonstrated that
endogenous generation of endothelin-1 in the forearm
plays an important role in the maintenance of resting
vascular tone in healthy subjects and in patients with
CRF who are independent of renal replacement therapy.
Also, we have demonstrated that the contribution of
endothelin-1 to resting vascular tone is decreased in CRF
as a consequence of reduced generation of endothelin-1.
However, our findings also suggest that the use of ECE
inhibitors may be of greater potential for control of hy¬
pertension associated with CRF than selective ETA re¬
ceptor antagonists. Further studies with systemic and
chronic dosing are needed to explore these issues.
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Background—Among patients with inde¬
pendent evidence of coronary disease and
recent onset unstable angina or non-Q
wave myocardial infarction the incidence
of subsequent cardiovascular events is
high. Markers predictive of adverse
cardiac outcome in unstable angina and
non-Q wave myocardial infarction need
to be defined more accurately.
Endothelin-1 is a potent endothelium
derived vasoconstrictor peptide that may
play a part in the pathophysiology of
acute myocardial ischaemia.
Aim and study design In a study that
specifically identified high risk patients a
group of 16 consecutive patients with
either unstable angina at rest or non-Q
wave myocardial infarction were
prospectively investigated to establish
whether these conditions arc associated
with high plasma immunorcactive
endothelin and whether endothelin
concentration at presentation is related
to cardiovascular event3 within the next
12 weeks. Controls consisted of a group of
40 healthy subjects.
Results—Patients had significantly
higher mean (SD) plasma endothelin at
presentation than did healthy controls
(7-4 (1-1) v 5-0 (1-2) pg/ml, P < 0-0001).
At nine weeks plasma endothelin was still
significantly higher in those patients who
had subsequent cardiovascular events,
(n = 9, acute myocardial infarction or
refractory angina with electrocardio¬
graphic changes and revascularisation
procedures, 8-5 (2-6) pg/ml, P < 0-005 v
controls) whereas its concentration
returned to normal in those patients
who had a favourable outcome (n = 7,
5-9 (0-7) pg/ml). Compared with those
patients who had an uneventful course,
patients with subsequent events had
significantly higher plasma endothelin,
both at presentation and at nine weeks
(P < 0-05 on both occasions).
Implications—Endothelin may con¬
tribute to the pathophysiology of acute
coronary syndromes and may relate to
subsequent cardiovascular outcome.
(Br Heart J 1994;72:436-441)
Patients presenting with recent onset unstable
angina or non Q wave myocardial infarction
constitute a group that is at high risk of pro¬
gression to further myocardial infarction or
sudden death.1 These patients have not been
shown to benefit from thrombolysis,2 and a
proportion of them fail to stabilise on antiang¬
inal treatment and aspirin and may experience
recurrent episodes of myocardial ischaemia
prompting revascularisation.1 In the anti¬
thrombotic therapy in acute coronary syn¬
dromes (ATACS) study there was no
difference in the cardiovascular outcome at
three months after presentation between the
group with unstable angina and that with non
Q wave infarction.' The search continues for
reliable markers to facilitate early identifica¬
tion of those patients with acute coronary syn
dromes who are at a high risk of developing
subsequent cardiovascular events, in whom
early intervention may be indicated.
Intracoronary thrombosis as a result of a
disrupted atherosclerotic plaque is regarded as
the pivotal mechanism in acute coronary syn
dromes and the angiographic and pathological
findings are not dissimilar in unstable angina
and non-Q wave infarction.4* Clinically, the
two diagnoses may not be distinguishable at
presentation and both are associated with the
release of sensitive markers of cardiac muscle
injury, such as troponin T.7 Abnormalities of
haemostasis8 10 and increased coronary reac¬
tivity to constrictor stimuli" have been sug¬
gested as possible pathogenetic factors in
acute coronary syndromes. Previous studies
have shown the importance of activation of
platelets and of the coagulation system in the
pathophysiological mechanism of acute
myocardial ischaemia,8 10 whereas the role of
endogenous vasoconstrictor substances has so
far received less attention.
Endothelin is a potent endothelium derived
vasoconstrictor peptide in animals'2 and
humans." Raised plasma concentrations of
endothelin have recently been reported in
patients with acute myocardial infarction and
in a heterogeneous group of patients with
symptomatic atherosclerosis.""'' In these the
plasma endothelin concentration was posi¬
tively correlated with the number of sites of
atherosclerotic involvement but not with age.
Patients with stable angina have, on the other
hand, been shown to have normal plasma
endothelin concentrations.1416
Our aim was to investigate prospectively
whether unstable angina and non-Q wave
myocardial infarction are associated with
changes in plasma immunoreactive endothe¬
lin and whether raised endothelin concentra
tions are associated with indicators of adverse
cardiovascular prognosis.
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Patients and methods
PATIENT SELECTION
This study was performed on patients
recruited for a multicentre trial of ATACS,
which compared the effectiveness of combina¬
tion antithrombotic treatment with aspirin
and anticoagulation v aspirin alone in patients
with unstable angina and non-Q wave
myocardial infarction.' The inclusion criteria
were (a) age > 21; (b) ischaemic chest pain
due to unstable angina or non-Q wave
myocardial infarction, with the qualifying
episode of chest pain within the 48 hours
before recruitment to ATACS, and (c) addi¬
tional evidence of ischaemic heart disease was
required. This evidence consisted of at least
one of the following: (a) electrocardiographic
changes during pain on admission suggesting
ischaemia—for example, ST segment depres¬
sion or elevation, or T wave inversion; (b) pre¬
vious myocardial infarction; (c) history of
typical exertional angina, with chest pain pre¬
cipitated by effort and relieved by rest or glyc¬
eryl trinitrate, or a previously positive exercise
test; id.) previous coronary angiography show¬
ing > 50% luminal narrowing in any coronary
artery. Patients with Q wave infarction at pre¬
sentation were excluded from ATACS. As
stipulated by the protocol, no patient was
treated with thrombolysis, and coronary
angiography was performed on clinical indica¬
tions only.
Based on screening forms, 4-5 patients
were screened for each patient identified for
the study. Among 51 patients recruited into
the ATACS study in our centre, prospective
endothelin measurements were undertaken in
the last 16 consecutive patients. Our control
group consisted of 40 healthy volunteers,
mean (SD) age 34 (17), range 20-78. Eleven
control subjects were in the same age range as
the patients (59 (13), range 40-74).
STUDY DESIGN
The patients were prospectively followed up
for a period of 12 weeks with assessments at
least every three weeks in the cardiology
clinic. Blood samples were taken on the first
morning after admission and at nine weeks of
follow up from all patients, except for two
patients from whom follow up samples could
not be obtained for technical reasons. The
controls were sampled on one occasion only.
Venous blood was taken from an antecubital
vein into chilled potassium EDTA tubes, put
immediately on ice and centrifuged at
4000 rpm for 30 min at 4°C. Plasma was
stored at — 70°C until assay. Clinicians were
blinded to the results of endothelin measure¬
ments.
ANALYTICAL PROCEDURES
Plasma immunoreactive endothelin was mea¬
sured by radioimmunoassay. SepPak C18 silica
columns (Waters Associates, Milford, MA,
USA) were equilibrated by washing with
methanol (5 ml), distilled water (5 ml), and
then 4% acetic acid (5 ml). Each 2 ml plasma
sample was diluted with 3 ml of 4% acetic
acid and loaded on to a column; these were
washed with 25% ethanol (3 ml), and eluted
with 4% acetic acid in 86% ethanol
(2 x 1 ml). The eluates were evaporated
under nitrogen in a water bath at 37°C, and
reconstituted in borate buffer of pH 8-4
(2 ml). Duplicate extracted samples and
standards containing 1 to 48 pg/ml of
endothelin-1 (each 200 /d) were incubated
with rabbit polyclonal antibody raised against
endothelin-1 (ITS Production BV, Wijchen,
The Netherlands; in 100 fil distilled water)
and '"I-endothelin-l (ITS; in 100 fi\ distilled
water). After vortexing, tubes were incubated
for 18 h at 4°C. Donkey antirabbit y globulin
bound on solid phase (ITS; 100 pt\) was
added to all tubes, except those for total
counts, and the tubes were incubated for 30
min at room temperature. The amount of
radioactivity in the antibody bound fraction
was determined by y counting for 2 min. The
recovery of added endothelin-1 was 84%.
Within and between assay coefficients of varia¬
tion were 2-4% (n = 6) and 4-2% (n = 5).
The sensitivity of this assay was 1 pg/ml
endothelin. Cross reactivity of the assay with
endothelin-1, endothelin-2, endothelin-3, and
proendothelin-1 was 100%, 52%, 96%, and
7%.
STATISTICAL ANALYSIS
Initial statistical analyses were performed on
the whole group of patients with unstable
angina and non-Q wave infarction (primary
analysis, n = 16). Subsequent more detailed
comparisons were carried out separately for
the two diagnostic categories (subsidiary
analysis: unstable angina, n = 10, and non-Q
wave myocardial infarction, n = 6).
Statistical analyses were performed with
Minitab statistical software (Minitab, Release
7). All values are expressed as mean (SD).
Individual comparisons between groups were
carried out with unpaired t test. Categorical
data were analysed by x2 test, with Yates' cor¬
rection, when appropriate. Correlation coeffi¬
cients were calculated with Pearson's test.
Two tailed tests were performed and P values
< 0 05 were considered to be significant.
Results
STUDY PATIENTS
The table shows the main characteristics of
the 16 patients. None was hypertensive at the
time of the study. Coronary artery disease was
verified in all patients by at least one of the
criteria: electrocardiographic changes on
admission (ST segment depression or eleva¬
tion or T wave inversion, n = 14 (88%)), car¬
diac catheterisation performed during the 12
weeks of follow up or before admission
(n = 8 (50%)) and a history of myocardial
infarction (n = 7 (44%)). At presentation all
patients were in Killip class I, and at nine
weeks all patients but one were free of left
ventricular failure.
UNSTABLE ANGINA V NON-Q WAVE INFARCTION
Although all 16 patients fulfilled criteria for
unstable angina on admission (all class IIIB
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Demographic and epidemiological data
AU Unstable angina Non-Q wave MI
No 16 10 6
Age (yr):
Mean (SD) 62 (10) 62 (8) 62 (12)
Range 44-77 50-76 4-78
Sex ratio (F/M) 4/12 3/7 1/5
Duration of angina (yr):
Mean (SD) 51 (7-5) 7-3 (8-7) 14 (2 1)
Median 2 4 0-3
Range 0-25 0-25 0-5
Previous MI 7 (44%) 6 1
Previous CABG/PTCA 2 (13%) 1 1
Coronary angiography:
Total 8 (50%) 7 1
1 vessel 3 (38%) 2 1
2 vessel 1 (12%) 1 0
3 vessel 4 (50%) 4 0
Ischaemic electrocardiogram at presentation 14 (88%) 9 5
Medical treatment:
Heparin 10 (63%) 9 1
Aspirin 16 (100%) 10 6
Beta-blockers 14 (88%) 8 6
Calcium antagonists 12 (72%) 10 2
Nitrates 13 (81%) 9 4
Mean (SD) creatine kinase (u/ml) 347 (631) 58 (26) 901 (812)
Range 28-2339 28-101 335-2339
CABG, coronary artery bypass grafting; MI, myocardial infarction; PTCA, percutaneous
transluminal coronary angioplasty.
according to Braunwald,'7—for example,
chest pain at rest within preceding 48 h), six
patients were subsequently shown to have
enzymatic evidence of an evolving non-Q
wave myocardial infarction (increase in car¬
diac enzymes, no electrocardiographic evi¬
dence of new Q waves). Patients with
unstable angina did not differ significantly
from those with non Q wave infarction with
respect to age, sex distribution, smoking
habits, history of hypertension and acute
myocardial infarction, incidence of ischaemic
electrocardiogram at presentation, and treat¬
ment with aspirin, /(-blockers, calcium chan-
Figure 1 Plasma
endothelin concentrations
were significantly higher in
patients with unstable
angina or non-Q wave
myocardial infarction
(n = 16), both at
presentation and at nine
weeks than in the controls
(n = 40).





























were significantly higher in
patients with subsequent
cardiac events (n = 9)
than in those who
remained event free
(n = 7), both at
presentation and at nine
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nel blockers, and nitrates (table). They tended
to have a longer history of previous angina
and a higher rate of performed angiography,
but these trends did not reach significance.
Significantly more patients with unstable
angina (n = 9) were treated with heparin or
anticoagulation regimens on admission and
during follow up, compared with patients with
non-Q wave myocardial infarction (n = 1,
X2 = 8-6, P < 0 005).
CARDIOVASCULAR OUTCOME
In the primary analysis of all 16 patients with
acute coronary syndromes, nine (56%)
patients had cardiovascular events during 12
weeks of follow up, whereas seven patients
remained event free or had only mild angina.
The cardiac events were as follows: four
patients had episodes of refractory angina
with electrocardiographic changes despite
maximal medical treatment, one developed
acute Q wave myocardial infarction, and four
underwent surgical revascularisation on
account of evidence of continuing ischaemia
(three coronary artery bypass grafting
(CABG) and one percutaneous transluminal
coronary angioplasty (PTCA)). In none of the
cases did a myocardial infarction or a revascu¬
larisation take place within four weeks of the
nine week sample being taken. Of the four
patients with episodes of refractory pain one
patient refused angiography, two had inoper
able coronary artery disease, and in one the
clinical symptoms resolved and he did not
proceed to angiography during the study
period.
Subsidiary analysis showed that the subse¬
quent event rate among patients with unstable
angina was six of 10 (three CABG, one
PTCA, two angina with electrocardiographic
changes), whereas three of six patients with
subendocardial infarction had subsequent
events (one myocardial infarction, two angina
with electrocardiographic changes). The event
rate at 12 weeks did not differ between un¬
stable angina and non-Q wave infarction
groups (x2 = 015, P = NS).
ENDOTHELIN CONCENTRATIONS
In the primary analysis of all 16 patients
(fig 1), plasma endothelin was significantly
raised both at presentation (7-4 (11) pg/ml)
and at nine weeks (7-6 (2-4) pg/ml), com¬
pared with healthy controls (5 0 (1-2) pg/ml,
P < 0 0001 on both occasions). At presenta¬
tion, those patients who developed subse¬
quent events (8 0 (0-9) pg/ml) and those who
remained event free (6-9 (10) pg/ml) had
higher endothelin concentrations than the
controls (P < 0 0001 and P < 0 005; fig 2).
At nine weeks, when compared with the con¬
trols, endothelin remained significantly raised
in those patients who had an unfavourable
progress (8-5 (2-6) pg/ml, P < 0 005 v con¬
trols), but it returned to normal values in
those patients who remained asymptomatic
(5-9 (0-7) pg/ml). Patients with subsequent
events had significantly higher endothelin
than those who remained event free, both at
presentation (P < 0 05) and at nine weeks
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(P < 0 05, fig 2). One of the patients had
signs and symptoms of mild left ventricular
failure nine weeks after presentation, but the
exclusion of this patient did not affect the
results from the nine week analysis.
In the analysis based on diagnosis patients
with unstable angina (7-9 (0-9) pg/ml) and
those with non-Q wave myocardial infarction
(6-8 (11) pg/ml) had significantly higher
endothelin concentrations at presentation
than healthy controls (P < 0-0001 and
P < 0 01). There was a small but significant
difference in endothelin concentrations at pre¬
sentation between patients who presented
with unstable angina and those who presented
with a subendocardial infarction (7-9 (0-9) v
6-8 (11) pg/ml, P < 0 05). At nine weeks,
endothelin remained higher both in the un¬
stable angina (7-8 (2-5) pg/ml) and the non-Q
wave infarction groups (7-3 (2-5) pg/ml) than
in the control population (P = 0 0002 and
P < 0 005). At nine weeks there was no dif¬
ference in the endothelin concentrations
between patients who initially presented with
either unstable angina or subendocardial
infarction.
All comparisons between patients and con¬
trols were subsequently repeated with the age
matched control group (n = 11). None of the
conclusions were altered nor were the mea¬
sures of significance abrogated by this analy¬
sis.
In view of the highly significant P values
obtained for the above comparisons, the dif¬
ferences remained significant even after
adjustments for multiple comparisons.
Comparison of patients with and without
events was performed only once at each of the
analysed time points and in this instance the
results were of borderline significance




There was no difference in endothelin con¬
centrations on admission between smokers,
non-smokers, and ex-smokers (7-3 (1-1) v 7-8
(1-0) pg/ml) or between patients who received
heparin and those who did not (7-8 (0-9) v
7-0 (1-2) pg/ml). Endothelin concentrations
did not differ between men and women (7-3
(1-1) v 8-1 (0-8) pg/ml). There was no correla¬
tion between endothelin concentrations and
age, either in the patients (r = 0-23,
P = 0-38) or in the controls (r = 0-06,
P = 0-72). We showed no correlation
between endothelin concentrations and either
systolic (r = 0-38, P = 014) or diastolic
blood pressure (r = 0 07, P = 0-8) or the
number of involved coronary arteries, as
found by coronary angiography (r = 0 03,
P = 0-94).
Discussion
This is the first prospective investigation of
the relation between plasma endothelin and
cardiovascular outcome in acute coronary
syndromes. We have shown a persistent
increase of plasma immunoreactive endothe¬
lin, lasting for at least nine weeks after admis¬
sion, in a group of high risk patients
presenting with unstable angina or non-Q
wave myocardial infarction. Also, we have
shown an association between endothelin
concentrations at presentation and subse¬
quent cardiovascular outcome.
Previous studies of endothelin in acute
myocardial infarction have reported an early
rise in plasma endothelin, with a subsequent
progressive fall to normal values, completed
within 3-14 days of the infarct.14 18 20 Our
results, which show that unstable angina and
non-Q wave myocardial infarction are associ¬
ated with high circulating endothelin at pre¬
sentation, are consistent with those previous
findings. Persistently increased circulating
endothelin, present only in those patients who
developed subsequent cardiovascular events,
has not previously been reported.
There have been few previous studies of
endothelin concentrations in unstable angina
and these have provided conflicting
results.1621 22 Ray et al and Stewart et al found
no difference in endothelin concentrations in
plasma and coronary sinus samples between
patients with unstable angina, stable angina,
and controls.2122 Also, in the study by Ray et al
endothelin concentrations in unstable angina,
although comparable with those in stable
angina, were significantly lower than in a
group of patients with acute myocardial
infarction.21 In contrast, in a study of 29
patients with unstable angina, Qiu et al
reported that endothelin concentrations were
high at presentation compared with healthy
controls, and decreased progressively to nor¬
mal at six hours.16 In their study, the size of
the initial increase of endothelin concentra¬
tion in unstable angina was comparable with
that found in 29 patients with acute myocar¬
dial infarction.
None of the previous studies of endothelin
in acute coronary syndromes has provided
cardiac outcome data. In our high risk popu¬
lation (56% event rate at 12 weeks) we have
shown that endothelin concentrations at pre¬
sentation may relate to subsequent cardiac
events. The event rate in our population was
higher than that usually described for unstable
angina. It is conceivable that the populations
studied by Ray et al and Stewart et al were of
relatively lower risk and this may explain why
they had no evidence of increased endothelins
at the time of presentation. It is not clear,
however, why in our study patients with
unstable angina tended to have higher
endothelin concentration at presentation than
the non-Q wave infarction group. Qiu et al
also reported a different time course of the
increase in endothelins in unstable angina and
myocardial infarction: in unstable angina the
concentrations decreased progressively to nor¬
mal values by six hours, whereas in myocar¬
dial infarction there was a further increase at
6 h, then a decrease at 12 hours. In the
absence of multiple endothelin measure¬
ments, we cannot speculate as to whether
different dynamics of the endothelin rise
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could have contributed to the reported differ¬
ences in endothelin concentrations in our
patients. It has also to be considered whether
these differences could have been related to
more extensive use of heparin in our patients
with unstable angina than in those who pre¬
sented with subendocardial infarction.
Although the evidence of an effect of heparin
on the generation of endothelins is limited,
heparin induced inhibition rather than stimu
lation of endothelin-1 expression and produc¬
tion by cultured endothelial cells has been
reported.21 In view of these findings, the pat¬
tern of heparin use would, if anything, tend to
diminish the observed differences in endothelin
concentrations between patients with unstable
angina and non-Q wave infarction in our pop¬
ulation.
In agreement with previous studies'"'16 we
did not show a correlation between endothe¬
lin concentrations and common clinical char
acteristics, including age, systolic and
diastolic blood pressure, smoking, and the
extent of coronary artery disease.
We cannot differentiate which specific
endothelin isoforms contribute to the rise in
total plasma immunoreactivity in the studied
population, because our assay cross reacts
substantially with all three isoforms. As
endothelin-2 is usually undetectable in
plasma21 this isoform is unlikely to constitute a
large proportion of total immunoreactivity.
Thus endothelin-1 and/or endothelin-3 may
have contributed to the rise in circulating
endothelin. Proendothelin-1 also cross reacts
with our antibody, although only to a minor
degree (7%), and is unlikely to have
accounted for the rise in endothelin
immunoreactivity.
Both increased generation and decreased
clearance of endothelin could have caused the
rise in plasma concentrations in patients with
coronary syndromes. Plasma creatinine
remained normal in all these patients, how¬
ever, and thus increased generation seems
more likely to have accounted for the rise.
There is evidence from experimental studies
that endothelin production is enhanced by
shear stress, impaired release of nitric oxide,
and physiological stress.2""26 Both thrombin
and transforming growth factor-/? are also
known to stimulate endothelin production in
cell culture.27 28 As unstable angina is linked
with markers of a hypercoagulable state,8 10 it
is conceivable that excessive generation of
thrombin or release of transforming growth
factor-/? from activated platelets may con¬
tribute to increased endothelin concentrations
in acute coronary syndromes. This hypothesis
would be indirectly supported by previous
reports that endothelin concentrations were
positively correlated with both thrombin-
antithrombin III complex and /? thromboglob-
ulin concentrations in patients presenting
with acute myocardial infarction.14
Any increase in generation of endothelins
in our patients may have been a localised phe¬
nomenon or it may have occurred as a sys¬
temic process. If the increase occurred in the
heart, high local concentrations of endothelin
may have been reached. When present in suffi¬
ciently high concentrations endothehn may
cause direct local or systemic vasoconstriction
and potentiate platelet aggregation.2"1,1 In
cases of a chronic increase, endothelin may
stimulate proliferation of vascular smooth
muscle cells in atherosclerotic plaques."
Ultimately, endothelin could be implicated in
the pathophysiological mechanism of acute
coronary syndromes and its biological actions
may actively contribute to myocardial
ischaemia. Indeed, there is evidence that anti¬
bodies to endothelin limit the infarct size in
animal models.12 Alternatively, high endothe¬
lin concentrations may be a consequence of
intermittent episodes of myocardial
ischaemia. In either case endothelin could
prove to be a useful prognostic marker for
adverse outcome in acute coronary syn¬
dromes. If confirmed in larger prospective
studies, the findings of this study raise a possi
bility of influencing the cardiovascular out¬
come in acute coronary syndromes with use of
the recently described specific inhibitors to
the generation of endothelin.21
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Abstract
Cardiac arrest is associated with major metabolic disturbances, including severe hypoxia and large increases in circu¬
lating catecholamines, both of which are known to stimulate generation of the potent endothelium-derived vaso¬
constrictor peptide endothelin-1. We have, therefore, examined plasma immunoreactive endothelin concentrations
following cardiac arrest. Blood was sampled at 10-min intervals from a central venous catheter inserted at onset of
resuscitation in 38 patients (13 female; mean age, 67 years) presenting with cardiac arrest to the Accident and Emer¬
gency Department at the Royal Infirmary of Edinburgh. Plasma immunoreactive endothelin concentrations
(mean ± S.D.) in patients following cardiac arrest (5.4 ± 2.3 pg/ml) were no different from those in healthy subjects
(5.1 ± 1.2 pg/ml). There was no significant difference between endothelin concentrations at presentation in survivors
and non-survivors of cardiac arrest. However, non-survivors had a significant fall in endothelin concentrations with
time from onset of resuscitation from 5.4 ± 2.2 pg/ml to 3.5 ± 1.8 pg/ml (P- 0.002), while survivors had a non¬
significant increase in concentrations. On multiple regression analysis there was a significant association between
higher plasma endothelin concentration and survival (r = 0.37; P = 0.009). The failure of plasma endothelin to increase
after cardiac arrest is unexpected. Although the fall in plasma endothelin with time in non-survivors may reflect the
adverse physiological milieu that occurs during cardiac arrest, it is also possible that low endothelin concentrations
contribute to the poor prognosis in this condition.
Key words: Resuscitation; Ventricular fibrillation; Asystole; Ischaemic heart disease; Endothelin; Endothelium;
Vasoconstrictor peptides; Catecholamines
1. Introduction stacyclin [1], and vasoconstrictors, such as angio¬
tensin II [2] and endothelin-1 [3]. Endothelin-1 is
The vascular endothelium, which forms the a potent vasoconstrictor and pressor peptide with
inner lining of all blood vessels, produces both a uniquely prolonged action in both animals [3]
vasodilator agents, such as nitric oxide and pro- and man [4,5]. Endothelin-1 is a member of a fami-
ly of related isoforms, endothelin-1, -2 and -3, and
* Corresponding author. endothelin-1 is the major isoform produced within
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the vasculature [6]. Although very high concentra¬
tions have been measured in patients on haemo-
dialysis [7], sufficient to exert effects on vascular
tone [8], in most circumstances endothelin-1
appears to be a locally acting autocrine and para¬
crine rather than a circulating hormone. Plasma
concentrations of endothelin are likely to repre¬
sent overspill from much higher concentrations at
the interface between endothelium and vascular
smooth muscle cell, similar to the situation for
catecholamine release from nerve terminals.
Increased circulating concentrations of endo¬
thelin are found in diseases associated with region¬
al vasoconstriction, including Prinzmetal's angina
[9], Raynaud's disease [10] and cardiac failure
[11,12]; in the last, plasma endothelin correlates
with the severity of pulmonary hypertension. Plas¬
ma endothelin is also elevated in cardiogenic
[13,14] and septic shock [15,16], possibly as a
homeostatic response to maintain arterial
pressure.
Cardiac arrest results in circulatory standstill
and, even with adequate resuscitation, arterial
blood pressure, oxygenation and pH are greatly
reduced. During cardiac arrest there is a marked
increase in sympathetic discharge, producing
substantially higher plasma catecholamine concen¬
trations than recorded in any other condition [17],
We hypothesised that plasma endothelin would
increase during cardiac arrest, not only because
factors that stimulate endothelin-1 production,
such as catecholamines [3,18] and hypoxia [19],
increase in cardiac arrest, whatever the cause, but
also because impaired renal function would
decrease clearance of endothelin-1 [20], We have,
therefore, measured plasma concentrations of
immunoreactive endothelin in patients following
cardiac arrest, and assessed their relationship with
arterial blood oxygenation and survival.
2. Methods
2.1. Patients and protocol
All patients presenting with cardiac arrest to the
Accident and Emergency Department at the Royal
Infirmary of Edinburgh between 0900 and 1700 h
in the period October 1991 to February 1992 were
prospectively enrolled into this study, which was
approved by the local Ethics Review Committee.
The Accident and Emergency Department treats
approximately 400 cardiac arrests each year.
Resuscitation was carried out strictly according to
the current UK Resuscitation Council guidelines
[21,22], Where indicated, patients were intubated,
received DC countershock, and standard cardiac
resuscitation drugs in doses directed by treatment
protocols. A mechanical compression/ventilation
device (Thumper™) was used in all patients as an
aid to cardiopulmonary resuscitation.
Soon after the onset of resuscitation a central
venous catheter was inserted for administration of
drugs. Blood was withdrawn from this line at 10-
min intervals while circulatory standstill persisted.
In a subset of patients, a simultaneous arterial
sample was obtained on one occasion for blood
gas analysis. For each sample, 9 ml of blood was
added to 1 ml ethylenediamine-tetra-acetate
(EDTA potassium salt; final concentration 10
mmol/1). Each sample was separated at 4°C (within
10 min) and then stored at -20°C for 24 h before
being transferred to a -70°C freezer.
2.2. Analytical procedures
Plasma immunoreactive endothelin was
measured by radioimmunoassay [23], SepPak C18
silica columns (Waters Associates, Milford, MA)
were equilibrated by washing with methanol (5
ml), distilled water (5 ml) and then 4% acetic acid
(5 ml). Each 2-ml plasma sample was diluted with
3 ml of 4% acetic acid and loaded onto a column;
these were washed with 25% ethanol (3 ml), and
eluted with 4% acetic acid in 86% ethanol (2 x 1
ml). The eluates were evaporated under nitrogen in
a waterbath at 37°C, and reconstituted in borate
buffer of pH 8.4 (2 ml). Duplicate extracted
samples and standards containing 1-48 pg/ml of
endothelin-1 (each 200 /zl) were incubated with
rabbit polyclonal antibody raised against endo¬
thelin-1 (ITS Production B.V., Wijchen, Nether¬
lands; in 100 pi distilled water) and [l25I]endo-
thelin-1 (ITS; in 100 p\ distilled water). After
vortexing, tubes were incubated for 18 hours at
4°C. Donkey anti-rabbit gamma globulin bound
on solid phase (ITS; 100 p\) was added to all tubes,
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except to the total count tubes, and tubes were
incubated for 30 min at room temperature. After
adding distilled water (1 ml), tubes were centri-
fuged for 15 min at 2000 x g at room temper¬
ature. The amount of radioactivity in the
antibody-bound fraction was determined by
gamma counting for 2 min. The recovery of added
endothelin-1 was 84%. Intra- and inter-assay coef¬
ficients of variation were 2.4% (n = 6) and 4.2%
(n = 5), respectively. The sensitivity of this assay is
1 pg/ml endothelin. Cross reactivities of the assay
with endothelin-1, endothelin-2, endothelin-3 and
proendothetin-1 are 100, 52, 96 and 7%, respec¬
tively. The normal range (mean ± 2 S.D.) for
plasma immunoreactive endothelin with this
assay, derived from blood obtained from 19
healthy control subjects (six female; age, 20-38
year) maintained recumbent for 30 min, is 2.7-7.5
pg/ml (mean = 5.1).
2.3. Statistical analysis
Statistical analysis was performed using
Student's paired and unpaired /-tests, together
with simple and multiple regression analysis of
plasma immunoreactive endothelin against time
from resuscitation, arterial hydrogen ion concen¬
tration and oxygen tension (Pa02) in survivors and
non-survivors, taking significance at the 5% level.
Results are expressed as mean ± S.D., with
ranges provided where relevant.
3. Results
During the study period, 38 patients fulfilled the
entry criterion; 13 were female and 25 were male
with mean age 67 years (range, 49-91). Fifteen
patients left the resuscitation room alive and 23
died. The mean time from arrest to commence¬
ment of resuscitation was significantly shorter in
survivors (5 ± 7 min) than in non-survivors
(10 ± 8 min; P = 0.03). The primary documented
rhythm was ventricular fibrillation in 20, asystole
in 14 and electromechanical dissociation in four.
All 15 of the survivors had ventricular fibrillation.
All patients received intravenous adrenaline
(2.1 ± 1 mg), with non-survivors (2.9 ± 1 mg)
tending to receive higher doses than survivors
(1.3 ± 0.9 mg; NS). Non-survivors also received
more atropine (0.6 ± 0.2 mg) than survivors
(0.2 ± 0.2 mg; P = 0.01). The mean time from
onset of resuscitation to obtaining the first sample
for endothelin assay was 20 ± 14 min in survivors,
and 25 ± 12 min in non-survivors (P = 0.27), with
between one and four samples taken per patient
(mean = 2.1).
The mean plasma concentration of endothelin
was 5.4 ± 2.3 pg/ml in the first sample obtained
from all patients presenting with cardiac arrest.
This was not significantly different from our nor¬
mal range. Endothelin concentrations in the first
sample from survivors (5.9 ± 2.6 pg/ml) were not
significantly different from those in non-survivors
(5.1 ± 2.1 pg/ml). However, plasma endothelin
fell significantly between the first (5.4 ± 2.2
pg/ml) and last (3.5 ± 1.8 pg/ml; P = 0.002)
samples in those non-survivors who had serial
samples taken, but tended to increase in those
survivors who had serial samples taken (from
5.6 ± 2.4 pg/ml to 7.0 ± 2.8 pg/ml; P = 0.16; Fig.
1). In addition, while there was no significant cor¬
relation between endothelin concentrations and
time from institution of resuscitation in survivors
(r = 0.10; P = 0.68), there was a significant nega¬
tive correlation in non-survivors (r = -0.45;
P = 0.002; Fig. 1).
Nineteen patients had simultaneous samples
obtained for arterial blood gas analysis, with a
mean time to arterial sampling of 19 ± 11 min in
survivors and 26 ± 10 min in non-survivors (not
significantly different; P = 0.15). Arterial Pa02
was not significantly different between survivors
(mean = 21 ± 16 kPa) and non-survivors (mean =
20 ± 22 kPa; P = 0.89), and Pa02 did not cor¬
relate with plasma endothelin concentration in
either survivors (r = 0.13; P = 0.74) or non-
survivors (r = 0.09; P = 0.81). Hydrogen ion con¬
centration was significantly (P = 0.003) lower in
survivors (mean = 55 ± 18 mmol/1) than non-
survivors (mean - SI ± 22 mmol/1). There was a
positive correlation between the degree of acidosis
and endothelin concentration in the survivors
(r = 0.75; P = 0.02), but not in the non-survivors
(r = 0.26;P = 0.46; Fig. 2).
In a multiple regression analysis of endothelin
concentrations in all samples against outcome,
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Fig. 1. Plasma immunorcactivc endothelin concentrations plotted against time from institution of resuscitation in individual survivors
(A) and non-survivors (B) from cardiac arrest. Endothelin concentrations fall with time in non-survivors (P = 0.002), but not survivors
(F-0.16), of cardiac arrest. Correlation between plasma cndothclin and time is also shown and is significant for non survivors
(r = -0.45; P = 0.002), but not for survivors (r = 0.10; P = 0.68).
time from resuscitation, arterial hydrogen ion
concentration and Pa02, there was a significant
positive association with outcome (r = 0.37;
P = 0.0009), but not with the other factors.
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Fig. 2. Correlation between plasma immunoreactive endothelin
concentration and arterial hydrogen ion concentration in
survivors (r = 0.75; P = 0.02) from cardiac arrest.
4. Discussion
In this study, plasma immunoreactive endo¬
thelin was not elevated in patients with cardiac
arrest. This is an unexpected finding, given the
severe metabolic disturbance that occurs following
cardiac arrest. This includes severe hypoxaemia,
metabolic acidosis and massive release of cate¬
cholamines [17]; factors which stimulate genera¬
tion of endothelin-1 [3,18,19], Further, it might be
expected that plasma endothelin concentrations
would increase due to decreased renal clearance
during circulatory standstill and resuscitation. It is
unlikely that our negative findings could be
accounted for by the difference in ages between the
patients and the control group, because plasma
endothelin concentrations do not appear to be
affected by age [24],
Plasma endothelin may fail to rise early after
cardiac arrest because endothelin-1 is not stored
within endothelial cells and de novo synthesis of
the peptide takes several hours to occur. This is
certainly the case for stimulation of generation of
endothelin-1 in vitro by hypoxia and catechol-
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amines [3,18,19], However, plasma endothelin can
increase within minutes in vivo in man, in response
to stimuli such as orthostasis and the cold pressor
test [6]. Generation of endothelin-1 by isolated
endothelial cells is stimulated by shear stress [25],
Therefore, endothelin concentrations may fail to
increase because of decreased exposure of endo¬
thelial cells to shear stress during cardiac arrest,
particularly pulsatile shear stress. In addition, the
adverse physiological conditions that occur during
cardiac arrest may prevent DNA transcription,
protein production from mRNA or the activity of
proendothelin-1 converting enzyme. Such condi¬
tions may help to explain why endothelin concen¬
trations fall with time in non-survivors.
Although such factors may account for the lack
of elevation of endothelin-1 concentrations early
in resuscitation, they do not explain why en¬
dothelin concentrations are not increased later in
the course of the arrest. It is possible that other
mechanisms come into play to prevent increases in
endothelin generation. These may include an
increase in the generation of nitric oxide, and of A-
and C-type natriuretic peptides, as well as rapid
destabilisation of the mRNA for endothelin-1
[6,26].
Although there was no difference in plasma
endothelin concentrations at presentation between
survivors and non-survivors, there was a signifi¬
cant positive association between outcome and
plasma endothelin concentrations in multiple
regression analysis. This relation with outcome
may help to explain the associations we observed
with time and hydrogen ion concentrations in the
non-survivors and survivors, respectively.
As opposed to blood flow to the heart and
brain, blood flow to peripheral tissues is very poor
during cardiopulmonary resuscitation. This leads
to local tissue hypoxia, even in the presence of
apparently adequate arterial Pa02. This in turn
causes a local metabolic acidosis, which may stim¬
ulate production of endothelin-1, which will tend
to accumulate in pooled blood in these tissues. The
positive correlation of endothelin concentrations
with hydrogen ion only in survivors, may therefore
be most readily explained by higher peripheral
tissue blood flows during resuscitation in these
patients, with greater venous return of peripheral
blood, containing high concentrations of endo¬
thelin-1. The failure of plasma endothelin to cor¬
relate with hydrogen ion in non-survivors is not
explained by survivors having a longer delay to ar
terial sampling, allowing more time for generation
of endothelin, because survivors tended to have a
shorter time from resuscitation to arterial sam¬
pling than non-survivors. Neither can the associa¬
tion be attributed to a greater degree of acidosis in
survivors, reflecting a more potent stimulus for
generation of endothelin, because this group had
significantly lower hydrogen ion concentrations.
Because plasma endothelin concentrations are
not elevated at presentation in patients with
cardiac arrest, it is likely that endothelin has no
major role as a circulating pressor hormone in this
condition. However, the failure of circulating
endothelin concentrations to increase does not
exclude a role for endothelin in the cardiovascular
response to cardiac arrest. Sustained endothelin
generation may occur without an increase in circu¬
lating endothelin, because generation is directed
away from the lumen of the blood vessel. Here,
experimental evidence may be helpful, using
specific receptor antagonists or inhibitors of pro-
endothelin-1 converting enzyme in animal models
to determine whether local generation of endo¬
thelin contributes to the restoration of vascular
tone following cardiac arrest.
During cardiac arrest and cardiopulmonary re¬
suscitation, vasopressor agents such as adrenaline
are used to increase systemic vascular resistance in
order to improve myocardial and cerebral blood
flow [27], As endothelin-1 has potent long lasting
vasoconstrictor, pressor and positive inotropic
effects [6], high endothelin concentrations may be
beneficial during cardiac arrest. Although the cor¬
relation of plasma endothelin with outcome may
reflect the adverse physiological milieu that occurs
during cardiac arrest, it is also possible that the fall
in endothelin concentrations in non-survivors con¬
tributes to their poor prognosis.
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Reduced Responsiveness to Endothelin-1 in Peripheral Resistance
Vessels of Patients With Syndrome X
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Edinburgh, Scotland
Objectives. This study sought to assess the contribution and
action of nitric oxide and endothelin-1 in peripheral resistance
vessels of patients with syndrome X.
Background. Patients with syndrome X may have a generalized
disorder of vascular and endothelial function, promoting vaso¬
spasm.
Methods. Changes in blood flow responses to intrabrachial
infusion of the endothelium-dependent vasodilators substance P
and acetylcholine, the endothelium-independent nitric oxide do¬
nor sodium nitroprusside and the endothelin type A (ETA)
receptor antagonist BQ-123 were assessed using venous occlusion
plethysmography in 10 patients with syndrome X and 10 matched
control subjects. Vasoconstrictor responses to the nitric oxide
synthase inhibitor l-A^'-monomethyl arginine (l-NMMA) and
endothelin-1 were also determined.
Results. There were no significant differences in the responses
to acetylcholine, substance P, sodium nitroprusside or BQ-123
between patients and control subjects. However, despite similar
degrees of vasoconstriction in response to l-NMMA in both
groups, endothelin-1 caused a reduction in forearm blood flow of
only 20 ± 2% in patients with syndrome X compared with 35 ± 3%
in matched control subjects at 90 min (p < 0.001). Although
plasma endothelin-1 concentrations were not significantly higher
in patients with syndrome X (4.8 vs. 4.0 pg/ml, p = 0.17), the
vasoconstriction caused by endothelin-1 infusion correlated in¬
versely with plasma endothelin-1 concentrations (r = —0.51, p =
0.04).
Conclusions. Patients with syndrome X had normal basal and
stimulated nitric oxide activity and basal endogenous ETA
receptor-mediated vascular tone. However, despite otherwise nor¬
mal vascular function, there was reduced responsiveness to exog¬
enous endothelin-1, possibly reflecting overactivity of this system
and ETa receptor downregulation.
(J Am Coll Cardiol 1998;31:1585-90)
©1998 by the American College of Cardiology
Over 100 years ago, Sir William Osier described a condition of
"hysterical angina" or "pseudoangina" in patients who had
typical anginal pain but were found to have normal coronary
arteries after death (1). With the emergence of electrocardi¬
ography and coronary angiography, this condition became
known as syndrome X (2). The precise definition of this
syndrome varies among centers and clinicians. However, a
relatively homogeneous group of patients can be defined on
the basis of typical anginal chest pain, a positive exercise
tolerance test and a normal coronary angiogram (3,4).
Results from several major studies suggest that within
syndrome X there is a substantial subgroup of patients with
abnormal vascular responses. Various investigators have doc-
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umented impaired coronary vascular reserve with abnormal
responses to vasodilators (5-8) and to atrial pacing (9,10).
Some investigators (11) have postulated that in this subgroup
of patients with syndrome X, the chest pain is a consequence of
increased coronary resistance vessel tone leading to ischemic
pain—so-called "microvascular angina"—and that this may be
due to endothelial dysfunction (6,8,12). Evidence in favor of an
ischemic origin of the chest pain in syndrome X arises from
histologic abnormalities seen in myocardial biopsies (13), the
reduction of myocardial blood flow (by positron emission
tomography and thallium scanning) (7,13,14) and the identifi¬
cation of elevated coronary sinus lactate concentrations (10).
Moreover, the vascular abnormalities of syndrome X are not
confined to the coronary circulation because impaired reactive
hyperemia to forearm ischemia (12) and structural alterations
in the small arteries of the skin and subcutaneous tissue (15)
have been detected. Therefore, there may be a generalized
dysfunction of vascular or endothelial function, as opposed to
a local coronary abnormality, in syndrome X.
Both the nitric oxide and endothelin systems contribute to
the maintenance of basal peripheral vascular tone in humans
(16,17). The aim of the current study was to assess the
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Abbreviations and Acronyms
ANOVA = analysis of variance
ECG = electrocardiogram
ETa receptor = endothelin type A receptor
ET„ receptor = endothelin type B receptor
i.-NMMA = L-M'-monomethyl arginine
vWF = von Willcbrand factor
peripheral resistance vessels of patients with syndrome X. The
peripheral vascular actions of endogenous and exogenous
nitric oxide and endothelin-1 were determined using the nitric
oxide synthase inhibitor, l-A^-monomethyl arginine (l-
NMMA), the nitric oxide donor, sodium nitroprusside, the
endothelin type A (ETA) receptor antagonist, BQ-123, and
endothelin-1 peptide. In addition, endothelial cell function was
assessed using the endothelium-dependent, nitric oxide-
generating vasodilators, substance P and acetylcholine (18).
Methods
Patients. Patients with syndrome X were recruited accord
ing to the criteria in Table 1 and were matched by age and
gender with healthy control subjects. The patients had under¬
gone coronary angiography and exercise treadmill tests within
12 months of the study and were considered to have normal
smooth coronary arteries on angiography by two independent
cardiologists. All subjects attended a screening visit and re¬
ceived a clinical examination, rest electrocardiogram (ECG),
echocardiogram and oral glucose tolerance test. Control sub¬
jects did not have a history of chest pain or clinically significant
disease and had a normal rest ECG and echocardiogram.
Studies were undertaken with the approval of the Lothian
Research Ethics Committee and were in accordance with the
Declaration of Helsinki. Each subject gave written informed
consent before entry into the study.
Assays. Plasma endothelin-1 (Peninsula Laboratories Eu¬
rope Ltd., St. Helens, United Kingdom) and big endothelin-1
(Peninsula Laboratories Europe Ltd.) were determined by
radioimmunoassay (19); von Willebrand factor (vWF) antigen
(Dako A/S, Glostrup, Denmark) and insulin (Boehringer
Mannheim GmbH Diagnostica, Mannheim, Germany) by an
enzyme-linked immunosorbent assay; and nonesterified fatty
acid (Wako, Neuss, Germany), triglyceride (Boehringer Mann¬
heim GmbH Diagnostica, Mannheim, Germany) and choles¬
terol (Boehringer Mannheim GmbH Diagnostica, Mannheim,
Germany) by an enzymatic colorimetric method. Low density
lipoprotein cholesterol was determined by the method of
Friedewald et al. (20).
Study design. Blood flow was measured in both forearms
by venous occlusion plethysmography using mercury-in-Silastic
strain gauges applied to the widest part of the forearm, as
described previously (17,21). Blood pressure was monitored in
the noninfused arm at intervals throughout each study using a
scmiautomatcd, noninvasive oscillometry sphygmomanometer
(22) (Takeda UA 751, Takeda Medical Inc, Tokyo, Japan).
The brachial artery of the nondominant arm was cannulated
with a 27-standard wire gauge steel needle (Cooper's Needle
Works Ltd., Birmingham, United Kingdom) under 1% lido-
caine (xylocaine; Astra Pharmaceuticals Ltd., Kings Langley,
United Kingdom) local anesthesia. The total rate of intraarte¬
rial infusions was maintained constant throughout all studies at
1 ml/min. Substance P (Clinalfa AG, Laufelfingen, Switzer¬
land), sodium nitroprusside (Nipride; Roche, Welwyn Garden
City, United Kingdom), acetylcholine (Miochol; Iolab, Brack-
Table 1. Inclusion and Exclusion Criteria for Study
Inclusion Criteria Exclusion Criteria
Age between 21 and 75 years Hypertension (systolic blood pressure >160 mm Hg or
diastolic blood pressure >90 mm Hg)
Typical anginal chest pain Diabetes mellitus
Echocardiography
>2-mm horizontal or downsloping ST segment Left ventricular hypertrophy (>1.3-mm thickness
depression (60 ms after the J point) on exercise of posterior wall of left ventricle)
treadmill testing using the Bruce protocol Regional wall motion abnormalities
Valvular heart disease (trivial mitral
Angiographicalty normal smooth coronary arteries incompetence was permitted)
Impaired ventricular function
Electrocardiography
Left ventricular hypertrophy (>35 mm from
summation of amplitude of S wave in lead V,
and R wave in lead or V„)
Left bundle branch block
Pathologic 0 waves or T wave inversion
Any evidence of coronary artery atherosclerosis
Previous myocardial infarction
History of dyspepsia, peripheral vascular disease or
cerebrovascular disease
Other significant cardiac disease
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Table 2. Characteristics of Study Group













Age (years) 56 ± 1 55 ±3 56 ±2 54 ±3 54 ±3 55 ±4
Gender (M/F) 4/11 4/7 4/6 4/6 3/7 3/7
Body mass index (kg/m2) 28 ± 1 25 ± 1* 28 ±2 25 ± 1* 28 ±2 25 ± 1*
Blood pressure (mm Hg)
Systolic 138 ± 4 127 ±3 139 ±5 127 ±3 137 ±4 128 ±3
Diastolic 78 ± 1 77 ±2 79 ±2 77 ±2 79 ±2 78 ±2
Heart rate (beats/min) 71 ± 1 70 ± 1 70 ± 1 70 ± 1 70 ± 1 70 ± 1
ST segment depression during treadmill exercise 2.7 ± 0.2 — 2.6 ± 0.2 — 2.7 ± 0.1 —
testing (mm)
Plasma endothelin-1 (pg/ml) 4.8 ± 0.5 4.0 ± 0.2 4.5 ± 0.6 4.0 ± 0.2 4.8 ± 0.5 4.0 ± 0.3
Plasma big endothelin-1 (pg/ml) 20 ±2 18 ±2 17 ± 0.7 18 ±1.7 20 ± 1.5 19 ± 1.9
Plasma vWF (Ill/ml) 1.17 ±0.12 0.98 ± 0.05 1.13 ±0.16 0.97 ± 0.05 1.3 ±0.2 0.98 ± 0.05
Total cholesterol (mg/dl) 258 ± 15 268 ± 23 260 ± 21 257 ± 23 258 ± 23 276 ± 24
LDL cholesterol (mg/dl) 174 ± 13 197 ± 22 175 ± 18 186 ± 22 178 ± 19 202 ± 24
HDL cholesterol (mg/dl) 55 ±4 47 ±5 58 + 5 47 ±5 50 ±5 49 ± 5
Triglycerides (mg/dl) 141 ± 15 120 ± 22 134 ± 18 121 ± 24 146 ± 19 124 ± 25
Oral glucose tolerance
Fasting glucose (mmol/liter) 4.9 ± 0.2 4.9 ± 0.2 5.0 ± 0.2 4.9 ± 0.1 5.0 ± 0.1 4.9 ± 0.2
2-h glucose (mmol/liter) 5.1 ± 0.4 5.2 ± 0.4 5.0 ± 0.4 4.9 ± 0.4 5.2 ± 0.5 5.4 ± 0.4
Fasting insulin (IU/ml) 8.9 ± 1.5 10.9 ± 2.7 7.2 ± 1.3 9.7 ± 2.7 9.9 ± 2.1 11.6 ±2.9
2-h insulin (IU/ml) 45.3 ± 14.5 KJ G/l bo 1+ NO 36.5 ± 15 22.6 ± 5.6 59.0 ± 22.5 28.0 ± 6.1
Fasting NEFA (mEq/liter) 584 ±71 572 ± 76 541 ±60 550 ± 81 626 ± 108 604 ± 77
2-h NEFA (mEq/liter) 26 ± 12 33 ± 13 29 ± 17 36 ± 14 32 ± 18 36 ± 14
Thyroid stimulating hormone (mU/liter) 2.0 ± 0.6 1.3 ±0.3 2.0 ± 0.6 1.4 ±0.3 2.5 ± 0.8 1.2 ±0.2
Thyroxine (pmol/liter) 15.2 ± 0.9 15.3 ± 0.8 15.1 ± 1.0 15.3 ± 0.8 14.9 ± 1.0 15.6 ± 0.8
Urea (mmol/liter) 5.8 ± 0.3 5.2 ± 0.3 5.8 ± 0.3 5.2 ± 0.3 5.8 ± 0.4 5.1 ±0.4
*p = 0.02 (unpaired t test). Data are presented as mean value ± SD. F = female; HDL
NEFA = nonesterified fatty acids; Pts = patients; vWF = von Willebrand factor.
= high density lipoprotein; LDL = low density lipoprotein ; M = male:
nell, United Kingdom), l-NMMA (Clinalfa AG), endothelin-1
(Clinalfa AG) and BQ-123 (American Peptide Company) were
administered after dissolution in 0.9% saline (Baxter Health¬
care Ltd., Thetford, United Kingdom). Before the subjects
underwent each of the studies, aspirin was discontinued for 10
days and vasoactive or nonsteroidal anti-inflammatory drugs
for at least 5 half-lives. All subjects abstained from alcohol for
24 h and from food and caffeinated drinks for at least 5 h
before each study. Subjects rested recumbent in a quiet,
temperature-controlled room maintained at 23.5 to 24.5°C.
Before participating in one of the following protocols, saline
was infused for the first 30 min to allow time for equilibration,
with forearm blood flow measured every 10 min and the final
measurement taken as basal blood flow.
Nitric oxide system. In 10 patients with syndrome X and 10
age- and gender-matched control subjects, intrabrachial sub¬
stance P was administered at 1, 2 and 4 pmol/min (18,23);
sodium nitroprusside at 5, 15 and 30 nmol/min (23); and
acetylcholine at 27.5, 55 and 110 nmol/min (16,18,23) for 6 min
at each dose. Administration of the three agents was separated
by 20-min saline infusions and given in random order. Finally,
after a further 20-min saline infusion, i.-NMMA was adminis¬
tered at 4 pmol/min (16,18) for 10 min. Forearm blood flow
measurements were made for the last 3 min of each infusion
period.
Endothelin system. In 10 patients with syndrome X and 10
age- and gender-matched control subjects, intrabrachial BQ-
123 was administered at 10 nmol/min (17) for 90 min. On a
separate study day, at least 1 month later, endothelin-1 was
administered at 5 pmol/min (17) for 90 min. Forearm blood
flow measurements were made for 3 min every 6 min.
All subjects were not able to attend both the nitric oxide
and endothelin studies; five patients and nine control subjects
were common to both phases.
Data analysis and statistics. Study group size, based on
reproducibility data deiived from forearm resistance vessel
responses to endothelin-1, gave a 90% power to detect a 24%
difference in blood flow responses at a significance level of 5%.
Data were examined, as appropriate, by two-way analysis of
variance (ANOVA) with repeated measures, the two-tailed
unpaired Student / test and regression analysis using Excel
version 5.0 (Microsoft). All results are expressed as the mean
value ± SEM. Statistical significance was set at the 5% level.
Results
Subject characteristics. Patients with syndrome X were
well matched with control subjects for age, gender and serum
lipid and thyroid profiles (Table 2). The rest ECG was normal
in both patients and control subjects, with no baseline ST
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Figure 1. Responses in forearm blood flow to incremental doses of
substance P (circles [pmolmin]), acetylcholine (squares [nmol/min])
and sodium nitroprusside (triangles [nmol/min]) in patients with
syndrome X (solid symbols) and control subjects (open symbols). There
were no significant differences between patients and control subjects.
segment changes. Body mass index was significantly higher in
the patients with syndrome X (p = 0.02), with a trend (0.10 >
p > 0.05) toward higher systolic blood pressures and 2-h
plasma insulin concentrations. There were no significant dif¬
ferences in other hemodynamic or metabolic variables. There
were no significant differences in mean plasma vWF (p -
0.16), endothelin-1 (p = 0.17) or big endothelin-1 concentra¬
tions (p = 0.58).
Nitric oxide system. There were no significant differences
in length (25.4 ± 0.7 vs. 25.2 ± 0.7 cm) or basal bluud (low
(3.8 ± 0.4 [range 2.9 to 9.2] vs. 3.3 ± 0.5 [range 1.0 to 6.3]
ml/100 ml per min) of the infused forearm in patients with
syndrome X versus control subjects (24). There were no
significant changes in blood pressure, heart rate or blood flow
in the noninfused forearm during the course of the studies.
Substance P. acetylcholine and sodium nitroprusside all
caused dose-dependent vasodilation in the infused forearm
(p < 0.001 for all) (Fig. 1). l-NMMA caused a 36.7 ± 3.4%
(p < 0.001) and 38.4 ± 3.1% (p = 0.007) reduction in forearm
blood flow in patients with syndrome X and control subjects,
respectively. There were no significant differences in the blood
flow responses to substance P, acetylcholine, sodium nitroprus¬
side or l-NMMA between patients and control subjects.
Endothelin system. There were no significant differences in
basal blood flow of the infused forearm on the endothelin-1
(3.5 ± 0.8 [range 2.3 to 6.2] vs. 4.2 ± 0.5 [range 1.8 to 10.2]
ml/100 ml per min) and BQ-123 (3.2 ± 0.9 [range 1.7 to 6.4] vs.
4.1 ± 0.5 [range 1.0 to 10.0] ml/100 ml per min) study days in
patients with syndrome X versus control subjects. There were
no significant changes in blood pressure, heart rate or blood
flow in the noninfused forearm during the course of the
BQ-123 and endothelin-1 study days.
BQ-123 caused a progressive vasodilation (p < 0.001 by
ANQVA for both groups), which appeared to reach a maxi¬
mum by 72 min (Fig. 2). At 90 min. forearm blood flow was
increased by 39 ± 6% in the patients with syndrome X and
37 ± 9% in the control subjects. There was no significant
difference between patients and control subjects.
Endothelin-1 caused a progressive vasoconstriction (p <
0.001 by ANOVA for both groups), which appeared to reach a
maximum by 66 min (Fig. 2). The reduction in forearm blood
flow was significantly (p < 0.001 by two-way ANOVA) less in
the patients with syndrome X (20 ± 2% [range 9% to 29%] at
90 min) than in the control subjects (35 ± 3% [range 25% to
53%]) at 90 min. Using data from all subjects, the degree of
vasoconstriction produced by endothelin-1 infusion was in¬
versely correlated with plasma endothelin-1 concentrations
(r = -0.51, p = 0.04), but the correlation with mean arterial
pressure was not significant (r = 0.19, p = 0.41).
Discussion
A number of previous studies have used broader criteria for
defining syndrome X, including patients with >1 mm ST
segment depression (8,25-27) and those with minor, "hemo-
dynamically nonsignificant" atherosclerotic plaques in the cor¬
onary arteries (27,28). In an attempt to define a more precise
group of patients with syndrome X, we employed criteria of
>2 mm ST segment depression on exercise testing in combi¬
nation with typical anginal chest pain and normal smooth
coronary arteries on angiography. Patients with other potential
causes of chest pain or with coexisting conditions associated
with microangiopathy were excluded. In agreement with pre¬
vious studies (26,29), our patients with syndrome X tended to
be insulin-resistant, although they also had a larger body mass
index and tended to have a higher systolic blood pressure.
Syndrome X and endothelin-1. For the first time, to our
knowledge, we report that patients with syndrome X, as
compared with control subjects, have a reduced responsiveness
of peripheral resistance vessels to endothelin-1 despite normal
vasodilation to the ETA receptor antagonist BQ-123. In an
earlier study with a larger number of patients (n = 40), Kaski
Figure 2. Responses in forearm blood How to 90-min infusions of
BQ-123 (circles) and endothelin-1 (squares) in patients with syndrome
X (solid symbols) and control subjects (open symbols), p < 0.001
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et al. (25) reported a significant elevation in plasma
endothelin-1 concentrations (3.8 ± 1.3 vs. 2.9 ± 0.7 pg/ml) in
patients versus control subjects. We did not demonstrate a
significant elevation in plasma endothelin-1 or big endothelin-1
concentrations in our patients with syndrome X, although the
magnitude was similar to the previous study and probably
reflects the fact that the study was not powered to detect such
a difference. However, interestingly, we did find an inverse
correlation between endothelin-1-induced vasoconstriction
and circulating plasma endothelin-1 concentrations. This sug¬
gests that in the presence of higher endothelin-1 concentra¬
tions, possibly related to increased endothelin generation,
there may be ETA receptor downregulation such that the
overall contribution of ETA receptor-mediated vascular tone
remains unchanged. Although ETA receptor downregulation
may explain the reduction in vasoconstriction to exogenous
endothelin-1, endothelin type B (ETB) receptor function may
also be important and merits further investigation. Indeed,
abnormalities of ETB receptor function have been demon¬
strated in the coronary vessels of an animal model of heart
failure (30), in the peripheral resistance vessels of patients with
chronic heart failure (31) and in human atherosclerotic vessels
(32).
We have recently shown that the majority of the vasodila¬
tion seen with selective ETA receptor antagonism results from
nitric oxide release (33). Given our findings of normal nitric
oxide-mediated responses in syndrome X, it may not be
surprising that the BQ-123 responses were similar in the two
groups. Thus, detecting a reduction or augmentation of endog¬
enous endothelin-l-mediated vasoconstriction may be ob¬
scured by the nitric oxide release seen with BQ-123.
Syndrome X and nitric oxide. Despite evidence in support
of a nitric oxidc-medialed endothelial dysfunction involving
the coronary resistance vessels of patients with syndrome X
(6,8,28,34), we were unable to detect a significant abnormality
affecting normal basal and stimulated release of, and sensitivity
to, nitric oxide in the resistance vessels of the forearm circu¬
lation in vivo. This is in agreement with the findings of normal
endothelium-dependent and -independent nitric oxide-
mediated vasorelaxation in structurally abnormal peripheral
resistance arteries of patients with syndrome X studied ex vivo
(15). However, in a post hoc analysis, we did find that plasma
concentrations, of vWF were above the normal i angc (0.42 to
1.22 IU/ml) in six patients with syndrome X, but in none of the
control subjects (p < 0.01 by chi-square test). Given our
findings and those of Kaski et al. (25). it would appear that
patients with syndrome X may have a generalized endothelial
dysfunction that does not universally affect the nitric oxide
system.
Study limitations. The failure to detect differential re¬
sponses to endothelium-dependent nitric oxide-mediated pe¬
ripheral vascular responses may reflect the relative hypercho¬
lesterolemia of the study groups. Both the patient and control
groups had relatively high mean scrum cholesterol concentra¬
tions, although this is consistent with the average prevailing
serum cholesterol concentrations in the Scottish population
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(35). This may have conferred some degree of endothelial
dysfunction on the subjects (36) and obscured the contribution
of further dysfunction. In addition, the slow onset and offset of
action of endothelin agonists and antagonists mean that only
one dose of each agent can be administered on each study day.
Thus, a full dose-response relation cannot easily be deter¬
mined. Moreover, further characterization of responses medi¬
ated by the ETB receptors is now needed to further clarify this
response. There also remains the possibility that the observed
differences are related to the disparity in body mass index
between the two groups.
Conclusions. Our study suggests that despite normal over¬
all peripheral resistance vessel function, there appears to be a
reduced responsiveness to endothelin-1 in patients with syn¬
drome X, consistent with increased endothelin-1 production
and ETa receptor downregulation. Further studies are now
required to fully characterize the role of the endothelin system
in both the peripheral and coronary circulations in this condi¬
tion.
Wc acknowledge the assistance of Dr. Rudolph Riemersma, Neil Johnston and
Frances Stenhouse in performing the assays.
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Hormonal and renal differences between low dose
and high dose angiotensin converting enzyme
inhibitor treatment in patients with chronic heart
failure
























Objective—To assess the differential
effects of low dose (S mg) and high dose
(20 mg) lisinopril treatment on cardiovas¬
cular hormones, renal function, and
blood pressure over 24 hours in patients
with heart failure.
Design—Double-blind crossover study.
Setting—Department of Clinical Phar¬
macology, Ninewells Hospital and
Medical School, Dundee.
Patients—19 patients with chronic heart
failure and left ventricular ejection frac¬
tion ^ 45%.
Results—Plasma concentrations of aldos¬
terone and endothelin were lower on the
20 mg dose (plasma aldosterone mean at
peak drug effect: 90-7 v 152*0 pg/ml,
P< 0*001; mean at trough effect: 124-7 v
174*4 pg/ml, P<0-01; plasma endothelin
at trough effect 4*70 v 6-04pmol/l, P =
0*03). Creatinine clearance was lower on
20mg lisinopril (68*7 v 82*1 ml/min,
P<0*05). The area under the curve for
diastolic blood pressure over 24 hours was
significantly lower on 20 mg (mean differ¬
ence 3*0 mm Hg, P = 0*04); for systolic
blood pressure there was a similar trend
(mean difference 5*7 mmHg, P = 0*05).
Plasma concentrations of atrial natri¬
uretic peptide (ANP) and B-type natri¬
uretic peptide were similar for both
doses; urinary excretion of ANP was
lower on 20 mg (12*2 v 13*6 pmol,
P < 0*05).
Conclusions—These results indicate that
within the usual therapeutic; r^rige, high
doses of lisinopril cause greater suppres¬
sion of selected cardiovascular hormones
than low doses in heart failure, but are
associated with lower creatinine clear¬
ance in some patients.
(Heart 1996;75:576-581)
Keywords: heart failure; ACE inhibition; liainopril;
hormones
The role of angiotensin-converting enzyme
(ACE) inhibitors in the treatment of heart fail¬
ure is well-established but the optimal dose is
unknown. Each of the large studies that
showed improved survival with ACE inhibitors
in heart failure used relatively high doses of
enalapril: in CONSENSUS the mean dose
was 18-4 mg,1 in VeHFT II it was 15 mg,2 and
in the SOLVD treatment limb it was 16-6 mg.1
Often the doses of ACE inhibitors prescribed
for patients with heart failure in clinical prac¬
tice are much lower, although there is little
evidence to suggest that these low doses are
effective.4 The effects of low dose (5 mg once a
day) and high dose (35 mg once a day) lisino¬
pril on mortality in over 3000 patients with
severe heart failure will be determined by the
international ATLAS trial which is due to be
completed in 1997.
It is evident from heart failure research that
the hormonal response to drug treatment is a
major determinant of its efficacy. ACE
inhibitors have a range of hormonal effects in
addition to inhibiting the conversion of
angiotensin I to angiotensin II; ACE itself is a
non-specific enzyme with several substrates,
including bradykinin—a peptide with a range
of cardiovascular and renal effects. ACE
inhibitors may therefore increase the activity of
bradykmin5 and may also indirectly affect the
turnover of other vasoactive peptides, such as
the endothelins that are released from
endothelial cells in response to angiotensin II.6
The haemodynamic effects of ACE inhibitors
may also influence the release of the cardiac
natriuretic peptides, atrial natriuretic peptide
(ANP) and B-type natriuretic peptide (BNP).7
Recent studies have shown that raised plasma
concentrations of these peptides are important
adverse prognostic indicators in patients with
ischaemic heart disease,8' suggesting that a
reduction in their secretion rates from the
heart with treatment may predict a long-term
benefit.
Though it is likely that these diverse hor¬
monal effects of ACE inhibitors, and their bio¬
logical consequences, will have different
dose-response relations, there are few data
available on the dose-related effects of ACE
inhibitors. In this study we compared directly
the effects of two doses of an ACE inhibitor,
lisinopril, in a crossover trial in patients with
heart failure who were already on long-term
ACE inhibitor treatment. The doses used (5
mg once a day and 20 mg once a day) were
chosen to represent the bottom end and the
top end of the usual therapeutic range in heart
failure. Furthermore in this study we mea¬
sured blood pressure and plasma and urine
electrolyte and hormonal concentrations over
a 24 hour period to explore possible differ¬
ences between the doses at both peak and
trough drug effect.
Hormonal and renal differences between low dose and high dose angiotensin convening enzyme inhibitor treatment 577
Patients and methods
We performed a double blind, randomised,
crossover study to compare the effects of low
dose and high dose lisinopiil in patients with
heart failure over a 24 hour period. The study
protocol was approved by the local committee
on medical research ethics. Twenty one
patients with symptomatic heart failure sec¬
ondary to ischaemic heart disease (NYHA
class n-HI) and left ventricular ejection frac¬
tion (LVEF) <; 45% were recruited. All
patients gave informed consent to participate
in the study. Two patients were unable to
complete the study protocol for personal rea¬
sons and were therefore excluded from the
efficacy analyses. All patients had been treated
with a diuretic and ACE inhibitor for at least
one month before the study. LVEF was mea¬
sured by radionuclide ventriculography within
three months of the study.
During a two week run-in period all patients
were treated with lisinopril 10 mg once a day
in place of their usual ACE inhibitor medica¬
tion and in combination with their usual
diuretic treatment. After two weeks, patients
were randomised to change their dose of
lisinopril to either 5 mg once a day or 20 mg
once a day in addition to their usual dose of
diuretic (fig 1). This new dose lasted for two
weeks; on the final day of the two week period
on this treatment the patients were admitted
to the research unit to be studied over 24
hours. After a clinical assessment the dose of
lisinopril was given under supervision with all
concomitant medication. Blood sampling and
measurements of heart rate and blood pres¬
sure were made at regular intervals throughout
the 24 hours (fig 1). All urine passed during
the study period was collected for analysis of
creatinine, electrolytes, and ANP concentra¬
tion. Urine collections from three patients
were incomplete and all urine results from
these patients were excluded from the analysis.
After this study period, patients took 10 mg
lisinopril once a day in addition to all usual
medication for two weeks, after which they
received another two weeks of treatment with
either lisinopril 5 mg once a day or 20 mg once
a day according to the randomisation plan. On
Figure I (A) Study plan
showing daily dose of
lisinopnl and timing of
study days. (B) Schedule of
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the last day of this second treatment period the
patients were again studied over 24 hours as
described above. The order of administration
of low dose and high dose lisinopril was gov¬
erned by balanced randomisation. Patient
compliance was assessed by a tablet count.
Blood pressure measurements and all blood
samples were taken after 30 minutes supine
bed rest. Throughout the rest of the study
period the patients were free to walk around;
mealtimes and bedtimes were standardised as
shown in figure 1. Blood pressure was mea¬
sured with a semi-automated sphygmo¬
manometer (Dinamap) placed around the left
arm. All of the measurements and laboratory
analyses were performed by individuals who
were blinded to the treatment.
NATRIURETIC PEPTIDE ASSAYS
Venous blood was taken into chilled tubes
containing EDTA and aprotinin (Trasylol,
Bayer, 4000 kallikrein inactivation units per
tube). Plasma was separated immediately and
stored at — 70°C until the measurement of
ANP-like immunoreactivity (ANP-li) and
BNP-li. Each peptide was measured in all of
the samples from a patient in a single assay
rim. Plasma was applied to C8 solid phase
extraction columns which had been pretreated
with 4 ml methanol, 4 ml distilled water, and
4 ml 1% trifluoroacetic acid. The columns
were washed with 9 ml of 1 % trifluoroacetic
acid and samples were eluted with 4 ml of
95% methanol and 1% trifluoroacetic acid.
Samples were dried and the radioimmunoas¬
say was performed with commercial kits sup¬
plied by Peninsula: ANP 1-28 (human,
canine) and BNP 32 (human). Recovery of
added peptides was 88% for ANP and 86% for
BNP. The coefficients of variability for each
assay were: ANP inter-assay = 11-8%, intra-
assay = 12-6%; BNP inter-assay = 14-8%,
intra-assay = 9-9%. Urinary ANP was mea¬
sured, without any prior extraction procedure,
by radioimmunoassay.
ENDOTHEUN ASSAYS
Samples were taken and stored as described
above for the natriuretic peptide assays.
Plasma immunoreactive endothelin was mea¬
sured by radioimmunoassay as described pre¬
viously.10 The recovery of added endothelin
was 84%. Intra and inter assay coefficients of
variability were 2-4% and 4-25 respectively.
The sensitivity of this assay is 2 pg/ml
endothelin. Cross reactivity of the assay with
endothelin-1, endothelin-2, endothelin-3, and
proendothelin is 100, 52, 96, and 7% respec¬
tively
ALDOSTERONE ASSAYS
Blood samples for measurement of plasma
aldosterone activity were taken into lithium-
heparin tubes; plasma was separated immedi¬
ately and stored at - 20°C until analysis.
Radioimmunoassay was performed using a
standard commercial kit (Sorin, Italy). The
intra-assay coefficient of variability was 7-8%
and the inter-assay coefficient of variability
was 9-6%.
578 Davidson, Couue, Webb, Struthers
Table I Patient characteristics
Figure 2 (A) Systolic
and (B) diastolic blood
pressure over 24 hours in
patients taking 5 mg and
20 mg of lisinopril. Results
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PLASMA ACE ACTIVITY
Blood samples for measurement of plasma
ACE activity were taken into lithium-heparin
tubes; plasma was separated immediately and
stored at — 20°C until analysis. Plasma ACE
activity was determined by the spectrophoto-




Before the study, blood samples were taken for
detection of the insertion/deletion polymor¬
phism of the gene for angiotensin-converting
enzyme. This was determined from leucocyte
DNA using the polymerase chain reaction.12
STATISTICAL ANALYSIS
For plasma concentrations of ANP, BNP, and
aldosterone the results were summarised as
mean at peak effect (mean of 6 and 13-5 hour
values for aldosterone; mean of 6 and 10 hour
values for ANP and BNP), mean at trough
effect (mean of 22 and 24 hour values for
aldosterone; mean of 22, 23, and 24 hour val¬
ues for ANP and BNP), and area under the
curve for the values over 24 hours (calculated
according to the trapezoidal method and
divided by the time period). For blood pres¬
sure and heart rate, values were expressed as
area under the curve. These summary mea¬
sures were compared between treatments
using the analysis of variance methods
(ANOVA) of Grizzle," which incorporate
effects due to period and carry-over of the pre¬
vious treatment. The analysis for these vari¬
ables is presented using differences between
adjusted means for the two treatments
(adjusted for treatment period effects). All
other variables, which had one or two values
for each dose were compared using two-tailed
paired r-tests. The assessment of carry-over
effects is a between-patient evaluation and the
test for carry-over was therefore performed at
the 10% level of significance. All other tests
were performed at the 5% level of significance.
Results
Baseline characteristics of the patients are
shown in table 1. The compliance rate was
> 85% for each patient in all parts of the
study. There were no significant differences in
symptomatic status, clinical findings, or
patient weight between the two doses of lisino¬
pril. There was no evidence of a significant
period or carry-over effect for any of the vari¬
ables measured.
BLOOD PRESSURE AND HEART RATE
Blood pressure values on each dose of lisino¬
pril are shown in figure 2. The mean area
under the curve for systolic blood pressure was
lower during the high-dose phase than during
the low-dose phase, although this effect was of
borderline statistical significance (P = 0 05).
The difference between the adjusted treatment
means (5 mg dose minus 20 mg dose) was 5-7
(95% CI 0 0 to 1 T5) mm Hg. The mean area
under the curve for diastolic blood pressure
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Table 2 Plasma electrolytes 24 hour unnary electrolytes and atrial natriuretic peptide
(ANP) excretion and creatinine clearance in patients taking 5 mg and 20 mg ofUsinopnl
(mean (SD))
Lutnopnl dose
Variable 5 mg 20 mg
Plaama (Na) (mmol/1) 137 3 (2-45) 138 1 (2 43)
Plaxma (K) (mmol/1) 4 11 (0-47) 4 18 (0 38)
Plum* (creatinine) (mmol/1) 1117 (22 1) 113 4 (25-7)
24 hour urine Na excretion (mmol) 207 6 (82 8) 212 0 (83-6)
24 hour urine K excretion (mmol) 88-4 (27 8) 80-2 (22 1)
Creatinine clearance (ml/mm) 82 2 (27-1) 68 7 (24-4)*
24 hour urinary ANP excretion (pmol) 13 6 (4-3) 12-2 (4-5)f
*P < 0*05 for 5 mg v 20 mg, fP = 0-02 for 5 mg v 20 mg.
was significantly lower during the high-dose
phase than during the low-dose phase (P =
0-04). There was no significant difference in
heart rate between doses.
PLASMA /URINARY ELECTROLYTES AND
CREATININE CLEARANCE
Creatinine clearance was significantly lower on
the 20 mg dose than on the 5 mg dose (fig 3).
There were no significant differences between
plasma and urinary electrolyte concentrations
between doses (table 2).
Figure 4 Plasma
aldosterone concentrations
over 24 hours in patients
taking 5 mg and 20 mg
hsmopnL Results are
expressed as mean (SEM).
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Table 3 Plasma ACE activity in groups divided
according to ACE genotype (mean (SD))
ACE genotype
Lisinopril dose
5 mg 20 mg
DD (n = 7) 14-38 (2 79) 10-27 (3-76)
ID (n = 7) 11-49 (8-87) 8-87 (2 62)
II (n = 5). 9 80 (4-67) 7-95 (2 62)
Total (n = 19) 12-11 (3 83) 9 14 (3-07)*
'Area under curve over 24 hours expressed as standard inter¬
national units. P < 0-01 for 5 mg v 20 mg.
ACE, angiotensin converting enzyme.
ALDOSTERONE CONCENTRATIONS
Plasma aldosterone concentrations were sig¬
nificantly lower on the 20 mg dose than on the
5 mg dose (fig 4). Mean at peak effect 90-7 v
152 0 pg/ml, P < 0 001; mean at trough effect
124-7 v 174-4 pg/ml, P<0-01. For the area
under the curve, the difference between the
treatment means (5 mg dose minus 20 mg
dose) was 44-0 (95% CI 24-0 to 63-9) pg/ml
(P < 0-001).
NATRIURETIC PEPTIDE CONCENTRATIONS
Plasma concentrations of natriuretic peptides
are shown in figure 5. There were no signifi¬
cant differences in the area under the curve or
the concentrations at peak or trough drug
effect for either ANP or BNP on the two
doses. Urinary excretion of ANP over 24
hours was significantly lower on 20 mg lisino¬
pril than on the 5 mg dose.
ENDOTHEI IN CONCENTRATIONS
Plasma concentrations of endothelin at six
hours (peak drug effect) were 4-74 v 3-27
pmol/1 on 5 mg lisinopril and 5-01 v 2-98 on
20 mg lisinopril (mean (SD), P = NS). At 22
hours (trough drug effect) concentrations were
6-04 v 3-58 pmol/1 on 5 mg lisinopril and 4-70
v 2-72 pmol/1 on 20 mg lisinopril (P = 0-03).
Figure 5 Mean plasma
concentrations over 24
hours of (A) atrial
natriuretic peptide and (B)
B-type natriuretic peptide
in patients taking 5 mg
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Plasma ACE activity was significantly lower on
high-dose than on low-dose lisinopril (table
3). There was a non-significant trend towards
lower ACE activity on both doses of lisinopril
in patients with the II genotype than in
patients with either the ID or DD genotype.
Discussion
The results of this study demonstrate signifi¬
cant dose-related effects of lisinopril within the
usual therapeutic range in patients with
chronic heart failure. It is important to note
that because all of the patients were estab¬
lished on ACE inhibitor treatment for at least
one month before the study, they had all
received a minimum of six weeks treatment
before the first study day. In fact, as figure 1
shows, most patients had been treated with
ACE inhibitors for considerably longer peri¬
ods; the results therefore represent the
response to chronic ACE inhibition. As
expected, the higher dose of lisinopnl caused a
greater degree of inhibition of ACE than the
lower dose. There was no evidence of a large
difference in the dose-response relation for any
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of the variables measured between the three
groups of insertion/deletion polymorphisms of
the ACE gene, but this study was not designed
to detect such a difference and the numbers of
patients with each of the three genotypes were
small.
The superior suppression of aldosterone
produced by the higher dose of lisinopril is
striking. The early morning rise in plasma
aldosterone which was seen on both doses of
lisinopril occurred before the patients got out
of bed. It is uncertain whether this was due
primarily to the diurnal pattern of adrenocorti-
cotrophic hormone (ACTH) release or due to
reduced drug effect at this time; the large dif¬
ference in early morning aldosterone concen¬
trations between the two doses suggests an
important drug effect, but even on the higher
dose the suppression of aldosterone was not
sustained over the 24 hour period. The impor¬
tance of aldosterone in heart failure is that it
has been shown experimentally to cause a
wide range of potentially detrimental effects.
These include increased potassium and mag¬
nesium excretion (which may promote
arrhythmias),14 impairment of baroreceptor
function,15 and stimulation of myocardial
fibrosis.16 We found that during long-term
treatment with an ACE inhibitor suppression
of aldosterone can be improved by increasing
the dose of the ACE inhibitor but this sup
pression was incomplete, especially in the
early morning. Further suppression of plasma
aldosterone may be achieved by using even
higher doses of an ACE inhibitor, nocturnal
dosing with an ACE inhibitor, the addition of a
receptor antagonist, or a combination of these
approaches.
The role of the endothelins in the patho
physiology of cardiovascular disease is not
clearly established. It is known that the plasma
concentrations of these peptides are increased
in heart failure17 and the concomitant increase
in plasma concentrations of big endothelin-1 is
consistent with increased production of
endothelins in heart failure.18 It has recently
been reported that blockade of endothelin
receptors causes vasodilatation in patients with
heart failure," which suggests that endothelin
contributes to the increase in vascular tone
associated with this condition. Previously
there have been conflicting reports of the
effects of short-term ACE inhibition on
plasma endothelin in experimental and clinical
heart failure20 21; the data from the current
study provide the first evidence that endothe¬
lin concentrations can be suppressed more by
high dose than by low strengthened by our
observation that the higher dose of lisinopril
reduced endothelin concentrations despite a
fall in creatinine clearance, suggesting that
reduced secretion of endothelins, rather than
increased renal clearance, was reponsible for
the effect. ACE inhibitors may reduce the
secretion of endothelin by reducing the con¬
centration of angiotensin II, a potent stimulant
for endothelin release,22 or by increasing
bradykinin activity, resulting in increased
production of nitric oxide, an inhibitor of
endotheiin release.21 On the basis of current
knowledge it is uncertain whether the
observed difference in endothelin concentra¬
tions is of clinical relevance, but it suggests an
intriguing alternative mechanism for some of
the beneficial effects of ACE inhibitors.
The observed differences in blood pressure
between the two doses of lisinopril are small
overall, but six hours after dosing (that is, peak
drug effect) the mean systolic blood pressure
was about 10 mm Hg lower and the mean
diastolic blood pressure was about 1 mm Hg
lower on high dose than on low dose lisinopril
(fig 2). Though most patients had very little
change in creatinine clearance between doses,
in some patients it dropped considerably on
the higher dose. This was not associated with a
rise in serum creatinine during the two weeks
of the study, but it is possible that such alter
ations in renal function might be detrimental
in the long term.
The similar plasma concentrations of atrial
and B-type natriuretic peptide on each dose
are surprising in view of the described differ¬
ences in blood pressure. It seems likely that
the reduction in afterload produced by the
higher dose would result in a reduced secre¬
tion of these peptides from the myocardium, a
process that is thought to depend mainly on
cardiac stretch.24 Previous studies have
reported a reduction in natriuretic peptide
concentrations during acute ACE inhibition in
heart failure7 but other investigators showed
that the relation between plasma ANP conccn
orations and pulmonary capillary wedge pres
sure is weakened during ACE inhibition,25 a
phenomenon which has not been fully
explained. It is likely that in the present study
any favourable cardiac effect of high dose
lisinopril is offset by reduced renal clearance of
ANP and BNP, due to reduced renal blood
flow. This explanation is supported by the
lower urinary concentrations of ANP on high
dose than on low dose lisinopril.
In conclusion, suppression of plasma aldos¬
terone and endothelin concentrations was
greater on the'20 mg dose of lisinopril than on
the 5 mg dose, but the observed falls in creati¬
nine clearance associated with the higher dose
may outweigh these beneficial effects in clini¬
cal practice. The issue of the optimal dose of
ACE inhibitor should be settled by the results
of the ATLAS (Assessment of Treatment with
Lisinopril and Survival) trial which will ulti¬
mately provide data on clinical endpoints. In
the meantime it is essential that renal function
is monitored as the dose of ACE inhibitor is
titrated upwards in patients with heart failure.
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Vasodilator Effects of Endothelin-Converting
Enzyme Inhibition and Endothelin ETA Receptor
Blockade in Chronic Heart Failure Patients
Treated With ACE Inhibitors
Michael P. Love, MB, ChB, MRCP; William G. Haynes, MB, ChB, MD, MRCP;
Gillian A. Gray, BSc, PhD; David J. Webb, MB, BS, MD, FRCP;
John J.V. McMurray, BSc, MB, ChB, MD, MRCP
Background The importance of endothelin-1 in chronic heart
failure (CHF) is unclear. We therefore investigated the effects of
endothelin-converting enzyme (ECE) inhibition and endothelin
ETa receptor blockade in CHF patients treated with ACE inhib¬
itors. We also compared the function of ETA and ETB receptors
in healthy subjects and patients with CHF.
Methods and Results Locally active doses of study drugs
were infused into the nondominant brachial artery while forearm
blood flow (FBF) was measured by venous occlusion plethys¬
mography. In CHF patients (n=10), phosphoramidon (a com¬
bined ECE and neutral endopeptidase inhibitor) and BQ-123 (an
ETa receptor antagonist) increased FBF by 52±10% (P=.0Q06)
and 31 ±6% (P=.002), respectively, and thiorphan (a selective
neutral endopeptidase inhibitor) reduced FBF by 15±5%
(P=.0007). Forearm vasoconstriction to endothelin-1 (an ETA
and ETb receptor agonist) was significantly blunted in CHF pa¬
tients compared with control subjects (both n=10; CHF versus
control subjects, F>< .001), whereas vasoconstriction to sarafo-
toxin S6c (an ETb receptor agonist) was significantly enhanced
in CHF patients compared with control subjects (both n= 10; CHF
versus control subjects, P<.05).
Conclusions ECE inhibitors and ETa receptor antagonists
may be useful as vasodilator agents in CHF patients already re¬
ceiving treatment with an ACE inhibitor. Both ETA and ETb re¬
ceptors can mediate agonist-induced vasoconstriction in healthy
subjects and patients with CHF, but further studies are required
to clarify the contribution of each receptor subtype in mediating
the effects of endogenous endothelin-1. (Circulation. 1996;94:
2131-2137.)
Key Words • endothelin • heart failure • vasodilatation
• vasoconstriction • receptors
Chronic heart failure is an important and increas¬ingly common healthcare problem. Even withfull conventional medical therapy, CHF imp irs
quality of life more than most other chronic medical
illnesses and carries an extremely poor prognosis.1 The
development of novel and more effective therapeutic
strategies for CHF is therefore an important priority in
cardiovascular medicine.
In terms of symptoms and survival, the greatest im¬
pact on the medical management of CHF has been made
by the ACE inhibitors2; angiotensin II receptor antago¬
nists have recently shown similar therapeutic promise.3
This has led to the view that vasodilatation through neu¬
roendocrine modulation may be the most appropriate
and effective therapeutic strategy in CHF. Novel thera-
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pies capable of achieving a greater reduction in vascular
resistance than is possible with current treatment mo¬
dalities are urgently required.
The endothelins are a family of endogenous peptides
with potent vasoconstrictor, antinatriuretic, and mito-
genic properties that may be important in the patho¬
physiology of CHF.4 Endothelin-1, the principal en¬
dothelin isoform generated in the human vasculature,5
has uniquely sustained vasoconstrictor actions and has
been shown to contribute to basal vascular tone in hu¬
mans.6 Plasma levels of the peptide are increased two¬
fold to threefold in CHF of all causes in proportion to
the symptomatic and hemodynamic severity of the syn¬
drome.7"'5 Big endothelin-1, the biologically inactive
precursor of mature endothelin-1, may be preferentially
increased in CHF,13,15 suggesting enhanced endothelial
synthesis or secretion of the peptide. Plasma big en¬
dothelin-1 also predicts prognosis, with a higher con¬
centration predicting a greater likelihood of death or
need for cardiac transplantation.13
We have addressed the contribution of endothelin-1 to
peripheral vasoconstriction in CHF by pursuing two pos¬
sible therapeutic interventions suggested by the cellular
processing and actions of endothelin-1.4 In study A, we
investigated the effects of blocking the generation (via
ECE inhibition) and action (via selective endothelin ETA
receptor blockade) of endothelin-1 in a heterogeneous
group of patients with conventionally treated CHF. We
have also tried to clarify the role of the two principal
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Selected Abbreviations and Acronyms
CHF = chronic heart failure
ECE = endothehn-converting enzyme
FBF = forearm blood flow
NEP = neutral endopeptidase
endothelin receptor subtypes, ETA and ETB, in mediating
vasoconstriction in vivo.16,17 Vascular smooth muscle ETA
receptors were previously believed to be solely respon¬
sible for mediating endothelin-1-induced vasoconstric¬
tion, whereas endothelial ETB receptors were believed to
mediate vasodilatation through release of prostacyclin
and/or nitric oxide. More recently, it has been suggested
that vascular smooth muscle ETB receptors might also
mediate vasoconstriction.18 21 Knowledge of the contri¬
bution of each receptor subtype to vasoconstriction has
obvious implications for the potential therapeutic use of
selective or nonselective endothelin receptor antagonists
in CHF. In study B, we attempted to clarify the role of
constrictor ETA receptors by comparing the vascular ef¬
fects of the selective ETA receptor antagonist BQ-123 in
healthy subjects and patients with CHF. In study C, we
tried to assess the relative importance of ETA and ETB
receptors by comparing the vascular effects of endoth¬
elin-1 (a nonselective [ETA and ETB] receptor agonist)
and sarafotoxin S6c (a selective ETB receptor agonist) in
healthy subjects and patients with CHF.
Methods
Subjects
Studies were conducted with the approval of the local ethics
committee and the written, informed consent of each CHF patient
and healthy control subject.
Fourteen patients with chronic (>3 months) stable heart failure
participated in study A. No specific cause of CHF was excluded,
but no patients had concomitant hypertension, diabetes mellitus,
or chronic renal failure. Each was receiving maintenance treat¬
ment with a diuretic and a maximal dose of an ACE inhibitor
(either captopril 50 mg TID, enalapril 10 mg BID, or lisinopril
10 mg UID). Medication was continued as usual before and dur¬
ing the day of studies because we wished to evaluate the effects
of ECE inhibition and ETA receptor blockade over and above the
effects of conventional medical therapy for CHF. Patient char¬
acteristics are summarized in Table 1.
Six patients with chronic stable heart failure and 10 healthy
control subjects participated in study B. Ischemic heart disease
was the underlying cause of heart failure in each case, and no
patients had concomitant hypertension, diabetes mellitus, or
chronic renal failure. All CHF patients were receiving mainte¬
nance treatment with a diuretic, digoxin, and ACE inhibitor, and
no control subject was taking any regular medication. The med¬
ication of CHF patients was withheld for 24 hours before studies.
Patient characteristics are summarized in Table 2.
Ten patients with chronic stable heart failure and 10 healthy
control subjects participated in study C. The underlying cause of
heart failure was ischemic heart disease in 9 patients and alco¬
holic cardiomyopathy in 1; none had concomitant hypertension,
diabetes mellitus, or chronic renal failure. All CHF patients were
receiving maintenance treatment with a diuretic and ACE inhib¬
itor, and no control subject was taking any regular medication.
The medication ofCHF patients was withheld for 24 hours before
studies. Patient characteristics are summarized in Table 3.
Drug Infusion and FBF Measurement
Studies were performed with subjects resting supine in a quiet
clinical laboratory maintained at a constant temperature between
Table 1. Patient Characteristics, Study A
(Phosphoramidon, Thiorphan, and BQ-123 Protocols)
Protocol
Phosphoramidon Thiorphan BQ-123
Sex, n 9 M/1 F 10 M 9 M/1 F
Age, y (mean=SD) 66±4 68 = 3 64 = 4
Primary diagnosis, n
Ischemic heart
disease' 6 8 7
Dilated
cardiomyopathy! 1 1 1
Alcoholic





II 6 4 6
III 4 6 3
IV 1
Drug therapy, n
ACE inhibitor 10 10 10
Diuretic 10 10 10
Digoxin 6 7 6
Amlodipine 3 4 3
Oral nitrate 3 4 1
/3-Blocker 0 1 3
"Documented previous myocardial infarction or confirmed by coronary
angiography.
tNormal coronary arteries at coronary angiography.
^Severe mitral regurgitation.
23°C and 25°C. Subjects were asked to abstain from caffeine-
containing drinks, alcohol, and cigarette smoking on study days
and to fast for at least 2 hours before studies commenced.
With 1% lidocaine used for local anesthesia, an unmounted
27-standard wire gauge steel cannula (Coopers Needle Works)
was inserted into the brachial artery of the nondominant arm and
Table 2. Patient and Control Subject Characteristics,




Sex, n 6 M 10 M
Age, y (mean tSD) 67 = 4 60=6
Primary diagnosis, ischemic heart disease,' n 6
NYHA functional class, n
II 2
III 4
Mean ejection fraction,! % 23=2 65 =3!
Baseline FBF,§ II mL-min• 100 mL ' 3.3±0.3 4.0=0.3
Baseline mean arterial pressure, II mm Hg 86 = 3 93=2







"Documented previous myocardial infarction or confirmed by coronary
angiography.
tCalculated from short- and long-axis M-mode echocardiogram at mi¬
tral leaflet tips.
tTwo control subjects were insufficiently echogenic to allow quantifi¬
cation of their ejection fractions but had subjectively normal left ventricular
systolic function.
§Expressed as mean of infused and noninfused arms.
II The small baseline differences in FBF and mean arterial pressure be¬
tween patients and control subjects were not statistically significant.
Love el al Endothelin in Chronic Heart Failure 2133
Table 3. Patient and Control Subject Characteristics,




Sex, n 10 M 10 M
Age, y (mean±SD) 61 ±3 59±5
Primary diagnosis, n
Ischemic heart disease" 9
Alcoholic cardiomyopathyf 1






Mean ejection fraction,}: % 29±2 63±3
Baseline forearm blood flow,§ II
mL-min"' 100 mL"'
ET-1 protocol COo+lCO o+lo
S6c protocol 3.54:0.3 4.1 ±0.6
Baseline mean arterial pressure, II mm Hg
ET-1 protocol 98±2 91 ±2
S6c protocol 96±2 91 ±2
Baseline heart rate, II bpm
ET-1 protocol 71 ±3 67±2







ET-1 indicates endothelin-1; S6c, sarafotoxin S6c.
'Documented previous myocardial infarction or confirmed by coronary
angiography.
tNormal coronary arteries at coronary angiography.
^Calculated from short- and long-axis M-mode echocardiogram at mi¬
tral leaflet tips.
§Expressed as mean of infused and noninfused arms.
II None of the small baseline differences in FBF, mean arterial pressure,
and heart rate between patients and control subjects were statistically
significant.
connected to a constant-rate infusion pump (Wellmed P1000) via
a 16-gauge epidural catheter (Portex Ltd). Physiological saline
(0.9%) was infused at 1 mL/min for an equilibration period of
^30 minutes before infusion of study drugs. Locally active doses
of drugs were dissolved in physiological saline and administered
at 1 mL/min.
FBF was measured by venous occlusion plethysmography with
indium (gallium)-in-Silastic strain gauges applied to the widest
aspect of each forearm.22 The hand circulation was excluded dur¬
ing periods of blood flow measurement by inflation of wrist cuffs
to 220 mm Hg. Upper arm cuffs were inflated to 40 mm Hg for
10 in every 15 seconds to prevent venous outflow and obtain
plethysmographic recordings. Voltage output from a Vasculab
SPG 16 strain-gauge plethysmograph (Medasonics Inc) was
transferred to an Apple Macintosh computer (LC III, Apple Com¬
puter Inc) for analysis with a MacLab analog-to-digital convener
and Chart software (version 3.2.8; both from AD Instruments).
In all studies, FBF was measured in both arms at 10-minute
intervals during saline equilibration and at 5-minute intervals dur¬
ing study drug infusion. In study A only, saline was infused for
a further 30 minutes after discontinuation of drug infusion with
blood flow measured every 10 minutes. The last Ave measure¬
ments of FBF during each =3-minute recording period were av¬
eraged, and the mean percentage change from baseline in the ratio
of flow between the infused and noninfused arms was calculated.
This method of analysis uses the noninfused arm as a contem¬
poraneous control and ensures that the effects of study drugs are
distinguished from any other external or environmental factors.22
Blood pressure and heart rate were recorded in the noninfused
arm at 10-minute intervals throughout all studies with a well-
validated semiautomated sphygmomanometer (Takeda UA-751.
Takeda Medical Inc).
Data Analysis
All results are expressed as mean values with 95% CIs in the
text and SEM in figures. The significance of the effect of each
study agent on FBF was examined with Statview 4.02 software
(Abacus Concepts Inc) for the Apple Macintosh computer to per¬
form repeated-measures ANOVA. An unpaired t test was per¬
formed to test the significance of the difference in peak antagonist
and agonist effects between healthy subjects and patients with
CHF in studies B and C. Differences were considered statistically
significant at a value of P<.05.
Detailed Protocols
Study A: ECE Inhibition, NEP Inhibition, and
Selective ETA Receptor Blockade
Three single-blind protocols were performed, each in 10 pa¬
tients with CHF. Phosphoramidon (Clinalfa AG) was infused at
30 nmol/min for 60 minutes, a dose sufficient to achieve local
forearm concentrations equivalent to the IC50 of phosphoramidon
for ECE assuming resting FBF of =50 mL/min.23 Phosphoram¬
idon, however, also inhibits NEP, the enzyme responsible for the
degradation of various biologically active peptides, including
bradykinin, substance P, natriuretic peptides, angiotensin 11, and
endothelin-1 itself.24,25 We therefore compared its effect with that
of thiorphan (Sigma Chemical Co Ltd), a selective inhibitor of
NEP.26 Thiorphan was also infused at 30 nmol/min for 60
minutes because it is effectively equipotent with phosphoramidon
as an inhibitor of NEP.24 Concentrations of thiorphan > 100-fold
greater than achieved at this rate of infusion have no inhibitory
effect on ECE.23 The selective ETA receptor antagonist BQ-123
(American Peptide Co) was infused at 100 nmol/min for 60
minutes, a dose sufficient to achieve local forearm concentrations
10-fold higher than the pA2 for BQ-123 at the ETA receptor.27
Study B: Selective ETA Receptor Blockade
Ten healthy control subjects received brachial artery infusion
of the selective ETA receptor antagonist BQ-123 at 100 nmol/min
for 90 minutes, again a dose sufficient to achieve local forearm
concentrations 10-fold greater than the pA2 for BQ-123 at the
ETa receptor.27 We also infused BQ-123 for 90 minutes in 6 more
patients with CHF because it was not clear whether a maximal
effect had been obtained after 60 minutes of infusion in study A.
Study C: Nonselective (ETA and ET„) Receptor
Agonism and Selective ET„ Receptor Agonism
On separate days at least 1 week apart and in single-blind fash¬
ion, 10 healthy control subjects and 10 patients with CHF re¬
ceived brachial artery infusion in random, balanced order of phar¬
maceutical grade endothelin-1 (Clinalfa AG) and sarafotoxin S6c
(Sigma Chemical Co Ltd) at 5 pmol/min for 60 minutes. This
dose of both agonists has previously been shown to cause slow-
onset vasoconstriction in human forearm resistance vessels.21 As¬
suming resting FBF of =50 mL/min, infusion of 5 pmol/min of
endothelin-1 and sarafotoxin S6c would achieve a local concen¬
tration of each peptide in the infused forearm of about 0.1
nmol/L. Endothelin-1 would be expected to act equally on both
ETa and ETB receptors at this concentration, given that the K,
values for endothelin-1 at ETA and ETB receptors are 0.6 and 0.12
nmol/L, respectively.28 Sarafotoxin S6c would be expected to be
highly selective for the ETB receptor (K„ 0.25 nmol/L) because
its local forearm concentration would be at least 70 000-fold
lower than its K, at the ETA receptor (>7300 nmol/L).28
Results
Heart rate, blood pressure, and FBF in the noninfused
arm did not change significantly in any study protocol,
confirming that drugs had only local actions on the forearm
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Fig 1. Effect of brachial artery infusion of phosphoramidon
30 nmol/min (■), thiorphan 30 nmol/min (O), and BQ-123 100
nmol/min (□), each for 60 minutes in 10 patients with CHF.
Hatched bar represents period of study drug infusion. Phos¬
phoramidon (P=.0006) and BQ-123 (P=.002) caused pro¬
gressive forearm vasodilatation, whereas thiorphan caused
progressive forearm vasoconstriction (P=.0007).
vasculature of the infused arm and had no systemic hemo¬
dynamic effects.
Study A: ECE Inhibition, NEP Inhibition, and
Selective ETA Receptor Blockade
Phosphoramidon caused slow-onset vasodilatation, with
a peak increase in FBF of 52± 10% at 80 minutes (CI, 32%
to 72%; ANOVA versus baseline, P=.0006; Fig 1), ie, 20
minutes after discontinuation of phosphoramidon infusion.
Thiorphan caused slow-onset vasoconstriction, with a
peak reduction in FBF of 15±5% at 90 minutes (CI, -6%
to —24%; ANOVA versus baseline, P=.0007; Fig 1), ie,
30 minutes after discontinuation of thiorphan infusion.
BQ-123 caused slow-onset vasodilatation, with a peak in¬
crease in FBF of 31 ±6% at 60 minutes (CI, 20% to 42%;
ANOVA versus baseline, P=.002; Fig 1), ie, at the end of
BQ-123 infusion.
Study B: Selective ETA Receptor Blockade
BQ-123 caused slow-onset vasodilatation in control




Fig 2. Effect of brachial artery infusion of BQ-123 100 nmol/min
for 90 minutes in 6 patients with CHF (■) and 10 age-matched
healthy control subjects (O). Hatched bar represents period of BQ-
123 infusion. Vasodilatation to BQ-123 tended to be blunted in CHF
patients compared with control subjects (P=. 14).
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Fig 3. Effect of brachial artery infusion of endothelin-1 5 pmol/min
for 60 minutes in 10 patients with CHF (■) and 10 age-matched
healthy control subjects (O). Hatched bar represents period of
peptide infusion. Vasoconstriction to endothelin-1 was signifi¬
cantly blunted in CHF patients compared with control subjects
(Pc.001).
minutes (CI, 34% to 74%; ANOVA versus baseline,
Pc.0001; Fig 2). As in study A, BQ-123 caused slow-
onset vasodilatation in CHF patients, with a peak increase
in FBF of 33±4% at 90 minutes (CI, 26% to 40%;
ANOVA versus baseline, PC.0001; Fig 2). Vasodilatation
to BQ-123 tended to be blunted in CHF patients compared
with control subjects (CHF versus control subjects,
P=.14); the maximal increase in FBF at 90 minutes was
not statistically significantly different between CHF pa¬
tients and control subjects unless the solitary control sub
ject whose FBF was unaffected by BQ-123 infusion was
excluded from the analysis (CHF versus control subjects,
P=.04).
Study C: Nonselective (ETA and ETB) Receptor
Agonism and Selective ET„ Receptor Agonism
Endothelin-1 caused slow-onset vasoconstriction in
control subjects and patients with CHF (Fig 3). Endothe¬
lin-1 reduced FBF by 41 ±4% in control subjects (CI,
— 34% to —49%; ANOVA versus baseline, P<.00()1) and
by 25±3% in patients with CHF (CI, —19% to —31%;
-soJ
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Fig 4. Effect of brachial artery infusion of sarafotoxln S6c 5
pmol/min for 60 minutes in 10 patients with CHF (■) and 10 age-
matched healthy control subjects (O). Hatched bar represents
period of peptide infusion. Vasoconstriction to sarafotoxin S6c
was significantly enhanced in CHF patients compared with con¬
trol subjects (P< .05).
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ANOVA versus baseline, PC.OOOl) after 60 minutes of
infusion. Vasoconstriction to endothelin-1 was signifi¬
cantly blunted in CHF patients compared with control sub¬
jects (CHF versus control subjects, Pc.OOl). Sarafotoxin
S6c also caused slow-onset vasoconstriction in control
subjects and patients with CHF (Fig 4). Sarafotoxin S6c
reduced FBF by 29±3% in control subjects (CI, -24% to
—34%; ANOVA versus baseline, P<.0001) and by 39±4%
in patients with CHF (CI, —31% to -47%; ANOVA ver¬
sus baseline, P<.0001) after 60 minutes of infusion. Va¬
soconstriction to sarafotoxin S6c was significantly greater
in CHF patients than control subjects (CHF versus control
subjects, Pc.05).
Discussion
These studies demonstrate that endothelin-1 contrib¬
utes importantly to peripheral vascular resistance in pa¬
tients with CHF and suggest that ECE inhibitors and en¬
dothelin ETa receptor antagonists may be useful as
vasodilator agents, even in patients who are already re¬
ceiving treatment with an ACE inhibitor. We have also
shown that both ETA and ETB receptors can mediate va¬
soconstriction in the peripheral vasculature of healthy
subjects and patients with CHF, a finding that may have
important implications for the potential therapeutic use
of endothelin receptor antagonists.
Studying the effects of agents that block either the gen¬
eration or action of endothelin-1 in vivo is the only way
to clarify the putative pathophysiological role of the pep¬
tide in CHF. A major advance in the field of endothelin
research has been the cloning and characterization of
ECE,23 but at present no specific and selective inhibitors
of the enzyme exist. Several selective and nonselective
endothelin receptor antagonists potentially suitable for
human therapeutic use are at various stages of clinical
development.29
The best available pharmacological tool at present for
studying the effects of blocking the generation of endothe¬
lin-1 is the combined ECE and NEP inhibitor phosphor-
amidon.23 Phosphoramidon caused a substantial (=50%)
increase in FBF when a locally active dose was infused
into the brachial artery of patients with CHF (Fig 1). Given
the broader substrate specificity of NEP than of ECE,24'25
this vasodilatation could theoretically have been due to
NEP rather than ECE inhibition, causing local accumula¬
tion of one of the many dilator substances metabolized by
NEP. However, brachial artery infusion of the selective
NEP inhibitor thiorphan caused forearm vasoconstriction
in patients with CHF (Fig 1), indicating that the vasodilata¬
tion observed with phosphoramidon was most likely due
to inhibition of ECE, with simultaneous NEP inhibition
probably offsetting the magnitude of its overall vasodilator
effect. The specific mechanism underlying the effect of
thiorphan is likely to be complex, given the many vaso¬
active factors known to be metabolized by NEP, but the
most probable explanation is that of local accumulation of
constrictor substances, such as angiotensin II or endothe¬
lin-1 itself. Further studies will be necessary to elucidate
the mediators underlying the vasoconstrictor response to
NEP inhibition.
Further evidence that endothelin-1 contributes to pe¬
ripheral vascular resistance in CHF is provided by our
studies with the selective ETA receptor antagonist BQ-
123. Brachial artery infusion of a locally active dose of
BQ-123 for 60 minutes increased FBF by =30% in pa¬
tients with CHF in study A. Whereas maximal vasodila¬
tation to phosphoramidon was observed 20 minutes after
its infusion was discontinued (suggesting persisting in¬
hibition of ECE), the vasodilatory effect of BQ-123 de¬
clined immediately after discontinuation of its infusion,
in keeping with its action as a competitive antagonist at
the ETa receptor. The maximum response to BQ-123
was probably achieved after 60 minutes of infusion in
study A (Fig 1) because the effect of BQ-123 appeared
to reach plateau by 60 minutes in study B without any
significant incremental vasodilatation after 60 minutes
(Fig 2). ECE inhibition appeared to cause greater va¬
sodilatation than selective ETA blockade in study A, but
further studies with varying doses and durations of in¬
fusion of both phosphoramidon and BQ-123 would be
required to validate any direct comparison of their ef¬
fects. Our principal aim was to determine whether an-
tiendothelin drugs have therapeutic potential as vaso¬
dilator agents in patients with CHF already receiving
conventional medical therapy rather than to compare the
relative effects of ECE inhibition and ETA receptor
blockade.
Though we investigated only the short-term effects of
ECE inhibition and ETA receptor blockade in a single vas¬
cular bed, responses in human forearm resistance vessels
are thought to be broadly representative of responses in
other resistance beds. Indeed, our observations support and
extend the recent findings of Kiowski et al,30 who reported
that acute bolus administration of a mixed ETA and ETB
receptor antagonist, bosentan, significantly reduced sys¬
temic and pulmonary vascular resistance in patients with
CHF. A crucial difference from our own studies was that
these hemodynamic effects were observed in patients
whose ACE inhibitors had been discontinued for >4
plasma half-lives. Importantly, our observations suggest
that antiendothelin drugs have the potential to offer hemo¬
dynamic benefit in CHF patients over and above that al¬
ready obtained with an ACE inhibitor.
Collectively, our agonist and antagonist studies suggest
that both ETa and ETB receptors can mediate vasoconstric¬
tion in forearm resistance vessels of healthy subjects and
patients with CHF. Our agonist studies in healthy control
subjects are consistent with similar recently reported stud¬
ies in healthy volunteers.21 The lesser mean constriction
to sarafotoxin S6c than to endothelin-1 in control subjects
(Figs 3 and 4) implies that both ETA and ETB receptor
subtypes mediate vasoconstriction, but it is difficult to ex¬
trapolate our results to quantify the relative contribution
of each receptor subtype in mediating the effects of en¬
dogenous endothelin-1; further comparative studies with
selective ETA and ETB receptor antagonists, when avail¬
able for use in humans, will clarify this issue.
We found that the forearm vasodilator effect of the se¬
lective ETa receptor antagonist BQ-123 tended to be
blunted in CHF patients compared with healthy control
subjects (Fig 2). Although this raises the possibility of ETA
receptor downregulation in CHF, any comparison of the
effects of BQ-123 between CHF patients and control sub¬
jects must be made with extreme caution. The time course
of the effect of BQ-123 and the need for brachial artery
cannulation do not lend themselves to repeated dose-re¬
sponse studies; consequently, we cannot be certain that we
have demonstrated the maximal effect of BQ-123 in the
forearm vasculature. Additionally, because we were reluc¬
tant to withhold drug treatment from our CHF patients for
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any longer than 24 hours before studies, it is possible that
persisting vascular effects of their medication (in particu
lar of ACE inhibition) may have contributed to the differ¬
ence observed between patients and control subjects.
Our finding that the vasoconstrictor effect of endothelin
1 was attenuated and that of sarafotoxin S6c was enhanced
in the forearm vasculature of CHF patients compared with
control subjects (Figs 3 and 4) suggests changes in ETA
and ETb receptor sensitivity similar to those observed by
Cannan et al31 in the coronary vasculature of dogs with
experimental CHF. However, the functional significance
of these apparent alterations in receptor sensitivity is un¬
clear; further studies comparing the hemodynamic effects
of selective ETA and ETB receptor antagonists are neces¬
sary to delineate the relative importance of each receptor
subtype in regulating vascular tone. The divergent nature
of the agonist responses we observed in patients with CHF,
ie, the blunted constrictor effect of endothelin-1 coupled
with the enhanced constrictor effect of sarafotoxin S6c,
makes it unlikely that the differences observed were sim¬
ply due to any persisting vascular effect of the patients'
medication. Similarly, although the small baseline differ¬
ences in FBF, mean arterial pressure, and heart rate be¬
tween patients and control subjects (Table 3) might have
influenced vascular responsiveness to each agonist, these
differences on their own would not explain the divergent
variation in responses in patients with CHF. It is, however,
important to acknowledge that our studies cannot defini¬
tively exclude the possible existence of a dilator subtype
of ETa receptor sensitive to endothelin-1 or another spe¬
cies of constrictor receptor sensitive to sarafotoxin S6c in
patients with CHF.
Our studies with BQ-123 support an important role for
ETa receptors in mediating the constrictor effects of en¬
dogenous endothelin-1 in patients with CHF, but the role
of ETb receptors in this regard needs further clarification.
Whether selective ETB receptor blockade would result in
a net vasoconstrictor or vasodilator effect in healthy sub¬
jects or patients with CHF is not currently known and
cannot be determined from our present data. Our obser¬
vation that forearm vasoconstriction to sarafotoxin S6c
was enhanced in patients with CHF might be partly re¬
lated to endothelial dysfunction,32 resulting in diminished
endothelial ETB receptor-mediated release of dilator sub¬
stances, but whether this is indicative of a shift in the
relative functional importance of endothelial and vascu¬
lar smooth muscle ETB receptors in CHF requires further
investigation.
In summary, our findings have potentially important
therapeutic implications. Our central and most important
finding from a clinical perspective was that ECE inhibition
and ETa receptor blockade produced a significant addi¬
tional reduction in forearm vascular resistance in patients
with CHF already treated with conventional medical ther¬
apy, including an ACE inhibitor. For a new treatment mo¬
dality to be of real value in CHF, it will have to offer
hemodynamic benefit over and above that obtained with
an ACE inhibitor; antiendothelin drugs appear to have this
potential. If both ETA and ET„ receptors do indeed mediate
vasoconstriction in patients with CHF, then this suggests
that use of a nonselective receptor antagonist or a selective
ECE inhibitor would be necessary to achieve optimal in¬
hibition of the constrictor effects of endogenous endothe¬
lin- 1. The ideal receptor antagonist would probably be one
that blocked constrictor ETA and ET„ receptors but pre¬
served endothelial ET„ receptor-mediated vasodilatation;
such antagonists with differential selectivities for constric
tor and dilator ETB receptor subtypes have not yet been
developed. Much is still to be learned about the role of the
endothelins in human physiology and pathophysiology,
but if orally active endothelin receptor antagonists and
ECE inhibitors produce sustained systemic hemodynamic
changes of the type we have observed in the forearm, then
they may represent a further therapeutic advance in the
treatment of CHF.
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Early therapeutic experience with the endothelin
antagonist BQ-123 in pulmonary hypertension
after congenital heart surgery
B Prendergast, D E Newby, L E Wilson, D J Webb, P S Mankad
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Objective—To assess the effect ofendothe¬
lin type A (ETa) receptor antagonism in
infants with pulmonary hypertension fol¬
lowing corrective surgery for congenital
heart disease.
Design—Open label, preliminary study.
Setting—Tertiary paediatric cardiotho-
racic surgical centre.
Patients—Three infants (aged 3 weeks, 7
weeks, and 8 months) with postoperative
pulmonary hypertension unresponsive to
conventional treatment, including inhaled
nitric oxide.
Interventions—Patients received incre¬
mental intravenous infusions (0.1 to 0.3
mg/kg/h) of the ETA receptor antagonist
BQ-123.
Main outcome measures—The response
to BQ-123 administration was determined
using continuous invasive monitoring of
cardiorespiratory variables.
Results—BQ-123 infusion caused a reduc¬
tion in the ratio of pulmonary to systemic
pressures (0.62 (0.01) to 0.52 (0.03), mean
(SEM)) with an accompanying decrease in
right ventricular stroke work index (4.6
(0.4) to 2.5 (0.3) g/m) and a tendency for
the cardiac index to rise (2.1 (0.2) to 2.7
(0.6) 1/min/kg/m2). This was associated
with a well tolerated fall in the arterial
partial pressure of oxygen (16.5 (4.1) to
12.4 (3.3) kPa) and mean systemic arterial
pressure (57 (3) to 39 (3) mm Hg).
Conclusions—ETA receptor antagonism in
infants with postoperative pulmonary
hypertension after corrective surgery for
congenital heart disease led to significant
improvement in pulmonary haemody-
namic indices. However, these benefits
were associated with reductions in sys¬
temic blood pressure and arterial oxygen
saturation, the latter consistent with a
ventilation-perfusion mismatch. On the
basis of these results, studies in pulmo¬
nary hypertension will need to proceed
with caution.
(.Heart 1999;82:505 508)
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Postoperative pulmonary hypertension is a
common clinical problem following successful
surgical correction of congenital heart defects
and may lead to significant morbidity and
mortality.1 Its occurrence relates both to
pre-existing pulmonary hypertension and the
acute effects of surgery and cardiopulmonary
bypass. Dysfunction of the pulmonary vascular
endothelium appears to be a major contribut¬
ing factor for the development of pulmonary
hypertension in this group of patients.
Endothelin-1 is an extremely potent endo¬
thelium derived vasoconstrictor peptide2 which
is released and cleared in the pulmonary
circulation.' Plasma concentrations of
endothelin-1 are increased in subjects going to
high altitude,4 in patients with chronic heart
failure,' and in patients with pulmonary
hypertension." Moreover, in these conditions,
the degree of pulmonary hypertension and
pulmonary vascular resistance correlates
closely with plasma endothelin-1 concen¬
trations.4 6 Children with pulmonary
hypertension7 and persistent pulmonary hyper¬
tension of the newborn* also have raised
plasma endothelin-1 concentrations that corre¬
late with disease severity," are particularly
marked after cardiopulmonary bypass,4 and
may play a role in its pathogenesis.10
Studies in animal models of pulmonary
hypertension have reported reversal of pulmo¬
nary hypertension with endothelin receptor
antagonists" 12 and endothelin converting en¬
zyme inhibition." Indeed, in a sheep model of
pulmonary hypertension induced by aortopul-
monary shunting in utero, endothelin antago¬
nism eliminated the postoperative increase in
pulmonary vascular resistance following car¬
diopulmonary bypass." Reddy and colleagues"
concluded that endothelin antagonism war¬
rants further study in children at risk of
pulmonary hypertension after surgical repair
with cardiopulmonary bypass. There have been
no published clinical studies to date assessing
the therapeutic benefits of endothelin antago¬
nism in postoperative pulmonary hyper¬
tension.
We report our preliminary experience with
the therapeutic use of the endothelin type A
(ETA) receptor antagonist, BQ-123, in three
infants with postoperative pulmonary hyper¬
tension following corrective surgery for con¬
genital heart disease.
Methods
Written informed parental consent was ob¬
tained for each child and the study was
approved by the local research ethics com¬
mittee.
BQ-123 (American Peptide Company, Sun¬
nyvale, California, USA) was given under a
Department of Health (UK) Doctors and
Dentists Exemption Certificate.
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Table I Patient characteristics
Age VCkight
Patient (weeks) Sex (fO Diagnosis Procedure Inotropes and vasodilators
1 3 Female 3100 Anomalous aortic origin of left
pulmonary artery, patent foramen ovale,
persistent arterial duct
Mobilisation of left pulmonary artery
with formation of pulmonary artery
bifurcation, closure of patent foramen
ovale, division of persistent arterial duct
Dopamine 3 ^g/kg/min
2 7 Male 3500 Obstructed partial anomalous
pulmonary venous drainage, left
pulmonary artery stenosis, atrial septal
defect
Right pulmonary vein to right atrium
anastamosis, atrial diverting patch, left
pulmonary artery patch
Dobutamine 20 ng/kg/min
Glyceryl trinitrate 2 mg/kg/min
3 25 Female 6100 Ventricular septal defect, persistent
arterial duct (Aicardi and Poland
syndromes)
Patch closure of ventricular septal defect,






























The three infants (aged 3 weeks, 7 weeks,
and 8 months) were anaesthetised according to
our standard protocol. Phenoxybenzamine (1
mg/kg) was given before establishing cardio¬
pulmonary bypass. Corrective surgery was per¬
formed after inducing systemic hypothermia
and cold crystalloid cardioplegic arrest. A ther-
modilution pulmonary artery flow catheter (3
F; Baxter Health Care, Thetford, UK) and a
left atrial line were inserted before discontinu¬
ing cardiopulmonary bypass.
After chest closure, the infants were returned
to the intensive care unit and maintained on a






















Figure 1 Effect of BQ-123 (0.1 to 0.3 mgikgonin) on cardiac index (*),
pulmonary/systemic ratio (<■), heart rate (O). and mean systemic (c) and pulmonary fn)
arterial pressure in infants with postoperative pulmonary hypertension following corrective
surgery for congenital heart disease. (F.rmr bars are SFM, n = 3.)
h), fentanyl (5.0 pg/kg/h), and midazolam (0.1
mg/kg/h). Following rewarming, the ratio of
pulmonary to systemic arterial pressure (P/S
ratio) was determined using invasive monitor¬
ing. Infants were entered into the study if they
did not have a residual left to right shunt on
echocardiography and had a P/S ratio greater
than 0.5 which did not respond to standard
treatment, including inhaled nitric oxide (10
ppm increasing to 20, 30, and 40 ppm for 30
minutes at each dose). During the study
period, the amount of sedation and inotropic
support was maintained constant and atrial
pressures kept stable using packed red blood
cells or human albumin solution. Following
stabilisation for three hours, BQ-123 was
dissolved in 0.9% saline and given intra¬
venously at 0.1, 0.2, and 0.3 mg/kg/h, for 30
minutes at each dose.
Data are presented as mean (SEM). Haemo-
dynamic variables were measured in triplicate
at each time point and the mean taken. Recog¬
nising the small sample size and inherent vari¬
ation between haemodynamic variables, non-
parametric analyses (Wilcoxon rank sum) were
used to compare variables before, during, and
after BQ-123 infusion. Statistical significance
was assumed at the 5% level.
Results
Characteristics of the patients are shown in
table 1.
Baseline left and right atrial pressures were
9.6 (1.2) and 7.3 (0.3) mm Hg, respectively,
and did not change during or after BQ-123
infusion. However, the P/S ratio fell in all
patients during BQ-123 administration
(p < 0.001; fig 1) and returned to baseline
about 90 minutes after discontinuation of the
infusion. Concomitant with the changes in the
P/S ratio, the systemic arterial pressure fell (fig
1), although the fall was proportionately less
than for the pulmonary arterial pressure and
was well tolerated. Right ventricular stroke
work index mirrored the changes in P/S ratio
and fell significantly in response to BQ-123
infusion, from 4.56 (0.31) to 2.90 (1.90)
g.m/nr (p < 0.001). The cardiac index tended
to increase and left ventricular stroke work
index fell from 8.0 (0.9) to 6.2 (0.9) g.m/nT
(p < 0.001) but there were no changes in heart
rate, acid-base balance, or urine output.
Despite haemodynamic improvements, the
arterial partial pressure of oxygen fell in all
three infants during BQ-123 infusion, from
16.5 (4.1) to 12.4 (3.3) kPa. Because of the
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reduction in arterial oxygen partial pressures,
nitric oxide (20 ppm) was reintroduced into
the ventilatory circuit of two infants two hours
after starting the BQ-123 infusion (patients 1
and 3). Both infants then responded promptly
to nitric oxide administration, with the partial
pressures rising from 7.4 to 8.2 kPa and from
8.4 to 10.5 kPa. The third infant (patient 2) did
not receive inhaled nitric oxide because in that
infant the partial pressure of oxygen was 18.6
kPa at its nadir. Qualitatively, this did not
appear to correlate with cardiopulmonary
bypass time.
No adverse effects were seen on withdrawal
of BQ-123 and all three infants survived to the
30th postoperative day.
Discussion
Although potentially life threatening, postop¬
erative pulmonary hypertension following cor¬
rective surgery for congenital heart disease is
usually reversible. When conventional treat¬
ment, including inhaled nitric oxide, fails
further measures such as extracorporeal circu¬
latory support and membrane oxygenation
may be required. We have conducted the first
preliminary study to examine the therapeutic
effects ofETa receptor antagonism under such
circumstances. Although we were able to show
a significant improvement in pulmonary
haemodynamic indices, this was associated
with arterial hypoxaemia and systemic hypo¬
tension.
Endothelin-1 is continuously released by
the endothelium and contributes to the main¬
tenance of basal vascular tone1516 and blood
pressure.17 " It is therefore not surprising that
BQ-123 caused a reduction in systemic as well
as pulmonary arterial pressure and this is con¬
sistent with the haemodynamic effects seen
with the acute administration of BQ-123 in
patients with heart failure." However, in these
three infants, ETA receptor antagonism ap¬
peared to be more selective for the pulmonary
vascular bed, with a proportionately greater
effect in comparison with the systemic
circulation. This suggests that endothelin-1
provides a greater contribution to the mainte¬
nance of vascular tone in the pulmonary
circulation in postoperative pulmonary hyper¬
tension.
In animal models of pulmonary hyper¬
tension induced by aortopulmonary shunting,
not only have raised plasma endothelin-1 con¬
centrations been found, but also an increased
pulmonary vasoconstrictor response to
endothelin-1 infusion.20 These findings may, in
part, relate to the upregulation of endothelin-1
and endothelin converting enzyme expression,
as well as the 10-fold downregulation of the
ET„ receptor within the pulmonary
vasculature.21 The balance of receptor expres¬
sion is therefore largely shifted to the vasocon¬
strictor ETa receptor and this may exacerbate
the pulmonary hypertension. Thus it would be
anticipated that selective ETA receptor antago¬
nism would produce a greater reduction in
pulmonary vascular resistance than combined
ETa and ET„ receptor antagonism.
A degree of systemic hypotension and
impaired oxygenation is the inevitable conse¬
quence of effective systemic vasodilatation and
these are the limiting factors in the clinical use
of conventional agents. Intrapulmonary
ventilation/perfusion matching is dependent
upon local hypoxic vasoconstrictive reflexes
and so is impaired by pulmonary vasodilata¬
tion. Although they were initially unresponsive
to inhaled nitric oxide, improved oxygenation
was seen in the two patients who received
inhaled nitric oxide (20 ppm) after ETA recep¬
tor antagonism. This effect may be related to
the recently described improvement in pulmo¬
nary vascular responsiveness to nitric oxide
following ETa receptor antagonism.22 The
mechanisms of this effect remain to be
established, but in an animal model of pulmo¬
nary hypertension, ETA receptor antagonism
was associated with both an improvement in
endothelium dependent vasodilatation and an
increase in pulmonary vascular smooth muscle
sensitivity to nitric oxide.22
This first preliminary report of the use of
ETa receptor antagonism in infants with post¬
operative pulmonary hypertension following
corrective surgery for congenital heart disease
suggests an improvement in the pulmonary to
systemic ratio and right ventricular stroke-
work index. However, these benefits were
counterbalanced by potentially adverse reduc¬
tions in arterial oxygenation and systemic
blood pressure. These findings suggest that
endothelin antagonism, particularly in combi¬
nation with inhaled nitric oxide, may represent
a valuable new approach to the treatment of
refractory postoperative pulmonary hyper¬
tension which merits further but cautious
investigation.
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Abstract Objective: Septic shock is
characterised by a decrease in sys¬
temic vascular resistance. Neverthe¬
less, regional increases in vascular
resistance can occur which may
predispose to organ dysfunction,
including the adult respiratory dis¬
tress syndrome (ARDS). Because
endothelial damage is a major fea¬
ture of acute lung injury, we exam¬
ined whether the potent endothelial
vasoconstrictor peptide endothelin-
1 plays a pathophysiological role in
sepsis or ARDS.
Design: Plasma endothelin was
measured in mixed venous, pul¬
monary capillary and arterial
blood, and the relationship with
outcome measures was determined.
Setting: The intensive care unit of
a university leaching hospital.
Patients and participants: A con¬
secutive series of well-characterised
patients with sepsis syndrome, both
with (n = 11) and without (n = 15)
ARDS, and ventilated controls
without sepsis or ARDS (n = 7).
Measurements and results: Plasma
endothelin was significantly ele¬
vated in patients with sepsis alone
and in patients with sepsis and
ARDS. Plasma endothelin did not
differ among mixed venous, pul¬
monary capillary and systemic ar¬
terial blood. On multiple regression
analysis, plasma endothelin corre¬
lated positively with organ failure
score and with oxygen consump¬
tion, and negatively with the
Pa02:Fi02 ratio. There was no
correlation with plasma creatinine,
suggesting that decreased renal
clearance did not account for the
high plasma endothelin concen¬
trations.
Conclusions: Although the lung
does not appear to be the major site
of endothelin production in critical¬
ly ill patients with sepsis, increased
endothelin production may contrib¬
ute to regional increases in vacular
resistance, hypoperfusion, and the
development of organ failure, in¬
cluding ARDS, in patients with
sepsis.
Key words: Adult respiratory
distress syndrome ■ Endothelin •
Endothelium • Intensive care •
Lung ■ Sepsis
Introduction
Endotheiin-1 is a 21-amino-acid peptide, first isolated
in 1988 [1] and subsequently shown to be a potent and
long-lasting vasoconstricting agent in humans [2], In
most circumstances, endothelin-1 is a local paracrine or
autocrine, rather than a circulating hormone. Plasma
endothelin is elevated in cases of cardiogenic and septic
shock, possibly as part of a homeostatic response to
maintain arterial pressure [2],
The adult respiratory distress syndrome (ARDS),
which often complicates the clinical course of patients
with severe sepsis, is characterised clinically by hy¬
poxia, diffuse infiltrations on chest X-ray and decreased
pulmonary compliance, and carries a poor prognosis.
ARDS is associated with pulmonary vasoconstriction
and increased microvascular permeability [3], Because
these features may be caused by endothelin [2], this
peptide may be implicated in the pathogenesis of
ARDS.
In this study, we measured circulating plasma con¬
centrations of edothelin in well-characterised patients
with sepsis syndrome, with and without ARDS. We also
examined whether there is net clearance or production
of endothelin across the pulmonary circulation.
Subjects and methods
Thirty-three patients admitted to the Intensive Therapy Unit at the
Western General Hospital between May and December 1992 were
enrolled in the study, which was approved by the local ethics
committee. Patients were subdivided into three groups: those with
sepsis without ARDS (n = 15); those with both sepsis and ARDS
(n = 11); and a 'control' group of head-injured patients with neither
sepsis nor ARDS and with no evidence of systemic or pulmonary
pathology (n = 7). All patients were mechanically ventilated, and all
but 5 of the control group had pulmonary artery catheters in place
for clinical reasons. Sepsis and ARDS were defined in accordance
with published criteria [4, 5],
The severity of illness was scored in three ways: by an Acute
Physiology and Chronic Health Evaluation (APACHE II) score,
recorded 24 h after admission; a Murray Acute Lung Injury Score
[3]; and an Organ Failure Score. The latter score ranges from zero
(best) to ten (worst-), depending on the severity of dysfunction in five
organ systems (pulmonary, cardiovascular, renal, hepatic and hem¬
atological), determinations that are based on the criteria described
by Goris [6]. In addition, the doses of vasoactive drugs administered
to each patient to maintain optimal blood pressure and cardiac
output were recorded.
Following categorisation, and within 48 h of either admission to
the ITU or the development of sepsis or ARDS. full haemodynamic
measurements were made, including thermodilution cardiac output
(Table I). Immediately after these measurements, simultaneous ar¬
terial and mixed venous (pulmonary artery) samples were taken to
determine haemoglobin, oxygen tension and oxyhaemoglobin satu¬
ration. from which oxygen delivery and oxygen consumption were
calculated, and to estimate plasma immunoreactive endothelin con¬
centrations. In the five control subjects in whom a pulmonary artery
catheter was not present, arterial and central venous samples were
used for plasma endothelin estimations: cardiac output was not
measured and no derived measures were recorded. Immediately after
arterial and mixed venous sampling, a further sample for plasma
endothelin assay was obtained from the distal port of the pulmonary
artery catheter with the balloon inflated to occlude the pulmonary
artery. This was assumed to represent pulmonary capillary blood.
Plasma endothelin concentrations were measured by radioimmuno¬
assay [7], Cross-reactivity of the assay with endothelin-1. en-
dothelin-2, endothelin-3 and proendothelin-1 is 100%. 52%, 96%
and 7%, respectively. The normal range (mean ± 2 SD) for plasma
Table I Characteristics of
patient groups (SFR systemic
vascular resistance; MAP mean
irterial pressure; PVR
mlmonary vascular resistance)
Head injuries Sepsis alone Sepsis and A
N umber of patients 7 15 11
Number of survivors 7 13 6
APACHE II score 13.0 ± 1.9 26.0 + 2.4* 25.0 ± 2.0*
Organ Failure Score 0.3 ± 0.9 3.3 + 0.6* 4.6 + 0.6*
Lung Injury Score 0.6 ± 0.2 1.9 ± 0.1* 3.0 ± 0.1*'
P,02 (kPa) 18.7 ± 1.1 16.5 ± 1.1 12.3 + 1.2*'
P~0,:Fi02 (kPa) 54.0 ± 7.2 31.0 + 2.4* 19.0 ± 2.0*'
Oxygen consumption (ml-2 min"1 m') 110 + 10* 121 ± 7 147 + 15
Oxygen delivery (ml"' min"1 m "2) 581 ± 28* 599 + 42 586 + 39
SVR (dyne.s/cm5) 1070 + 413* 850 ± 93 741 + 55
MAP (mmHg) 97 + 6 82 + 4* 79 + 3*
PVR (dyne/s/cm5) 109 + 6* 226 ± 29 207 + 35
Noradrenaline dose (pig kg" ' h~ 1) 0.6 + 0.6 8.7 + 4.0 7.5 ± 4.7
Adrenaline dose (pg kg" 1 h" 1) 0 6.9 + 2.2 4.7 + 1.9
Dopamine dose (gg kg"1 min " 1) 0 1.4 + 0.5 0.7 + 0.5
Dobutamine dose (ggkg"'min"') 0 1.5 ± 0.5 0
Plasma creatinine (pmol/l) 74 + 5 242 + 38* 236 + 69
Mixed venous endothelin (pg/ml) 9.4 + 1.5 22.0 ± 3.3* 40.8 + 14*
Pulmonary capillary endothelin (pg/ml) 6.6 ± 0.4* 22.6 ± 2.9 45.1 + 14.4
Arterial endothelin (pg/ml) 9.1 ± 1.2 21.3 ± 2.7* 44.5 + 15.8*
p < 0.05 vs. controls; f p < 0.05 vs. sepsis alone
u = 2 in the head injury group for these parameters
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immunoreaciive cndothclin with this assay in our hands is
2.7-7.5 pg'ml (mean = 5.1).
Unless otherwise stated, all results are expressed as mean ±
standard error of the mean. Statistical analyses were performed
using StatView 512 + software for the Macintosh microcomputer
(Brainpower, Calabasas, Calif.). Data were examined using Student's
unpaired r-test, together with multiple regression analyses of plasma
immunoreaciive endothelin against the other recorded factors.
Results
Details of patients and outcome are shown in Table 1.
The control group had normal cardiovascular and pul¬
monary function. Patients with sepsis alone and with
sepsis and ARDS had significantly higher Apache II,
organ failure and lung injury scores than the control
subjects, indicating more severe illness. As compared
with controls, both these groups also demonstrated
haemodynamic compromise, characterised by hypo¬
tension necessitating vasoactive drug therapy and im¬
paired pulmonary function with lower ratios of Pa02 to
Fi02. The main differences between the patients with
sepsis alone and with sepsis and ARDS were that the
latter had worse lung function, as shown by higher
Murray lung injury scores, lower Pa02 and a lower
Pa02:Fi02 ratio. The two groups of patients with
sepsis did not differ according to any other indices of
illness severity, haemodynamic function or oxygen
transport.
There were no significant differences between mixed
venous, pulmonary capillary and arterial immunoreac-
tive endothelin concentrations in any group (Table 1).
Plasma endothelin was higher in patients with sepsis,
both with and without ARDS. than in controls. Al¬
though plasma endothelin was higher in septic patients
with ARDS than in those without ARDS, this differ¬
ence was not statistically significant. Endothelin con¬
centrations tended to be higher in non-survivors
(35.1 + 13 pg/ml) than in survivors (21.3 ± 4.8 pe/ml;
P = 0.23).
Upon multiple regression analysis performed to
determine which factors were independently correlated
with plasma endothelin, there were positive associ¬
ations with both organ failure score and oxygen con¬
sumption, and a negative association with the
PaO::Fi02 ratio (Fig. 1): the overall regression coeffi¬
cient was 0.92 (P = 0.0001). There was no correlation
with any of the other factors given in Table 1.
Discussion
Our results, consistent with those of others [8, 9], show
that plasma immunoreactive endothelin concentra¬
tions are markedly increased in patients with sepsis,
multiple organ failure and ARDS, as compared with
ITU controls or healthy subjects. We also demonstrate,
for the first time, that the degree of organ failure,
efficiency of pulmonary oxygen exchange and rate of
oxygen consumption all correlate independently with
plasma endothelin. Although we cannot specify which
of the endothelin isoforms produced the rise in plasma
immunoreactivity in our studies, endothelin-2 is unde¬
tectable in plasma [2], Furthermore, an earlier study
using an endothelin-1 specific assay appears to impli¬
cate this endothelially derived isoform [9].
Both increased generation and decreased clearance
of endothelin may have caused the rise in plasma con¬
centrations in patients with severe sepsis. Interestingly,
despite the presence of impaired renal function in most
patients with sepsis and contrary to the findings in
patients wtih chronic renal failure [2], there was no
correlation between plasma endothelin and plasma cre¬
atinine. This strengthens the case for the occurrence of
increased generation of endothelin in sepsis, although
other vascular beds, including the liver and skeletal
muscles, may also contribute to the clearance of
endothelin.
Plasma endothelin concentrations did not differ
among mixed venous, pulmonary capillary wedge and
systemic arterial samples from any of the patient
groups, including controls; increased pulmonary gen¬
eration of endothelin thus does not seem to occur in
sepsis and ARDS. In previous studies examining pul¬
monary arteriovenous ratios of plasma endothelin,
healthy subjects were shown to clear endothelin across
the pulmonary vascular bed. with a ratio of arterial to
venous endothelin that was substantially less than
unity [8-10]. We found no evidence for clearance of
endothelin across the pulmonary circulation in our
'controls'. Rather than drawing a comparison with
healthy subjects, we studied critically ill. head-injured
patients undergoing mechanical ventilation, consider¬
ing that those constituted a more closely matched con¬
trol group for the patients with sepsis and ARDS.
Because our control subjects did not extract endothelin
across the lung, this may be a feature of mechanical
ventilation or of the critically ill. Our findings empha¬
sise the need for an appropriate control group in order
to demonstrate reliably that sepsis or ARDS is asso¬
ciated with altered endothelin metabolism. It has been
reported that patients with ARDS have pulmonary
arteriovenous ratios for endothelin substantially
greater than unity [8], This was not the case in our
patients, nor in those reported in another study [9],
most of whom had co-existing sepsis, which is the usual
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Fig. 1 Scattergrams showing the relationship between mixed ve¬
nous endothelin concentrations and the three factors (Organ Failure
Score. PjO;: FiO, and oxygen consumption) which correlated inde¬
pendently with endothelin on multiple regression analysis. Relevant
regression coefficients (r) and significance values (p) are given on
each scattergram.
and because ARDS is characterised by increased pul¬
monary vascular resistance and microvascular per¬
meability, the very high circulating concentrations of
endothelin in septic patients with ARDS may contrib
ute to the pathophysiology of lung damage. This possi¬
bility is strengthened by the independent, though weak
(r = — 0.17), negative association of plasma endothelin
with the Pa02: Fi02 ratio on multiple regression analy¬
sis. The absence of a correlation between plasma en¬
dothelin and pulmonary vascular resistance suggests
that the major pulmonary effect of endothelin in sepsis
and ARDS may be on microvascular permeability. The
association of organ failure score with endothelin sug
gests that regional vasoconstriction in sepsis may be
due. at least in part, to increased plasma endothelin.
The association between plasma endothelin and
oxygen consumption is unexpected, as endothelin is not
generally regarded as a hormone that plays a major
role in control of metabolic rate. It is possible that this
association reflects other unmeasured factors, such as
increased concentrations of endogenous and exo¬
genous catecholamines and of growth factors, which
act to stimulate both metabolic rate and endothelin
production [2]. One may speculate that, of the three
variables independently associated with endothelin
concentration, one (oxygen consumption) may reflect
alterations in the regulation of endothelin generation,
while the others (Pa02:Fi02 ratio and organ failure
score) may reflect pathophysiological activities of en¬
dothelin. However, the question of whether local gen¬
eration of endothclin is a cause or a consequence of
ARDS and multiple organ failure in sepsis syndrome
will only be answered by studies with inhibitors of endo¬
thelin synthesis or endothelin receptor antagonists [2],
Our findings of very high plasma endothelin con¬
centrations in patients with severe sepsis and ARDS,
and their correlation with organ dysfunction, suggest
that local increases in endothelin generation may com¬
promise vital organ perfusion. Thus, there may be
a place for the newly described endothelin receptor
antagonists in the treatment of patients with sepsis and
ARDS.
Because endothelin-1 causes pulmonary vasocon¬
striction and enhances microvascular permeability [2],
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Activation ofendothelin ETA receptors masks the constrictor role
of endothelin ETB receptors in rat isolated small mesenteric
arteries
Emma J. Mickley, * 'Gillian A. Gray & David J. Webb
Clinical Pharmacology Unit and Research Centre, University of Edinburgh, Western General Hospital, Edinburgh, EH3 2XU and
•Department of Pharmacology, University of Edinburgh, I George Square, Edinburgh, EH8 9XJ
1 Endothelin-1 (ET-1) produces constriction of the rat mesenteric vascular bed in vivo via ETA and ETB
receptor subtypes. The aim of this study was to investigate the relative roles of these receptor subtypes in
rat isolated, endothelium-denuded, small mesenteric arteries, under pressure, by use of ET-1; the ETA
receptor antagonist, BQ-123; the ETB receptor selective agonist, sarafoloxin S6c (SRTX S6c); the ETB
receptor selective antagonist, BQ-788; and the ETA/ETB antagonist, TAK-044.
2 In 3rd generation mesenteric arteries, ET-1 (10~l3-I0~7 M) produced concentration-dependent
contractions (pD2 9.86). SRTX S6c (10_ 12 — 10 7 m) also induced concentration-dependent contractions
in 53% of arteries studied, although the E„„ was much less than that obtained with ET-1 (10.7 + 2.9%
vs 101.9 + 2.6% of the 60 mM KCl-induced contraction).
3 Neither ETB receptor desensitization, by a supra-maximal concentration of SRTX S6c (10 7 m), nor
incubation with BQ-788 (3 x 10"* m), had any significant effect on the ET-1 concentration-response
curve, although both treatments tended to enhance rather than inhibit responses to ET-1.
4 In the presence of BQ-123 (10 6 m), responses to low concentrations of ET-1 (up to 10 10 m) were
unaffected but responses to concentrations of ET-I above 10~'° m were significantly inhibited.
5 SRTX S6c desensitization followed by incubation with BQ-123 (10 6 m) or co-incubation with BQ-
788 (3 x 10"' m) and BQ-123 caused inhibition of responses to all concentrations of ET-1, resulting in a
rightward shift of the ET-1 concentration-response curve. The same effect was obtained by incubation
with TAK-044 (10"' m and 3x 10~7 m).
6 Thus, responses of rat small mesenteric arteries to ET-1 are mediated by both ETA and ETB
receptors. The relative role of ETB receptors is greater than that predicted by the small responses to
SRTX S6c or by resistance of ET-l-induced contraction to ETB receptor desensitization or BQ-788. The
effect of ETb receptor desensitization or blockade is only revealed in the presence of ETA receptor
blockade, suggesting the presence of a 'crosstalk' mechanism between the receptors. These results
support the concept that dual receptor antagonists, like TAK-044, may be required to inhibit completely
constrictor responses to ET-1.
Keywords: Endothelin-1; sarafotoxin S6c; ETA receptors; ETB receptors; BQ-123; BQ-788; TAK-044
Introduction
It is now well established that the vasoactive effects of the
peptide endothelin-1 (ET-1) are mediated via both ETA (Arai
el al., 1990) and ETB receptors (Sakurai el al., 1990). Admin¬
istration of ET-1 to anaesthetized or conscious rats leads to a
brief decrease, followed by a long lasting increase, in blood
pressure (Yanagisawa el al., 1988) that is accompanied by in¬
creased resistance in virtually all vascular beds studied (Gar¬
diner el al., 1994; Allcock el al., 1995). Prior administration of
an ETa receptor antagonist, e.g. BQ-123 or FR 139317, en¬
hances the initial depressor effect of ET-1 (an ETb receptor-
mediated effect) and reduces the pressor effect (McMurdo el
al., 1993; Gardiner el al., 1994) However, the pressor and
regional constrictor effect of ET-1 is not fully inhibited by ETA
receptor antagonists, even with high doses, implying that ETB
receptors may also have a vasoconstrictor role (McMurdo el
al., 1993). Consistent with this possibility, the ET„ receptor
selective agonist, sarafotoxin S6c (SRTX S6c) was found to
produce vasoconstriction in pithed rats (Williams el al., 1991;
Clozel el at., 1992).
In vitro experiments have also demonstrated ETA receptor
antagonist-resistant responses to ET-1 (Ihara el al., 1992;
Sumner el al., 1992; Fukuroda el al., 1994b) and constrictions
to SRTX S6c (Moreland et al., 1992; Sumner el al., 1992; La
Douceur el al., 1993; Gray el al., 1994) As a consequence of
1
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these in vitro data, it has been suggested that constrictor ETB
receptors have a role only in large calibre vessels and in the
venous circulation (Moreland el al., 1992; Davenport & Ma-
guire, 1995). However, in the conscious rat (Gardiner el al.,
1994) and the anaesthetized ganglion-blocked rat (Allcock el
al., 1995), ET-l-induced reduction of blood flow to the me¬
senteric resistance bed is partly resistant to ETA receptor in¬
hibition. Reduction of regional blood flow in response to
SRTX S6c is also most marked in the mesenteric bed of the
pithed rat (Clozel el al., 1992). In man, ET-1 constrictions in
upper limb blood vessels are also partly resistant to BQ-123
and constrictions to SRTX S6c can be seen (Haynes el al.,
1995; Strachan el al., 1995). Thus, there may be an important
role for constrictor ETB receptors in mediating vascular resis¬
tance and blood pressure. Indeed, the recently described non-
peptide ETB receptor antagonist, Ro 46-8443, causes a reduc¬
tion in blood pressure in anaesthetized, normotensive rats
(Clozel & Breu, 1996).
In contrast to the evidence for ET„ receptor-mediated
constriction of the rat mesenteric bed in vivo, in vitro studies of
perfused mesenteric beds or human and rat isolated mesenteric
arteries mounted in wire or perfusion myographs have led to
the conclusion that constrictor ET„ receptors have little
(Tschudi & Luscher, 1994; Takase el al., 1995; Deng el al.,
1995; Touyz el al., 1995) or no role (D'Orleans-Juste el al.,
1993) in this vascular bed. All of these studies have based their
conclusions on inhibition of ET-l-induced contraction by ETA
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receptor antagonists, or responses to ETB selective agonists.
The aim of the present study was to investigate further the role
of ETb receptors in mediating constriction in pressurized rat
mesenteric arteries by use of ET-1, the ETA receptor antago¬
nist, BQ-123 (lhara et al., 1992), the ETB selective agonist
SRTX S6c (Williams et al., 1991), the ET„ receptor selective
antagonist, BQ-788 (Ishikawa et al., 1994) and the ETA/ETB
antagonist, TAK-044 (Kikuchi et al., 1994).
Some of this work has been presented to the British Phar¬
macological Society (Mickley et at., 1995).
Methods
Male Wistar rats (10 16 weeks old) were killed by ex-
sanguination and the mesenteric bed immediately excised and
placed into cold, oxygenated Krebs-Henseleit solution. Third
order branches of the mesenteric artery (internal diameter
150-350 pm) were dissected (~3 mm length) and mounted
between two glass microcannulae in a small vessel arteriograph
(Living Systems Instrumentation Inc., Burlington, U.S.A.).
The vessel was constantly superfused with warmed (37°C),
oxygenated (95% 02; 5% C02) Krebs-Henseleit solution
(composition, in mm: NaCl 118, KCI 4.7, CaCI2 2.5, MgSO<
1.2, KH2PO< 1.2, NaHC03 25 and glucose 5.5). The in¬
traluminal pressure of the vessel was raised to 60 mmHg and
maintained at this pressure with a pressure servo unit without
further intraluminal perfusion. Luminal diameter was mea¬
sured with a video dimension analyser (Living Systems In¬
strumentation Inc., U.S.A.) and by hand, with a calibrated
micrometer, when the optical dimension analyser was unable
to detect differences in optical density at smaller lumen dia¬
meters. After an equilibration period of 60 min, the vessels
were exposed twice to modified Krebs-Henseleit solution
containing 60 mm KCI (equimolar replacement of NaCl by
KCI) in order to produce maximum constriction. KCI induced
a reduction in lumen diameter but never to the level where the
lumen was completely occluded (see Table 1). The endothelium
was removed by passing an air bubble through the lumen of
the vessel (Falloon et al., 1993; Smith, 1996) and complete
denudation was confirmed by addition of acetylcholine (ACh
10 6 m) to vessels pre-constricted with phenylephrine (PE
10 vi). In all vessels, the relaxation induced by ACh before
the passage of an air bubble (usually back to resting diameter),
was completely abolished after endothelial denudation. After
washing, a closed system with a total volume of 30 ml of
Krebs-Henseleit solution was constantly superfused at a con¬
stant flow rate of 5 ml min ' It was this reservoir of Krebs-
Henseleit solution to which the agonists and antagonists were
applied, keeping the volume at 30 ml by removing one ml of
Krebs and adding one ml of the drug in a stepwise fashion (as
previously described, Smith et al., 1995). Responses were re¬
corded 5 min after addition of each agonist concentration,
which was sufficient time for an equilibrium response. All of
the following studies were carried out in random order and
only one concentration response curve to ET-I or SRTX S6c
was performed per tissue None of the drug treatments resulted
in complete occlusion of the vessel lumen within the concen¬
tration range studied (see Table I)
ET-I and SRTX S6c study
In the first set of experiments cumulative concentration-re¬
sponse curves to ET-1 (10 "-3x10 8 m, n=10) or SRTX
S6c (10"12- 10 7 m, n= 17) were obtained as described above.
Receptor antagonism study
In the second set of experiments, vessels were exposed to either
BQ-123 (10 6 m, n = 8), BQ-788 (3 x 10 8 m, n = 8), TAK-044
(10 8 and 3x10 7 m, n = 4 and 8 respectively), BQ-123 + BQ-
788 (concentrations as before, n = 8) or vehicle (n = 8) for
30 min, before concentration-response curves to ET-1 (10
3x 10 8 m) were obtained. For these experiments, agonists
were prepared in a solution of antagonist so that addition to
the perfusion circuit did not dilute the antagonist solution
superfusing the tissue. In some experiments, the vessels were
exposed for 30 min to SRTX S6c (10 7 m) twice (with a wash
out period of 10 min between each exposure), in order to de¬
sensitise the ETb receptor before commencement of the ET-1
concentration-response curve. This was carried out both in the
absence and in the presence of BQ-123 (n = 8 each). In all ex¬
periments, the time-course of the protocol was the same; 2 h
after verification of the removal of the endothelium, the con¬
centration-response curve to ET-1 was begun.
Data analysis
The results are calculated as a percentage of maximum con¬
striction obtained with the second exposure to 60 mm KCI
Krebs solution and are expressed as mean+ s.e.mean. Where a
maximum response to the agonist was obtained, the negative
log of the concentration causing half-maximal contraction
(pD2) was calculated by linear regression analysis and com¬
pared by unpaired one-tailed t test. The concentration-re¬
sponse curves were compared by one-way ANOVA followed
by Fisher's least significant difference test. Significance was
taken at P<0.05.
Materials
ET-1 and SRTX S6c were purchased from Novabiochem
(Nottingham, U.K.) and BQ-788 (N-cis-2,6-dimethylpiperi-
dinocarbonyl-l-y-MeLeu-D-T rp(COOCH ,)-d-N le, sodium
salt) from Neosystems (Strasbourg, France), all were recon¬
stituted in 50:50 methanol; distilled water. BQ-123 (cyclo(t)-
Trp-d-Asp-t.-Pro-d-Vel-l-Leu]) from Neosystems (France)
and TAK-044 (cyclo|D-a-Asp-3-[(phenylpiperazin-1-yl)carbo-
nyl]-l-Ala-a-Asp-d-2-(2-thienyl)-Gly-L-Leu-D-Trp] disodium
salt) synthesised by Takeda Chemical Industries (Osaka, Ja¬
pan) were reconstituted in 0.9% saline, placed in aliquots and
stored frozen at -20"C until use All peptide agonists and
antagonists were diluted in Krebs-Henseleit solution contain¬
ing 0.1 % bovine serum albumin (BSA: Sigma, Poole, U.K.). In
r»Me I Mean resting lumen diameters and lumen diameters after exposure to 60 mM KCI solution or after the maximum
concentration of endothelin-l (ET-I) or sarafotoxin S6c (SRTX S6c) in each experimental group
i BQ-I2J
Er ' t SRTX I BQ-I2.I i SK I X t TAK-044 ' / A K 1)44
control SR'f'X S6c iR(J-l2i < HQ-7NX .S'rtr r/r.vmv I RQ-7HA Sftc descns <10 "m) (JxIO'm)
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• 60 111 M KCI diameter Slit 4g ( a Sift SI t 1 4X t 3 S3 t i SO t t IS I t SO t ■>
Max I T I SRTX She
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all antagonist experiments the ET-1 concentrations were di¬
luted in 0.1% BSA Krebs-Henseleit solution with the appro¬
priate antagonist. ACh (chloride salt, Sigma, Poole, U.K.) and
PE (hydrochloride salt; Fisons, U.K.) were prepared in saline
at stock concentration of 10 2 m, placed in aliquots, and
stored at — 20°C until use when diluted in Krebs-Henseleit
solution.
Results
Effects of 60 mM KCI
In all experiments 60 mM KCI superfusion constricted the ar¬
teries, an effect which was reversible, back to initial resting
diameter, on washout (Table I). The initial diameter remained
constant until agonist-induced constriction was generated.
Effects of ET-1 and SRTX S6c
ET-I constricted the arteries in a concentration-dependent
manner (Figure 1, pD2 9.86, Ema„ 101.9±2.6% KCI induced
contraction at 10 8 m ET-1, n = 10). SRTX S6c also produced
a concentration-dependent contraction (Figure I), but the re¬
sponse was extremely variable, the maximum response ob¬
tained with 3 x 10 8 m SRTX S6c ranging from 0 to 39% of
KCI contraction (mean response = 10.7 + 2.9%, n - 17). In fact,
only 9 of the 17 vessels (53%) responded to SRTX S6c.
Effect of ETA receptor blockade
Incubation with BQ-123 (10 6 m) before and during exposure
to ET-1 (Figure 2) had no effect on contractile responses to low
concentrations of ET-1 (10~" to 10 10 m) but resulted in in¬
hibition of responses to concentrations of ET-1 between 10 10
and 3 x 10 8 M. Incubation with BQ-123 significantly inhibited
the constrictions to 10 9 and 3 x 10 9 M ET-1 (7> = 0.006 and
0.01, respectively) when compared by ANOVA. However, the
effect of BQ-123 on the overall pD2 of the ET-1 concentration-
response curve did not reach statistical significance (pD2 9 15
(n = 8) vs 9 86 (n 10) NS, P -- 0.094).
Effect of ETK receptor desensilization or blockade
Exposure to a supra-maximal concentration of SRTX S6c
(10 7 M), to achieve ETB receptor desensitization, produced
an initial constriction in 4 out of the 8 vessels studied (mean
response = 8.1 + 3.5% KCI constriction). The vessel diameter
returned to the initial resting value during the first 30 min
exposure to SRTX S6c. No constriction was seen, in any of
the vessels studied, during the second exposure to SRTX S6c
confirming that tachyphlaxis had occurred. The ET-1 con¬
centration-response curve was not significantly altered by ei¬
ther ETb receptor desensitisation (Figure 3a, pD2 = 9.88,
n- 8) or following incubation with the selective ETB receptor
antagonist, BQ-788 (3x10~8m, Figure 3b, pD2= 10.02,
n = 8), although both treatments tended to shift the ET-1
concentration-response curve to the left (/' = 0.5 and 0.34,
respectively).
Effect of combined ETA and ETB receptor blockade
Co-incubation of vessels with BQ-123 (10 6 m) and BQ-788
(3 x 10 8 m) resulted in a parallel shift of the ET-1 concen¬
tration-response curve to the right (Figure 4, n = 8). Incubation
with BQ-123 (10 6 m) following desensitization of ETB re¬
ceptors with 10 7 m SRTX S6c caused a similar rightward
shift (Figure 4, n = 8). Incubation of vessels with the ETA/ETB
receptor antagonist, TAK-044 (Figure 5, 10 8 M, n = 4 and
3 x 10 1 m, n = 8) also caused a parallel concentration-depen¬
dent shift to the right of the ET-1 concentration-response
curve. As the maximum response to ET-1 was not reached
within the concentration range studied it was not possible to
calculate pD2 values for ET-1 in experiments with BQ-123 plus
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Figure I Comparison of the contractile responses to endothelin-1
(I I-l. Q) and sarafotoxm S6c (SRTX S6c. A) in rat small
mesenteric arteries M l (n 10) produced a maximal constriction
<>l Similar proportion to 60 mM kC'l al 1 x 10 ' m SRTX S6c
(// 17) induced small constrictions at the highest concentrations,
suggesting a small population ol f I receptors present on the
smooth muscle ol the resistance arteries All values are mean and
vertical lines show s e mean
Figure 2 I.lVect of the MA receptor antagonist BQ-121
endothehn-l (Ml) concentration-response curve in
mesenteric arteries Preincubation with HQ-12.1 (It) m)
.10 mm <#. // K) shifted the responses to the higher
ol P I -l in a parallel fashion to the right All values
vertical lines show s r mi'rin . (I (IS cnmnart'd lo .m





Figure 3 The effects of selective ETB receptor blockade on
endothelin-l (F.T-1)-induced constrictions in rat small mesenteric
arteries. The vessels were exposed to either (a) sarafotoxin S6c
(SRTX S6c; 10 7 M, A, n = 8) twice before addition of ET-I or (b)
BQ-788 (Jx 10 8 M. ■, n = 8) pre-incubated for 30 min before the
start of the ET-I concentration-response curve. In both treatments
the ET-I concentration-response curves tended to be shifted slightly
to the left as compared to control (O). (though not significant,
P =■ 0.54 and 0.42, respectively, as compared by ANOVA) All values
are mean and vertical lines show s.e.mean.
Discussion
Previous in vivo studies have clearly indicated a role for ET„
receptors in mediating vasoconstriction in resistance beds, but
their role has been difficult to demonstrate in isolated re¬
sistance vessels. In the present study, we show that a role for
ET„ receptors in rat isolated mesenteric arteries emerges when
both ETa and ETB receptors are blocked, whereas blockade of
ETa receptors alone only partially inhibited ET-I-induced
contraction and inhibition of ET„ receptors alone had no ef¬
fect. This phenomenon is similar to previous observations in
rabbit pulmonary artery (Eukuroda el al., I994c), rat trachea
(Clozel & Gray. 1995) and h uman bronchus (Eukuroda el al..
log [ET—11 m
Figure 4 The effects of non-selective ETA/ETB combination
treatment on endothelin-l (ET-l)-induced constrictions in rat small
mesenteric arteries. The vessels were exposed to either vehicle (O),
BQ-123 plus BQ-788 (10 6 M and 3 x 10 " M, □, n = 8) or pre-
incubated with sarafotoxin S6c twice (each 10 7 m) plus BQ-123
(10 6 M, ■, n = 8). Both treatments significantly shifted the ET-I
concentration-response curve to the right in a parallel fashion
(P = 0.0001 for both). All values are mean and vertical lines show
s.e.mean.
log [ET—11 m
Figure 5 The effects of the non-selective ETA/ETB receptor
antagonist TAK-044 on endolhelin (ET-I (-induced constrictions in
rat small mesenteric arteries. The vessels were pre-incubated for
30 min with either 10 8 M (A. « 4) or 3 x 10 7 M (A, " H) TAK-
044 Both treatments significantly inhibited the ET-1 concentration-
response curve (P = 0.0002 and 0 0001 respectively) as compared to
control (O) All values are mean and vertical lines show s.e.mean
1996), and may be explained by the existence of a crosstalk'
mechanism between the ETA and ETB receptors
In initial experiments we used the highly selective ETB re¬
ceptor agonist SRTX S6c (Williams el al., 1991) to investigate
the presence of ETB receptors in pressurised mesenteric ar¬
teries SRTX S6c produced concentration-dependent con-
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striclion bul the maximum constriction reached only ~ 10% of
that routinely seen with ET-1, much less than would have been
predicted from previous in vivo experiments (Clozel el at.,
1992). However, the magnitude of responses to SRTX S6c is in
agreement with responses obtained by Taltase el al. (1995) and
Deng et al. (1995), in rat mesenteric arteries studied in the
perfusion and wire myograph, respectively. Interestingly, in all
three studies, the contractions of SRTX S6c occurred al rela¬
tively high concentrations (10 nM). The ET„ receptor agonists,
BQ-3020 and IRL 1620, were equally ineffective in the rat
perfused mesenteric bed at concentrations up to I nM (D'Or-
leans-Juste el al., 1993). This is quite different to the ETB
agonist responses induced in large blood vessels, which are
generally larger and occur at lower concentrations (Moreland
el al., 1992, Sumner el al., 1992; LaDouceur el al., 1993; Gray
el al., 1994). Another interesting feature of our results, not
mentioned by previous investigators, is the variability in re¬
sponsiveness to SRTX S6c. While some vessels failed to re¬
spond, others gave up to ~ 40% of the maximum contraction
obtained with ET-1. This might tie explained by differential
distribution of ET„ receptors in the mesenteric bed, although
3rd generation branches of the main mesenteric artery were
routinely used for these studies. Another possibility is varia¬
tion in intrinsic myogenic tone that these vessels can develop
when under pressure. In a separate experiment, in which ves
sels mounted in the wire myograph were studied, we found that
no responses were obtained to STRX S6c until some tone was
introduced by a low concentration of the stable thromboxane
analogue, U46619 (Mickley et al., 1995).
An alternative approach for the investigation of the role of
ETb receptors is to remove the influence of ETB receptors,
either by desensitization (LaDouceur el al., 1993) or by use of
a selective ETB receptor antagonist, like BQ-788 (Ishikawa el
al., 1994). In the present study, neither of these interventions
inhibited ET-1 induced contraction, a result which would
support the view that ETB receptors have little or no role in rat
mesenteric arteries. Interestingly, both desensitization and BQ-
788 treatment seemed to potentiate responses to ET-1 slighty,
although this effect was not significant. Seo (1996) recently
found a similar potentiation of ET-1-induced constriction by
the HTb receptor antagonist, Res 701-1 in human gastroepi¬
ploic arteries. There are several possible explanations for these
observations. Potentiation of contractions by ET„ receptor
antagonists would be expected in the presence of the vascular
endothelium due to blockade of endothelial ETB receptor-
mediated release of relaxing factors by ET-1 However, this is
an unlikely explanation for the present results as the endo¬
thelium was effectively removed by passing of an air bubble
through the lumen of the vessels, as evidenced by the loss of
relaxant responses to acetylcholine Previous histological stu¬
dies in our laboratory have also shown complete removal of
the endothelium by this method (Smith, 1996). The experi¬
ments of Seo (1996) were also conducted in endothelium-de-
nuded vessels Alternatively, potentiation might have been
caused by displacement of ET-I from low affinity ET„ clear¬
ance receptors (Fukuroda el al., 1994a) by BQ-788, but this
would not account for the similar effect of receptor desensiti-
salion Another alternative, suggested by Seo (1996), is the
presence of sensitive ETB receptors on smooth muscle which
inhibit or negatively modulate ETA receptor-mediated con¬
strictions to ET-1
Erom the results obtained with SRTX S6c, BQ-788, and
desensitization alone, one would predict that blockade of ETA
receptors, by use of a selective competitive antagonist, like BQ-
123 (Ihara el at., 1992), would cause a parallel rightward shift
of (he ET-1 concentration-response curve However, in the
presence of BQ-123 the ET-1 concentration-response curve in
mesenteric arteries under pressure was biphasic, only responses
to high concentrations of F.T-I being shifted to the right in a
paiallel manner by BQ-123, consistent with competitive an¬
tagonism at the FIa receptor Interestingly, the BQ-121-re-
sistant, possibly ET„-medialed. responses to ET-1 were at the
lower end of the dose-response curve, consistent with the
presence of a high affinity ETB receptor. Takase el al. (1995)
obtained similar results with the ETA receptor antagonist,
PR 139317 in rat mesenteric arteries, although in that case the
ETA-resistant component was smaller than seen here. Takase
el al. perfused the vessels al a pressure of 30 mmHg, half of
that used in the present study. Given our observation that
increased tone may reveal constrictor ETB receptors, as implied
by the responses to SRTX S6c (Mickley el al., 1995), the lower
pressure used by Takase el al. (1995) may account for the
smaller ETA receptor antagonist-resistant element of the ET-1
curve The results of the present study are consistent with the
ETA receptor antagonist resistant reduction in mesenteric
blood flow induced by ET-1 in vivo found by Gardiner el al.
(1994) and Allcock el al. (1995).
In order to investigate whether the residual ETA antagonist
resistant portion of the ET-1 response is mediated by ETB
receptors, we used combined treatment with BQ-123 and either
desensitization or BQ-788. Both of these combination treat¬
ments resulted in a parallel shift of the ET-1 concentration-
response curve. In fact, the BQ-123-sensitive portion was
moved further to the right than with BQ 123 alone, in agree
ment with Fukuroda el al. (1996) who described a similar
phenomenon in human bronchi. Responses to ET-1 were also
inhibited, in a concentration-dependent manner, by TAK-044,
a peptide antagonist with similar potency at both ETA and ET„
receptors (Kikuchi el al., 1994).
These results demonstrate a clear role for ETB receptors
in mediation of constrictor responses to ET-1 in small me¬
senteric arteries that is only revealed when ETA receptors, in
addition to ETB receptors, are blocked. The lack of effect of
ETb receptor blockade or desensitization alone seerffs to
indicate that ETA receptors can somehow compensate for
the inactivation of ETB receptors. Similar observations have
been obtained in vascular (Fukuroda el at., 1994c) and non¬
vascular (Clozel & Gray, 1995; Fukuroda et at., 1996) tis¬
sues. The concept of receptor 'crosstalk' has been proposed
to explain these observations. The mechanism is not fully
understood, although interactions at the second messenger
level have been suggested, such that blockade of the ET„
receptor releases an inhibitory mechanism acting at the ETA
receptor (Fukuroda et al., 1996). Allosteric interactions be¬
tween ET receptors have been suggested to account for the
results of radioligand binding studies in rat heart (Soko-
lovsky, 1993). Further biochemical studies are required to
elucidate the interactions between ET receptors co-existing
in the same tissue and the mechanism of the apparent
crosstalk phenomenon. Interestingly, similar interactions
have been described between ar and a2-adrenoceptors acti¬
vated by noradrenaline (Daly et al., 1988).
In the rat, the mesenteric bed receives a high proportion of
cardiac output and thus resistance in this bed is an important
determinant of total peripheral resistance and of blood pres¬
sure. The present results show that simultaneous blockade of
both ETa and F.T„ receptors is required for complete inhibi¬
tion of constrictor responses to ET-1 in the rat mesentery in
vitro. This agrees with observations that blockade of both re¬
ceptors is required to inhibit ET-1-induced increases in blood
pressure in vivo (McMurdo el al., 1993). The role of ETB re¬
ceptors in regulating constrictor responses to ET-1 might he
even greater in human resistance vessels, where ET„ agonists
have a greater direct effect than in other species in vitro (Takase
et at., 1995, Mickley, unpublished observations) and in vivo
(Haynes et al., 1995)
In some pathophysiological states associated with increased
peripheral resistance and increased plasma concentrations of
ET-1. there is evidence for an upregulalion of smooth muscle
ETb receptors; most notably in heart failure in dogs (Caiman
el ni. 1996) and man (Love el al., 1996); in atherosclerosis
(Winkles et al., 1993; Dagassan el at., 1996) and in hyperten¬
sion (Kanno el al., 199.3; Balra el al.. 1993). The results of the
present study suggest that blockade of both ETA and I I B re¬
ceptors may be required for effective inhibition of ET-1-in
duced constriction in these diseases This study was conducted
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in vessels without endothelium. However, in the presence of
endothelium, ET„ receptor blockade can actually enhance re¬
sponses to ET-1 by blocking the release of nitric oxide and
prostacyclin through endothelial ETB receptor stimulation (De
Nucci et al., 1988). Thus, the effectiveness of endothelin re¬
ceptor blockade therapeutically will depend on the level of
endothelial ET„ receptor stimulation and on the relative se¬
lectivity of the antagonist for endothelial and smooth muscle
ETB receptors, the ideal antagonist allowing ET-1 to act at the
endothelial ETB receptor while blocking its efTecls at smooth
muscle ETA and ETB receptors.
E.J.M. is the recipient of an MRC Studentship. This work was
supported by the British Heart Foundation (Grant No. FS/94003)
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A Nonradioactive Method for Localization of Endothelin
Receptor mRNA In Situ
Pauline E. McEwan, *01ivier Valdenaire, Louise Sutherland, tDavid J. Webb, and
Gillian A. Gray
Departmentr; of Pharmacology and fClinical Pharmacology, University of Edinburgh, Scotland; and *Preclinical Research,
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Summary: To investigate relationships between the distribu¬
tion of endothelin (ET) receptor expression and histopathology
of heart and blood vessels, we developed a method of nonra¬
dioactive in situ hybridization in paraffin sections. Rat mesen¬
teric bed, rat heart, and human uterine artery were fixed in
formalin and embedded in paraffin ETA and ET„ receptor cD-
NAs were subcloned into plasmid vectors for synthesis of sense
and anti-sense probes. Digoxigenin (DIG)-UTP was incorpo¬
rated into every twentieth to twenty-fifth nucleotide of the
newly transcribed cRNA. mRNA was detected in situ using an
anti-DIG alkaline phosphatase antibody and an alkaline phos¬
phatase substrate. In blood vessels, ETA receptor mRNA was
localized to the medial smooth muscle layer and ET„ receptor
mRNA to the endothelial and adventitial layers. Hearts from
rats that had undergone coronary artery ligation for induction of
CHF showed intense staining for ETB receptor mRNA in the
scarred and infarcted zone of the left ventricle. This method
provides a suitable alternative to radioisotope labeled probes
for detection of ET receptor mRNA. It allows better preserva¬
tion of tissues, shorter detection time, and improved morphol¬
ogy for microscopic analysis. Key Words: ET- Receptors
mRNA—In situ hybridization—Digoxigenin.
Since the description of endothelin (ET) in 1988 (I)
and subsequent cloning of the genes for the ET receptor
subtypes ETA and ETB and endothelin-converting en¬
zyme (ECE), there has been a wealth of interest in the ET
system in a number of pathophysiologic conditions, such
as hypertension, atherosclerosis, and heart failure (2).
The most commonly used methods to investigate the role
of ET and its receptors at the molecular level in tissues
such as heart and blood vessels are limited to techniques
that require either cultures of cells, homogenates of tis¬
sue for mRNA extraction, or the use of potentially haz¬
ardous radioactive isotopes. Although cell culture meth¬
ods provide preliminary evidence of receptor activity and
yield valuable information about intracellular and extra¬
cellular events (3), the cells are removed from their
physiologic environment and therefore little information
is gained about where the receptors are expressed within
the whole tissue and how the receptors are organized in
relation to other cell types. Moreover, Northern blotting
techniques require tissues to be homogenized for blotting
of RNA onto nitrocellulose membranes and, because
most tissues are heterogeneous, it can be difficult to lo¬
calize ET receptor expression to a particular cell type.
In situ hybridization is a technique in which tissue
sections can be probed with cRNA. Normally, cRNA is
labeled with radioactive isotopes such as 1sS, !H, or ,2P
for use as cRNA probes. However, not only does this
method require a specially designated laboratory for ra¬
dioisotope use but frozen tissue sections also tend to be
used to facilitate detection of the hybridized mRNA by
autoradiography. The use of cryotomy often means that
morphology and microscopic resolution of the tissues are
compromised by ice crystal damage during the freezing
process (4), and sections tend to be fragile, resulting in
tissue degradation and loss by the rigorous posthybrid-
ization process. Furthermore, the development process
for autoradiographs is arduous and can take several
months before results are available for analysis.
The aim of the present study, therefore, was to simul¬
taneously correlate expression studies with histopatho¬
logic changes in rat and human heart and in blood vessels
by developing a sensitive nonradioactive method of lo¬
calizing ET receptors in situ, in which results can be
obtained within days with minimum loss of cell detail,
for examination by brightfield microscopy.
MATERIALS AND METHODS
Rat mesenteric blood vessels, rat heart, and human uterine
arteries were dissected free of fat and fixed in 10% formalin.
Tissues were dehydrated in alcohol, embedded in paraffin, V
pm sections were mounted on 3-aminopropyltriethoxysilane-
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(TTiSI'A)-coated slides, and sections were dew axed in xylene,
alcohol, and PBS. Sections were treated with 0.2 M hydroehlo
l ie acid for 20 mill, washed in 0.3',L Triton \ 100. incubated
with proteinase K (40 (jcy,/mI Tris Id) I A holler, pi I X) at >! (
lor 30 mitt, and washed in 0.1 M trielhanolamine with 0,3'T
acetic anhydride.
In situ hybridization
PCR products of human BTA (600 hp) and rat T.T„ receptor
(800 bp) were subcloned into Bluescript SK (Stralagene. La
Jolla. CA, U.S.A.) or p("RII (Invilrogen) plasmiil vectors.
Single-stranded digoxigenin (DIG)-lahcled (Boehringer Mann
heim. Germany) sense and anti-sense probes were synthesized
using linearized templates and SP6, T.3. and 17 RNA polymer¬
ases (Promega, Madison, Wl, U.S.A.). Probe concentration and
integrity were determined by dot-immunoblotting and lormal-
Id A
Sense
FIG. 2. A: Human uterine artery treated with anti-sense probe to
ETa receptors. ETfl receptor mRNA (black) is distributed in the
arterial media (M). B: ETA receptor sense control in human uter¬
ine artery, showing no evidence of ETA receptor mRNA. The







B 1 2 0 pg 1 pg ^®0ng ^®n2
FIG. 1. A: A 1% agarose gel showing (Lane i) 1-kb DNA ladder,
(Lane ii) rat ETB receptor 800-bp sequence, and (Lane lii) human
ETA receptor 600-bp sequence cut from PCR II with ECoR I
restriction enzyme. B: RNA dot-blot of human ETA and rat ETB
receptor sense and anti-sense probes showing 20 pg, 1 pg, 100
ng, and 10 ng concentrations of DIG-labeled RNA
dehyde gel electrophoresis. Sections were incubated with pie-
hybridization (prehyb) solution (5 M NaCl, I M Tris, SO mM
Denhardl's, 250 mM EDTA, 10 mg/ml salmon sperm DNA, 50
nig/ml yeast tRNA) lor 2 h at 5()°C. then treated with sense or
anti-sense cRNA diluted in 1:1 hybridization buffer (prehyb
and 0.2 g/ml dextran sulfate) and deionized formamide over¬
night at 42°C. Sections were washed in 2x standard sodium
citrate (SSC) buffer at 22°C and 60"C with ().2x SSC/deionized
lormamide, then treated with RNase (50 p,g/ml) for 30 min at
37UC. rinsed in maleic acid buffer, treated with 10% sheep
serum at 22"C for I h, and then incubated with an anti-l)IG
alkaline phosphatase-conjugated antibody (diluted 1:2,000 in
I '/> sheep serum) for 2 h at 22°C. mRNA was detected using
alkaline phosphatase substrate and nitroblue tetrazolium chlo-
ride/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) di¬
luted 1:40 in Tris-HCI/MgCI. pH 6.5. Sections treated with
sense probes were counterstained with hematoxylin and
mounted in aquamount (Bl)ll. Boole, U.K.). Messenger RNA
appeared black. Other tissue sections were treated with elastic
vail Gicson's stain for elastic and collagen.
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in cardiovascular diseases such as atherosclerosis and
heart failure (2). Although the main source of ET-1 is
presumed to be the endothelial cells, some evidence sug¬
gests that, in pathophysiologic states, cells other than the
endothelium are able to produce ET (6). It is therefore,
possible, that autocrine or paracrine ET systems exist in
tissues of the cardiovascular system. Although a role for
the ET receptors in disease is suggested by studies with
ET receptor antagonists (7,8), little is known about the
role of the ET receptors at the molecular level in disease,
and this is an area of ET research that remains to be
investigated. The use of DIG-labeled probes is ideal for
assessing changes in expression of the components of the
ET system in situ. Changes in receptor expression can be
localized to particular cell types and correlated with mor¬
phologic and pathophysiologic changes in tissues.
Acknowledgment: The authors thank the British Heart
Foundation (PG95136, PG96109), the National Heart Research
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Functional Studies in Small Arteries Do Not Support a Primary
Role for Endothelin in the Pathogenesis of Raynaud's Disease
*|Paula J. W. Smith, *Charles J. Ferro, fDaniel S. McQueen, and *David J. Webb
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Summary: Endothelin-1 (ET-1) has been implicated in the
pathogenesis of Raynaud's disease (RD). This study examined
the effect of cooling on the response to ET-1 in human mi-
crovessels. Subcutaneous small arteries were dissected from
gluteal fat biopsies taken from patients with RD (n = 20) and
from age- and sex-matched control subjects (n = 17) and were
cannulated in a small vessel arteriograph. Cumulative concen¬
tration-response curves to ET-1 (10~12 to 3 x 10 7 M) were
obtained in vessels at 37°C and 24°C, with the endothelium
either intact or removed (n = 6 per group). There were no
significant differences in responses to ET-1 between RD pa¬
tients and controls in either intact or denuded vessels, at either
37°C or at 24°C. There was, however, a significant endothe-
lium-dependent interaction between the groups when the effect
of temperature on the response to ET-1 was examined (p =
0.01; two-way ANOVA). Whereas cooling tended to reduce the
sensitivity in RD, the opposite effect was observed in controls.
Measurements of plasma ET-1 did not reveal any significant
difference between patients with RD and healthy controls.
These results suggest that ET-1 does not play a primary patho¬
physiologic role in RD. ET-1 might be responsible for medi¬
ating the prolonged vasospasm in RD, but secondary to another
factor(s), such as impaired endothelium-dependent vasodilata¬
tion. Key Words: Raynaud's disease—Endothelium—
Endothelin—Cooling—Small arteries—Human.
A temperature-dependent disorder of the endothelium
involving overproduction of the vasoconstrictor endothe¬
lin-1 (ET-1) might be the critical factor underlying the
pathogenesis of the prolonged cold-induced vasospasm
of Raynaud's disease (RD). In 1990, Zamora and col¬
leagues (1) performed cold provocation studies in RD
patients and found an exaggerated increase in ET-1 con¬
centration in venous blood draining the cold-challenged
arm compared to the control arm or to responses in
healthy control subjects. Basal ET-1 levels were also
elevated in RD patients, a finding that has been sup¬
ported by others (2). In addition, a rapid increase in
plasma ET-1 during the cold-pressor test in healthy sub¬
jects has been reported (3). Although these results are
consistent with a role for ET-1 in mediating the pro¬
longed cold-induced vasospasm of RD, others have
found that ET-1 concentrations do not increase during
cold exposure in RD (4,5), creating some uncertainty as
to whether or not this peptide has a primary role in RD.
Of course, plasma concentrations of ET-1 are not neces¬
sarily a good predictor of its pathogenetic role in disease,
because ET is preferentially secreted abluminally and is
therefore unlikely to be acting as a circulating hormone,
with elevated levels merely reflecting spillover from its
release in the vasculature.
In this study we examined constrictor responses to
ET-1 in subcutaneous small arteries isolated from gluteal
fat biopsies taken from RD patients and from age- and
sex-matched control subjects to investigate the pathoge¬
netic role of this peptide in RD. We hypothesize that any
defect present in the digital circulation will be manifest
in arteries taken from the gluteal region because there is
evidence to suggest that RD may be part of a generalized
vasospastic disorder, in that there is a higher incidence of
RD in patients with migraine and/or variant angina (6-8).
The temperatures of 37°C and 24°C were chosen in the
present study because they are directly comparable with
many published reports and represent body temperature
and moderate cooling, respectively.
MATERIALS AND METHODS
The protocol of this study was approved by the Lothian
Research Ethics Committee and written, witnessed, informed
consent was obtained from each subject. Seventeen control
subjects (29-64 years; three men, 14 women) and 20 RD pa¬
tients (28-62 years; three men, 17 women) were recruited in
this study (Table 1). All subjects has an alcohol intake of <14
(women) and <21 (men) units per week and were normotensive
|systolic blood pressure <140 mm Hg; diastolic blood pressure
<90 mm Hg; mean arterial pressure 92 ± 2 mm Hg lor controls
Address correspondence and reprint requests to Prof D. J. Webb tit University of Edinburgh, Department of Medicine, Western General Hospital.
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TABLE 1. Subject and patient details and baseline (lata for vessels
studied at 37°C and 24"C
Control subjects Raynaud's patients
37"C 24"C 37 °C 24°C
Age (years) 41 ± 4 37 ± 3 48 ± 3 46 + 3
Sex ratio (M:F) 1:8 2 :6 2:9 1 :8
Lumen diameter ■P* oc 1+ 39 328 ±21 321 ± 30 304 + 20
% Contraction to KCI 65 ± 4 68 ± 3 65 ± 2 69 ± 2
% Relaxation to ACh 72 ± 7 65 ± 12 72 ± 11 81 ± 5
Values are mean ± SEM. Mean duration of RD was 18 ± 3 years. One patient
had Raynaud's phenomenon associated with Sjogren's syndrome. Three control
subjects and one RD patient were smokers. Except for one control subject and one
RD patient who were taking hormone replacement therapy, none of the volunteers
was receiving any medication at the time of the study and all were in general good
health. Values represent n = 12 for lumen diameter and % contraction to KCI
(intact and denuded vessels), and n = 6 for % relaxation to ACh (intact vessels
only). Resting lumen diameter (p.m); potassium chloride (KCI) (60 mAf); acetyl¬
choline (ACh) (I0~6 M).
vs. 94 ± 2 mm Hg for RD patients (p = 0.48)]. Subjects
abstained from aspirin-containing drugs for 1 week, and from
caffeine-containing drinks or alcohol for 12 h before the biopsy
was taken.
Skin biopsies approximately 2 cm long, 0.75 cm wide, and
0.75 cm deep were taken from the gluteal region under local
anesthesia (9) (1% lignocaine; Astra Pharmaceuticals Ltd.,
U.K.) and were placed directly into physiologic salt solution
(PSS) (mM: 118 NaCl, 4.7 KCI, 2.5 CaCl2, 1.2 MgS04, 1.2
KH2P04, 25.0 NaHC03, 0.026 EDTA, and 5.5 glucose). Small
arteries with a mean luminal diameter of 324 ± 13 p,m (n = 48)
were excised under a dissection microscope and cannulated in
a perfusion myograph (Living Systems Instrumentation, Bur¬
lington, VT, U.S.A.). If two arteries were taken from the same
biopsy, each was randomized to a different experimental group,
1.e., 37°C or 24°C. A pressure servo unit maintained intralu¬
minal pressure, without flow, at 50 mm Hg. Luminal diameter
was measured using a video dimension analyzer. After a 60-
90-min equilibration period during which the vessel chamber
was superfused with PSS, continuously gassed with 95% 02/
5% C02, and the temperature raised to 37°C, the contractility
of the microvessels was assessed separately using norepineph¬
rine 10~5 M (NE; Sigma, U.K.) and potassium chloride 60 mM
(KCI; Sigma). Acetylcholine l()~6 M (ACh; Sigma) was given
during maximal contraction to NE to assess endothelial integ¬
rity. Removal of the endothelium was achieved by passing air
through the lumen of the vessel and was confirmed by the loss
of ACh-induced relaxation during constriction to NE. Cooling
was achieved by passing the superfusate through a rapid heat-
exchange Peltier element (Moor Instruments, Millwey, Axmin-
ster, Devon, U.K.) before it entered the arteriograph. Cumula¬
tive concentration-response curves to ET-1 (l(r12 to 3 x 1(T7
M; Novabiochem, U.K.) were generated in either intact or de¬
nuded vessels at 37°C or 24°C (n = 6 per group).
Plasma separated from whole blood samples was stored at
-70°C until ET-1 levels were measured by radioimmunoassay.
Immunoreactive ET was extracted from acidified plasma using
200 mg CI8 preparative columns (Bond Elut; Phenomenex,
U.K.). Extracted samples and duplicate standards (100-p.l ali-
quots) were incubated with rabbit polyclonal antibody raised
against ET-1 (100 pi I; Peninsula Labs, U.K.). After incubation
tor 24 h at 4°C, | l25I]ET-1 (100 |xl; Peninsula Labs) was added
and incubated for a further 24 h at 4°C. Goat anti-rabbit y-
globulin (100 p.1; Peninsula Labs) and normal rabbit serum
(100 p.!; Peninsula Labs) were then added and incubated at
room temperature for 90 min. Immune complexes were pre¬
cipitated and centrifuged at 4°C to remove the supernatant. The
amount of radioactivity in the precipitate was determined by
-y-counting for 1 min. The recovery of added ET-1 was 89%.
The sensitivity of this assay is 0.5 pg/ml, and crossreactivity
with ET-1. ET-2, ET-3, and big ET-1 is 100, 7, 7, and 10%,
respectively.
Data analysis
Kruskall-Wallis nonparametric tests were performed to
compare the responses between 37°C and 24°C groups and/or
intact and denuded groups, because the variances between the
groups differed significantly (p < 0.05; Bartlett's test). Two-
way ANOVA was used to examine the influence of tempera¬
ture and subject group on responses. Student's unpaired t test
was used to compare plasma ET-1 levels between RD patients




Mean resting lumen diameter, percent contraction to
KCI, and percent relaxation to ACh did not differ sig¬
nificantly between the control subjects studied at 37°C
and 24°C, and the RD patient group at 37°C and 24°C
(Table 1). ET-1 produced a concentration-dependent
constriction in all vessels. There were no significant
changes in sensitivity or maximal contraction to ET-1
after cooling or denudation of vessels from control sub¬
jects or RD patients (Table 2). Figure 1 shows concen¬
tration-response curves to ET-1 in intact arteries from
RD patients and controls at 37°C (Fig. 1A) and 24°C
(Fig. IB). Comparison of responses between control and
RD arteries showed no significant difference in EC50 or
£,nax values (j> = 0.15; Kruskall-Wallis test) (Table 2).
However, in intact arteries there was a significant inter¬
action between RD patients and control subjects when
the effect of temperature on the sensitivity to ET-1 was
examined (/; = 0.01; two-way ANOVA). Vessels from
RD patients showed a trend of reduced sensitivity to
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TABLE 2. ECW and Emax values for endothelin-l concentration-response curves in human resistance
arteries obtained from gluteal biopsies
Control subjects Raynaud's patients
37°C 24°C 37°C 24°C
EC50 intact 4.1 ± 1.0 x 10"'M 1.9 ± 0.4 x 10-,° M 2.1 1'c 0.3 x 10"' M 3.1 ±0.7 x 10"'M
EC,„ denuded 3.2 ± 1.1 x 10"'° M 5.4 ± 1.5 x 10"10 M 4.7 1b 1.3 x I0~'° M 4.2 ± 1.1 x 10~'° M
Ema( intact 117 ± 10 122 + 5 122 ±4 124 + 4
£».. denuded 124 ±7 114 ± 3 117 + 9 120 ±4
ET-I responses were expressed as a percentage of the contraction to potassium chloride (KC1) (60 mM) at 37°C. EC50 (the
concentration producing half-maximal KCI contraction) and (the maximal contraction relative to KCI) values are shown
as mean ± SEM; n = 6 for each group. EC50 values were calculated from individual log concentration-response curves via
Graphpad Prism 2.1.
ET-1 during cooling (EC50 = 2.1 ± 0.3 x 1(T10 M at
37°C vs. 3.1 ± 0.7 x 10~10 M at 24°C) in contrast to
control vessels, in which cooling tended to increase sen¬
sitivity to ET-1 (ECS0 = 4.1 ± 1.0 x 10~'° M at 37°C vs.
1.9 ± 0.4 x 10"10 M at 24°C).
Plasma ET-1 levels
Plasma ET-1 levels were not significantly different
between RD patients and control subjects (4.02 ± 0.20
pg/ml for controls vs. 4.47 ± 0.24 pg/ml for RD; p =
0.18; Student's unpaired t test) (Fig. 2).
DISCUSSION
In this study, using small arteries obtained from glu¬
teal fat biopsies, we did not find a significant difference
in the responsiveness to ET-1 between RD patients and
control subjects, either at 37°C or at 24°C, in intact or
denuded arteries. If ET-1 is implicated in the pathogen¬
esis of RD, one might expect to find either an enhanced
response to exogenous ET-1 compared to controls, ow¬
ing to increased smooth muscle sensitivity, or a de¬
pressed response, secondary to smooth muscle desensi-
tization through receptor downregulation if endogenous
ET levels are increased during cooling in RD patients
(see below). The fact that no significant difference was
found implies that ET is not a primary candidate in the
pathogenesis of RD, assuming that gluteal microvessels
share the same responsiveness to ET-1 as those of the
digital circulation.
Our present data reveal that, despite the lack of sig¬
nificant influence of temperature or disease on ET-1 re¬
sponses, arteries from RD patients behave differently in
response to cold stimulu than those from control sub¬
jects, as evidenced by the significant interaction between
the groups. Whereas cooling tended to reduce the sensi¬
tivity to ET-1 in vessels from patients with RD, the
opposite was observed in control arteries. This phenom¬
enon was seen only in arteries with an intact endothe¬
lium, suggesting that endothelium-dependent mecha¬
nisms were responsible. Recent studies in our laboratory
demonstrate that endothelium-dependent dilatation is
significantly attenuated in arteries from RD patients at
37°C compared to 24°C (Smith, unpublished data). This
may contribute to the small, nonsignificant trend of
greater sensitivity to ET-1 at 37°C compared to 24°C in
vessels from RD patients.
Vasospasm in RD may result from increased produc¬
tion and/or reduced metabolism of ET-1 as opposed to
enhanced contractile responsiveness. There are conflict¬
ing reports of plasma ET-1 levels in RD: whereas some
groups have shown increased basal levels in RD patients
(1,2), others find no difference compared to the control
group (4,5). We did not find elevated basal ET-1 levels
in patients with RD compared to controls. Plasma levels
FIG. 1. Comparison of the contractile response
to ET-1 in subcutaneous resistance arteries iso¬
lated from control subjects and RD patients:
concentration-response curves to ET-1 (ex¬
pressed as % response to KCI, 60 m/W) at (A)
37°C and (B) at 24°C in intact vessels from con¬
trol subjects (O; n = 6) and RD patients (•; n =
6). All values are mean ± SEM.
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FIG. 2. Plasma endothelin concentrations (pg/ml) in healthy con¬
trols (open column; n - 15) and patients with Raynaud's disease
(shaded column; n = 18).
are not necessarily a good predictor of pathogenetic roles
because ET-1 is predominantly secreted abluminally and,
in addition, differences between studies may be partly
due to the number of vasospastic episodes experienced
by the patient group before blood sampling, with raised
ET-1 levels reflecting residual circulating peptide. Per¬
haps more informative data come from measurement of
plasma ET-1 concentrations during cold challenge, al¬
though there is still a discrepancy in the results among
published studies. A rapid increase in plasma ET-1 dur¬
ing the cold pressor test in healthy subjects has been
reported (3), which is exaggerated in patients with RD
(1). In contrast, others found no significant difference in
cold-challenged plasma ET-1 levels in RD patients com¬
pared to controls (b).
To our knowledge, this is the first study to examine
constrictor responses to ET-1 in isolated vessels from
RD patients. Our results suggest that ET-1 does not play
a primary pathophysiologic role in RD because a differ¬
ence in responsiveness to ET-1 was not observed be¬
tween vessels from RD patients and controls and because
plasma levels of ET-1 did not differ between the groups.
ET-1 might be responsible for mediating vasospasm in
RD, the prolonged nature of which favors the involve¬
ment of a long-lasting constrictor such as ET-1, but it is
likely to be .secondary to other factors. Impaired endo-
thelium-dependent vasodilatation could be such a factor.
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Endothelin receptors cloned, endothelin
converting enzyme characterized and
pathophysiological roles for endothelin
proposed
In 1988, Yanagisawa and col¬
leagues1 isolated from the culture
medium of vascular endothelial
cells a novel 21 amino-acid pep¬
tide, endothelin, which is the
most potent vasopressor com¬
pound yet discovered1"^. A family
of mammalian endothelin iso-
peptides (ET-1, ET-2 and ET-3;
Fig. 1) has since been identified5
of which only ET-1 is produced
by endothelial cells, through
formation of a 38 amino acid pre¬
cursor, 'big ET-1'. This is sub¬
sequently processed by an un¬
usual cleavage achieved by a
putative 'ET-1 converting enzyme'
(ECE).
Developments in endothelin re¬
search were brought up to date at
a symposium held recently in
Tsukuba*, home of the team re¬
sponsible for discovery of the
peptide. These included the
further characterization of ECE,
cloning of cDNA encoding two
distinct endothelin receptors, and
evidence supporting a role for
endogenous ET-1 in health and
disease.
'Second International Conference on Endo¬
thelin, University of Tsukuba, japan, 9-12
December 1990.
Endothelin converting enzyme
In porcine aortic endothelial
cells, the 39 amino acid inter¬
mediate, big ET-1, is hydrolysed
at the Trp21-Val22 bond by the
putative endothelin converting
enzyme (ECE) to generate ET-1
and a C-terminal fragment. Al¬
though big ET-1 and ET-1 have
similar pressor activity in whole
animals, big ET-1 generates less
than 1% of the contractile activity
of ET-1 in isolated preparations
(P. D'Orleans-Juste, William
Harvey Research Institute). Hence,
conversion of big ET-1 by ECE is
essential for induction of physio¬
logical responses in vivo. There
was widespread consensus at the
meeting that physiological ECE
activity resides with a novel
metal-dependent neutral protease,
and not (as had previously been
suggested) with the cathepsin D-
like protease which also degrades
ET-1 but which is kinetically slow
and active only at acid pH.
Membrane preparations de¬
rived from cultured vascular
endothelial cells (Y. Matsumura,
Osaka University of Pharma¬
ceutical Sciences; M. Yano, Banyo
Pharmaceutical Co., Tokyo) were
shown to produce substantial con¬
version of big ET-1 to ET-1 at
neutral pH. This effect was abol¬
ished by metal chelators (EDTA
and 1,10-phenanthroline), and
inhibited by the neutral metallo-
protease inhibitor, phosphor-
amidon, but not by other protease
inhibitors. Phosphoramidon also
reduced secretion of ET-1 and in¬
creased secretion of big ET-1 by
endothelial cells in culture, and
reduced the conversion of big
ET-1 to ET-1 by polymorpho¬
nuclear leukocytes (W. Sesse,
William Harvey Research Insti¬
tute). In anaesthetized ganglion-
blocked rats, E. McMahon (Mon¬
santo Co., St Louis) confirmed^-8
that the pressor response to big
ET-1, but not ET-1, is blocked by
the metalloprotease inhibitor
phosphoramidon (ID50 5 mg kg-1),
but not by inhibitors of serine
protease (leupeptin), thiol protease
(E-64), or of other metalloproteases
(captopril and kelatorphan). A
further metalloprotease inhibitor,
thiorphan, also blocked responses
to big endothelin, but with much
lower potency (ID50 60 mg kg-1).
Phosphoramidon was originally
identified as a potent inhibitor of
the bacterial metalloprotease
thermolysin, although it also in¬
hibits other metalloproteases,
most notably neutral endopepti-
dase-24.11 (Ref. 9). However,
phosphoramidon, and kelator¬
phan and thiorphan (also metallo¬
protease inhibitors) are essentially
equipotent as inhibitors of endo-
peptidase-24.11 (Ref. 10) so that
the lack of effect of kelatorphan on
big ET-1 conversion suggests that








Fig 1. Amino acid sequences of peptides from the endo¬
thelin family Fitted circles, amino acid residues different
from those in ET-1 sequence. For ET-2 and ET-3, the
disulfide-bond topologies and the chain lengths of these
predicted peptides are drawn by analogy with ET-1
© 1W1. Elsevier Science Publishers Ud (UK) 0145 - 6147/91/W2 00
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blood does not appear to be a
major site of big endothelin con¬
version (Y. Watanabe, Mitsu-
bishiyuka Bioclinical Labs, Tokyo),
it appears that the most likely can¬
didate for conversion of circu¬
lating big ET-1 in vivo is the
membrane-bound phosphorami-
don-sensitive ECE. However,
cytosolic preparations from endo¬
thelial cells also exhibit ECE ac¬
tivity, insensitive to phosphor-
amidon (Matsumura), and other
ECEs may be responsible for
intracellular processing of big
ET-1.
McMahon described responses
to intravenous administration of
metalloprotease inhibitors in con¬
scious rats. Infusion of phosphor-
amidon over four hours lowered
mean arterial pressure in both
Wistar-Kyoto and spontaneously
hypertensive rats (SHR.) compared
with saline control infusion (see
Fig. 2). Kelatorphan, at the same
dose, had no effect on blood
pressure, confirming that phos-
phoramidon is not acting on
neutral endopeptidase-24.11.
These findings suggest that endo¬
thelin may play a physiological
role in blood pressure regulation
and that, with the development of
specific inhibitors, ECE may rep¬
resent an important therapeutic
target for pharmacological inter¬




additional support for the mul¬
tiple endothelin receptor subtypes
previously identified on the basis
of agonist affinities (ET-1 > ET-3;
ET-1 = ET-3; ET-3 > ET-1)3-11.
In addition, direct evidence for at
least two distinct receptors, using
molecular biological techniques,
was presented by two groups
(H. Arai, Kyoto University Faculty
of Medicine; T. Sakurai, Univer¬
sity of Tsukuba). These findings
have subsequently been published
in Nature12-13.
Arai and colleagues employed
an expression cloning strategy.
Using a bovine lung cDNA library
they isolated a cDNA clone which
encoded a receptor shown to be
functional in their Xenopus oocyte
assay system. The endothelin re¬
ceptor sequence encoded by this
clone consisted of 427 amino acid
residues (48.5 kDa). After trans-
fection of the cloned cDNA into
monkey COS cells there was
saturable binding of 125l-labelled
ET-1 to membranes prepared from
these cells (Kd 0.18 dm). Displace¬
ment experiments showed ET-1 to
be the most potent inhibitor of
radioligand binding to this recep¬
tor (Kj 0.9 nM), with order of
potency ET-1 > ET-2» ET-3 >
sarafotoxin S6b.
Sakurai and colleagues, using a
somewhat different expression
cloning approach, also constructed
a cDNA library from poly(A) +
RNA prepared from rat lung, a
tissue that is rich in endothelin
binding sites. Sub-pools of cDNA
were transfected into COS-7 cells,
which have no detectable endo
thelin receptor, and screened for
expression of endothelin binding
sites by incubation with 125I-
labelled ET-1 followed by auto¬
radiography. A single clone con
ferring ET 1 binding wasdsolatcd,
and an encoded receptor sequence,
consisting of 415 amino acid resi¬
dues (46.9 kDa), was identified.
Subsequent displacement studies
indicated similar affinities for the
endothelin isoforms (ET-1 = ET-2
= ET-3). This receptor was shown,
in COS-7 cells, to be coupled
through a G protein to phospho-
lipase C with production of ino¬
sitol phosphates and a transient
increase in intracellular Ca2+.
Fortuitously, the receptors iso¬
lated by the two groups are struc¬
turally and functionally distinct,
though they share several features.
Each contains seven membrane
spanning domains, and exhibits
significant sequence and topo¬
graphical similarity with the photo¬
receptor rhodopsin and other G
protein-coupled receptors. Both
receptors also contain two poten¬
tial N-glycosylation sites within
the N-terminal region, and serine
residues in the third cytoplasmic
loop and the cytoplasmic C-
terminal tail which may be phos-
phorylated by serine/threonine
kinases and therefore are potential
target sites for receptor regulation.
Cloning of endothelin receptor
cDNAs will facilitate investigation
of endothelin receptor distri¬
bution, regulation and function,
as well as their potential role in
pathophysiological processes.
Northern blot analysis showed
that mRNA for both receptors can
be detected in a variety of tissues,
including heart, lung, kidney and
brain. An important difference,
however, is that the ET-l-'selec-
tive' receptor is expressed in
aorta, while the 'nonselective
receptor' is not. Speaking on be¬
half of the Committee on Receptor
Nomenclature and Drug Classifi¬
cation constituted by IUPHAR,
P. Vanhoutte (Baylor College of
Medicine) recommended that the
ET-l-'selective' receptor described
by Arai, and which may be the
vascular smooth muscle receptor,
be named the ETA receptor, and
the nonselective receptor de¬
scribed by Sakurai, be named the
ETb receptor. In the context of Ihe
confusion which might otherwise
arise, an early agreement on the
classification of endothelin reccp
tors must be welcomed, although
an alphabetical classification is a
departure from the usual numeri¬
cal systems (perhaps Ej). It is to
be hoped that the identification of
other receptors (including the ET
3-'selective' receptor) will soon
follow. Definitive pharmaco¬
logical confirmation of the sub¬
types of endothelin receptor, how¬
ever, awaits the development of
selective antagonists. None were
described at the meeting, though
it is clear that with the therapeutic
potential of such agents, much




ditional sites of ET-1 expression,
and the interaction of ET-1 with
EDRF/NO. B. Dardik (Ciba-Geigy
Corp., Summit, USA) showed sus¬
tained release of endothelin-like
immunoreactivity (ET-LI) by rat
aortic smooth muscle cell in cul¬
ture, and inhibition by cyclohex-
imide indicates the involvement
of de novo protein synthesis. ET-LI
was also found in human mono¬
cytes and human tissue macro¬
phages, and ET-1 mRNA was
shown to be induced by phorbol
ester in macrophage culture (H.
Ehrenreich, NIH, Bethesda). Poly¬
morphonuclear leukocytes (PMN)
and lymphocytes do not generate
ET-LI, but activated PMN appear
to act indirectly to increase pro¬
duction and metabolism of ET-1
generated by endothelial cells
(M. Yoshizumi, University of
Tsukuba). In light of this, endo¬
thelin regulation at sites of inflam¬
mation is likely to be complex.
The pressor activity of ET-1 is
strongly limited by release of




































rig. 2. Effect of intravenous infusion of saline (3ml h~'; square), phosphoramidon
(20mg lrg~'h~'; circle), or kolatorphan (20mg kg ' h1; triangle) on mean arterial
pressure (MAP) in conscious spontaneously hypertensive (open symbols) and Wistar-
•Kyoto rats (solid symbols). *p < 0.05 compared to saline infused rats. Kindly supplied
by Dr E. McMahon.
prostacyclin and EDRF/NO (Ref.
4). E. Bassenge (Freiburg Univer¬
sity) examined the influence of
EDRF/NO on endothelin release
in cultured endothelial cells.
The phosphodiesterase inhibitor
IBMX and NO donator SIN-1
alone increased cGMP levels two¬
fold, and together sevenfold, but
did not affect ET-1 production or
release. In addition, 8-bromo-
cGMP did not suppress basal or
thrombin-stimulated endothelin
release. These findings indicate
that EDRF/NO does not exert
feedback inhibition of endothelin
release.
Interestingly, cerebral micro-
vessel endothelial cells grown on
filters were shown by S. Yoshi-
moto (University of Tokyo) to re¬
lease ET-1, mainly across the
'basal membrane', suggesting that
endothelin release may be di¬
rected towards vascular smooth
muscle and away from the vas¬
cular lumen.
Physiology and pathophysiology
Evidence for modulation of
adrenergic and cholinergic neuro-
effector transmission by ET-1 was
presented by P. Wiklund (Karo-
linska Institute). Localization of
very dense endothelin binding in
the carotid body, in the nodose
and superior cervical ganglia, and
in nucleus of the tractus solitarius,
where chemoreceptor afferents
terminate, all suggest involvement
of endothelin in the arterial chemo¬
receptor reflex (D. McQueen, Uni¬
versity of Edinburgh).
Low concentrations of ET-1
were shown by H. Lippton
(Louisiana State University) to
dilate pulmonary vessels through
activation of ATP-sensitive K +
channels. During pulmonary
alveolar hypoxia, ET-LI in rat lung
is increased (G. Shirakami, Kyoto
University School of Medicine)
md with prolonged hypoxia, con-
itrictor sensitivity to ET-1 in-
rreases and dilatation is lost (S.
\dnot, Institut Henri Beaufour,
,es Ulis). These findings raise the
>ossibility that ET-1 may be in-
'olved in sustaining chronic hy-
>oxic pulmonary hypertension.
T-LI was also found by Ehren-
eich in samples at broncho-
■ulmonary lavage, and to correlate
vith disease activity in patients
rith Wegener's granulomatosis.
Elevated levels of plasma ET-1
re re found in patients with myo¬
cardial infarction, vasospastic
angina, cardiogenic and septic
shock, sub-arachnoid haemor¬
rhage, renal failure and a vari¬
ety of connective tissue disorders.
There remains some controversy
over whether plasma ET-1 is in¬
creased in hypertension or dia¬
betes, and in this regard the im¬
portance of adequate numbers of
subjects and appropriate controls
is crucial. J. Lundberg (Karolinska
Institute, Stockholm) described
elevated levels of ET-LI in umbili¬
cal arterial plasma (15 pM, increas¬
ing to 94 pM after establishment of
fetal breathing), compared with
maternal plasma (2 pM), and ET-1
immunostaining is heavy in
umbilical vessels (J. Wharton,
Hammersmith Hospital), raising
the interesting possibility that
endothelin may be responsible for
umbilical cord closure.
Perhaps the most compelling
evidence in support of a patho¬
physiological role for ET-1 was
described by K. Yokokawa (Osaka
City University Medical School).
He reported two cases of haeman-
gio-endothelioma of the scalp, a
rare malignant tumour, associated
with hypertension and elevated
plasma ET-1 levels. Blood pressure
and plasma ET-1 fell in both cases
after surgical excision of the
tumour and, in one patient, recur¬
rence was associated with re¬
development of hypertension and
raised endothelin levels. In one
case tumour content of ET-1 and
ET-1 mRNA was shown to be
higher than in normal skin.
Plasma endothelin levels in these
patients were 15-20-fold higher
than in normal subjects which,
considering the rapid clearance of
ET-1 from the circulation14
suggests profound secretion of
ET-1 by the tumour. Selective
venous sampling would have
strengthened the argument.
□ □ □
There are now many indications
that the endothelins are involved
as local factors in regulation of
the cardiovascular system, and
evidence to suggest that ET-1 may
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Editorial Review
The endothelin family of peptides: local hormones with
diverse roles in health and disease?
William G. HAYNES and David J. WEBB
University of Edinburgh, Department of Medicine, Western General Hospital, Edinburgh, U.K.
INTRODUCTION
The vascular endothelium forms the inner lining
of all blood vessels and acts, not simply as a barrier
between blood and vascular smooth muscle, but
rather as a modulator of vascular function. The
endothelium is now known to play a key role in the
regulation of coagulation, lipid transport, immuno¬
logical reactivity and vascular tone. Over the last 20
years it has become clear that a number of import¬
ant vasodilator and constrictor substances are pro¬
duced by endothelial cells [1], The first identified
was prostacyclin, which acts both as a potent
vasodilator and as an inhibitor of platelet aggrega¬
tion [2]. In 1980, Furchgott & Zawadzki [3]
demonstrated the presence of a second, locally
acting, non-prostaglandin, endothelium-dependent
vasodilator factor that was named endothelium-
derived relaxing factor (EDRF) and which has since
been identified as nitric oxide [4].
The isolation of EDRFs prompted a search for
counterbalancing constricting factors (or EDCFs).
The pulmonary vascular conversion of angiotensin I
to angiotensin II was already known [5], and
endothelial angiotensin-converting enzyme (ACE)
activity has since been demonstrated in most blood
vessels [6]. By 1985, the vascular endothelium had
been shown to generate at least two other vaso¬
constrictor substances, one of which produced pro¬
longed vasoconstriction lasting more than 60min [7,
8], in contrast to the brief actions of other media¬
tors of vascular tone. This long-acting agent, which
appeared to be a peptide, was isolated and
sequenced in 1988 by Yanagisawa et al. [9] from
endothelial cell cultures, and called endothelin. It is
a 21-amino acid peptide of unusual structure, and is
the most potent vasoconstrictor agent yet identified.
Its long-lasting vasoconstrictor and pressor actions
have since been confirmed in human subjects [10,
11], and there is now increasing evidence to suggest
that endothelin may be important in cardiovascular
regulation [1, 12, 13]. In this article we review the
physiology of endothelin, with particular emphasis
on its putative role in cardiovascular, renal and
respiratory disease. For more detailed review of the
intracellular and neuroendocrine actions of the
endothelins, see elsewhere [14, 15],
THE ENDOTHELIN FAMILY
The endothelins are a family of three related
peptides [16], each of 21 amino acids (Fig. 1). Each
isoform contains two intra-chain disulphide bridges
linking paired cysteine amino acid residues, and
producing an unusual semi-conical structure.
Endothelin-2 exhibits the closest structural similar¬
ity to endothelin-1, differing by only two amino acid
residues, while endothelin-3 differs by six amino
acids. The disulphide bridges and C-terminal
domain appear to be necessary for the actions of the
peptide as their removal leads to substantial loss of
biological activity [17, 18]. Endothelin-1, the pep¬
tide originally identified by Yanagisawa et al. [9],
and endothelin-2 are the more potent vaso¬
constrictors [16].
In their original description, Yanagisawa et al. [9]
noted similarities in structure between endothelin
and several peptide neurotoxins, such as the bee
venom, apamin, and a-scorpion toxin, both of which
contain multiple disulphide bridges. Endothelin was
subsequently found to have a close structural simi¬
larity (Fig. 1) to sarafotoxin S6b, a snake venom
toxin from Actractaspis engaddensis, the Israeli bur¬
rowing asp [19], which causes death from myocar¬
dial ischaemia and infarction through development
of coronary vasoconstriction [20, 21].
GENERATION
Regulation of production
Yanagisawa et al. [9] demonstrated that
endothelin-1 mRNA may be induced in endothelial
cells through exposure to adrenaline, thrombin and
the Ca2+ ionophore A23187. Adrenaline-stimulated
endothelin-1 production appears to be mediated
through a,-adrenoceptors, because it is inhibited by
Key words: blood pressure, blood vessel, endothelium, peptide, mitogen, vascoconstrictor.
Abbreviations: ACE, angiotensirv-converting enzyme; ADH, antidiuretic hormone; ANP, atrial natriuretic peptide; [CaJ,](1 intracellular free CaJ 4 concentration; ECE,
endothelin-converting enzyme; EDRF, endothelium-derived relaxing factor; GFR, glomerular filtration rate; SHR, spontaneously hypertensive rats; WKY, Wistar-Kyoto rats.
Correspondence: Dr W G Haynes, University Department of Medicine, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, U K
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Endothelin-l
Endothelin-3
Fig. I. Amino acid sequences of the three members of the endothelin family, and of the structurally related snake
venom toxin sarafotoxin S4b. Shaded circles indicate where amino acids differ from endothelin-l.
the selective a!-adrenoceptor antagonist prazosin,
but not by the selective a2-adrenoceptor antagonist
yohimbine [22] or the /(-adrenoceptor antagonist
propranolol [23]. Endothelin-l production, on the
basis of induction of mRNA or elevated immuno-
reactive endothelin-l concentrations, is also stimu¬
lated by other vasoactive hormones, including
angiotensin II and arginine vasopressin [24, 25], by
the isoform endothelin-3 [26], by cytokines and
growth factors, including transforming growth factor
fi [27] and interleukin-1 [28], by physical stimuli,
including hypoxia [29, 30] and shear stress [31],
and by exposure to free radicals [22] and endotoxin
[32], Interestingly, glucocorticoids increase produc¬
tion of endothelin-l by cultured vascular smooth
muscle by up to 500% but have no effect on
endothelial cell endothelin-l production [33].
Production of endothelin-l is inhibited by
endothelium-derived nitric oxide [34] and by the
nitrovasodilators, which donate nitric oxide [35], It
is interesting to speculate that decreased generation
of nitric oxide may account for the stimulatory
effects of glucocorticoids on vascular smooth muscle
cell endothelin production, since these agents are
known to inhibit nitric oxide synthase in vascular
smooth muscle cells [36]. Atrial natriuretic peptide
(ANP), which, like nitric oxide, acts by increasing
intracellular cyclic GMP concentrations, also inhi¬
bits generation of endothelin-l [35] at concen¬
trations that are similar to those found in patients
with chronic heart failure [37], A key role for cyclic
GMP in the control of endothelin-l production is
supported by the fact that 8-bromo-cyclic GMP, a
cyclic GMP mimetic, inhibits production of
endothelin-l, whereas a guanylate cyclase inhibitor.
Methylene Blue, potentiates it [34],
Molecular genetics
Each member of the endothelin family is repre¬
sented by a separate gene that encodes a specific
precursor for the mature isoform [16], The human
gene for preproendothelin-1, the precursor of
endothelin-l, is located on chromosome 6 [38],
whereas that for preproendothelin-3 [39] is on
chromosome 20. There are several regulatory DNA
sequences in the non-transcribed regions of the gene
[40], At the 5' flanking region there are binding
sites for nuclear factor 1 and acute-phase reactant
regulatory elements, which may mediate the induc¬
tion of mRNA for endothelin-l by transforming
growth factor /( and acute physiological stress,
respectively (Fig. 2).
The 5' region also contains a base pair sequence
( — 109 to —102) that is identical with the well-
characterized AP-1 site, which is known to mediate
hormone and growth factor responsiveness for other
eukaryotic genes [41, 42]. This AP-1 site is necess¬
ary for transcription of the preproendothelin-1 gene,
and is sensitive to the tumour promoter 12-0-
tetradecanoyl-phorbol 13-acetate, which acts to
increase intracellular inositol trisphosphate and
Ca2+ concentrations. This process activates protein
kinase C, and induces expression of the proto-
oncogenes c-fos and c-jun. The products of these
genes then bind to the AP-1 site to stimulate
preproendothelin-1 gene expression [40]. Angioten¬
sin II and arginine vasopressin activate protein
kinase C to induce endothelin gene expression via
the AP-1 site [25], In addition, this site probably
contributes to the tissue specificity of
preproendothelin-1 gene transcription, as a result of
endothelial cell-specific expression of proteins that
bind to the AP-! site [41, 42].
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The 3' flanking region of the gene contains a
region which codes for poly AUUUA mRNA
sequences, similar to those of transiently expressed
cytokines and growth factors [40], These AU-rich
sequences may mediate selective destabilization of
preproendothelin-1 mRNA, accounting for its rela¬
tively short half-life of 15min [13].
Sites of production
Immunoreactive endothelin-1, or expression of
mRNA for preproendothelin-1, can be detected in a
wide variety of tissues, including blood vessels [34],
heart, lung, pancreas, spleen [39], kidney [43],
posterior pituitary [44] and cerebral neurons [45].
In the vasculature, endothelin-1 is the major isoform
expressed within endothelial cells [39, 40], and so is
probably the most important for local regulation of
vascular tone. Vascular smooth muscle cells also
produce endothelin-1 in vitro, although the rate of
production is about 100-fold less than by endothe¬
lial cells [33, 46]. Despite the lower level of produc¬
tion, the relatively greater mass of vascular smooth
muscle cells in larger blood vessels suggests that
smooth muscle may here contribute substantially to
local endothelin-1 production. Although endothelin-
2 immunoreactivity cannot be detected in human
plasma [47], immunostaining of vascular endothe¬
lial cells, using highly selective antisera to
proendothelin-2, can demonstrate the presence of
this isoform of endothelin [48]. This raises the
possibility that local production of endothelin-2
may play a role in control of vascular tone.
Immunoreactivity to endothelin-3, or expression of
mRNA for proendothelin-3, can be detected in the
central nervous system, anterior pituitary, lung, pan¬
creas and spleen, but not in endothelial cells or
cardiac tissue [39, 45, 48, 49],
Biosynthesis
Human preproendothelin-1 consists of 212 amino
acids, containing a characteristic hydrophobic secre¬
tory sequence at the N-terminal, suggesting that the
prepro-form is transported across the nuclear mem¬
brane for further processing. Preproendothelin-1 is
cleaved (Fig. 2) at Lys-52-Arg-53 and at Lys-91-
Arg-92 by dibasic-pair specific endoproteases to
form proendothelin-1, a 38-amino acid precursor
peptide [9], Since the bathing medium of cultured
vascular endothelial cells contains proendothclin-1
as well as endothelin-1 [50], and since
proendothelin-1 is found in plasma at higher con¬
centrations than mature endothelin-1 [47], it
appears that proendothelin-1 is secreted by endothe¬
lial cells before conversion to endothelin-1. Never¬
theless, mature endothelin-1 has been detected
within the cytoplasm of human vascular endothelial
cells [48], suggesting that some conversion occurs
within the cell.






Fig. 2. Synthetic pathway for production of the endothelins (ET).
The major potential sites for therapeutic modulation are shown on
the right. •See text for details of the regulatory elements of the
endothelin-1 gene. Abbreviation: preproET, preproendothelin.
proendothelin-1 occurs through an unusual cnzymic
cleavage, at the Trp-21-Val-22 site, by the action of
an 'endothelin-converting enzyme' (ECE) [9], Three
fractions of endothelial cells have been shown to
display ECE activity: two intracellular and one
membrane-bound. One of the intracellular ECE
fractions is an aspartic protease, most active at
PH 3.5 and with the immunoreactivity of cathepsin
D [51]. This enzyme is, however, unlikely to
account for endothelial cell production of
endothelin-1, as it cleaves proendothelin-1 at Asn-
18—He-19 as well as at Trp-21-Val-22 [52], and
pepstatin, an inhibitor of cathepsin D, does not
affect endothelial cell production of endothelin-1
[53]. The second intracellular ECE fraction is an
intracellular metalloendopeptidase, probably sensi¬
tive to phosphoramidon [13], This enzyme may be
responsible for the intracellular processing of
proendothelin-1, particularly in tissues, such as the
central nervous system, where proendothelin-1 is
not released from cells [13],
The physiologically most important ECE appears
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to be membrane-bound [54], active at neutral pH,
sensitive to metal ions and inhibited by phosphora-
midon [55]. This neutral metalloendopeptidase does
not circulate in blood [56] and is different from
ACE [57, 58]. It has been suggested that ECEs
display isoform specificity, with endothelial ECE
converting proendothelin-1 ten times more readily
than proendothelin-3 [59], However, because phos-
phoramidon completely inhibits the functional
effects of proendothelin-2 and proendothelin-3 in
the rat [60], the enzymes that convert the pre¬
cursors of the other endothelin isoforms may have
similar properties to the endothelial ECE described
above. Endothelial ECE is not the same enzyme as
neutral endopeptidase-24.11, which degrades a
number of peptides, including ANP, and ir also
inhibited by phosphoramidon, since ECE activity is
not affected by the potent neutral endopeptidase
inhibitors thiorphan or kelatorphan [ 13,57], Recently,
SQ 28,603, a further neutral endopeptidase-24.11
inhibitor, has been shown to block the functional
effects of proendothelin-1 in the rat, as well as to
potentiate the effects of ANP, implying that this
compound is also an inhibitor of ECE [61], There
are qualitative differences between the cardiovascu¬
lar responses to proendothelin-1 after ECE inhibi¬
tion with SQ 28,603 and phosphoramidon, raising
the possibility that several different ECEs may be
involved [61]. In addition, there appear to be
regional variations in ECE activity, because, at
doses with similar systemic pressor effects,
proendothelin-1 and endothelin-1 differ in their
effects in vivo on some vascular beds, such as the
kidney [58] and mesenteric arcade [62].
Release
Like prostacyclin and nitric oxide, endothelin-1
does not seem to be stored intracellularly in most
tissues. Generation de novo was first suggested by
Yanagisawa et al. [9], using as evidence the fact
that production of endothelin-1 by cultured endo¬
thelial cells cannot be detected until at least 30min
after stimulation with thrombin. In addition, the
protein synthesis inhibitor cycloheximide can
prevent release of endothelin by cultured vascular
endothelial cells [63] and intact aortic strips [34],
However, immunoreactive endothelin-1 concen¬
trations can increase in response to certain stimuli
more rapidly than would be expected if endothelin-1
were always synthesized de novo. These stimuli
include shear stress on rabbit cultured endothelial
cells [31], upright tilt in patients with vasovagal
syncope [64] and a cold pressor test on human
subjects, with a sevenfold increase in endothelin-1
concentrations within 2min [65]. Moreover,
endothelin-1 immunoreactivity can be detected in
granular form within the posterior pituitary [44],
where the granules are depleted by water
deprivation.
Plasma concentrations
Circulating concentrations of endothelin-like
immunoreactivity in venous plasma have been
reported to vary between 0.25 and 20pg/ml [1, 66],
and are very dependent upon assay conditions [66].
This immunoreactivity comprises proendothelin-1
(65%), endothelin-1 (25%), and endothelin-3 (10%)
[47, 67]. The source of endothelin-3 is unknown,
although it may be either neural or endocrine
in origin. Endothelin-2 has not been detected in
human plasma. Circulating concentrations of
endothelin-1 are approximately tenfold lower than
those which cause vascular contraction in vitro [9]
or in vivo [68], although concentrations at the
interface between endothelial cell and vascular
smooth muscle are likely to be much higher. The
presence of endothelin in lymphatic fluid suggests
bidirectional release of the peptide, particularly as
systemically infused endothelin does not appear in
lymph [69], In addition, cultured endothelial cells
release substantially more endothelin to the base¬
ment membrane side (i.e. abluminally) than lumi-
nally [70]. Thus, endothelin-1 appears to be primar¬
ily a locally acting paracrine hormone rather than a
circulating endocrine hormone. However, the level
of endothelin-1 in the venous plasma may be useful
as a marker for endothelial synthesis of the peptide,
as it is likely to reflect overspill from local produc¬
tion. Additionally, in certain pathophysiological cir¬
cumstances, such as renal failure (see below), circu¬
lating endothelin-1 concentrations may be sufficient
to exert biological effects [68, 71].
Clearance
Radiolabeled endothelin-1 is rapidly cleared from
the circulation after bolus injection into animals,
with a half-life of less than 1 min. High tissue uptake
by the lungs and kidneys reflects the large number
of high-affinity binding sites in these organs [72], In
these experiments, over 90% of radioactivity was
concentrated in the cell membrane/internal organelle
fraction, suggesting that the clearance of endothelin-
1 is by binding and then internalization. Plasma
endothelin-1 concentrations vary inversely with
renal function, suggesting either increased produc¬
tion or reduced clearance of endothelin-1 by the
diseased kidney [73, 74], Prolonged plasma and
biological half-lives of endothelin-1 in bilateral
nephrectomized rats suggest that the major effect of
renal disease is through impaired clearance [75].
Enzymic degradation of endothelin by neutral
endopeptidase-24.11 also occurs [76], although the
biological significance of this action is unclear,
because inhibitors such as thiorphan do not poten¬
tiate the systemic effects of exogenous endothelin-1
[58]. In humans, intravenously administered
endothelin-1 has a calculated half-life of less than
3.6 min, with clearance by both the splanchnic and
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renal vascular beds [77], However, the cardiovascu¬
lar effects persist for considerably longer [11, 68].
SIGNAL TRANSDUCTION
Binding sites and receptors
There are specific high-affinity binding sites for
the endothelins [78] in blood vessels, heart, adrenal
glands, kidneys and brain, their distribution lending
support to a role in cardiovascular regulation [79,
80]. Dissociation of endothelin from these sites is
extremely slow [81], and endothelin-receptor com¬
plexes are rapidly internalized into vascular smooth
muscle cells [82], Persistence of binding may
mediate the uniquely prolonged contractile effects of
endothelin although indirect evidence suggests that
these effects may be due to an, as yet unidentified,
late intracellular signalling event [83], Differing
functional responses to endothelin isopeptides and
evidence from radiolabeled endothelin binding
experiments suggest the existence of at least three
receptor types for the endothelins [16, 84, 85, 86],
One type seems to bind endothelin-1 preferentially,
the second is non-selective between endothelin-1
and -3, while the third binds endothelin-3 preferen¬
tially; two of these receptors have been isolated by
expression of cloned cDNA in vitro.
One receptor (ETA) was first isolated from a
bovine lung cDNA library, and has a high affinity
for endothelin-1 (binding potency: endothelin-
1 >endothelin-2»endothelin-3), with a KD of
0.2 nmol/1 [87]. Recently, the human ETA receptor
has been cloned and localized to chromosome 4 [88,
89]; this consists of 427 amino acids and has 94%
sequence identity with the bovine receptor. ETA
receptor mRNA is expressed in many human
tissues, with the highest expression in the aorta,
heart, lung and kidney. No mRNA can be detected
in the liver or endothelial cells, suggesting selective
vascular expression of this receptor in smooth
muscle cells [88]. A cyclic pentapeptide (BE-
18257B), which is a selective antagonist at the
ETa receptor, has been isolated from Streptomyces
misakiensis [90]. BE-18257B displaces endothelin-1
but not endothelin-3 from binding sites in vascular
smooth muscle, and antagonizes the vasoconstrictor
effects in vitro and the pressor effects in vivo of
endothelin-1 [9], Other, more potent, ETA antago¬
nists have since been isolated, including BQ-123
[91], FR 139317 [92] and CGS 26343A [93],
A second endothelin receptor (ETB) was first
cloned from a rat cDNA library [94], having equal
affinity for all three endothelins (binding potency:
endothelin-1 =endothelin-2 = endothelin-3). This ET„
receptor has also been cloned from human DNA,
having 442 amino acids [95, 96] and 88% sequence
identity with the rat ETB receptor, but only 55%
sequence identity with the human ETA receptor.
ET„ receptor mRNA is expressed in human tissues
but, in contrast to the ETA receptor, largely in
cerebral cortex and cerebellum, with moderate
expression in lung, kidney, adrenal, aorta and cul¬
tured vascular endothelial cells [96].
The deduced structure for both ETA and ET„
receptors has much in common with the superfamily
of G-protein-coupled receptors, having seven hydro¬
phobic membrane-spanning domains, and a rela¬
tively long extracellular N-terminal, although there
is only a 25% sequence identity with other peptide
receptors. The third postulated endothelin receptor
type, having greater affinity for endothelin-3 than
for the other isoforms [85, 86], has not yet been
cloned. Endothelin receptor number, as measured
by binding of radiolabeled endothelin-1, is regu¬
lated by a variety of factors. Ischaemia [97] and
cyclosporin A [98] appear to increase the number
of endothelin receptors, whereas elevated
endothelin-1 concentrations [99], angiotensin II and
phorbol esters [100] decrease receptor number.
Intracellular events
Endothelin-1 exerts its actions through a complex
series of intracellular events that include phospho-
lipase C activation, increased gene transcription and
interactions with membrane ion channels. An
increase in intracellular free Ca2+ concentration
([Ca2 + ]j) is the final common event thought to
mediate the vasoconstrictor and other actions eli¬
cited by the endothelins. After binding to receptors,
endothelin-1 activates phospholipase C via a pertu-
sis toxin-insensitive G-protein [101], This causes a
rapid increase (within 30 s) in the intracellular con¬
centration of water-soluble inositol trisphosphate
[102], which releases Ca2+ from intracellular stores
[103]. Phospholipase C activation also increases
membrane diacylglycerol [102], thus activating pro¬
tein kinase C [104],
[Ca2 + ]j is increased in a biphasic manner by
endothelin-1 [81, 101, 105]. Initially there is a rapid
peak in [Ca2 + ]j with concentrations elevated up to
ten-fold above normal [81], due to inositol
trisphosphate-mediated release of Ca2+ from intra¬
cellular stores. [Ca2 + ]j then falls to a plateau
concentration approximately double the resting con¬
centration. The plateau phase can be sustained for
up to 20min [105], but does not occur in the
absence of extracellular Ca2+ [81], suggesting that
entry of extracellular Ca2+ is responsible. The rapid
rise in [Ca2 + ]j appears to occur only at high
endothelin-1 concentrations (> nanomolar), whereas
the sustained increase can occur alone at lower
concentrations [106].
Endothelin-1 can also induce vasoconstriction of
Ca2 +-depleted tissues kept in a Ca2 + -free medium.
This is abolished by the protein kinase C inhibitor
H-7 [107], suggesting that protein kinase C activa¬
tion may account in part for the contractile activity
of the endothelins, by sensitizing the contractile
apparatus of the cell to Ca2 + , as described for
noradrenaline [108]. Protein kinase C-mediated
490 W. G. Haynes and D. J. Webb
sensitization of the contractile apparatus may occur
by activation of the Na+/H+ antiporter, because
endothelin-1 causes intracellular alkalinization [105,
109], thus sensitizing contractile myofilaments to
Ca2 + . This suggestion is supported by inhibition of
endothelin-1 induced alkalinization by protein
kinase C inhibitors [110]. In addition, activation of
protein kinase C by endothelin-1 increases the tran¬
scription of growth-promoting genes [105],
In view of the characteristically prolonged vaso¬
constrictor effects of endothelin-1, much interest has
focused on the mechanisms underlying the sustained
rise in [Ca2 + ]|. It was initially suggested that
endothelin-1 might be an endogenous agonist of the
dihydropyridine-sensitive voltage-operated Ca2 +
channel [9, 111], because endothelin-1-induced con¬
tractions were dependent on extracellular Ca2+ and
antagonized by dihydropyridine Ca2+ antagonists.
However, it has since been shown that the effect of
dihydropyridine Ca2+ antagonists on endothelin-
induced contraction in vitro is non-competitive
[112], and that contractions in response to endothe-
lin can still develop, although to a lesser extent, in
the absence of extracellular Ca2+ [113]. It is now
thought unlikely that endothelin-1 is an endogenous
agonist of the dihydropyridine-sensitive voltage-
operated Ca2+ channel, although it may act to open
these channels indirectly. There is, however, increas¬
ing evidence that endothelin-1 may interact with
ATP-sensitive K+ channels [114-117].
ACTIONS OF THE ENDOTHELINS
Vascular effects
Endothelin-1 causes long-lasting contraction of
large arteries, and in the isolated porcine coronary
artery has a potency 10-fold higher than any other
known constrictor substance [9], Endothelin-2 and
endothelin-3 also constrict isolated large arteries,
although endothelin-3 is less potent than the other
isoforms [16], All endothelins cause transient
endothelium-dependent vasodilatation before the
development of constriction (see below) [118].
Resistance vessels are very sensitive to the effects of
endothelin-1, as indicated by increases in perfusion
pressure of the isolated rat perfused mesenteric bed
[17, 119], but veins may be even more sensitive
[118, 120], In man, brachial artery infusion of
endothelin-1 leads to dose-dependent vaso¬
constriction of the forearm resistance bed, of slow
onset and prolonged duration, lasting more than 2h
after infusion is stopped [10, 121], Endothelin-1 also
causes venoconstriction in humans, with characteris¬
tics similar to those in arteries [116],
The endothelins are potent pressor agents in vivo
in animals, with endothelin-3 evoking the least
response [9, 16], The effect lasts for more than
60min after bolus injection, and is preceded by
transient hypotension, lasting a few minutes, which
is most marked for endothelin-3 [16], This hypo¬
tension may reflect a pharmacological, rather than
physiological, response to the briefly sustained high
concentrations of endothelins that occur after bolus
administration [122]. Under more physiological
conditions, in which endothelin concentrations rise
more slowly, such as occur after administration of
proendothelins, hypotension does not occur [123].
Nevertheless, the hypotensive response to bolus
administration may be useful in demonstrating the
endothelial actions of the endothelins (see below).
Coronary and renal vascular beds are more sensitive
to systemic endothelin-1 than the splanchnic and
hindquarters beds, which may vasodilate at low
doses [124-126]. Infusion of endothelin-1 over 7
days leads to sustained hypertension in rats,
mediated through an increase in total peripheral
resistance [127], which is salt-dependent [128]. In
healthy human subjects, systemic administration of
low doses of endothelin-1, mimicking the effects of a
generalized increase in vascular generation,
produces a modest increase in blood pressure [11].
Interactions with other local mediators of vascular
tone. The endothelins stimulate nitric oxide gene¬
ration by cultured endothelial cells [129, 130] and
isolated vessels [131]. The early and brief vasodila¬
tor and hypotensive actions of bolus doses of the
endothelins appear to be due, in part, to the release
of nitric oxide from endothelial cells, as nitric oxide
synthase inhibitors, such as /VG-nitro-L-arginine
methyl ester, substantially attenuate these effects
[132, 133], Perhaps more relevant physiologically,
nitric oxide synthase inhibitors also potentiate the
constrictor and pressor effects of endothelin-1, sug¬
gesting that there is an autocrine feedback mecha¬
nism to modulate vasoconstriction to endothelin, by
stimulation of the endothelial generation of nitric
oxide [132, 133], Endothelin-1 also increases prosta¬
cyclin generation by cultured endothelial cells [129],
and cyclo-oxygenase inhibitors potentiate
endothelin-l-induced constriction [134], suggesting
that vascular generation of vasodilator prosta¬
glandins attenuates constriction induced by
endothelin-1. In human veins in vivo, prostacyclin
appears to be more important than nitric oxide in
modulating responses to endothelin-1 in veins [135].
However, prostaglandins may not mediate the hypo¬
tensive response to the endothelins, since this is
unaffected by cyclo-oxygenase inhibition [136], The
hypotensive response to the endothelins does not
appear to be due to stimulation of ^-adrenoceptors
as selective /^-adrenoceptor antagonists do not
prevent the dilator response [137]. It is, however,
possible that activation of K+ channels contributes
to the dilator response to endothelin by causing
membrane hyperpolarization [137], Platelet-
activating factor, a further endothelium-derived
vasodilator, is also released by endothelin-1 and
may mediate or modulate some of its actions [138].
Therefore, stimulation of endothelial cell gene¬
ration of relaxant factors by endothelins attenuates,
but does not prevent, their long-lasting vaso-
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Fig. 3. Generation and actions of endothelin-l in the blood vessel wall. Endothelial is generated via cleavage of its precursor
proendothelin-l by membrane-bound ECE. The mature peptide can then act locally either at vascular smooth muscle cell ETA
receptors to directly cause vasoconstriction, or at endothelial cell ETB receptors to stimulate production of endothelium-derived
vasodilators. Note that ETB receptors may also be present on vascular smooth muscle cells, where they cause vasoconstriction. 'See
the text for details of the mechanisms by which endothelin-l increases [Ca1*],. Abbreviations: PRO ET, proendothelin-l; ET,
endothelin-l.
constrictor effects. This autocrine effect is probably
mediated through the non-isopeptide-selective ETB
receptor expressed on endothelial cells (Fig. 3).
There is, however, recent evidence to suggest that
this receptor is also present on vascular smooth
muscle cells, as selective agonists of ETB receptors,
such as [Ala1,3, "• 15]endothelin-l and sarafotoxin
S6c, cause vasoconstriction of isolated animal ves¬
sels [139, 140], This ETB-receptor-dependent vaso¬
constriction varies between vessels and species,
being more apparent in veins than arteries [140],
Variations in the distribution of receptor subtypes
may explain why endothelin-3 is equipotent to
endothelin-l as a vasodilator (endothelial cell,
ETB-mediated), but less potent as a vasoconstrictor
(vascular smooth muscle, mainly ET.-mediated)
[13H.
In addition to acting as a direct vasoconstrictor,
endothelin-l may potentiate the actions of the sym¬
pathetic nervous system in threshold doses [141,
142], although this effect has not been demonstrated
in man [121],
Growth effects
Endothelin-l is a potent mitogen for cultured
vascular smooth muscle cells [143, 144], Swiss 3T3
fibroblasts [145], cardiocytes [146] and glomerular
mesangial cells [105, 147], This occurs, in part,
because of increased expression of mRNA for the
growth promoting proto oncogenes c fos and c myc
[143]. Endogenous endothelin-l may play an auto¬
crine role in controlling endothelial cell growth, as
anti-endothelin y-globulin inhibits DNA synthesis
by cultured endothelial cells [148].
Cardiac effects
Endothelin-l is a potent constrictor of coronary
vessels after local administration in vivo to animals,
causing myocardial ischaemia [149] and fatal ven¬
tricular arrhythmias [150]. Systemic administration
causes prolonged coronary vasoconstriction in ani¬
mals, and the coronary resistance bed is more
sensitive to the effects of endothelin than other
resistance beds, excepting the kidney [125].
Endothelin-l has potent positive chronotropic [151]
and inotropic [152] effects in vitro, with the positive
inotropic effects apparent at lower doses than those
which cause coronary vasoconstriction [153]. At
high doses, positive inotropism is opposed by
ischaemia. Endothelin-l impairs diastolic relaxation
of the left ventricle in vitro, leading to a reduction in
cardiac filling [154], In vivo, although positively
inotropic at low doses, higher doses cause cardiac
output to fall [124, 155], probably due to a combi¬
nation of systemic vasoconstriction, increasing after-
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load, and coronary vasoconstriction, causing myo¬
cardial ischaemia.
Renal effects
Endothelin-1 contracts afferent and efferent arter¬
ioles equally in vitro [156], and thus reduces both
renal plasma flow and glomerular filtration rate
(GFR) in the isolated perfused kidney [157]. This
contrasts with the selective effect of angiotensin II
on the efferent arteriole. The renal circulation in vivo
is also exquisitely sensitive to the effects of
endothelin-1, with marked reduction in renal blood
flow and GFR [124], even at sub-pressor doses of
the peptide [147]. Intraglomerular capillary
hydraulic pressure shows little change, as expected
from effects on both afferent and efferent arterioles.
In contrast, the glomerular capillary ultrafiltration
coefficient is markedly reduced, probably due to
endothelin-1-induced mesangial cell contraction
leading to a reduction in glomerular capillary sur¬
face area, accounting in part for the fall in GFR.
Surprisingly, despite decreases in renal blood flow
and GFR, at low doses endothelin-1 increases urin¬
ary Na+ excretion [147, 158]. This natriuresis may
be due to enhanced production of ANP [159], to
inhibition of the renal response to antidiuretic hor¬
mone [160], to pressure natriuresis or to a combi¬
nation of these effects.
Respiratory effects
Endothelin-1 is a potent constrictor of pulmonary
resistance vessels [161] and bronchioles, causing
long-lasting bronchoconstriction when administered
by aerosol to animals [162]. Endothelin-1 is synthe¬
sized by bronchial epithelial cells [163], and stimu¬
lates bronchiolar subepithelial fibrosis and the pro¬
duction of chemoattractants for leucocytes [164],
Central nervous system effects
Binding sites for endothelin-1 are present in the
thalamus, hypothalamus, basal ganglia and brain¬
stem [79]. The endothelins constrict cerebral arter¬
ies both in vitro and in vivo, and the effects of
endothelin-1 on the basilar artery of the dog last for
at least 3 days after intracisternal injection [165],
Topical application of exogenous endothelin-3 to
the hypothalamus exerts profound effects on salt
and water balance in rats, with potent inhibition of
thirst in water-deprived animals [49]. In addition,
binding sites for endothelin-1 are present in the
carotid bifurcation, and topical application of the
peptide inhibits baroreceptor, and stimulates chemo-
receptor, responses at this site [166], Intraventricu¬
lar administration of low dose endothelin-1
increases blood pressure and heart rate through
stimulation of central sympathetic outflow [167],
supporting a role for the endothelins in cardiovascu¬
lar homoeostasis.
Endocrine effects
Endothelin-1 has complex effects on the renin-
angiotensin-aldosterone system, inhibiting release of
renin from isolated rat glomeruli [168], but stimu¬
lating endothelial ACE activity [169], In the rat
isolated mesenteric bed, endothelin-1 stimulates the
tissue renin-angiotensin system, increasing gene¬
ration of renin and angiotensin II [170]. In the
adrenal gland, endothelin-1 stimulates release of
aldosterone from isolated cortical zona glomerulosa
cells [171], and adrenaline from medullary chromaf¬
fin cells [172], Administration of endothelin-1 in
vivo to animals increases renin, aldosterone and
adrenaline concentrations [173], renin concentration
apparently rising because of endothelin-1-induced
renal vasoconstriction.
Endothelin-3, in non-pressor doses, stimulates the
rat hypothalamic-pituitary-adrenal axis, increasing
release of corticotrophin-releasing hormone, adreno-
corticotrophic hormone and, thereby, of corticoster-
one [174], In cultured anterior pituitary cells,
endothelin-1 and endothelin-3 directly inhibit pro¬
lactin secretion, while stimulating gonadotrophin
secretion [175]. The endothelins may also play a
role in the posterior pituitary, as they are present in
hypothalamic paraventricular and supraoptic nuclei,
and their projections into the posterior pituitary,
and concentrations are reduced by water depletion
[44], Concentrations of both endothelin-1 and anti¬
diuretic hormone (ADH) rise in parallel during
upright tilt in normal subjects and are unchanged
during tilt in patients with diabetes insipidus [64],
Although the suggestion has been made that
endothelin-1 is acting as a classical circulating hor¬
mone in these circumstances, this seems unlikely, as
its concentration is less than that necessary to cause
direct vasoconstriction. However, endothelin-1 may
have an autocrine or paracrine role in control of
ADH release as infusion of the peptide increases
ADH concentrations in dogs [173],
Endothelin-1 stimulates ANP production and
release by cultured atrial myocytes in vitro [176,
177], and circulating concentrations of ANP are
increased by infusion of endothelin-1 in rats [178].
ANP attenuates the effects of endothelin-1, as it
dose-dependently relaxes endothelin-1 pre¬
contracted, aortic strips [179, 180], However, the
vasodepressor effects of ANP are qualitatively differ¬
ent from those of endothelin-1, suggesting that ANP
does not mediate the transient hypotensive re¬
sponses of endothelin-1 [181],
PATHOPHYSIOLOGY
In the absence of human studies using inhibitors
of endothelin generation, or antagonists of endothe-
lin receptor binding, much of the work on the role
of endothelin in pathophysiology has been based on
changes in circulating plasma concentrations of
immunoreactive endothelins. These are dependent
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not only on generation, but also on receptor-
mediated clearance and enzyme-mediated metabo¬
lism of the peptide. In some studies, sensitivity to
endothelin-1 has been examined, but as receptor
number can be downregulated by increased
endothelin-1 concentrations [99], these studies may
also prove difficult to interpret.
Hypertension
Some investigators have used elevated concen¬
trations of circulating immunoreactive endothelin-1
to suggest increased production in essential hyper¬
tension [182]. However, clearance of endothelin-1 is
dependent on renal function [73, 75], and the very
high concentrations found in severe and accelerated
phase hypertension are probably due to impaired
renal clearance. This is supported by results from
animal models of accelerated hypertension, where
endothelin-1 concentrations are raised and correlate
positively with creatinine [183]. There seems to be
no difference in generation of endothelin-1 between
normotensive Wistar-Kyoto (WKY) and sponta¬
neously hypertensive (SHR) rats, as assessed by
hypotensive responses to phosphoramidon, an inhi¬
bitor of ECE [57]. Studies in hypertensive patients
with normal renal function have shown similar
concentrations of endothelin-1 to those in normo¬
tensive subjects [184]. Indeed, in this study the
negative correlation between blood pressure and
plasma endothelin-1 concentration in the hyper¬
tensive group makes a global increase in generation
of endothelin-1 unlikely as a cause of essential
hypertension.
In animal studies comparing WKY and SHR,
both conduit and resistance vessels from the hyper¬
tensive rats are more sensitive to the effects of
endothelin-1 [185-188], In vivo, endothelin-1 has a
greater pressor effect in SHR than WKY [189], The
mechanism for this enhanced sensitivity to
endothelin-1 is unclear, as the number of binding
sites for endothelin-1 in aortic smooth muscle [186]
and heart [190] are lower in SHR, suggesting
increased post-receptor sensitivity, although these
studies may be confounded by altered vascular
structure in established hypertension. There is, how¬
ever, a relative increase in the number of binding
sites for endothelin-1 in the brain of SHR as
compared with WKY [190], so there may be
increased central nervous system sensitivity to the
peptide in hypertension.
Recent studies with endothelin receptor antago¬
nists support for a role for endothelin-1 in experi¬
mental animal hypertension. The ETA antagonist
BQ-123 acutely lowers blood pressure in salt-loaded
stroke-prone SHR, but not in salt-deprived controls
or in WKY [191], When administered chronically,
BQ-123 lowers blood pressure, and prevents the
developments of stroke and renal abnormalities in
stroke-prone SHR [191], CGS 26343A, another
I. Ta receptor antagonist, lowers blood pressure in
low-renin animal models of hypertension (SHR and
deoxycorticosterone acetate-salt rats), but not in
control animals or in high-renin animals [93], These
results do not indicate the mode (increased gene¬
ration or sensitivity) by which endothelin-1 may
contribute to hypertension in these animal models.
The vasodilator function of the endothelium is
impaired in essential hypertension, and responses to
endothelium-dependent relaxant agents are reduced
[192], This may be due to impaired release of
endothelium-derived dilators (prostacyclin and nitric
oxide). Alternatively, there may be greater produc¬
tion of, or sensitivity to, endothelium-derived vaso¬
constrictors, such as endothelin-1. Even if the
impaired dilator response is solely due to decreased
production of nitric oxide, the balance between
endothelium-derived dilator and constrictor factors
may alter to favour vasoconstriction.
The potent mitogenic effects [143] of endothelin-1
might potentially contribute to hypertension-
induced hypertrophy of vascular smooth muscle,
thus amplifying any vasoconstrictor influences [193,
194]. In addition, endothelin-1 might promote the
development of left ventricular hypertrophy in
hypertension, a factor that adversely affects progno¬
sis [195], The growth-promoting properties of
endothelin-1 may also contribute to the develop¬
ment of atherosclerosis. Atherosclerotic human
blood vessels show strong immunostaining for
endothelin-1, and patients with atherosclerosis have
raised plasma concentrations of the peptide, with
the highest concentrations in patients with the
largest number of affected vessels [196],
Increased production of endothelin-1 certainly
appears to be associated with one secondary form of
hypertension, albeit rare. Yokokawa et al. [197]
have described two cases of the skin tumour,
haemangio-endothelioma, in which hypertension
was associated with increased plasma endothelin-1
concentrations (Fig. 4). Biopsies of tumour cells
displayed increased expression of mRNA for
endothelin-1, and strong immunohistochemical
staining for the peptide. Blood pressure and
endothelin-1 concentrations returned to normal in
both cases after surgical resection of the tumours
and, in one patient, recurrence of the tumour led to
further increases in both blood pressure and plasma
endothelin-1 concentration.
Digital and coronary vasospasm
There are a number of vascular conditions that
are characterized by instability of tone in small
arteries, such as Raynaud's disease and Prinzmetal's
angina, associated with vasospasm in digital and
coronary vessels, respectively. Patients with the
latter have an increased incidence of Raynaud's
phenomenon, migraine and ocular vasospasm [198],
suggesting that such instability of vascular tone may
be a more widespread phenomenon, perhaps due to
an imbalance between endothelium-derived dilator
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Fig. 4. Sequential plasma endothelin concentrations (0) and mean
blood pressure (O) in two patients with malignant
haemangio-endothelioma ( . case I; —, case 2). See the text for
details. The stippled area indicates the normal range of plasma endothelin-l
concentrations in humans with this assay. Reproduced with permission from
[197],
and constrictor factors. Indeed, circulating
endothelin-l concentrations are elevated in patients
with Raynaud's disease and coronary vasospasm,
between episodes of spasm, consistent with a gener¬
alized endothelial abnormality associated with
increased endothelin-l production [199, 200], In
Raynaud's disease, circulating concentrations
increase further after a cold challenge to the hand
[199], and endothelin-l concentrations are higher
still in venous blood draining the cold-challenged
hand. By contrast, in coronary vasospasm,
endothelin-l concentrations do not increase further
during ischaemic episodes [200], suggesting that
another factor, such as decreased nitric oxide pro¬
duction, may be responsible for initiating the attack.
By contrast, plasma concentrations of endothelin-l
are normal in patients with either stable [201] or
mild unstable [202] angina. Endothelial dysfunction,
associated with increased generation of endothelin-l,
may therefore predispose to vasoconstriction in
vasospastic states.
Myocardial infarction and heart failure
Circulating concentrations of endothelin-l and
proendothelin-1 rise rapidly after myocardial infarc¬
tion, with concentrations raised two- to three-fold
on the day of infarction, and only returning to basal
over the next 7-10 days [203], The duration and
degree of elevation is proportional to the severity of
infarction, as judged by Killip class, with the highest
concentrations found in cardiogenic shock [201].
These findings are consistent with the elevated
endothelin-l concentrations described in other
forms of shock [204], and suggest that in such
severe hypotensive states, endothelin-l may act as a
'mechanism of last resort' to maintain blood pres¬
sure and perfusion of vital organs. However, this
interpretation of the findings may be open to
question since impaired renal function in hypoten¬
sive shock will reduce renal clearance of
endothelin-l.
In addition to elevated plasma concentrations,
immunoreactive endothelin-l also increases substan¬
tially (six-fold) in cardiac tissue after experimental
myocardial infarction in rats [205], with this
increase lasting longer than that in plasma [206].
Interestingly, the number of cardiac binding sites for
endothelin-l increase after either ischaemia alone
(by 62%) or ischaemia with reperfusion (by 140%)
[97]. Interestingly, pretreatment with anti-
endothelin y-globulin in a rat model of myocardial
infarction causes a 40% decrease in infarct size [205,
206]. Thus a combination of increased cardiac
endothelin-l content and additional binding sites for
the peptide may contribute to extension of infarct
size by compromising blood flow in reperfused
areas.
It has been speculated that endothelin-l may also
play a role in the neurohumoral maladaption to
chronic heart failure and, like the renin-angiotensin
system, contribute to the morbility and mortality
associated with this condition. In animal models of
heart failure, endothelin-l concentrations rise three¬
fold, and correlate closely with pulmonary capillary
wedge pressure [207], Endothelin-l concentrations
are also elevated in patients with chronic heart
failure [208, 209] and are correlated closely with the
degree of pulmonary hypertension [210],
Renal failure
Plasma immunoreactive proendothelin-1, endo¬
thelin-l and endothelin-3 concentrations are ele¬
vated in renal failure, and are raised two-four-fold
in patients on haemodialysis, probably reflecting
impaired renal clearance of these peptides [73, 74],
However, renal production of endothelin-l may also
contribute, as there are increases in both renal
cortical endothelin-l production [211] and urinary
endothelin excretion [212] in animal models of
reduced renal mass. Urinary endothelin and protein
excretion are positively correlated in these animals
[212], suggesting that endothelin may contribute to
the rate of progression of chronic renal failure.
Elevated plasma concentrations of endothelin may
also play a role in the development or maintenance
of hypertension in chronic renal failure. In contrast
to essential hypertension, endothelin-l concen¬
trations in haemodialysis patients are positively
correlated with blood pressure [213]. Interestingly,
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concentrations of endothelin-3, but not those of
endothelin-1, rise further during haemodialysis; this
may reflect production or release of endothelin-3 by
the central nervous system in response to dialysis-
induced hypotension [213].
Acute renal failure due to post-ischaemic acute
necrosis is characterized by intense renal vaso¬
constriction. This may be mediated by endothelin-1,
which is a potent renal vasoconstrictor [157], since
production of, and sensitivity to, the peptide is
increased by hypoxia [29, 97]. Circulating plasma
concentrations of endothelin are increased in
patients with post-ischaemic renal failure [214]. A
role for endothelin-1 is supported by the finding
that, in animals, renal immunoreactive endothelin
increases, for at least 24 h, after 45min of bilateral
renal artery occlusion [215]. Pretreatment of these
animals with a monoclonal antibody against
endothelin ameliorates renal failure. In addition,
infusion of anti-endothelin y-globulin into a branch
artery of a rat kidney 48 h after ischaemic insult will
reverse renal vasoconstriction [216],
Gram-negative septic shock is associated with a
reduction in peripheral vascular resistance and
blood pressure, which is thought to be due to
endotoxin, and other mediators, stimulating nitric
oxide production [217]. Paradoxically, renal vaso¬
constriction occurs during septic shock, leading to
acute renal failure [218]. As endotoxin stimulates
endothelin-1 release, both in vitro and in vivo [32],
and local administration of anti-endothelin y-
globulin completely reverses endotoxin-induced
renal vasoconstriction [159], endothelin may be
responsible for acute renal failure in this situation.
Endothelin-1 may also contribute to the hyper¬
tension and renal impairment caused by cyclosporin
A. Production of endothelin-1 in vitro [219] and in
vivo [220] is stimulated by cyclosporin A, which
also increases renal endothelin-1 receptor number
[98]. Also, cyclosporin A-induced renal vaso¬
constriction is substantially attenuated by anti-
endothelin y-globulin [220],
Respiratory disease
Plasma concentrations of endothelin-1 in venous
blood are elevated in patients with primary and
secondary pulmonary hypertension [221]. Also, the
pulmonary circulation seems to generate more
endothelin-1 than it clears in primary pulmonary
hypertension, as the ratio of arterial to venous
concentrations of endothelin-1 is significantly
greater than unity (~2.2) [221], This is not the case
for healthy control subjects, who have an arterial to
venous ratio substantially less than unity (~0.6). In
addition, a role for endothelin-1 in the adult respira¬
tory distress syndrome, which is associated with
elevated pulmonary vascular resistance in the face of
normal pulmonary artery occlusion pressures, is
suggested by marked increases in mixed venous and
wedged pulmonary artery concentrations of
endothelin-1 [222].
Asthma is a disease characterized by episodes of
reversible bronchoconstriction. Substantially in¬
creased amounts of endothelin-1, as measured by
immunoreactive staining, have been demonstrated in
the bronchial epithelium of asthmatic patients as
compared with control subjects [164]. In addition,
during severe attacks of asthma there are increased
concentrations of endothelin-1 in both plasma and
bronchoalveolar lavage fluid [223]. These findings,
taken in conjunction with the ability of the peptide
to cause marked bronchoconstriction [162], make
endothelin-1 a strong candidate for further investi¬
gation as a mediator in asthma.
THERAPEUTIC POTENTIAL
Selective ECE inhibitors [55] and endothelin-1
receptor antagonists [90-93] are only beginning to
be made available for basic research, but should
provide powerful insights into the physiology and
pathophysiological role of the endothelins. Pro¬
longed intravenous infusion of a relatively non¬
selective agent, phosphoramidon, which inhibits
both ECE and neutral endopeptidase-24.11, lowers
the blood pressure of both WKY and SHR by
approximately 15% after 4h [57]. In contrast, kela-
torphan, an inhibitor of neutral endopeptidase-
24.11, does not alter blood pressure, implying that
the effect of phosphoramidon is due to inhibition of
ECE. These results are consistent with a role for
endothelin in regulation of blood pressure, and
suggest that the therapeutic potential of ECE inhibi¬
tors should be investigated at a later stage in man.
Endothelin receptor antagonists are at a very early
stage of development [90-93], but may allow selec¬
tive interruption of the actions of particular iso-
forms of endothelin. For example, an antagonist at
the ETa receptor would block constrictor responses
to endothelin-1, while leaving any ET„-
receptor-mediated vasodilator effects of the endothe¬
lins unaffected. There is recent evidence that ETA
receptor antagonists cause the expected decrease in
blood pressure in rats with experimental hyperten¬
sion [93, 191]. Vasodilator drugs which act by
opening K+ channels also markedly inhibit
endothelin-1-induced vasoconstriction [114, 116],
although the therapeutic role of these drugs remains
unclear.
The use of ACE inhibitors, such as captopril and
enalapril, and angiotensin II receptor antagonists,
such as saralasin and losartan (Dup 753), have
helped to define the role of the renin-angiotensin
system in health and disease, and ACE inhibitors
have become established as effective treatment for
patients with hypertension and heart failure. As
endothelin-1 is an extremely potent constrictor,
pressor and mitogenic agent, it is possible that ECE
inhibitors and endothelin receptor antagonists may.
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Table I. Role of endothelin in pathophysiology. The diseases in which
endothelin may play a role are shown.














in future, offer substantial therapeutic benefits in
these and other vascular conditions.
CONCLUSIONS
The endothelins are potent long-acting endoge¬
nous vasoconstrictor and growth-promoting pep¬
tides, first isolated from vascular endothelial cells.
The widespread expression of mRNA for the
endothelins, and the distribution of their receptors,
suggests that these peptides may play an important
role in local regulation of the cardiovascular, respir¬
atory, endocrine and central nervous systems.
Endothelin-1 is the predominant peptide generated
by vascular endothelial cells, and is the most potent
vasoconstrictor and pressor agent yet identified.
Endothelin-1 may serve as a long-acting physio¬
logical antagonist to the short-lived effects of the
endothelium-derived vasodilators, prostacyclin and
nitric oxide, and may also act as a vasoconstrictor
'of last resort' under circumstances of extreme
cardiovascular stress.
There is substantial experimental evidence to sug¬
gest that endothelin-1 may be involved in the
pathophysiology of vasospastic conditions, renal
failure and asthma (Table 1). In some conditions,
such as chronic renal failure or myocardial infarc¬
tion, it is not clear whether the high circulating
concentrations of endothelin-1 are a cause or conse¬
quence of the underlying condition. Even if endothe¬
lin is not the primary cause of these diseases, the
peptide may contribute to their progression. Deve¬
lopment of agents that interfere with the production
or actions of the endothelins may increase know¬
ledge of the physiological and pathological roles of
the endothelins, and generate drugs with potentially
novel benefits in the treatment of cardiovascular
and respiratory disease.
Note added in proof
Orally active non-peptide endothelin receptor
antagonists were recently reported at the Third Inter¬
national Conference on Endothelin in Houston
Texas, U.S.A. (15-17 February 1993), and an
shortly expected to enter clinical development.
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Endothelin: progress in pharmacology
and physiology
The discovery of the potent vaso¬
constrictor family of peptides,
endothelin-1 (ET-1) in 1988 (Ref. 1),
and ET-2 and ET-3 in 1989 (Ref. 2),
led rapidly to the cloning of two
receptor subtypes, ETA (agonist
potency: ET-1 > ET-2 >> ET-3)
and ETb (ET-1 = ET-2 = ET-3)3.
There has subsequently been con¬
siderable progress in characteriz¬
ing both the pharmacology and
physiology of endothelin, particu¬
larly with the development of
specific receptor agonists and
antagonists, as reported at a recent
conference*.
Generation and metabolism
Progress towards isolation of
the endothelin-converting en¬
zyme remains disappointing.
Although the enzyme appears
to be membrane bound, the
question remains whether it is
intracellular. Substantial endo¬
thelin-converting enzyme activity
in endothelial cell membranes
appears to be located within the
endoplasmic reticulum (G. Gui,
University of Texas, Dallas). V. J.
Harrison (William Harvey Research
Institute, London), however, pre¬
sented evidence that intracellular
vesicles might be an important
site of proET-1 processing.
Stimulation of endothelin
production by shear stress and
hypoxia is well recognized. How¬
ever, J. A. Frangos (Pennsylvania
State University) showed that the
effect of shear stress may be bi-
phasic at high levels of shear, with
initial protein kinase C-dependent
stimulation of endothelin pro¬
duction, and later nitric oxide-
dependent inhibition. Interest¬
ingly, an in vivo model of acute
hypoxia in dogs is associated with
increases in both plasma and
urinary endothelin (A. Nir, Mayo
Clinic, Rochester). Two groups
have demonstrated that heparin
inhibits ET-1 expression and
* Third International Conference on l.niio-
thehn, Houston. Texas. USA. IS -17 February
1993
generation by cultured endo¬
thelial cells (T. Imai, Tokyo
Medical and Dental University;
K. Yokokawa, Osaka City Univer¬
sity), possibly via nitric oxide.
Although ET-1 and ET-2 are
equipotent as constrictors, ET-2
has not been detected previously
in human tissues. Using immuno-
cytochemistry with highly specific
antibodies to precursors of the
different endothelin isoforms,
C. Plumpton (University of
Cambridge) demonstrated the
presence of ET-2, in addition to
ET-1 and ET-3, in human pul¬
monary, cardiac and vascular
tissue. This group also demon¬
strated that the preproET-2 gene
may generate several alternative
spliced variants in different
human tissues, suggesting that
splicing may play an important
regulatory role, possibly by alter¬
ing the post-transcriptional pro¬
cessing of ET-2 or by generation of
alternative functional variants
(G. O'Reilly, University of Cam¬
bridge). M. Paul (University of
Heidelberg) described transgenic
rats overexpressing the human
ET-2 gene, insertion of the human
ET-1 gene having produced a
lethal effect during development.
Blood pressure was not increased,
despite a fourfold elevation in
concentrations of circulating
immunoreactive endothelin.
Although impaired renal func¬
tion is associated with reduced
clearance of endothelin, the
relative contributions from urin¬
ary excretion, receptor mediated
clearance and enzyme mediated
metabolism are unclear. S. Kaw
(William Harvey Research Institute,
London) showed the substantial
capacity of the kidney for in¬
activating ET-1. A. Y. Jeng (Ciba-
Geigy, New Jersey) isolated a
candidate ET-1- (and ET-3-) de¬
grading protease from rat kidney,
inactive against proET-1 and
proET-3, which cleaved the
C-terminal tryptophan from ET-1
to yield a peptide with vasocon¬
strictor potency three orders of
magnitude less than ET-1.
Receptors
Endothelin receptors are un¬
usual in that the ETA and ETB
subtypes were isolated and cloned
before the development of sub-
type-selective ligands. To define
the molecular basis of ligand-
binding selectivity, A. Sakamoto
(University of Kyoto) constructed
chimeric endothelin receptors and
showed that regions containing
transmembrane domains I—III and
VII were necessary for ETA,
whereas IV-VI were necessary for
ETg-specific binding. Mutation of
Cysl48 and Cys229 to Ala in the
first and second extracellular loops
of the ETb receptor abolished ET-1
binding (B. Haendler, Schering,
Berlin). C. Miyamoto (Nippon-
Roche, Kamakura) showed that
the 13 C-terminal amino acids,
and the amino acids of the
C-terminal end of the third intra¬
cellular loop, are involved in signal
transduction.
Molecular biology studies4
suggest that only the ETA receptor
is expressed in vascular smooth
muscle, with vascular expression
of the ETb receptor confined to
endothelial cells, where it causes
release of vasodilator prosta¬
glandins and nitric oxide. How¬
ever, at least in animals, studies
with ETB-selective agonists, such
as sarafotoxin S6c, suggest that
ETB-like receptors may also
mediate vasoconstriction. There is
now increasing evidence that the
venous circulations of the dog and
rabbit have vasoconstrictor ETB
receptors (N. J. Lodge and S.
Moreland, Bristol-Myers Squibb,
Princeton; I. Watts, Glaxo, Ware).
The ratio of ETA and ETB
receptors may vary within and
between vascular beds, and be¬
tween species. J. L. Balwierczak
and D. F. Rigel (Ciba-Geigy,
Summit) found evidence for both
ETa- and ETB-mediated coronary
vasoconstriction; constriction of
large conduit arteries and arrythmo-
genesis was attributable to ETA
receptors in the dog, while con¬
striction of the coronary resistance
bed additionally involves ETB
receptors in the dog and rat.
D. P. Brooks (SmithKline Beecham,
King of Prussia) confirmed that
vasoconstriction in rat kidney is
mediated by ETB receptors. By
contrast, in the dog, renal vaso¬
constriction is mediated exclu¬
sively by the ETA receptor
(Brooks), and reduction of renal
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Fig. 1. Structures of selective and nonselective endothelin receptor agonists and
antagonists.
vascular resistance following
intra-renal infusion of BQ123
(A. L. Clavell, Mayo Clinic) sug¬
gests a role for these receptors in
maintenance of basal tone. The
dog may be a better model than the
rat for the human kidney, in
which only ETA receptors can be
localized to the vasculature (F. E.
Karet, University of Cambridge).
The importance of ETB-medi-
ated vasoconstriction in man is
unclear. Although ETB receptor
protein (by ligand binding) and
ETb mRNA (by reverse transcrip¬
tase polymerase chain reaction)
have been detected in the media
of a number of human blood
vessels, the ETB-selective com¬
pounds have little or no agonist
activity, and Schild plots using the
ETA-selective antagonist BQ123
show a slope close to one in these
preparations (A. P. Davenport,
University of Cambridge).
BQ123 (Ref. 5) and FR139317
(Ref. 6) have become established
as highly selective ETA antagon¬
ists, while IRL1038 appears to be a
selective antagonist at the ETB
receptor (H. Karaki, University of
Tokyo). An ETA-selective agonist
has not yet been reported, in
contrast to the diversity of ETB
agonists (Fig. 1). M. Clozel
(Hoffman-La Roche, Basel) pro¬
vided the first report of a non-
peptide, orally active endothelin
receptor antagonist, Ro462005, de¬
tected by random screening. This
sulphonamide derivative is a com¬
petitive nonselective antagonist at
ETA and ETB receptors, has no
partial agonist activity, and is in¬
active against other vasoconstric¬
tors. Ro462005 antagonizes ET-1-
induced constriction of rat aorta
and small mesenteric arteries (ETA
receptors; pA2 6.5) and sarafotoxin
S6c-induced constriction of rat
trachea and dilatation of small
mesenteric arteries (ETB recep¬
tors; pA2 6.1) (G. A. Gray; Hoffman-
La Roche Basel). In the rat, Ro462005
inhibits the pressor response to
proET-1 and both the depressor
and pressor responses to ET-1.
Ro462005 prevents renal vasocon¬
striction after 45 min renal is-
chaemia, and cerebral vasocon¬
striction in a model of subarach¬
noid haemorrhage. Interestingly,
Ro462005 doubled plasma ET-1
concentrations (with no effect on
plasma proET-1) in conscious rats,
while BQ123 and FR139317 had no
such effect. B-M. Loffler (Hoffman-
La Roche, Basel) postulated that
Ro462005 may be displacing ET-1





could not be attributed to ac¬
tivation of the recognized sub¬
types of ETa or ETb receptors, as
defined by existing antagonists.
T. D. Warner (William Harvey Re¬
search Institute, London) and H.
Karaki presented functional evi¬
dence for non-isopeptide-selective
endothelin receptors, insensitive
to ETb (and ETA) antagonists,
in rabbit pulmonary artery and
isolated rabbit stomach strips
(Warner), and porcine pulmonary
veins and rabbit saphenous veins
(Karaki).
Intracellular actions
Endothelins are known to ac¬
tivate phospholipase C through a
process involving a G protein-
coupled receptor. S. Eguchi (Tokyo
Medical and Dental University)
demonstrated that endothelin
receptors may also be coupled
to adenylyl cyclase and cAMP
formation, activation occurring
through ETa receptors in cultured
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vascular smooth muscle cells, and
inhibition through ETB receptors
in endothelial cells. Inositol tri¬
phosphate formation does not
appear to account for the pro¬
longed contractile effects of ET-1,
which are largely dependent on
extracellular Ca2+, and may result
from coupling of endothelin
receptors with ion channels. S. Hu
(Ciba-Geigy, Summit) demon¬
strated that ET-1 and ET-3 open
Cl~ channels, and close ATP-
insensitive K+ channels, in cul¬
tured rat mesangial cells, thus
causing membrane depolariz¬
ation. W. G. Haynes (University
of Edinburgh) reported that
cromakalim, an ATP-sensitive K +
channel opener, was more effec¬
tive at preventing venoconstric-
tion to ET-1 in vivo in humans
than the dihydropyridine Ca2+
antagonist nicardipine, suggest¬
ing that ET-1 interacts with ATP-
sensitive K+ channels, indepen¬
dent of dihydropyridine-sensitive
Ca2+ channels, in human vascular
tissue.
Endothelial interactions
ET-1 stimulates the generation
of endothelium-derived dilators,
such as prostacyclin and nitric
oxide, probably by activation of
an endothelial cell ETB receptor.
P. D'Orleans-Juste (University of
Sherbrooke) showed, in perfused
rat lung and rabbit kidney, that
ETa receptors mediate prosta¬
cyclin release. S. Taddei (Baylor
College of Medicine, Houston),
reported that endothelial ETA
receptors may mediate release of
the constrictor prostanoid throm¬
boxane A2 in spontaneously
hypertensive rats. ETB receptors
may also be linked to release of an
endothelium-dependent hyper-
polarizing factor, distinct from
nitric oxide (M. Nakashima, Baylor
College of Medicine; I. Sakuma,
Hokkaido University), that acts in
part by opening apamin-sensitive
small-conductance Ca2+-activated
K+ channels (Sakuma). In
humans, constriction of hand
veins by ET-1 is modulated in vivo
by the production of prostacyclin,
but not nitric oxide (D. J. Webb,
University of Edinburgh).
ET-1 stimulates atrial natriuretic
peptide release, which inhibits
the production and actions of ET-
1, and attenuates ET-l-stimulated
proliferation of vascular smooth
muscle cells (D. Neuser, Bayer,
Wuppertal). C-type natriuretic
peptide (CNP), which has similar
actions to atrial natriuretic pep¬
tide, is co-localized with ET-1 in
endothelial cells (D. M. Heublein,
Mayo Clinic). Intracoronary ad¬
ministration of CNP inhibited
coronary production of endothelin
in dogs (R. S. Wright, Mayo Clinic),
and systemic CNP prevented the
rise in plasma endothelin occurring
in a dog model of heart failure
(R. R. Brandt, Mayo Clinic).
Pathophysiology
Evidence in support of a role for
endothelin in cardiovascular,
renal and cerebrovascular disease
was also provided. T. Tennessen
(University of Oslo) reported that
endothelin is released from the
heart following 10 min of myo¬
cardial ischaemia in anaesthetized
pigs. C. C. Zaugg (University
Hospital, Basel) demonstrated that
on reperfusion of the isolated rat
heart there is exaggerated coronary
vasoconstriction to ET-1, com¬
pared to the thromboxane A2
analogue U46619.
F. C. Wilkins (University of
Mississippi, Jackson) described a
conscious dog model for the in¬
creased circulating endothelin
concentrations found in some dis¬
eases. ET-1 infusion at 2.5ngkg_1
min-1 for 7 days increased plasma
ET-1 by two- to threefold, increas¬
ing peripheral vascular resistance
and producing a sustained eleva¬
tion of blood pressure. This sug¬
gests that moderately elevated
circulating ET-1 concentrations can
affect vascular tone, either directly
or indirectly. Nevertheless, to attain
these same plasma levels with
endogenous production, concen¬
trations at the interface between
the endothelium and vascular
smooth muscle are likely to be
considerably higher, so the true
contribution of ET-1 to vasocon¬
striction in such diseases may be
underestimated by the model.
Inhibition of the action of ET-1 at
ETa receptors, using BQ123, was
reported to lower blood pressure
in conscious spontaneously
hypersensitive rats but not
Wistar-Kyoto rats (E. H. Ohlstein,
SmithKline Beecham, King of
Prussia). Clozel showed that
Ro462005 also failed to lower
blood pressure in normotensive
rats. These findings contrast with
a published report of adminis¬
tration of intravenous bolus
BQ123 to anaesthetized Sprague-
Dawley rats, in which blood
pressure was reduced7.
Endothelin has potent mito-
genic actions, and has been im¬
plicated in the pathogenesis of
atherosclerosis. Infusion of ET-1
increased the severity of myo-
intimal hyperplasia following
balloon angioplasty to the rat
common carotid artery 0- Trachten-
berg, Washington University,
St. Louis; S. A. Douglas, SmithKline
Beecham, King of Prussia), and
increased receptor binding of
[125I]ET-1 (M. R. Dashwood, Royal
Free Hospital, London) occurs in
sections of saphenous vein- grafts
with atheroma and neovascular¬
ization. This increased binding
may be growth factor mediated,
since epidermal, platelet-derived
and fibroblast growth factors
increase [125I]ET-1 binding to
cultured human vascular smooth
muscle cells (P. Bonin, Upjohn,
Kalamazoo). Atheromatous vein
grafts from hyperlipidaemic
rabbits failed to vasodilate to low
(physiological) concentrations of
ET-1 (H. G. Davies, Duke Uni¬
versity, Durham), possibly reflect¬
ing relative loss of endothelial ETB
receptors.
The inner medullary collecting
duct of the kidney produces sub¬
stantial amounts of ET-1, and con¬
tains a high density of endothelin
receptors. Exogenous ET-1
potently inhibits water reabsorp-
tion and Na+/K+-transporting
ATPase activity. Spontaneously
hypertensive rats (SHR) produce
less ET-1 from the inner medullary
collecting duct than Wistar-Kyoto
rats8; this possibly underlies a
tendency to salt and water reten¬
tion in the SHR. The idea that
locally generated ET-1 plays a
tonic physiological role in regu¬
lation of salt and water transport
in the terminal nephron is sup¬
ported by evidence that vaso¬
pressin produces a greater in¬
crease in cAMP when cultured
duct cells are pre-incubated with
specific ET-1 antisera, and by the
finding that renal medullary ET-1
increases during salt loading
(D. Kohan, University of Utah, Salt
Lake City). Interestingly, endo¬
thelin generation is increased by
both ciclosporin and FK506,
potent immunosuppressive agents
(Y. Takeda, Kanazawa University).
At clinically relevant doses, the
effect is smaller with FK506 than
228 TiPS-Junc 1993 [Vol. 141
ciclosporin, which may help to
explain why it is less nephrotoxic.
Many of these observations
now require confirmation in
studies using specific receptor
antagonists or endothelin con¬
verting enzyme inhibitors. Extra¬
polating results from animal
models to human diseases is still
problematic, and clinical studies
and human models are eagerly
awaited.
□ □ □
The past two years have seen
substantial advances in the field
of endothelin research. Although
endothelin receptors distinct from
ETa and ETB/ and the putative
converting enzymes, have not yet
been isolated and cloned, there
has been progress in the develop¬
ment of specific agonists and
antagonists at the known endo¬
thelin receptors. There is now
considerable evidence that endo-
thelins play a role in regulation of
cardiovascular and renal function,
and these are clear indications of
diseases in which they may be
implicated. Considering the ben¬
efits of angiotensin-coverting en¬
zyme inhibition in heart failure,
interruption of the actions of
endothelin may also be important
in diseases where it acts as a
contributory, rather than a caus¬
ative, factor. Given the known
inter-species differences, and the
recent identification of vascular
ETb receptors, it is difficult to
predict whether ETA-selective or
nonselective agents will have the
greater clinical utility. With the
development of orally active
endothelin receptor antagonists,
we are now within sight of clinical
studies to answer these questions.
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5-HTrlike receptors: six down and still
counting
The application of molecular
cloning techniques in the field of
pharmacology has uncovered a
diversity of neurotransmitter
receptors that may be exploited to
lead to targeted, selective drug
development. There is no better
example of this multiplicity than
5-HT receptors in general and
5-Enyiike receptors in particular,
and to date six 5-HT^like re¬
ceptors have been cloned:
5-HT1A, 5-HTlc, 5-HT1Da, 5-HT1Dp
(5-HT1B), 5-HT1f and 5-HT1F
(5-HT1Ep).
The genomic clone encoding the
5-HT1A receptor was the first
5-HT^like receptor clone to be
isolated in 1987 (Ref. 1), although
it was not fully characterized until
1988 (Ref. 2). The characterization
of a functional cDNA encoding
the 5-HTlc receptor followed
in the same year3. The higher
sequence homology shared be¬
tween the rat 5-HTlc and 5-HT2
receptors (69%) compared to that
between the 5-HT,c and 5-HT1A
receptors (29%) was reflected in
their similar pharmacological pro¬
files and second-messenger sys¬
tems (stimulation of phospho-
lipase C-mediated phospho-
inositide turnover) and this has
led to a suggestion that the 5-HTlc
receptor should be reclassified
into the 5-HT2 subclass.
Another member of the 5-HT]-
like class of 5-HT receptors, the
5-HTiB receptor, has, for some
years, been thought to be a
species homologue of the 5-HT1D
receptor and to be confined to the
rat and mouse4. This notion, how¬
ever, was questioned in the early
1990s when a seemingly confus¬
ing array of 5-HT1D-like receptor
clones from different species were
reported by several independent
laboratories5^7.
The picture became clearer
when two distinct genes encoding
two members of the 5-HT]D sub¬
family were cloned in the human,
and the receptors were named
5-H1 ioa and 5-HT|[2B (Refs- 8,9).
The proteins encoded by these
two genes exhibit 63% identity
with each other but retain a
similar pharmacology. In contrast,
the previously named rat 5-HT1B
receptor is 93% identical with the
human 5-HT1Dp receptor yet has a
distinctly different pharmacology.
In fact, the differences between
these receptors were shown to be
due to a single amino acid sub¬
stitution of Thr to Asn at position
355 in transmembrane domain
(TM) VII (Ref. 10). Although both
amino acids are uncharged polar
residues, the Asn allows (3-
adrenoceptor antagonists such as
pindolol and propranolol to bind
to the rat homologue with a
greater affinity than to the
5-HT1D(S receptor.
The existence of a further
5-HT,-like receptor was indicated
by the emerging story of the
5-HT1D receptor. The 5-HT1D
recognition site was first reported
by Heuring and Peroutka11 in
1987. This group described a
binding site in bovine brain
membranes that could be labelled
with low nanomolar concen¬
trations of [3H]5-HT in the pres¬
ence of 100 nM 8-OH-DPAT and
100nM mesulergine, blocking out
5-HT]a and 5-HTlc receptors,
respectively. Several other groups
subsequently confirmed these
findings but consistently reported
that displacement studies, under
(P) 199.3. llseviei Science Publisher, I td (UK) 0165 - 6147/93/S06 (X)
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Endothelin-I (ET-1) was originally isolated in 1988 as a
secretory product ofcultured porcine aortic endothelial cells
(Yanagisawa el al., 1988) and was shown to be a potent
vasoconstrictor and pressor peptide. This effect has subse¬
quently been confirmed in healthy human subjects (see
Haynes & Webb, 1993). The pressor response is often
preceded by a short phase of vasodilatation which may be
due to ET-stimulated release of vasodilator prostaglandins
and nitric oxide (sec Simonson & Dunn, 1991). Three
isopcptides have been identified (ET-1, ET-2 and ET-3) each
of which is encoded by a separate gene (Inoue et al., 1989).
The gene products (preproETs) are cleaved within the cell to
generate inactive 38-39 amino acid peptides (proETs) which
are subsequently cleaved to active isoforms by the action of
putative ET converting enzymes (ECEs). The isopeptides all
comprise 21 amino acids with two intra-chain disulphide
bonds, ET-2 and ET-3 differing from ET-1 by two and six
amino acids respectively. ET-1 and ET-2 are more potent
than ET-3 as vasoconstrictors.
ET-1 gene expression in vascular endothelium is increased
by exposure of cells to adrenaline, thrombin, angiotensin II,
transforming growth factor-/? (TGF-/?), interleukin-1, the
calcium ionophore A23I87, hypoxia and shear stress (see
Haynes & Webb, 1993). ET-1 production is inhibited by
endothelium-derivcd nitric oxide. Secretory granules con¬
taining ET have been identified in the central nervous system
but not in the vascular endothelium where the major
regulation of ET production may occur at the level of gene
expression. Immunorcactive ET is produced in a variety of
tissues including blood vessels, lungs, kidney and nervous
system. ET-1 is the major isoform found in vascular
endothelium while ET-3 may be the predominant form in
neural tissue. Vascular smooth muscle cells also produce ET-
Correspondcnce: Dr R. L. Kennedy, Department of Medicine.
The University of Edinburgh, Western General Hospital. Crewe
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I in vitro, although at a rate 100-fold less than endothelial
cells (Resink el al., 1990). Despite the lower level of
production, the relatively greater mass of vascular smooth
muscle cells in larger blood vessels suggests that smooth
muscle may contribute substantially to local ET-1 produc¬
tion.
Circulating concentrations of ET are typically between
0-25 and 20 ng/1, below the concentration generally asso¬
ciated with biological effects. It seems likely, therefore, that
ETs function predominantly as paracrine or autocrine agents
rather than as circulating hormones. The plasma half-life is
short and ETs are cleared from the circulation mainly by the
kidney. Two classes of ET receptor were originally identified
using molecular cloning techniques, the bovine ETA (Arai et
al., 1990) and rat ETB receptor (Sakurai et al., 1990). These
receptors have since been cloned from human tissues (see
Haynes & Webb, 1993). The ETA receptor (binding potency
ET-1 = ET-2 > ET-3) mediates vasoconstriction to ET-1.
The ETB receptor (binding potency ET-1 = ET-2 = ET-3),
which was originally thought only to mediate endothelium-
dependent vasodilatation, has recently also been shown to
cause vasoconstriction (Bigaud & Pelton, 1992), more
prominent in veins than in arteries (Moreland et al., 1992;
Sumner et al., 1992). There is relatively strong pharmacologi¬
cal evidence (Warner et al., 1989; Douglas & Hiley, 1990;
Harrison et al., 1992) in favour of an additional ETC receptor
(ET-3 > ET-1). Although conclusive evidence of its isolation
has not yet been provided, suggesting that it shares limited
homology with the known sub-types, a candidate receptor
has been reported from Xenopus mclanophorcs. ET recep¬
tors, like many other hormone receptors, have seven trans¬
membrane loops and their intracellular action is mediated
through signal-transducing G proteins. Interaction of ET-1
with its receptor on vascular smooth muscle results in
activation of phospholipase C with release of the second
messengers diacylglycerol and inositol trisphosphate (IP*)-
The former activates protein kinase C leading to the
phosphorylation of key intracellular proteins while the latter
increases free intracellular calcium.
There is intense research interest in the role of ETs in the
regulation of vascular tone and in the pathogenesis of
hypertension and vascular disease. ETs act as mitogens for a
variety of cell types including cancer cells (Shichiri et at.,
1991). Because of the widespread distribution of I T recep¬
tors, the production of ET in many cell types, and their
powerful actions at a cellular level, it is likely that ETs are a
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component of the complex network of locally acting regula¬
tory factors which exists in all organs. This review focuses on
the emerging role of ETs in regulating the endocrine system.
Endothelins and the anterior pituitary
The best documented endocrine actions of ETs, to date, arc
on the hypothalamic-pituitary axis. In the rat, ET and ET
receptors have been identified in the hypothalamus and
pituitary gland (Matsumoto et al., 1989; Samson et til.,
1991 a; Takahashi et al., 199la; Domae et al., 1992).
Dispersed rat pituitary cells release ET-3, an effect which is
markedly stimulated by insulin-like growth factor-l (IGF-I)
and inhibited by TGF-/1 (Matsumoto et al., 1990). The effect
of ET on prolactin release depends on concentration and
experimental design. At higher concentrations (in the nano¬
molar range) there is transient stimulation of prolactin
release (Stojilkovic et al., 1990; 1991; Samson et al., 1991b).
This effect is mediated through activation of phospholipase
C with consequent increased intracellular calcium. However,
the predominant, and most sustained, effect of ET is to
inhibit prolactin secretion (Samson et al., 1991b; Kanyicska
et al., 1991a, b; Domae et al., 1992). Although ET-3 is the
major isoform in the pituitary, ET-1 is more potent at
inhibiting prolactin release (Kanyicska et al., 1991 a, b) while,
at least in the rat, ET-2 may be the most potent isoform with
inhibition of prolactin release at 1 pM (Samson & Skala,
1992). Inhibition by staurosporine suggests that this action is
mediated by protein kinase C. The inhibitory action of ET is
not mediated via the dopamine receptor (Samson et al., 1990;
Samson & Skala, 1992) and is not sensitive to dihydropyri-
dinc calcium channel blockade (Samson et al., 1991b;
Samson & Skala, 1992). It is, however, abolished with
pertussis toxin and presumably, therefore, involves a G
protein (Burris et al., 1991).
ETs stimulate the release of LH, FSH, growth hormone
and TSH (Stojilkovic et al., 1990; Samson et al., 1991b;
Kanyicska et al., 1991a, b). These actions are inhibited by
dihydropyridine calcium channel blockers (Samson et al.,
1991b). The stimulation of pituitary hormone release
appears to be a local effect since it is not reproduced by cither
intracerebrovcntricular or peripheral venous injection of ET
(Samson et al., 1991b). However, Moretto et al. (1993) have
recently shown ET-3 to stimulate GnRH release from
arcuate nucleus-median eminence fragments and from a
GnRH-secreting neuronal cell line. ET-3 also stimulated
release of prostaglandin E2. The stimulation of GnRH
release was blocked by inhibitors of prostaglandin synthesis.
The above observations have all been made using rat
pituitary, and the actions of ET on human pituitary have not.
thus far, been investigated. There is potential for ET to act as
a modulator of growth and function both physiologically
and in pituitary tumours.
Effects of endothelins on sodium and water balance
These effects are complex. Immunoreaclive ET has been
identified in the paraventricular and supraoptic nuclei of the
hypothalamus and in the terminals of these neurones in the
posterior pituitary of the rat (Yoshizawa et al., 1990). The
endothelin containing secretory granules of these cello are
depleted when the animal is deprived of water In normal
human subjects, plasma ADH and ET-1 concentrations rise
in parallel during upright tilt (Kaufmann et al., 1991). This
response is lost in patients with diabetes insipidus. There is
evidence from studies in dogs that ET may be involved in
regulation of ADH release since infusion of ET increases
plasma ADH concentration (Nakamoto et al., 1989). Intra-
ccrcbroventricular injection of ET-1 stimulates release of
ADH (Matsumura et al., 1991), an effect which is antago¬
nized by the simultaneous administration of brain natriuretic
peptide (Makino et al., 1992).
In the kidney, ET-1 appears to have at least two separate
actions. The first is vasoconstriction, affecting both afferent
and efferent arterioles, and leading to reduced glomerular
filtration and, at high doses, sodium retention (Lopez-Farre
et al., 1989). The second is natriurcsis. The inner medullary
collecting duct (IMCD) of the kidney produces substantial
amounts of ET-1 (Kohan, 1991), and contains a high density
of endothelin receptors (Kohan et al., 1992). Exogenous ET-
1 blocks sodium reabsorption by inhibiting Na'-K1-
ATPase activity (Zeidcl et al., 1989), and water reabsorption
by inhibiting the effects of ADH on tubular osmotic
permeability (Oishi et al., 1991). More recently (Kohan &
Padilla, 1993), it has been shown that ET- release and ET-1
mRNA expression is reduced by exposure of cultured rat
IMCD, but not endothelial or vascular cells, to increased
osmolality. Urinary ET-1 excretion and inner medullary ET-
1 m RNA were also shown to be reduced by volume depletion
in vivo in rats. Taken together, these findings suggest that
locally generated ET-1 plays a tonic physiological role in
regulation of salt and water transport in the terminal
nephron, with changes in local generation influencing both
natriuresis and diuresis. Interestingly, spontaneously hyper¬
tensive rats have less IMCD production of ET-1 than
Wistar Kyoto rats (Hughes et al., 1992), and associated
sodium retention may contribute to hypertension in this
strain of rats.
The effects of ET-1 on other vasorcgulatory hormones are
less clear. In rat kidney cortical slices, isolated glomeruli, and
isolated juxtaglomerular cells, ET-1 inhibits basal and
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stimulated renin release by a calcium dependent mechanism
(Rakugi et al., I990; Moe et al., I99l). However, ET-I
directly stimulates angiotensin II generation in endothelial
cells and in the isolated rat mesenteric bed (Rakugi et al.,
1990; Kawaguchi et al., I99l). ET stimulates aldosterone
release from isolated bovine and rat adrenal (Cozza et al.,
1989; Rosolowski & Campbell, I990; Hinson et al., I99la).
In the intact animal, ET-l administration increases plasma
renin and aldosterone concentrations, probably because of
renal vasoconstriction (Nakamoto et al., 1989). ET-l is a
potent stimulus for atrial natriuretic peptide mRNA ac¬
cumulation and peptide release from cultured atrial myo¬
cytes (Fukuda et al., 1989) and circulating concentrations of
atrial natriuretic peptide are increased by ET-l infusion in
rats(Staschetal., 1989; Garciaetal., 1990). Atrial natriuretic
peptide reduces the basal and stimulated secretion of ET
from cultured endothelial cells, raising the possibility of a
feedback regulatory mechanism (Saijonmaa et al., 1990;
Kohmo et al., 1991). The vasoconstrictor action of ET-l is
antagonized by atrial natriuretic peptide (Suzuki et al.,
1991). Thus, ETs have a variety of effects on sodium
regulatory hormones but their precise effect, if any, in
regulation of sodium balance is not known.
Other actions of endothelins on the endocrine glands
Many of the observations reported here remain unconfirmed
and their exact significance is not at this stage certain.
The recent identification of ET-l immunoreactivity in
porcine thyroid cells is of interest and may be relevant in
goitrogenesis (Colin et al., 1992) although the actions of ET
on thyroid cell growth and function remain to be fully
evaluated. Recently, Tsushima et al. (1992) have shown that
ET enhances IGF-I stimulated DNA synthesis in rat FRTL-
5 thyroid cells. ET receptors harve been identified on human
erythrocytes (Jackson et al., 1992) and incubation of thyro-
cytes with ET inhibits thyroglobulin release by a cyclic
nucleotide-independent mechanism. The binding of ET to
human thyrocytes is increased by exposure of cells to TGF-/J
(Tseng et al., 1993). Human thyrocytes also release ET and
this release may be modulated by TGF-/) and by TSH (Tseng
et al., 1993). It has long been known that endothelial
proliferation and capillary enlargement are early features in
goitre development (Wollman et al., 1978; Ericson & Woll-
man, 1980; Many et al., 1984). Vascular endothelium is also a
source of interleukin-l (Miyazaki et al., 1989) which is not
only a potent mitogen for thyroid cells but also increases ET-
1 release from vascular endothelium (Yoshizumi et al., 1990).
A further relevant recent observation is that patients with
hypo or hyper thyroidism have increased plasma concentra¬
tions of fibronectin and vonWillebrand factor, both ofwhich
are derived from endothelial cells (Arnaout el al., 1992).
A role for ET in maintenance of calcium balance has been
postulated. Rat parathyroid cells express mRNA for pre-
proET, secrete ET-l peptide and express ETA receptors
(Fujii et al., 1991). Cloned rat parathyroid cells release ET-l
in response to atrial and brain natriuretic peptides (De Feo et
al., 1991). This is the opposite effect to that of atrial
natriuretic peptide on endothelial cells. There are no docu¬
mented effects of ET on parathyroid hormone secretion. It is
tempting to speculate that ET could be involved in the
pathogenesis of the hypertension which accompanies hyper¬
parathyroidism. Bone cells, like other endocrine tissues, are
in close contact with extensive vascular networks and may,
therefore, be exposed to high concentrations of ET.
Recently, Alam et al. (1992) have shown that ET-l inhibits
osteoclastic bone resorption and cell motility of osteoclasts,
effects which are not mediated by changes in intracellular
calcium.
It is not known whether ET is secreted by, or has actions
on, the endocrine pancreas. Endothelial proliferation and
damage contributes to the micro and macro-vascular com¬
plications of diabetes. Plasma ET concentrations are
increased in patients with diabetes (Takahashi et al., 1990)
and in some animal models of diabetes (Takahashi et al.,
1991b). Impaired conversion of ET precursors to active
peptide has recently been described in patients with diabetes
(Tsunoda et al., 1991).
Endothelins may be involved in the regulation of repro¬
ductive function. Thus, immunoreactive ET has been identi¬
fied in the corpus luteum of superovulated rats (Usuki et al.,
1991) and in the medium of cultured porcine granulosa cells
(Iwai etal., 1991). Recently, ETA receptors were identified on
porcine granulosa cells (Kamada et al., 1992). Incubation of
these cells with ET stimulated accumulation ofwater soluble
inositol phosphates and increased intracellular calcium.
These authors also reported that ET enhanced progesterone
secretion. Previously ET has been shown to inhibit luteiniza-
tion of granulosa cells, inhibiting LH-induccd cAMP ac¬
cumulation, progesterone secretion and morphological
changes (Iwai et al., 1991). Ergul et al. (1993) have shown
that ET-l enhances steroidogenesis and proto-oncogene
expression in a cell line derived from transformed murine
Leydig cells although ET-l was not mitogenic for these cells.
ET-l is secreted by endometrial cells (Orlando et al., 1990)
increasing intracellular calcium and inducing myometrial
contraction (Word et al., 1990). Messenger RNA for all three
isotypes of ET and for ETA and ET„ receptors is present in
human endometrium (O'Reilly et al., 1992). ETA receptor
mRNA was the more abundant in the proliferative phase of
the cycle while ETB was predominant in the secretory and
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menstrual phases. High affinity ET receptors are present in
human myometrium and appear to be regulated by ovarian
steroids, being more abundant in premenopausal women
(Schiff et al., 1993). Human placenta expresses ET gene and
secretes ET-1 and ET-3 peptides (Benigni et al., 1991). ET
receptors have been identified on human trophoblastic cells
as well as on placental vascular smooth muscle (Mondon et
al., 1993). Placental production of ET is almost certainly
responsible for the increased plasma concentrations of ET
seen in pregnancy and may contribute to systemic and renal
haemodynamic changes. Plasma ET is particularly increased
in women with pre-eclampsia (Kamoi et al., 1990; Taylor et
al., 1990). Branch et al. (1991) showed that serum from
women with prc-eclampsia actually inhibited ET production
by endothelial cells although this observation was not
confirmed by others (Brown et al., 1991). The mechanism
which controls ET production in pregnancy requires further
investigation. ET is found at high concentrations in murine
seminal plasma (Casey et al., 1992), although its function is
unknown at present.
There are effects of ET on both the adrenal cortex and
medulla. Femtomolar concentrations of ACTH stimulate
ET release from isolated, perfused rat adrenal and ET
stimulates glucocorticoid secretion by dispersed rat adrenal
cells (Hinson et al., 1991b). ET-1 and ET-3 are also potent
stimulators of steroid secretion from human adrenal cortex
cells (Hinson el al., 1991c). Administration of ET increases
catecholamine secretion in intact animals (Goetz et al., 1988;
Miller et al., 1989). ET also potentiates the responses to
catecholamines (Wong-Dusting et al., 1990). Specific ET
receptors have been identified on PC 12 phaeochromocytoma
cells (Martin etal., 1990) and ET-1 stimulates catecholamine
release from medullary chromaffin cells (Boarder & Mar¬
riott, 1989). A rare form of secondary hypertension is that
associated with malignant haemangioendothelioma. These
vascular neoplasms secrete large amounts of ET-1 into the
circulation (Yokokawa et al., 1991).
Conclusions
ET peptide secretion and ET receptors are widespread in the
endocrine system. In most cases, the specific stimulus to ET
production and the effects of ET on the growth and function
of endocrine cells have not been fully characterized. We can
thus largely only speculate as to the physiological and
pathophysiological roles of these peptides in endocrinology.
Furthermore, most of the work on ET production and action
in endocrine tissues has been in rats and ET effects on human
endocrine tissues have not been investigated. However, these
peptides are likely to be produced in, and have actions on.
endocrine tissues in all species. Recent work has demon¬
strated that ETs and ET receptors are expressed in human
thyroid and reproductive tissues. The potent effects of ETs
on cellular second messenger systems makes further investi¬
gation of their endocrine effects mandatory. Like other
locally acting cytokines and growth factors their precise
actions and the relative importance of these actions will be
difficult to disentangle. The recent development of specific
ET receptor antagonists (see Haynes & Webb, 1993) will
allow further progress.
In the rat pituitary there is good evidence that ET inhibits
prolactin secretion while stimulating the secretion of other
anterior pituitary hormones. The interaction of ET with
hypothalamic releasing factors and the production or action
of ET on different cell types in the pituitary remain to be
investigated. Endothelins may be involved in salt and water
balance having actions on ADH release as well as on the
rcnin-angiotcnsin-aldosterone system. Many of the other
observations on ET in endocrine tissues are, as yet, uncon¬
firmed and further studies are required.
The effects of ET on growth of endocrine cells are of
interest since endocrine tissues are highly vascular and may
thus be exposed to high local concentrations of ET. This may
well be important in relation to goitre development. There is
now much evidence to suggest that ET is a potent growth
factor in many cell types. Its role in cell proliferation in
endocrine tumours needs to be explored.
Thus, while the effects of ETs on endocrine tissues remain
unclear in many cases, evidence is emerging to suggest they
may play an important part in a complex network of
autocrine and paracrine factors which modulate the actions
and production of the classical endocrine hormones.
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Endothelins come of age
The reports by Clozel and colleagues13 of a
pathophysiological role for endothelin, based on the first
studies with orally active endothelin antagonists, emphasise
the rapidity of progress in this area since the isolation of
endothelin-1 in 1988.4 Moreover, this work, in conjunction
with the results of other studies on the role of endothelin in
health and disease, indicates the exciting clinical potential
of endothelin antagonists.
The endothelins are a family of three peptides with
extremely potent and characteristically sustained
vasoconstrictor and vasopressor actions. They also have
mitogenic and neuroendocrine properties.5 Endothelin-1
predominates in the vascular endothelium, where it is
generated from proendothelin-1 through the action of a
unique neutral metalloprotease, "endothelin converting
enzyme". Two distinct endothelin receptors were cloned in
1990.'-7 The ETA receptor is preferentially activated by
endothelin-1 and is highly expressed in vascular smooth
muscle cells. It is the main receptor subtype causing
vasoconstriction. The ET„ receptor is activated equally by
all three endothelin isoforms and is present on the luminal
surface of endothelial cells, where it mediates release of
endothelium-dependent vasodilator substances, and on the
smoothmuscle of some tissues, where it causes constriction.
The presence of an ETC receptor subtype, preferentially
activated by endothelin-3, remains controversial.
Many studies have shown raised plasma concentrations
of immunoreactive endothelin in conditions associated with
systemic vasoconstriction, including chronic heart failure,
pulmonary hypertension, and vasospastic disorders such as
Raynaud's disease and Prinzmetal's angina.5 However,
endothelin-1 acts in a paracrine fashion rather than as a
circulating hormone, because vascular endothelin-1 release
is mainly abluminal. Consequently, plasma concentrations
are a poor reflection of local production. Increased tissue
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concentrations of, or binding sites for, endothelin may be
more useful; both are found in renal disease and myocardial
infarction, providing stronger evidence of a local role for
endothelin. Persuasive evidence likewise exists for the
sustained vasospasm following subarachnoid haemorrhage.
Here, plasma immunoreactive endothelin concentrations
are highest in patients with cerebral vasospasm, and
cerebrospinal fluid endothelin concentrations are raised
only in this subgroup. However, to confirm that production
of endothelin-1 fulfils a function in health and contributes
to pathophysiology studies with specific inhibitors of its
generation or action were needed.
The first such studies, in rats, showed that the endothelin
converting enzyme inhibitor, phosphoramidon, lowered
blood pressure,8 indicating that endothelin may contribute
to cardiovascular homoeostasis. However, these results had
to be confirmed with specific receptor blockers, because
phosphoramidon is also a weak inhibitor of the neutral
endopeptidase that degrades atrial natriuretic peptide.
Endothelin antibodies have been used in several
experimental preparations in the rat, where they ameliorate
the acute renal failure after arterial occlusion and prevent
the renal dysfunction associated with cyclosporin. In
addition, they limit the extent of myocardial infarction,
even when they are given before coronary artery occlusion.
More recent studies with the ETA-specific antagonist,
BQ123, and the combined ETA and ETB antagonists,
Ro 46-2005 and Ro 47-0203, broadly confirm these
findings. In a rat model of chronic renal failure with
reduced renal mass, dependent more on abnormal growth
and fibrosis than on vasoconstriction, BQ123 prevents renal
dysfunction and structural changes.9 In a rat model of
subarachnoid haemorrhage, in which autologous blood
is given into the cistema magna, pretreatment with
Ro 46-2005 profoundly reduces cerebral vasospasm.1 In a
similar model in the rabbit, Ro 47-0203 reverses established
vasospasm2 without affecting blood pressure. Studies with
antagonists also support a role for endothelin-1 in the
maintenance of hypertension in spontaneously
hypertensive and deoxycorticosterone-salt treated rats,3,10
and for regulation ofblood pressure in conditions ofsodium
depletion.1
Thus, there is now considerable experimental and some
clinical evidence for involvement of endothelin in
cardiovascular and renal disease,5 where it represents a
novel target for therapeutic intervention. There are no
effective drug treatments for acute or chronic renal failure,
and there is still a substantial need for better treatment in
subarachnoid haemorrhage, myocardial infarction, and
congestive heart failure. Endothelin antagonists should be
explored in these conditions, and may also prove useful in
hypertension. Orally active inhibitors have now been
developed and these questions will shortly be put to the test
in clinical trials.
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Adverse reaction reporting and new
antipsychotics
Remoxipride, clozapine, and risperidone number among a
new generation of antipsychotics. The most cautious
conclusions from the clinical trial data are that these
compounds are as effective as the older antipsychotic agents
but with far fewer extrapyramidal side-effects.1 Clozapine
is probably better than the classic drugs but, because of the
risk of neutropenia and agranulocytosis, is restricted to
treatment-resistant or intolerant patients, with strict
haematological monitoring.2 These new agents also have
interesting modes of action that may point the way to a
better understanding of schizophrenia and more efficient
drug development in the future. Thus clozapine, for a
highly effective antipsychotic, has peculiarly low
occupancy at D-, receptors in vivo,3 whereas remoxipride
has high selectivity for the mesolimbic-specific D2b
receptor.4
The Committee on Safety of Medicines (CSM) in the
UK lately issued a warning of 8 reports of aplastic anaemia
among 50 000 patients world wide associated with
remoxipride and 4 cases ofmyocarditis in 5000 UK patients
exposed to clozapine.5 The CSM rightly urges caution—
but what do we know about the still widely used classic
antipsychotics, especially in view of their less favourable
side-effect profile?
Notwithstanding the basic difficulties that classic drugs
are only partly effective and liable to cause several
neurological, endocrine, and autonomic side-effects,
phenothiazines and similar drugs are additionally
associated with arrhythmias, hepatic abnormalities,
agranulocytosis, thrombocytopenia, convulsions,
neuroleptic malignant syndrome, myocarditis, severe
tardive dyskinesia, and sudden death.6 The frequency of
agranulocytosis with phenothiazines is 1/1300,7 which is
probably an underestimate since adverse events with
standard agents are likely to be under-reported. Thus both
myocarditis and life-threatening blood dyscrasias are
associated with the older compounds. So, is the burden of
risk with remoxipride and clozapine any greater than for
phenothiazines? With respect to myocarditis, clozapine use
is restricted to treatment-resistant schizophrenia; such
patients will almost certainly have had long exposure to
phenothiazines which are themselves a potential cause of
the cardiac lesions. Moreover,myocarditis is a very difficult
condition to define, and is an incidental finding in 10% of
routine necropsies.8 Although inflammatory changes were
reported in the clozapine cases (CSM, personal
communication) it is not clear if these abnormalities were
associated with the myocyte degeneration or necrosis
required in the Dallas classification ofmyocarditis.'
Second, much is made of the risk-benefit analysis of the
new drugs. At worst they are equieffective and better
tolerated then classic neuroleptics. Without proper
quantifiable comparisons with other drugs it is difficult to
compare the risk profile, but careful elimination of high-
risk patients and regular monitoring, to which
schizophrenic patients are entitled, will lessen the risk.
Resorting to central monitoring, as some suggest, takes the
important burden of clinical responsibility away from
psychiatrists and runs the risk of pricing the new drugs off
the market altogether.
Schizophrenia is a common and devastating illness. I
believe the new generation of antipsychotics represents an
improvement, and pharmacological research into their
mechanisms of action is likely to yield even better agents.
The call for closer medical monitoring of these drugs is a
welcome step in bringing about overall better care for
schizophrenics, but just because the new drugs are being
made to walk the plank by the drug regulatory agencies we
cannot presume that older and potentially dangerous agents
are "safe".
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Endothelin Antagonism in Heart Failure
David J. Webb, MD, FRCP, FRCPE, FFPM
Endothelin-1, generated by vascular endothelium,causes sustained vasoconstriction, mainlythrough an action on the ETA receptor subtype;
in some tissues, vascular ETB receptors contribute. As
well as affecting tone in resistance and capacitance
vessels, endothelin augments the activity of the renin-
angiotensin and sympathetic nervous systems, stimulates
ontogenesis, and can cause renal vasoconstriction and
sodium retention. Since these are features of heart
failure, the endothelin system is an attractive target for
therapeutic intervention. Plasma endothelin concentra¬
tions in heart failure are two to four times normal and
correlates with symptomatic and hemodynamic indexes
of severity. A crucial question is whether endothelin
contributes to the pathophysiology of heart failure or
simply acts as a marker of its severity.
Kiowski et al1 now report evidence that endotheiin-1
contributes to vasoconstriction in severe chronic heart
failure. Twenty-four patients with New York Heart
Association class HI chronic heart failure and ejection
fractions ^30% received either the combined ETA and
ETb receptor antagonist bosentan (100 mg, then 200 mg,
each over a period of 15 minutes and separated by 1
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hour) or vehicle, both given intravenously, randomly,
and double-blind. Angiotensin-converting enzyme inhib¬
itors were discontinued for four half-lives before each
study. Baseline endothelin-1 and big endothelin-1 con¬
centrations were increased and correlated directly with
the extent of pulmonary hypertension, with right and left
heart filling pressures, and with pulmonary vascular resis¬
tance as well as inversely with cardiac output. Compared
with placebo, bosentan reduced mean arterial pressures by
8%, pulmonary artery pressures by 14%, and pulmonary
artery wedge pressures by 9%: cardiac index was increased
by 14%. and systemic and pulmonary vascular resistances
were reduced bv 17% and 33%, respectively. Interestingly,
heart rate did not change, and plasma concentrations of
angiotensin II and norepinephrine were unaltered.
That endothelin-1 contributes to basal vascular tone
and blood pressure was already known, but Kiowski's
group provided the first evidence that this mechanism
operates in patients with heart failure. Since there was
no control group without heart failure, their study does
not tell us the extent to which bosentan acted against
pathophysiologically raised tone, nor do we know yet
whether the benefits add to those of angiotensin-con¬
verting enzyme inhibitors or are sustained. Finally, we
did not learn from this study whether the increased
vasoconstrictor tone is mediated primarily by ETA or
ETb receptors.
Reference
1. Kiowski W, Sutch G, Hunziker P, Kim J. Oechslin E. Schmitt R,
Jones R. Bertel O. Evidence for endothelin-L-mediated vasocon¬
striction in severe chronic heart failure. Lancet. 1995;340:732-736.
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Summary The endothelin family of peptides are extremely potent endogenous vasocon¬
strictor and pressor agents. Of the 3 isoforms, endothelin-1 is the major isoform
produced by the vascular endothelium and is, therefore, likely to be of most
importance for regulation of vascular function. Two endothelin receptor subtypes
have so far been cloned in mammalian species; ETa and ETb. Both receptor
subtypes are found on smooth muscle cells and mediate the vasoconstrictor and
pressor actions of endothelin. The ETb receptor is also found on vascular endo¬
thelial cells and mediates endothelin-dependent vasodilatation through release of
nitric oxide and prostacyclin.
Since their discovery in 1988, the endothelins have been the subject of intense
research on their physiological function and potential pathophysiological role in
cardiovascular disease. There is now good evidence that endothelin regulates
vascular tone and blood pressure, and studies to support the development of
endothelin receptor antagonists in conditions associated with chronic vasocon¬
striction, such as hypertension and heart failure, as well as in vasospastic disor¬
ders, such as subarachnoid haemorrhage and Raynaud's disease.
There are now a number of selective ETa and combined ETa/b receptor an¬
tagonists available for preclinical studies. However, it is still not clear which of
these will prove to be of most therapeutic value. Some of these agents are cur-
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rently being assessed in early phase clinical trials. Endothelin receptor antagonists
represent a novel therapeutic approach to a fundamental and newly discovered
endogenous vasoconstrictor mechanism. The results of the current clinical trials
are awaited with considerable interest.
The endothelins (ETs), first discovered by
Yanagisawa and colleagues in 1988,1111 comprise a
family of 3 related peptides (ET-1, ET-2 and ET-3),
each of 21 amino acids, with 2 intrachain disulph-
ide bridges linking paired cysteine residues (fig. 1 ).'3'
Since 1988, researchers have focused on the poten¬
tial pathophysiological role of these peptides in a
number of cardiovascular diseases.
ET-1 is the most potent mammalian vasocon¬
strictor peptide known,'1 31 with veins being 3 to 10
times more sensitive to the effects of ET-1 than
arteries, both in virro'4' and in vivo.'51 ET-1 is also
the major isoform produced by endothelial cells'6'
and is probably the most important isoform in the
cardiovascular system.
Human ET-1 is generated as preproET-1 (fig. 1),
a 212 amino acid peptide that is enzymatically
cleaved in 2 stages to form a 38 amino acid precur¬
sor, big ET-l.'2' Big ET-1 is further processed to
form the active peptide by the action of endothelin
converting enzyme (ECE).'1-7'
ECE-1 is a unique membrane-bound metallo-
protease that has recently been recognised. It
cleaves both intra- and extracellular big ET-1 to
ET-1 at neutral pH, and is structurally related to
neutral endopeptidase 24. II.'8' It may provide a
useful target for pharmacological intervention.
However, this ECE is relatively selective for big
ET-1 and pharmacological studies indicate that
there are several other ECEs with different charac¬
teristics.
An additional ECE, ECE-2, has also been iden¬
tified.'9' ECE-2 has an acidic pH optimum, and
probably acts as an intracellular enzyme cleaving
endogenously synthesised big ET-1 to ET-1 at the
trans-Golgi network, where the vesicular fluid is
acidified.
Circulating levels of ET-1 are low'10' and ap¬
proximately 80% of ET-1 synthesised by endothe¬
lial cells is secreted abluminally,"112' suggesting
that ET-1 has primarily paracrine and autocrine ac¬
tions. A neurohumoral role for the endothelins has
also been proposed.'13'
On the basis of molecular studies, 2 endothelin
receptors have so far been characterised in mam¬
malian species.'1415' The ETa receptor is relatively
selective for ET-1,'l4' whereas the ETb receptor has
equal affinity for all 3 ET isoforms.'15' Results
from early studies"617' suggested that the ETA re¬
ceptor is restricted to vascular smooth muscle and
mediates vasoconstriction, whereas the ETb recep¬
tor is restricted to the endothelium and mediates
vasodilatation through the production of endothe-
lium-dependent vasodilators, such as nitric oxide
and prostacyclin.'2-3' However, it is now recog¬
nised that this concept is an oversimplification be¬
cause ETb receptors are also expressed on vascular
smooth muscle cells'18' and contraction of human
smooth muscle can be generated through either
ETa or ETb receptor stimulation.'19-20' However, in
a wide range of human vessels in vitro, ET-1-
mediated vasoconstriction occurs predominantly
via the ETA receptor'21' and the importance of the
smooth muscle ETB receptor in humans remains to
be clarified.
A putative ETc receptor, selective for ET-3, has
been cloned from a toad melanophore cDNA li¬
brary,'22' but has not yet been identified within the
mammalian genome.
Following brief vasodilator and vasodepressor
actions mediated by endothelial ETB receptors,'1'
ET-1 causes sustained vasoconstrictor'23' and pres¬
sor effects'24' in humans. Endogenous generation
of ET-1 has also been shown to contribute to the
maintenance of basal vascular tone and blood pres-
sure.'25"27'
There are many ET receptor antagonists either
in, or shortly to be entering, clinical develop¬
ment (table I). Some are peptidic in nature and
only likely to be suitable for short term use,
whereas others are orally active and may, therefore,
have wider applications in the treatment of cardio-
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Fig-1 . Endothelin synthesis and pathways. Each endothelin iso-
form is a product of a separate gene that codes for a large
precursor protein mRNA. The human endothelin-1 gene is on
chromosome 6 and codes for a 212 amino acid precursor pro¬
tein known as preproendothelin-1. Synthesis of this protein is
stimulated by hypoxia, shear stress and circulating hormones
such as angiotensin II, insulin and bradykinin, as well as by
growth factors and cytokines. Preproendothelin-1 is processed
by dibasic pair specific endopeptidases to form a 38 amino acid
protein referred to as big endothelin-1, which is further cleaved
by an endothelin converting enzyme (ECE) to the mature pep¬
tide, endothelin-1. Endothelin-1 acts on both endothelin A and
B receptor subtypes located on vascular smooth muscle cells.
These receptors mediate the vasoconstrictor, pressor and mi-
togenic effects of endothelin-1. The endothelin B receptor is also
found on vascular endothelial cells and mediates the vasodilator
actions of endothelin-1 (see Haynes & Webb121 for further de¬
tails).
vascular disease. Some are ETA-selective, whereas
others are combined ETA/ETB antagonists. As vas¬
cular smooth muscle ETA and ETB receptors can
both mediate vasoconstriction in humans,'19-201
there may be some advantages from blocking both
of these receptors. However, there may be some
benefits from leaving the endothelial ETB receptor
unaffected, as it is known to mediate vasodilata¬
tion. Indeed, there is some evidence that the endo¬
thelial and smooth muscle ETB receptors can be
distinguished pharmacologically,'28' so it may be
possible to develop agents with appropriate selec¬
tivity.
A pathophysiological role for the endothelins
has been postulated in a wide number of dis¬
eases.'2-29' This article examines specifically the
evidence implicating ET-1 in the pathophysiology
of cardiovascular disease and discusses the poten¬
tial ofendothelin receptor antagonists in cardiovas¬
cular medicine. For a more detailed review of the
role of the endothelins in cardiovascular disease
the reader is referred elsewhere.'30'
1. Hypertension
In their original paper, Yanagisawa et al.'1'
suggested that disturbances in the control of endo¬
thelin production could contribute to the pathogen¬
esis of hypertension. In addition to its vasocon¬
strictor and pressor effects, ET-1 has positively
inotropic'31' and mitogenic'32' properties and an
antinatriuretic action.'33' ET-1 also increases cen¬
tral'34-35' and peripheral sympathetic activity,'36-37'
and stimulates the generation of renin, angiotensin
II,'38' aldosterone'39' and adrenaline (epineph¬
rine).'40'
Furthermore, at threshold and subthreshold lev¬
els, ET-1 potentiates contractile responses to other
vasoconstrictor substances such as noradrenaline
(norepinephrine) and serotonin (5-hydroxytrypt-
amine; 5-HT).'41' It would, therefore, appear to be
entirely appropriate to examine the potential for
ET-1 to be involved in the pathophysiology of hy¬
pertension.
Knockout gene experiments are unrevealing in
this regard. ET-1,'42' ET-3,'43' ETA[44] and
ETb[43 ] knockouts all cause severe developmental
disturbances. This observation shows the impor¬
tance of the endothelins in growth and develop-
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Table I. Endothelin receptor antagonists
Selectivity Compound Company Comments
ETa BQ-123 Banyu Cyclic pentapeptide
BQ-153 Banyu Linear tripeptide
BQ-485 Banyu Linear tripeptide
FR-139317 Fujisawa Pseudo-tripeptide
TTA-386 Takeda Synthetic hexapeptide
PD-151242 Parke-Davis Pseudo-tripeptide
50-235 Shionogi Caffeoyl ester
97-139 Shionogi Modification of 50-235
BMS-182874 Bristol-Myers Squibb Benzenesulphonamide3
ETb BQ-788 Banyu Tripeptide
RES-701-1 Kyowa Flakko Kogyo Co. 16-amino-acid cyclic peptide endothelial ETb selective
ETa and ETb PD-142893 Parke-Davis Linear hexapeptide
PD-145065 Parke-Davis Linear hexapeptide
TAK-044 Takeda Cyclic hexapeptide
RO-462005 Floffman-La Roche Sulphonamide"
Bosentan (RO-470203) Sulphonamide3
CGS-27830 Ciba-Geigy Irreversible binding, unstable
SB-209670 SmithKline Beecham Carboxylic acid derivative3
a Orally active.
ment, but is not helpful in clarifying their physio¬
logical effects in cardiovascular regulation.
Plasma endothelin levels are not increased in
animal models of hypertension unless malignant
hypertension or renal dysfunction are present.1451
However, because ET-1 is preferentially secreted
abluminally,1"121 locally increased production
may not necessarily result in increased plasma en¬
dothelin levels. Indeed, increased immunoreactive
endothelin levels have been reported in both aortic
and mesenteric arteries of DOCA-salt hyperten¬
sive rats, despite normal plasma endothelin levels,
suggesting that increased vascular generation of
ET-1 may be involved in some forms of hyperten¬
sion.1461 Elevation of plasma levels of big ET-1 and
the C-terminal fragment of big ET-1 may be useful
in showing that ET-1 production is increased.1471
In vitro studies using resistance arteries taken
from animal models of hypertension have shown
either increased1481 or decreased1491 vascular sensi¬
tivity to ET-1. Systemic doses of ET-1 in vivo have
greater pressor effects in spontaneously hyperten¬
sive rats (SHR) than in Wistar-Kyoto rats'501 and in
renovascular hypertensive rabbits than in normo-
tensive ones.15'1 The interpretation of these results
is difficult given the propensity for vascular hyper¬
trophy to nonspecifically enhance responses to
vasoconstrictors.
Endothelin-specific antibodies1521 and the selec¬
tive ETa antagonists BQ-1231531 and FR1393171541
have been shown to lower blood pressure in animal
models of hypertension. Long term administration
of BQ-123 has been reported to prevent the devel¬
opment of stroke and renal abnormalities in stroke-
prone SHR.1551 Non-peptide combined ETa/ETb
receptor antagonists, SB-2096701561 and RO-
4620051571, lower blood pressure in SHR and con¬
scious, normotensive, salt-depleted monkeys, re¬
spectively.
Although some studies152 551 have reported a re¬
duction of blood pressure only in hypertensive
animals, it must be remembered that the absolute
effects of antihypertensive agents are proportion¬
ately greater the higher the pretreatment blood
pressure. Few studies have been of sufficient
power to justify the interpretation that endothelin
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receptor antagonists lower blood pressure only in
hypertensive animals.
Plasma endothelin levels are not increased in
patients with essential hypertension and normal re¬
nal function,158 591 although very high levels are
found in severe and malignant hypertension,1601
probably as a result of impaired renal clearance.
Increased plasma endothelin levels have been re¬
ported in the presence of normal renal function in
patients with pre-eclampsia.16'1 Plasma endothelin
levels were also increased in 2 patients who devel¬
oped hypertension with the skin tumour haem-
angioendothelioma.1621 Tumour cells showed in¬
creased expression of ET-1 mRNA and increased
staining for the peptide. Blood pressure returned to
normal in both cases after tumour resection, and
recurrence of the tumour in one of the patients was
associated with a further rise in blood pressure and
plasma endothelin levels.
Sensitivity to ET-1 in vitro appears to be de¬
creased in resistance arteries taken from hyperten¬
sive patients,1631 but increased in the capacitance
vessels of hypertensive patients in v/vo.159' These
latter vessels do not develop hypertrophy. Thus, it
is possible that increased sensitivity to, and not
necessarily increased production of, ET-1 may be
involved in the pathophysiology of hypertension,
indicating an abnormality at the receptor or
postreceptor level.
The selective ETA receptor antagonist BQ-123
has been shown to produce arterial vasodilatation
in both healthy volunteers1251 and hypertensive pa¬
tients.1641 Also, TAK-044, a combined ETa/ETb re¬
ceptor antagonist, has recently been reported to
lower blood pressure in healthy men.1271
Hypertension is associated with the develop¬
ment of several cardiovascular diseases, including
angina pectoris, myocardial infarction, peripheral
vascular disease and cerebrovascular disease. It is
possible that the vasoconstrictive properties of ET-
1 could contribute to myocardial ischaemia and
that the proliferative effects of ET-1 could contrib¬
ute to vascular and cardiac hypertrophy and the
atherosclerotic process. Indeed, plasma endothelin
levels are increased in advanced atherosclerosis,1651
and expression of ET-1 mRNA is increased in the
vascular smooth muscle of atherosclerotic human
arteries.1661 Furthermore, increased tissue endo¬
thelin immunoreactivity has been reported in the
active atherosclerotic lesions associated with un¬
stable angina.1671
With the multitude of drugs already available to
treat hypertension, a new class of antihypertensive
agents may seem unnecessary. However, endo¬
thelin receptor antagonists may prove more effec¬
tive than current therapies in preventing or revers¬
ing some of the important complications that are
little affected by current therapy, such as myocar¬
dial infarction.1681
2. Unstable Angina and
Myocardial Infarction
The sarafotoxins, potent vasoconstrictor pep¬
tides isolated from snake venom with close struc¬
tural similarity to the endothelins, cause death from
myocardial ischaemia and infarction secondary to
coronary vasoconstriction.1691 Exogenously ad¬
ministered ET-1 also produces myocardial isch¬
aemia1701 by causing coronary vasoconstriction.
Plasma endothelin levels17'1 and myocardial ET-1
binding sites1721 are increased during reperfusion
following ischaemia in animals. Interestingly, in
animal models of myocardial infarction, ECE in¬
hibitors,1731 monoclonal antibodies against ET-
1,174' selective ETA antagonists1751 and combined
ETa/ETb antagonists1761 have been reported to re¬
duce myocardial infarct size.
In humans, plasma endothelin levels are in¬
creased in acute myocardial infarction and unstable
angina,1771 suggesting a possible pathophysiologi¬
cal role for ET-1. Patients with stable angina do not
have increased plasma endothelin levels.1781 The
higher the plasma endothelin level in myocardial
infarction1791 and unstable angina1801 the worse the
prognosis. Plasma endothelin levels on the third
day after myocardial infarction are significantly re¬
lated to mortality,1791 and plasma endothelin levels
at 9 weeks after hospitalisation with unstable an¬
gina or non-Q-wave myocardial infarction are sig¬
nificantly related to the incidence of further cardio-
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vascular events.'801 Patients undergoing fibrinoly¬
sis during the acute phases of myocardial infarc¬
tion have been shown to have reduced plasma en¬
dothelin levels compared with patients who did not
have early reperfusion.'811 As discussed previously,
the increased tissue endothelin immunoreactivity
in active atherosclerotic plaques causing unstable
angina'67' suggests a possible local role for ET-1 in
the associated vasospasm.
The use of endothelin receptor antagonists in
acute myocardial infarction may be of clinical ben¬
efit. First, they may limit infarct size and thereby
reduce or slow the progression to heart failure. Sec¬
ondly, they may reduce the incidence of further
ischaemic events or the need for revascularisation.
Thirdly, they may prevent remodelling after infarc¬
tion, possibly in a fashion similar to ACE inhibi¬
tors. However, given the wide range of drugs cur¬
rently available for the treatment of myocardial
infarction, and the probability of diminishing re¬
turns with additional therapy, companies may be
wary of developing endothelin receptor antago¬
nists in this indication.
Coronary sinus ET-1 levels are increased during
and immediately after percutaneous transluminal
coronary angiography (PTCA).'82' Although FT-1
could be involved in the ischaemia, acute vaso¬
spasm and abrupt vessel closure related to PTCA,
these complications are uncommon and readily re¬
versible with conventional therapy. The main
weakness of PTCA is the relatively high risk of
restenosis at a later stage. Clinical restenosis oc¬
curs in up to 30% of patients within the first year
following the procedure'83' and is characteris¬
tically associated with vascular smooth muscle
proliferation. Although there is currently no exper¬
imental evidence that endothelin antagonists re¬
duce experimental restenosis, it is conceivable,
given the co-mitogenic actions of ET-1, that pro¬
longed treatment with an oral endothelin antago¬
nist might be useful. Similar arguments are rele¬
vant to graft occlusion after coronary artery bypass
grafting.
3. Variant Angina
Prinzmetal's or variant angina, first described in
1959,'84' is characterised by chest pain developing
at rest, frequently in the early morning, and asso¬
ciated with ST elevation on the electrocardiogram.
The pain is usually relieved by nitroglycerin (gly¬
ceryl trinitrate). Coronary spasm has been demon¬
strated at angiography in patients with this condi¬
tion, as well as the absence of fixed stenotic
lesions.'85'
Patients with variant angina are known to have
endothelial dysfunction affecting the L-arginine-
nitric oxide system'86' and, as a powerful vaso¬
constrictor of human'41' and canine'70' coronary
arteries, ET-1 has been implicated in the patho¬
physiology of this condition.'87' ET-1 also potenti¬
ates the coronary vasoconstriction induced by se
rotonin and noradrenaline in isolated human
arteries.'41' Patients with variant angina have in¬
creased plasma endothelin levels during provoca¬
tion of coronary vasospasm'88' and one study has
also found basal plasma levels of endothelin to be
increased.'89' Interestingly, there is an increased
prevalence of primary Raynaud's disease and mi¬
graine in patients with variant angina'90'9'' and, as
discussed later, ET-1 has also been implicated in
the pathophysiology of these vasospastic disor
ders.
It appears, therefore, that ET-1 has a pathophys¬
iological role in variant angina, either as a mediator
of coronary vasospasm or by sensitising the vas¬
culature to other vasoconstrictors. In either case,
endothelin receptor antagonists might prove useful
in the management of this condition.
4. Heart Failure
The many definitions of congestive heart failure
(CHF) highlight only selected features of this com¬
plex syndrome.I92' Patients with CHF have objec¬
tive evidence of major cardiac dysfunction at rest,
develop ankle swelling and are typically breathless
or fatigued either at rest or during exertion.'92'
Neuroendocrine activation occurs in patients with
CHF'92'91' and elevation of plasma levels of nor-
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physiological role for endothelin in this condition.
However, considerably more experimental evi¬
dence from animal models is required before clin¬
ical trials with endothelin antagonists are likely to
be embarked on in this indication.
9. Migraine
Migraine headache is a very common condition
characterised by a persistent unilateral headache of
moderate to severe intensity frequently accompa¬
nied by nausea, vomiting and photophobia and
sometimes associated with an aura.1149' The preva¬
lence of migraine ranges widely, depending on the
diagnostic criteria used. However, using the Inter¬
national Headache Society Classification,'149' the
1-year-period prevalence ofmigraine is =10%.|l50'
Serotonin appears to play an important role in the
pathophysiology ofmigraine'15" and serotonin re¬
ceptor agonists have proved of major therapeutic
value in its treatment.'152"154'
Studies have shown local cerebral hypoperfu¬
sion during migraine attacks, especially those as¬
sociated with an aura.'155"157' This hypoperfusion
can last for several hours after the onset of the pain
and can be followed by hyperperfusion. The vaso¬
constriction associated with the first phase of a mi¬
graine attack could be attributed, at least in part, to
the release of vasoactive substances, such as the
endothelins. Indeed, plasma endothelin levels have
been found to be increased during migraine head¬
aches.'158'159' Levels of endothelin have not been
found to be higher between attacks, or in patients
with episodic or chronic tension headaches,'1591
suggesting that the rise in endothelin is specific to
migraine and not merely a response to headache.
Therefore, it appears possible that endothelin has
a role in the pathophysiology of migraine either
directly or by mediating the effects of 5-HT. Alter¬
natively, endothelin may be produced as a result of
brain ischaemia"48' or changes in vascular shear
stress'160' and hence be a secondary phenomenon.
It has been proposed that dural blood vessels
play a central role in headache pathogenesis.'16"
Indeed, both the ergot alkaloids'162' and sumatrip¬
tan'16" block peripheral small-fibre-dependent
neurogenic inflammation within the dura mater in
a rat model. It also appears that endothelin receptor
antagonists may block neurogenic inflammation,
providing additional support for the view that these
agents may be useful in the treatment of migraine
headaches.
10. Acute Ischaemic Renal Failure
Acute renal failure (ARF) secondary to renal
ischaemia is characterised by intense renal vaso¬
constriction and severe depression of renal func¬
tion that may necessitate haemodialysis.'164 165'
The renal vasculature is very sensitive to the ac¬
tions of endothelin. When infused at doses that
have minimal vasoconstrictive effects, ET-1 inhib¬
its sodium reabsorption by its actions on the ETA
receptor in the rat,'1661 and by its actions on the ETb
receptor in the dog.'167' A possible autocrine role
for endothelin in the regulation of body volume
status and water reabsorption has been pro¬
posed.' 1681 At higher doses, exogenous ET-1 causes
potent and long-lasting vasoconstriction similar to
that seen in ARF,'169170' together with a reduction
in renal blood flow, GFR and urine produc¬
tion.'171172' In the rat, the renal vasoconstriction to
ET-1 is mediated by the ETb receptor,'173' whereas
in the dog, renal vasoconstriction appears to be me¬
diated by the ETA receptor.'167'
As a consequence of the interspecies variations
in renal endothelin receptor function, caution
should be applied when extrapolating the results
from animal experiments to humans. The human
kidney, as in the dog, is rich in ETb receptors.
There are at least twice as many ETB receptors as
there are ETA receptors, which are limited mainly
to the vasculature.'174' On this basis, the dog may
be a better model of human ARF than the rat.
Renal ischaemia and reperfusion increase im-
munoreactive ET-1 binding affinity,'1751 ETA and
ETb receptor numbers on the renal vascula¬
ture,'176177' ET-1 mRNA expression"78' and
plasma and urine immunoreactive ET-1 in rats.'1701
In the rat, antiendothelin monoclonal antibodies
prevent renal vasoconstriction following isch-
aemia-induced ARF."70' This has been confirmed
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with the selective ETA antagonist BQ-123,'166,179-180'
and the combined ETa/ETb antagonists RO-
4620051571 and TAK-044."8" In the dog, BQ-123
has no effect on the reduction in GFR produced by
ischaemia."82-183' Although renal vasoconstriction
in the dog is mainly ETA receptor-mediated,11741
the combined ETa/ETb antagonist SB-209670
does attenuate this reduction in GFR.'183' This sug¬
gests that endothelin may be involved in the patho¬
physiology of ARF in the dog by actions other than
vasoconstriction, possibly through its actions on
the renal tubules, mediated by the ETB receptor.1183'
In humans, plasma immunoreactive ET-1 levels
are significantly increased in ARF."84' There is
currently no effective drug therapy for ARF11651
and, from the accumulating animal evidence, en¬
dothelin receptor antagonists show great potential
in this condition. From the work done on dog mod¬
els of ARF and the similarities in receptor distribu¬
tion between dog and human kidneys, combined
ETA/ETB receptor antagonists may be more useful
in the treatment of ARF than selective ETA or ET«
antagonists.
Endothelin has also been implicated in the acute
renal dysfunction and hypertension associated with
nephrotoxic agents such as cyclosporin1185186' and
x-ray contrast media.1187' With the increasing use
of cyclosporin in immunosuppressive drug re¬
gimens, endothelin receptor antagonists may have
an expanding potential role in the treatment of
cyclosporin nephrotoxicity.
11. Conclusions
Endothelin antagonists have proved extremely
useful in extending our understanding of cardio¬
vascular physiology and for providing new insights
into the pathophysiology of cardiovascular dis¬
ease. A broad body of experimental and clinical
evidence now exists to support the clinical devel¬
opment of drugs that block the production or ac¬
tions of endothelin for use in cardiovascular med¬
icine. There is particularly good evidence to
support their development in conditions associated
with chronic vasoconstriction, such as hyperten¬
sion and heart failure, as well as in vasospastic con¬
ditions, such as SAH and Raynaud's disease.
To date, most of the work has been with en¬
dothelin receptor antagonists. With the recent clon¬
ing of ECE-1, it is likely that selective ECE inhib¬
itors will soon be developed, and these may also
prove to have properties of benefit in the treatment
of cardiovascular disease. It is still not clear
whether combined ETA and ETb antagonists have
therapeutic advantages over selective ETA antag¬
onists, as both these receptors can contribute to
ET-l-induced vasoconstriction in humans. Theo¬
retically, the combination of an ETA receptor
antagonist with a smooth muscle-selective ETB re¬
ceptor antagonist would be most effective because
it would leave dilator ETb receptors unblocked.
However, antagonists with this selectivity are still
awaited.
Currently, combined ETA and ETB receptor an¬
tagonists appear to have the widest potential for
clinical application and several such agents are cur¬
rently being assessed in phase 1 trials. These drugs
represent a novel therapeutic approach to a funda¬
mental and newly discovered vasoconstrictor
mechanism and the results of the clinical trials are
awaited with considerable interest.
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ABSTRACT. Endothelin (ET)-l, an endothelium-derived peptide, is the most potent vasoconstrictor agent
described to date. ET-1 also has positive inotropic and chronotropic effects in the heart and is a co-mitogen in
both cardiac and vascular myocytes. The major elements of the system involved in formation of ET-1 and its
isopeptides, as well as the receptors mediating their effects, have been cloned and characterised. Antagonists
of the ET receptors are now available, and selective inhibitors of the ET-converting enzymes are being
developed. Early studies using receptor antagonists support the involvement of ET-1 in the pathophysiology
of several cardiovaacular dir——f The relative merits of ET-converting enzyme inhibitors' and receptor
antagonists for the treatment of cardiovascular disease are discussed. Copyright © Elsevier Science Inc.
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CONTRACTIONrelaxation
FIGURE 1. Endothelium-
derived factors that regulate vas¬
cular smooch muscle tone- ET-lt
formed in endothelial cells
through the action of ECE from
its precursor peptide prepro
ET-1, promotes both constric¬
tion and proliferation of the
underlying smooth muscle cells
through both ETA- and ETB-
type receptors. NO derived
from L-arginine and prostacyclin
(PGI2) derived from arachi-
donic acid (AA) cause relax¬
ation through cyclic GMP
(cGMP) and cyclic AMP
(cAMP), respectively, and also
inhibit the vasoconstrictor and
proliferative actions of ET-1.
ET-1 can initiate relaxation
through these pathways via stim¬
ulation of ETB-type receptors
located on the vascular endo¬
thelium. See text for details.
1. INTRODUCTION
Contrary to early impressions that the endothelial cell
monolayer lining blood vessels simply functioned as a diffu¬
sion barrier, it is now recognised that the endothelium has a
pivotal role in maintaining vascular homeostasis (Vane et
al., 1990). Over the past 20 years, there has been a rapid
development in our understanding of the central role that
locally acting endothelium-derived hormones play in the
physiology of blood vessel function. Furthermore, endothe¬
lial cell dysfunction is now recognised as being a crucial
factor underlying the pathophysiology of cardiovascular dis¬
ease (Ltischer, 1992). Important milestones that have con¬
tributed to our current understanding (Fig. 1) include the
discovery of prostacyclin (Moncada et al., 1976), the classi¬
cal experiments of Furchgott that revealed the role of the en-
ilotbel ium in mediating relaxation in response to acetylcho
line (Furchgott and Zawadski, 1980), the identification of
nitric oxide (NO) derived from L-arginine as an endothe
lium-derived relaxing factor in 1987 (Ignarro et al., 1987;
Palmer ef al
, 1987), and the recognition, in 1985, that en
dothelial cells in culture release a constrictor factor into the
bathing medium (Hickey et al., 1985; Gillespie et al., 1986).
In 1988, Yanagisawa et al. reported that this endothe
lium-derived factor, the most potent constrictor described
to date, was a 21 amino acid peptide, which they termed
endothelin (ET) (Yanagisawa et al., 1988b). Subsequent
studies have shown that the ET isolated from endothelial
cells is one of a family of isopeptides (Fig. 2), all of which
are formed through a two-step processing pathway (Fig. 3)
from their respective precursor peptides that share high se¬
quence homology, but are encoded by distinct genes. It is
also now clear that the ET isopeptides share remarkable
structural similarity to the sarafotoxins (SRTXs), peptides
isolated from the venom of the Israeli burrowing asp Atrac-
taspis engaddensis (Kloog et al., 1988). The ETs and the
SRTXs act through common receptors to evoke a multitude
of effects. Indeed, isoforms of SRTX have been utilised ex¬
tensively as tools for the characterisation of ET receptors
(Sokolovsky, 1994).
ET-1 is the major isopeptide produced by human endo¬
thelial cells and is present in greatest concentration in the
blood. When exogenous ET-1 is infused into the human
forearm, it causes profound and long lasting vasoconstric¬
tion, indicating its potential as an important regulator of
vascular tone in humans (Clarke el al., 1989a; Vierhapper
et al., 1990). Although endogenous ET-1 can be detected
in the human circulation, the concentrations are very low
(in the picomolar range). However, as ET-1 is released pre¬
dominantly in an abluminal direction towards the underly
ing smooth muscle (Wagner et al., 1992a), the tissue con¬
centration is likely to be sufficiently bigh to activate local
receptors. Recent studies carried out using inhibitors of ET
synthesis or receptor antagonists suggest that ET 1 is re
leased tonically to maintain basal systemic vascular resis
tance in humans (Haynes and Webb, 1994). In this way,
ET -1 might balance the dilator actions of NO, which is also
thought to be released in a tonic manner (Vallance et al.,
1989; Haynes et al., 1993). However, these two agents do
not function in an exactly parallel manner to control tone.
While synthesis of NO can be increased within minutes in
response to various stimuli, ET synthesis is regulated at the





FIGURE 2. Structures of the ET isopeptides and SRTX S6c.
The filled circles indicate the amino acids that differ from those
in ET-1.
transcriptional level with a resultant delay in release
(Yanagisawa et al., 1988a; Boulanger and Luscher, 1990).
The two agents also differ with respect to the duration of
their action. NO has a short half-life and its effects can be
terminated quickly by cessation of release. In contrast, the
evidence to date suggests that endothelial ET-1 binds to its
receptors on smooth muscle irreversibly and its constrictor
and pressor actions are of long duration (Hirata et al., 1988;
Yanagisawa et al., 1988b).
Intensive research carried out since the original descrip¬
tion of ET-1 has greatly improved our understanding of the
ET 'system,' from the genes that encode for ET-1 and its
isopeptides, to the enzymes involved in its synthesis and the
receptors and signalling pathways that mediate its actions.
The purpose of this review is to summarise our current un¬
derstanding of the ET system, then to consider the pros¬
pects for pharmacological intervention using ET-converting
enzyme (ECE) inhibitors and ET receptor antagonists, par¬




2.1. Endothelin Qenes and Regulation
The first descriptions of ET-1 and cloning of the comple¬
mentary DMA (cDNA) encoding its precursor prcpro ET 1
(Itoh et al., 1988; Bloch et al., 1989b) were rapidly followed
by identification of at least three genes encoding 'ET like'
sequences in mammalian genomes (Inoue et al., 1989). These
sequences subsequently were shown to encode the precur¬
sors of ET-2 and ET-3, in addition to prepro ET-1. In the
human genome, the ET 1 gene is found on chromosome 6
(Bloch et al., 1989b; Hoehe et al., 1993), the ET-2 gene on
chromosome 1 (Bloch et al., 1991) and the ET-3 gene on
chromosome 20 (Bloch et al., 1989a).
Like other eukaryotic genes, the genes that encode the
ET precursors have promoter regions through which exter
nal factors arc able to modulate transcription (reviewed in
Hilkert et al., 1992; Benatti et al., 1994). Selective gene
modification has demonstrated regions necessary for high
level transcription (Lee et al., 1990; Wilson et al., 1990;
Lee et al., 1991b) and also regions that might determine
the tissue selectivity of ET-1 expression (Benatti et al.,
1993). Extracellular factors can influence ET-1 generation
both positively and negatively through liberation of a series
of intracellular mediators that modulate gene transcription
(Table 1). Several agents, including insulin, thrombin, low
density lipoprotein, angiotensin 11, vasopressin and ET-1 it¬
self (Emori et al., 1991; Boulanger et al., 1992; Emori et al.,
1992; Kohno et al., 1992; Benatti et al., 1994) enhance ET-1
generation via activation of protein kinase C (PKC). Re¬
sponsiveness to PKC is mediated by binding of the proto-
oncogenes Jun and Fos to the Activator Protein-1 tran¬
scription regulatory element of the ET-1 promoter (Curran
and Franza, 1988; Lee et al., 1991a). PKC activation is also
thought to be a mechanism by which low levels of shear
stress (1.8 dyne/cm2) enhance endothelial ET-1 release
(Kuchan and Frangos, 1993; Wang et al., 1993). Interest¬
ingly, higher levels of shear stress (>6 dyne/cm2) activate
another mechanism that inhibits ET-1 mRNA transcrip¬
tion (Kuchan and Frangos, 1993; Malek et al., 1993). This
effect is prevented by inhibitors of NO synthesis and by me¬
thylene blue, an inhibitor of guanylate cyclase, suggesting
that endothelial cells release NO in response to shear stress
and inhibit ET-1 synthesis through formation of cyclic
GMP. Cyclic CMP is also implicated in inhibition of ET-1
synthesis by thrombin (Boulanger and Luscher, 1990), hep¬
arin (Yokokawa et al., 1993), atrial and brain natriuretic
peptides (Kohno et al., 1992) and by the prostanoids pros¬
taglandin E2 and prostacyclin (Prins et al., 1994). One action
of cyclic GMP is to reduce the availability of intracellular cal¬
cium, an action that might be relevant for inhibition of ET-1
synthesis, as calcium chelation similarly reduces ET-1 libera¬
tion from endothelial cells (Emori et al., 1992).
Recent studies have shown that different isoforms of the
ET precursor mRNA can arise due to the presence of alter¬
native transcription initiation sites in the ET-1 gene that
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FIGURE 3. Processing pathway
of ET-1. The gene encoding
ET-1 on chromosome 6 con¬
tains 5 exons and 4 interven¬
ing intron sequences. The 5'
end of the gene contains pro¬
moter sequences through which
external factors (including angio¬
tensin II [Ang II] and low density
lipoprotein [LDL]) can influence
gene transcription. The mRNA
untranslated regions at both 5'
and 3' ends (hatched areas), the
3' untranslated region, has a
role in determination of mRNA
stability. Once translated, an
amino terminal signal sequence
(amino acids 1-17) is cleaved
on secretion of the prepro pep¬
tide from the nucleus. Big ET-1
is formed through proteolysis of
pro ET-1 by dibasic pair endo-
peptidase enzymes, then mature
ET-1 is formed through cleavage
of big ET-1 at Trp^-Val22 by a
specific ECE. See text for details.
are controlled by different promoter regions (Benatti et al.,
1993) and also by alternative splicing of the ET-2 and ET-3
genes during transcription (O'Reilly et al., 1992, 1993).
The consequences for translation efficiency and for subse¬
quent conversion of the ET precursors remain to be shown.
Future investigations should also demonstrate whether in¬
sertion polymorphisms identified in the noncoding region
of the ET-1 gene (Stevens and Brown, 1995) might, like
the polymorphisms in the angiotensin-converting enzyme
(ACE) gene (Cambien et al., 1994), prove to be related to
risk of developing cardiovascular disease.
2.2. Processing of the Endothelin Precursors
All of the ETs are formed through a two-step processing
pathway from their respective precursor peptides. In the
case of human ET-1 (Fig. 3), removal of the signal sequence
on secretion of the 212 amino acid prepro ET-1 from nu¬
cleus to cytoplasm is followed by the first proteolytic step
that cleaves between Lys52-Arg53 and Arg^-Arg91 to release
the 38 amino acid precursor, big ET-1. This step is thought
to be similar to the processing of other peptide hormones
and may be dependent on one of the recently described
proprotein convertases (Steiner et al., 1992; Seidah et al.,
1993). Furin, a proprotein convertase of the constitutive
secretory pathway, has been proposed as a likely candidate
(Laporte et al., 1993). Examination of the carboxy terminal
portions of pro ET-1 remaining after cleavage of big ET-1
reveals the presence of sequences that encode 'ET-like'
peptides (Yanagisawa et al., 1988a; Bloch et al., 1989b,
1991). Although these peptides have significant structural
homology to the mature ETs, with the relative positions of
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TABLE 1. Factors that Influence ET-1 Biosynthesis
Gene
promoter
Factor Effect Cellular signal element Reference
Thrombin Increase PLC/PKC AP-1 Emori et al., 1992
Decrease NO/cGMP Boulanger and Liischer, 1990
Heparin Decrease NO/cGMP Yokokawa et al., 1993
PG12/PGE2 Decrease cGMP Prins et al., 1994
ANP/BNP Decrease cGMP Kohno et al., 1992
LDL Increase PLC/PKC API Boulander et al., 1992
Insulin Increase PLC/PKC AP-1 Oliver etal., 1991
Ang 11 Increase PLC/PKC AP-1 Emori et al., 1991
Vasopressin Increase PLC/PKC AP-1 Emori et al., 1991
Shear stress Increase Disruption ofCytoskeleton Morita et al., 1993
Increase PKC Kuchan and Frangos, 1993
Decrease NO/cGMP Kuchan and Frangos, 1993
Hypoxia Increase Elton ct al., 1992
Cyclosporin Increase TGF-P NF-1 Takeda et al., 1993
PGI2, prnstacylin, PGE;, prostaglandin E2; ANP, atrial natriuretic peptide; BMP, brain natriuretic peptide; LDL, low density lipoprotein; Ang II, angio¬
tensin 11; PLC, phospholipase C; cGMP, cyclic GMP; THE [1, transferming growth factor-fl, NF-1, nuclear factor !.
the four cysteine residues conserved, they do not appear to
retain any biological activity (Yanagisawa et al., 1988a;
Cade et al., 1990).
Big ET-1 is several orders of magnitude less active than
ET-1 for displacement of binding to ET receptors and also
in stimulating vascular constriction in vitro (Hirata et al.,
1990). Final processing of big ET-1 to release the biologi¬
cally active 21 amino acid ET-1 requires selective cleavage
of the Trp2l-Val22 bond in the carboxy terminal of big ET-1,
catalysed by activity referred to as ECE. Several ECE-like
enzyme activities representing different endopeptidase
classes have been identified (reviewed in Opgenorth et al.,
1992; Turner and Murphy, 1995). These include serine pro¬
teases (Yanagisawa et al., 1988b; McMahon et al., 1989;
Takaoka et al., 1990a; Kaw et al., 1992; Wypij et al., 1992),
aspartic proteases, such as pepsin (Takaoka et al., 1990b)
and carhepsin D (Sawamura et al . 1990), and soluble thiol
protease (Deng et al., 1992). Although inhibitors of these
enzymes can prevent conversion of big ET-1, their contri¬
bution to ET-1 biosynthesis is not thought to be of major
physiological significance. Cleavage by some of them at po¬
sitions in addition to Trp2l-Val22 results in simultaneous
degradation of ET. Some of these pathways, however,
might play a role in pathophysiological ET-1 production,
for example, in states associated with mast cell degranula-
tion (Wypij et al., 1992) or neutrophil activation (Kaw et
al., 1992).
The physiologically relevant ECE is thought to be a
membrane-bound, zinc-containing metalloprotease that is
inhibited by the neutral (metallo) endopeptidase (NEP
24.11) inhibitor phosphoramidon (Opgenorth et al., 1992).
The activity of this ECE is not affected by thiorphan, an¬
other NEP inhibitor, or by inhibitors of the neutral metal¬
loprotease ACE. Two other minor forms of metalloprotease
enzyme with ECE activity have been described, both" of
which are soluble. One of them is sensitive (Takada et al.,
1991) and the other insensitive (Matsumura, Y. et al.,
1991b) to inhibition by phosphoramidon. The physiologi¬
cal relevance of the phosphoramidon-sensitive metallopro¬
tease ECE is demonstrated by the ability of phosphorami¬
don, but not thiorphan, to inhibit the regional and
systemic effects of big ET-1 in vivo (Fukuroda et al., 1990;
Matsumura et al., 1990; McMahon et al., 1991).
2.3. Characteristics of Cloned
Endothelin-Converting Enzymes
Purification of rat and bovine ECE (Ohnaka et al., 1993;
Takahashi et al., 1993) was rapidly followed by molecular
cloning and characterization of the enzyme from rat (Shi-
mada et al., 1994), bovine (Ikura et al., 1994; Schmidt et
al., 1994; Xu et al., 1994) and human tissue (Schmidt et
al., 1994; Shimada et al., 1995; Yorimitsu et al., 1995).
This enzyme, termed ECE-1, has a neutral pH optimum
and is inhibited by phosphoramidon. More recently, a sec¬
ond novel enzyme, termed ECE-2, was cloned (Emoto and
Yanagisawa, 1995). Like ECE-1, this enzyme is inhibited by
phosphoratnidon, but unlike ECE-1, it has an acidic pH op¬
timum. These enzymes might also have differential cellular
distribution. ECE-1 is widely distributed, but not found in
neurons and glia in the brain, which are known to produce
mature ETs (Xu et al., 1994). ECE-2, in contrast, seems to
he most abundantly expressed in neural tissues (Emoto and
Yanagisawa, 1995).
ECE-1 is a Type II integral membrane protein composed
of 754 or of 758 amino acids, with a short N-terminal cyto¬
plasmic tail, a hydrophobic transmembrane domain and a
large extracellular domain containing a zinc binding motif
that is common to the catalytic domains of many metallo-
proteases (Fig. 4). ECE-1 has 10 potential glycosylation
sites, and expression studies suggest that a high level of gly¬
cosylation is important for full enzymatic activity (Shimada
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HGURE4. Schematic ot plasma
membrane bound ECE-1. From
the predicted amino acid
sequence, ECE-1 is thought to
be a Type II integral membrane
protein with a highly glycosy¬
lated, long C-terminal containing
a Zn binding catalytic domain, a
transmembrane domain and an
N-terminal of variable length.
The ECE-1 proteins can exist as
dimers formed through disul-
phide bonds (-S-S-) between con¬
served cysteine residues.
Although shown bound to
plasma membrane, the ECE-1
protein might also exist in a form
bound to the membranes of intra¬
cellular organelles. See text for
details. Adapted from Turner and
Murphy (1995).
et al., 1995). ECE-1 also has a number of conserved cys¬
teine residues, and recent studies have suggested that ECE-1
might exist as a disulphide-linked dimer (Schmidt et al.,
1994; Turner and Murphy, 1995). While the putative ex¬
tracellular domains of ECE-1 in different tissues share over
95% sequence homology, examination of the N-terminal
domains reveals differences in both length and sequence
homology. Two groups can be distinguished, one with 51-
52 (Schmidt et al., 1994; Shimada et al., 1994) and one
with 56 amino acids in the N-terminal (Ikura et al., 1994;
Xu et al., 1994; Shimada et al., 1995). These isoforms might
arise through alternative splicing of the ECE gene during
transcription (Yorimitsu et al., 1995). Northern analysis re¬
veals that the tissue distribution of these ECE-1 isoforms
might be different (Valdenaire et al., 1995). No differences
in activity, however, have been detected to date, with both
forms converting big ET-1 in preference to big ET-2 or big
ET-3. Amino acid sequences in the C-terminal of the big
ET isopeptides, particularly residues 27-34, seem to be im¬
portant determinants of substrate recognition by ECE-1
(Okada et al., 1991; Xu et al., 1994). ECE-2 also converts
big ET-1 preferentially (Emoto and Yanagisawa, 1995).
This substrate selectivity suggests that there may be yet an¬
other ECE(s) selective for big-ET-2 or big ET-3 still to he
discovered.
ECE-2 is also a Type II integral membrane protein, com¬
posed of 787 amino acids, with 59% overall identity to
ECE-1 (Emoto and Yanagisawa, 1995). The structure of
ECE-2 is similar to ECE-1, it has a short N-terminal, a sin¬
gle transmembrane domain and a large C-terminal contain¬
ing a zinc-binding motif in the catalytic domain. It is also
highly glycosylated.
The deduced sequences of both ECE-1 and ECE-2 have
relatively high'homology with NEP and human Kell blood
group protein, a putative NEP (Ikura et al., 1994; Schmidt
et al , 1994; Shimada etal., 1994; Xuetal., 1994; Yorimitsu
et al., 1995; Emoto and Yanagisawa, 1995). Despite their
structural similarity, NEP and ECE have quite different
cleavage site selectivity. NEP rapidly degrades many small
peptides, including ET-1 itself, by cleavage at multiple in¬
ternal sites, while ECE-1 cleaves only the Trp2l-Val22 bond
of the big ETs (Vijayaraghaven et al., 1990; Xu et al.,
1994). The specificity of ECE-2 for cleavage of big ET-1 is
yet to be formally confirmed (Emoto and Yanagisawa,
1995).
Both ECE-1 and ECE-2 are predicted to be integral
membrane proteins, but the primary site for cleavage of en¬
dogenous big ET-1 could be at the plasma membrane or at
an intracellular membrane site. Exogenous big ET-1 can be
converted to ET-1 fn vivo (McMahon et al., 1991), in vitro
(Auguet et al., 1992) and in COS cells transfected with the
ECE-1 gene (Xu et al., 1994), consistent with localisation
of ECE at an accessible plasma membrane site. This would
be analogous to conversion of angiotensin I to angiotensin
11 by plasma membrane-bound endothelial ACE (Caldwell
et al., 1976). However, only 5-10% of exogenous big ET-1
is converted by ECE-1 transfected COS cells (Xu et al.,
1994), and transformation by ECE-2 transfected COS cells
is negligible (Emoto and Yanagisawa, 1995). This contrasts
with the finding that 50-90% of the total ET peptide se¬
creted by cultured endothelial cells or by COS cells
cotransfected with the prepro ET-1 and ECE-1 or ECE-2
genes is mature ET-1 (Sawamura et al., 1991; Xu et al.,
1994; Emoto and Yanagisawa, 1995). Thus, the process for
endogenous formation of ET -1 appears to be much more ef¬
ficient than that involved in conversion of exogenous big
ET-1. The current consensus is that endogenous big ET-1 is
most likely to be converted during its transit through the
intracellular constitutive secretory pathways, especially
within the Golgi apparatus. This conclusion is consistent
with immunohistochemical staining for ET-1 in the cyto¬
plasm of endothelial cells and the reported ability of a low
density intracellular fraction to convert big ET-1 to the ma¬
ture peptide (Gui et al., 1993; Harrison et al., 1993). The
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pH in the secretory granules of the trans-Golgi network is
around 5.5-5.7, within the range at which conversion of
big ET-1 by ECE-2 is optimal (Emoto and Yanagisawa,
1995). Formation of ET-1 in secretory vesicles that can rec¬
ognise transport pathways would also provide a suitable
mechanism to explain the directional release of ET-1 to¬
wards the abluminal surface of endothelial cells (Wagner et
al., 1992a). However, ECE-1, which has a neutral pH opti¬
mum, would not efficiently convert big ET-1 under the
acidic conditions found within the secretory granules, its
intracellular location remains to be determined. Despite
the fact that endogenous big ET-1 is converted relatively
efficiently by intracellular ECE, a proportion of it is still se¬
creted in the unconverted form, accounting for the big ET -1
detectable in plasma. Circulating big ET-1 concentrations
are somewhat below the Km of ECE-1, but it seems likely
that some of the big ET-1, like exogenously administered
big ET-1, can be converted by plasma membrane-bound
ECE-1. A mechanism by which secreted big ET -1 could be
adequately concentrated for more efficient conversion by
plasma membrane-bound ECE-1 has been proposed re¬
cently (Barnes et al., 1995; Turner and Murphy, 1995). The
suggestion is that ECE is localised in caveoli, invaginations
of the plasma membrane that are abundant in endothelial
and smooth muscle cells. Immunohistochemical studies us¬
ing antisera directed against the purified ECE-1 protein
demonstrate clustering of ECE-1 on the surface of endothe¬
lial cells; this would be consistent with localisation in cave¬
oli (Barnes et al., 1995). Future studies will show whether
big ET-1 can be secreted directly into these caveoli for
physiological ET-1 synthesis.
2.4. Endothelin-Converting Enzyme Inhibitors
While phosphoramidon effectively inhibits ET-1 formation
from big ET-1, its therapeutic potential is limited both by
its low potency and by its lack of selectivity for ECE. 1CW
values for inhibition of purified ECE-1 by phosphoramidon
range from 0.35 pM to 0.8 (jlM, several orders of magnitude
higher than the lC^ for inhibition of NEP 24-11 (Ohnaka
et al., 1993; Shimada et al., 1994). Interestingly, the po¬
tency of phosphoramidon against purified ECE-2 is approx¬
imately 250-fold higher than against ECE-1 (4 nM; Emoto
and Yanagisawa, 1995). Several strategies have been used
to develop inhibitors of ECE that are more potent and more
selective than phosphoramidon (Table 2). As most of these
studies were conducted prior to the identification of ECE-2,
the type of ECE against which the inhibitors are tested is
not usually specified. Compounds based on the structure of
phosphoramidon have slightly increased potency and are
approximately 400-fold more selective for ECE than phos¬
phoramidon itself, but they retain their relative selectivity
for NEP 24-11 (Fukami et al., 1994; Balwierczak et al.,
1995). It might be argued that compounds like these and
the recently described orally active CGS 26303 (De Lom-
baert et al., 1994; Trapani et al., 1995), which also inhibits
NEP 24.11, have therapeutic advantages over selective
ECE inhibitors in that they would potentiate levels of the
vasodilator atrial natriuretic peptide, which is broken down
by NEP. However, as NEP also breaks down a number of
constrictor peptides, including ET-1 itself and angiotensin
11, concomitant NEP inhibition might actually negate any
beneficial vasodilator action afforded by inhibition of ECE.
[D-Val22] Big ET-l(16-38), an analogue of big ET-1, inhib¬
its big ET-1 conversion in vitro, although its potency is less
than that of phosphoramidon (Morita et al., 1994). [Phe22]-
big ET-1 [19-37] is more potent than phosphoramidon as
an inhibitor of big ET-1 conversion in the isolated rabbit
kidney, but like ET-1, is broken down by NEP and, there¬
fore, must be co-administered with an NEP inhibitor (Cla-
ing et al., 1995). The aspergillomarasmines (Matsuura et
al., 1993) and more recently, the compound WS 79089A
TABLE 2: Inhibitors of ECE Activity
ECE inhibition
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Takahashi et al., 1993
Tsurumi et al., 1994
Takahashi etal., 1993
De Lomhaert et al., 1994
Balwierczak et al., 1995
Fukami et al., 1994
Descombes et al., 1995
Matsuura et al , 1993
Tsurumi et al., 1994
Tsurumi et al., 1995
Morita et al., 1994
Claing et al., 1995
Bihovsky el al , 1995
Bihovsky et al , 1995
The inhibitors are described in relation to their potency for inhibition of I t h relative to phosphoramidon 111 the same system where this information is
available and also in relation to their selectivity tor inhibition of H( T compared with NET 24 1 1 (NEP).
116 G. A. Gray and D.). Webb
(FR 901533; Tsurumi et al., 1994) are examples of ECE in¬
hibitors found through screening of fermentation broth. FR
901533 is more selective for ECE than NEP 24-11, while
maintaining a similar potency to phosphoramidon for ECE
inhibition (ICW = 0.73 p.M). FR 901533, unlike phos¬
phoramidon, also has equal potency for inhibition of ECE-1
and ECE-2 (Emoto and Yanagisawa, 1995). The hydrox-
amic acid derivatives are the most interesting of the re
cently described ECE inhibitors (Bihovsky et al., 1995).
Among these, the P7' (3-Ala derivative is reported to be a
potent inhibitor of human bronchiolar smooth muscle
ECE, with lower potency for inhibition ofNEP. The recent
cloning of the ECE isoenzymes should improve the devel¬
opment of more selective and more potent ECE inhibitors.
However, the problem of accessibility will also have to be
faced should the intracellular ECE prove to be of more im¬
portance physiologically. Intracellular conversion of big
F.T-1 hy FCF-1 is inhibited much less potently by phos
phoramidon and FP. 901533 than extracellular conversion,
most likely because of the lesser accessibility of the intracel¬
lular site (Xu et al., 1994).
2.5. Sites of Endothelin
Synthesis in the Cardiovascular System
ET-1 was first isolated from medium of cultured porcine en¬
dothelial cells (Yanagisawa et al., 1988b), but is also re¬
leased by human endothelial cells in culture (Clozel and
Fischli, 1989). In human blood vessels of varying origin,
immunoreactive ET-1 is detected primarily in association
with the endothelial cell layer (Howard et al., 1992;
Tokunaga et al., 1992; Opgaard et al., 1994; Properzi et al.,
1995), consistent with the idea that ET-1 is released by en¬
dothelial cells to act on the underlying smooth muscle cells
(Fig. 1). In situ hybridization for ECE-1 mRNA also shows
the most intense labelling over the vascular endothelial
cells of most tissues (Xu et al., 1994). Removal of the en¬
dothelium, however, does not completely prevent the ac¬
tion of hig FT-I in the perfused rat mesenteric bed (Hisaki
et al., 1993), suggesting that smooth muscle cells can also
synrhesise FT-1 Smooth muscle cells in culture express
F.T-1 mRNA and release FT-1 (Resink et al., 1990; Yu and
Davenport, 1995), hut only diffuse immunohistochemical
labelling for ET-1 can be detected overlying the medial
smooth muscle layer of human blood vessels (Tokunaga et
al., 1992). Interestingly, immunohistochemical staining for
ET-1 is intense over atherosclerotic plaques of human coro¬
nary arteries (Lerman et al., 1991a), particularly over mac¬
rophages and intimal smooth muscle cells in active lesions
(Zeiher et al., 1995). It may be that only the proliferative
phenotype of smooth muscle cells, such as those in culture
or in atherosclerotic plaques, can actively secrete ET-1.
To date, the majority of studies that have investigated
the presence of the ET isopeptides in the human circulation
have focused on measurement of immunoreactive ET-1 or
its precursor big ET-1. However, immunoreactive big ET-2,
FT -1 and big ET-1 can also he detected in human plasma
(Matsumoto et al., 1994; Gerbes et al., 1995), suggesting
that blood vessels might synthesize other isopeptides in ad¬
dition to ET-1. In human coronary arteries, big ET-2 im-
munoreactivity is detectable in the endothelial cytoplasm
(Howard et al., 1992), and prepro ET-2 mRNA can be lo¬
cated in the medial layer using in situ hybridisation
(O'Reilly et al., 1993). There is also evidence that human
smooth muscle cells in culture can release ET-3 in addition
to ET-1 (Yu and Davenport, 1995).
Radioimmunoassay of human heart extracts demonstrates
the presence of immunoreactive ET-1, -2 and -3, as well ET-1
precursor pro-ET-1 (Plumpton et al., 1993). Mature ET-1 is
detectable in a number of human cardiac cells, including atrial
and ventricular myocytes (Wei et al., 1994) and endocardial
endothelial cells (Giaid et al., 1991), but it is unclear whether
it is generated in these cells. In blood vessels, ET-1 is gener¬
ated in endothelial cells to act on the underlying smooth
muscle. An analogous situation might exist in the heart,
with endocardial endothelial cells being the primary site of
production. Cultured endocardial cells express ET-1 mRNA
and also secrete ET-1 (Mebaaza et al., 1993), and there is indi¬
rect evidence that ET-1 is released m vivo by endocardial cells
lining the ventricular myocardium, particularly following is-
chaemia (Tonnessen et al., 1993). However, prepro ET-1
mRNA is also expressed in cultured neonatal rat cardiomy-
ocytes (ho et al., 1993) and in human cardiomyocytes (Gi¬
aid et al., 1995). Northern analysis reveals the presence of
ECE-1 mRNA (Xu et al., 1994) and ECE-2 mRNA (Emoto
and Yanagisawa, 1995) in bovine ventricular tissue, but the
precise cellular location remains to be determined.
2.6. Clearance and Degradation of Endothelin
The plasma half-life of ET-1 in humans is less than 1.5 min
because of its efficient extraction by the splanchnic and re
nal vascular beds (Weitzberg et al., 1991; Gasic et al.,
1992). Although ET-1 is also reported to be taken up by the
lungs (Stewart et al., 1991), there are indications that pul¬
monary clearance is less important in humans than in other
species (Ray et al., 1992; Hemsen et al., 1995). Extraction
of ET 1 follows binding to cell surface receptors, which arc
then internalised, allowing degradation to be carried out
within the cell (Angg&rd et al., 1989; Gandhi et aJ., 1993),
perhaps in lysosomes (Loffler et al., 1991). The observation
that circulating concentrations of ET-1 are increased by a
mixed ETA/ETB receptor antagonist (Loffler et al., 1993) or
by an ETB receptor selective antagonist (Fukuroda et al.,
1994), but not by ETA selective antagonists, is suggestive of
a role for ETB type receptors in clearance of ET-1 Low-affinity
ETb type binding sites that might serve this purpose have
been found in arteries and veins (Gray et al., 1994; Teerlink et
al., 1994a). A possible candidate for an intracellular degrading
enzyme is a soluble protease found in human platelets, vascular
smooth muscle and endothelial cells (Jackman et al., 1992,
1993). A deamidase enzyme with similar characteristics re¬
cently was purified from rat kidney (Deng et al., 1994; Janas et
al., 1994). The ETs can also be degraded by NEPs (E.G.
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24-11), which are associated with venous and arterial en¬
dothelial cell plasma membranes (Llorens-Cortes et al.,
1992), as well as by an enzyme released from the perfused rat
mesenteric bed (Perez-Vicario et al., 1995). Activated poly¬
morphonuclear lymphocytes are able to rapidly inactivate
ET-1 through release of a protease, believed to be cathepsin
G, which degrades ET by cleavage of Hisl6-Leu17 (Fagny et
al., 1992; Patrignani et al., 1992). This process may have a
role in acute inflammation following adhesion of polymor¬
phonuclear lymphocytes to vascular endothelial cells.
3. ENDOTHELIN RECEPTORS
Specific binding sites for [l25I] ET-1 can be classified according
to their relative affinities for the ET lsopeptides. The ETA type
site is characterised by its very high (subnanomolar) affinity for
ET-1 and ET-2 and its 70- to 100-fold lower affinity for ET-3,
while the ETB site has high and equal affinity for all 3 isopep-
tides (Table 3). These binding characteristics are reflected in
the agonist potency of the isopeptides in isolated tissues, dem¬
onstrating that the binding sites represent functional receptors
(Maggi etal., 1989; Warner etal., 1989).
3.1. EndothelinA and EndothelinB Receptors:
Cloning, Qene Regulation, and Structural Features
Within 2 years of the initial description of ET (Yanagisawa
et al., 1988b), the genes encoding the ETA and ETB type re¬
ceptors that mediate its actions were cloned and character¬
ised (Arai et al., 1990; Sakurai et al., 1990; Lin et al.,
1991). The cDNAs encoding the human ETA and ETB re¬
ceptors predict 427 and 442 amino acids, respectively, and
the overall identity between the two mature proteins is re¬
ported to be between 55% and 64%, depending on the tis¬
sue studied (Adachi et al., 1991; Hayzer et al., 1992; Arai et
al., 1993; Elshourbagy et al., 1993). The ETA and ETB re¬
ceptor genes, located on chromosomes 4 (Hosada et al.,
1992) and 13 (Arai et al., 1993), respectively, have similar
structural organisation, suggesting that they originated from
the same ancestral gene. Although functional studies sug¬
gest the existence of further heterogeneity among ET re¬
ceptors (reviewed in Bax and Saxena, 1994), analysis of hu¬
man genomic DNA with probes specific for the human ETA
and ETb receptors reveals only two hybridising fragments
(Sakamoto et al., 1991). Thus, if genes encoding other ET
receptors exist in the mammalian genome, they must have
quite low sequence similarities to the two known ET recep¬
tor genes. Screening of amphibian cDNA libraries has re¬
vealed the existence of two alternative receptor clones, nei¬
ther of which have been detected yet in the mammalian
genome. The first, cloned from Xenopus dermal melano-
phores, shows relative selectivity for ET-3, consistent with
a putative ETC receptor subtype (Karne et al., 1993). The
second, cloned from Xenopus heart, is termed ETAX because
of its high relative affinity for ET-1, like the ETA receptor,
but uncharacteristic low affinity for the ETA receptor selec¬
tive ligand BQ-123 (Kumar et al., 1994).






Agonist ET-1 ETa/ET„ 160 pin 110pm Saeki etal., 1991
ET-3 etb 4.5 nM 70 pm Saeki etal., 1991
SRTX S6c etr 4 5 pM 20 pM Williams et al., 1991
IRL 1620 etb 16 pM 200 pM Takai et al., 1992
BQ-3020 ETb 940 nM 200 pM Ihara et al., 1992b
Antagonist: peptide BQ-123 ETa 7.3 nM 18 pM lhara et al., 1991
FR 139317 eta 1 nM 7 pM Aramori et al., 1993
TTA-386 ETa 0.34 nM < 1 pM Kitada et al., 1993
BQ-518 ETa 1.2 nM 55 pM Fukami et al., 1995a
BQ-788 etr 1300 nM 1.2 nM Ishikawa et al , 1994
Res 701-1 ETr <5 pM 10 nM Tanaka et al., 1994
RQ-017 ETr 3.8 nM 0.8 nM Fukami et al., 1995b
IRL 2500 ETr 94 nM 1.3 nM Balwierczak et al., 1995
PD 145065 eta/etb 3.5 nM 15 nM GxJy et al., 1993
TAK-044 eta/etb 0.1 nM 1.8 nM Kikuchi et al., 1994
Antagonist: nonpeptide 97-139 eta 1 nM* 1 pM* Mihara et al., 1994
BMS 182874 ETa 55 nM* >20 pM* Stein etal., 1994
LU 127043 eta 6 nM* 1 pM* Raschack et al., 1995
PD 155080 eta 7.4 nM 4 5 pM Doherty et al., 1995
Ro 46-8443 ETB 7 pM 40 nM Brandli et al., 1996
Ro 47-0203 (bosentan) ETa/ETb 4.7 nM 95 nM Clozcl et al., 1994
CC3S 278 30 eta/et„ 16 nM 295 nM Mugrage et al , 1993
SB 209670 ETa/ETb 0.2 nM 1 8 nM Ohlstein el al , 1995
PD 160672 ETa/ETb 0.8 nM 44 nM Doherty et al , 1995
SB 2 17242 ETa/ETb 1 nM* 1 1 1 nM* Rarone et al , 1995
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As with the ET genes, the nontranscribed 5' flanking re¬
gions of the ET receptor genes contain a number of regions
involved in regulation of gene transcription (Hosada et of.,
1997; Arai et al., 1993). Exogenous factors can act through
these regions to increase receptor transcription, for exam
pie, up-regulation of ETA receptor mRNA by insulin (Frank
et al., 1993) or ETB receptor mRNA by angiotensin 11
(Kanno et al , 1993) These mechanisms may be important
in regulation of responsiveness to the ETs in pathophysio¬
logical states. ETb receptor mRNA is selectively increased
in marmosets fed a high cholesterol diet (Elshourbagy ct al.,
1993) and following glycerol-induced acute renal failure in
rats (Roubert et al., 1994). In contrast, ET receptor expres¬
sion is reduced in atherosclerotic human arteries (Winkles
et al., 1993) and in the lungs of rats with pulmonary hyper¬
tension (Yorikane et al., 1993). One of the major factors
that reduces ET receptor number at the cell surface is pro¬
longed exposure to ET -1 itself, because of down-regulation
or feedback inhibition of receptor expression (Hirata et al.,
1988), or both of these in combination. In endothelial
cells, ETB receptor expression is decreased because exposure
to high local concentrations of ET-1 reduces the stability of
mRNA molecules rather than reducing transcription
(Sakurai et al., 1992). The 3' untranslated regions of both
genes contain potential polyadenylation signals that may
mediate selective destabilisation of the receptor mRNA
(Ogawa et al., 1991; Hosada et al., 1992; Arai et al., 1993).
Polymorphisms in the noncoding region of the ETA re¬
ceptor gene have been identified in the human genome
(Stevens and Brown, 1995), although the consequences for
receptor function currently are unknown. Variants of the
ET receptor mRNA can arise through alternative Gplicing
of the ETA and ETB receptor genes during transcription
(Miyamoto et al., 1994; Shyamala et al., 1994). The tran¬
scribed regions of both receptor genes encode sites for post-
translational modification that influence the tertiary struc¬
ture of the receptor and its linkage to intracellular messenger
systems, including consensus sites for N-glycosylation, sev¬
eral potential sites for palmitoylation to anchor the recep¬
tor to the cell membrane, and serine residues that may be
substrates for regulatory phosphorylation by serine threo¬
nine kinases (Hosada et al., 1991; Nakamuta et al., 1991;
Ogawa etal., 1991; Elshourbagy et al., 1993). Phosphoryla¬
tion may play a role in the down-regulation of ET receptors
that follows prolonged exposure to the ET isopeptides (Hirata
etal., 1988; Roubert et al., 1991; Miasiro and Paiva, 1992).
Given the likely importance of the post translational modi¬
fication sites for receptor binding and function, it seems
possible that some of the receptor heterogeneity observed
in functional studies could arise through modification of
these sites by alternative splicing. However, at least for the
human ETB receptor, two splice variants do not exhibit any
difference in binding or linkage to intracellular signalling
pathways (Shyamala et al., 1994).
Intracellular site
extracellular site
FIGURE 5. The predicted structure of the human ETA receptor with its 7 transmembrane spanning domains. Filled circles represent
amino acids (aa) in the second transmembrane domain identified as being of importance for ligand binding. See text for details. Adapted
from Adachi et al. (1993).
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All of the cloned ET receptor genes predict a heptaheli-
cal membrane spanning structure, common to members of
the G-protein-coupled receptor superfamily and similar to
many neuropeptide receptors (Fig. 5; Burbach and Meijer,
1992). The regions of greatest sequence conservation be¬
tween the ET receptors and other G-protein-coupled receptors
are concentrated within the hydrophobic transmembrane
segments. Amongst the ET receptors, the 7 transmembrane
domains and cytoplasmic loops of the receptors are highly
conserved, but the N-terminal and other extracellular do¬
mains exhibit differences in both length and amino acid se¬
quences (Ogawa et al., 1991; Elshourbagy et al., 1992).
The extracellular N-terminal regions of peptide G-pro-
tein-coupled receptors are known to be important for
ligand binding (Nagayama et al., 1991). Proteolytic trunca¬
tion studies reveal that of the ET receptor N-terminal
amino acids, only those in closest proximity to the first
transmembrane domain are essential for ET binding (Hash-
ido et al., 1991; Kosuka et al., 1991). Computer-assisted
molecular modelling, based on the known coordinates of
bacteriorhodopsin, recently has been applied in conjunc¬
tion with site-directed mutagenesis, to investigate noncon-
served amino acids in the ETA and ETB receptors that may
be important in determination of ligand selectivity. These
studies have identified Tyr129 (Krystek et al., 1994; Lee et
al., 1994) and Lys140 (Adachi et al., 1994) in the second
transmembrane domain of the ETA receptor (Fig. 5) and
181 Lys in the third transmembrane domain of the ETB re¬
ceptor (Zhu et al., 1992) as being of potential importance
for ligand binding. It has been proposed that the ET recep¬
tors can be divided into two distinct parts, one comprising
transmembrane domains I, II, III and VII that is involved in
ligand receptor binding and the other comprising trans¬
membrane domains IV, V and VI that determines isopep
tide selectivity (Sakamoto et al., 1993). Consistent with
this proposal, ETR-like binding characteristics can be con¬
ferred on the ETA receptor by substitution of transmem¬
brane regions IV, V and VI and their intervening loops
with the corresponding regions of the ETB receptor (Ada¬
chi etai, 1993; Sakamoto et al., 1993). The predicted third
cytoplasmic domain of the ET receptors is very short (ap¬
proximately 30-50 residues), a feature common to G-pro-
tein-coupled receptors that have peptide ligands (Elshour¬
bagy et al., 1993). This region, and in particular the
C-terminal end, is implicated in coupling of the human F.TA
receptor to G-proteins and subsequent liberation of intracellu¬
lar Ca2 + (Adachi et al., 1993; Hashido et al., 1993).
3.2. Agonists at Endothelin Receptors
All of the ET and SRTX peptides possess four cysteinyl res¬
idues that form two disulphide bridges, three polar charged
side chains (residues 8-10) and a we 11-conserved hydropho¬
bic. (.-terminus (residues 16-21, Fig. 2). Examination of the
binding characteristics of these peptides reveals that the
1- I \ receptor has much more rigid structural requirements
lor ligand binding than the ETB receptor (reviewed in Er-
hardt, 1992; Sokolovsky, 1992; Huggins et al., 1993). Both
the amino-terminal loop structure and the carboxy termi¬
nal linear portion with Trp in position 21 are vital for high
affinity ETA receptor binding. In contrast, only the linear
carboxyI terminal and the Trp21 is essential for high-affinity
binding to the ETB receptor (Kimura et al., 1988). A num¬
ber of selective ETB receptor ligands have been designed
based on this linear portion, including BQ-3020 (N-acetyl-
[Ala1115] ET-1 (6-21); lhara et al., 1992b) and IRL 1620
(N-succinyl-(Glu9, Ala"'15] ET-1 (8-21); Takai et al.,
1992). ET-3 and SRTX S6c can also be considered as ETB
selective ligands, ET-3 having approximately 2000-fold and
SRTX S6c 30,000-fotd selectivity for binding to the ETB
rather than the ETA receptor (Williams et al., 1991). Al¬
though both of these ligands contain loop and linear por¬
tions like ET-1, they have different amino acid sequences
within the inner loop portion, which might account for
their lower affinity at the ETA receptor.
3.3. Endothelin Receptor Antagonists
Since the first description of compounds that could inhibit
the binding or actions of ET-1 in 1991 (lhara et al., 1991;
Spinella et al., 1991), a large number of ET receptor antag¬
onists, peptide and nonpeptide, selective and nonselective,
have become available. The characteristics of some of these
are shown in Table 3; for a fuller consideration, the reader
is referred to several recent review articles (Warner, 1994;
Gray, 1995; Luscher and Wenzel, 1995).
Peptide antagonists have been obtained by chemical
modification of ET-1 itself, or of microbial products with
ET receptor binding activity (lhara et al., 1991; Spinella et
al., 1991). BQ-123 is a cyclic pentapeptide derived from
microbial broth that has relatively high potency for binding
to the ETa receptor subtype (lhara et al., 1992a). Although
several more ETA antagonists are now available (Table 3),
studies using BQ-123 first confirmed the role of ET in a
number of pathologies (Moreland, 1994). Among the pep¬
tide antagonists, the hexapeptide TTA-386 (hexamethyl-
eneiminocarbonyl-Leu-Trp-Ala-PAla-Tyr-Phe) is the most
potent ETA receptor antagonist described to date (Kitada et
al., 1993). BQ-788 (Ishikawa etal., 1994) is a peptide com¬
pound that is more selective for inhibition of ET-1 binding
to the ETB receptor (Table 3). Res 701-1 was also initially
described as an ETB selective antagonist (Tanaka et al.,
1994), but recent studies show that is has approximately
equal affinity at the ETA and ETB receptor subtypes (He et
al., 1995). The first nonselective ET receptor antagonists to
be described were also peptides (Cody et al., 1992; Lam et
al., 1992). TAK-044, is a cyclic hexapeptide with approxi¬
mately 20-fold higher affinity at the ETA compared with
the ETB receptor (Kikuchi et al., 1994). This compound,
unlike many of the other peptide antagonists, has a rela¬
tively long duration of action following i.v. administration
in vivo (Ikeda et al., 1994). Although useful as research
tools, the potential of peptides as therapeutic agents may be
limited by their short duration of action, as well as by their
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lack of oral availability. With these problems in mind,
much research effort has been applied to the development
of orally active nonpeptide antagonists.
Potent nonpeptide antagonists (Table 3) have been de¬
veloped through optimisation of compounds isolated from
plant extracts (Fujimoto et al., 1992; Mihara et al., 1994)
and microbial broths (Ohashi et al., 1992), or screened
from chemical libraries (Clozel et al., 1993; Mugrage et al.,
1993; Clozel et al., 1994; Ohlstein et al., 1994; Stein et al.,
1994). SB 209670, a nonselective antagonist, is amongst
the most potent of these. This compound inhibits the ac¬
tion of ET-1 in vivo, whether administered i.v. or p.o. (Ohl¬
stein etal., 1994; Douglas etal., 1995a).
3.4. Distribution and Function of
Endothelin Receptors in the Cardiovascular System
In vascular tissue, ETA receptor mRNA is expressed pre¬
dominantly in smooth muscle (Arai et al., 1990; Hori et al.,
1992; Yang et al., 1993), while ETB receptor mRNA is most
abundant in endothelial cells (Hosada et al., 1991; Ogawa
et al., 1991; Molenaar et al., 1993; Winkles et al., 1993).
These findings are consistent with the view that constric¬
tion of vascular smooth muscle is mediated predominantly
by ETa receptors and that constriction is modified by re¬
lease of relaxing factors from the endothelium through
stimulation of ETB receptors (Fig. 1). However, in some iso¬
lated blood vessels, the constrictor response evoked by ET-1
has both ETA antagonist sensitive and insensitive components
(Fig. 6; reviewed in Bax and Saxena, 1994) and in vivo, pressor
responses to ET-1 cannot be completely inhibited by ETA
receptor antagonists (Cristol et al., 1993; McMurdo et al.,
1993). Furthermore, ETB selective agonists can evoke con¬
striction in vitro (Moreland et al., 1992; Sumner et al.,
1992; Shetty et al., 1993) and pressor responses in vivo
(Williams et al., 1991; Bigaud and Pelton, 1992; Clozel et
al., 1992). These observations are suggestive of the pres¬
ence of ETb receptors that mediate constriction on vascular
smooth muscle cells. Indeed, ETB receptor mRNA is de¬
tectable both in the medial smooth muscle of human arter¬
ies (Davenport et al., 1993; Maguire et al., 1994) and in
cultured smooth muscle cells (Batra et al., 1993; Winkles et
al., 1993). The relative contributions of ETA and ETB recep¬
tors to vasoconstriction is variable and depends on species and
the vessel type studied (Davenport and Maguire, 1994). ETB
receptors are generally more important in the low pressure
venous circulation (Moreland et al., 1994). In isolated hu¬
man blood vessels, it is the ETA receptor subtype that pri¬
marily mediates constriction in large calibre arteries (Dav¬
enport and Maguire, 1994), but recent studies show that
the relative functional role of ETB receptors is greater in
small calibre arteries (Tschudi and Liischer, 1994; Deng et
al., 1995; Takase et al., 1995). The balance of receptors might
be altered under pathophysiological conditions. For exam¬
ple, ETb receptor expression is increased during the change
of cultured vascular smooth muscle cells from a contractile




FIGURE 6. ET-1-induced constriction of the isolated rabbit
saphenous vein. The dose-response curve shows a component
that is sensitive and a component that is insensitive to inhibition
by the ETA receptor antagonist BQ-123 (10 5 M). Reproduced
from Gray et al. (1994), with permission of the copyright
holder, The American Physiological Society, Bethesda.
(Batra etal., 1993) and under the influence of angiotensin
II (Kanno et al., 1993). Interestingly, the nonselective ET
receptor antagonists bosentan (Clozel et al., 1994) and PD
142893 (Warner et al., 1993) have differential potency on
the endothelial ETB and smooth muscle ETB receptors, sug¬
gesting that they might represent discrete receptor sub¬
types. Subtypes of vascular ETA receptor that are insensitive
to BQ-123 have also been proposed (Bodelsson and Stern-
quist, 1993; Moreland, 1994; Sudjarwo et al., 1994).
Although ETa receptor mRNA cannot be detected in
endothelial cells derived from the peripheral vasculature
(Davenport et al., 1993; Winkles et al., 1993), it is reported
to be expressed by cultured cerebromicrovascular endothe¬
lial cells (Stanimirovic et al., 1994). High-affinity binding
sites typical of ETA receptors can also be detected on rat
brain microvascular endothelial cells (Frelin et al., 1991).
These receptors are linked to activation of phospholipase
C, but their functional role in situ is currently unclear.
In the human heart, ETA and ETB receptor mRNAs have
similar distribution, with both found within the atrioven¬
tricular node, the penetrating and branching bundles of
His, in atrial and ventricular myocardium, and in endocar¬
dial cells (Molenaar et al., 1993). ET-1 is a positive inotro¬
pic agent in human atrial and ventricular cardiac muscle
strips (Schomisch Moravec et al., 1989; Zerkowski et al.,
1992). In isolated rat cardiomyocytes, ET-1 is also reported
to have positive chronotropic actions (Jones et al., 1992).
In addition, within the ventricular myocardium, ET-1 may
have a role in mediating cardiac hypertrophy, as it potenti¬
ates the hypertrophic actions of angiotensin 11 in rat cardio¬
myocytes (Ito et al., 1993; Neyses et al., 1993).
4. ENDOTHELIN IN
CARDIOVASCULAR PHYSIOLOGY
The widespread expression of mRNA for the ET isoforms
and the wide distribution of ETA and ETB receptors in car-
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dtovascular tissues, and in pathways regulating the sympa¬
thetic nervous system, suggest that the ET system may play
an important role in cardiovascular control. ET-1, the pre¬
dominant endothelial isopeptide, is probably the isoform of
most importance in regulation of vascular tone. ET-1 ap¬
pears to be primarily a locally acting substance because re¬
lease is predominantly abluminal (Wagner et cd., 1992a)
and circulating plasma concentrations are usually not suffi¬
cient to elicit vasoconstriction directly (Haynes and Webb,
1993b). Here, the vascular physiology of the ET system is
reviewed in relation to studies with ET agonists and antag¬
onists. However, given that ET-1 is not a circulating hor¬
mone, it is not clear to what extent studies with exogenous
ET can reproduce the physiological effects of the ET sys¬
tem. Generally, more reliance probably can be placed on
studies using receptor antagonists.
4.1. The Pressor Response
In their original paper, Yanagisawa and colleagues (1988b)
showed that i.v. administration of a bolus dose of ET-1
markedly increases blood pressure in chemically denervated
rats (Fig. 7). This pressor effect is sustained for more than
60 min, in contrast to the brief effects of all other endoge¬
nous vasoconstrictor substances. ET-2 and ET-3 have also
been shown to increase blood pressure in the rat (Inoue et
cd., 1989), with ET-3 evoking the least response and having
the shortest action. Similar pressor responses to the ETs
have been demonstrated subsequently by other investiga¬
tors in a range of other mammals (Braquet et al., 1989; Per-
now etui., 1989; Miyamori et al., 1990; Dieguez et al., 1992),
including humans (Vierhapper et al., 1990; Weitzberg et
al., 1991; Sprensen et al., 1994). The pressor response in
humans appears not to be affected by pretreatment with cy¬
closporin, the Ca2+ antagonist nifedipine, or cyclo-oxygen-
ase inhibition with indomethacin (Vierhapper et al., 1992).
The sustained increase in arterial pressure occurs despite
rapid clearance of ET-1 from the circulation within a few
minutes (AnggSrd et al., 1989; Vierhapper et al., 1990),
mainly through receptor binding, and is consistent with the
extremely slow dissociation of ET-1 from its vascular recep¬
tors (Hirata et al., 1988). In rats, bilateral nephrectomy re¬
duces the clearance of exogenous ET-1 and leads to a more
prolonged pressor response to ET-1 (Kohno et al., 1989),
suggesting that the kidneys play an important role in its
clearance.
Continuous infusion of ET-1 or ET-3 over 7 days leads to
sustained hypertension in rats, mediated through an in¬
crease in total peripheral resistance (Morterisen et al.,
1990). Although sodium balance did not appear to change
during these studies, it was interesting that the hyperten¬
sion could be prevented by salt restriction (Mortensen and
Fink, 1992a), perhaps by altering vascular sensitivity to ET-1
or through an interaction with the renin-angiotensin sys¬
tem. In the dog (Lerman et al., 1991b), infusion of lower
doses of ET-1, sufficient to double plasma concentrations of
the peptide, do not increase blood pressure, but do produce
systemic vasoconstriction.
Bolus i.v. administration of big ET-1 causes a pressor ef¬
fect of similar magnitude to that of ET-1 (Kashiwabara et
al., 1989; Gardiner et al., 1991; McMahon et al., 1991; Pol¬
lock and Opgenorth, 1991). However, big ET-1 is ~100
times less potent as a direct vasoconstrictor of bUxxl vessels
in vitro than ET-1 (Kashiwabara et al., 1989), suggesting
that big ET-1 does not exert its actions through direct bind¬
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FIGURE 7. Brief depressor and sustained pressor effect following i.v. bolus injection of porcine ET-1 (ET, 1 nmol/kg) in 'he anaes-
thet ised, chemically denervated rat. The baseline diastolic pressure is shown by a broken line. Reproduced from Yanagisawa et ill.
( l^HHb), with permission of the authors and the copyright holder, Macmillan Magazines Limited, London.
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peptide. Confirmation that the pressor activity of big ET-1
is dependent on generation of ET-1 by ECE comes from the
inhibition by the ECE inhibitor phosphoramidon of the
pressor response to big ET-1, but not ET-1 (Gardiner et al.,
1991; McMahon et al., 1991; Pollock and Opgenorth,
1991). In contrast, inhibitors of ACE and NEP do not
block the pressor effects of big ET-1 (McMahon et al.,
1991; Pollock and Opgenorth, 1991). There may be regional
variation in ECE activity, because mesenteric vasoconstric¬
tion to systemic big ET-1 is less sensitive to phosphorami¬
don than vasoconstriction in the renal and hindquarters
vascular beds (Gardiner et al., 1991). Big ET-2 and big ET-3
also have vasoconstrictor actions similar to their mature
forms when administered in vivo in rats (Gardiner et al.,
1992; Pollock et al., 1993; Matsumura et al., 1993), al¬
though the magnitude of the response is smaller than that
of ET-2 and ET-3. These responses also appear to involve
conversion by ECE, because they can be inhibited by phos¬
phoramidon. In contrast to studies in the rat, big ET-3 had
no pressor response in the anaesthetised guinea pig (D'Or-
leans-Juste et al., 1991). The authors suggest ECE is selec¬
tive for the N- and C-terminal sequences of big ET-1. These
varying results with big ET-2 and big ET-3, together with
the recent in vitro isolation and characterisation of ECE iso-
forms selective for big ET-1 (Xu et al., 1994; Emoto and
Yanagisawa, 1995), suggest the presence of more than one
ECE. The contrasting findings in vivo may reflect species
differences in the expressions of different ECE isoforms.
At least two subtypes of vascular ET receptors exist; the
ETa and ETB. Vasoconstriction to ET-1 was initially
thought to be mediated solely by vascular smooth muscle
cell ETa receptors, with ETB receptors restricted to the
endothelium, where they mediate generation of endothe-
lium-derived dilator substances. However, the existence of
a vasoconstrictor ETB receptor has been demonstrated sub¬
sequently in vitro, and selective ETB receptor agonists have
been shown to increase blood pressure in a numher of spe¬
cies (Williams et al., 1991; Douglas and Hiley, 1991; Clozel
etai, 1992, Gardiner et al., 1994b; Moreland et al., 1992).
Further in vivo evidence for a constrictor ETR receptor has
been derived from antagonist studies, in which ETA recep¬
tor antagonists do not fully block the pressor response to
ET-1 (McMurdo et al., 1993; Gardiner et al., 1994b).
These results suggest that both ETA and ETB receptors me¬
diate the pressor effects of ET-1. The combined ETA/R re¬
ceptor antagonist bosentan effectively blocks all of the hae-
modynamic effects of ET-1, -2 and -3, and of big ET-1
(Gardiner etai, 1994a), suggesting that non-ETA, non-ETB
receptors play little or no role in this response. Studies us¬
ing systemic administration of ETB selective agonists and
antagonists have not been reported in humans yet, but sys¬
temic administration of the combined ETA/ETB antagonist
TAK-044 reduces blood pressure (Haynes et al., 1996).
The pressor response to ET-1 may be mediated indirectly
through generation of other constrictor substances. Vaso¬
constrictor prostanoids appear to potentiate regional vaso¬
constriction to ET-1, although cyclo-oxygenase inhibition
does not appear to attenuate the pressor effect to ET-1
(Gardiner etai., 1990a). The role of platelet-activating fac¬
tor remains unclear (Kurose et al., 1991; Filep et al.,
1991b). The sympathetic and renin-angiotensin systems
may also contribute to the pressor response, but are dis
cussed later (Section 4.4).
4.2. The Depressor Response
All three ET isoforms cause transient hypotension after bo¬
lus administration (shown for ET-1 in Fig. 7). This vasode¬
pressor action precedes the sustained pressor effect and is
most marked for ET-3 (Inoue et al., 1989). The selective
ETb receptor agonists SRTX S6c and [Ala1'3'"'15] ET-1
have also been shown to cause transient hypotension in rats
and cynomolgus monkeys (Moreland et al., 1994). How¬
ever, the hypotension may reflect a pharmacological, rather
than physiological, response to the briefly sustained high
concentrations of ETs that occur following bolus adminis¬
tration (Ohlstein et al., 1990). In particular, under perhaps
more physiological conditions, in which ET-1 concentra¬
tions are allowed to rise more slowly (Mortensen and Fink,
1990; Gardiner et al., 1993), such as following i.v. infusion
of ITT-1 or its precursor big ET-1, hypotension does not occur.
Nevertheless, the transient hypotension to bolus ET does
demonstrate the endothelial actions of these peptides,
which appear to be caused by generation of endothelium-
dependent dilating factors and mediated by endothelial cell
ETr receptors. Inhibitors of NO synthase attenuate the hy¬
potension to ET-1 (Whittle et al., 1989; Gardiner et al.,
1990c; Fozard and Part, 1992; Rogerson et al., 1993; Filep et
al., 1993; Granstam et al., 1993), although the attenuation
is often incomplete (Gardiner et al., 1990c; Fozard and
Part, 1992; Filep et al., 1993), implying that other factors
may contribute. Inhibition of cyclo-oxygenase (Rogerson et
al., 1993; Granstam et al., 1993; Filep et al., 1991a) also re¬
duces the depressor effecr, although this is nor a universal
finding (De Nucci et al., 1988). In addition, the sustained
pressor effect of ET is usually potentiated by inhibition of
either NO (Gardiner et al., 1990c; Filep et al., 1993) or
prostaglandin generation (Rogerson et al., 1993; De Nucci
et al., 1988), indicating that the pressor effect of ET-1 is
modulated by the stimulated release of endothelium-depen-
dent vasodilators. Furthermore, the ability of ETA receptor
antagonists to enhance the vasodilator activity of ET -1 also
suggests a functional antagonism between constrictor and
dilator actions (Cirino et al., 1994). However, in some vas¬
cular beds such as the rat hindquarters, there does not ap¬
pear to be a major role for NO or prostacyclin in mediating
vasodilatation to ET-1 (Ohlstein et al., 1990; Gardiner et
al., 1989), suggesting that other mediators may be involved.
Among these other mediators, endothelium-derived hyper-
polarising factor is a potential candidate, but atrial natri¬
uretic peptide does not appear to contribute (Fozard and
Part, 1992).
Depressor responses to ET-1 have not been demonstrated
in humans, although a parallel transient dilatation during
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local brachial artery infusion has (Haynes et al., 1995; and
see Section 4.3), most probably because the use of high
doses of ET -1 has been avoided for reasons of safety.
4.3. Regional Vascular Responses
The systemic haemodynamic response to exogenous ET is
the sum of its actions on the heart, peripheral vasculature,
nervous system, kidney and endocrine glands. There appear
to be wide regional variations in the responses to ETs m
vivo, and these may depend on the experimental circum¬
stances, and certainly on species, vessel type and vessel size.
Infusion of ET-1 locally into the femoral artery of the an¬
aesthetised dog (Clarke et al., 1989b), or into the human
brachial artery (Clarke et al., 1989a), causes a sustained re¬
duction in limb blood flow, without transient vasodilata¬
tion. After initial vasodilatation, a similar sustained re¬
sponse is elicited in the rat mesentery (Gardiner et al.,
1990a), but not in the rat hind limb (Gardiner et al., 1989),
when ET is administered systemically. The discrepancy be¬
tween vasoconstriction produced by local administration of
ET into a vascular bed and its absence during systemic ad¬
ministration may be merely a feature of the various resis¬
tance circuits in parallel and the greater action of ET in
some vascular beds than others.
In humans, brachial artery infusion of ET-1 causes a
slowly developing dose-dependent reduction in forearm
blood flow, with vasoconstriction sustained for more than 2
hr after halting the infusion (Clarke et al., 1989a; Cock-
croft et al., 1991). When given via the brachial artery
(Haynes et al., 1995), low doses of the ETR selective ago¬
nists ET-3 and SRTX S6c also produce vasoconstriction in
human resistance vessels in vivo, consistent with vascular
ETB receptors mediating at least part of the functional re¬
sponse to ET-1 in these vessels (Fig. 8). ETB agonists can
produce transient forearm vasodilatation, but only at high
doses on bolus administration, suggesting that this may not
be a physiological response. In these vessels, vasoconstric¬
tion is modulated by stimulated release of dilator prosta¬
glandins (unpublished observations), but not NO (Kiowski
et al., 1991). Co-infusion of Ca2+ channel antagonists can
overcome forearm vasoconstriction to ET-1 (Kiowski et al.,
1991; Andrawis et al., 1992), but this effect may not be spe¬
cific to ET-1 because of the high basal tone in forearm resis¬
tance vessels, against which these agents may be acting,
and the finding that vasoconstriction to angiotensin II is
blocked to an equal or greater extent (Clarke et al., 1989a).
ET-1 (Clarke et al., 1989a) and SRTX S6c (Haynes et
al , 1995) both cause sustained constriction of human dor¬
sal hand veins in vivo, suggesting that both vascular ETA
and ETb receptors contribute to venoconstriction to ET-1
in humans (Fig. 8). Indeed, this is further supported by the
capacity for BQ-123 to attenuate venoconstriction in vivo
to ET-1, but not SRTX S6c (Strachan et al., 1995). Here,
there remains a portion of the ET-1 response that is not in¬
hibited by 13Q-1 23 and is likely to be ETR mediated. In ad¬
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FIGURE 8. Vasoconstriction in the forearm (a) and venocon¬
striction in the hand vein (b) following infusion of ET-1 (■, 5
pmol/min) or SRTX S6c (□, 5 pmol/min) into the brachial
artery (a) and the dorsal hand vein (b) of healthy human sub¬
jects. Values are mean ± SEM; n + 6 for each group, i.a., intra¬
arterial. Reproduced from Haynes et al. (1995), with permission
of the copyright holder, American Heart Association, Dallas.
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1993a) and SRTX S6c (Strachan et al., 1995) are markedly
attenuated by endothelial ETB-mediated production of va¬
sodilator substances prostacyclin and NO. However, veno-
dilatation to the ETs has not been shown in human skin ca¬
pacitance vessels (Haefeli et al., 1993). Venoconstriction in
vivo is blocked more effectively by the KATP channel opener
cromakalim than the Ca2+ channel antagonist nicardipine
or by hydralazine (Haynes and Webb, 1993c), suggesting
that ET-1 responses in human veins depend only in part on
Ca2+ entry through dihydropyridine-sensitive Ca2+ chan¬
nels. In addition, the greater efficacy of KAn> channel open¬
ing agents is consistent with ET-1 acting to close KAXP
channels, causing plasma membrane depolarisation and
vasoconstriction by mechanisms additional to opening of
voltage-operated Ca2+ channels.
In humans, brachial artery administration of big ET-1
causes a dose-dependent forearm vasoconstriction that is
completely blocked by phosphoramidon, suggesting that
the effects of the precursor are mediated through conver¬
sion to the mature peptide by ECE (Haynes and Webb,
1994). The blockade of constriction to big ET-1 by phos¬
phoramidon is unlikely to have been due to inhibition of
ET receptor binding, because vasoconstriction to ET -1 was
unaffected by phosphoramidon and because conversion to
ET-1 and its C-terminal fragment was confirmed in plasma
samples taken from the veins draining the infused forearm
(Plumpton et al., 1995). Because circulating blood exhibits
little ECE activity (Watanabe et al., 1991a), conversion of
big ET-1 in the forearm probably occurs via vascular ECE
situated within the forearm blood vessels. The difference in
potency between big ET-1 and ET -1, and the ratio of C-ter-
minal fragment to big ET-1 in venous blood, both indicate
that local ECE converts about 10% of luminally presented
big ET-1 to ET-1, consistent with ~10% conversion of ex¬
ogenous big ET-1 by cells expressing the ECE-1 gene (Xu et
al., 1994).
Additional variations in regional vascular responses are
indicated by the observation, in the skin microcirculation,
that vasoconstriction appears to be mediated solely by ETA
receptors (Wenzel ecal., 1994).
4.4. Effects on the Heart
ET-1 is a potent and long-lasting constrictor of coronary
vessels in vivo in many species (Clozel and Clozel, 1989;
Kurihara et al., 1989; Pernow et al., 1989; Hirata et al.,
1990), producing marked reductions in coronary blood flow
and causing associated myocardial ischaemia. Coronary an¬
giograms reveal these effects are primarily due to effects on
small coronary arteries (Kurihara et al., 1989; Hirata et al.,
1990). The coronary resistance bed is more sensitive to the
effects of ET than other resistance beds, excepting the kid¬
ney (Clozel and Clozel, 1989). The initial hypotension pro¬
duced by ET is associated with an increase in heart rate and
cardiac output, suggesting that it is secondary to systemic
vasodilatation. In contrast, the pressor response to ET is as¬
sociated with bradycardia and a reduction in stroke volume,
causing a marked reduction in cardiac index (Miller et al.,
1989). The chronotropic effects of ET-1, at least in vivo, ap¬
pear to be reflex in origin because heart rate does not
change when ET-1 is administered after blockade of cardiac
efferent neural mechanisms (Gardiner et al., 1990b). The
reduction in stroke volume is probably due to a combina¬
tion of systemic vasoconstriction increasing afterload and
coronary vasoconstriction causing myocardial ischaemia
(Miller et al., 1989; Yang et al., 1991). In separate studies,
both anti- and pro-arrhythmic effects have been suggested
for ET-1. In isolated ventricular myocytes, ET-1, acting
through ETa receptors, inhibits a protein kinase A-depen-
dent chloride current, an action that should help to protect
the ventricle against arrhythmias (James et al., 1994). How¬
ever, in anaesthetised pigs, administration of ET-1 initiates
fatal ventricular arrhythmias (Ezra et al., 1989). Further¬
more, in rat models of acute myocardial ischaemia, exoge¬
nous ET-1 reduces the threshold for ventricular fibrillation
(Zhao etal., 1994) and increases the severity and incidence
of ischaemic arrhythmias (Garjani et al., 1995). Interest¬
ingly, again in the rat acute ischaemia model, the ETA
receptor antagonist BQ-123 reduces the incidence of ar¬
rhythmias when administered at low doses, but when ad¬
ministered at higher doses, which may no longer be ETA re¬
ceptor selective, it is pro-arrhythmic (Garjani et al., 1995).
Clearly, further investigations are required to investigate
the pro- and antiarrhythmic effects of ET-1.
In humans, infusion of ET-1 tends to reduce cardiac out¬
put (Wagner et al., 1992b), probably through a barorecep-
tor-mediated decrease in heart rate, although an increase in
afterload may also contribute. Coronary vasoconstriction
has not been observed in clinical studies, but is recognised
to occur in humans who are bitten by the burrowing asp A.
engaddensis, the venom of which contains SRTXs (Weiser
et al., 1984).
4.5. Effects on the Kidney
ET-1 has two main direct actions on the kidney, renal vaso¬
constriction and increased tubular sodium and water loss.
These effects probably reflect separate sites of action and
perhaps separately regulated ET systems in blood vessels
and renal tubules. ET -1 is a potent constrictor of both affer¬
ent and efferent glomerular arterioles in vivo, resulting in re¬
duced renal plasma flow and glomerular filtration rate, and
hence, reduced urine flow and sodium excretion (King et
al., 1989; Lerman et al., 1991b). The ET receptor subtype
mediating renal vasoconstriction appears to be very depen¬
dent on species, involving, for example, ETA receptors in
the dog (Brooks et al., 1994) and ETB receptors in the rat
(Cristol et al., 1993). The modulatory role of prostanoids
remains unclear (Cao and Banks, 1990b; Munger et al.,
1993). ET-1 also appears to have diuretic and natriuretic ef¬
fects, although it presently is unclear whether or not these
are related to changes in arterial pressure (King et al., 1989;
Perico et al., 1991). Both groups suggest that a direct action
of ET-1 on the proximal tubules contributes to diuresis and
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natriuresis, probably mediated by tubular ETR receptors. In
conscious rats, big ET-1 causes smaller decreases in renal
blood flow and glomerular filtration rate than ET-1 (Gar¬
diner et al., 1993; Hoffman et al., 1990). This difference
may occur because big ET-1 is more readily converted to
the mature peptide in tubular capillaries, where ET-1 medi¬
ates diuresis and natriuresis, than in the glomeruli and arte¬
rioles, where ET -1 decreases renal blood flow and glomeru¬
lar filtration rate. In humans, distribution of ET receptor
mRNA (Karet and Davenport, 1995) is consistent with re¬
nal vasoconstriction being mediated by ETA receptors and
the tubular actions by ETR receptors.
In humans, systemic infusion of ET-1 causes renal vaso
constriction similar to that observed in the splanchnic bed
(Weitzberg et al., 1991), but more marked than in the leg
(Gasic et al., 1992). Infusion of ET-1 decreases renal so¬
dium excretion (S0rensen et al., 1994), even at doses insuf¬
ficient to cause renal vasoconstriction (Rabelink et al.,
1994). Thus, to date, there is no in two evidence in humans
for a renal tubular diuretic action of ET-1, although studies
with selective ET receptor antagonists may prove more in¬
formative.
4.6. Effects on the Pulmonary Circulation
In the pulmonary circulation, ET-1 is a potent vasodila¬
tor at low doses (Lippton et al., 1991; Deleuze et al., 1992;
Wong et al., 1993) and vasoconstrictor at high doses in vivo
(Kadowitz et al., 1991). In vitro, the vasoconstrictor effects
of ET-1 in human pulmonary resistance vessels are medi¬
ated through both ETA and ETB receptors (McCulloch and
Maclean, 1995). The pulmonary vasodilator response, at
least in newborn lambs, appears to be mediated in part by
the release of NO, and may involve KAXr channels, but does
not involve vasodilator prostanoids (Wongetal., 1993). In
humans, a dose of ET-1 sufficient to increase systemic vas¬
cular resistance by about 10% does not increase pulmonary
vascular resistance (Wagner et al., 1992b). This area clearly
merits further investigation.
4.7. Interactions With the Nervous System
ET-1 has central actions that may contribute to its pressor
actions. Intracerebroventricular administration of low doses
of ET-1 increases blood pressure through stimulation of
central sympathetic outflow in the rat (Ouchi et al., 1989;
Yamamoto et al., 1991) and rabbit (Matsumura, K. et al.,
1991). This pressor effect occurs with doses of ET-1 that are
not sufficient to increase blood pressure when administered
i.v. Also, centrally administered ET-1 appears to sensitise
the baroreceptor reflex by reducing resting parasympathetic
tone (Itoh and van Den Busse, 1991). In addition, chronic
intracerebroventrtcular infusion of low dose ET-1 for 7 days
progressively increases blood pressure, in association with
increased urinary catecholamine and vasopressin excretion
(Nishimura et al., 1991). Furthermore, the presence of
granules with ETC immunoreactivity, together with the
profound effects on salt and water balance in rats, with sub¬
stantial inhibition of thirst in water deprived animals, when
ET-3 is topically applied to the hypothalamus (Samson et
al., 1991), suggests that ET may be involved in central reg¬
ulation of fluid and electrolyte balance.
ET-1 may also have a role in the peripheral autonomic
nervous system. Binding sites for ET-1 are present in the ca¬
rotid bifurcation, and topical application of the peptide in¬
hibits baroreceptor and stimulates chemoreceptor, re¬
sponses at this site (Spyer et al., 1991). In addition, ET-1
may potentiate the peripheral actions of the sympathetic
nervous system in threshold doses (Wong-Dusting et al.,
1990; Yang et al., 1990). Furthermore, ET-1 markedly ele¬
vates venous tone in vivo in rats via a reflex increase in sym
pathetic nerve activity and activation of a adrenoreceptors
(Waite and Pang, 1992). However, in humans, a peripheral
interaction of ET-1 with the sympathetic nervous system
has not been demonstrated in forearm resistance (Cock-
croft et al., 1991) or cutaneous capacitance vessels (Haynes
et al., 1994) of healthy subjects in vivo.
4.8. Interactions With Endocrine Systems
ET-1 tends to increase the activity of the renin-angio¬
tensin-aldosterone system, except that it inhibits renin re¬
lease from isolated rat glomeruli in vitro (Rakugi et al.,
1988). ET-1 stimulates the tissue renin-angiotensin system
of the rat mesenteric bed, increasing generation of renin
and angiotensin II (Rakugi et al., 1990). ET-1 also stimu¬
lates endothelial ACE activity (Kawaguchi et al., 1991). In
the adrenal gland, ET-1 stimulates release of aldosterone
from isolated cortical zona glomerulosa cells (Cozza et al.,
1989) and adrenaline from medullary chromaffin cells
(Boarder and Marriott, 1989). In vivo, administration of
ET-1 to animals increases renin, as well as aldosterone and
adrenaline concentrations (Nakamoto et al., 1989; Cao and
Banks, 1990a); renin secretion probably occurring as a re¬
sult of ET-1-induced renal vasoconstriction. The pressor re¬
sponse to ET-1 is unaffected by pretreatment with the ACE
inhibitor captopril (Cao and Banks, 1990a), whereas renal
vasoconstriction is abolished by captopril, implying some
regional variations in the interaction between ET-1 and
the renin-angiotensin system. In contrast, to the acute pres¬
sor response, hypertension caused by chronic infusion of
ET-1 appears to be completely prevented by concomitant
administration of captopril (Mortensen and Fink, 1992b),
suggesting that the chronic pressor response may be medi¬
ated via the renin-angiotensin system or that this system in
some way is permissive. Flowever, chronic infusion of ET-1
does not increase plasma angiotensin II concentrations
(Mortensen and Fink, 1992b), implying either that ET-1
interacts with a tissue renin-angiotensin system or that the
effect of captopril is not mediated through decreased angio¬
tensin II generation, perhaps involving kinins. These observa¬
tions may be of clinical relevance and require confirmation.
Concentrations of ET-1 and vasopressin increase in par¬
allel during upright tilt in healthy subjects and are un¬
changed during tilt in patients with diabetes insipidus
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(Kaufmann etal., 1991). Although the suggestion has been
made that ET-1 is acting as a classical circulating hormone
in these circumstances, this seems unlikely, given that
plasma concentrations are below that necessary to cause di¬
rect vasoconstriction. In addition, such rapid changes in
plasma ET perhaps may reflect alterations in ET clearance
rather than generation. Nevertheless, ET-1 may play an au¬
tocrine or paracrine role in control of vasopressin release
because infusion of the peptide increases vasopressin con¬
centrations in dogs (Nakamotoetal., 1989).
Circulating concentrations of atrial natriuretic peptide
are increased by infusion of ET-1 in rats (Stasch et al.,
1989; Garcia et al., 1990), and pretreatment of rats with
antiserum to atrial natriuretic peptide potentiates the pres¬
sor response to ET-1 (Valentin et al., 1991). Thus, endoge-
nously generated atrial natriuretic peptide may modulate
the vasoconstriction to ET-1 in vivo. Brain natriuretic pep¬
tide concentrations are increased after bolus injection of
ET-1 in rats, partly through a change in blood pressure and
partly through direct stimulation by ET-1 (Horio et al.,
1992). The relevance of atrial peptides in modulating re¬
sponses to ETs in humans remains to be determined.
4.9. Endothelin and Basal Vascular Tone
There is increasing evidence from studies using ECE inhibi¬
tors and ET receptor antagonists that basal generation of
ET-1 contributes to the maintenance of basal vascular tone
and to regulation of blood pressure. Many studies conclude
that ET receptor antagonists have no effect on blood pres¬
sure in normotensive animals. However, carefully designed,
adequately powered studies that have followed haemody-
namic responses for several hours after administration of an
ECE inhibitor or ET receptor antagonist do provide evi¬
dence for a role of ET -1 in regulation of basal vascular tone.
Such studies are able to take into account the slow reversal
of ET-1-induced vasoconstriction by anti-ET agents (Warner
et al., 1994). Inhibition of ET generation by administration
of the ECE inhibitor phosphoramidon slowly decreases
mean arterial pressure in normotensive and spontaneously
hypertensive rats (SHRs) over several hours (McMahon et
al., 1991). Similar results have been obtained more re¬
cently using ET receptor antagonists. Intravenous infusion
of the selective ETA receptor antagonist BQ-123 into nor¬
motensive Sprague-Dawley rats decreases mean arterial
pressure by ~15% over 60 min (Pollock and Opgenorth,
1993). In addition, a 6-hr infusion of BQ-123 decreases
blood pressure by —-15% in Wistar-Kyoto (WKY) normo¬
tensive and spontaneously hypertensive rats (Nishikibe et
al., 1993). Although blood pressure did not decrease signif¬
icantly in normotensive rats in this study, probably owing
to the small numbers studied and the smaller absolute
changes in blood pressure in these animals, they fell on the
same regression line for effects of treatment as the hyper¬
tensive animals, suggesting that the relative magnitude of
the hypotensive response to the ETA antagonist is no
greater in hypertensive then normotensive rats. Further¬
more, the combined ET^ antagonist Ro 46-2005 has been
shown to dose-dependently lower blood pressure by —30%
over several hours in sodium-depleted squirrel monkeys
(Clozel et al., 1993). Finally the ETA antagonist BQ-123
and the ETA/ETB antagonist bosentan both lower blood
pressure by —20% in anaesthetised and conscious guinea
pigs (Wniant et al., 1994). The hypotensive effect of
bosentan is not affected by blockade of the sympathetic or
parasympathetic nervous systems, or by inhibition of renin,
cyclooxygenase, bradykinin or NO. Bosentan has no addi¬
tional hypotensive effect to BQ-123 when co-administered
with the ETa antagonist, suggesting that ET-1 contributes
to the maintenance of resting arterial blood pressure pre¬
dominantly through activation of ETA receptors in these
animals. Together, these results imply that ET-1 contrib¬
utes to the maintenance of blood pressure under physiologi¬
cal conditions, at least in some species, probably through its
actions as a potent arteriolar vasoconstrictor.
It was hoped that studies with transgenic animals might
improve our understanding of ET's role in blood pressure
control. However, neither ET-1 overexpressing rats nor
ET-1 gene-deficient mice are viable (Kurihara et al., 1994;
Maemura et al., 1995). In the latter case, homozygous ET-1
deletion mice have serious craniofacial abnormalities that
result in death from asphyxia soon after birth, demonstrat¬
ing a role for ET-1 in development of pharyngeal arch-
derived tissues and organs (Kurihara et al., 1994). Heterozy-
gotes, although anoxic, are viable and have reduced plasma
and tissue ET-1 concentrations, but paradoxically, slightly
higher blood pressure than the wild-type mice. The reasons
for the increased blood pressure are not understood com¬
pletely; preliminary studies have demonstrated that sensi¬
tivity to ET-1 is not increased in these mice, nor is release
of endothelium-dependent relaxant factors reduced. Ele¬
vated blood pressure is unlikely to indicate a hypotensive
role for ET-1, it is more likely to be explained by changes in
the chemoreceptor reflex and increases in the sympathetic
drive in the heterozygotic mice. Rats overexpressing the
ET-2 gene are viable, but not hypertensive, perhaps be¬
cause the highest gene expression is in the kidney rather
than in the blood vessels and because plasma levels of ET-2
are only marginally increased (Leifeldt et al., 1995).
Brachial artery infusion studies have been used to ex¬
plore the role of ET-1 in maintenance of basal vascular
tone in humans (Haynes and Webb, 1994). The ECE and
NEP inhibitor phosphoramidon caused progressive vasodi¬
latation of forearm resistance vessels, whereas a selective
NEP inhibitor thiorphan caused vasoconstriction, suggest¬
ing that generation of ET-1 by ECE provides an important
contribution to the maintenance of basal vascular tone in
humans. This work is supported by the results of additional
studies in which brachial artery infusion of the ETA recep¬
tor antagonist, BQ-123 also caused progressive substantial
forearm vasodilatation (Fig. 9). These results suggest that
endogenous generation of ET-I maintains forearm vascular
tone in humans, at least in part through activation of ETA
receptors. However, a role for ETR receptors cannot be ex-

























FIGURE 9. Brachial artery infusion of ET-1 to healthy human
subjects causes significant forearm vasoconstriction (•) that
can be abolished by co-infusion of the ETA receptor antagonist
BQ-123 (O). Infusion of BQ-123 alone causes progressive and
substantial forearm vasodilatation (■). Values are mean ±
SEM; n = 6 for each group. Reproduced from Haynes and
Webb (1994), with permission of the copyright holder, The
Lancet Ltd., London.
eluded presently, and studies with ETR receptor antagonists
are urgently needed to resolve this issue.
More recently, a major cardiovascular role for ET-1 sug¬
gested by studies in the forearm has been confirmed on sys¬
temic administration of an ET receptor antagonist in humans
(Haynes et al., 1996). Studies in healthy normotensive sub¬
jects have shown that i.v. administration of doses of 10-
1000 mg of the peptide comhined FTA/ETB receptor antag¬
onist TAK-044 causes ~10% reduction of blood pressure
that is sustained for at least 4 hr, predominantly through an
effect on peripheral vascular resistance. The change in
blood pressure occurs at doses as low as 10 mg, and is ac¬
companied by an increase in cardiac index. Systemic doses
as low as 30 mg were able to abolish the local vasoconstric¬
tion to ET-1 given into the brachial artery up to 3 hr later.
As in animal studies (Loffler et al., 1993; Fukuroda et al.,
1994), TAK-044 caused an increase in plasma ET concen¬
tration. This appears to be due to an effect on clearance,
rather than production, because ETR, but not ETA block¬
ade, increases plasma ET-1 and ET-5 concentrations with¬
out increasing big ET-1 concentrations (Loffler et al.,
1993). Additionally, only ETB receptor blockade increases
the half-life of exogenous [1251]-ET-1. Furthermore, the in¬
crease in plasma ET is substantial and occurs within 15
min, which is unlikely to be related to de novo generation of
ET-1. The rise in plasma ET-1 was not unfavourable; in
fact, it provided a measure of efficacy correlating closely
with the fall in blood pressure.
Few mediators, besides ET-1, have been shown to have
such a fundamental physiological role in maintenance of
basal vascular tone. Sustained vasoconstriction elicited by
ET-1 may act in concert with the short-lived effects of
other regulatory systems, such as the sympathetic nervous
system and MO, to stabilise vasomotor tone, while preserv
ing flexibility in its dynamic control. These results, and
those from animals, suggest that orally active ECE inhibi¬
tors and ET receptor antagonists may have potential thera¬
peutic uses as novel vasodilator agents in situations of
chronic vasoconstriction and in conditions characterised
by ET-1 -mediated vasospasm.
5. ENDOTHELIN IN
CARDIOVASCULAR PATHOPHYSIOLOGY
Several requirements are necessary before it is appropriate
to attribute a role to ET in cardiovascular disease. These in¬
clude: (i) evidence that ET mimics, or causes, the conse¬
quences of this disease; (ii) that production of ET or its re¬
ceptors are increased in the disease; and (iii) that inhibitors
of the production or actions of ET can ameliorate the dis¬
ease process. In many conditions, some of these require¬
ments have been fulfilled, but not all. Increased plasma ET
concentrations and increased vascular sensitivity to ET can
be particularly misleading: the former because ET is re¬
leased abluminally (Wagner et al., 1992a), is not generally a
circulating hormone (Haynes and Webb, 1993b), and its
plasma concentrations may be more dependent on clear¬
ance than production; and the latter because increased pro¬
duction may lead to receptor down-regulation and reduced
sensitivity to exogenous peptide (Bloch et al., 1989a),
whereas reduced production may lead to receptor up-regu-
lation and increased sensitivity. Unless responses to exoge¬
nous ET are interpreted in the light of ET receptor number
and affinity, the results of such studies may suggest that ET
is not involved in pathological conditions in which its pro¬
duction is increased. In contrast, studies with antagonists
are particularly important, and these have been aided by
the rapid development of selective and potent antagonists
at ETa and ETB receptors. Another potentially confound¬
ing factor when examining responses in blood vessels is the
influence of the structural changes that can occur in hyper¬
tension and heart failure and are discussed in Section 4-3.
This section addresses the major cardiovascular diseases in
which the ET system has been implicated and in which in¬
hibition of the production or effects of ET might offer new
therapeutic perspectives.
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5.1. Hypertension
Established essential hypertension is a condition character¬
ised by a high blood pressure in association with increased
peripheral vascular resistance. Cardiac and vascular hyper¬
trophy may also develop, and are associated with a worse
prognosis. In the early stages, and in borderline hypertension,
cardiac output appeals to increase and sympathetic tone may
be enhanced. This common condition, affecting around
10% of the adult population, makes a major contribution to
the population burden from cardiovascular disease, predis¬
posing particularly to myocardial infarction, stroke, and heart
and kidney failure. A number of effective hypotensive drugs
are available for the treatment of this condition, although
none are fully effective against the commonest consequence
of essential liypeitension, myocardial infarction. In addition,
the mechanisms causing essential hypertension are still
poorly understood, and the drugs presently available may not
act to oppose the important causal mechanisms.
The endothelium is an attractive target for investigation
in essential hypertension, and in cardiovascular disease in
general. It is clear that NO plays an important role in regu¬
lation of vascular tone and platelet aggregation (Vane et
al., 1990), and endothelial dysfunction related to the
L-arginine/NO system occurs in hypertension, diabetes
mellirus and hyperlipidacmia (Vallance and Moncada,
1994), all of which conditions predispose to an increased
risk of cardiovascular disease. ET-1 is also an attractive tar¬
get for investigation in hypertension because it has potent
vasoconstrictor and pressor properties, is mitogenic and can
cause vessel hypertrophy, and it appears to enhance sympa¬
thetic fulieliou in vino.
5.1.1. Endothelin concentrations and production. In ani¬
mal models of hypertension, ET-1 concentrations are not
raised unless accelerated hypertension is present, in which
case, they correlate positively with plasma creatinine (Yan
et al., 1990; Suzuki el al., 1990; Vemulapalli et al., 1991;
Kohno et al., 1991). Local mesenteric vascular generation
of ET appears to be increased in cirro in SHP. compared
with WKY rats (Miyamori et al , 1991). However, others
have found ET immunoreactivity to be increased in blood
vessels from deoxycorticosterone acetate (DOCA)-salt rats,
but decreased in blood vessels from SHR as compared with
normotensive WKY rats (Lariviere et al., 1993). In func¬
tional studies in rats, the hypotension following infusion of
the ECE inhibitor phosphoramidon was similar in WKY
and SHR (McMahon et al., 1991). Also against a role for
increased generation of ET-1 in the pathophysiology of ex¬
perimental hypertension is the finding that polymorphisms
of the prepro ET-1 gene do not co-segregate with blood
pressure or cardiac weight in inbred Dahl rats (Cicila et al.,
1994). Interestingly, the ET-3 gene does appear to be
linked to a locus that regulates blood pressure in these rats
and in humans, variations in the prepro ET-1 and ETA
genes recently were shown to be linked to hlixxl pressure in
a population study (Stevens and Brown, 1995).
Renal effects of ET may also potentially contribute to the
development of hypertension. The vascular/glomerular ac¬
tions (mainly ETA) predispose to sodium retention and may
be enhanced in the SHR (Tomobe et al., 1988). The renal
tubular actions (mainly ETB) act to increase urinary sodium
and water excretion. Generation of ET-1 in the renal me¬
dulla, particularly the collecting duct, is reduced in SHR
compared with WKY rats (Kitamura et al., 1989; Hughes et
al., 1992) and, therefore, may contribute to sodium reten¬
tion and hypertension in this species. Patients with essen¬
tial hypertension excrete less immunoreactive ET in urine
than normotensive controls (Hoffman et al., 1990), empha¬
sising the need for further investigation in this area.
Plasma immunoreactive ET concentrations were re¬
ported to be elevated in the first studies in hypertensive pa
tients (Kohno et al., 1990; Saito et al., 1990; Shichiri et al.,
1990). However, clearance of ET-1 is very dependent on
renal function (Kohno et al., 1989; Koyama et al., 1989),
and the high concentrations found in severe and acceler¬
ated phase hypertension are, at least in part, secondary to
impaired renal clearance of ET. Studies in well-character¬
ised hypertensive patients with normal renal function have
shown similar concentrations of ET-1 to those in well-
matched normotensive subjects (Davenport et al., 1990;
Schiffrin and Thibanlr, 1991; Haak et al , 1997; Haynes et
al., 1994). Indeed, in one study, there was a negative corre¬
lation between blood pressure and plasma ET-1 in the hy¬
pertensive group (Davenport et al., 1990), making a global
increase in generation of ET-1 unlikely as a cause of essen¬
tial hypertension. In the hypertension associated with pre¬
eclampsia of pregnancy, plasma ET is elevated despite nor
mal renal function, consistent with a role for ET in the
pathophysiology of this hypertensive condition (Florijn et
al., 1991).
Increased production of ET-1 occurs in one secondary
form of hypertension, albeit rare. In 1991, Yokokawa and
colleagues described two cases of the skin tumour hacman
gioendothelioma in which hypertension was associated
with increased plasma ET concentrations. Biopsies of tu¬
mour cells displayed increased expression ofmRNA for pre
pro ET 1 and strong immunohistochemical staining for the
peptide. Blood pressure and plasma ET concentrations re¬
turned to normal in both cases following surgical resection
of the tumours, and in one patient, recurrence of the tu¬
mour led to a further increase in both blood pressure and
plasma ET.
5.1.2. Sensitivity to endothelin. In studies designed to
examine vascular sensitivity to ET-1 in hypertension, it is
important to be aware that the development of vascular hy¬
pertrophy will tend to amplify responses in the hyperten¬
sive vessels (Folkow, 1978). In studies comparing WKY and
SHR, both conduit and resistance vessels from the SHR are
more sensitive to the effects of ET-1 (Tomobe et al., 1988;
Clozel, 1989; Maclean and McGrath, 1990; Criscione el
al., 1990). In the Dahl salt sensitive rat, vascular respon¬
siveness to ET is enhanced prior to, but not after, tbe devel-
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opment of hypertension (Goligorsky et al., 1991). Other in¬
vestigators have reported decreased sensitivity to ET in the
aorta and mesenteric resistance arteries from SHR (Dohi et
al., 1991), DOCA-salt rats (Deng and Schiffrin, 1992) and
renovascular hypertensive animals (Dohi et al., 1991; Rob¬
erts-Thompson et al., 1994). This may be a consequence of
receptor down-regulation secondary either to increased lo¬
cal generation of ET or raised blood pressure (Larivifcre et
al., 1993). Down-regulation of receptors is suggested by the
decreased Ca2+ response to ET-1 of isolated vascular
smooth muscle cells from SHR (Touyz et al., 1994). In this
regard, it is interesting that sensitivity to ET in hyperten¬
sive animals can be restored by antihypertensive therapy
(Dohi etal., 1992).
Systemic doses of ET-1 in vivo have greater pressor effects
in SHR than WKY rats (Miyauchi et al., 1989a) and in reno¬
vascular hypertensive than normotensive rabbits (Roberts-
Thompson et al., 1994). The mechanism for this enhanced
sensitivity to ET-1 is unclear because the number of bind¬
ing sites for ET-1 in aortic smooth muscle (Clozel, 1989)
and heart (Gu et al., 1990) are lower in SHR, suggesting in¬
creased postreceptor sensitivity or the influence of vascular
hypertrophy. There is, however, a relative increase in the
number of binding sites for ET-1 in the brain of SHR, as
compared withWKY rats (Gu etal., 1990), so there may be
increased CNS sensitivity to the peptide in hypertension.
In patients with essential hypertension, in vitro efficacy of
ET in subcutaneous resistance arteries appears to be re¬
duced (Schiffrin et al., 1992). However, in vivo, the situa¬
tion is rather different. A recent study (Haynes et al., 1994)
has investigated whether vasoconstriction to ET-1 is al¬
tered in patients with essential hypertension as compared
with well-matched normotensive control subjects (Fig. 10).
Responses were examined to local infusion of ET-1 into
hand veins, rather than arteries, because the venous system
may contribute to the high cardiac output reported to occur
in early hypertension and because the confounding effects
of vascular hypertrophy do not occur in hand veins
(Haynes etal., 1994; Eichler et al., 1989). Sympathetic re¬
sponses were also examined in this study because ET-1 has
been shown to potentiate sympathetic responses in vitro
(Ouchi et al., 1989; Matsumura, K. et al., 1991; Wong-
Dusting et al., 1990; Yang et al., 1990). ET-1 caused a slow-
onset venoconstriction in both groups of subjects, with the
maximal effect reached by 90 min. However, maximal
venoconstriction to ET-1 was substantially greater in hy¬
pertensive patients than in control subjects (Fig. 10). Sym¬
pathetically mediated venoconstriction was also enhanced
in the hypertensive patients, but not in the control subjects
(Fig. 10).
These studies (Haynes et al., 1994) have shown that pa¬
tients with essential hypertension have enhanced venocon¬
striction to ET-1. These results might be explained by de¬
creased local venous ET-1 generation, although plasma ET
concentrations were similar to those in normotensive sub¬
jects. The negative correlation with blood pressure in the
normotensive subjects is against this phenomenon, occur-
, ^ , ET-1 (5 pmol/iTiln) * ;$V-
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FIGURE 10. (a) Venoconstriction to ET-1 in normotensive
(O) and hypertensive (•) subjects, (b) Sympathetically medi¬
ated venoconstriction induced by single deep breath before and
during infusion of ET-1 in hypertensive and normotensive sub¬
jects. Values are the mean ± SEM, n = 8 for each group.
Reproduced from Haynes et al. (1994), by copyright permis¬
sion of The American Society for Clinical Investigation, New
York.
ring solely as a consequence of the increase in blood pres¬
sure, and a causal relationship with the elevation of blood
pressure is supported by the positive correlation in the hy¬
pertensive subjects. Enhanced facilitation of sympathetic
vasoconstriction appears to be a separate phenomenon be¬
cause the lack of basal tone in these vessels precludes an
explanation for enhanced venoconstriction to ET -1 by po¬
tentiated sympathetic responsiveness. In addition, the sym¬
pathetic effect appears to be confined to hypertensive pa¬
tients because, as well as in this study, it was not seen in a
separate study in normotensive subjects (Cockroft et al.,
1991). Interestingly, and very importantly, ventricular ET
immunoreactivity, ventricular ET binding sites, and cardiac
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myocyte prepro ET-1 mRNA are increased in the hearts of
animals with cardiac hypertrophy caused by suprarenal aor¬
tic banding (Arai et al., 1995). These findings are consis¬
tent with, and strongly supportive of, a role for ET-1 in the
pathogenesis of cardiac hypertrophy caused by pressure
overload, and suggest that ET antagonists may be capable of
reversing cardiac hypertrophy.
5.1.3. Studies with inhibitors and antagonists. Both ECE
inhibitors and FT receptor antagonists lower blood pressure
in hypertensive rat models (McMahon etal., 1991; Bazil et
al., 1992; Nishikibe et al., 1993; McMahon et al., 1993).
The ETA receptor antagonist BQ-123 acutely lowers blood
pressure in stroke-prone SHR, but not in control SHR or
WKY rats (Nishikibe et al., 1993). When administered
chronically, BQ-123 prevents the development of stroke
and renal abnormalities in stroke-prone SHR (Nishikibe et
al., 1993). This ETA receptor antagonist also lowers blood
pressure in low-renin animal models of hypertension (the
SHR and DOCA-salt treated rats), but not in control ani¬
mals or in a high-renin animal model of hypertension (Bazil
etal., 1992).
There is now also evidence that ET receptor antagonists
cause vasodilatation in hypertensive patients (Ferro et al.,
1996). In addition, the combined ETA/ETB antagonist
TAK-044 lowers blood pressure in healthy normotensive
humans (Haynes et al., 1996). As might be expected on
this basis, acute administration of the orally active com¬
bined ETa/ETb antagonist bosentan recently has been re¬
ported to lower blood pressure in subjects with essential hy¬
pertension.* At present, there is no evidence that drugs
based on blocking the ET system will be selectively 'antihy¬
pertensive' rather than hypotensive. However, based on va¬
sodilator, antimitogenic and sympatholytic properties, they
may offer particular advantages in the treatment of hyper¬
tension and the prevention of myocardial infarction. In¬
deed, given the potential role of ET-1 in the atherosclerotic
process, an antiatherosclerotic action may be of substantial
importance (see Section 5.2). The development of ET re¬
ceptor antagonists for the treatment of hypertension is
likely to be a major focus for clinical investigation over the
next few years.
5.2. Ischaemic Heart Disease
The SRTXs, potent vasoconstrictor peptides isolated from
snake venom with close structural similarity to the ETs
(Sokolowsky et al., 1990), cause death from myocardial
ischaemia and infarction secondary to coronary vasocon¬
striction (Wollberg et al., 1987). Exogenously administered
ET-1 also produces myocardial ischaemia (Kurihara et al.,
1989) by causing coronary vasoconstriction. Plasma ET
* Si limit!, R., Relz, G. G., Fell, D., Lebmeier, R., Prayer, G., Stahnke, P.
I. , Sinner, W. It., Karworth, A. and Jones, C. R. (1995) Effects of the
novel endoihelin receptor antagonist bosentan in hypertensive patients.
In Proceedings ol the 7th Meetiny of the European Hypertension Society,
June, 1995, Milan, Italy.
concentrations (Valesco et al., 1994) and myocardial ET-1
binding sites (Liu et al., 1990) are raised following is-
chaemia/reperfusion in animals. However, the evidence
suggesting a beneficial effect of ET antagonism upon myo¬
cardial infarct size has been contradictory. The ETA receptor
antagonists FR 139317 (McMurdoetal., 1994) and BQ-123
(Krause et al., 1994) had no effect on infarct size in rabbit
and canine model of myocardial infarction and repcrfusion.
In a rabbit model, infarct size was reported to be reduced
following intraventricular administration of a low dose of
ET-1, suggesting that ET-1 might have a cardioprotective
role (Hide et al., 1995). In contrast, monoclonal antibodies
against ET-1 (Watanabe et al., 1991b), ECE inhibitors
(Grover et al., 1992), selective ETA antagonists (Grover et
al., 1993) and combined ETA/ETB antagonists (Watanabe
et al., 1995) were all reported to reduce infarct size in rat
and canine models, supporting the view that endogenous
ET-1 worsens rather than improves the myocardial damage
that follows ligation of the coronary artery.
In humans, plasma ET is raised in acute myocardial in¬
farction and unstable angina (Miyauchi et al., 1989b), sug¬
gesting a possible pathophysiological role for ET-1, whereas
patients with stable angina do not have raised plasma ET
(Ray et al., 1992). The higher the plasma ET in myocardial
infarction (Omland et al., 1994) and unstable angina
(Wieczorek et al., 1994), the worse the prognosis. Plasma
ET concentrations on the third day after myocardial infarc¬
tion significantly related to mortality (Omland et al.,
1994), and plasma ET concentrations at 9 weeks after hos¬
pitalisation with unstable angina or non Q-wave myocar¬
dial infarction significantly related to the incidence of
further cardiovascular events (Wieczorek et al., 1994). Pa¬
tients undergoing fibrinolysis during the acute phases of
myocardial infarction have been shown to have reduced
plasma ET compared with patients who did not have early
reperfusion (Lechleitner et al., 1993).
ET-l could contribute to myocardial ischaemia and the
proliferative effects of ET-1 could contribute to vascular
and cardiac hypertrophy and the atherosclerotic process.
Indeed, plasma ET concentrations are raised in advanced
atherosclerosis (Winkles et al., 1993), and expression of
ET-1 mRNA is increased in the vascular smooth muscle of
atherosclerotic human arteries (Winkles et al., 1993). Fur¬
thermore, increased tissue ET immunoreactivity has been
reported in the active atherosclerotic lesions associated
with unstable angina (Zeiher et al., 1995).
The use of ET receptor antagonists in acute myocardial
infarction may be of clinical benefit. First, if they limit in¬
farct, they would slow the progression to heart failure. Sec¬
ond, they may reduce the incidence of further ischaemic
events or the need for revascularisation. Third, they may
prevent remodelling after infarction in a similar fashion to
ACE inhibitors. However, given the wide range of drugs
currently available for the treatment of myocardial infarc¬
tion, and the likely diminishing returns with additional
therapy, pharmaceutical companies may be wary of devel¬
oping FT receptor antagonists for this indication.
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Coronary sinus ET-1 levels are raised during and imme¬
diately after percutaneous transluminal coronary angio
plasty (PTCA) (Taharaet al., 1991). Although ET-1 could
be involved in the ischaemia, acute vasospasm, and abrupt
vessel closure related to PTCA, these complications are un¬
common and readily reversible with conventional therapy.
The main weakness of PTCA is the relatively high risk of
restenosis. Clinical restenosis occurs in up to 30% of pa
tients within the first year following the procedure (MER
CATOR Study Group, 1992) and is characteristically
associated with vascular smooth muscle proliferation. In ex¬
perimental models of angioplasty, ET-1 levels are raised af¬
ter balloon denudation of the endothelium (Azuma et al.,
1994) and areas of neointima formation show increased ex
pression of prepro ET 1, ECE 1, ETA and ETB receptor
mRNAs (Wang et al., 1995). Studies with ET antagonists
in these models show that smooth muscle proliferation is
inhibited by an ETA/ETB antagonist TAK-044 (Tsujino et
al., 1995), but not by the ETA antagonist BQ-123 (Azuma
et al., 1994; Douglas et al., 1995b). Thus, it is conceivable,
given the potent mitogcnic property of ET-1, that pro¬
longed treatment with an oral ETA/ETB oi ETB antagonist
may be useful in PTCA. Similar arguments are relevant to
graft occlusion after coronary artery bypass grafting.
Prinzmetal's, or variant angina, first described in 1959
(Prinzmetal et al., 1959), is characterised by chest pain de¬
veloping at rest, frequently in the early morning, and asso¬
ciated with ST elevation on the electrocardiogram. The
pain is usually relieved by glyceryl trinitrate. Coronary
spasm has been demonstrated at angiography in patients
with this condition, as well as the absence of occlusive le¬
sions (Dhurandhar et al., 1972). Patients with variant an¬
gina are known to have endothelial dysfunction, and as a
powerful vasoconstrictor of human (Yang et al., 1990) and
canine (Kurihara et al., 1989) coronary arteries, ET-1 has
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FIGURE 11 Bar graph of plasma ET concentration of healthy
subjects (normal) and CHF patients, grouped according to the
severity of heart failure as assessed by the New York Heart
Association (NYHA) score. Values are the mean ± SEM.
Reproduced from Wei et al. (1994), with permission of the
authors and the copyright holder, American Heart Association,
Dallas.
(Liischer, 1991). ET-1 also potentiates the coronary vaso¬
constriction induced by serotonin and noradrenaline in iso
lated human arteries (Yang et al., 1990). Patients with vari¬
ant angina have elevated plasma ET during provocation of
coronary vasospasm (Matsuyama et al., 1991), and one
study has also found basal plasma ET concentrations to be
elevated (Artigou et al., 1993). Interestingly, there is an in¬
creased prevalence of primary Raynaud's disease and mi
grainc in patients with variant angina (Miller ct al., 1981;
O'Keefe etal., 1992), and ET-1 has also been implicated in
the pathophysiology of all of these vasospastic disorders
(Haynes and Webb, 1993b).
It appears, therefore, that ET-1 has a pathophysiological
role in variant angina, either as a mediator of coronary va
sospasm or by sensitising the vasculature to other vasocon
strictors. In either case, ET receptor antagonists might
prove useful in the management of this condition.
5.3. Heart Failure
Congestive heart failure (CHF) is characterised by low car¬
diac output, sodium and water retention, peripheral vaso¬
constriction and activation of the renin-angiotensin-aldo¬
sterone axis (Zelis and Flaim, 1982; Francis et al., 1984).
ET-1 may be involved in the pathophysiology of CHF as
part of the neurohumoral response to cardiac failure (Stew¬
art, 1993), and its actions (Miller et al., 1989) would cer¬
tainly contribute to the vicious circle of haemodynamic dc
cline associated with this condition.
Plasma ET concentrations are raised in animal models of
CHF (Cavero et al., 1990) and in patients with CHF (Mc-
Murray et al., 1992). The increase in plasma ET concentra¬
tion correlates closely with the degree of haemodynamic
and functional impairment (Fig. 11; Wei et al., 1994;
Pacher et al., 1993), with higher concentrations predicting
a greater likelihood of death or need for cardiac transplan¬
tation (Pacher et al., 1993). Although impaired renal func¬
tion and decreased clearance of ET-1 may be involved in
generating high plasma ET, raised plasma big ET-1 concen¬
trations suggest that increased production may also contrib¬
ute (Pacher et al., 1993; Wei et al., 1994). Also, ET-1 re¬
lease by cultured cells is increased in the presence of
angiotensin II and vasopressin, levels of which arc elevated
in CHF (Emori et al., 1991). In patients with intractable
heart failure after myocardial infarction (Tohmo et al.,
1994), i.v. infusion of enalaprilat (the active form of enala-
pril) produced a clinical improvement, as well as a reduc¬
tion in plasma ET.
The ETa receptor antagonist BQ-123 and the ECE in¬
hibitor phosphoramidon cause peripheral vasodilatation
when infused into the forearm circulation of patients with
stable CHF already on treatment with a loop diuretic and a
maximal dose of an ACE inhibitor (Love et al., 1994). In
comparison to healthy subjects, vasodilatation to BQ 123
tended to he reduced and that to phosphoramidon in¬
creased in patients with CHF, consistent with up-regula-
tion of ETR-mediated vasoconstriction. More recent studies
* p«-0.05 vj. i id Hitil
t p<0.05 vs. NYHA III
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TABLE 4. Haemodynamic Effects of the ET Receptor
Antagonist Bosentan in Patients with Chronic Heart Failure
Bosentan
0 100 mg i.v. 200 mg i.v. P
MAP (mmHg) 84 78 75 <0.001
CI (L/min/m2) 2.13 2.41 2.43 <0.001
SVR (dvn.sec.cm~1') 1479 1736 1187 <0.001
PCWP (mmHg) 22.5 20.8 19.8 <0.001
RAP (mmHg) 11.1 9.5 9.1 <0.001
HR (beats/min) 86 85 85 NS
Effect of bosentan on mean arterial pressure (MAP), cardiac index (CI),
systemic vascular resistance (SVR), pulmonary capillary wedge pressure
(PCWP), right atrial pressure (RAP) and heart rate (HR) in patients with
severe (NYHA Grade lllz-lV) heart failure. Values are shown before infu¬
sion (0), at 60 min after infusion of 100 mg bosentan and at 60 min after
the subsequent infusion of 200 mg bosentan,each administered i.v. over 15
min. p values for repeated measures ANOVA.
Adapted from Kiowski et al., (1995).
Reprinted with permission from the American College of Cardiology
(Journal of the American College of Cardiology [1995] Special Issue: 44th
Annual Scientific Session, American College of Cardiology, New Orleans,
March 19 25, 1995, Absuact 779-1).
with ET-1 and the ETB specific agonist SRTX S6c are also
consistent with this hypothesis (Love et al., 1996). Angio¬
tensin II concentrations are increased in CHF and, interest¬
ingly, angiotensin II has been shown to down-regulate total
ET binding sites (Roubert et al., 1989), but up-regulate ETB
receptor mRNA (Kanno et al., 1993). Given that ETB re¬
ceptors can mediate vasoconstriction (Haynes et al., 1995),
it may be that vasoconstrictor ETB receptors have greater
functional significance in CHF. Encouragingly, recent stud¬
ies have shown that systemic doses of the combined ETA/
ETb antagonist bosentan in patients with severe chronic
heart failure produces sustained systemic, pulmonary and
peripheral venous vasodilatation, and improved cardiac
performance, without causing reflex tachycardia (Table 4;
Kiowski et al., 1995). Interestingly, in an animal model of
CHF, bosentan provided additional haemodynamic benefit
when combined with an ACE inhibitor (Teerlink et al.,
1994b).
These observations justify the development of combined
ETa/ETb antagonists for the treatment of CHF. Vasodilata¬
tion has proved to be the most effective of the recent thera¬
peutic approaches to CHF (Cohn et al., 1991; The SOLVD
Investigators, 1991), and, therefore, the results of longer-
term clinical studies of ET receptor antagonists in CHF pa¬
tients must be awaited with interest.
5.4. Cerebrovascular Disease
5.4.1. Ischaemic Stroke. The evidence for a pathophysi¬
ological role for ET-1 in ischaemic stroke is relatively weak.
Increased plasma and cerebrospinal fluid (CSF) concentra¬
tions of ET have been found in animal models of stroke
(Willette et al., 1993). Although there have been few stud¬
ies with ET antagonists, the combined ETA/ETB receptor
antagonist SB 209670 has been shown to protect from isch-
aemia-induced neuronal degeneration in a gerbil stroke
model (Ohlstein et al., 1994). Plasma ET is also raised in
humans after ischaemic stroke (Ziv et al., 1992), suggesting
a possible pathophysiological role for ET in this condition.
However, considerably more experimental evidence from
animal models is required before clinical trials with ET an¬
tagonists are likely to be embarked on in this indication.
5.4.2. Subarachnoid haemorrhage. The development of
cerebral vasospasm within the first 2 weeks after subarach
noid haemorrhage (SAH) is responsible for much of the
morbidity and mortality associated with this condition
(Asanoet al., 1990; Seifert et al., 1995), and ET-1 has been
implicated in mediating SAH-induced vasospasm. ET-1 is a
potent vasoconstrictor of isolated cerebral arteries (Asano
et al., 1989) and its effects are potentiated after SAH
(Alafaci et al., 1990). Plasma ET levels are raised in a ca¬
nine model of SAH (Yamamura et al., 1992), and injection
of exogenous ET-1 into the CSF of dogs reproduces the va¬
sospasm that occurs following SAH (Asano et al., 1989).
Furthermore, both thrombin and oxyhaemoglobin, which
arc present in high concentrations in SAH, are known to
induce ET-1 release (Yanagisawa et al., 1988a; Schini et al.,
1989; Mayberg et al., 1990).
Inhibition of the enzymatic conversion of big ET-1 to
ET-1 by phosphoramidon reduces the vasospasm seen in a
dog model of SAH (Matsumura, Y. et al., 1991a), as do
monoclonal antibodies to ET-1 (Yamamura et al., 1992).
The selective ETA antagonists BQ-123 (Clozel and Wa-
tanabe, 1993), BQ-485 (Itoh et al., 1993) and FR 139317
(Nirei et al., 1993) have also been shown to reduce vaso¬
spasm in other models of SAH. The combined ETA/ETB an¬
tagonist bosentan markedly reduces the delayed cerebral
vasospasm that follows injection of autologous blood into
the cisterna magna in a rabbit model of SAH (Roux et al.,
1995). Bosentan also reverses an established spasm in this
model when given i.v. without lowering systemic blood
pressure (Fig. 12; Roux et al., 1995). This finding may be of
great significance if bosentan is able to reverse vasospasm in
humans at a dose that has no systemic effects, as the major
complication of nimodipine, the current preferred treat¬
ment for SAH, is hypotension with the potential risk of fur¬
ther cerebral hypoperfusion.
Plasma and CSF ET concentrations are significantly
raised in patients after SAH (Masaoka et al., 1989; Seifert
et al., 1995) and are highest in those patients who develop
vasospasm (Suzuki etal., 1992). Thus, it appears that ET-1
may be implicated in the pathophysiology of delayed vaso¬
spasm following SAH. ET receptor antagonists may provide
an important addition to the limited range of drugs cur¬
rently available for the management of SAH, and clinical
studies must be awaited with great interest.
5.5. Raynaud's Disease
Raynaud's disease is a common condition in colder climates
(Belch, 1991). It is characterised by the development of ep¬
isodic ischaemia, usually in exposed extremities and associ¬
ated with exposure to cold, hormones, drugs and emotional
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FIGURE 12. Reversal of chronic
basilar artery spasm after exper¬
imental SAH in (a) rabbit (sin¬
gle haemmorhage) and (b) dog
(double haemmorhage), by sys¬
temic administration of an ET
receptor antagonist, bosentan.
SAH was induced by injection
of autologous blood into the cis¬
ternal magna. Changes in cross-
sectional area of the basilar
artery are displayed with the
corresponding arterial pressure
after treatment. Reproduced
from Roux et al. (1995), with
permission of the copyright
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stimuli (Cotton and Khan, 1986). Although many treat¬
ment.', aic available fui patients with Raynaud's disease,
none is effective in the majority of subjects (Cooke and
Nicolaides, 1990) and the pathophysiology remains unre¬
solved. Howevei, there is an association between Raynaud's
disease and other vasospastic conditions, including mi¬
graine and variant angina (Miller et al., 1981; O'Keefe et
id., 1992), suggesting that there may be a vascular defect com
moii to these conditions. A defect in endothelium depen
dent dilatation in the veins of patients with Raynaud's dis
ease has been reported (Bedarida ctal., 1993). Overproduction
of ET -1, reduced production of endothelium-dependent va¬
sodilator substances, or a combination of these effects, may
account for the vasospasm seen in Raynaud's disease.
Clinical studies have shown that plasma ET increases
rapidly during the cold-pressor test in healthy subjects,
peaking at 1 min after immersion of the arm in cold water
(Iyhrquist et al., 1990), and cold provocation tests in pa¬
tients with Raynaud's disease have shown an exaggerated
increase in ET concentrations in venous blood draining the
cold challenged arm, compared with both the control arm
and with responses in healthy control subjects (Zamora et
al., 1990). Elevated basal plasma ET has been reported in
Raynaud's patients between vasospastic episodes consistent
with increased production (Zamora et al., 1990).
These results support a role for ET-1 in the pathophysiol¬
ogy of Raynaud's disease. 1 lowever, so far there have been
no confirmatory studies using ET antagonists, which would
need to be more effective and better tolerated than the cur¬




The ETs are potent vasoconstrictor, pressor and co mitoge
nic peptides with uniquely sustained actions. They also
have effects on the heart, kidney, endocrine glands and
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nervous system that augment their pressor action. The ETs
act on the endothelium to mndnlarp their direct actions by
stimulating generation of NO and prostaglandins. Despite
these many actions, doubt had been expressed about the
physiological relevance of the FTs However, recent studies
now clearly show that ET-1 plays a fundamental physiolog¬
ical role in maintenance of basal vascular tone and blood
pressure in humans. Nevertheless, the relative importance
of each of the characterised pharmacological responses to
the ETs require further clarification, not least because this
may help in deciding which of the various ET antagonists
to develop for specific clinical indications This is particu¬
larly important in regard to the selectivity of ECE for the
different isoforms and in different tissues, as well as the rel¬
ative importance of vascular and endothelial ETB receptors.
There is now a wealth of evidence that ETs are impli¬
cated in the pathophysiology of cardiovascular diseases, in¬
cluding conditions such as hypertension and chronic heart
failure, that are characterised by sustained vasoconstriction,
as well as conditions such as unstable angina and SAH,
characterised by development of vasospasm In animal
models of these conditions, FT antagonists generally appear
to improve outcome. The combined FTA/ETB receptor an¬
tagonists TAK-044 and bosentan recently have been shown
to lower blood pressure (Haynes er al , 1996; Sehmitt et al.,
1995), suggesting utility in hypertension, and bosentan has
been shown to have favourable haemodynamics in patients
with chronic heart failure (Kiowski et al., 1995). In addi¬
tion, in a human forearm model of vasoconstriction, sys¬
temic TAK-044 blocks the vasoconstriction to locally in¬
fused ET-1, suggesting that such antagonists may be
valuable in the management of conditions associated with
ET-mediated vasospasm. The results of such studies bode
well for the clinical development of ET antagonists in
states of acute and sustained vasoconstriction. For manage¬
ment of acute conditions, such as myocardial infarction and
SAH, peptide ET antagonists without oral activity may
have a place. However, even in these conditions there are
still some grounds for developing orally active drugs, and it
is encouraging to find that a range of these agents are now
under development.
However, many questions presently remained unan¬
swered, not least of which is whether these agents will
prove safe and well tolerated in long-term use. More subtly,
it is unclear whether selective ETA receptor antagonists or
combined ETA/ETB antagonists are needed. Certainly,
where they have been used in clinical studies, combined
ETA/ETB antagonists appear to have favourable haemody-
namics. Also, there is evidence that smooth muscle ETB re¬
ceptors contribute to the vasoconstriction to ET-1 in vivo in
humans (Haynes et al., 1995), and there is a suggestion that
vascular ETB responses may be of greater importance in
heart failure (Love et al., 1994). Nevertheless, the loss of
endothelial ETB-mediated responses may be a disadvantage,
given the beneficial effects of NO on platelet aggregation,
and this matter requires clarification. Given the pharmaco¬
logical evidence for a distinction between endothelial and
smooth muscle ETB receptors (Warner et al., 1993), devel¬
opment of a combined ETA/smooth muscle ET„ antagonist
might be optimal, if perhaps currently unrealistic.
The development of ECE inhibitors to block generation
of ETs is an interesting concept, analogous to the develop
ment of ACE inhibitors. To date, however, it is unclear
whether there are several ECEs, and whether all of these
should or could be blocked by one agent. Also, some of the
drugs appear not to easily gain access to the important in
tracellular ECE-1 and ECE-2 enzymes (Xu et al., 1994;
Emoto and Yanagisawa, 1995). In addition, most of the cur¬
rently available ECE inhibitors also have an action against
NEP, and this may reduce their vasodilating capacity
(Haynes and Webb, 1994). An alternative approach might
be to aim for broader substrate specificity by inhibiting
ECE, ACE and NEP, thereby combining the benefit of the
ACE inhibitors with the potential additional benefits asso
ciated with ECE inhibition and raised concentrations of
atrial peptides.
Many ET receptor antagonists are under development
and at least some of these are already in clinical develop
ment. The clinical potential for inhibiting the ET cyctem,
indicated by animal studies, is soon to be tested in humans,
and it is to be hoped, as with the renin angiotensin system,
that novel and important drugs for the treatment of cardio
vascular disease will be the outcome.
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Editorials
The endothelin system in cardiovascular disease
Discovery to drug development in under a decade
The function of the vascular endothelium hasbecome a major focus of research. This is partlybeca se f the succes of drugs (such as the
angiotensin converting enzyme inhibitors, the nitro-
vasodilators, and aspirin) which act through mechan¬
isms related to endothelial function, and partly because
endothelial dysfunction is now thought to be an
important early factor predisposing to atherogenesis.'
Endothelin-1 is a recently discovered endothelium
derived vasoconstrictor and pressor peptide with
mitogenic properties,2 which is now recognised to
influence basal vascular tone and blood pressure.5
Endothelin antagonists are currendy in development
and may provide an important new approach to the
treatment of cardiovascular disease/
Endothelin-1 is generated from an inactive precur¬
sor, "big" endothelin-1, through the action of a unique
endothelin converting enzyme. The mature peptide
acts on endothelin type A and endothelin type B
receptors. In blood vessels, endothelin-1 causes
vasoconstriction largely through stimulating the
endothelin type A receptor on smooth muscle cells,
although type B receptors may also contribute in some
vessel types. Vasoconstriction is modulated by genera¬
tion of the vasodilators, nitric oxide and prostacyclin,
mediated by type B receptors on endothelial cells.
The main approaches to drug treatment are
inhibition ofendothelin converting enzyme and antago¬
nism of endothelin receptors. Most success has so far
been achieved with receptor antagonists, either selective
endothelin type A or combined type A and B receptor
antagonism. Whereas endothelin type A receptors are a
natural target for treatment, the benefits of inhibition of
type B receptors will depend on the balance between its
constrictor and dilator actions. Several drugs of both
types are currendy under clinical evaluation/
Endothelin-1 is present in plasma and may thereby
widely influence vascular tone. However, it is mainly
released towards smooth muscle and functions
primarily as a locally acting paracrine factor rather
than a circulating hormone. The generation of
endothelin-1 is increased by a wide range of vasoactive
and inflammatory mediators, changes in shear stress
of the vessel wall, and, importandy, by hypoxia.
Evidence now suggests a role for endothelin-1 in local
ischaemia (including myocardial infarction5 and acute
renal failure6), vasospasm (including Raynaud's
disease7 and subarachnoid haemorrhage"), and sus¬
tained vasoconstricdon (including hypertension1 and
heart failure). But it is its role in the pathophysiology of
chronic heart failure that is attracting most interest-
Chronic heart failure causes substantial morbidity
and mortality and is a major consumer of healthcare
resources/ It leads to stimulation of compensatory
neurohumoral reflexes, including effects on die renin-
angiotensin and sympathetic nervous systems, which
also serve to increase peripheral vascular resistance,
renal sodium reabsorption, and cardiac workload. This
leads to a vicious circle of declining cardiac function,
which provides a rationale for the use of angiotensin
converting enzyme inhibitors.
Neurohumoral activation and tissue hypoxia should
also increase the production of endothelin-1; and the
actions of endothelin-1 (vasoconstriction and
co-mitogenesis, leading to cardiac and vascular hyper¬
trophy, enhanced activity of the renin-angiotensin and
sympathetic nervous systems, and increased renal
vasoconstriction and sodium retention) are all consistent
with the circulatory abnormalities found in patients with
chronic heart failure. Indeed, plasma endothelin
concentrations are elevated in chronic heart failure,
mainly through an increase in plasma concentrations of
big endothelin-1, consistent with increased generation
of endothelin-1. Plasma concentration of big endo¬
thelin-1 correlates well with severity of heart failure10"
and is the most powerful predictor ofoutcome."
In the first clinical study bosentan, an antagonist to
combined endothelin receptors A and B, was given
intravenously to patients with severe chronic heart fail¬
ure who had stopped angiotensin converting enzyme
inhibitors.10 This increased their cardiac output and
reduced systemic and pulmonary vascular resistance
without inducing reflex tachycardia or increasing
plasma concentrations of angiotensin II or noradrena¬
line. More recent studies show that single doses of the
endothelin type A receptor antagonist BQ-123 and the
endothelin converting enzyme inhibitor phosphorami-
don produced haemodynamic benefits in patients tak¬
ing angiotensin converting enzyme inhibitors." These
benefits were sustained during chronic oral treatment
with bosentan (W Kiowski, personal communication).
The beneficial effect of angiotensin converting enzyme
inhibitors on mortality was predicted from an animal
model of heart failure/15 It is therefore promising to
find that BQ-123 substantially improved 12 week
survival from 43% to 85% in this coronary occlusion
model of heart failure," as well as improving
haemodynamic function and cardiac remodelling.
There is now substantial evidence to support
further clinical investigation of endothelin receptor
antagonists in several cardiovascular diseases and par¬
ticularly in chronic heart failure. We need further clini¬
cal studies to show whether selective endothelin type A
or combined A and B receptor antagonists are likely to
produce the greatest benefit, and major clinical trials to
confirm that these agents provide benefits in morbidity
and mortality beyond those associated with conven¬
tional treatment of a diuretic and angiotensin convert¬
ing enzyme inhibitor.
David E Newby
Clinical lecturer m cardiology
David J Webb
Christistm professor of therapeutics and clinical
pharmacology
Clinical Pharmacology Unit and Research Centre,
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The medical health emergency card
Not to assuage public concern, but to make users'lives easier
The idea ofan emergency card carried by patientswith certain conditions—for example,diabetes—is not new. A similar card for mentally
ill patients is also not new: a users' group, Survivors
Speak Out, first introduced a crisis card in 1989, and
interest has since grown.1 Known as a mental health
emergency card, its aim is to enable patients to give
advance directives about their management As such the
card ptoses particular problems, not least in relation to
the legal status of advance directives.2 At first sight men¬
tal health emergency cards seem to have something for
everyone.' However, contradictions in the objectives of
different groups have delayed their widespread imple¬
mentation and led to an atmosphere of distrust
Survivors Spieak Out the inventor of the card, has
recendy withdrawn its version. Its aim was to increase
users' self determination in the event of a loss of men¬
tal capacity. But users now complain that mental health
professionals are increasingly helping patients to com¬
plete their cards.4 They fear that patients will be
coerced into including potentially damaging infor¬
mation.
Different objectives led to trusts developing cards at
the request of the public, professional carers, and the
police. For these groups one of the failures of commu¬
nity care is that some of the most vulnerable patients
are lost to follow up,' sometimes because of lack of
communication between services. The hop>e was that
die card would alert professionals to previous contacts
with other services.
Finally, the recommendation that the Royal
College of Psychiatrists should develop a card was a
res[M>nse to public concern about violent mentally ill
offenders.' Thus the public may see these cards as a
way of identifying potentially dangerous padents. The
police and other professionals may also see them as a
means of helping determine disposal-for example,
dirough court diversion schemes.
But professionals also face difficulties in helping
people with these cards. It is unclear whether, in the
face of a clear advance directive on a card, their clinical
judgment should Ik- overriden. Despite a discussion
document from the Law Society in 1989* and an
enthusiastic endorsement from the Commons health
select committee,' the legal status of these cards
remains unclear. Currently both voluntary and
non-voluntary bodies are awaiting the conclusions of a
commons working group on the Law Commission
reptort on mental capacity" before proceeding with
protential card schemes.
There is no evidence from the UK or elsewhere on
the success or otherwise of mental health emergency
cards and on what any success may deprend. In the
absence of such data, practical asptects of the card are
also a source ofdisagreementWho, for example, should
fill it out' That this has become an issue is probably
more a symptom ofmistrust than a fundamental prob¬
lem. An obvious tension exists between privacy and
information, and many fear that the cards may further
stigmatise ill patients—or, worse, that the information
may be used aginst the holder. One compromise might
be simply to include only a contact name and number
(accessible 24 hours) that would provide a bona fide
caller with further information and the name of an
advocate for the patient. Such a card might then be
offered widely without suggesting a history ofmental ill¬
ness, while to some extent meeting the objectives of dif¬
ferent groups. Such minimal information would also fit
on to a necklet or bracelet, which might be more practi¬
cal for some patients.
Finally, which patients should carry the cards? It is
hard to imagine them being anything but voluntary,
and they must certainly not be simply a knee jerk
respxrnse to public concern. Whether or not a mental
health emergency card can satisfy both users and pro¬
fessionals remains to be seen. But the cards will Ire suc¬
cessful only if patients accept and use them.
L P Weston
Senior registrar
Shrodells Unit, Watford General Hospital,
Hertfordshire WD 1 8HB
L A l^awson
Senior registrar
New Possibilities NHS Trust,
Bridge, Essex CM8 1EQ
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Endothelin: from molecule to man
This article is based on a lecture given to the British Pharmacological Society at their December 1995
meeting in Brighton following the award to Professor David Webb in 1994 of the SmithKline Beecham Prize
for Research
D. J. Webb
Clinical Pharmacology Unit and Research Centre, The University ofEdinburgh, Western General Hospital, Edinburgh EH4 2XU, UK
Background
Until relatively recently, the vascular endothelium was
thought to act as little more than a passive barrier to
diffusion. However, in the last few years, with the discovery
of prostacyclin, nitric oxide and endothelin-1, a central role
has emerged for the endothelium in the regulation of
vascular smooth muscle cell tonus and growth, immunolog¬
ical reactivity, blood coagulation and lipid metabolism. This
field of research has matured rapidly (Figure 1) and, in a
recent foresight exercise on behalf of the British Heart
Foundation, Medical Research Council and Wellcome Trust
[1], the vascular endothelium was identified as the area
commanding the highest priority in cardiovascular research
over the next 10 years.
My own interest in this area originally developed while
working in the MRC Blood Pressure Unit in Glasgow.
Observations in the first clinical trial of a renin inhibitor in
man suggested the functional importance of a vascular renin-
angiotensin system [2] and, later, at St George's Hospital in
London I was able to show this by combining forearm
plethysmography techniques with brachial artery infusions
of locally active doses of angiotensin I, angiotensin II,
bradykinin and angiotensin converting enzyme (ACE)
inhibitors [3, 4], Surprisingly, these studies demonstrated in
vivo that the endothelium of the forearm resistance vessels
has a considerable capacity to generate angiotensin II locally,
equivalent to that of the pulmonary circulation (4, 5J.
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Figure 1 Annual numbers of papers in the biomedical sciences
including the word 'endothelium' in the title, keywords or
abstract from 1980 to 1996 inclusive, based on information from
the Bath Information and Database Service (BIDS) F.MBASE.
peptide, endothelin-1 [6], a more potent endothelium-
derived vasoconstrictor and pressor agent even than
angiotensin II, was of major interest to the cardiovascular
research community, and followed closely on the identifi¬
cation of the endothelium-derived relaxing factor (EDRF)
as nitric oxide [7], At this early stage it was difficult to gain
access to more than small quantities of synthetic
endothelin-1. However, it was clear that local infusion
techniques could allow delineation of the vascular effects of
endothelin-1 more clearly, with greater safety, and with
lower doses, than would be the case with systemic dosing.
In collaboration with Dr John Clarke and Professor Attilio
Maseri at the Royal Postgraduate Medical School, we began
clinical pharmacology studies at St George's Hospital in
London in 1988, and our first pharmacodynamic observations
were published the following year [8],
Subsequent progress in endothelin research [9, 10] has
maintained an extremely rapid pace such that we were able
to perform the first human pharmacology studies with an
inhibitor of endothelin generation, phosphoramidon, in
1992 and with an endothelin receptor antagonist, BQ-123,
in 1993. Indeed, after only 8 years, the clinical development
of drugs targeting the 'endothelin system' in cardiovascular
disease is now well advanced [11]. The first major clinical
study in heart failure patients was reported in 1995 [12] and
phase III trials should begin shortly. From a combination of
fundamental and applied research it has become apparent
that the 'endothelin system' is of central importance to the
maintenance of normal cardiovascular function in healthy
man and that endothelin-1 is likely to be a key mediator in
the pathophysiology of cardiovascular disease.
The main aim of this paper is to review current knowledge
of the endothelin system; particularly its physiological function
in the cardiovascular system and its role in cardiovascular
disease. Although I will focus on human pharmacology and
physiology, and in particular on the work of our group in
Edinburgh, it must be recognised that all of the major
advances in clinical research have depended critically on the
identification and development of selective pharmacological
probes through work on animal and isolated tissues. A
subsidiary aim of this review is to demonstrate that clinical
pharmacology studies can provide a critical contribution to
our understanding of human cardiovascular physiology and
pathophysiology, and to the process ofearly drug development
and identification of suitable therapeutic targets.
Endothelin synthesis
Endothelin 1 is the most potent vasoconstrictor and pressor
peptide known. Originally identified in the culture medium





Figure 2 Structure of the endothelin family of peptides, and the related snake venom peptide sarafotoxin S6c.
of porcine aortic endothelial cells [6], it is now recognised
to be a member of a family comprising three isoforms (13]:
endothelin-1, endothelin-2 and endothelin-3 (Figure 2).
Each isoform contains 21 amino-acids, two intra-chain
disulphide bonds constraining overall structure, and a
conserved C-terminal sequence necessary for biological
activity [13]. This structure is unique among the mammalian
peptides but is shared by the sarafotoxins, snake venom
peptides from the Israeli burrowing asp, Actractaspis engad-
densis, one of which, sarafotoxin S6c, has proved particularly
valuable as a pharmacological probe. While there is evidence
that endothelin-2 may possibly function as a mediator in
the kidney, and endothelin-3 may act as mediator in the
gut and nervous system, endothelin-1 is the major
isoform generated in blood vessels and appears to be of
greatest significance in cardiovascular regulation. Hence,
endothelin-1 is the major focus of this review.
Within the human genome, the endothelins are each
represented by a separate gene encoding a specific precursor
for the mature isoform 113]. In the 5' flanking sequence
there are binding sites for activating protein-1 and nuclear
factor 1 through which angiotensin II and transforming
growth factor (3 act respectively to induce endothelin-1
expression. There are also binding sites for acute phase
reactants which may mediate the effects of acute physiologi¬
cal stress. In the 3' region there is a sequence regulating
selective destabilisation of preproendothelin-1 mRNA, poss¬
ibly accounting for its short half-life. These sites serve as
potential mechanisms for regulating production ofendothelin
at the level of transcription and translation. Although
endothelin-1 can be identified within endothelial cells, it
remains unclear whether intracellular stored peptide rep¬
resents an important pool available for rapid release and,
currently, regulation of endothelin synthesis is thought to
be primarily at the level of gene transcription, with de novo
production and release occurring in response to. endothelial
cell stimulation. A large number of factors have now been
shown to increase endothelin-1 synthesis (Figure 3): these
include vasoactive hormones, inflammatory mediators and
physico-chemical factors such as altered vascular shear stress
and hypoxia. Other factors—including nitric oxide, nitric
oxide donor drugs, natriuretic peptides and the dilator
prostanoids—serve to inhibit endothelin-1 generation by
promoting production of cyclic GMP or cyclic AMP [10].
The initial product of the human endothelin-1 gene is
preproendothelin-1, a peptide of 212 amino acid residues
(Figure 3). After removal of a short secretory sequence,
proendothelin-1 undergoes cleavage by a dibasic pair specific
endoprotease—probably furin—to generate the 38 amino-
acid peptide, 'big endothelin-T [6]. Subsequent conversion
to the mature, biologically active peptide, endothelin-1,
occurs through the action of endothelin converting enzymes
(ECE-1 and ECE-2). This family ofmetalloprotease enzymes
is related to neutral endopeptidase-24.11 (NEP) and the Kell
protein but unrelated to angiotensin converting enzyme.
ECE-1 [14] appears to be the physiologically active ECE
and, by alternative gene splicing, it exists in two different
isoforms—ECE-la and ECE-lb—with functionally distinct
roles and tissue distributions. ECE-la appears to be an
intracellular enzyme expressed in the Golgi apparatus of
cells, such as the endothelial cells, that synthesise
endothelin-1. In contrast, responder cells, such as vascular
10 © 1997 Blackwell Science Ltd Br) Clin Pharmacol, 44, 9-20
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Figure 3 Factors that alter
endothelin-1 (ET-1) synthesis and the
pathway for endothelin-1 generation:
See text for details. IL-1 =
interleukin-1; TGFfi = transforming
growth factor 3; LDL = low-density
lipoprotein; ANP, BNP, CNP =
atrial, brain, and c-type natriuretic
peptides. (From an original design
from Professor P. Vanhoutte).
smooth muscle cells, express extracellular ECE-lb that
can convert extracellular big endothelin-1 to mature
endothelin-1 [15]. ECE-1 and ECE-2 are both inhibited by
phosphoramidon, a combined F.CE NEP inhibitor but not
by the selective NEP inhibitor, thiorphan, or by the ACE
inhibitor, captopril. Both enzymes are selective for big
endothelin-1, raising the possibility that other ECEs with
selectivity for big endothelin-2 and -3 will be identified.
Through prevention of the generation of the endothelins,
ECE-1 must be a potential target tor drug treatment.
The gene encoding endothelin-1 can be detected in a
wide variety of tissues, including the endothelial and smooth
muscle cells of blood vessels, heart, lung, brain, kidney,
pancreas and spleen. The gene encoding endothelin-2 may
also be found in the vascular endothelium, as well as
the smooth muscle of the large and small intestine,
myocardium, stomach, kidney, placenta and uterus.
Endothelin-3 expression predominates in the brain but is
also found in the lung, gastro-intestinal tract and kidney.
Big endothelin-1, endothelin-1 and endothelin-3 are present
in plasma at picomolar concentrations that are probably
insufficient to exert a direct influence on vascular tone.
Endothelin-1 is generally thought to be a paracrine and
autocrine mediator rather than an endocrine hormone.
Indeed, endothelin-1 is largely secreted abluniinally by
endothelial cells towards the adjacent vascular smooth muscle
© 1997 Blackwell Science Ltd Br J Clin Pharmacol. 44. 9-20
[16], so that concentrations are likely to be substantially
higher at the interface between endothelial and vascular
smooth muscle cells than in blood, consistent with a
primarily local action. In addition, the half-life of
endothelin-1 in blood is short, at less than 5 min, with
clearance predominantly via receptor binding and metabolism
in the lungs and kidneys [17].
Endothelin receptors
The endothelins act on two receptor subtypes, ETA and
ETb, characterized on the basis of their pharmacology
(Table 1). Endothelin-1 has a similar binding affinity for
ETa and ETU receptors—in the nanomolar range—but has
a much higher binding affinity for the ETA receptor than
endothelin-3. In contrast, endothelin-1 and endothelin-3
have equal affinity for the ETU receptor. Understanding of
the function of endothelin receptors has been aided by the
use of specific pharmacological agonists and antagonists.
Endothelin-3 and sarafotoxin S6c are respectively ~2000
fold and ~ 30 000 fold selective as agonists at the ET|(
receptor and BQ-123 and BQ-788 are selective antagonists
respectively at ETA and ET|, receptors. The human ETA
and ETk receptors have been cloned and exhibit — T>()%
homology. ETA receptor mRNA can be detected in many
tissues, with the highest expression in aorta, heart and
I I
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kidney. The ETA receptor predominates on vascular smooth
muscle cells and is responsible for causing vasoconstriction
in both large and small blood vessels [18], It is also the
major receptor subtype in the heart [19]. In contrast, ETA
mRNA cannot be detected in the liver or endothelial cells
[20]. The ETD receptor can be detected in endothelial and
vascular smooth muscle cells and is predominantly found in
brain, lung, kidney and aorta [21]. The ETlf receptor on
endothelial cells modulates vasoconstriction in response to
endothelin-1 through the production of vasodilator sub¬
stances including prostacyclin and nitric oxide. It is now
widely recognised that the ETU receptors on vascular smooth
muscle cells can mediate vasoconstriction, particularly in
small resistance vessels and veins. The significance of the
vasoconstrictor ETB receptor will be discussed later. There
has been a recent tendency to sub-classify the ET1S receptor
on the basis of responses to selective agonists and antagonists
[22] but this currently cannot be justified on a molecular
basis.
The ETa and ETB receptors are classical heptahelical
rhodopsin-like G-protein coupled receptors that activate
phospholipase C leading to hydrolysis of phosphatidyl
inositol and generation of cytosolic inositol triphosphate
and membrane bound diacylglycerol [9], Inositol triphosph¬
ate causes an early rapid rise in [Ca" ], through its release
from intracellular stores. A more sustained rise of intracellular
calcium occurs through opening of membrane Ca"
channels. Diacylglycerol activates protein kinase C, increas¬
ing sensitivity of the contractile apparatus to Ca" , activates
nuclear signalling mechanisms—with possible effects on
long term regulation of cellular function—and causes a rise
in the intracellular pH through an effect on the sodium-
hydrogen ion exchange membrane pump. Endothelin-1 may
also interact with the ATP-sensitive potassium channel, so
contributing to the nse in [Ca" + ],. In addition, it may
activate phospholipase A2, increasing production of arachi-
donic acid, and hence of prostacyclin (PGI2) and thrombox¬
ane A2 [10].
The endothelins bind tightly to their receptors in a
'pseudo-irreversible' manner and the endothelin-receptor
complex is rapidly internalized. Slow dissociation from
their receptors may account for prolonged actions of the
endothelins. Endothelin receptor expression is itself regulated
by exposure to endothelin-1 so that agents that enhance
endothelin-1 production, such as angiotensin II and certain
growth factors, can cause endothelin receptor downregul-
ation |23|. In contrast, endothelin receptor number can be
upregulated; for instance, by ischaemia [24], cyclosporin
[25] and interleukin-ip [261.
Developmental biology
Gene defects affecting the endothelin system have been
described for both animals and man. Gene knockouts for
the preproendothelin-1 gene in mice cause lethal abnormali¬
ties affecting the development of craniofacial, cardiovascular
and pharyngeal pouch structures [27, 28). Interestingly, these
abnormalities have also been found in teratogenicity studies
during the pre-clinical development of a range of ETA
receptor antagonists indicating, at least during development,
that endothelin-1 may be the natural ligand for the ETA
receptor and that endothelin-1 has an important role in the
development of the pharyngeal arches, heart and great
vessels. Indeed, it has been suggested that endothelin-1/ETA
receptor anomalies may contribute to the Pierre-Robin and
Treacher-Collins syndromes [29], One anomalous finding
in these studies was the development of raised blood pressure
in the endothelin-1 knockout mice. However, evidence is
emerging that the elevation of blood pressure is related to
sympatho-adrenergic overactivity caused by the severe
hypoxia that is a consequence of the facial/pharyngeal
anomalies [29].
Both endothehn-3 and ETU receptor mutations lead to
the formation of aganglionic megacolon and coat pigmen¬
tation anomalies in animals [30], In this case, genetic
abnormalities of either the preproendothelin-3 gene or the
ETU receptor have been documented in congenital neurocri-
stopathies associated clinically with Hirschsprung's disease
[31] and the Waardenberg-Shah syndrome [32]. Hence, the
interaction of endothelin-3 with the ETB receptor appears
to be important for the development of cells within the
neural crest.
Cardiovascular pharmacology
Bolus administration of endothelin-1 is known to cause a
marked pressor effect lasting for more than 60 nun [6] in
contrast to the brief effects of all other endogenous
vasoconstrictor substances. Despite rapid clearance of the
peptide from blood, this sustained pressor effect has been
confirmed from studies in man [33, 34], and is mediated
predominantly through an increase in peripheral vascular
resistance. The pressor effect tends to reduce cardiac output
[351, probably through a baroreceptor mediated decrease in
12 © 1997 Blackwell Science Ltd Br J Clin Pharmacol. 44, 9 20
ET and the cardiovascular system
heart rate, although an increase an afterload may possibly
contribute. Coronary vasoconstriction is recognised to occur
in humans who are bitten by the burrowing asp, Actractaspis
engaddensis, the venom of which contains sarafotoxins [36)
and the coronary vasoconstrictor effect of the endothelins
has more recently been confirmed in healthy subjects (34],
It is also known that after bolus administration in animals,
endothelin-1 causes transient hypotension associated with
systemic vasodilatation through stimulation of the endothelial
ET|, receptor. However, such studies require high doses of
endothelin-1 and, because endothelin-1 preferentially causes
vasoconstriction in the renal, cardiac and cerebral circu¬
lations, such studies should clearly be avoided in man.
One way to address directly the potential vasoconstnctor
and dilator effects of the endothelins in vivo in man is to
combine bilateral forearm blood flow measurements with
unilateral brachial artery infusion of vasoactive drugs at
subsystemic, locally active doses. Because forearm muscle
blood flow is only ~ 50 ml min 1 compared with a cardiac
output of ~ 5000 ml min 1 substantial local effects can be
achieved without a systemic action. By avoiding confounding
effects on organs such as the brain, kidney and heart, as well
as potential influences on neurohumoral reflexes, vascular
responses can be attributed to a direct effect of the drug,
providing a powerful, reproducible and safe method of
directly assessing vascular responses in vivo [37, 38],
Importantly, the responses obtained are also broadly predic¬
tive of those seen in the systemic and coronary circulation
[38],
Continuous infusion of endothelin-1 into the brachial
artery causes a slowly developing dose-dependent reduction
in forearm blood flow, with vasoconstriction sustained for
more than 2 h after halting the infusion [8], When given
via the brachial artery, low doses of the ETB selective
agonists, endothelin-3 and sarafotoxin S6c, also produce
vasoconstriction in human resistance vessels iti vivo, consistent
with vascular ETB receptors mediating at least part of the
functional response to endothelin-1 in these vessels [39], In
human blood vessels in vitro, threshold concentrations of
endothelin-1 potentiate contractions to noradrenaline [40].
However, a peripheral interaction of endothelin-1 with the
sympathetic nervous system has not been demonstrated in
forearm resistance [411 or cutaneous capacitance vessels [42|
of healthy subjects in vivo. Endothelin-1 and endothelin-3
[39], and sarafotoxin S6c (unpublished observations), can
produce transient forearm vasodilatation, the dilator response
to endothelin-3 and sarafotoxin S6c being greater and more
prolonged than that to endothelin-1 consistent with involve-
lient of the endothelial ET1( receptor. However, vasodilat¬
ation to the endothelins occurs only at high doses on bolus
adi iliiiistiation, suggesting that this is nut a physiological
response [39], In human hand veins [43], vasoconstriction is
modulated predominantly by stimulated release of dilator
prostaglandins.
Endothelin-1 and sarafotoxin S6c both cause sustained
constriction of human doisal hand ccius in vivo [8, 39],
suggesting that both vascular ETA and ETB receptors can
contribute to venoconstriction to endothelin-1 in humans.
Venoeonstriction in vivo is blocked more effectively by the
KA | |, channel opener, cromakalim, than the Ca~ + channel
antagonist, nicardipine or by hydralazine [441, suggesting
that endothelin-1 responses in human veins depend only in
part on Ca"+ entry through dihydropyridine-sensitive Ca" +
channels. In addition, the greater efficacy of KAn> channel
opening agents is consistent with endothelin-1 acting to
close KATp channels, causing plasma membrane depolaris-
ation and vasoconstriction by mechanisms additional to
opening of voltage-operated Ca2+ channels.
Cardiovascular physiology
Although studies with agonists are of considerable interest,
when a mediator is not a classical circulating hormone the
results can be frankly misleading and studies with antagonists
are likely to be considerably more informative.
The first endothelin 'antagonist' described was the ECE
inhibitor, phosphoramidon [45], and we decided to begin
our investigation in the forearm. However, to determine a
dose that would inhibit ECE we first had to examine
responses to big endothelin-1. Brachial artery administration
of big endothelin-1 caused a dose-dependent forearm
vasoconstriction that could be blocked completely by
phosphoramidon (30 nmol min 1), suggesting that the
effects of the precursor are mediated through conversion to
the mature peptide by ECE [46], The blockade of
constriction to big endothelin-1 by phosphorainidon is
unlikely to have been due to inhibition of endothelin
receptor binding, because vasoconstriction to endothelin-1
was unaffected by phosphoramidon and because conversion
to endothelin-1 and its C-terminal fragment was confirmed
in plasma samples taken from the veins draining the infused
forearm [47], Also, because circulating blood exhibits little
ECE activity [48], conversion of big endothelin-1 in the
forearm presumably occurs via vascular, probably endothelial,
ECE situated within the forearm resistance vessels. The
difference in potency between big endothelin-1 and
endothelin-1, and the ratio of C-temiinal fragment to big
endothelin-1 in venous blood, both indicated that local ECE
converts about 10% of luminally presented big ET-1 to
ET-1, consistent with ~10% conversion of exogenous big
ET-1 by cells expressing the ECE-1 gene [14], Big
endothelin-1 does not cause venoconstriction in hand veins
[49], even though these vessels respond to endothelin-1 [8],
suggesting that ECE activity may not be present in all
vessel types.
Administration of phosphoramidon (30 nmol min )
alone |46| resulted in a slowly progressive vasodilatation
(Figure 4), consistent with a role for endothelin-1 in
maintenance of basal vascular tone. Although phosphorami¬
don is an imperfect tool, because it also acts as an inhibitor
of NEE, this latter action is unlikely to explain the
vasodilatation because potent and selective inhibitors of NEE
cause slowly progressive forearm vasoconstriction [46]
(Figure 4). This effect of NEE inhibitors is likely to be
caused by accumulation of a vasoconstrictor agent which
may be endothelin-1, because it is a substrate for metabolism
by NEE and the vasoconstriction is not blocked by an ACE
inhibitor. This observation may also account for the increase
in plasma endothelin by NEE inhibitors in clinical trials 150]
and their failure to lower blood pressure in hypertensive
subjects.
Confirmation that endogenous endothelin-1 generation
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Figure 4 Forearm vasoconstriction to
brachial artery infusion of endothelin-1
(5 pmol niin~ •) is abolished by the
co-infusion of BQ-123 (100 nmol min ;
O). Infusion of the ETA antagonist BQ-123
(100 nmol nnn □) or the ECE inhibitor
phosphoramidon (30 nmol min ; ©) alone
produce progressive foreami vasodilatation
whereas the NEP inhibitor thiorphan
(30 nmol nun-1; O) causes progressive
vasoconstriction. Adapted from Haynes and
Webb [46], with kind permission of the
Lancet. See text for details.
contributes to the maintenance of basal tone in forearm
resistance vessels of healthy human subjects came from
studies with the cyclic pentapeptide ETA receptor selective
antagonist, BQ-123 [51], and the cyclic hexapeptide
combined ETA/1) antagonist TAK-044 [52], given via the
brachial artery. Both agents caused a progressive vasodilat¬
ation of the forearm vessels [46, 53] The substantial effect
of BQ 123 (Figured) suggests that vasoconstriction to
endothelin-1 is mediated mainly through the ETA receptor
on vascular smooth muscle. Subsequent studies have con¬
tinued this effect of BQ-123, and shown that it can be
achieved with lower doses and when given for a shorter
period [54], Together, the l-argimne/nitric oxide system,
the sympathetic nervous system and the endothelin system
are currently the only mediator systems known to maintain
basal vascular tone. It now remains to be shown how the
endothelin system is regulated, though this is likely to be
predominantly at a local level.
The greater effect of BQ-123 than a substantial local dose
of TAK-044 would be consistent with a mainly dilator role
for the ET1S receptor. Further and more direct support for
this view comes from recent arterial experiments with an
ET1S selective inhibitor, BQ-788 [55]. This agent causes
progressive forearm vasoconstriction in healthy subjects [56],
consistent with greater functional importance of the dilator
than the constrictor ETlf receptor under physiological
circumstances. On this basis, a proportion of the dilator
response to BQ-123 is likely to be mediated by nitric oxide
and prostacyclin acting through the unopposed endothelial
El), receptor. It might also be anticipated that this
component of the response might be reduced in condi¬
tions associated with endothelial dysfunction (see later).
Interestingly, vasoconstriction appears to be mediated solely
by ETa receptors in the human skin microcirculation, again
on the basis of studies with antagonists [57].
Responses of the forearm resistance vessels to drugs given
into the brachial artery are usually predictive of the responses
in the major resistance beds that serve to regulate blood
pressure [38], Indeed, for the L-arginine-nitric oxide system,
the substantial—and at the time unexpected—reduction of
forearm blood flow associated with administration of the
nitric oxide synthase inhibitor, l-/\ -monomethyl-arginine
(l-NMMA) [58], predicted the substantial increase in
peripheral vascular resistance that would be associated with
systemic administration (59], Similar predictions, though for
an opposite effect, were made for systemic endothelin
receptor antagonism based on the data with BQ-123. These
predictions were confirmed recently in healthy subjects (53]
with another peptide drug, TAK-044, which is currently in
clinical development.
TAK-044, which functionally inhibits both ETA and ETH
mediated responses [52, 60], was given to healthy subjects
at a range of doses from 10-1000 mg systemically and was
generally well tolerated [53], A 15 min intravenous infusion
of TAK-044 at the highest dose of 1000 mg reduced systolic
blood pressure by ~ 4%, diastolic blood pressure by ~ 18%,
and systemic vascular resistance by ~ 26% over a 24 h period
(Figure 5), suggesting that a major part of the effect ot
TAK-044 is mediated in the resistance vessels. At this dose,
but not consistently at lower doses, the major haemodynamic
14 © 1997 Blackwell Science Ltd Br J Clin Pharmacol, 44. 9 20


























































Figure 5 Graph showing
time course of the effects of
the highest dose of TAK-044
(1000 mg) on mean arterial
pressure (MAP), heart rate
(HR), stroke index (SI),




arterial pressure (P< 0.001)
and total peripheral resistance
(P<0.001) and increased
heart rate (P<0.001), stroke
index (P=0.034) and cardiac
index (PCO.OOl); these
effects were maximal at 4 h
and sustained for at least
12 h. Data shown represent
placebo-corrected changes
from predose (change from




et al. [53], with kind
permission of the American
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effect on systemic vascular resistance was accompanied by a
compensatory increase in cardiac output and heart rate. The
substantial and long lasting effect of TAK-044 on systemic
vascular resistance is even more remarkable considering the
short half life of this peptide in the circulation and confirms
that endogenous endothelin generation is critical for cardio¬
vascular homeostasis and control of blood pressure, as
originally proposed by Yanagisawa [6],
Systemically administered TAK-044 also abolished the
vasoconstriction to endothelin-1 infused via the brachial
artery for up to 3 h [53] but inhibited responses only
partially at 8 and 12 h (unpublished data). Such studies can
confirm the efficacy of endothelin receptor antagonists and
determine the duration of their action. This appears to be
especially important for this class of drug, where standard
pharmacokinetic parameters do not always predict the
pharmacodynamic activity achieved.
Cardiovascular pathophysiology
There are a number of mechanisms whereby
endothelin-1 may be involved in cardiovascular disease, for
instance: reduced production in congenital cardiac anomalies;
enhanced production in congestive heart disease; reduced
receptor number or affinity in Hirschsprung's disease;
enhanced receptor number or affinity with cyclosporin
treatment; reduced peptide clearance in chronic renal failure;
and an unopposed action with endothelial dysfunction
affecting the i-argimne/nitric oxide systems, which may be
a factor in Raynaud's disease. Given the potentially beneficial
© 1997 Blackwell Science Ltd Br J Clin Pharmacol. 44. 9-10 15
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effects of nitric oxide to cause vasodilatation, and inhibit
platelet aggregation and vascular growth, and the potentially
adverse effects of endothelin 1 to promote vasoconstriction
and vascular growth it is of considerable interest that many
of the conditions associated with endothelial dysfunction
causing reduced nitnc oxide production, including athero¬
sclerosis [61, 62], are further compounded by increased
production of endothelin 1. Indeed, it is clear that these
systems do not function independently. Endothelin-1 gener¬
ation is enhanced by a range of other constrictor and growth
promoting substances and inhibited by dilators including
nitric oxide (Figure 3). Conversely, endothelin-1 promotes
the production of nitnc oxide but may also account for
some of the vasoconstnction that accompanies its inhibition
by i-NMMA and clinically for the development of tolerance
to exogenous nitrate administration [63j.
As well as having direct effects on vascular tone,
endothelin-1 may enhance vascular tone indirectly: by
augmenting vasoconstnction to other agents, such as
angiotensin II, noradrenaline, serotonin; by enhancing
central and penpheral sympathetic function; and by activating
the renin-angiotensin system. Endothelin-1 is also a
co-mitogen, enhancing cell division and proliferation, gene
expression, protein synthesis and, ultimately, promoting
hypertrophy of vascular smooth muscle, as well as cardiac
myocytes and fibroblasts [64, 65], Thus, endothelin 1 may
serve to amplify vasoconstnction through the development
of vascular hypertrophy.
There is a growing literature [10, 11] in support of a role
tor endothelin-1 in the pathophysiology of a wide range of
cardiovascular diseases. These include ischaemic heart disease
and atherosclerosis, as well as conditions associated with
either sustained vasoconstriction—including hypertension,
chronic heart failure, chronic renal failure, primary pulmon¬
ary hypertension—or with intermittent vasospasm—includ
ing Raynaud's disease, subarachnoid haemorrhage and acute
renal failure Hereafter, the review will focus on the
considerable body of evidence implicating the endothelin
system in chronic heart failure and suggesting that it may be
a suitable target for therapeutic intervention.
Chronic cardiacfailure
Chronic heart failure (CHF) is a common, disabling
condition that causes substantial morbidity and mortality,
and is a major consumer of health service resources [66],
This complex condition is associated with stimulation of
compensatory neurohumoral reflexes, including effects on
the renin-angiotensin and sympathetic nervous systems, that
serve to maintain perfusion pressure hut also act to increase
penpheral vascular resistance, renal sodium reabsorption and
cardiac workload. This leads to a 'vicious circle' of declining
cardiac function and provides a rationale for the current
mainstay of treatment, which is vasodilator therapy with
ACE inhibitors. Although current treatment regimens are
undoubtedly successful, CHF still carries a substantial
morbidity and mortality [66] and there is room for additional
therapeutic manoeuvres.
The now well documented reduction in mortality with
ACE inhibitors in patients with CHF and left ventricular
dysfunction after myocardial infarction [66[ was predicted
from animal models [671. A recent report that the ETA
receptor antagonist, BQ-123, substantially improved
12 week survival from 13 to 85% in a coronary occlusion
model of CHF [68] as well as haemodynamic function and
cardiac remodelling is, therefore, very promising for the
clinical developments in this area. Also, interestingly, raised
plasma endothelin concentrations appear to be an extremely
powerful predictor of 1 year mortality after acute myocardial
infarction [69],
Neurohumoral activation and tissue hypoxia should
increase endothelm-1 production, and the actions of
endothelin-1—vasoconstriction, co-mitogenesis, leading to
cardiac and vascular hypertrophy, enhancement of renin-
angiotensin and sympathetic nervous system activity, and
promotion of renal vasoconstriction and sodium retention
arc all consistent with the circulatory abnormalities found in
this condition. Indeed, plasma endothelin concentrations arc
elevated in CHF, mainly through an increase in plasma big
endothelin-1 [70], consistent with increased synthesis, rather
than decreased clearance, of endothelin-1. Plasma immuno-
reactive endothelin correlates with the degree of haemo¬
dynamic [71] and functional impairment [72] in CHF, is
associated with a worse prognosis—irrespective of the cause
of the cardiac failure—and predicts mortality or the need
for cardiac transplantation [73], Currently, measurement of
plasma big endothelin 1 concentration is the best available
predictor of outcome in CHF [74] Interestingly, changes
in plasma immunoreactive endothelin reflect the clinical
response to the fl adrenoceptor blocker carvedilol in patients
with CHF [75], although it is not clear whether the drug is
producing its benefits through direct inhibition of the
endothelin system or by an effect on cardiac performance.
In the first clinical trial of an endothelin antagonist in
CHF [12], in patients withdrawn from ACE inhibitor
treatment, acute intravenous administration of the combined
ETa/u antagonist, bosentan, increased cardiac output and
reduced systemic and pulmonary vascular resistance without
inducing reflex tachycardia or increasing plasma concen¬
trations of angiotensin II or noradrenaline (Figure 6) These
beneficial haemodynamic effects of inhibition of the
endothelin system are similar to those associated with ACE
inhibition, and beg the question whether they would add
to the effects of optimal treatment with an ACE inhibitor
[76]. Studies with local brachial artery administration of the
ECE inhibitor, phosphoramidon, and the ETA receptor
antagonist, BQ-123, have addressed this issue in patients
with CHF [77], Even though these patients were maintained
on ACE inhibitors, both agents caused substantial vasodilat¬
ation of the forearm resistance vessels, predicting that
endothelin receptor antagonists might have additional value
in the treatment of CHF. Indeed, from recent studies, it
does appear that the beneficial haemodynamic effects of
bosentan occur in the presence of ACE inhibitors and are
sustained on chronic oral treatment (W. Kiowski; personal
communication).
In local infusion studies, the vasoconstriction to
endothelin-1 was reduced in CHF patients compared with
matched control subjects in both resistance vessels [771 and
hand veins [78] consistent with increased endothelin-1
generation. In contrast, vasoconstriction to the selective
ETt! receptor agonist, sarafotoxin S6c, was enhanced. These
16 © 1997 Blackwell Science Ltd Br) Clin Pharmacol, 44, 9-20
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Figure 6 Changes of cardiac index, stroke
volume, systemic vascular resistance and
pulmonary vascular resistance (a) and of
arterial, pulmonary artery, pulmonary
artery wedged and right atrial pressures (b)
in patients with severe congestive heart
failure after intravenous placebo (unshaded
columns) or bosentan (shaded columns).
Bosentan 100 mg was administered
intravenously at 0 min and a further
200 mg was given at 60 min. All eight
parameters were significantly improved by
acute administration of bosentan
(P<0.05) without change in heart rate.
Adapted and reproduced from Kiowski
et at. [12], with kind permission of the
Lancet.
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observations arc also seen in the coronary vessels in
experimental CHF [79] and ETI( receptors are also upregul
ated in human CHF [80], consistent with widespread
upregulation of the smooth muscle, and perhaps endothelial,
ET|S receptor in this condition. Enhanced constriction to
sarafotoxin S6c may, at least in part, be due to endothelial
dysfunction affecting responses mediated through the endo¬
thelial ETIS receptor and suggests that constrictor ET[j may
be of greater importance in some diseases than they are
under physiological circumstances. Nevertheless, in patients
with CHF, the response to arterial administration of the
selective ETlf antagonist, BQ-788, is vasoconstriction,
suggesting that the dilator response predominates and that
selective ETA antagonists might, therefore, offer some
advantages in this condition.
Unresolved issues
A number ofmajor issues concerning endothelin antagonists
remain unresolved. The first and most important of these is
the choice of the appropriate therapeutic target. On purely
scientific grounds there would certainly be sufficient
justification for clinical investigation of endothelin antagon-
© 1997 Blackwell Science Ltd Br / Clin Pharmacol. 44. 9-20
istr, in essential hypertension, congestive heart failure, primary
pulmonary hypertension, subarachnoid haemorrhage, stroke
and acute ischaemic renal failure. However, there are a
number of other issues for pharmaceutical companies to
consider including the existence of currently effective
treatment (essential hypertension), the lack of a sufficiently
predictive model for the disease (angioplasty restenosis) and
concerns over whether the market size is sufficiently large
to justify the development (subarachnoid haemorrhage and
primary pulmonary hypertension). There is obviously also a
need to keep the overall budget for such compounds within
reasonable bounds so companies need to be selective in their
research programmes. Nevertheless, it can be expected that
the role of endothelin antagonists will be explored in clinical
studies in a number of these candidate diseases and it is
likely—as, for instance, with the capacity of ACE inhibitors
to delay the progression of renal failure—that some of the
potential uses of endothelin antagonists cannot easily be
anticipated at this stage. For instance, the potential anti-
mitogenic action of endothelin antagonists may be critical
in heart failure [68| and perhaps also in conditions like
essential and pulmonary hypertension, and may even be
relevant for cancer therapy |8l|.
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Although the first effective 'endothelin antagonist' was an
ECE inhibitor there appear to have been few recent
developments in this area. All of the four or more endothelin
antagonists in early clinical development, as well as at least
15 more in preclinical development |11], are endothelin
receptor blockers. Most of these are orally active, although
TAK04 J is a peptide and is therefore being developed for
indications requiring relatively brief administration. Some of
these agents are combined ETA/B antagonists, whereas others
are selective ETA antagonists. There are currently no
selective ETB antagonists that are clearly intended for clinical
development although it might be argued that they would
piuduce an uigjii-seleuive effect in pulmonary hypertension,
avoiding systemic hypotension, given that hypoxic pulmon¬
ary vasoconstriction appears to be primarily mediated by
ETB receptors [82] whereas responses to endothelin-1 in
the peripheral circulation appear to be determined primarily
by effects on the ETA receptor.
The more general issue of whether selective ETA or
combined ETA/B receptor antagonists will have greater
utility has certainly not yet been resolved. Our current
knowledge, from studies in healthy people and those with
heart failure is that the major target must be the ETA
receptor. Inhibition of the ETU receptor leads to peripheral
vasoconstriction and, unlike inhibition at the ETA receptor,
causes substantial elevation of plasma concentrations of
endothelin-1 [12, 53], probably by effects on clearance or
displacement from ETB receptors [83, 84]. However, the
function of ETB receptor may be more critical in some
diseases or in, for instance, the cardiac and renal vascular
beds, and the role of ETB receptors in overall human
cardiovascular control and pathophysiology has yet to be
determined.
Summary
Endothelin-1 is an endothelium-derived vasoconstnctor and
co-mitogenic agent which acts as a local paracnne and
autocrine mediator, and is the most potent and sustained
vasoconstnctor and pressor substance yet identified. On the
basis of studies in healthy man, endothelin-1 is now known
to play an important physiological role in maintaining
peripheral vascular tone and blood pressure. Endothelin-1
also has actions which might influence the function of
the heart, kidney and nervous system. However, their
physiological importance remains to be determined.
Abnormalities of the endothelin system are now recognised
to occur in a range of diseases associated with vasoconstric¬
tion, vasospasm and vascular hypertrophy and it appears that
endothelin-1 may be causal, or at least contributory, in some
of these pathophysiological processes. The use of endothelin
receptor antagonists in experimental models of cardiovascular
disease and in human clinical pharmacology studies has
indicated a number of conditions—including hypertension,
heart failure, acute renal failure, subarachnoid haemorrhage,
and pulmonary hypertension—in which further clinical
studies would be worthwhile. A number of peptide and
orally-active non-peptide endothelin receptor antagonists
are now under clinical investigation and further studies are
now required in specific diseases to determine whether
selective ETA or combined ETA/B receptor antagonists
would be more effective.
The discovery of endothelin-1, and the design of
endothelin antagonists, has been among the most promising
developments in cardiovascular medicine since the launch
of ACE inhibitors 15 years ago. Major clinical trials are now
needed to confirm the predicted benefits for endothelin
antagonists in patients with cardiovascular disease.
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Endothelin: new discoveries and
rapid progress in the clinic
David J. Webb, Juan C. Monge, Ton J. Rabelink and Masashi Yanagisawa
Following the discovery of endo¬
thelial (ET-1) in 1988 (Refs 1, 2),
research on this potent vasopressor
and growth-promoting peptide has
made rapid progress. The use of
transgenic models and highly selec¬
tive endothelin receptor antagonists
has identified important develop¬
mental and physiological roles for the
ET system as well as major conse¬
quences of its overactivity in a range
of cardiovascular diseases3. Clinical
studies now also support the
development of ET antagonists in
hypertension4 and heart failure56. A
recent conference on endothelin*
addressed new developments in the
field, focusing primarily on the role of




The subcellular localization of
endothelin converting enzymes
(ECEs) and the site of physiological
activation of big ET-1 remain contro¬
versial. The meeting opened with a
session devoted to this topic. A. P.
Davenport (University of Cambridge,
UK) reported that a major site of ECE
expression in humans is the vascular
endothelium. He related the expres¬
sion of ECE in human tissues with
the distribution of big-ET and
mature ET-1, and provided the first
evidence of subcellular localization
of ECE to the Weibel-Palade bodies,
as well as to the cell surface, of
human endothelial cells of both large
conduit and smaller resistance ves¬
sels from heart, lung, brain and
adrenal gland. ECE immunoreactiv-
ity was also present on bronchial
epithelial cells, neurones and glia
and, less abundantly, on the surface
of vascular smooth cells.
Using site-directed mutagenesis,
M. Hoang (University of Leeds, UK)
and B-M. Loffler (Hoffman-La Roche,
Switzerland) reported further
refinements in structure-activity
relations of ECE-1, describing
residues important for catalytic activ¬
ity and glycosylation. ECE-1 has ten
potential N-glycosylation sites, and
glycosylation was found to have a
major impact on its physicochemical
properties. However, singlemutants
(Asn to Asp) did not affect enzy¬
matic activity. In contrast, double
mutation of Asn632 and Asn651 abol¬
ished enzymatic activity whereas
triple mutation of Asn residues 316,
362 and 382 had no effect. These find¬
ings suggest the functional impor¬
tance of glycosylation of specific
domains, and not single sites.
An elegant series of experiments by
T. Kido (Kyoto University, Japan)
using transfected cells provided the
evidence that processing of pro ET-1
into big ET-1 by a furin-like protease
is an essential step prior to its
proteolytic activation by ECE-1. N.
Emoto (University of Texas South¬
western Medical Center, Dallas,
USA) reported that two alternatively
spliced ECE-1 isoforms, termed ECE-
la and ECE-lb, differ only in the first
30 amino acids in the N-terminal cyto¬
plasmic tails. These account for differ¬
ent subcellular localization in native
vascular cells and in transfected
Chinese Hamster Ovary (CHO) cells.
ECE-1 a is the predominant isoform in
cultured vascular endothelial cells
where it resides strictly within intra¬
cellular secretory structures and can
be detected by immunostaining when
the cells are permeabilized. ECE-la is
constitutively transported to the lipo¬
somes where it is rapidly degraded. In
contrast, ECE-lb, the isoform found in
cultured smooth muscle cells, is
transported by the default pathway to
the plasma membrane where it is
located as an ectoenzyme and can be
detected by immunostaining without
permeabilization of the cells. Analy¬
ses of mutations and chimeric ECE-
1 / transferrin receptor constructs
demonstrated that the cytoplasmic
tail of ECE-la contains signals that are
necessary and sufficient for lysosomal
targeting. These findings are consist¬
ent with a model in which conversion
of big ET-1 in 'generator' cells, such as
the endothelium, is predominantly an
intracellular process but big ET-1 can
also be cleaved by the cell-surface
ECE-1 expressed in 'target7 cells, such
as vascular smooth muscle.
H. Funke-Kaiser (Benjamin
Franklin University Hospital,
Germany) reported that ECE-1
mRNA is expressed in two isoforms,
also termed a and b, which differ
only in their 5' ends. Transfection
experiments with the reporter-gene
luciferase, in cultured bovine aortic
endothelial cells, demonstrated that
a fragment of 1.5 kb of genomic DNA
immediately upstream of exon 3 of





L. N. Pierre (University of
Cambridge, UK) presented the
virtually exclusive role of the ETA
receptor in ET-l-induced constriction
of human pial arteries. D. J. Webb
(University of Edinburgh) used
selective ETA and ETB antagonists
(BQ123 and BQ788, respectively) to
show a vasodilatory role of the ETB
receptor in human forearm resistance
vessels in vivo, presenting evidence
that endogenous ET-1 confers basal
constrictor tone via ETA receptors
on vascular smooth muscle which
is modulated by endothelial cell
NO-dependent ETB-mediated dilator
tone7. Although there has been con¬
siderable debate over the functional
importance of the vascular smooth
muscle ETb receptor8, from these
studies, and others described later,
the functional role of the constrictor
ETB receptor in human vessels
remains in doubt.
The endothelial ETB receptor is
known to be linked to the production
of the vasodilators NO and prosta¬
cyclin. M. Jougasaki (Mayo Clinic,
Rochester, USA) described studies in
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demonstrating that ETB receptor
stimulation by sarafotoxin 6c (S6c)
can also increase the secretion of
adrenomedullin, a circulating vaso-
dilatory and natriuretic peptide of
vascular endothelial and smooth
muscle cell origin. Also, in anaes¬
thetized dogs, an infusion of
S6c resulted in an increase in
plasma adrenomedullin concen¬
trations. These results establish an
autocrine-paracrine role of the ETB
receptor in the regulation of a further
and potentially important endo¬
thelial vasoactive system.
Post-translational modifications,
such as phosphorylation and palmi-
toylation, play an important role in
the regulation of G protein-coupled
receptors. C. Schroeder (Johannes
Gutenberg University of Mainz,
Germany) reported that the human
ETa and ETB receptors are both
palmitoylated but only the ETB
receptor is phosphorylated in a
ligand-dependent manner. Evidence
was also presented that phosphoryl¬
ation causes rapid ETB receptor
inactivation, possibly accounting for
the well-known tachyphylaxis to
ETb receptor agonists, whereas ETA
inactivation is slower and associated
with receptor internalization. C>n the
basis of earlier work9-10, Y. Abe (Uni¬
versity of Tsukuba, Japan) described
a number ofmutant ETB alleles found
in patients with Hirschsprung's dis¬
ease, and used transient transfection
techniques to show that, although all
of these mutants bound endothelin
with high affinity, binding sites were
reduced in some cases and, to a vary¬
ing degree, all of the mutants were
significantly deficient in signal trans¬
duction as measured by phospho-
inositide hydrolysis, intracellular Ca2+
mobilization and extracellular signal-
related kinase (ERK)-2 activation.
Loss of function of the receptors may,
therefore, represent the molecular
mechanism of Hirschsprung's dis¬
ease in these kindreds. P. D'Orleans-
Juste (University of Sherbrooke,
Canada) and R. D. Naik (University
of Saskatchewan, Canada) indicated
a potentially important role for
nuclear Ca2+ mobilization in endo¬
thelin receptor signalling.
A particularly elegant piece of
medicinal chemistry was presented
by T. W. von Geldern (Abbott, USA),
who showed that highly ETA-
selective, mixed F,TA/ET[V and highly
ETB-selective antagonists were
derived by subtle modifications of a
single chemical skeleton (ABT627,
the active enantiomer of A127722).
R. N. Willette (SmithKlineBeecham,
USA) reported a strong correlation
between the degree of plasma
ET-1 elevation on administration of
antagonist and the affinity of the
drug towards the ETB receptor,
further confirming the 'clearance'
role of the ETB receptor for ET-1. In
further key studies, T. J. Opgenorth
(Abbott, USA) showed that the non-
peptide ETB-selective antagonist,
A192621, causes sustained, and
progressive, hypertension in rats.
Pathophysiology
Much of the meeting was devoted
to pathophysiology, mainly in the
cardiovascular field. Most of the work
is still in animals but new and impor¬
tant clinical studies were reported.
Cardiovascular disease
The circulation is an important
clinical target for ET antagonists.
Two years ago5, acute adminis¬
tration of the mixed ETA/B antagonist,
bosentan, was shown to produce
systemic and pulmonary vasodila¬
tation in patients with chronic heart
failure (CHF). However, a concern
with vasodilator therapy in CHF has
been that reduction in blood pressure
might induce adverse counterregu-
latory neurohumoral activation. How¬
ever, M. Ohnishi (Shiga University of
Medical Science, Otsu, Japan) showed
in dogs, and W. Kiowski (University
of Zurich, Switzerland) showed in
CHF patients, that ET receptor block¬
ade attenuates activity of the renin-
angiotensin and sympathetic nervous
systems despite blood pressure
lowering. Interestingly, Kiowski also
showed that haemodynamic benefits
with oral bosentan (1000mg twice
daily) can be sustained for at least
14 days of treatment and, on the
basis of a blinded clinical assessment,
that symptoms are improved
by treatment. Although bosentan
appeared to provide benefit, and
large-scale clinical outcome studies
are under way, it remains unclear
whether a selective ETA antagonist
or a mixed ETA/B antagonist would
be preferable. Recent studies in the
rat coronary occlusion model suggest
that selective ETA antagonists may
be effective in reducing mortality11.
Additional work was presented at
the meeting indicating in humans
that vasoconstriction of coronary
and resistance vessels is largely ETA
mediated in CHF. In agreement, in
dogs with heart failure (which prob¬
ably have a vascular endothelin
receptor distribution similar to
humans), selective ETA receptor
blockade with A127722 (D. Borgeson;
Mayo Clinic, Rochester, USA) and
with T0201 (Ohnishi) appeared to be
very effective in improving left
ventricular function and reducing
pulmonary vascular resistance.
ET-1 also has pro-arrhythmogenic
effects and arrhythmias are a major
cause of death in CHF. Consequently,
ET antagonism might reduce mortal¬
ity through preventing arrhythmias
as well as by preventing pump failure
and cardiac remodelling. This concept
was supported by M. Raschack
(Knoll, Ludwigshafen, Germany),
who showed that selective ETA recep¬
tor blockade with LU135252 could
reduce ischaemia-induced ventricu¬
lar arrhythmias in pigs. Furthermore,
P. Turbucz (Semmelweis University,
Budapest, Hungary) reported very
high ET levels in the pericardial fluid
of patients with CHF and also
showed, in dogs, that pericardial ET
could be causally linked to ventricu¬
lar arrhythmia.
ET-1 induces hypertrophy in cul¬
tured cardiac myocytes and ET recep¬
tor antagonists prevent cardiac hyper¬
trophy and adverse remodelling in a
myocardial infarction model of CHF
caused by left coronary artery li¬
gation11. M. Harada (Kyoto Uni¬
versity, Japan) reported that cardiac
non-myocytes (NMCs) - mostly
cardiac fibroblasts - stimulate cardio-
myocyte hypertrophy in vitro by
secreting ET-1. Pure cardiomyocyte
and NMC cultures prepared from
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neonatal rat ventricles under cyclical
stretch (20 cycles per minute) gener¬
ated a hypertrophic response only in
co-culture and this response could be
blocked by treatment with the selec¬
tive ETa antagonist BQ123. These
results indicate an ETA-mediated
paracrine action of NMCs on car-
diomyocytes.
A number of participants reported
the beneficial actions of ET antagon¬
ists in rat models of hypertension
and its complications, including
vascular remodelling, endothelial
dysfunction, cerebral oedema, pro¬
teinuria and death due to fulminant
hypertension. ETA selective non-
peptide antagonists were shown by
Y. Matsuo (S0139; Shinogi & Co.,
Osaka, Japan) to reduce brain oedema
and infarction induced by transient
middle cerebral artery occlusion and
by E. L. A. Blezer (A127722; Uni¬
versity of Utrecht, The Netherlands)
to prevent dose-dependently cerebral
oedema in stroke-prone spontan¬
eously hypertensive rats.
Models of subarachnoid haemor¬
rhage (SAH) have been widely
shown fo respond to ET receptor
antagonists. Importantly, V. Breu
(Hoffman-La Roche) presented evi¬
dence of reversal of post-SAH cer¬
ebral vasospasm by the mixed ETA/B
antagonist bosentan in patients, as
well as by the ETA-selective par¬
enteral antagonist, Ro611790 in a
double-haemorrhage canine model.
Interestingly, A. L. Kwan (Uni¬
versity of Virginia, USA) showed
that the alternative approach of
using a nonpeptide ECE inhibitor
(CGS26303) to prevent endothelin
generation is effective in preventing
and reversing SAH-induced spasm.
Pulmonary disease
In relation to obstructive lung dis¬
ease, a number of papers reported the
prevention and reversal of hypoxia-
induced pulmonary hypertension
with ETA-selective antagonists, and
S. Haleen (Parke-Davis) showed no
rebound in pulmonary pressure on
stopping therapy. Another important
area of interest was lung transplanta¬
tion. Here, allograft dysfunction
is characterized by pulmonary
hypertension and obliterative bron¬
chiolitis and associated with strong
ET-1 and ECE immunoexpression in
the airways epithelium and infiltrat¬
ing inflammatory cells. S. Takeda
(Osaka University, Japan) reported
that overexpression of ET-1 by HVJ
(Sendai virus)-liposome gene transfer
into the trachea ofWistar rats resulted
in bronchiolitis obliterans whereas
gene transfer into the pulmonary
artery increased medial thickness in a
manner similar to that found in pul¬
monary hypertension, consistent with
a role for ET-1 in allograft failure. Also
consistent with this view, A. Lee
(McGill University, Canada) reported
that the ETA/B antagonist, SB209670,
im-proved both allograft function and
survival of transplanted lungs in dogs.
It is also possible that ET antag¬
onism will be useful in transplan¬
tation of other solid organs such as
the kidney, liver and heart, where
ischaemia-reperfusion and adminis¬
tration of cyclosporine may lead to
excess activation of the ET system.
Indeed, beneficial effects were pre¬
sented for the ETa/b antagonist,
TAK044 by W. Tanaka (Hyogo
College of Medicine, Japan) for
protection of rat liver grafts, and
have previously been reported in
experimental renal transplantation12.
Renal disease
B. Hocher (Free University of
Berlin, Germany) recognized glomeru¬
losclerosis and renal interstitial fibro¬
sis as the most prominent phenotype
of human ET-1 transgenic mice, an
effect linked to apoptosis. Such
studies exemplify the potential role of
ET-1 in renal disease. However,
effects of ET antagonists in animal
models are influenced both by ET-1
dependency of the model and by
interspecies differences. Although
studies in the rat are most common,
the ETB receptor mediates vaso¬
constriction in this species, whereas
in dog and man renal vasoconstric¬
tion appears to be ETA mediated.
Moreover, the ETB receptor in the
kidney has been implicated in Na*
and water homeostasis and tubular
regeneration12. Indeed, key studies
with ET-1 and an ETA-selective
(SB234551) and mixed ETA/B antag¬
onist (SB209670) in chronically instru¬
mented dogs (described by D. P.
Brooks; SmithKlineBeecham, USA)
clearly show that selective ETA antag¬
onism can prevent radiocontrast-
induced renal vasoconstriction and,
separately, reveal the presence of an
ETB-mediated vasodilatation and
natriuresis. Nevertheless, this does
not imply that mixed antagonismwill
be ineffective in renal disease. Indeed,
in acute experiments in dogs with
endotoxaemia C. Mitaka (Tokyo
Medical and Dental University,
Japan) demonstrated that mixed
ETa/b blockade (TAK044) could pre¬
vent renal hypoperfusion. Compara¬
tive long-term studies in various renal
disease models in dogs, and clinical
studies in humans, are needed to
determine the best approach.
Importantly, C. Ferro (University
of Edinburgh, UK) reported the first
clinical study in patients with
chronic renal disease. Whilst the
ETa/b antagonists, TAK044 and
SB209670 induce only mild renal
vasodilatation in healthy subjects as
reported by G. Siitsch (University of
Zurich, Switzerland) and D. Jorkasky
(SmithKlineBeecham, Philadelphia,
USA) respectively, intravenous
TAK044 750mg in patients with
renal failure (baseline glomerular fil¬
tration rate, 25mlmin-') caused 10%
reduction of mean arterial pressure,
24% reduction in systemic vascular
resistance, and a favourable pattern
of changes in renal vascular resist¬
ance and effective filtration fraction
similar to those seen with ACE in¬
hibitors. Interestingly, ACE inhibitor
therapy in these patients was
stopped only 24 h before TAK044
administration, implying, with this
degree of renal failure, that the
effects of endothelin antagonism
may add to those of ACE inhibition.
Transgenic/knockout models
The meeting closed with work on
genetic approaches to elucidating the
function of the ET system in the whole
animal. H. Morita (University of
Tokyo, Japan) reported further mech¬
anistic analysis of the small elevation
of blood pressure in heterozygous
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ET-l gene-deficient mice13. This is not
related to salt sensitivity and is likely
to he due to hypovir sympathetic acti¬
vation. A. G. Baynash (University of
Texas Southwestern Medical Center,
Dallas, USA) reported for the first
time that an ET-2 knockout mouse
model is apparently normal at birth
but then develops a phenotype of
severe growth retardation. She
showed that ET-2 is an essential mol¬
ecule for postnatal growth, probably
involved in the regulation of intestinal
function. ECE-1 knockout mice re¬
ported by H. Yanagisawa (University
of Texas Southwestern Medical Cen¬
ter, Dallas, USA) provided convincing
genetic evidence that ECE-1 is a bona
fide converting enzyme in vivou. These
mice showed the existence of dual ET-
mediated pathways in the normal
development of neural crest tissues.
However, they also showed the exist¬
ence of converting enzyme(s) that are
not ECE-1 or ECE-2. Using isolated
vascular beds from heterozygous ETA
receptor and ECE-1 knockout mice,
N. Berthiaume (University of Texas
Southwestern Medical Center, Dallas,
USA) clearly showed that reduction
of the activity of these genes by half is
sufficient to cause significant alter¬
ations in vascular function.
Finally, using several genetic tricks
to 'rescue' the lethal phenotype of
ETB-deficient animals, T. Ohuchi and
C. Gariepy (University of Texas
Southwestern Medical Center, Dallas,
USA) each showed that adult ETB-
deficient mice and rats exhibit signif¬
icantly elevated blood pressure
under healthy, baseline conditions. In
these mice, the hypertension was
shown to be salt-sensitive and resist¬
ant to ETa blockade, strongly impli¬
cating the function of the ETB receptor
as a physiologically relevant natri¬
uretic receptor in the kidney.
Summary
This fifth international conference
on ET serves to underline the rapid
pace of development of our under¬
standing of the very versatile ET
system. On the one hand, the body
uses ETs at several stages in embry¬
onic development, in normal post¬
natal growth, and in cardiovascular
homeostasis under healthy condi¬
tions. On the other hand, over¬
whelming evidence now exists that
ET-l plays important pathophysio¬
logical roles in conditions of de¬
compensated vascular homeostasis.
Indeed, in CHF this evidence is
sufficient to justify the large-scale
studies of morbidity and mortality
needed to market ET antagonists as
medicines. Other potentially impor¬
tant cardiovascular indications for
ET antagonists are still emerging -
including hypertension, stroke, sub¬
arachnoid haemorrhage and renal
failure - and all are likely to be the
subject of clinical trials over the next
few years. As yet, there has been
little work outside the cardiovascular
and renal fields, but other areas,
such as cancer treatment, may also
prove promising15.
New molecules with increasing
selectivity (ETA and ETB) continue to
emerge and may be valuable. Inhibi¬
tion of ECE-1 remains as an alterna¬
tive approach and nonpeptide ECE
inhibitors now exist. There appears to
be a consensus that ETA blockade is
beneficial in cardiovascular and renal
disease. However, several strands of
work presented at the meeting - the
hypertensive salt-sensitive phenotype
of rescued ETB knockout mice, the sus¬
tained and progressive hypertensive
effects of ETB-selective antagonism in
rats, ETB-mediated vasodilatation and
natriuresis in dogs, and nitric oxide
dependent ETB-mediated vasodila¬
tation in humans - all suggest that
ETB-mediated vascular and renal
responses may be protective. The
development of selective ETA antag¬
onists, therefore, now seems fully
justified. In the future, direct compari¬
sons in animal models, and patients,
of ETa and ETA/B antagonists will be
important in determining the value of
additional ETB receptor blockade in
individual diseases.
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Endothelin as a regulator of cardiovascular function
in health and disease
William G. Haynes3 and David J. Webbb
The endothelins are a family of endothelium-derived
peptides that possess characteristically sustained
vasoconstrictor properties. Endothelin-1 appears to be
the predominant member of the family generated by
vascular endothelial cells. In addition to its direct vascular
effects, endothelin-1 has inotropic and mitogenic
properties, influences homeostasis of salt and water,
alters central and peripheral sympathetic activity and
stimulates the renin-angiotensin-aldosterone system.
Studies with endothelin receptor antagonists have
indicated that endothelin-1 probably has complex
opposing vascular effects mediated through vascular
smooth muscle and endothelial ETA and ETB receptors.
Endogenous generation of endothelin-1 appears to
contribute to maintenance of basal vascular tone and
blood pressure through activation of vascular smooth
muscle ETa receptors. At the same time, endogenous
endothelin-1 acts through endothelial ETB receptors to
stimulate formation of nitric oxide tonically and to
oppose vasoconstriction.
In view of the multiple cardiovascular actions of
endothelin-1, there has been much interest in its
contribution to the pathophysiology of hypertension.
Results of most studies suggest that generation of, or
sensitivity to, endothelin-1 is no greater in hypertensive
than it is in normotensive subjects. Nonetheless, the
deleterious vascular effects of endogenous endothelin-1
may be accentuated by reduced generation of nitric oxide
caused by hypertensive endothelial dysfunction. It also
appears likely that endothelin participates in the adverse
cardiac and vascular remodelling of hypertension, as well
as in hypertensive renal damage. Irrespective of whether
vascular endothelin activity is increased in hypertension,
anti endothelin agents do produce vasodilatation and
lower blood pressure in hypertensive humans. There is
more persuasive evidence for increased endothelin-1
activity in secondary forms of hypertension, including
pre-eclampsia and renal hypertension. Endothelin-1 also
appears to play an important role in pulmonary
hypertension, both primary and secondary to diseases
such as chronic heart failure. The hypotensive effects of
endothelin converting enzyme inhibitors and endothelin
receptor antagonists should be useful in the treatment of
hypertension and related diseases. Development of such
agents will increase knowledge of the physiological and
pathological roles of the endothelins, and should
generate drugs with novel benefits. J Hypertens
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Introduction
l'hc vascular endothelium plays a key role in the regulation
ot coagulation, lipid transport, immunological reactivity
and vascular tone. Several important vasodilator and con¬
strictor substances arc produced by endothelial cells. The
first identified was prostacyclin, which is a potent vaso¬
dilator and inhibitor of aggregation of platelets [1]. In 1980,
a non-prostaglandin, cndothelium-dependcnt vasodilator
factor was postulated [2]. This endothclium-derivcd relax¬
ing factor (EI)RE) was subsequently identified as nitric
oxide (3|. The isolation of EDRE prompted a search
for counterbalancing endothclium-derivcd constricting
factors (KI)CI'). By 1985, the vascular endothelium had
been shown to generate a vasoconstrictor substance that
produced prolonged vasoconstriction [4]. This long-acting
agent appeared to be a peptide. It was finally isolated and
sequenced from endothelial cell cultures in 1988 and called
endothelin [5]. Three isopeptides of endothelin have since
been identified, endothelin-1, cndothelin-2 and endo-
thclin-3, each containing 21 amino acids [6] (Tig. 1).
Endothelin-1, the peptide originally identified hy
Yanagisawa, is the most potent vasoconstrictor and the pre¬
dominant isoform expressed in vasculature [6,7],
Endothelin-1 is a potent vasoconstrictor, has inotropic anil
mitogenic properties, influences homeostasis of salt and
water and stimulates the renin-angiotensin-aldosterone
and sympathetic nervous systems. Thus, the overall effect
0263 6352 r 1998 Lippincott-Raven Publishers
1082 Journal of Hypertension 1998, Vol 16 No 8
Fig. 1 Fig. 2
Endothelin-1
Endothelin-3
Amino acid sequences of the three members of the endothelin family
and of the structurally related snake venom toxin sarafotoxin S6b.
Each isoform contains two intra-chain disulphide bridges linking
paired cysteine amino acid residues, thus producing an unusual
semi-conical structure. Shaded circles indicate where amino acids
differ from those of endothelin-1.
of the actions of endothelin is usually to increase vascular
tone and blood pressure. Endothclin might, therefore,
play an important role in the pathophysiology of cardiac,
vascular and renal diseases associated with regional or
systemic vasoconstriction. Anti-endothelin therapy could
be beneficial in treating diseases associated with sustained
vasoconstriction, such as essential hypertension, chronic
heart failure (CHF) and chronic renal failure. In this
article we review the biology of the cndothelins and
discuss in detail their putative roles in the pathophysi¬
ology of hypertension and related conditions.
Generation of endothelin
Molecular genetics and regulation of generation
Each member of the endothelin family is represented by
a separate gene that encodes a specific precursor for the
mature isoform [6], In the 5' flanking region there are
binding sites for activating protein 1 and nuclear factor 1,
which mediate the induction of mRNA for endothelin-1
by angiotensin II and transforming growth factor-ff,
respectively [7-9], The 3' Hanking region of the mRNA
contains adenine-uracil-rich sequences that mediate
selective destabilization of preproendothelin-1 mRNA,
accounting for its relatively short biological half life of
15 min. Generation of endothelin-1 is increased by many
stimuli, including vaso-active hormones, growth factors,
hypoxia, shear stress, lipoproteins, free radicals, endo¬
toxin and cyclosporin [10] (Fig. 2). Production of endo¬
thelial is inhibited by stimuli that act to increase intra¬
cellular level of cyclic guanosinc monophosphate (cGMP),
including cndothelium-dcrivcd nitric oxide, nitrovaso-
dilators, natriuretic peptides, heparin and prostaglandins
110] (E.g. 2).
Factors regulating synthesis of endothelin-1 (ET-1) and the pathway
for generation of ET-1. See text for details of the regulatory elements
of the preproendothelin-1 gene. 11-1, interleukin-1; TGFb, transforming
growth factor-(i; LDL, low-density lipoprotein; ANP, atrial natriuretic
peptide; BNP, brain natriuretic peptide; CNP, C-type natriuretic
peptides; a.a., amino acids.
Sites of generation
The major site of generation of endothelin-1, assessed in
terms of expression of mRNA for preproendothelin-1 and
the presence of intracellular converting enzyme, is in
endothelial cells [6,7,11], Endothclin-1 is also produced
by the heart, kidney, posterior pituitary and central
nervous system [10]. Human aortic vascular smooth
muscle cells also express mRNA for endothelin-1,
although its production is about 100 fold less than that in
endothelial cells. Limited amounts of endothelin-2 arc
produced in endothelial cells, heart and kidney [12,13].
Endothelin-3 appears to be selectively expressed in the
endocrine, gastro-intestinal and central nervous systems,
but not in endothelial cells [10].
Biosynthetic pathway
The initial product of the human endothclin-1 gene is prc-
proendothclin-1, a 212 amino acid peptide (big. 2).
I'rocndothelin-1 is formed after removal of a short secre¬
tory sequence, and is then cleaved by furin to generate a
38 amino acid peptide, big endothelin-1 [5], Big endothe¬
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formation of mature endothelin-1 requires cleavage of big
endothelin-1 by one of several unique endothelin con¬
verting enzymes (ECE). This family of metalloproteases
is related to neutral endopeptidase-24.11 and Kell protein,
but not to angiotensin converting enzyme. ECE-1 is the
physiologically active ECE [15], It possesses two splice
variants, ECE-la and ECE-1 b, that have functionally dis¬
tinct roles and tissue distributions [11]. ECE-la is
expressed in the Golgi apparatus of 'producer' cells, such
as endothelial cells, and appears to be responsible for intra¬
cellular processing of big endothelin-1 to endothelin-l in
such cells. ECE-1 b is expressed in 'responder' cells, such
as vascular smooth muscle cells, and is transported to the
plasma membrane where it acts to cleave extracellular big
endothelin-1. A second form of ECE (ECE-2) has been
cloned and characterized [16]. ECE-2 is similar to ECE-1
in that it is membrane bound, inhibited by phosphorami-
dnn and exhibits selectivity for big endothelin 1.
However, ECE-2 is active only at acidic pH (5.5) and is
not expressed on the cell's surface [16]. Thus, ECE-2
could act as an intracellular enzyme responsible for the
conversion of endogenously synthesized big endothelin-1
in acidic environments. ECE-1 and ECE-2 are relatively
selective for big endothelin-1, having much less activity in
cleaving big endothelin-2 and big endothelin-3. It is prob¬
able that there are other, as yet unidentified, ECE that are
responsible for cleavage of endothelin-2 and endothelin-
3. Both ECE-1 and ECE-2 are inhibited by phosphorami-
don, but not by selective neutral endopeptidase and
angiotensin converting enzyme (ACE) inhibitors [10].
Intra-arterial administration of big endothelin-1 to humans
produces dose-dependent forearm vasoconstriction [17].
Co-infusion of the ECE inhibitor phosphoramidon com¬
pletely prevents development of vasoconstriction in
response to big endothelin-1. Thus, it is likely that vaso¬
constriction in response to big endothelin-1 reflects its vas¬
cular conversion to the mature peptide by ECE. Because
circulating blood does not exhibit ECE activity [18], con¬
version of big endothelin-1 in the forearm probably occurs
via action of vascular ECE situated in endothelial cells.
Endothelin-1 is about 10-fold more potent as a constrictor
of the forearm bed than is big endothelin-1, implying that
local cell-surface ECE converts about 10% of luminally
presented big endothelin-1 to endothelin-1. Further evi¬
dence that ECE activity is responsible for forearm vaso¬
constriction in response to big endothelin-1 comes from
measurement of plasma concentrations of cndothclin-1,
big endothelin-1 and the inactive C-terminal fragment of
cndothelin-1 (CTE) formed by cleav age of big endothelin-
1 in venous blood from infused and non-infused forearms
[ 19], Concentrations of big endothelin-1, endothelin-1 and
CTE in venous blood from the infused arm, but not those
in venous blood from the control arm, increase significantly
during infusion of big endothclin-1. The ratio of CTE to
big cndothclin-1 is about 0.1, indicating that about 10% of
the precursor is converted by ECE [19], which is consistent
with functional data [17]. This 10% conversion rate for
exogenously applied big endothelin-1 found in human
studies is similar to that observed in vitro for exogenous big
cndothelin-1 in cells transfected with cDNA for ECE-1
[15].
Plasma concentrations of endothelin
Circulating concentrations of endothelin-like immunore-
activity in venous plasma are in the range 1-10 pmol/1 in
healthy subjects [20,21] and are strikingly dependent upon
assay conditions [22]. This immunoreactivity comprises
big endothelin-1 (-60%), endothelin-1 (-30%) and
endothelin-3 (-10%) [20,21], although some investigators
have not been able to detect big endothelin-1 in healthy
subjects [23], Endothelin-2 has not been detected in
human plasma. Circulating concentrations of endothelin-1
are lower than those which cause vascular contraction
in vitro and in vivo, although concentrations at the inter
face between an endothelial cell and vascular smooth mus¬
cle are likely to be much higher. Indeed, cultured
endothelial cells secrete substantially more endothelin-1
towards the adjacent vascular smooth muscle than they do
luminally [24]. Thus, endothelin-1 appears to be primar¬
ily a locally acting paracrine substance rather than a circu¬
lating endocrine hormone. Venous plasma endothclin 1
concentrations have been used as a marker for endothelial
synthesis of the peptide, though circulating endothelin-1
is rapidly cleared from the circulation. Circulating con¬
centrations of big endothelin-1 and CTF appear to reflect
generation of cndothelin-1 more accurately [19,25].
Clearance of endothelins
Endothelin-1 is rapidly cleared from the circulation after
bolus intravenous injection, with a biological half life of
about 1 min, although its pressor effects are sustained for
up to 60 min [26,27], A substantial proportion of clearance
of endothelin-1 appears to occur through receptor binding
and then internalization. Pulmonary clearance of radio-
labelled endothelin-1 can be blocked by pretreatment
with a large dose of unlabelled endothelin-1, supporting
the hypothesis that its clearance is receptor mediated [26],
Blockade of endothclin receptors of the ETM subtype, but
not of the ETA subtype, increases plasma concentrations
of endothelin-1 and endothelin-3 [28] and prolongs the
biological half life of exogenous [l2SI]-endothclin-l [29],
Blockade of ETit receptors increases circulating level of
endothelin-1 within 15 min [28,30] and does not affect
concentrations of big endothclin-1 and C-terminal frag¬
ments [25,28], confirming that the increase is mediated by
displacement of cndothelin-1 from receptors rather than
through generation de novo. Plasma concentrations of
immunorcactive endothelin vary inversely with renal func¬
tion [31]. Prolongation of plasma and biological half lives
of cndothclin-1 in bilaterally ncphrcctomizcd rats suggests
that the major effect of renal disease, is through impair¬
ment of its clearance [32]. Selective assays reveal that
patients with chronic renal failure have marked elevations
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in plasma concentration of cndothelin-1 with little or no
change in concentrations of big cndothclin-1 [11). Such
elevations in level of mature cndothclin-1, without
changes in level of big endothclin-1, are most likely to be
due to lower than normal renal clearance of endothclin-1.
Enzymatic degradation of the endothelins by endopepti-
dases, particularly by neutral endopeptidase, also occurs
[33].
Receptors and signal transduction
Endothelin receptors
The endothelins act on two receptor subtypes, ETA
and ET|(, characterized on the basis of their pharma¬
cology (Table 1). The ETA receptor is preferentially
activated by cndothelin-1 (A; = 0.6 nmol/1) but not by
endothelin-3 (A'j = 140 nmol/1) [34,35]. Messenger RNA
for the ETa receptor is expressed most highly in the aorta,
heart and kidney but not in endothelial cells, suggesting
that vascular expression of this receptor occurs selectively
in smooth muscle cells [36], Potent peptide and non-
peptide ETA antagonists have been synthesized, the
prototype being the cyclic pentapeptide BQ-123 [37]. The
ET|, receptor is activated equally by cndothclin-1
(A'j = 0.12 nmol/1) and by endothclin-3 (A, = 0.06 nmol/1).
Messenger RNA for the ETh receptor is most highly
expressed in cultured endothelial cells [38]. Activation of
this endothelial cell ET|t receptor leads to production of
vasodilator substances, including nitric oxide and
prostaglandins. Messenger RNA for the ETh receptor has
also been shown to be present in vascular smooth muscle
[39], where it could mediate vasoconstriction [40]. Several
agonists selectively activate the ETM over the ETA
receptor. They include endothelin-3 (-2000-fold selec¬
tivity) and sarafotoxin S6c (-300 000-fold selectivity) [35].
BQ-788 is a selective peptide antagonist of the PZTu
receptor [41],
The deduced structure for the ETV and ETB receptors
has much in common with the superfamilv of rhodopsin-
like G-protein-coupled receptors, having seven hydro¬
phobic membrane-spanning domains and a relatively
long extracellular N terminal, although there is only a
25% sequence homology with other peptide receptors.
Number of endothelin receptors is regulated by a variety
of factors. Ischacmia and cyclosporin increase the number
of endothelin receptors [42,43], whereas cndothelin-1,
angiotensin II and phorbol esters decrease number of
receptors (44,45).
Intracellular events
Binding of cndothelin-1 to ETA or ETB receptors
produces G-protcin dependent activation of phospholi-
pasc G. This leads to hydrolysis of phosphatidyl inositol
and generation of cytosolic inositol trisphosphate and
membrane-bound diacvlglycerol [46,47]. Inositol tris¬
phosphate causes a rapid increase in intracellular concen¬
tration of calcium ([Ca2t];), through its release from
intracellular stores [48]. A more sustained rise in [Ca2+],
occurs through opening of membrane Ca2+ channels [48].
Diacylglycerol activates protein kinase C, increasing sensi¬
tivity of the contractile apparatus to changes in [Ca2+];
[49]. Diacylglycerol also activates nuclear signalling mech¬
anisms - with possible effects on long-term regulation of
cellular function and growth - and increases intracellular
pH through effects on the sodium-hydrogen ion exchange
pump. In addition, there is evidence from in-vitro and in-
vivo studies that endothelin-1 closes membrane K+ chan¬
nels [50-53]. Closure of these channels prevents efflux of
K7 from the cell, thereby favouring depolarization of
membrane and contraction of smooth muscle. Finally,
cndothelin-1 can activate phospholipase \z, increasing
generation of prostacyclin and thromboxane A2 [54],
Actions
Cardiac actions
Endothelin-1 has potent positive chronotropic and
inotropic effects in vitro [55]. Endothclin-1 is a potent
constrictor of coronary vessels, causing myocardial
ischacmia and fatal ventricular arrhythmias [56], In vivo,
although endothclin-1 is positively inotropic at low doses,
higher doses cause cardiac output to fall [57], probably
due to a combination of a high aftcrload and myocardial
ischaemia from coronary vasoconstriction. Systemic doses
of cndothelin-1 decrease cardiac output in humans, prob¬
ably through a baroreceptor-mediated decrease in heart
rate, although an increase in afterload might also
contribute [58].
Direct vascular actions
Endothelin-1 causes sustained contraction of conduit
arteries, with a potency 10-fold higher than those of other
constrictors [5]. All three endothclins cause transient
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cndothelium-dependent vasodilatation before the devel¬
opment of constriction, though this is most apparent for
endothelin-3 [59]. Resistance vessels and veins are partic¬
ularly sensitive to the effects of endothelin-1 [59].
Vasoconstriction in response to endothelin-1 was initially
thought to be mediated solely by vascular smooth muscle
cell ETa receptors. Endothelial cell ETB receptors were
thought to mediate vasodilatation through generation of
endothelium-derived dilator substances (Fig. 3). More
recent evidence suggests that ETB receptors also mediate
vasoconstriction [40] (Fig. 3). Vasoconstriction in response
to ETB receptor agonists is variable and appears to depend
markedly on species, vessel type and vessel size [39]. The
physiological role of vascular ETB receptors is best clari¬
fied by studies with receptor antagonists - these data are
discussed later.
The endothelins increase blood pressure in vivo in animals
for at least 60 min after a bolus dose [5]. The coronary
and renal vascular beds in animals are most sensitive to
the vasoconstrictor effects of systemic endothelin-1 [57].
The mesenteric bed also vasoconstricts in response to
systemic endothelin-1, whereas the hindquarters skeletal
muscle bed exhibits little constriction [60]. These differ¬
ences among beds may be related to differences in
constrictor (ETA and ETB) and dilator receptors (ETB).
The pressor effect of bolus doses of endothelin is usually
preceded by transient hypotension that is most marked
for cndothclin-3 [6] and is mediated by endothelial ETB
receptors. Under more physiological conditions, in which
concentrations of endothelin rise more slowly, hypoten¬
sion does not occur [61]. Nevertheless, the hypotensive
response to bolus administration could be useful in
demonstrating the endothelial actions of the endothclins
(see below).
Fig. 3
Vascular actions of endothelin 1 (ET). BIG ET, big endothelin-1;
ECE, endothelin converting enzyme.
Infusion of cndothclin-1 into the brachial artery of humans
slowly decreases forearm blood flow in a dose-dependent
manner [62,63], with vasoconstriction sustained for 2 h
after infusion of cndothelin-1 has been halted [62].
Because vasoconstriction in response to endothelin-1 is
slow to develop and reverse, most clinical investigators
have used prolonged infusions rather than bolus doses of
endothclin-1. When identical doses are infused over 60
and 5 min, greater vasoconstriction is observed with the
more prolonged infusion [40], Prolonged infusions also
have potential safety advantages. However, this approach
does limit plotting of dose-response curves, making it
somewhat difficult to compare sensitivity to endothelin-1
between groups. In antagonist studies, this limitation can
be addressed by using prolonged infusions of maximal
doses of antagonists, to ensure that full inhibition of
responses to endothclin-1 is obtained. Intra-arterial admin¬
istration of a bolus endothclin-1 or endothelin-3 produces
transient vasodilatation before development of vasocon¬
striction [40]. Endothelin-1 also causes slow-onset, sus¬
tained constriction of cutaneous veins in vivo [62,64],
Intravenous infusion of endothelin-1 increases blood
pressure in human subjects by 5-10% at doses of about
1 pmol/kg per min administered for over 60 min [27,58],
As in animals, the haemodynamic effects are slow to come
into effect and are sustained for more than 60 min.
Systemic administration of endothelin-1 is also accom¬
panied by coronary, renal and splanchnic vasoconstric¬
tion [58,65,66]. Depressor responses to systemic doses of
endothelin-1 have not been shown to occur in humans,
probably because endothelin-1 has been administered by
slow intravenous infusion for safety reasons.
Interactions with other endothelial mediators of vascular
tone
The cndothclins stimulate generation of nitric oxide by
vascular endothelial cells [67] (Fig. 3). The transient early
vasodilator actions of the endothelins are attenuated by
nitric oxide synthase inhibitors [68], Perhaps more rele¬
vant physiologically is that nitric oxide synthase inhibitors
also potentiate the constrictor and pressor effects of
endothelin-1, suggesting that there is an autocrine feed¬
back mechanism modulating vasoconstriction in response
to endothclin by stimulation of the endothelial generation
of nitric oxide [68], Endothelin-1 also increases generation
of prostacyclin by cultured endothelial cells [67] and cyclo-
oxygenase inhibitors potentiate endothelin-1-induced
constriction [68], suggesting that vasodilator prosta¬
glandins play a similar modulatory role (Fig. 3). Vcno-
eonstrietion to endothclin-1 in humans is potentiated by
cyclo-oxygenase inhibition, but not by nitric oxide
synthase inhibition, suggesting that prostanoids alone
modulate the effects of endothelin-1 on veins [64], In addi¬
tion, endothelin-1 appears to increase endothelial genera¬
tion of the potent vasodilator peptide adrenomcdullin [69].
These endothelial effects of endothelin-1 that increase
generation ot vasodilators appear to be mediated by the
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KT|, receptor, which perhaps acts by physiologically antag¬
onizing ETa receptor-mediated vasoconstriction.
Physiological role of endothelin-1 in maintenance
of vascular tone
There has been much controversy about the physiolog¬
ical relevance of endogenous generation of endothelin-1
to the maintenance of basal vascular tone and blood
pressure. Some of this was related to the unexpected
finding that mice with one cndothclin 1 gene deleted
paradoxically have slightly higher blood pressure than do
controls, despite their lower circulating concentration of
endothclin-1 [70], However, evidence that the elevation
of blood pressure in this model is due to sympatho-adrenal
overactivity caused by hypoxia secondary to abnormali
ties in facial/pharyngeal development is emerging [11].
Parenthetically, the occurrence of such anomalies suggests
that cndothelin-1 plays an important role in development
of the pharyngeal arches, heart and great vessels [70].
Although it is now widely recognized that endothelin-1
docs regulate arterial pressure under physiological condi
tions, there is still debate regarding the contributions of
ETa and ETB receptors, particularly the latter.
The best way to address rhe physiological role of endoge¬
nous endothelin-1 is to examine the hacmodynamic
effects of drugs that selectively block the generation or
actions of endothelin-1. Inhibition of ECE or ETA recep¬
tors slowly decreases arrerial pressure in normotensive
animals [71-74], This hypotensive effeer of anri-
endorhelin rhcrapy is not apparent in short term studies
(i.e. < 10 min) [75-77], A slow onset of vasodilatation
would be consistent with the sustained vasoconstrictor
effects of endothclin-1 which last for up to 2 h after an
infusion has been halted [62] and also with the finding
that endothelin receptor antagonists only slowly reverse
rhe pressor effects of endothelin-1 in animals [78]. Intra
arterial administration of the ECE inhibitor and neutral
endopeptidase inhibitor phosphoramidon to humans
causes slow-onset forearm vasodilatation, suggesting that
endogenously generated cndothelin-1 plays a physiolog¬
ical vasoconstrictor role [17]. This effect is not due to
inhibition of neutral endopeptidase, because the selective
neutral endopeptidase inhibitors candoxatril and thior-
phan do not cause vasodilatation [17,79]. Indeed, local
infusion of neutral endopeptidase inhibitors causes a
modest forearm vasoconstriction that might reflect inhi¬
bition of the metabolism of endothelin-1 [17,33,79,80],
Parenthetically, peripheral vasoconstriction secondary to
inhibition of neutral endopeptidase could underlie the
failure of this class of agents to decrease blood pressure
in hypertensive patients [81], Local blockade of forearm
resistance vessel ETA receptors with the peptide BQ-123
or of both E TA and ETB receptors with the peptide TAK-
044 also causes slow-onset forearm vasodilatation,
supporting the hypothesis that endogenous endothelin-1
plays a role in physiological maintenance of vascular tone
[17,30], Interestingly, at maximal doses, ETA receptor
antagonism with BQ 123 causes more vasodilatation than
docs combined ETA/B receptor antagonism with TAK 011.
Systemic administration of TAK-044 to human subjects
produces systemic vasodilatation and decreases arterial
pressure by 10-20%, confirming the physiological impor¬
tance of endogenous generation of endothelin-1 [30]. The
non-peptide ET^, antagonist bosentan also lowers arte¬
rial pressure in normotensive humans [82]. Taken
together, these data suggest that endogenously generated
cndothclin 1 acts through ETA receptors to promote vaso
constriction and maintain blood pressure.
More recently, evidence that endogenous endothelin-1
exerts additional actions causing vasodilatation and natri
uresis and decreasing blood pressure, mediated through
endothelial and renal ETB receptors, has been accumu¬
lating. First, ET|t receptor antagonists, such as A192621,
cause sustained and progressive hypertension in animals
[11]. Second, maximal local ETA receptor antagonism
causes more vasodilatation in humans than does maximal
local ETa/b antagonism [17,30]. Third, intra-arterial infu¬
sion of the ETb receptor antagonist BQ-788 produces
sustained vasoconstriction in humans and opposes the
vasodilator action of BQ-123 [83]. Fourth, the kidney is
rich in ETB receptors that prevent tubular reabsorption
of sodium and thereby cause natriuresis [84—88]. Lack of
these renal ETB receptors in ETB knockout mice and
rats causes sensitivity to salt, and hypertension that is not
reversible with bloekade of ETA reeeptors [11] The vaso¬
constrictor effects of ETb receptor antagonists would be
consistent with blockade of tonic endothelial. ETB
receptor mediated stimulation of formation of nitric oxide
(Fig. 3). However, it is worth remembering that ETB
receptor antagonists increase concentrations of endo¬
thelin-1 by blocking clearance receptors [28,29] and that
this phenomenon could also account for the pressor effects
of blockade of ETB receptors. Indeed, there is evidence
that the pressor effects of ETB receptor antagonism are
present even when formation of nitric oxide is inhibited
and that these effects can be blocked by ETA antagonism
[89]. Even so, most data suggest that tonic stimulation of
the ETb receptor causes natriurcsis and tends to decrease
blood pressure under physiological circumstances.
In summary, there appears to be sufficient endogenous
generation of cndothclin-1 for it to play a physiological
role in control of vascular tone and blood pressure.
However, the overall cardiovascular effect of endogenous
endothelin-1 depends on the balance between ETA-medi-
ated and ETB-mediatcd effects. Activation of vascular
smooth muscle ETA receptors causes vasoconstriction and
tends to elevate blood pressure. Activation of endothelial
and renal ETB reeeptors promotes vasodilatation and
natriuresis and tends to decrease blood pressure.
Interestingly, forearm vasodilatation in response to the
E'l\ receptor antagonist BQ-123 can be blocked either
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by inhibition of nitric oxide synthesis or by blockade of
ET|) receptors [83], Thus, much of the vasodilator effects
of ETa receptor blockade may be due to unmasking of
the underlying ET|,-mediated dilator tone. The hypoten¬
sive effects of combined ET^,, receptor antagonists on
healthy subjects suggest that the overall physiological
effect of endothelin-1 is to increase blood pressure [30].
Obviously, the cardiovascular effects of endogenous
generation of endothelin-1 may change in cardiovascular
disease if there are changes in the numbers or functions
of ETa and ETB receptors. For example, impairment of
endothelial generation of nitric oxide would be expected
to attenuate dilator responses of ETB receptors and
promote constrictor responses of ETA receptors.
Cell growth and inflammation
Endothelin-1 is a potent mitogen for vascular smooth
muscle cells [90], cardiac myocytes [91] and glomerular
mesangial cells [92]. Endothelin-1 increases expression of
mRNA for the growth-promoting proto-oncogenes c-fos
and c-myc [90]. The endothelins are also potent stimula¬
tors of monocyte production of cytokines that activate
macrophages. These cytokines include tumour necrosis
factor, interleukins (1, 6 and 8) and granulocyte-
macrophage colony-stimulating factor [93].
Renal actions
Endothelin-1 has two main direct actions on the kidney,
causing renal vasoconstriction and loss of tubular sodium
and water, these actions probably reflecting separate sites
of production in renal blood vessels and tubules.
Endothelin-1 contracts afferent and efferent arterioles
equally in vitro [94] and thus reduces both renal plasma
flow and glomerular filtration rate (GFR) [95-97].
Endothelin-l-induced renal vasoconstriction involves
ET|( receptors in the rat [72] but mainly ETA receptors
in the dog and human [98,99]. Renal vasodilatation occurs
after infusion of BQ-123 into dogs, suggesting that
vascular generation of endothelin-1 contributes to basal
renal vascular tone [72]. Endothelin receptor antagonists
decrease effective renal vascular resistance in humans by
about 10%, without changing GFR [11], suggesting that
the predominant effect of endogenouslv generated
endothelin-1 is on the efferent arteriole.
Despite its potent vasoconstrictor properties, at low doses
endothelin-1 increases urinary excretion of Na* [92,97].
There is substantial production of endothelin-1 by the
inner medullary collecting duct cells [85] and renal tubular
epithelial cells have a high density of endothelin recep¬
tors, mainly of the ET|t subtype [84], Several lines of
evidence suggest that this locally produced endothelin-1
plays an important role in modulation of renal excretion
of sodium and water (Fig. 4). First, endothelin-1 blocks
reabsorption of sodium by inhibiting tubular Na'/K'-
A 1 I'ase activity in the proximal tubule and collecting duct
1100]. Second, endothchn-1 blocks reabsorption of water
in the collecting duct by inhibiting the effects of anti¬
diuretic hormone (ADF1) on tubular osmotic permeability
[101,102]. Third, renal tubule generation of endothelin-1
is reduced by an increase in osmolality in vitro and by
volume depletion in vivo [86,103]. Fourth, the number of
endothelin receptors in glomeruli and tubules of volume-
depleted rats is greater than normal [103]. Fifth, the
cAMP response of inner medullary collecting duct cells
to ADH is potentiated in the presence of specific
cndothclin-1 antisera, suggesting that endogenous pro¬
duction of endothelin-1 tonically inhibits responses to
ADH [87]. These tubular effects also occur with ETu
receptor agonists and are not blocked by the ETA receptor
antagonist BQ-123, suggesting that they are mediated by
ETb receptors [88,104]. The hypothesis that ETlt recep¬
tors are involved is supported by the finding that ETB
knockout mice have hypertension secondary to renal
retention of sodium [11], Taken together, these findings
suggest that locally generated endothelin-1 plays a tonic
physiological role in regulating transport of salt and water
in the terminal nephron, with increases in local genera¬
tion promoting natriuresis and diuresis via activation of
ETit receptors (Fig. 4).
Nervous system
Intracerebroventricular administration of non-systemic
doses of endothelin-1 acutely and chronically increases
blood pressure through stimulation of central sympathetic
outflow [105-107]. Endothelin-1 could also have a role in
the peripheral autonomic nervous system. Binding sites
for endothelin-1 are present in the carotid bifurcation and
topical application of the peptide inhibits baroreceptor
responses and stimulates chemoreceptor responses at this
site [108]. In addition, endothclin-1 might potentiate the
peripheral actions of the sympathetic nervous system at
threshold doses [109]. However, local potentiation of
peripheral sympathetic vasoconstrictor activity has not
been demonstrated to occur in humans [63].
Endocrine actions
Endothelin-1 has contrasting effects on the rcnin-
angiotensin-aldosterone system, inhibiting release of
renin from isolated rat glomeruli [110] but stimulating
endothelial ACE activity [111]. Endothelin-1 stimulates
the tissue renin-angiotensin system in the rat isolated
mesenteric bed [112]. Interestingly, angiotensin II
increases endothelin-1 tissue levels and ECE activity in
vivo and the haemodvnamic and proliferative effects of
angiotensin II can be prevented by blockade of ETA
receptors [113,114], These findings raise the possibility
of there being a positive-feedback loop linking
endothelin-1 and angiotensin II in disease states such as
heart failure. Endothelin-1 stimulates release of aldos¬
terone from isolated cortical zona glomcrulosa cells [ 115]
and of adrenaline from medullary chromaffin cells [ 116],
Endothelin-1 stimulates production and release of atrial
natriuretic peptide (ANP) by cultured atrial myocytes
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Effects of renal tubular endothelin-1 on reabsorption of sodium and water in (a) normotensives and (b) hypertensives. Under physiological
circumstanceo, renal tubule epithelial cells generate endothelial that acts on epithelial cell ETB receptors to inhibit reabsorption of sodium (less
activity of NaVK+ ATPase) and reabsorption of water (less activity of ADH). This action thereby promotes excretion of sodium and water. In
experimental and essential hypertension, less renal generation of endothelin-1 than normal occurs (I Endothelin-1). This will result in less tonic
inhibition of tubular reabsorption of sodium and water and thus lead to retention of sodium.
in vitro and in vivo [117,118]. Pretreatmcnt of rats with
antiserum to ANP potentiates the pressor response to
endothelin-1 [119], Thus, endogenously generated ANP
can modulate the vasoconstrictor actions of endothelin-1
in vivo. The endothelins have complicated effects on the
pituitary, thyroid and parathyroid glands and on bone
metabolism; these have been reviewed in detail elsewhere
[1-0],
Endothelin and essential hypertension
The actions of endothelin-1 which increase vascular tone,
activate the sympathetic nervous and rcnin-angiotensin-
aldosterone systems and increase mitogenesis make it
a plausible candidate mediator in the pathogenesis of
hypertension and its complications (Fig. 5). In the absence
of human studies using KCK inhibitors or endothelin
receptor antagonists, much of the work on the role of
endothelin-1 in human pathophysiology has been based
on changes in circulating plasma concentrations of
immunoreactive endothelins. However, it is important
to bear in mind that these are dependent not only on
generation, but also on renal and receptor-mediated clear¬
ance and enzyme-mediated metabolism of the peptide.
Sensitivity to endothelin-1 has been examined in some
studies, but, because number of receptors can be down-
regulated by increases in concentration of endothelin-1
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Fig. 5
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Potential pathways by which endothelin-1 might contribute to the
pathophysiology of hypertension or its complications. *An increase in
vascular activity of endothelin-1 could cause retention of sodium
through ETA receptor-mediated renal vasoconstriction. There is also
persuasive evidence that there is a deficiency of tubular generation
of endothelin-1 in hypertension that could attenuate ETB receptor-
mediated facilitation of tubular excretion of sodium and water (see
text and Fig. 4). VSM, vascular smooth muscle; RAAS,
renin-angiotensin-aldosterone system; SNS, sympathetic nervous
system; T, increase; J,, decrease.
[14] and responses may be altered by vascular remodel¬
ling, these results may also prove difficult to interpret.
Generation of endothelin in hypertension
Concentrations of cndothclin-1 in animal models of hyper¬
tension arc not raised unless accelerated hypertension is
present, in which case they are positively correlated to
plasma level of creatinine [121,122], Local mesenteric
vascular generation of endothclin-1 in vitro in tissues from
spontaneously hypertensive rats (SHR) appears to be
greater than that in tissues from normotensivc control
Wistar-Kyoto (WKY) rats [123]. There appear to be strain-
related differences because, although immunoreactivity to
endothelin and expression of endothelin in blood vessels
from deoxycorticosterone acetate (DOCA)-salt rats arc
greater than those in blood vessels from normotensive
WKY rats, those in blood vessels from SHR are lower
[124,125], The hypothesis that alteration of generation
of cndothclin-1 plays no role in the pathophysiology of
experimental hypertension is supported by the fact that
polymorphisms of the prcprocndothclin-1 gene are not
co-segregated with blood pressure or cardiac weight for
inbred Dahl rats [126]. Interestingly, there is linkage
between a locus near the prcprocndothclin-3 gene and
blood pressure for these rats [126].
Several investigators have invoked increased concentra¬
tions of circulating immunoreactive endothelin to suggest
that production of endothelin is increased in human
essential hypertension [127,128]. However, because clear¬
ance of endothelin-1 depends on normal renal function
[31,32], the increased concentrations of endothelin-1
found in severe and accelerated phase hypertension arc
probably secondary to an impairment of renal clearance.
Results of studies concerning hypertensive patients with
normal renal function have shown that they have similar
concentrations of immunoreactivc endothelin to those in
normotensives [129-131]. Indeed, in one study a nega¬
tive correlation between blood pressure and plasma level
of immunoreactive endothelin was observed for the
hypertensive group [129], making it unlikely that a global
increase in generation of endothelin-1 is a cause of
essential hypertension. Because African-Americans with
hypertension have much higher concentrations of
immunoreactive endothelin than do Caucasians, it is
possible that there are racial differences in formation of
endothclin-1 [132]. A polymorphism in an untranslated
region of exon 1 of the preprocndothelin-1 gene that abol¬
ishes a BsiYl restriction site has been identified [133].
There are significant differences in BsiYl preproen-
dothelin-1 genotype between patients with essential
hypertension and normotensive controls, with a strong
correlation between diastolic blood pressure and the poly¬
morphism [133].
Sensitivity to endothelin in hypertension
The results of studies examining vascular sensitivity to
endothelin-1 in hypertension need to be interpreted
cautiously, because of the confounding potentiating
effects of vascular hypertrophy. In animal studies
comparing WKY rats and SI IR, both conduit (renal artery
and aorta) and mesenteric resistance vessels from the SI 1R
have been shown to be more sensitive to the effects of
endothelin-1 [134,135]. However, other investigators have
reported finding decreased sensitivity to endothelin-1 in
the aorta and mesenteric resistance arteries from SHR
[136], DOCA-salt rats [137] and renovascularly hyper¬
tensive animals [138,139], It is possible that decreased
sensitivity to endothclin-1 is related to down-regulation
of endothelin receptors secondary to increased local
generation of endothelin-1 or high blood pressure [ 124).
Systemic doses of endothelin-1 have greater pressor
effects on SI IR than they do on WKY rats 1140] and reno¬
vascularly hypertensive rabbits [139], There are fewer
binding sites for endothclin-1 in aortic smooth muscle
1141] and heart [ 142] in SHR than there are in WKY rats.
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There arc, however, relatively more binding sites for
cndothelin-1 in the brain of SHR than there are in the
brain of WKY rats [142], so there could be a greater than
normal sensitivity of the central nervous system in SHR
to the peptide.
Some of the differences in responsiveness to endothclin-
1 that have been observed may be related to differences
in local generation of endothelin-1 and in the relative
proportions of endothelin ETA and ETB receptor subtypes
in different vessels. However, it should be remembered
that studies of vascular responses in hypertension may be
confounded by the presence of vascular hypertrophy in
resistance vessels. In-vitro efficacy of endothelin-1 in
subcutaneous resistance arteries in patients with essential
hypertension appears to be less than that in normoten-
sives [143]. Responsiveness to endothelin-1, but not
norepinephrine, in cutaneous hand veins, vessels in which
vascular hypertrophy does not occur, of untreated patients
with essential hypertension is increased [131]. There is a
positive correlation between venoconstriction in response
to cndothelin-1 and blood pressure in hypertensive
subjects [131]. In addition, endothelin-1 appears to poten¬
tiate sympathetically mediated vasoconstriction in hyper¬
tensive but not normotensive subjects [131]. These
findings suggest that endothelin-1 contributes to the
elevation of preload observed during the early stages of
essential hypertension. In summary, the results of studies
examining sensitivity to endothelin-1 in hypertension
suggest that sensitivity in resistance vessels is reduced,
whereas sensitivity in capacitance and conduit vessels,
particularly veins and renal arteries, is increased.
Impairment of responses of resistance vessels to endothc-
lium-dependent dilators has been demonstrated to occur
in essential hypertension [144], although this finding is
by no means universal [145]. Even if impairment of
endothelial dilator function in hypertension is solely due
to decreased production of nitric oxide, the balance
between vascular smooth muscle ETA receptor-mediated
vasoconstriction and endothelial ETB receptor-mediated
dilatation will be altered in favour of vasoconstriction.
This hypothesis is supported by the finding that tonic
ET|t receptor-mediated generation of nitric oxide appears
to oppose the vasoconstrictor effects of endogenous
cndothelin-1 in healthy humans [83], Interestingly,
dysfunction ol endothelial vasodilator in hypercholes-
tcrolaemic rabbits is associated with an ETA receptor-
mediated increase in coronary tone [146].
Renal effects of endothelin in hypertension
There appear to be two separate endothelin 'systems'
mediating opposing actions in the kidney. The first is
vasoconstriction both of afferent and of efferent
glomerular arterioles, ultimately leading to retention of
sodium [96], probably mediated through activation of ETA
receptors [99], Because the renal artery of the SHR is
more sensitive to cndothelin-1 than is that of WKY rats
[134], greater than normal renal vascular generation of
endothclin-1 could promote hypertension. The second
major site of generation of cndothelin-1 in the kidney is
the renal tubule, where it mediates excretion of salt and
water [85-88,100,102], probably through activation of ET|,
receptors [84]. Less endothelin-1 is generated in the renal
medulla, particularly the collecting duct, of SHR than is
generated in that of WKY rats [147,148]. Because tubular
generation of endothelin-1 increases urinary excretion of
sodium and water, any deficiency in renal tubule
endothelin-1 could cause retention of sodium and thus
hypertension in rats of this strain. Patients with essential
hypertension have been shown to have less urinary excre¬
tion of immunoreactive endothelin than do normotensive
controls [149], suggesting that local tubular deficiency of
endothelin-1 predisposes hypertensive humans to reten¬
tion of sodium (Fig. 4).
ECE inhibitors and endothelin antagonists in
hypertension
Anti-endothclin therapy with ECE inhibitors and
endothclin receptor antagonists lowers blood pressure in
normotensive and hypertensive rats [71,72,74,150-156].
Although some studies have reported a more marked
decrease in blood pressure in hypertensive animals
[151,153], others have observed proportional decreases in
blood pressure in animals of normotensive and hyper¬
tensive strains [71,152]. Studies with sufficient power
have not yet been performed, so it is still not known
whether anti-endothelin therapy causes a proportionately
greater fall in blood pressure in hypertensive than it does
in normotensive animal models. Animal models of salt-
sensitive hypertension (DOCA-salt and Dahl rats) and
malignant hypertension (stroke-prone SHR) appear to be
especially sensitive to the hypotensive effects of endo¬
thelin receptor antagonism, suggesting that endothelin-1
plays an important role in these variant of hyper¬
tension [154,155,157-159], In contrast, models of mild-
to-moderatc polygenic hypertension (young SHR) and
renovascular hypertension (Goldblatt rats) are relatively
insensitive to endothelin receptor blockade [160,161],
That there is a close interaction between endothelin-1
and the renin-angiotensin system [113,114] might suggest
that the hypotensive effect of anti-endothelin therapy on
hypertensive animals already receiving an ACE inhibitor
would be blunted. However, there is convincing evidence
that the roughly 20% reduction in blood pressure caused
by ETA/H receptor antagonism with bosentan is additive
to the roughly 20% decrease caused by ACE inhibition,
with a total decrease in blood pressure in hypertensive
dogs of 43% [162].
Administration of BQ-123 into the brachial artery of
subjects with essential hypertension causes forearm
vasodilatation of a similar degree to that observed with
normotensive subjects [163], Administration of the ETA,|t
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receptor antagonist bosentan at a dose of 1000 mg twice
daily for 4 weeks decreases 24 h ambulatory diastolic blood
pressure in patients with essential hypertension by about
10 mml Ig [164]. This reduction in blood pressure was sim¬
ilar to that achieved with a 20 mg dose of the ACE
inhibitor enalapril [164]. The hypotensive effect of bosen¬
tan on hypertensive patients is similar to that observed in
normotensive subjects [30], suggesting that endothelin-1
activity may not be specifically increased in essential
hypertension. Nonetheless, the blood-prcssure-lowering
effects of anti-endothelin therapy will undoubtedly prove
valuable in treating patients who are resistant to, or intol¬
erant of, first-line antihypertensive agents. The effects of
endothelin-1 on vascular growth and renal function indi¬
cate that these drugs may have specific advantages in pre¬
venting the complications of hypertension.
Endothelin and complications of hypertension
The potent mitogenic effects of endothelin-1 [90] may
contribute to hypertension-induced hypertrophy of
vascular smooth muscle, thus amplifying any vasocon¬
strictor influences [165,166]. Indeed, there is evidence
that marked enhancement of vascular expression of
endothelin-1 occurs in some hypertensive models, partic¬
ularly salt-sensitive hypertensive rat models [125,159],
Endothelin ETA receptor antagonists are able to normalize
vascular structure in DOCA-salt SHR, although they do
not normalize arterial pressure [125,167]. This reversal of
vascular hypertrophy could be due to an increase in apop-
tosis (programmed cell death) of vascular smooth muscle
cells [167]. Chronic blockade of ETA receptor decreases
arterial pressure and reduces vascular remodelling in salt-
sensitive Dahl rats [159]. Combined blockade of ETA and
ET|S receptors completely prevents cerebral arteriolar
hypertrophy in stroke-prone SHR, even though arterial
pressure decreases only partially towards normality [154].
The abnormal distensibility and lower than normal
external diameter (remodelling) of cerebral arterioles in
stroke-prone SHR arc not altered by blockade of
endothelin receptors [154].
Endothelin-1 could also promote development of left
ventricular hypertrophy, a factor that adversely affects
prognosis in hypertension [168]. Blockade of endothelin
receptors in SHR, stroke-prone SHR and DOCA-salt rats
reduces both blood pressure and cardiac mass
[155,169,170]. These results support the hypothesis that
endothelin-1 plays a role in the disordered cardiac growth
observed in hypertension.
In addition, renal dysfunction in hypertension can be
mediated by endothclin-1. Glomerular ETA and FT,,
receptors in SHR are uprcgulated [ 156], Acute blockade of
E'l\ receptors increases renal blood flow in SHR and
DOCA-salt rats [156,171], In contrast, acute combined
blockade of 1ST\ and ETK receptors decreases GER,
suggesting that up-regulation of 1". T,| receptors can act to
maintain GER in hypertensive rats [156]. Chronic blockade
of endothclin receptors prevents renal dysfunction and
fibrosis in genetically hypertensive rats [169,170], presum¬
ably reflecting inhibition of the growth-promoting effects
of endothelin-1.
Finally, the growth-promoting properties of endothelin-1
may contribute to the development of atherosclerosis.
Patients with atherosclerosis have raised plasma concen¬
trations of endothelin, with the highest concentrations in
patients with the largest numbers of affected vessels [172].
Atherosclerotic human blood vessels exhibit increased
expression of mRNA and immunostaining for endothelin-
1. Immunoreactivity for endothelin-1 is especially evident
in hypercellular, macrophage-rich atherosclerotic lesions
with many microvessels [173]. Patients with recent
evidence of myocardial ischaemia and active coronary
atherosclerotic lesions have very high tissue levels of
cndothelin-1 immunoreactivity [173], Blockade of ETA
receptors in hyperlipidaemic hamsters inhibits formation
of early atherosclerotic lesions by reducing the number
and size of macrophage-foam cells [174]. Thus, in addi¬
tion to its blood-pressure-lowering effects, anti-endothelin
therapy could be anti-mitogenic, with potential advan¬
tages in treating hypertensive patients who exhibit
vascular remodelling, left ventricular hypertrophy and
atherosclerosis.
Endothelin and secondary hypertension
Haemangioendothelioma
Increased production of endothclin-1 appears to occur in
patients with haemangiocndothelioma, a rare skin tumour.
Yokokawa etal. [175] have described two cases ofhacman-
gioendothelioma in which hypertension was associated
with increased plasma concentrations of cndothelin-1.
Biopsies of tumour cells revealed increased expression of
endothelin-1 mRNA and strong immunohistochemical
staining for the peptide. Blood pressure and concentra¬
tions of endothclin-1 returned to normal after surgical
resection of the tumours and recurrence of the tumour
led to increases both in blood pressure and in plasma level
of endothelin.
Pre-eclampsia
Circulating concentrations of immunorcactivc endothelin
in women with pre-eclampsia are greater than those in
non-hypertensive pregnant women, even when their renal
function is normal [176,177]. Treatment of pre-eclampsia
with magnesium sulphate reduces plasma concentrations
of endothclin-1 [177]. Increased generation of cndothelin-
1 could therefore play a role in the pathophysiology of
pre-eclampsia.
Chronic renal failure
Complications of atherosclerosis arc the commonest cause
of death among patients with chronic renal failure and
hypertension is an important contributor to this excess
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mortality. Chronic renal failure, once it has become estab¬
lished, tends to progress to end-stage renal failure
requiring therapy with dialysis. In animals with the low-
renal-mass model of progressive chronic renal failure,
there are increases in renal levels of preproendothelin-1
mRNA, cortical tissue levels of immunoreactive endo¬
thelial and urinary excretion of endothelin [178,179]. In
addition, renal generation of cndothelin-1 is positively
correlated to urinary excretion of protein and glomerulo¬
sclerosis in such animals [178,179]. Furthermore, glom¬
erular expression of mRNA for ETA and ETB receptors
is increased in experimental glomerulosclerosis [180].
Finally, administration of an endothelin ETA receptor
antagonist prevents the development of hypertension,
glomerular damage and renal insufficiency in rats with low
renal mass [181]. The results of these studies support
that cndothelin-1 plays an important role in progression
of chronic renal failure.
Plasma concentrations of endothelin-1 in patients with
chronic renal failure are 1-2-fold greater than normal,
whereas values in those undergoing haemodialysis are
2-4-fold greater than normal [31]. Increased circulat¬
ing endothelin-1 concentrations may reflect impairment
of clearance; however, the fact that urinary excretion of
endothelin-1 is also increased [182] suggests that renal
generation of cndothelin-1 in this disease is increased. It
is possible that increased urinary excretion of endothelin-
1 merely reflects a homeostatic effort to decrease tubular
reabsorption of sodium. However, results of studies with
cndothclin receptor antagonists suggest that endothelin-
1 plays a pathogenic role in renal failure. Administration
of the ETa/„ receptor antagonist TAK-044 to patients with
chronic renal failure reduces blood pressure by 11% and
renal vascular resistance by 10% [11]. Interestingly,
blockade of ETA and ETB receptors decreases filtration
fraction substantially, whilst maintaining GFR, suggesting
that endogenous generation of endothclin-1 contributes
to renal hvperfiltration [11],
Responsiveness to endothclin-1 of cutaneous veins of
normotensive and hypertensive patients with chronic
renal failure who are not yet undergoing dialysis has been
examined [183], Although there is no difference between
responses in controls and normotensive patients with
chronic renal failure, venoconstriction in response to
endothelin-1 in hypertensive patients is attenuated.
Because these patients have higher than normal concen¬
trations of immunoreactive endothelin, their decreased
responsiveness could reflect down-regulation of cndo¬
thclin receptors secondary to increased generation or
decreased clearance of the peptides. Results of further
studies have demonstrated that patients with chronic renal
failure have impairment of forearm vasodilatation in
response to brachial artery infusion of the ETA antago¬
nist BQ-123, suggesting that vascular generation of
endothelin-1 in this disease is probably decreased [184],
Alternatively, this might reflect endothelial dysfunction
leading to decreased tonic ETB-mcdiated formation of
nitric oxide.
Erythropoietin
Erythropoietin therapy is used to reverse the anaemia of
chronic renal disease, but is associated with clinically
important hypertension in a substantial number of
patients. In-vitro data suggest that production of
cndothelin-1 by endothelial cells is increased by expo¬
sure to erythropoietin [185]. However, plasma concentra¬
tions of immunoreactive endothelin are not increased by
erythropoietin therapy [186]. Alteration of endothelin
receptors is also not likely to underlie the association of
erythropoietin therapy with hypertension, because
forearm vasoconstriction in response to intra-arterial infu¬
sion of endothelin-1 decreases, rather than increases, after
erythropoietin therapy has been started ] 186].
Cyclosporin A
Endothelin-1 could also contribute to the hypertension
and renal impairment caused by cyclosporin A. Production
of endothclin-1 is stimulated by cyclosporin A [187],
which also increases the number of renal endothelin-1
binding sites [43]. In addition, cyclosporin-induced renal
vasoconstriction is substantially attenuated by adminis¬
tration of the ETa receptor antagonist BQ-123 [188,189],
Cyclosporin-induced hypertension is inhibited by
blockade of ETA and ETB receptors [190]. Flowever,
cyclosporin A treatment does not increase plasma concen¬
trations of immunoreactive endothelin in healthy human
subjects [191], Administration of the novel immunosup¬
pressant tacromilus also appears to increase secretion of
endothelin-1 in vitro [192]. Both cyclosporin A and
tacromilus increase urinary excretion of endothelin-1 after
liver transplantation [193].
Endothelin and pulmonary hypertension
Primary pulmonary hypertension
Pulmonary hypertension is characterized pathophysiolog-
ically by endothelial injury, proliferation of vascular
smooth muscle cells and vasoconstriction of pulmonary
resistance vessels. The vasoconstrictor and mitogenic
effects of endothclin-1 make it a plausible contributor to
the pathophysiology of pulmonary hypertension. Plasma
concentrations of immunoreactive endothelin-1 in primary
pulmonary hypertension are markedly increased [194].
Also, the pulmonary circulation seems to generate more
cndothelin-1 than it clears in primary pulmonary hyper¬
tension, because the arterial : venous concentration ratio
of endothelin-1 is significantly greater than unity (-2.2)
[194]. This is not the case for healthy controls, who have
an arterial : venous ratio substantially less than unity
(-0.6). In addition, patients with primary pulmonary
hypertension exhibit increased immunorcactivity and
expression of mRNA for endothelin-1 in the endothelial
cells of hypcrtrophicd pulmonary vessels, with the degree
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of expression proportional to pulmonary vascular resis¬
tance [195]. These findings arc consistent with the
hypothesis that endothclin-1 plays a pathophysiological
role in progression of primary pulmonary hypertension.
Secondary pulmonary hypertension
Pulmonary hypertension more often occurs secondarily to
conditions such as chronic obstructive airway disease ('cor
pulmonale') and CHF. In healthy subjects, 30 min of
hypoxacmia causes a twofold increase in circulating levels
of immunoreactive endotheiin-1, similar to those observed
in patients with cor pulmonale [196]. Thus, it is possible
that endothelin-1 is involved in this form of secondary
pulmonary hypertension. Indeed, plasma concentrations
of endothelin-1 in venous blood in patients with
secondary pulmonary hypertension are increased [194].
There is no difference between arterial and venous
concentrations of endothelin-1 in secondary pulmonary
hypertension, in contrast to the apparent clearance of
endothelin-1 across the pulmonary circulation in healthy
subjects. Patients with secondary pulmonary hypertension
also exhibit increased pulmonary vascular expression of
endothelin-1 [195].
CHF
CHF is probably the commonest cause of secondary
pulmonary hypertension. Neurohumoral activation occurs
in CHF, with increases in sympathetic nerve activity and
in circulating concentrations of adrenaline, noradrenaline,
renin, angiotensin II, aldosterone and vasopressin. It has
been hypothesized that these neurohumoral changes, by
causing peripheral vasoconstriction and retention of
sodium, contribute to the pathophysiology of CHF. The
proven mortality benefits of ACT inhibitor therapy in
treating CHF support the neurohumoral hypothesis.
I lowevcr, despite the benefits of ACE inhibitor therapy,
morbidity and mortality ot patients with CI If arc still
markedly increased.
Expression of endothelin-1 and ETV receptors in animals
with experimental heart failure is increased [197], In addi¬
tion, chronic administration of ET v or of E'I\ and ETB
antagonists reduces cardiac preload and afterload as well
as preventing progressive left ventricular dilatation for
several months after coronary ligation [197,198], Such
animals have markedly better long-term prognoses, the
percentage of animals surviving increasing from 43 to 85%
after administration of BQ-123 and from 47 to 65% after
administration of bosentan [197,198], It is possible that
the higher percentage of animals surviving after admin¬
istration of BQ-123 reflects an adverse effect of the addi¬
tional blockade of E FB receptors that occurs with
administration of bosentan. It might be relevant that, in
a comparison of selective E I \ and FT,, receptor antago¬
nists with a canine model of heart failure, selective E I
receptor antagonism with RES-701-l increased intra¬
cardiac pressures and decreased cardiac output and renal
How of blood. These potentially adverse effects did not
occur during blockade of ETA receptors, which had bene¬
ficial effects [199],
Concentrations of immunorcactive endothclin in patients
with CHF are greater than normal [200,201], correlated
closely to the degree of haemodynamic and functional
impairment [23,202] and associated with increased
mortality and need for cardiac transplantation [202]. Big
endothelin-1 is a substantial component of total circu¬
lating immunoreactive endothelin in CHF [23,202],
perhaps reflecting increased generation of endothelin-1,
rather than decreased clearance, in this condition.
Early phase clinical studies with the ETA/|, receptor antag¬
onist bosentan concerning patients with severe CHF have
shown that sustained peripheral, pulmonary and venous
vasodilatation occurs, together with improvement of
cardiac performance, without reflex tachycardia [203],
These beneficial haemodynamic effects are similar to
those obtained after ACE inhibition, which raises the
question of whether anti-endothelin therapy would have
similar effects on patients already receiving maximal ACE
inhibitor therapy. This question was addressed in studies
with local brachial artery administration of the ECE
inhibitor phosphoramidon and the F"TA antagonist BQ-
123 to CHF patients receiving ACE inhibitors [204]. Both
of these agents produced substantial vasodilatation of
forearm resistance vessels, suggesting that endothclin
receptor antagonists have useful effects additional to those
of ACE inhibition in treating CHF [204]. Indeed, results
of recent studies with chronic oral administration of the
ETa/d antagonist bosentan suggest that beneficial effects
of anti-endothclin therapy do occur in CHF patients
receiving ACE inhibitors [205]. Chronic therapy with oral
boscntan for 14 days reduced systemic and pulmonary
vascular resistances in these patients by 24 and 20%
respectively [205], Despite there having been decreases
in mean arterial pressure, there was no increase in circu¬
lating noradrenaline levels and a blunting of the usual
diuretic-induced activation of the renin—angiotensin
system [206], Clinical status of 35% of patients adminis¬
tered boscntan improved compared with 0% for placebo
[205],
Although boscntan apparently is of haemodynamic and
clinical benefit in treating CHF, there is intense debate
regarding whether selective ETA blockade or non-selec¬
tive E'l'vi, blockade would be more beneficial in treating
this disease. Interestingly, vasodilatation in response to
BQ-123 appears to be reduced and that in response to
phosphoramidon increased in CHF [204], This would
be consistent with occurrence of up-rcgulation of E I',,-
mediated vasoconstriction, which has been demonstrated
experimentally to occur in dogs [207]. Indeed, increased
ET|,-mediated vasoconstriction has been shown to occur
in forearm resistance vessels and hand veins of CI IF
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patients [208], Nonetheless, patients with CHF do exhibit
vasoconstriction in response to the ETB receptor antago¬
nist BQ-788, suggesting that the predominant vascular
role of this receptor is to mediate vasodilatation under
resting conditions [208], These data, together with the
results of animal studies presented above, suggest that
selective ETA blockade may be preferable in treating
CHF.
Conclusions
The endothelins exert uniquely sustained vasoconstrictor
actions and also activate the renin-angiotensin-aldos¬
terone and sympathetic nervous systems and promote
mitogenesis. Endothelin-1 is the predominant form gener¬
ated by endothelial cells and therefore is likely to be the
most important isoform in cardiovascular regulation.
Inhibition of ECE or blockade of endothelin receptors
produces vasodilatation and decreases blood pressure in
normotensive subjects, suggesting that endogenous gener¬
ation of endothelin-1 plays an important physiological role
in the maintenance of blood pressure. The only other
factors, besides endothelin-1, that have been shown to
have a similar fundamental physiological role in mainte¬
nance of basal vascular tone are the sympathetic nervous
system and nitric oxide. Results of recent studies suggest
that the overall effects of endogenous endothelin-1 on
blood pressure are the results of a complex interplay
between tonic activation of vasoconstrictor vascular
smooth muscle ETA receptors and tonic activation of
vasodilator endothelial ETB receptors.
I he role of endothelin-1 in hypertension has been
contentious. There appears to be no abnormal excess
vascular generation of, or sensitivity to, endothelin-1 in
some animal models and in humans with mild polygenic
hypertension. However, endothelial damage secondary to
hypertension will decrease the usual physiological antag¬
onism by nitric oxide of the vasoconstrictor effects of
endothelin-1. There is also evidence that overall activity
of the endothelin system is increased under certain
circumstances, notably salt-sensitive hypertension, accel¬
erated phase hypertension, pre-eclampsia and renal
hypertension. In addition, endothelin-1 could contribute
to the vascular, cardiac and renal complications of hyper¬
tension, including atherosclerosis, left ventricular hyper¬
trophy and dysfunction and progressive renal disease. The
blood-pressure-lowering effects of ECE inhibitors and
endothelin receptor antagonists observed in normotensive
and hypertensive subjects should provide a valuable addi¬
tional option for treating patients with hypertension.
Most of the apparently deleterious effects of endothehn-
1 appear to be mediated through ETA receptors. Selective
1*. I \ receptor antagonists block the vasoconstrictor effects
of endogenous endothclin-1, whilst preserving the
vasodilator and natriuretic effects mediated by E l'B recep¬
tors. Antagonists at I-, I x receptors have been shown to
have impressive benefits in treating several experimental
models of cardiovascular disease. The role of the ETB
receptor is less clear, because it may mediate both dele¬
terious (vasoconstriction) and beneficial (vasodilatation
and natriuresis) effects. Blockade of the ETB receptor also
increases circulating concentrations of endothelin-1 by
blocking clearance receptors. Nonetheless, results of early
clinical studies in hypertension and CHF have shown that
there are clinical benefits with combined ET^n receptor
antagonists. Appropriately designed clinical trials to
examine whether combined ET^o blockade or selective
ETa blockade is superior in the treatment of hypertension
would be valuable. Further studies to elucidate the effects
of anti-endothelin therapy on the complications of hyper¬
tension and on related diseases, such as CHF and chronic
renal failure, are also needed.
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